

173953-24-00001310-Q Replimune Group, Inc. 20240808202408080806360806360 0001737953-24-000013 10-Q BA 20240630 20240808 Replimune Group, Inc.
20240630 2836 822082553 DE 0331 10-Q 34 001-38596 241186176 500 UNICORN PARK WOBURN MA 01801 (781) 222-9600 500 UNICORN PARK WOBURN MA 01801 10-Q 1 repl-
20240630.htm 10-Q repl-202406300001737953false06-

302025Q1P4Y6531002351xbrli:sharesiso4217:USDxbrli:sharesrepl:advancexbrli:purrepl:patientrepl:region00017379532024-04-012024-06-3000017379532024-08-
0500017379532024-06-3000017379532024-03-3100017379532024-04-012023-06-300001737953us-gaap:CommonStockMember2023-03-310001737953us-
gaap:AdditionalPaidInCapitalMember2024-03-310001737953us-gaap:RetainedEarningsMember2024-03-310001737953us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-
310001737953us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001737953us-gaap:CommonStockMember2024-04-012024-06-300001737953us-
gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001737953us-gaap:RetainedEarningsMember2024-04-012024-06-300001737953us-
gaap:CommonStockMember2024-06-300001737953us-gaap:AdditionalPaidInCapitalMember2024-06-300001737953us-gaap:RetainedEarningsMember2024-06-300001737953us-
gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001737953us-gaap:CommonStockMember2023-03-310001737953us-gaap:AdditionalPaidInCapitalMember2023-03-
310001737953us-gaap:RetainedEarningsMember2023-03-310001737953us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100017379532023-03-310001737953us-
gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001737953us-gaap:CommonStockMember2023-04-012023-06-300001737953us-
gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001737953us-gaap:RetainedEarningsMember2023-04-012023-06-300001737953us-gaap:CommonStockMember2023-06-
300001737953us-gaap:AdditionalPaidInCapitalMember2023-06-300001737953us-gaap:RetainedEarningsMember2023-06-300001737953us-
gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-3000017379532023-06-300001737953us-gaap:FairValueInputsLevel1Memberus-
gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-06-300001737953us-gaap:FairValueInputsLevel2Memberus-
gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-06-300001737953us-gaap:FairValueInputsLevel3Memberus-
gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-06-300001737953us-gaap:FairValueInputsLevel3Memberus-
gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-06-300001737953us-gaap:FairValueMeasurementsRecurringMemberus-
gaap:USGovernmentAgenciesDebtSecuritiesMember2024-06-300001737953us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-
gaap:USGovernmentAgenciesDebtSecuritiesMember2024-06-300001737953us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-
gaap:USGovernmentAgenciesDebtSecuritiesMember2024-06-300001737953us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-06-
300001737953us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-06-300001737953us-
gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-06-300001737953us-gaap:FairValueInputsLevel3Memberus-
gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-06-300001737953us-gaap:FairValueMeasurementsRecurringMemberus-
gaap:USTreasurySecuritiesMember2024-06-300001737953us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001737953us-
gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001737953us-gaap:FairValueInputsLevel3Memberus-
gaap:FairValueMeasurementsRecurringMember2024-06-300001737953us-gaap:FairValueMeasurementsRecurringMember2024-06-300001737953us-gaap:FairValueInputsLevel1Memberus-
gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-03-310001737953us-gaap:FairValueInputsLevel2Memberus-
gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-03-310001737953us-gaap:FairValueInputsLevel3Memberus-
gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-03-310001737953us-gaap:FairValueMeasurementsRecurringMemberus-
gaap:MoneyMarketFundsMember2024-03-310001737953us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-
gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310001737953us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-
gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310001737953us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-
gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310001737953us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-
310001737953us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-03-310001737953us-
gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-03-310001737953us-gaap:FairValueInputsLevel3Memberus-
gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-03-310001737953us-gaap:FairValueMeasurementsRecurringMemberus-
gaap:USTreasurySecuritiesMember2024-03-310001737953us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001737953us-
gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001737953us-gaap:FairValueInputsLevel3Memberus-
gaap:FairValueMeasurementsRecurringMember2024-03-310001737953us-gaap:FairValueMeasurementsRecurringMember2024-03-310001737953us-
gaap:USGovernmentAgenciesDebtSecuritiesMember2024-06-300001737953us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-04-012024-06-300001737953us-
gaap:USTreasurySecuritiesMember2024-06-300001737953us-gaap:USTreasurySecuritiesMember2024-04-012024-06-300001737953us-gaap:ShortTermInvestmentsMember2024-06-
300001737953us-gaap:ShortTermInvestmentsMember2024-04-012024-06-300001737953us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310001737953us-
gaap:USGovernmentAgenciesDebtSecuritiesMember2023-04-012024-03-310001737953us-gaap:USTreasurySecuritiesMember2024-03-310001737953us-
gaap:USTreasurySecuritiesMember2023-04-012024-03-310001737953us-gaap:ShortTermInvestmentsMember2024-03-310001737953us-gaap:ShortTermInvestmentsMember2023-04-012024-
03-310001737953us-gaap:OfficeEquipmentMember2024-06-300001737953us-gaap:OfficeEquipmentMember2024-03-310001737953us-gaap:ComputerEquipmentMember2024-06-
300001737953us-gaap:ComputerEquipmentMember2024-03-310001737953us-gaap:EquipmentMember2024-06-300001737953us-gaap:EquipmentMember2024-03-310001737953us-
gaap:LeaseholdImprovementsMember2024-06-300001737953us-gaap:LeaseholdImprovementsMember2024-03-310001737953us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2024-06-
300001737953us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2024-03-310001737953us-gaap:ConstructionInProgressMember2024-06-300001737953us-
gaap:ConstructionInProgressMember2024-03-310001737953repl:TermLoanFacilityMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2022-10-
060001737953repl:TermLoanFacilityTrancheOneMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2022-10-060001737953repl:TermLoanFacilityTrancheTwoMemberus-
gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2022-10-060001737953repl:TermLoanFacilityTrancheThreeMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2022-10-
060001737953repl:TermLoanFacilityTrancheFourMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2022-10-060001737953repl:TermLoanFacilityTrancheFiveMemberus-
gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2022-10

net11,403\$10,483\$ Research and development incentives receivable, non-current438\$ \$ 1,700\$ Right-to-use asset - operating leases4,475\$ 4,635\$ Right-to-use asset - financing leases36,629\$ 37,237\$ Total assets\$534,965\$ 487,722\$ Liabilities and Stockholders' EquityCurrent liabilities:Accounts payable\$864\$ 2,578\$ Accrued expenses and other current liabilities30,914\$ 33,981\$ Operating lease liabilities, current1,164\$ 1,161\$ Financing lease liabilities, current2,738\$ 2,718\$ Total current liabilities\$35,680\$ 40,438\$ Operating lease liabilities, non-current3,600\$ 3,771\$ Financing lease liabilities, non-current23,256\$ 23,410\$ Long term debt, net of discount45,192\$ 44,809\$ Other liabilities, non-current786\$ 786\$ Total liabilities\$108,514\$ 113,214\$ Commitments and contingencies (Note 14)Stockholders' equityCommon stock, \$0.001 par value; 150,000,000 shares authorized as of June 30, 2024 and March 31, 2024; 68,309,968 and 61,415,105 shares issued and outstanding as of June 30, 2024 and March 31, 2024, respectively68\$ 61\$ Additional paid-in capital1,177,113\$ 1,070,874\$ Accumulated deficit(755,054\$)(701,282\$)Accumulated other comprehensive income 4,324\$ 4,855\$ Total stockholders' equity426,451\$ 374,508\$ Total liabilities and stockholders' equity\$534,965\$ 487,722\$ The accompanying notes are an integral part of these condensed consolidated financial statements.3Table of ContentsREPLIMUNE GROUP,Â INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Amounts in thousands, except share and per share amounts)(Unaudited)Three Months Ended June 30, 20242023Operating expenses:Research and development\$42,972\$ 440,437\$ Selling, general and administrative14,395\$ 15,211\$ Total operating expenses\$57,367\$ 55,648\$ Loss from operations(57,367\$)(55,648\$)Other income (expense):Research and development incentives438\$ 393\$ Investment income4,711\$ 6,186\$ Interest expense on finance lease liability(534\$)(544\$)Interest expense on debt obligations(1,426\$)(1,115\$)Other income406\$ 1,374\$ Total other income (expense), net3,595\$ 6,294\$ Loss before income taxes\$(53,772\$)(53,772\$)Income tax provision\$ 201\$ Net loss \$(53,772\$)(49,555\$)Net loss per common share, basic and diluted\$(0.78)\$ (0.75)\$ Weighted average common shares outstanding, basic and diluted69,185,885\$ 66,367,702\$ The accompanying notes are an integral part of these condensed consolidated financial statements.4Table of ContentsREPLIMUNE GROUP,Â INC.CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS(Amounts in thousands)(Unaudited)Three Months Ended June 30, 20242023Net loss\$(53,772\$)(49,555\$)Other comprehensive loss:Foreign currency translation (loss) gain (432\$)(1,305\$)Net unrealized (loss) gain on short-term investments, net of tax of \$(0.99)(458\$)Comprehensive loss\$(54,303\$)(51,318\$)The accompanying notes are an integral part of these condensed consolidated financial statements.5Table of ContentsREPLIMUNE GROUP,Â INC.A CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY(Amounts in thousands, except share amounts)(Unaudited)Common stockAdditional paid-in capitalAccumulated deficitAccumulated other comprehensive lossTotal stockholders' equitySharesAmountBalances as of March 31, 202461,415,105\$ 61\$ 1,070,874\$ \$(701,282\$)\$ 4,855\$ 374,508\$ Issuance of prefunded warrants to purchase common stock, net of issuance costs\$ 48,500\$ \$ 48,500\$ \$ 48,500\$ Issuance of common stock in connection with private placement, net of placement agent fees and offering costs\$ 5,668,937\$ 6\$ 48,198\$ \$ 48,204\$ Foreign currency translation adjustment\$ 1\$ \$ 1\$ Exercise of stock options\$ 22,860\$ \$ 66\$ \$ 66\$ Vesting of RSUs\$ 463,841\$ \$ 48,500\$ Vesting of RSUs\$ 463,841\$ \$ 48,500\$ Stock-based compensation expense\$ 9,475\$ \$ 9,475\$ \$ 9,475\$ Net loss\$ (53,772\$)(49,555\$)Balances as of June 30, 202468,309,968\$ 68\$ 1,177,113\$ \$(755,054\$)\$ 4,324\$ 426,451\$ Balances as of March 31, 202367,314\$ 57\$ 1,034,994\$ \$(485,488\$)\$ 5,729\$ Foreign currency translation adjustment\$ 1\$ \$ 1\$ Unrealized loss on short-term investments\$ 48\$ \$ 48\$ Exercise of pre-funded warrants\$ 1,922,655\$ \$ 48,500\$ Exercise of stock options\$ 96,146\$ \$ 1,209\$ Vesting of RSUs\$ 281,211\$ \$ 48,500\$ Stock-based compensation expense\$ 8,846\$ \$ 8,846\$ Net loss\$ (49,555\$)(49,555\$)Balances as of June 30, 202358,976,325\$ 57\$ 1,045,049\$ \$(535,043\$)\$ 9,664\$ 514,029\$ The accompanying notes are an integral part of these condensed consolidated financial statements.6Table of ContentsREPLIMUNE GROUP,Â INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Amounts in thousands)(Unaudited)Three Months Ended June 30, 20242023Cash flows from operating activities:Net loss\$(53,772\$)(49,555\$)Adjustments to reconcile net loss to net cash used in operating activities:Stock-based compensation expense9,475\$ 8,846\$ Depreciation and amortization736\$ 621\$ Net amortization of premiums and discounts on short-term investments(2,788\$)(4,091\$)Noncash interest expense383\$ 257\$ Unrealized foreign currency transaction (gains) losses(406\$)(1,374\$)Changes in operating assets and liabilities:Research and development incentives receivable(437\$)(393\$)Prepaid expenses and other current assets1,817\$ (1,577\$)Operating lease, right-of-use-asset164\$ 148\$ Finance lease, right-of-use-asset607\$ 607\$ Accounts payable(1,615\$)(816\$)Accrued expenses and other current liabilities(3,160\$)(1,215\$)Operating lease liabilities(171\$)(153\$)Other non-current liabilities\$ 107\$ Net cash used in operating activities(49,167\$)(48,588\$)Cash flows from investing activities:Purchases of property, plant and equipment and software capitalization(1,669\$)(449\$)Purchase of short-term investments(105,475\$)(169,330\$)Proceeds from sales and maturities of short-term investments136,910\$ 177,140\$ Net cash provided by investing activities29,766\$ 7,361\$ Cash flows from financing activities:Proceeds from issuance of common stock in connection with private placement, net of placement agent fees and offering costs48,204\$ \$ 48,204\$ Proceeds from issuance of prefunded warrants to purchase common stock, net of placement agent fees and offering costs48,500\$ \$ 48,500\$ Principal payment of finance lease obligation(134\$)(104\$)Proceeds from exercise of stock options and pre-funded warrants67\$ 1,209\$ Net cash provided by financing activities96,637\$ 1,105\$ Effect of exchange rate changes on cash, cash equivalents and restricted cash(35\$)13\$ Net increase (decrease) in cash, cash equivalents and restricted cash77,201\$ (40,109\$)Cash, cash equivalents and restricted cash at beginning of period76,157\$ 148,226\$ Cash, cash equivalents and restricted cash at end of period\$153,358\$ 108,117\$ Supplemental disclosure of cash flow information:Cash paid during the period for interest\$1,052\$ 653\$ Supplemental disclosure of non-cash investing and financing activities:Purchases of property and equipment included in accounts payable and accrued expenses\$ 87\$ 412\$ The accompanying notes are an integral part of these condensed consolidated financial statements.7Table of ContentsREPLIMUNE GROUP,Â INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Dollars in thousands, except share and per share amounts)(Unaudited)1. Nature of the businessReplimune Group,Â Inc. (the "Company") is a clinical-stage biotechnology company with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. The Company's proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Replimune Group,Â Inc., whose predecessor was founded in 2015, is the parent company of its wholly owned, direct and indirect subsidiaries: Replimune Limited (Â€Replimune UKÂ€); Replimune,Â Inc. (Â€Replimune USAÂ€); Replimune Securities Corporation; and Replimune (Ireland) Limited. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, third-party intellectual property, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting capabilities. Even if the Company's product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. The Company's proprietary oncolytic immunotherapy product candidates, the Rpx product candidates, are based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with added payloads intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The Company currently has three Rpx product candidates, RP1, RP2 and RP3. RP1 is currently under development in multiple clinical trials, the most advanced being the anti-PD1 failed melanoma cohort of the IGYNT clinical trial, that, as reported in June 2024, had positive topline primary data analysis by independent central review. RP2 is currently in clinical development with planning underway for a potentially registration enabling clinical trial in uveal melanoma. Basis of presentationThe accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred recurring losses since its inception, including net losses of \$53.8 million and \$49.6 million for the three months ended June 30, 2024 and 2023, respectively. In addition, as of June 30, 2024, the Company had an accumulated deficit of \$755.1 million. The Company expects to continue to generate operating losses for the foreseeable future. As of the issuance date of these consolidated financial statements, the Company expects that its cash and cash equivalents and short-term investments will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance of these consolidated financial statements.2. Summary of significant accounting policiesPrinciples of consolidationThe accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and its direct and indirect wholly owned subsidiaries, Replimune UK, Replimune US, Replimune Securities Corporation and Replimune (Ireland) Limited after elimination of all intercompany accounts and transactions. Use of estimatesThe preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of stock-based awards. The Company bases its estimates on 8Table of Contentshistorical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Unaudited interim financial informationThe accompanying consolidated balance sheet as of June 30, 2024, the consolidated statements of operations, of comprehensive loss and of stockholders' equity for the three months ended June 30, 2024 and 2023 and the consolidated statements of cash flows for the three months ended June 30, 2024 and 2023 are unaudited. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company's financial position as of June 30, 2024 and the results of its operations for the three months ended June 30, 2024 and 2023 and its cash flows for the three months ended June 30, 2024 and 2023. The financial data and other information disclosed in these consolidated notes related to the three months ended June 30, 2024 and 2023 are unaudited. The results for the three months ended June 30, 2024 are not necessarily indicative of results to be expected for the year ending March 31, 2025, any other interim periods or any future year or period. The financial information included herein should be read in conjunction with the financial statements and notes in the Company's Annual Report on Form 10-K for the year ended March 31, 2024, which was filed with the Securities and Exchange Commission on May 16, 2024 (the "Annual Report"). During the three months ended June 30, 2024, there have been no changes to the Company's significant accounting policies as described in the Annual Report. Recently Issued Accounting PronouncementsIn December 2023, the Financial Accounting Standards Board issued Accounting Standards Update ("ASU") No. 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures." This ASU updates income tax disclosure requirements primarily by requiring specific categories and greater disaggregation within the rate reconciliation and disaggregation of income taxes paid by jurisdiction. This ASU is effective for annual periods beginning after December 15, 2024 and is applicable to the Company's fiscal year beginning April 1, 2025, with early application permitted. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and disclosures. In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures." The amendments in this update expand segment disclosure requirements, including new segment disclosure requirements for entities with a single reportable segment among other disclosure requirements. This update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company is currently evaluating the potential impact of this adoption on the consolidated financial statements and related disclosures.3. Fair value of financial assets and liabilitiesThe following tables present information about the Company's financial assets and liabilities measured at fair value on a recurring basis: Fair Value Measurements as of June 30, 2024 Using: Level 1 Level 2 Level 3 Total Cash equivalents Money market funds\$ 20,097\$ \$ 20,097\$ Short-term investmentsUS Government Agency bonds\$ 171,707\$ \$ 171,707\$ US Treasury bonds\$ 145,759\$ \$ 145,759\$ \$ 337,563\$ \$ 337,563\$ 9Table of ContentsFair Value Measurements as of March 31, 2024 Using: Level 1 Level 2 Level 3 Total Cash equivalentsMoney market funds\$ 41,077\$ \$ 41,077\$ Short-term investmentsUS Government Agency bonds\$ 199,821\$ \$ 199,821\$ US Treasury bonds\$ 146,390\$ \$ 146,390\$ \$ 387,288\$ \$ 387,288\$ The underlying securities in the money market funds held by the Company are all government backed securities. During the three months ended June 30, 2024 and 2023, there were no transfers between levels. Valuation of cash equivalents and short-term investmentsMoney market funds, U.S. Government Agency bonds and U.S. Treasury bonds were valued by the Company using quoted prices in active markets for similar securities, which represent a Level 2 measurement within the fair value hierarchy. Cash equivalents consisted of money market funds at June 30, 2024 and money market funds at March 31, 2024. Short-term investmentsAs of June 30, 2024 and March 31, 2024, the Company's available-for-sale investments by type consisted of the following: June 30, 2024 Amortized cost Gross unrealized gains Gross unrealized losses Credit Losses Fair value US Government agency bonds\$ 171,822\$ 33\$ (118\$)\$ 171,707\$ US Treasury bonds\$ 145,854\$ 1\$ (96\$)\$ 145,759\$ \$ 145,759\$ \$ 145,759\$ \$ 317,676\$ \$ 44\$ (214\$)\$ 317,466\$ March 31, 2024 Amortized cost Gross unrealized gains Gross unrealized losses Credit Losses Fair value US Government agency bonds\$ 199,905\$ 33\$ (117\$)\$ 199,821\$ US Treasury bonds\$ 146,417\$ 11\$ (38\$)\$ 146,390\$ \$ 146,390\$ \$ 346,322\$ \$ 44\$ (155\$)\$ 346,211\$ As of June 30, 2024 and March 31, 2024, available-for-sale securities consisted of investments that mature within one year. 10Table of Contents5. Property, plant and equipment, netProperty, plant and equipment, net consisted of the following: June 30, 2024 March 31, 2024 Office equipment\$ 1,487\$ 1,464\$ Computer equipment\$ 2,108\$ 1,975\$ Plant and laboratory equipment\$ 10,560\$ 10,423\$ Leasehold improvements\$ 1,886\$ 1,886\$ Capitalized software\$ 938\$ 3,515\$ Construction in progress\$ 1,034\$ 1,117\$ \$ 11,174\$ \$ 11,174\$ Total property, plant and equipment\$ 22,013\$ 20,380\$ Less: Accumulated depreciation(10,610\$)(9,897\$) \$ 11,403\$ \$ 10,483\$ Depreciation expense was \$0.7 million and \$0.6 million for the three months ended June 30, 2024 and 2023, respectively. Depreciation expense is recorded within research and development and selling, general and administrative expenses in the consolidated statement of operations.6. Accrued expenses and other current liabilitiesAccrued expenses and other current liabilities consisted of the following: June 30, 2024 March 31, 2024 Accrued research and development costs\$ 16,166\$ 16,376\$ Accrued compensation and benefits costs\$ 7,447\$ 13,906\$ Accrued professional fees\$ 370\$ 369\$ Other\$ 9,314\$ 9,330\$ \$ 33,887\$ \$ 33,887\$ 7Table of ContentsDebtOn October 6, 2022, the Company entered into a Loan and Security Agreement (the "Loan Agreement"), with Hercules Capital, Inc., as administrative agent, collateral agent and as a lender (the "Hercules"). Pursuant to the Loan Agreement, the Company can borrow term loans in an aggregate maximum principal amount of up to \$200.0Â million under multiple tranches (the "Term Loan Facility"). Under the Loan Agreement, the Company borrowed an initial amount of \$30.0Â million on the closing date, and at the Company's sole option, could have drawn, but did not draw down, an additional \$30.0Â million on or prior to September 30, 2023. The Company can also draw as additional term loan advances in an aggregate principal amount of up to \$115.0Â million during the term of the Term Loan Facility subject to achievement of specified performance milestones, and two additional term loan advances up to an aggregate principal amount of \$25.0Â million subject to certain terms and conditions, on or prior to the end of the interest-only period. The Company intends to use the proceeds of the Term Loan Facility for working capital and general corporate purposes. The Loan Agreement was subsequently amended (the "Amendment") on June 28, 2023 pursuant to which the Company agreed to draw an initial term loan advance in an aggregate principal amount not less than \$30.0Â million, provided that the aggregate amount of the term loan advances made under tranche 1 do not exceed \$30.0Â million, which reflects a decrease of \$30.0Â million from the \$60.0Â million in the original Loan Agreement for tranche 1. The total amount of the Loan Agreement, as well as the outstanding balance of the loan, is unchanged, but the option to borrow additional funds were redistributed from tranche 1 to tranche 2. The impact of this amendment is not a modification, as it does not relate to outstanding debt, but is rather an amendment that provides for a future potential benefit. There is no material impact to the financial statements as a result of the Amendment. A second amendment was made to the Loan Agreement (the "Second Amendment") on December 22, 2023 pursuant to which the Company agreed to draw a term loan advance in an aggregate principal amount not less than \$15.0Â million, provided that the aggregate amount of the term loan advances made under tranche 2 do not exceed \$15.0Â million on or prior to December 31, 2023. The Second Amendment re-allocated the total future consideration of the Loan Agreement to the future 11Table of Contents tranches extending through September 2026, subject to the terms and conditions of the Loan Agreement. The Second Amendment did not change the total aggregate maximum principal amount to be drawn under the Loan Agreement, which remains as up to \$200.0Â million. The Company evaluated the Second Amendment as a modification under relevant accounting guidance, and based on that analysis and the immaterial change in cash flows on current outstanding debt, it was determined that there was no material accounting impact. Upon closing of the Second Amendment, the Company

The outstanding principal balance of the Term Loan Facility bears interest payable in cash at a floating rate per annum equal to the greater of (i) 7.25% and (ii) the sum of the Prime Rate (which is capped at 7.25%) and 1.75%. Accrued interest is payable monthly following the funding of each term loan advance. In addition, the principal balance of the Term Loan Facility will bear a payment-in-kind interest at the rate of 1.50% ($\text{\AA}\text{\AA}\text{\AA}\text{\AA}\text{\AA}$ PIK Interest $\text{\AA}\text{\AA}\text{\AA}\text{\AA}\text{\AA}$), which PIK Interest will be added to the outstanding principal balance of the Term Loan Facility on each interest payment date. Borrowings under the Loan Agreement are repayable in monthly interest-only payments through September 2026. After the interest-only payment period, borrowings under the Loan Agreement are repayable in equal monthly payments of principal and accrued interest until October 2027. At the Company's option, the Company may prepay all or a portion of the outstanding borrowings, subject to a prepayment fee of 3.0% of the principal amount if prepayment had occurred during the 12 months following the closing date, 2.0% after 12 months following the closing date but prior to 36 months following the closing date, and 1.0% thereafter. The Loan Agreement contains customary facility fees, events of default and representations, warranties and affirmative and negative covenants, including a financial covenant requiring the Company to maintain unrestricted cash in an amount not less than 35% of the aggregate outstanding secured obligations under the Loan Agreement in accounts subject to a control agreement in favor of the Agent (the "Unrestricted Cash $\text{\AA}\text{\AA}\text{\AA}\text{\AA}\text{\AA}$ ") at all times which commenced on January 1, 2024. In addition, the Loan Agreement also contains a financial covenant that beginning on the later of (i) July 1, 2024 and (ii) the date on which the aggregate outstanding principal amount of the Term Loan Facility is equal to or greater than \$100.0 million, the Company is required to satisfy one of the following requirements: (1) achieve a minimum amount of trailing three-month net product revenue tested on a monthly basis, (2) maintain a market capitalization in excess of \$1.2A billion and Unrestricted Cash in an amount no less than 50% of the outstanding amount under the Term Loan Facility, or (3) maintain Unrestricted Cash in an amount no less than 85% of the outstanding amount under the Term Loan Facility. The Company paid a \$0.5A million facility charge and incurred debt issuance costs of \$1.5A million upon closing of the Loan Agreement. The Loan Agreement also provides for a final payment, payable upon maturity or the repayment of the obligations in full or in part (on a pro rata basis), equal to 4.95% of the aggregate principal amount of Term Loans advanced to the Company and repaid on such date, which is being accrued on the Company's consolidated balance sheet. The amount accrued for the final payment is \$0.6A million as of June 30, 2024 and \$0.5 million as of March 31, 2024. Unamortized debt issuance costs are recorded as a reduction of the carrying amount on the term loan and amortized as interest expense using the effective-interest method. In addition, unamortized deferred financing costs of \$1.1A million and \$1.2A million were recorded in other assets as of June 30, 2024 and March 31, 2024, respectively, related to the Company's right to borrow additional amounts from Hercules in the future and amortized to interest expense over the relevant draw period on a straight-line basis. Interest expense for the three months ended June 30, 2024 was \$1.4A million. The summary of obligations under the term loan as of June 30, 2024 and March 31, 2024 consisted of the following (in thousands): June 30, 2024 March 31, 2024 Principal loan balances \$45,923A \$45,749A Facility charge and diligence fee (251) (266) Unamortized issuance costs (1,123) (1,191) Accumulated end of term fee 643A 517A A A A A Long term debt, net \$45,192A \$44,809A The annual principal payments due under the Loan Agreement as of June 30, 2024 and March 31, 2024 were as follows: 12Table of ContentsJune 30, 2024March 31, 202420242024A A A A 2025A A A A 2026A A A A 202720,145A 20,145A Thereafter27,769A 27,769A Totals\$47,914A \$47,914A The table of future payments of long-term debt excludes the end of term charge of \$2.2 million, which is due upon the maturity of the loan 8 Stockholders' equityCommon stockAs of June 30, 2024 and March 31, 2024, the Company's certificate of incorporation, as amended and restated, authorized the Company to issue up to 150,000,000 shares of common stock, par value \$0.001 per share. The Company has reserved for common stock for the exercise of outstanding stock options and the vesting of restricted stock units, the number of shares remaining available for grant under the Company's 2018 Omnibus Incentive Compensation Plan and the Company's Employee Stock Purchase Plan (see Note 10) and the exercise of the outstanding warrants to purchase shares of common stock as follows: June 30, 2024March 31, 2024Stock options, issued and outstanding10,157,054A 8,652,256A Restricted and performance stock units3,370,183A 2,397,890A Stock options and restricted stock units, future issuance1,988,217A 2,284,141A Employee stock purchase plan, available for future grants3,405,175A 2,738,208A Pre-IPO warrants to purchase common stock497,344A 497,344A Pre-funded warrants10,211,969A 5,281,616A A A A A Total shares of common stock reserved for future issuance29,629,942A 21,851,455A Undesignated preferred stockAs of June 30, 2024, the Company's certificate of incorporation, as amended and restated, authorized the Company to issue up to 10,000,000 shares of undesignated preferred stock, par value \$0.001 per share. There were no undesignated preferred shares issued or outstanding as of June 30, 2024. ATM programOn August 3, 2023, the Company and Leerink Partners LLC (the "Current Agent") entered into a sales agreement, which was subsequently amended on May 16, 2024 (as so amended, the "2023 Sales Agreement"). Under the 2023 Sales Agreement, the Company may sell, from time to time, at its option, up to an aggregate of \$100.0 million of share of the Company's common stock, \$0.001 par value shares (the "Shares"), through the Current Agent, as the Company's sales agent. Any Shares to be offered and sold under the 2023 Sales Agreement will be issued and sold (i) by methods deemed to be an $\text{\AA}\text{\AA}\text{\AA}\text{\AA}\text{\AA}$ at the market offering $\text{\AA}\text{\AA}\text{\AA}\text{\AA}\text{\AA}$ (an $\text{\AA}\text{\AA}\text{\AA}\text{\AA}\text{\AA}$ ATM $\text{\AA}\text{\AA}\text{\AA}\text{\AA}\text{\AA}$) as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or if authorized by the Company, in negotiated transactions or block trades, and (ii) pursuant to a registration statement on Form S-3 filed by the Company with the Securities and Exchange Commission on August 3, 2023, as amended for an offering of various securities, including shares of the Company's common stock, preferred stock, debt securities, warrants and/or units for sale to the public in one or more public offerings. Subject to the terms of the 2023 Sales Agreement, the Current Agent will use reasonable efforts to sell the Shares from time to time, based upon the Company's instructions (including any price, time or size limits or other customary parameters or 13Table of Contentsconditions the Company may impose). The Company will pay the Current Agent a commission of up to 3.0% of the gross proceeds from the sale of the Shares. The Company has also agreed to provide the Current Agent with customary indemnification rights. During the three months ended June 30, 2024, the Company did not issue or sell any shares under the 2023 Sales Agreement. The Company cannot provide any assurances that it will issue any additional Shares pursuant to the 2023 Sales Agreement. Equity offeringsOn June 14, 2024, the Company completed a private placement transaction (the "Private Placement") pursuant to which the Company sold (a) 5,668,937 shares of the Company's common stock, at an offering price of \$8.82, and (b) in lieu of common stock to certain investors, pre-funded warrants to purchase 5,669,578 shares of the Company's common stock at an offering price of \$8.819 per warrant (the "2024 Pre-funded Warrants"). The Company received aggregate net proceeds in the Private Placement of approximately \$96.7 million after deducting placement agent fees and other offering expenses payable by the Company of approximately \$3.3 million. 9 Pre-funded WarrantsThe Company's pre-funded warrants are exercisable at any time after the date of issuance. Unless otherwise modified by a holder of a pre-funded warrant, no holder may exercise a pre-funded warrant if such holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of the Company's common stock outstanding immediately after giving effect to such exercise. A holder of the 2024 Pre-funded Warrants may increase or decrease this percentage to any other percentage not in excess of 9.99%, whereas a holder of the Company's pre-funded warrants issued prior to the 2024 Pre-funded Warrants, may increase or decrease this percentage up to 19.99%, by providing at least 61 days' prior notice to the Company. The 10,211,969 shares of the Company's common stock underlying the pre-funded warrants issued by the Company are not included in the number of issued and outstanding shares of the Company's common stock outstanding as reported on the consolidated balance sheet, though they are included in the Company's annual pool increase calculation as well as the weighted average outstanding common stock in the calculation of basic and diluted net loss per share, as described below in Note 11. During the three months ended June 30, 2024, a holder of the Company's pre-funded warrants exercised 739,225 of its pre-funded warrants for an exercise price of \$0.001 per pre-funded warrant and the Company issued 739,225 shares of Common Stock in exchange thereof. 10 Stock-based compensationStock-based compensation expenseStock-based compensation expense was classified in the consolidated statements of operations as follows: Three Months Ended June 30, 20242023Research and development\$4,226A \$3,298A Selling, general and administrative\$5,249A \$5,488A 9,475A \$8,846A A A A The following table summarizes stock-based compensation expense by award type for the three months ended June 30, 2024 and 2023: 14Table of ContentsThree Months Ended June 30, 20242023Stock options\$5,733A \$5,614A Restricted and performance stock units\$3,742A 3,232A \$9,475A \$8,846A 2015 Enterprise Management Incentive Share Option PlanThe 2015 Enterprise Management Incentive Share Option Plan of Replimune UK (the "2015 Plan") provided for Replimune UK to grant incentive stock options, non-statutory stock options, stock awards, stock units, stock appreciation rights and other stock-based awards. Incentive stock options were granted under the 2015 Plan only to the Company's employees, including officers and directors who were also employees. Non-statutory stock options were granted under the 2015 Plan to employees, members of the board of directors, outside advisors and consultants of the Company. 2017 Equity Compensation PlanIn July 2017, in conjunction with reorganization by Replimune Limited, pursuant to which each shareholder thereof exchanged their outstanding shares in Replimune Limited for shares in Replimune Group, Inc., on a one-for-one basis (the "Reorganization"), the 2015 Plan was terminated, and all awards were cancelled with replacement awards issued under the 2017 Equity Compensation Plan (the "2017 Plan"). Subsequent to the Reorganization, no additional grants have been or will be made under the 2015 Plan and any outstanding awards under the 2015 Plan have continued, and will continue with their original terms. The Company concluded that the cancellation of the 2015 Plan and issuance of replacement awards under the 2017 Plan was a modification with no change in the material rights and preferences and therefore no recorded change in the fair value of each respective award. The Company's 2017 Plan provides for the Company to grant incentive stock options or non-statutory stock options, stock awards, stock units, stock appreciation rights and other stock-based awards. Incentive stock options were granted under the 2017 Plan only to the Company's employees, including officers and directors who were also employees. Restricted stock awards and non-statutory stock options were granted under the 2017 Plan to employees, officers, members of the board of directors, advisors and consultants of the Company. The maximum number of common shares that may be issued under the 2017 Plan was 2,659,885, of which none remained available for future grants as of June 30, 2024. Shares with respect to which awards have expired, terminated, surrendered or cancelled under the 2017 Plan without having been fully exercised will be available for future awards under the 2018 Plan referenced below. In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for the grant of awards. 2018 Omnibus Incentive Compensation PlanOn July 9, 2018, the Company's board of directors adopted, and the Company's stockholders approved the 2018 Omnibus Incentive Compensation Plan (the "2018 Plan"), which became effective immediately prior to the effectiveness of the registration statement filed in connection with the Company's initial public offering. The 2018 Plan provides for the issuance of incentive stock options, non-qualified stock options, stock awards, stock units, stock appreciation rights and other stock-based awards. The number of shares of common stock initially reserved for issuance under the 2018 Plan is 3,617,968 shares. If any options or stock appreciation rights, including outstanding options and stock appreciation rights granted under the 2017 Plan (up to 2,520,247 shares), terminate, expire, or are canceled, forfeited, exchanged, or surrendered without having been exercised, or if any stock awards, stock units or other stock-based awards, including outstanding awards granted under the 2017 Plan, are forfeited, terminated, or otherwise not paid in full in shares of common stock, the shares of the Company's common stock subject to such grants will be available for purposes of the 2018 Plan. The number of shares reserved for issuance under the 2018 Plan will increase automatically on the first day of each April equal to 4.0% of the total number of shares of common stock outstanding on the last trading day in the immediately preceding fiscal year, which includes for these purposes, the 5,281,616 shares issuable upon exercise of those pre-funded warrants as of March 31, 2024, as described in Note 9 to these consolidated financial statements, or such lesser amount as determined by the Board. On April 1, 2024, the number of shares reserved for issuance under the 2018 Plan automatically increased by 2,667,868 shares pursuant to the terms of the 2018 Plan and based on total number of shares of common stock outstanding on March 31, 2024. As of June 30, 2024, 1,988,217 shares remained available for future grants under the 2018 Plan. 15Table of ContentsThe 2015 Plan, the 2017 Plan and the 2018 Plan are administered by the board of directors or, at the discretion of the board of

term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. The following table presents, on a weighted-average basis, the assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors: Three Months Ended June 30, 2024 2023 Risk-free interest rate 4.43% 3.60% Expected term (in years) 6.06 0. Expected volatility 76.3% 74.1% Expected dividend yield 0% 0% Stock options The following table summarizes the Company's stock option activity: Number of Shares Weighted Average Exercise Price Weighted Average Contractual Term (Years) Aggregate Intrinsic Value Outstanding as of March 31, 2024 652,256 \$16.94 6.61 \$5,748 Granted 1,744,401 \$7.73 Exercised (22,860) \$2.91 Cancelled (216,743) \$17.82 Outstanding as of June 30, 2024 157,054 \$15.37 6.84 8,837 Options exercisable as of June 30, 2024 152,459 \$16.16 5.40 \$6,541 Options vested and expected to vest as of June 30, 2024 157,054 \$15.37 6.84 8,837 As of June 30, 2024, there was \$35.74 million of unrecognized compensation cost related to unvested common stock options, which is expected to be recognized over a weighted average period of 2.8 years. The weighted average grant-date fair value of stock options granted during the three months ended June 30, 2024 and 2023 was \$5.37 and \$12.09, respectively. The aggregate intrinsic value of stock options exercised during the three months ended June 30, 2024 was \$0.1 million. Restricted and performance stock units 7 Table of Contents In January 2024, the Board approved a one-time PSU award under the 2018 Plan for all employees at the vice president level and below as of January 31, 2024, subject to non-market performance and service conditions. The grants will become vested upon the achievement of the approval of the Company's first Biologics License Application (BLA) for RP1 by the Food and Drug Administration (FDA) no later than June 30, 2026. If the Company does not achieve the approval of the Company's first BLA for RP1 before the expiration of June 30, 2026 then no PSU will be earned or vested. The grant date fair value for the PSUs is determined based on the market price of the Company's common stock on the grant date and is recognized over the requisite service period if and when the achievement of such performance condition is determined to be probable by the Company. The Company reassesses the probability of achieving the performance condition at each reporting period. As of June 30, 2024, the Company has not recognized any expense related to PSUs. A summary of the changes in the Company's RSUs and PSUs during the three months ended June 30, 2024 is as follows: Number of Restricted Shares Weighted Average Grant Date Fair Value Outstanding as of March 31, 2024 397,890 17.97 560,527 7.72 463,841 22.03 Cancelled (124,393) 15.23 Outstanding as of June 30, 2024 370,183 12.77 As of June 30, 2024, there was \$34.5 million of unrecognized compensation cost related to unvested restricted stock units, which is expected to be recognized over a weighted average period of 2.8 years. Of the \$34.5 million of total unrecognized compensation cost, performance based awards tied to the achievement of a company milestone account for approximately \$4.8 million. The performance based awards will vest upon achievement of the performance milestone. The remaining unrecognized compensation cost is related to restricted stock units which vest over time. 11 Net loss per share Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Three Months Ended June 30, 2024 2023 Numerator: Net loss (\$53,772) (\$49,555) Denominator: Weighted average common shares outstanding, basic and diluted 69,185,885 66,367,702 Net loss per share, basic and diluted (\$0.78) (\$0.75) The 10,211,969 shares of the Company's common stock issuable upon exercise of pre-funded warrants described in Note 9 to these consolidated financial statements are included as outstanding common stock in the calculation of basic and diluted net loss per share. The Company's potentially dilutive securities, which include stock options, unvested restricted and performance stock units and warrants to purchase shares of common stock that resulted from the conversion of warrants to purchase shares of series seed preferred stock existing before the Company's IPO, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: 18 Table of Contents Three Months Ended June 30, 2024 2023 Options to purchase common stock 10,157,054 9,067,305 Unvested restricted and performance stock units 3,370,183 2,069,415 Warrants to purchase common stock 497,344 497,344 14,024,581 11,634,064 12 Significant agreements Agreement with Bristol-Myers Squibb Company In February 2018, the Company entered into an agreement with Bristol-Myers Squibb Company (BMS). Pursuant to the agreement, BMS will provide to the Company, at no cost, a compound for use in the Company's ongoing clinical trial of RP1. Under the agreement, the Company will sponsor, fund and conduct the clinical trial in accordance with an agreed-upon protocol. BMS granted the Company a non-exclusive, non-transferable, royalty-free license (with a right to sublicense) under its intellectual property to its compound in the clinical trial and agreed to supply its compound, at no cost to the Company, for use in the clinical trial. In January 2020, this agreement was expanded to cover an additional cohort of 125 patients with anti-PD-1 failed melanoma. Unless earlier terminated, the agreement will remain in effect until (i) the completion of the clinical trial, (ii) all related clinical trial data have been delivered to both parties and (iii) the completion of any statistical analyses and bioanalyses contemplated by the clinical trial protocol or any analysis otherwise agreed upon by the parties. The agreement may be terminated by either party (x) in the event of an uncured material breach by the other party, (y) in the event the other party is insolvent or in bankruptcy proceedings or (z) for safety reasons. Upon termination, the licenses granted to the Company to use BMS's compound in the clinical trial will terminate. In April 2019, the Company entered into a separate agreement with BMS on terms similar to the terms set forth in the agreement described above, pursuant to which BMS will provide to the Company, at no cost, nivolumab for use in the Company's Phase 1 clinical trial of RP2 in combination with nivolumab. Agreement with Regeneron Pharmaceuticals, Inc. In May 2018, the Company entered into an agreement with Regeneron Pharmaceuticals, Inc. (Regeneron). Pursuant to the agreement the Company agreed to undertake one or more clinical trials with Regeneron for the administration of the Company's product candidates in combination with cemiplimab, an anti-PD-1 therapy developed by Regeneron, across multiple solid tumor types. The first of which, agreed in June 2018, is the Company's ongoing clinical trial testing RP1 in combination with cemiplimab versus cemiplimab alone in patients with CSCC. Each clinical trial will be conducted pursuant to an agreed study plan which, among other things, will identify the name of the sponsor and which party will manage the particular study, and include the protocol, the budget and a schedule of clinical obligations. Pursuant to the terms of the agreement, each party granted the other party a non-exclusive license of their respective intellectual property and agreed to contribute the necessary resources needed to fulfill their respective obligations, in each case, under the terms of agreed study plans. The Company does not expect any further reimbursements from Regeneron related to the initial study plan of June 2018 and the CERPASS trial. The agreement contains representations, warranties, undertakings and indemnities customary for a transaction of this nature. The agreement also contains certain time-based covenants that restrict the Company from entering into a third-party arrangement with respect to the use of its product candidates in combination with an anti-PD-1 therapy and that restrict Regeneron from entering into a third-party arrangement with respect to the use of cemiplimab in combination with an HSV-1 virus, in each case, for the treatment of a tumor type that is the subject of a clinical trial to which the covenants apply. Unless otherwise mutually agreed in a future study plan, these covenants are only applicable to the Company's ongoing Phase 2 clinical trial in CSCC. The agreement may be terminated by either party if (i) there is no active study plan for which a final study report has not been completed and the parties have not entered into a study plan for an additional clinical trial within a period of time after the delivery of the most recent final study report or (ii) in the event of a material breach. 19 Table of Contents The agreement with Regeneron is accounted for under ASC 808, Collaborative Arrangements (ASC 808), as both parties are active participants and each party pays its own compound costs and share equally in development costs. The Company accounts for costs incurred as part of the study, including costs to supply compounds for use in the study, as research and development expenses within the consolidated statement of operations. The Company recognizes any amounts received from Regeneron in connection with this agreement as an offset to research and development expense within the consolidated statement of operations. In July 2022, Regeneron informed the Company that the costs of the study have reached the initial budget for the initial study plan of June 2018 and that Regeneron's reimbursement of CERPASS study costs to the Company have completed in the period ending June 30, 2022 in relation to the initial study budget. As a result of this notice from, and the ongoing communications with, Regeneron, the Company has not recorded any cost-sharing reimbursements from Regeneron in prepaid expenses and other current assets in the consolidated balance sheet or as an offset to research and development expense within the consolidated statement of operations since Regeneron informed it that Regeneron's reimbursement of CERPASS study costs have completed. The Company does not expect any further reimbursements from Regeneron related to the initial study plan of June 2018. 13 Collaboration and other arrangements Roche In December 2022, the Company entered into a Master Clinical Trial Collaboration and Supply Agreement with Roche in relation to the Company's RP2 and RP3 programs in colorectal cancer, or CRC, and hepatocellular carcinoma, or HCC. Under the agreement, the companies intended to collaborate in 30 patient cohort signal finding studies in third-line, or 3L, CRC and in first- and second-line, or 1L and 2L, respectively, HCC. Following the Company's re-prioritization of its product development portfolio in December 2023, the Company has agreed with Roche to terminate the CRC collaboration and pursue the 2L cohort in HCC with RP2 only. Roche has expressed its intent to continue to supply its currently approved drugs, atezolizumab and bevacizumab for the 2L cohort in HCC but is unlikely to share costs following the Company's re-prioritization. The Company is in discussions with Roche about revising these agreements following the Company's changes to its RP2 and RP3 development plans. Under the terms of the initial agreement the Company retained the responsibility of operating the clinical trials as well as retaining all the rights to the development and commercialization of its product candidates. The agreement may be terminated by either party upon sixty days prior written notice to the other party. The agreement with Roche is accounted for under ASC 808, Collaborative Arrangements (ASC 808), as both parties are active participants and each party pays its own compound costs. The Company accounts for costs incurred as part of the study, including costs to supply compounds for use in the study, as research and development expenses within the consolidated statement of operations. The Company will recognize any amounts received from Roche in connection with this agreement as an offset to research and development expense within the consolidated statement of operations. During the three months ended June 30, 2024 and 2023, the Company did not make any payments to Roche under the terms of the agreement. The Company recorded \$0.0 million and \$0.7 million as an offset to research and development expenses during the three months ended June 30, 2024, and 2023, respectively. During the three months ended June 30, 2024 and 2023, the Company received payments under the terms of the agreement from Roche of \$1.8 million and \$0.2 million, respectively. As of June 30, 2024 and March 31, 2024, the Company recorded \$0.0 million and \$1.8 million as receivables from Roche in connection with this agreement, respectively. Incyte In July 2023, the Company entered into a Clinical Trial Collaboration and Supply Agreement with Incyte Corporation, or Incyte. Under the agreement, the companies will collaborate in a signal finding study in which Incyte will initiate and sponsor a clinical trial of INCB99280 (oral PD-L1 inhibitor) and RP1 in approximately 40 patients with unresectable, high risk CSCC in the neoadjuvant setting. Under the terms of the agreement, the Company will supply Incyte with RP1 for the study and share costs of the study equally with Incyte. The agreement may be terminated by either party upon (i) a material breach not reasonably cured within thirty (30) days; (ii) the discontinuation of development of its clinical drug candidate; (iii) the unethical or illegal business practices of the other party; or (iv) if the parties have not agreed on the protocol or budget within ninety (90) days of the effective date of the agreement. In addition, the Company may terminate the agreement upon the inappropriate or unsafe use of the RP1 product candidate. On July 30, 2024, Incyte announced it has discontinued further development of its oral small molecule PD-L1 inhibitor, which was the intended study drug in the Company's planned collaboration with Incyte. On August 1, 2024, the Company received notice of termination of the Clinical Trial Collaboration and Supply Agreement from Incyte. During the year ended March 31, 2024, the Company did not make any payments to, or receive any payments from, Incyte under the terms of this agreement. Additionally, no costs were recorded to research and development expenses during the three months ended June 30, 2024 related to this agreement. Amgen In August 2023 the Company entered into a Settlement Agreement with Amgen and mutually agreed to terminate the Company's challenges to Amgen's patents. In connection with the Settlement Agreement, the Company entered into a License and Covenant Agreement with Amgen in which the Company agreed to pay Amgen low single-digit royalty payments on net sales of its products that, but for the license, could be found to infringe a valid Amgen patent on a country-by-country and product-by-product basis. 14 Commitments and contingencies Leases The table below presents the lease-related costs which are included in the consolidated statements of operations for the three months ended June 30, 2024 and 2023: Three Months Ended June 30, 2024 2023 Lease cost Finance lease costs Amortization of right-to-use asset \$607.4 \$607.4 Interest on lease liabilities \$534.4 \$544.4 Operating lease costs \$281.4 \$280.4 Total lease cost \$1,422.4 \$1,431.4 The following table summarizes the classification of lease costs in the consolidated statement of operations for the three months ended June 30, 2024 and 2023 as follows: Three Months Ended June 30, 2024 2023 Finance Lease Costs \$4.4 Research and development \$607.4 \$607.4 Other income (expense) \$534.4 \$544.4 Operating Lease Costs Research and development \$229.4 \$229.4 Selling, general and administrative \$52.4 \$51.4 Total lease cost \$1,422.4 \$1,431.4 The following table summarizes the maturity of the Company's lease liabilities on an undiscounted cash flow basis and a reconciliation to the operating and financing lease liabilities recognized on its balance sheet as of June 30, 2024: 21 Table of Contents June 30, 2024 Operating leases Finance lease Total 2025 (remaining nine months) \$872.4 \$2,050.4 \$2,922.4 2026 1,714.2 799.4 3,970.4 2027 1,374.2 883.4 4,020.4 2028 1,086.4 2,969.4 4,055.4 2029 1,005.4 3,058.4 4,063.4 Thereafter 925.4 31,995.4 32,920.4 Total lease payments \$6,196.4 \$5,754.5 \$1,950.4 Less: interest 1,432.4 19,760.4 21,192.4 Total lease liabilities \$4,764.4 \$25,994.4 \$30,758.4 The following table provides lease disclosure as of June 30, 2024 and March 31, 2024: June 30, 2024 March 31, 2024 Leases Right-to-use operating lease asset \$4,475.4 \$4,635.4 Right-to-use finance lease asset \$6,629.4 \$7,237.4 Total lease assets \$41,104.4 \$41,872.4 Operating lease liabilities, current \$1,164.4 \$1,161.4 Finance lease liabilities, current \$2,738.4 2,718.4 Operating lease liabilities, non-current \$3,600.4 3,771.4 Finance lease liabilities, non-current \$2,256.4 2,314.0 Total lease liabilities \$30,758.4 \$31,060.4 The following table provides lease disclosure for the three months ended June 30, 2024 and 2023: Three Months Ended June 30, 2024 2023 Other information Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases \$152.4 \$263.4 Operating cash flows from finance leases \$534.4 \$544.4 Financing cash flows from finance leases \$134.4 \$104.4 Right-to-use asset obtained in exchange for new operating lease liabilities \$6.4 \$6.4 Weighted-average remaining lease term - operating leases 5.6 years 6.3 years Weighted-average remaining lease term - financing leases 15.3 years 16.1 years Weighted-average discount rate - operating leases 10.3% 10.3% Weighted-average discount rate - financing leases 8.3% 8.3% The variable lease costs and short-term lease costs were insignificant for the three months ended June 30, 2024 and 2023. Manufacturing commitments The Company has entered into an agreement with a contract manufacturing organization to provide clinical trial products. As of June 30, 2024 and March 31, 2024, the Company had committed to minimum payments under these arrangements totaling \$0.9 million and \$0.9 million, respectively. Indemnification agreements 22 Table of Contents In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its executive management team and its board of directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and therefore it has not accrued any liabilities related to such obligations in its consolidated financial statements as of June 30, 2024 or March 31, 2024. Legal proceedings The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities. 15 Income taxes The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company's tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The

amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.

16 Geographic informationThe Company operates in two geographic regions: the United States (Massachusetts) and the United Kingdom (Oxfordshire). Information about the Company's long-lived assets held in different geographic regions is presented in the tables below:

June 30, 2024	March 31, 2024	United States	\$10,006A	\$8,992A	United Kingdom	1,397A	1,491A	\$11,403A	\$10,483A
---------------	----------------	---------------	-----------	----------	----------------	--------	--------	-----------	-----------

23Table of ContentsItem 2. Management's discussion and analysis of financial condition and results of operations.You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited consolidated financial statements and related notes appearing in Part A I, A Item 1 of this Quarterly Report on Form A 10-Q, or this Quarterly Report, and with our audited consolidated financial statements and notes thereto for the year ended March A 31, 2024, included in our Annual Report on Form A 10-K for the fiscal year ended March A 31, 2024. In addition to historical information, some of the statements contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, constitute forward-looking statements within the meaning of Section A 27A of the Securities Act of 1933, as amended, and Section A 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. We have based these forward-looking statements on our current expectations and projections about future events. The following information and any forward-looking statements should be considered in light of factors discussed elsewhere in this Quarterly Report, particularly including those risks identified in Part A II, A Item 1A "Risk Factors" and our other filings with the Securities Exchange Commission, or SEC. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Quarterly Report. Statements made herein are as of the date of the filing of this Quarterly Report with the SEC and should not be relied upon as of any subsequent date. Even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Quarterly Report, they may not be predictive of results or developments in future periods. We disclaim any obligation, except as specifically required by law and the rules A of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

OverviewGeneralWe are a clinical-stage biotechnology company committed to applying our leading expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through our novel oncolytic immunotherapies. Our proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class, which we intend to establish as the second cornerstone of immune-based cancer treatments, alongside checkpoint blockade. Oncolytic immunotherapy exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response. Our product candidates incorporate multiple mechanisms of action into a practical "one-off-the-shelf" approach that is intended to maximize the immune response against a patient's cancer and to offer significant advantages over other approaches to inducing anti-tumor immunity, including personalized vaccine approaches. We believe that the bundling of multiple approaches for the treatment of cancer into single therapies will increase clinical efficacy and simplify the development path of our product candidates, while also improving patient outcomes at a lower cost to the healthcare system than the use of multiple different drugs. Our proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is intended to have unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. Our product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, and, with an attractive safety profile the RPx platform is expected to have the versatility to be developed alone or combined with a variety of other treatment options. We currently have three RPx product candidates in our development pipeline, RP1 (vusolimogene odeparepvec), our lead product candidate, RP2 and RP3. Although our fiscal year ends March 31st, our programs and program updates are reported on a calendar year basis. We are conducting a number of clinical trials of RP1, both as a monotherapy and in combination with anti-PD-1 therapy, with a focus on establishing a major skin cancer franchise.

24Table of ContentsOur leading clinical trial of RP1 is our IGNYTE trial, a multi-cohort Phase 1/2 clinical trial being conducted in collaboration with Bristol Myers Squibb Company, or BMS, under which BMS has granted us a non-exclusive, royalty-free license to, and is supplying at no cost, its anti-PD-1 therapy, nivolumab, for use in combination with RP1. The leading tumor specific cohort in the IGNYTE trial is our registration directed Phase 2 expansion cohort enrolling patients with anti-PD-1 failed cutaneous melanoma who are being treated with RP1 in combination with nivolumab. The anti-PD1 failed melanoma cohort from the IGNYTE clinical trial includes 140 patients who received RP1 plus nivolumab after confirmed progression while being treated with at least 8 weeks of prior anti-PD1 therapy (+/- anti-CTLA-4). The primary analysis by independent central review was triggered once all patients had been followed for at least 12 months. The topline results showed the overall response rate was 33.6% by modified RECIST 1.1 criteria, the primary endpoint as defined in the protocol, and 32.9% by RECIST 1.1 criteria, an additional analysis requested by the U.S. Food and Drug Administration, or FDA. Responses from baseline were highly durable, with all responses lasting more than 6 months and median duration of response exceeding 35 months. RP1 combined with nivolumab continues to be well-tolerated, with mainly Grade 1 or 2 "on-target" side effects, observed. The Company plans to submit the full primary analysis data from the anti-PD1 failed melanoma cohort including key secondary endpoint data and subgroups for presentation at an upcoming medical congress. Following a Type C meeting with the FDA, a confirmatory study design concept consisting of a 2-arm randomized trial with physician's choice of treatment as a comparator arm in anti-PD1 failed melanoma patients was agreed. The FDA requested that the Phase 3 confirmatory trial be underway at the time of a BLA submission under the accelerated approval pathway. In May 2024, we reported completing a successful Type C meeting with the FDA that confirmed alignment on our Chemistry, Manufacturing and Controls, or CMC, plans to support an IGNYTE anti-PD1 failed melanoma BLA submission. A pre-BLA meeting with the FDA is planned for September 2024 and a BLA submission for RP1 in combination with nivolumab in anti-PD1 failed melanoma is planned for the second half of 2024. In our non-melanoma skin cancer, or NMSC, cohort of the IGNYTE clinical trial, we provided a data update in December 2023 from the first 30 patients with at least 6 months of follow up including patients with cutaneous squamous cell carcinoma, or CSCC, Merkel cell carcinoma, or MCC, basal cell carcinoma, and angiosarcoma in this cohort. The data showed that treatment with RP1 in combination with nivolumab led to an ORR of 30% which is consistent with data from the anti-PD1 failed melanoma cohort with approximately one-third of patients responding and 60% demonstrating clinical benefit. The combination of RP1 and nivolumab was well tolerated in this patient population with a safety profile consistent with the overall experience seen with this treatment regimen to date. Enrollment remains open in this cohort. Furthering development of our RP1 clinical candidate, we have open for enrollment a Phase 1b/2 clinical trial of single agent RP1 in solid organ transplant recipients with skin cancers, including CSCC, which is referred to herein as ARTACUS or the ARTACUS trial, which we believe to be potentially registrational (in its own right or, subject to discussion with regulatory authorities, following enrollment of additional patients, including as a potential label expansion after an initial approval of RP1 in a different indication). We are currently enrolling up to 65 patients in the ARTACUS trial to assess the safety and efficacy of RP1 in liver, kidney, heart, lung, and hematopoietic cell transplant recipients with skin cancers. In November 2023 we presented initial data from the ARTACUS clinical trial of RP1 monotherapy in solid organ transplant recipients with skin cancers at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting. The data included 23 evaluable patients with CSCC (n=20) and Merkel cell carcinoma (n=3), demonstrating an overall response rate, or ORR of 34.5% and a complete response, or CR of 21%. RP1 monotherapy was well tolerated in these patients and the safety profile was similar to that observed in our other RP1 clinical trials in patients who are not immune suppressed. No immune-mediated adverse events or evidence of allograft rejection were observed. This data was also presented during oral presentation at the American Association of Cancer Research 2024 Annual Meeting in April 2024. We continue to enroll patients into this trial. As previously reported, the CERPASS clinical trial of RP1 in patients with CSCC continues as planned to assess duration of response, or DOR, progression free survival and overall survival with greater maturity. We are also developing or have been developing additional product candidates, RP2 and RP3, that have been further engineered to enhance anti-tumor immune responses and are intended to address additional tumor types, including traditionally less immune responsive tumor types. In addition to the expression of GALV-GP R(-) and human GM-CSF as in RP1, RP2 has been engineered to express an antibody-like molecule intended to block the activity of CTLA-4, a protein that inhibits the full activation of an immune response, including to tumors. RP3 has been engineered with the intent to further stimulate an anti-tumor immune response through activation of immune co-stimulatory pathways through the additional expression of the ligands for CD40 and 4-1BBL, as well as anti-CTLA-4 and GALV-GP R(-), but without the expression of GM-CSF. We continue the development of our clinical candidate RP2 with a focus on establishing a rare cancer franchise. Notably, as previously reported, from our Phase-1 clinical trial of RP2 alone and in combination with nivolumab, we have seen durable responses from a monotherapy cohort in a variety of difficult to treat tumors as well as in combination with anti-PD1 and in particular in patients with uveal melanoma. In November 2023, we presented updated data from a cohort of metastatic uveal melanoma patients during a Plenary Session at the 20th Annual International Society for Melanoma Research Congress. The updated data showed RP2 led to an ORR of 29.4% (5 of 17 patients; one of the responding patients was treated with RP2 monotherapy and four of the responding patients were treated with RP2 combined with nivolumab), including responses in patients with liver, lung, and bone metastases. The median DOR at the data cutoff was 11.47 months (range of 2.78 to 21.22 with responses ongoing). Nearly all patients (15 of 17, or 88.2%) in the study had progressed on or after immunotherapy with 25Table of Contents12 of 17 patients (70.6%) having previously received both anti-PD1 and anti-CTLA-4 therapies, including four of the responding patients. RP2 was generally well tolerated both as monotherapy and in combination with nivolumab with no additive adverse events observed. The most common grade 1 or 2 treatment related adverse events, or TRAEs, overall in both cohorts were pyrexia, chills, fatigue, hypotension and pruritis. Six patients had grade 3 TRAEs, including two cases of hypotension. There were no grade 4 or 5 TRAEs. In June 2024, we presented that the disease control rate for this cohort of patients was 58.8%. We have finalized the protocol based on FDA input and begun trial initiation activities for a registration-directed study of RP2 in metastatic uveal melanoma in patients who are immune checkpoints inhibitor-naïve. The study is a randomized trial of RP2 in combination with nivolumab vs. ipilimumab and nivolumab, or nivolumab for those ineligible for ipilimumab. The Company continues its signal finding trial of RP2 in combination with atezolizumab and bevacizumab in the 2L setting of patients with hepatocellular carcinoma (HCC) in collaboration with Roche. This Phase 2 clinical trial is expected to dose its first patient in the second half of 2024. RP1, RP2 and RP3 are administered by direct injection into solid tumors, guided either visually or by ultrasound, computerized tomography or other imaging methods. We believe that direct injection maximizes virus-mediated tumor cell death, provides the most efficient delivery of virus-encoded immune activating proteins into the tumor with the goal of activating systemic immunity, and limits the systemic toxicities that could be associated with intravenous administration. Activation of systemic immunity through local administration is intended to lead to the induction of anti-tumor immune responses leading to clinical response of tumors that have not themselves been injected.

FinancialSince our inception, we have devoted substantially all of our resources to developing our proprietary RPx platform, building our intellectual property portfolio, conducting research and development of our product candidates, business planning, raising capital and providing general and administrative support for our operations. To date, we have incurred significant operating losses and we have financed our operations primarily with proceeds from the sale of equity securities and to a lesser extent, the proceeds from the issuance of debt securities. Our ability to generate product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more of our product candidates. We do not have any products approved for sale and have not generated any revenue from product sales. Since our initial public offering, or IPO, on July A 20, 2018, we have raised an aggregate of approximately \$945.7 million in net proceeds to fund our operations, of which \$101.2 million was from our IPO, \$706.0 million was from four separate follow-on offerings, or the Public Offerings, that we closed in November A 2019, June A 2020, October A 2020 and December 2022, respectively, \$96.7 million was from our private investment in a public entity in June 2024, and \$41.9 million was from at-the-market offerings. We sold 7,407,936 shares of common stock in our IPO, an aggregate of 20,430,480 shares of our common stock and pre-funded warrants to purchase 9,484,238 shares of common stock in the Public Offerings, 5,668,937 shares of our common stock and pre-funded warrants to purchase 5,669,578 shares of common stock through our private investment in a public entity in June 2024, and 2,313,997 shares of common stock through our at-the-market facilities. Our net losses were \$53.8 million and \$49.6 million for the three months ended June A 30, 2024 and 2023, respectively. As of June A 30, 2024, we had an accumulated deficit of \$755.1 million. These losses have resulted primarily from costs incurred in connection with research and development activities and general and administrative costs associated with our operations. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. We anticipate that our expenses and capital requirements will fluctuate from period to period depending upon the Company's development programs and priorities. We expect to continue to incur costs in connection with our ongoing development activities, including further advancement of any preclinical activities and clinical trials of our product candidates across our platform, and if and as we "conduct our current and future clinical trials with RP1, RP2 and RP3," further preclinical development of our platform, "operate our in-house manufacturing facility," "seek to identify and develop additional product candidates," "seek marketing approvals for any of our product candidates that successfully complete clinical trials, if any," 26Table of Contents"establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval," "until our manufacturing facility is fully validated, continued limited manufacturing by third parties for clinical development," "maintain, expand, protect and defend our intellectual property portfolio," "hire and retain additional clinical, quality control, scientific and general and administration personnel," "acquire or in-license other drugs, technologies or intellectual property rights," and "add operational, financial and management information systems and personnel, including personnel to support our research and development programs, any future commercialization efforts and operations as a public company. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. As of June A 30, 2024, we had cash and cash equivalents and short-term investments of \$469.1 million. Based on our current operating plan, we believe that our existing cash and cash equivalents and short-term investments will enable us to fund our operating expenses and capital expenditure requirements through at least 12A months from the issuance of the consolidated financial statements included in this Quarterly Report. See "Liquidity and capital resources" and "Risk factors" "Risks related to our financial position and need for additional capital." Components of our results of operationsRevenueTo date, we have not generated any revenue from product sales as we do not have any approved products and do not expect to generate any revenue from the sale of products in the near future. If our development efforts for RP1 or any other product candidates that we may develop in the future are successful and result in regulatory approval, or if we enter into collaboration or license agreements with third parties, we may generate revenue in the future from a combination of product sales or payments from those collaborations or license agreements. Operating expensesOur expenses since inception have consisted solely of research and development costs and general and administrative costs. Research and development expensesResearch and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts and the development of our product candidates, and include: "expenses incurred under agreements with third parties, including clinical research organizations, or CROs, that conduct research, preclinical activities and clinical trials on our behalf as well as contract manufacturing organizations, or CMOs, that manufacture our product candidates for use in our preclinical and clinical trials," "salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions," "costs of outside consultants engaged in research and development functions, including their fees, stock-based compensation and related travel expenses," 27Table of Contents"the costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials," "costs related to compliance with regulatory requirements in connection with the development of our product candidates; and "facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs. These costs may be partially offset by cost-sharing arrangements under collaboration agreements that we may enter from time to time. We expense research and development costs as incurred. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our consolidated financial statements as prepaid or accrued research and development expenses. Our direct external research and development expenses are tracked on a

[illegible]

relinquish valuable rights to our technology, future revenue streams, research programs, or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or collaborations, strategic alliances or licensing arrangements with third parties when needed, we may be required to delay, limit, reduce and/or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Contractual obligations and commitmentsDuring the three months ended June 30, 2024, there were no material changes to our contractual obligations and commitments from those described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” “Contractual Obligations and Commitments” in our Annual Report on Form 10-K for the year ended March 31, 2024, which was filed with the SEC on May 18, 2023. CollaborationsBMSIn February 2018, we entered into a Clinical Trial Collaboration and Supply Agreement with BMS. Pursuant to the agreement, BMS is providing to us, at no cost, nivolumab, its anti-PD-1 therapy, for use in combination with RP1 in our ongoing Phase 1/2 clinical trial. Under the agreement, we will sponsor, fund and conduct the clinical trial in accordance with an agreed-upon protocol. BMS granted us a non-exclusive, non-transferrable, royalty-free license (with a right to sublicense) under its intellectual property to use nivolumab in the clinical trial and has agreed to supply nivolumab, at no cost to us, for use in the clinical trial. Both parties will own the study data produced in the clinical trial, other than study data related solely to nivolumab, which will belong solely to BMS, or study data related solely to RP1, which will belong solely to us. In January 2020, this agreement was expanded to cover an additional cohort of 125 patients with anti-PD-1 failed melanoma. Unless earlier terminated, the agreement will remain in effect until (i) the completion of the clinical trial, (ii) all related clinical trial data have been delivered to both parties and (iii) the completion of any statistical analyses and bioanalyses contemplated by the clinical trial protocol or any analysis otherwise agreed upon by the parties. The agreement may be terminated by either party (x) in the event of an uncured material breach by the other party, (y) in the event the other party is insolvent or in bankruptcy proceedings or (z) for safety reasons. Upon termination, the licenses granted to us to use nivolumab in the clinical trial will terminate. The agreement contains representations, warranties, undertakings and indemnities customary for a transaction of this nature. In April 2019, we entered into a separate agreement with BMS on terms similar to the terms set forth in the agreement described above, pursuant to which BMS will provide, at no cost to us, nivolumab for use in our Phase 1 clinical trial of RP2 in combination with nivolumab. RegeneronIn May 2018, we entered into a Master Clinical Trial Collaboration and Supply Agreement with Regeneron. Pursuant to the agreement we agreed to undertake one or more clinical trials with Regeneron for the administration of our product 34Table of Contentscandidates in combination with cemiplimab, an anti-PD-1 therapy developed by Regeneron, across multiple solid tumor types, the first of which, agreed in June 2018, is our ongoing Phase 2 clinical trial testing RP1 in combination with cemiplimab versus cemiplimab alone in patients with CSCC. Each clinical trial will be conducted pursuant to an agreed study plan which, among other things, will identify the name of the sponsor and which party will manage the particular study, and include the protocol, the budget and a schedule of clinical obligations. The first study plan related to the Phase 2 clinical trial in CSCC has been agreed. Pursuant to the terms of the agreement, each party granted the other party a non-exclusive license of their respective intellectual property and agreed to contribute the necessary resources needed to fulfill their respective obligations, in each case, under the terms of agreed study plans. Development costs of an agreed study plan will be split equally. In July 2022, Regeneron informed the Company that the costs of the study have reached the initial budget for the initial study plan of June 2018 and that Regeneron’s reimbursement of CERPASS study costs to the Company have completed in the period ending June 30, 2022 in relation to the initial study budget. As a result of this notice from, and the ongoing communications with, Regeneron, we have not recorded any cost-sharing reimbursements from Regeneron in prepaid expenses and other current assets in the consolidated balance sheet or as an offset to research and development expense within the consolidated statement of operations since Regeneron informed us that Regeneron’s reimbursement of CERPASS study costs have completed. The Company does not expect any further reimbursements from Regeneron related to the initial study plan of June 2018. The agreement contains representations, warranties, undertakings and indemnities customary for a transaction of this nature. The agreement also contains certain time-based covenants that restrict us from entering into a third-party arrangement with respect to the use of our product candidates in combination with an anti-PD-1 therapy and that restrict Regeneron from entering into a third-party arrangement with respect to the use of cemiplimab in combination with an HSV-1 virus, in each case, for the treatment of a tumor type that is the subject of a clinical trial to which the covenants apply. Unless otherwise mutually agreed in a future study plan, these covenants are only applicable to our ongoing Phase 2 clinical trial in CSCC. The agreement may be terminated by either party if (i) there is no active study plan for which a final study report has not been completed and the parties have not entered into a study plan for an additional clinical trial within a period of time after the delivery of the most recent final study report or (ii) in the event of a material breach. Roche In December 2022, we announced entering into a Master Clinical Trial Collaboration and Supply Agreement with Roche in relation to our RP2 and RP3 programs in colorectal cancer, or CRC, and hepatocellular carcinoma, or HCC. Under the agreement, the companies will collaborate in two 30 patient cohort signal finding studies in third-line, or 3L, CRC and in two 15 patient cohort signal finding studies in second-line, or 2L, HCC. Under the terms of the agreement, the companies will share costs and Roche will supply its currently approved drugs, atezolizumab and bevacizumab for 2L HCC and 3L CRC combined with RP3. Roche will also supply atezolizumab and bevacizumab for 2L HCC and 3L CRC combined with RP2. We have retained the responsibility of operating the clinical trials as well as retaining all the rights to the development and commercialization of our product candidates. The agreement may be terminated by either party upon sixty (60) days prior written notice to the other party. We are in discussions with Roche about revising these agreements following our changes to our RP2 and RP3 development plans. Incyte In July 2023, we entered into a Clinical Trial Collaboration and Supply Agreement with Incyte Corporation, or Incyte. Under the agreement, the companies will collaborate in a signal finding study in which Incyte will initiate and sponsor a clinical trial of INCB99280 (oral PD-L1 inhibitor) and RP1 in approximately 40 patients with unresectable, high risk CSCC in the neoadjuvant setting. Under the terms of the agreement, we will supply Incyte with RP1 for the study and share costs of the study equally with Incyte. The agreement may be terminated by either party upon (i) a material breach not reasonably cured within thirty (30) days; (ii) the discontinuation of development of its clinical drug candidate; (iii) the unethical or illegal business practices of the other party; or (iv) if the parties have not agreed on the protocol or budget within ninety (90) days of the effective date of the agreement. In addition, the Company may terminate the agreement upon the inappropriate or unsafe use of the RP1 product candidate. On July 30, 2024, Incyte announced it has discontinued further development of its oral small molecule PD-L1 inhibitor, which was the intended study drug in the Company’s planned collaboration with Incyte. On August 1, 2024, the Company received notice of termination of the Clinical Trial Collaboration and Supply Agreement from Incyte. Critical accounting policies and estimatesOur management’s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. While our significant accounting policies are described in greater detail in Note 2 to our consolidated financial statements appearing elsewhere in this Quarterly Report, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements. Accrued research and development expensesAs part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advanced payments. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. Examples of estimated accrued research and development expenses include fees paid to:•CROs in connection with performing research activities and conducting preclinical studies and clinical trials on our behalf;•CMOs in connection with the production of preclinical and clinical trial materials;•investigative sites or other service providers in connection with clinical trials;•vendors in connection with preclinical and clinical development activities; and•vendors related to product manufacturing and development and distribution of preclinical and clinical supplies. We base our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple CMOs and CROs that supply, conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expenses accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses. Stock-based compensationWe issue stock-based awards to employees, directors, consultants and non-employees in the form of stock options and restricted stock units. We measure such stock-based awards in accordance with ASC 718, Compensation—Stock Compensation, which requires all stock-based awards to be recognized in the consolidated statements of operations and comprehensive loss based on their fair value on the date of the grant and the related compensation expense for those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. We have, to date, only issued stock-based awards with service-based vesting conditions and record the expense for these awards using the straight-line method. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option, and our expected dividend yield. See Note 10 to our consolidated financial statements appearing elsewhere in this Quarterly Report for 36Table of Contentsmore information. Forfeitures are accounted for as they occur. The fair value of each stock-based award is estimated on the date of grant based on the fair value of our common stock on that same date. We classify stock-based compensation expense in our consolidated statements of operations in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified. Recently issued accounting pronouncementsA description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our consolidated financial statements appearing elsewhere in this Quarterly Report. Item 3. Quantitative and Qualitative Disclosures about Market Risks. Not applicable. Item 4. Controls and Procedures. Evaluation of Disclosure Controls and ProceduresThe term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such information is accumulated and communicated to a company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Under the supervision and with the participation of our management, including our Chief Executive Officer, Chief Financial Officer and Chief Accounting Officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of June 30, 2024. Based on this evaluation, our Chief Executive Officer, Chief Financial Officer and Chief Accounting Officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2024. In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected. Changes in internal control over financial reportingThere have been no changes in our internal control over financial reporting for the three months ended June 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 37Table of ContentsPART II “OTHER INFORMATION”Item 1. Legal Proceedings. We are not currently a party to any material legal proceedings. 48Item 1A. Risk FactorsInvesting in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with all of the other information in this Quarterly Report on Form 10-Q, including our consolidated financial statements and related notes and “Management’s” discussion and analysis of results of operations and financial condition. If any of the following risks are realized, our business, financial condition, operating results and prospects could be materially and adversely affected. In that event, the price of our common stock could decline, and you could lose part or all of your investment. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. Summary of risk factorsMaterial risks that may affect our business, operating results and financial condition include, but are not necessarily limited to, those relating to:•the timing, progress, and results of our preclinical studies and clinical trials for our product candidates, and the timing, scope or likelihood of regulatory filings and approvals for any of our product candidates;•our ability to develop and advance any future product candidates based on our novel proprietary RPx platform and successfully complete clinical trials;•our ability to develop our product candidates for use in combination with other checkpoint blockade therapies, including anti-PD-1;•our ability to successfully commercialize any product candidate for which we receive regulatory approval and our expectations regarding the size of the patient populations or the market acceptance of our product candidates if approved for commercial use;•our ability to compete with other biopharmaceutical companies, biotechnology companies and other third parties and risks associated with such third parties developing or commercializing products more quickly or marketing them more successfully than us;•negative developments in the field of immuno-oncology including clinical or commercial developments that may be attributed to our product candidates;•our history of losses, the likelihood that we will continue to incur substantial and increasing net losses in the future, and the likelihood that we will require additional financing to achieve our goals;•our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights covering RP1 and our other product candidates, claims others may make regarding rights in our intellectual property, and any potential infringement, misappropriation or other violation or alleged violation of any third-party intellectual property rights;•our ability to successfully complete transfer of our product manufacturing to our in-house manufacturing facility from our contract manufacturers including comparability analysis and to qualify, obtain approval for, and maintain successful operation, approval and qualification of our in-house manufacturing operations; •our ability to obtain and maintain sufficient quantities of raw material supplies to build or maintain our product candidate supplies or otherwise operate our in-house manufacturing facility; 38Table of Contents•our ability to obtain and maintain sufficient quantities of materials and supplies to conduct our clinical trials, such as comparative, control and/or standard of care therapies including chemotherapeutic agents that are currently in short supply in the industry; •the costs of operating our in-house manufacturing facility and our reliance on third-party collaborators and clinical trial service providers, which may be single or of limited source;•our compliance with domestic and foreign laws, rules and regulations and the consequences in the event that we fail to comply with such laws, rules and regulations;•our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals;•our competitive position, and developments and projections relating to our competitors and our industry; •the impact of the COVID-19 coronavirus, or COVID-19, as a global pandemic and related public health issues, including potential material supplies and supply chain disruptions, hiring and retaining talent, and global and national economic impacts such as inflation; and•the ongoing Russian-Ukrainian and Israel-Hamas military conflicts, and their impact on the global economy

and related governmental imposed sanctions and potential material supplies and supply chain disruptions and global or national economic impacts such as inflation.Risks related to product developmentOur product candidates are in the early stages of development, are not approved for commercial sale and might never receive regulatory approval or become commercially viable. We have never generated any revenue from product sales and may never be profitable.All of our product candidates are in research or development. We have not generated any revenues from the sale of products and do not expect to do so for at least the next several years. Our lead product candidate, RP1, and any other product candidates will require extensive preclinical and/or clinical testing and regulatory approval prior to commercial use. Our research and development efforts may not be successful. Even if our clinical development efforts result in positive data, our product candidates may not receive regulatory approval or be successfully introduced and marketed at prices that would permit us to operate profitably. We will not be able to commercialize our product candidates if our preclinical studies do not produce successful results and/or our clinical trials do not demonstrate the safety and efficacy of our product candidates.Our product candidates are susceptible to the risks of failure inherent at any stage of product development, including the occurrence of unexpected or unacceptable adverse events or the failure to demonstrate efficacy in clinical trials. Clinical development is expensive and can take many years to complete, and its outcome is inherently uncertain.The results of preclinical studies, preliminary study results, and early clinical trials of our product candidates may not be predictive of the results of later stage clinical trials. Our product candidates may not perform as we expect, may ultimately have a different or no impact on tumors, may have a different mechanism of action than we expect in humans, and may not ultimately prove to be safe and effective.Preliminary and final results from preclinical studies and early stage trials, and trials in compounds that we believe are similar to ours, may not be representative of results that are found in larger, controlled, blinded, and longer-term studies. Product candidates may fail at any stage of preclinical or clinical development. Product candidates may fail to show the desired safety and efficacy traits even if they have progressed through preclinical studies or initial clinical trials. Preclinical studies and clinical trials may also reveal unfavorable product candidate characteristics, including safety concerns. A number of companies in the biopharmaceutical industry have suffered significant setbacks in clinical trials, notwithstanding promising results in earlier preclinical studies or clinical trials or promising mechanisms of action. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. Moreover, should there be 39Table of Contentsan issue with the design of a clinical trial, our results may be impacted. We may not discover such a flaw until the clinical trial is at an advanced stage.We may also experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:â€¢the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials or be lost to follow-up at a higher rate than we anticipate, or may elect to participate in alternative clinical trials sponsored by our competitors with product candidates that treat the same indications as our product candidates;â€¢regulators or institutional review boards, or IRBs, may not authorize us or our investigators to commence a clinical trial, conduct a clinical trial at a prospective trial site, or amend trial protocols, or may require that we modify or amend our clinical trial protocols;â€¢we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites and/or contract research organizations, or CROs;â€¢clinical trials of our product candidates may produce negative or inconclusive results, or our studies may fail to reach the necessary level of statistical significance, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;â€¢our third-party contractors may fail to comply with regulatory requirements or the clinical trial protocol, or meet their contractual obligations to us in a timely manner, or at all, or we may be required to engage in additional clinical trial site monitoring;â€¢we, regulators, or IRBs may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks, undesirable side effects, or other unexpected characteristics of the product candidate, or due to findings of undesirable effects caused by a chemically or mechanistically similar therapeutic or therapeutic candidate;â€¢changes in manufacturing facilities or the manufacturing process for our product candidates may impact how our product candidates perform in clinical trials; â€¢changes could be adopted in marketing approval policies during the development period, rendering our data insufficient to obtain marketing approval;â€¢statutes or regulations could be amended or new ones could be adopted, especially in light of the upcoming reauthorization of the Prescription Drug User Fee Act;â€¢changes could be adopted in the regulatory review process for submitted product applications;â€¢the cost of clinical trials of our product candidates may be greater than we anticipate or we may have insufficient funds for a clinical trial or to pay the substantial user fees required by the FDA upon the filing of a Biologics License Application, or BLA, or equivalent authorizations from comparable foreign regulatory authorities;â€¢the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate or we may not be able to obtain them on favorable terms due to reasons such as international trade policies and supply chain disruptions;â€¢we may decide, or regulators may require us, to conduct or gather, as applicable, additional clinical trials, analyses, reports, data, or preclinical trials, or we may abandon product development programs. By example, the FDA may determine that larger trials, Phase 3 trials, randomized and controlled clinical trials, or clinical trials designed to replicate results found in our registration or pivotal trials are required before we may file a BLA or before the FDA will approve a marketing application; 40Table of Contentsâ€¢we may fail to reach an agreement with regulators or IRBs regarding the scope, design, or implementation of our clinical trials, and the FDA or comparable foreign regulatory authorities may require changes to our study designs or study data analysis that may make further study impractical or not financially prudent;â€¢regulators may ultimately disagree with the design or our conduct of our preclinical studies or clinical trials, finding that they do not support product candidate approval;â€¢we may have delays in adding new investigators or clinical trial sites, or we may experience a withdrawal of clinical trial sites;â€¢patients that enroll in our studies may misrepresent their eligibility or may otherwise not comply with the clinical trial protocol, resulting in the need to drop the patients from the study or clinical trial, increase the needed enrollment size for the clinical trial or extend its duration;â€¢there may be regulatory questions or disagreements regarding interpretations of data and results;â€¢the FDA or comparable foreign regulatory authorities may disagree with our study design, including endpoints, or our interpretation of data from preclinical studies and clinical trials or find that a product candidateâ€™s benefits do not outweigh its safety risks;â€¢the FDA or comparable foreign regulatory authorities may not accept data from studies with clinical trial sites in foreign countries;â€¢the FDA or comparable foreign regulatory authorities may disagree with our intended indications;â€¢the FDA or comparable foreign regulatory authorities may fail to approve or subsequently find fault with the manufacturing, testing, comparability or quality processes or our manufacturing facilities for clinical and future commercial supplies;â€¢the data collected from clinical trials of our product candidates, including our registration directed or registration intended trials, may not be sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere;â€¢the FDA may decide that our intended pathways, including accelerated approval, are not appropriate for our product candidates, requiring that we conduct additional studies. By example, in recent years the accelerated approval pathway has come under significant FDA and public scrutiny. Accordingly, depending on the results of our studies, the FDA may be more conservative in granting accelerated approval or, if granted, may be more apt to withdrawal approval if clinical benefit is not confirmed. Even if accelerated approval is granted, payors, including governmental payors, may be less willing to provide sufficient reimbursement for products approved via accelerated approval; â€¢the FDA or comparable foreign regulatory authorities may take longer than we anticipate to make a decision on our product candidates or necessary inspections before an approval can be issued may be delayed;â€¢we may not be able to demonstrate that a product candidate provides an advantage over current standards of care or current or future competitive therapies in development; andâ€¢we, the third parties on which we rely, and the FDA may have delays in the conduct of our respective operations as a result of the effects of the COVID-19 pandemic, which could result in delays or prevent our ability to receive marketing approval or commercialize our product candidates.Our development costs will also increase if we experience delays in testing or approvals, and we may not have sufficient funding to complete the testing and approval process for any of our product candidates. We may be required to obtain additional funds to complete clinical trials and prepare for possible commercialization of our product candidates. We do not know whether any preclinical tests or clinical trials beyond what we currently have planned will be required, will begin as planned, will need to be restructured, or will be completed on schedule, or at all. Significant delays relating to any preclinical or clinical trials also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully 41Table of Contentscommercialize our product candidates and may harm our business and results of operations. In addition, many of the factors that cause, or lead to, delays in clinical trials may ultimately lead to the denial of marketing approval of any of our product candidates. If any of these occur, our business, financial condition, results of operations, stock price and prospects may be materially harmed.Topline data may not accurately reflect the complete results of a particular study or trial.We may publicly disclose topline or interim data from time to time, which is based on a preliminary analysis of then-available efficacy and safety data which are based on preliminary analysis of key efficacy and safety data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimations, calculations, conclusions or analyses or may request different calculations or analysis than conducted and may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular drug candidate or drug and our company in general. In addition, the information we may publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, drug candidate or our business. If the topline data that we report differ from a future analysis of results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize our product candidates, our business, operating results, prospects or financial condition may be harmed.We anticipate that our product candidates will be used in combination with third-party drugs, some of which are still in development, and we have limited or no control over the supply, regulatory status, or regulatory approval of such drugs.Our product candidates may be administered in combination with checkpoint blockade drugs, a class of drugs that are intended to stop tumor cells from â€¢switching offâ€¢ an immune system attack against themselves. We have entered into agreements with BMS for the supply of nivolumab, its anti-PD-1 therapy, for use in connection with our ongoing IGNYTE Phase 1/2 trials with RP1, our Phase 1/2 clinical trial with RP2 and our Phase 1 and Phase 2 clinical trials with RP3 where we decide to use nivolumab. We have also entered into a clinical collaboration agreement with Regeneron, which includes the supply of cemiplimab, its anti-PD-1 therapy, for clinical trials conducted thereunder. We are using cemiplimab in the CERPASS trial, our first planned clinical trial under the Regeneron agreement. We may enter into additional agreements for the supply of anti-PD-1 products for use in combination with and for the continued development of one or more of our product candidates. Although we have entered into such collaboration and supply agreements, and may continue to do so, our partners may remain in control of the supply and other decisions relating to their products or product candidates and we rely on their adherence to the terms of such agreements for the proper execution of their obligations. Our ability to develop and ultimately commercialize our product candidates used in combination with nivolumab, cemiplimab or any other checkpoint blockade therapy will depend on our ability to access such drugs on commercially reasonable terms for the clinical trials and their availability for use with the commercialized product, if approved. We cannot be certain that current or potential future commercial relationships will provide us with a steady supply of such drugs on commercially reasonable terms or at all.Any failure to maintain or enter into new successful commercial relationships, or the expense of purchasing checkpoint blockade therapies in the market, may delay our development timelines, increase our costs and jeopardize our ability to develop our product candidates as commercially viable therapies. If any of these occur, our business, financial condition, results of operations, stock price and prospects may be materially harmed.42Table of ContentsMoreover, the development of our product candidates for use in combination with another product or product candidate may present challenges that are not faced for single agent product candidates. While we have opened a clinical trial for use of RP1 as a monotherapy, we are generally developing RP1 and our other product candidates for use in combination with anti-PD-1 or potentially anti-PD(L)-1 therapies, and may develop RP1 or our other product candidates for use with other therapies. Although we intend our IGNYTE anti-PD-1 failed melanoma cohort and our CERPASS trial to be registration directed, the FDA may require us to use more complex clinical trial designs in order to evaluate the contribution of each product and product candidate to any observed effects. It is possible that the results of these trials could show that any positive previous trial results are attributable to the therapy with which our products were combined and not our product candidates. Moreover, following product approval, the FDA may require that products used in conjunction with each other be cross-labeled for combined use. To the extent that we do not have rights to the other product, this may require us to work with a third party to satisfy such a requirement. Moreover, developments related to the other product may impact our clinical trials for the combination as well as our commercial prospects should we receive marketing approval. Such developments may include changes to the other productâ€™s safety or efficacy profile, changes to the availability of the approved product, and changes to the standard of care.In the event that BMS, Regeneron or any future collaborator or supplier cannot continue to supply their products on commercially reasonable terms or at all, we would need to identify alternatives for accessing an anti-PD-1 therapy. Additionally, should the supply of products from BMS, Regeneron or any future collaborator or supplier be interrupted, delayed or otherwise be unavailable to us, our clinical trials may be delayed, interrupted or halted. In the event we are unable to source a supply of an acceptable alternative anti-PD-1 therapy, or are unable to do so on commercially reasonable terms, our business, financial condition, results of operations, stock price and prospects may be materially harmed.An underlying problem with our proprietary RPx platform would adversely affect our business and may require us to discontinue development of product candidates based on the same or similar therapeutic approaches.We have invested, and we expect to continue to invest, significant efforts and financial resources in the development of product candidates based on our RPx platform. Our ability to generate any revenues from the sale of our product candidates will depend heavily on the successful development, regulatory approval and commercialization of one or more of these product candidates using our RPx platform. Since all of the product candidates in our current pipeline are based on our proprietary RPx platform, if any of our product candidates fail in development as a result of any underlying problem with our proprietary RPx platform, then we may be required to discontinue development of all product candidates that are based on our therapeutic approach. If we were required to discontinue development of our product candidates that are based on our therapeutics approach, or if any of them were to fail to receive regulatory approval or achieve sufficient market acceptance, we could be prevented from or significantly delayed in achieving profitability. We can provide no assurance that we would be successful at developing other product candidates based on an alternative therapeutic approach.If we fail to develop additional product candidates, our commercial opportunity could be limited.Our lead product candidate is RP1. A key part of our strategy is to pursue clinical development of RP1 and additional product candidates, including RP2 and, when appropriate RP3. Developing, obtaining marketing approval for, and commercializing additional product candidates will require substantial additional funding and will be subject to the risks of failure inherent in medical product development. We cannot assure our shareholders that we will be able to successfully advance any of these additional product candidates through the development process.Even if we obtain approval from the FDA or comparable foreign regulatory authorities to market additional product candidates for the treatment of solid tumors, we cannot assure our shareholders that any such product candidates will be successfully commercialized, widely accepted in the marketplace, or more effective than other commercially available alternatives. If we are unable to successfully develop and commercialize additional product candidates, our commercial opportunity may be limited and our business, financial condition, results of operations, stock price and prospects may be materially harmed.Risks related to regulatory approvalEven if our development efforts are successful, we may not obtain regulatory approval for any of our product candidates in the United States or other jurisdictions, which would prevent us from commercializing our product candidates. Even if we obtain regulatory approval for our product candidates, any such approval may be subject to limitations, including with respect to the approved indications or patient populations, which could impair our ability to successfully commercialize our product candidates.43Table of ContentsWe are not permitted to

market or promote or sell any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate's safety and efficacy for that indication. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities and clinical trial sites by, the regulatory authorities. If we do not receive approval from the FDA and comparable foreign regulatory authorities for any of our product candidates, we will not be able to commercialize such product candidates in the United States or in other jurisdictions. If significant delays in obtaining approval for and commercializing our product candidates occur in any jurisdictions, our business, financial condition, results of operations, stock price and prospects will be materially harmed. Even if our product candidates are approved, they may be subject to limitations on the indicated uses or patient populations for which they may be marketed, distribution restrictions, or other conditions of approval, contain significant safety warnings, including boxed warnings, contraindications, and precautions, not be approved with label statements necessary or desirable for successful commercialization, or contain requirements for costly post-market testing and surveillance, and other requirements, including the submission of a risk evaluation and mitigation strategy, or REMS, to monitor the safety or efficacy of the products. We have not previously submitted a BLA to the FDA, or a similar marketing application to comparable foreign regulatory authorities, for any product candidate, and we can provide no assurance that we will ultimately be successful in obtaining regulatory approval for claims that are necessary or desirable for successful marketing, or at all. The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are not able to obtain, or experience delays in obtaining, required regulatory approvals, we will not be able to commercialize our product candidates as expected, and our ability to generate revenue may be materially impaired. The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate's clinical development and may vary among jurisdictions and there may be varying interpretations of data obtained from preclinical studies or clinical trials, any of which may cause delays or limitations in the approval or a decision not to approve an application. These regulatory requirements may require us to amend our clinical trial protocols, conduct additional preclinical studies or clinical trials that may require regulatory or IRB approval, require additional or different analysis of clinical data or otherwise cause delays in the approval or rejection of an application. Any delay in obtaining or failure to obtain required approvals could materially adversely affect our ability to generate revenue from the particular product candidate, which may materially harm our business, financial condition, results of operations, stock price and prospects. If we experience delays in obtaining approval, if we fail to obtain approval of a product candidate or if the label for a product candidate does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate, the commercial prospects for such product candidate may be harmed and our ability to generate revenues from that product candidate may be materially impaired. The FDA or a comparable foreign regulatory authority may determine that our product candidates have undesirable side effects that could delay or prevent their regulatory approval or commercialization. There can be no assurance that undesirable side effects or serious adverse events will not be caused by or associated with RP1 or our other product candidates as they continue through or enter clinical development. Serious adverse events or undesirable side effects caused by our product candidates could cause us, our IRBs, and other reviewing entities or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. For example, if concerns are raised regarding the safety of a new therapeutic as a result of undesirable side effects identified during clinical or preclinical testing, the FDA or comparable foreign regulatory authority may order us to cease further development, decline to approve the product candidate or to issue a letter requesting additional data or information prior to making a final decision regarding whether or not to approve the product candidate. The FDA or comparable foreign regulatory authorities, or IRBs and other reviewing entities, may also require, or we may voluntarily develop, strategies for managing adverse events during clinical development, which could include restrictions on our enrollment criteria, the use of stopping criteria, adjustments to a study's design, or the monitoring of safety data by a data monitoring committee, among other strategies. The FDA or comparable foreign regulatory authority requests for additional data or information could also result in substantial delays in the approval of our product candidates. Undesirable side effects caused by any of our product candidates could also result in denial of regulatory approval by the FDA or comparable foreign regulatory authorities for any or all targeted indications or the inclusion of unfavorable information in our product labeling, such as limitations on the indicated uses for which the products may be marketed or distributed, a label with significant safety warnings, including boxed warnings, contraindications, and precautions, a label without statements necessary or desirable for successful commercialization, or may result in requirements for costly post-marketing testing and surveillance, or other requirements, including REMS, to monitor the safety or efficacy of the products, and in turn prevent us from commercializing and generating revenues from the sale of our product candidates. Undesirable side effects may limit the potential market for any approved products or could result in the discontinuation of the sales and marketing of the product, or withdrawal of product approvals. Later discovered undesirable side effects may further result in the imposition of a REMS, label revisions, post approval study requirements, or other testing and surveillance. If any of our product candidates is associated with serious adverse events or undesirable side effects or have properties that are unexpected, we may need to abandon development or limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk/benefit perspective. The therapeutic-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may materially harm our business, financial condition, results of operations, stock price and prospects. Changes in product candidate manufacturing or formulation may result in additional costs or delay. As product candidates are developed through preclinical studies to later stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, facilities, equipment and formulation, are altered along the way in an effort to optimize processes and results. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. Such changes may also require additional testing, or notification to, or approval by the FDA or a comparable foreign regulatory authority. This could delay completion of clinical trials, require the conduct of bridging clinical trials or studies, require the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and/or jeopardize our ability to commence product sales and generate revenue. Regulatory approval by the FDA or comparable foreign regulatory authorities is limited to those specific indications and conditions for which approval has been granted, and we may be subject to substantial fines, criminal penalties, injunctions, or other enforcement actions if we are determined to be promoting the use of our products for unapproved or off label uses, resulting in damage to our reputation and business. We must comply with requirements concerning advertising and promotion for any product candidates for which we obtain marketing approval. Promotional communications with respect to therapeutics are subject to a variety of legal and regulatory restrictions and continuing review by the FDA, Department of Justice, Department of Health and Human Services' Office of Inspector General, state attorneys general, members of Congress, and the public. When the FDA or comparable foreign regulatory authorities issue regulatory approval for a product candidate, the regulatory approval is limited to those specific uses and indications for which a product is approved. If we are not able to obtain FDA approval for desired uses or indications for our product candidates, we may not market or promote them for those indications and uses, referred to as off label uses, and our business, financial condition, results of operations, stock price and prospects may be materially harmed. We also must sufficiently substantiate any claims that we make for our products, including claims comparing our products to other companies' products, and must abide by the FDA's strict requirements regarding the content of promotion and advertising. While physicians may choose to prescribe products for uses that are not described in the product's labeling and for uses that differ from those tested in clinical trials and approved by the regulatory authorities, we are prohibited from marketing and promoting the products for indications and uses that are not specifically approved by the FDA. These off label uses are common across medical specialties and may constitute an appropriate treatment for some patients in varied circumstances. Regulatory authorities in the United States generally do not restrict or regulate the behavior of physicians in their choice of treatment within the practice of medicine. Regulatory authorities do, however, restrict communications by biopharmaceutical companies concerning off label use. If we are found to have impermissibly promoted any of our product candidates, we may become subject to significant liability and government fines. The FDA and other agencies actively enforce the laws and regulations regarding product promotion, particularly those prohibiting the promotion of off label uses, and a company that is found to have improperly promoted a product may be subject to significant sanctions. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. In the United States, engaging in the impermissible promotion of our products, following approval, for off label uses can also subject us to false claims and other litigation under federal and state statutes. These include fraud and abuse and consumer protection laws, which can lead to civil and criminal penalties and fines and agreements with governmental authorities that materially restrict the manner in which we promote or distribute therapeutic products and conduct our business. These restrictions could include corporate integrity agreements, suspension or exclusion from participation in federal and state healthcare programs, and suspension and debarment from government contracts and refusal of orders under existing government contracts. These False Claims Act lawsuits against manufacturers of drugs and biologics have increased significantly in volume and breadth. In addition, False Claims Act lawsuits may expose manufacturers to follow-on claims by private payers based on fraudulent marketing practices. This growth in litigation has increased the risk that a biopharmaceutical company will have to defend a false claim action, pay settlement fines or restitution, as well as criminal and civil penalties, agree to comply with burdensome reporting and compliance obligations, and be excluded from Medicare, Medicaid, or other federal and state healthcare programs. If we do not lawfully promote our approved products, if any, we may become subject to such litigation and, if we do not successfully defend against such actions, those actions may have a material adverse effect on our business, financial condition, results of operations, stock price and prospects. In the United States, the promotion of biopharmaceutical products is subject to additional FDA requirements and restrictions on promotional statements. If after one or more of our product candidates obtains marketing approval the FDA determines that our promotional activities violate its regulations and policies pertaining to product promotion, it could request that we modify our promotional materials or subject us to regulatory or other enforcement actions, including issuance of warning letters or untitled letters, suspension or withdrawal of an approved product from the market, requests for recalls, payment of civil fines, disgorgement of money, imposition of operating restrictions, injunctions or criminal prosecution, and other enforcement actions. Similarly, industry codes in foreign jurisdictions may prohibit companies from engaging in certain promotional activities and regulatory agencies in various countries may enforce violations of such codes with civil penalties. If we become subject to regulatory and enforcement actions our business, financial condition, results of operations, stock price and prospects will be materially harmed. Even if our product candidates receive regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense and limit how we manufacture and market our products. Any product candidate for which we obtain marketing approval will be subject to extensive and ongoing requirements of and review by the FDA and comparable foreign regulatory authorities, including requirements related to the manufacturing processes, post approval clinical data, labeling, packaging, distribution, adverse event reporting, shortage reporting, risk management plans, supply chain security, storage, recordkeeping, export, import, advertising, marketing, and promotional activities for such product. These requirements further include submissions of safety and other post-marketing information, including manufacturing deviations and reports, registration and listing requirements, the payment of annual fees, continued compliance with current Good Manufacturing Practice, or cGMP, requirements relating to manufacturing, quality control, quality assurance, and corresponding maintenance of records and documents, and good clinical practices, or GCPs, for any clinical trials that we conduct post approval. The FDA and comparable foreign regulatory authorities will continue to closely monitor the safety profile of any product even after approval. If the FDA or comparable foreign regulatory authorities become aware of new safety information after approval of any of our product candidates, they may withdraw approval, issue public safety alerts, require labeling changes or establishment of a REMS or similar strategy, impose significant restrictions on a product's indicated uses or marketing, or impose ongoing requirements for potentially costly post approval studies or post-market surveillance. Any such restrictions could limit sales of the product. We and any of our suppliers or collaborators, including our contract manufacturers, could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMPs and other FDA regulatory requirements. Application holders must further notify the FDA, and depending on the nature of the change, obtain FDA preapproval for product and manufacturing changes. In addition, later discovery of previously unknown adverse events or that the product is less effective than previously thought or other problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements both before and after approval, may yield various negative results, including: restrictions on manufacturing, distribution, or marketing of such products; restrictions on the labeling, including required additional warnings, such as black boxed warnings, contraindications, precautions, and restrictions on the approved indication or use; modifications to promotional pieces; issuance of corrective information; requirements to conduct post-marketing studies or other clinical trials; clinical holds or termination of clinical trials; requirements to establish or modify a REMS or similar strategy; changes to the way the product candidate is administered; liability for harm caused to patients or subjects; reputational harm; the product becoming less competitive; warning, untitled, or cyber letters; suspension of marketing or withdrawal of the products from the market; regulatory authority issuance of safety alerts, Dear Healthcare Provider letters, press releases, or other communications containing warnings or other safety information about the product candidate; refusal to approve pending applications or supplements to approved applications that we submit; recalls of products; fines, restitution or disgorgement of profits or revenues; suspension or withdrawal of marketing approvals; refusal to permit the import or export of our products; product seizure or detention; FDA debarment, suspension and debarment from government contracts, and refusal of orders under existing government contracts, exclusion from federal healthcare programs, consent decrees, or corporate integrity agreements; injunctions or the imposition of civil or criminal penalties, including imprisonment. Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, or could substantially increase the costs and expenses of commercializing such product, which in turn could delay or prevent us from generating significant revenues from its marketing and sale. Any of these events could further have other material and adverse effects on our operations and business and could adversely impact our business, financial condition, results of operations, stock price and prospects. The FDA's policies or those of comparable foreign regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates, limit the marketability of our product candidates, or impose additional regulatory obligations on us. Changes in medical practice and standard of care may also impact the marketability of our product candidates. If we are slow or unable to adapt to changes in existing requirements, standards of care, or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and be subject to regulatory enforcement action. Should any of the above actions take place, we could be prevented from or significantly delayed in achieving profitability. Further, the cost of compliance with post approval regulations may have a negative effect on our operations and business and could adversely impact our business, financial condition, results of operations, stock price and prospects. We conduct clinical trials for product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials. We currently conduct clinical trials outside the United States. The acceptance by the FDA or comparable foreign regulatory authority of study data from clinical trials conducted outside the United States or another jurisdiction may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such as inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. Additionally, the FDA's clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable

foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in product candidates that we may develop not receiving approval or clearance for commercialization in the applicable jurisdiction. Obtaining and maintaining marketing approval for our product candidates in one jurisdiction would not mean that we will be successful in obtaining marketing approval of that product candidate in other jurisdictions, which could prevent us from marketing our products internationally. Obtaining and maintaining marketing approval of our product candidates in one jurisdiction would not guarantee that we will be able to obtain or maintain marketing approval in any other jurisdiction, while a failure or delay in obtaining marketing approval in one jurisdiction may have a negative effect on the marketing approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable foreign regulatory authorities must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from and, in some cases, greater than, those in the United States, including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. Additionally, with the full departure of the United Kingdom from the European Union in January 2021, commonly referred to as Brexit, there is continuing regulatory uncertainty. Since a significant proportion of the regulatory framework in the United Kingdom is derived from European Union directives and regulations, and the degree to which the United Kingdom and European Union regulatory regimes align or diverge could materially impact the execution of our clinical trials or approval of our product candidates in the United Kingdom or the European Union. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign marketing approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed. If we obtain approval for any product candidate and ultimately commercialize that product in foreign markets, we would be subject to additional risks and uncertainties, including 48Table of Contents the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and the reduced protection of intellectual property rights in some foreign countries. Risks related to commercialization If we are unable to successfully commercialize any product candidate for which we receive regulatory approval, or experience significant delays in doing so, our business will be materially harmed. If we are successful in obtaining marketing approval from applicable regulatory authorities for RP1 or any of our other product candidates, our ability to generate revenues from our product candidates will depend on our success in: 49Table of Contents launching commercial sales of our product candidates, whether alone or in collaboration with others; 49Table of Contents receiving an approved label with claims that are necessary or desirable for successful marketing, and that does not contain safety or other limitations that would impede our ability to market the product candidates; 49Table of Contents creating market demand for our product candidates through marketing, sales and promotion activities; 49Table of Contents hiring, training, and deploying a sales force or contracting with third parties to commercialize product candidates in the United States; 49Table of Contents manufacturing product candidates in sufficient quantities and at acceptable quality and cost to meet commercial demand at launch and thereafter; 49Table of Contents establishing and maintaining agreements with wholesalers, distributors, and group purchasing organizations on commercially reasonable terms; 49Table of Contents creating partnerships with, or offering licenses to, third parties to promote and sell product candidates in foreign markets where we receive marketing approval; 49Table of Contents maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; 49Table of Contents our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights covering RP1 and our other product candidates, claims others may make regarding rights in our intellectual property, and any potential infringement, misappropriation or other violation or alleged violation of any third-party intellectual property rights; 49Table of Contents achieving market acceptance of our product candidates by patients, the medical community, and third-party payors; 49Table of Contents achieving appropriate reimbursement for our product candidates; 49Table of Contents effectively competing with other therapies; and 49Table of Contents maintaining a continued acceptable safety profile of our product candidates following launch. To the extent we are not able to do any of the foregoing, our business, financial condition, results of operations, stock price and prospects will be materially harmed. We face significant competition from other biopharmaceutical and biotechnology companies, academic institutions, government agencies, and other research organizations, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than us. If their product candidates are shown to be safer or more effective than ours, our commercial opportunity may be reduced or eliminated. The development and commercialization of cancer immunotherapy products is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary rights. We face competition with respect to our current product candidates, and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major biopharmaceutical companies, specialty biopharmaceutical companies, and biotechnology companies worldwide. There are a number of large biopharmaceutical and biotechnology companies that 49Table of Contents currently market and sell products or are pursuing the development of products for the treatment of solid tumors, including oncolytic immunotherapy and cancer vaccine approaches. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization. While our product candidates are intended to be used in combination with other drugs with different mechanisms of action, if and when marketed they will still compete with a number of drugs that are currently marketed or in development that also target cancer. To compete effectively with these drugs, our product candidates will need to demonstrate advantages in clinical efficacy and safety compared to these competitors when used alone or in combination with other drugs. Our commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are easier to administer or are less expensive alone or in combination with other therapies than any products that we may develop alone or in combination with other therapies. Our competitors also may obtain FDA or comparable foreign regulatory authority approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers, other third-party payors coverage decisions or third-party intellectual property rights that another may allege are violated by our product candidates. Certain of the companies with which we are competing or may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the biopharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in developing or acquiring technologies complementary to, or necessary for, our programs. If we are unable to successfully compete with these companies our business, financial condition, results of operations, stock price and prospects may be materially harmed. If we are unable to establish effective marketing, sales and distribution capabilities or enter into agreements with third parties to market and sell our product candidates, if they are approved, the revenues that we generate may be limited and we may never become profitable. We currently do not have a commercial infrastructure for the marketing, sale, and distribution of our product candidates. If and when our product candidates receive marketing approval, we intend to commercialize our product candidates on our own in the United States and potentially with pharmaceutical or biotechnology partners in other geographies. In order to commercialize our products, we must build our marketing, sales, and distribution capabilities or make arrangements with third parties to perform these services. We may not be successful in doing so. Should we decide to move forward in developing our own marketing capabilities, we may incur expenses prior to product launch or even approval in order to recruit a sales force and develop a marketing and sales infrastructure. If a commercial launch is delayed as a result of FDA or comparable foreign regulatory authority requirements or other reasons, we would incur these expenses prior to being able to realize any revenue from sales of our product candidates. Even if we are able to effectively hire a sales force and develop a marketing and sales infrastructure, our sales force and marketing teams may not be successful in commercializing our product candidates. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. We may also or alternatively decide to collaborate with third-party marketing and sales organizations to commercialize any approved product candidates in the United States, in which event, our ability to generate product revenues may be limited. To the extent we rely on third parties to commercialize any products for which we obtain regulatory approval, we may receive less revenues than if we commercialized these products ourselves, which could materially harm our prospects. In addition, we would have less control over the sales efforts of any other third parties involved in our commercialization efforts, and could be held liable if they failed to comply with applicable legal or regulatory requirements. We have no prior experience in the marketing, sale, and distribution of biopharmaceutical products, and there are significant risks involved in building and managing a commercial infrastructure. The establishment and development of commercial capabilities, including compliance plans, to market any products we may develop will be expensive and time consuming and could delay any product launch, and we may not be able to successfully develop this capability. We will have to compete with other biopharmaceutical and biotechnology companies, including oncology-focused companies, to recruit, hire, train, manage, and retain marketing and sales personnel, which is expensive and time consuming and could delay any product launch. Developing our sales capabilities may also divert resources and management attention away from product development. 50Table of Contents In the event we are unable to develop a marketing and sales infrastructure, we may not be able to commercialize our product candidates in the United States or elsewhere, which could limit our ability to generate product revenues and materially harm our business, financial condition, results of operations, stock price and prospects. Factors that may inhibit our efforts to commercialize our product candidates include: 49Table of Contents the inability to recruit, train, manage, and retain adequate numbers of effective sales and marketing personnel; 49Table of Contents the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe our product candidates; 49Table of Contents our inability to effectively oversee a geographically dispersed sales and marketing team; 49Table of Contents the costs associated with training sales and marketing personnel on legal and regulatory compliance matters and monitoring their actions; 49Table of Contents an inability to secure adequate coverage and reimbursement by government and private health plans; 49Table of Contents the clinical indications for which the products are approved and the claims that we may make for the products; 49Table of Contents limitations or warnings, including distribution or use restrictions, contained in the products' 49Table of Contents approved labeling; 49Table of Contents any distribution and use restrictions imposed by the FDA or comparable foreign regulatory authorities or to which we agree as part of a mandatory REMS or voluntary risk management plan; 49Table of Contents third-party intellectual property rights that another may allege are violated by our product candidates; 49Table of Contents liability for sales or marketing personnel who fail to comply with the applicable legal and regulatory requirements; 49Table of Contents the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and 49Table of Contents unforeseen costs and expenses associated with creating an independent sales and marketing organization or engaging a contract sales organization. Our product candidates are based on a novel approach to the treatment of cancer, which makes it difficult to predict the time and cost of product candidate development. We have concentrated all of our research and development efforts on product candidates based on our proprietary RPx platform, and our future success depends on the successful development of this therapeutic approach. There can be no assurance that any development problems we experience in the future will not cause significant delays or unanticipated costs, or that such development problems can be solved. Should we encounter development problems, including unfavorable preclinical or clinical trial results, the FDA and foreign regulatory authorities may refuse to approve our product candidates, or may require additional information, tests, or trials, which could significantly delay product development and significantly increase our development costs. Moreover, even if we are able to provide the requested information or trials to the FDA, there would be no guarantee that the FDA would accept them or approve our product candidates. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process, or developing or qualifying and validating product release assays, other testing and manufacturing methods, and our equipment and facilities in a timely manner, which may prevent us from completing our clinical trials or commercializing our product candidates on a timely or profitable basis, if at all. In addition, the clinical trial requirements of the FDA and comparable foreign regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The FDA and comparable foreign regulatory authorities have limited experience with the approval of oncolytic immunotherapies. Only one oncolytic immunotherapy, T-Vec, has received FDA approval to date. Any product candidates that are approved may be subject to extensive post approval regulatory requirements, including requirements pertaining to manufacturing, distribution, and promotion. We may need to devote significant time and resources to compliance with these requirements. If our product candidates do not achieve broad market acceptance, the revenues that we generate from their sales may be limited, and we may never become profitable. 51Table of Contents We have never commercialized a product candidate for any indication. Even if our product candidates are approved by the appropriate regulatory authorities for marketing and sale, they may not gain acceptance among physicians, patients, third-party payors, and others in the medical community. If any product candidates for which we obtain regulatory approval do not gain an adequate level of market acceptance, we could be prevented from or significantly delayed in achieving profitability. Market acceptance of our product candidates by the medical community, patients, and third-party payors will depend on a number of factors, some of which are beyond our control. For example, physicians are often reluctant to switch their patients and patients may be reluctant to switch from existing therapies even when new and potentially more effective or safer treatments enter the market. Efforts to educate the medical community and third party payors on the benefits of our product candidates may require significant resources and may not be successful. If any of our product candidates is approved but does not achieve an adequate level of market acceptance, we could be prevented from or significantly delayed in achieving profitability. The degree of market acceptance of any of our product candidates will depend on a number of factors, including: 49Table of Contents the efficacy of our product candidates in combination with marketed checkpoint blockade drugs; 49Table of Contents the commercial success of the checkpoint blockade drugs with which our products are co-administered; 49Table of Contents the prevalence and severity of adverse events associated with our product candidates or those products with which they are co-administered; 49Table of Contents the clinical indications for which the products are approved and the approved claims that we may make for the products; 49Table of Contents limitations or warnings contained in the product's 49Table of Contents FDA-approved labeling or those of comparable foreign regulatory authorities, including potential limitations or warnings for our product candidates that may be more restrictive than other competitive products; 49Table of Contents changes in the standard of care for the targeted indications for our product candidates, which could reduce the marketing impact of any claims that we could make following FDA approval or approval by comparable foreign regulatory authorities, if obtained; 49Table of Contents the relative convenience and ease of administration of our product candidates by direct injection into tumors, a less common method for the administration of oncology therapies than systemic administration, which may result in slower adoption of our therapies; 49Table of Contents the relative convenience and ease of administration of any products with which our product candidates are co-administered; 49Table of Contents the cost of treatment compared with the economic and clinical benefit of alternative treatments or therapies; 49Table of Contents the availability of adequate coverage or reimbursement by third parties, such as insurance companies and other healthcare payors, and by government healthcare programs, including Medicare and Medicaid; 49Table of Contents the price concessions required by third-party payors to obtain coverage; 49Table of Contents the extent and strength of our marketing and distribution of our product candidates; 49Table of Contents the safety, efficacy, and other potential advantages over, and availability of, alternative treatments already used or that may later be approved; 49Table of Contents distribution and use restrictions imposed by the FDA or comparable foreign regulatory authorities with respect to our product candidates or to which we agree as part of a REMS or voluntary risk management plan; 49Table of Contents the timing of market introduction of our product candidates, as well as competitive products; 49Table of Contents our ability to offer our product candidates for sale at competitive prices; 49Table of Contents the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; 52Table of Contents 49Table of Contents the extent and strength of our manufacturing operations and our third-party manufacturer and supplier support; 49Table of Contents the actions of companies that market any products with which our product candidates are co-administered; 49Table of Contents the approval of other new products; 49Table of Contents adverse publicity about our product candidates or any products with which they are co-administered, or favorable publicity about competitive products; and 49Table of Contents potential product liability claims. The successful commercialization of our product candidates, if approved, will depend in part on the extent to which government authorities and health insurers establish adequate reimbursement levels and pricing policies. Sales of any approved drug candidate will depend in part on the availability of coverage and reimbursement from third-party payers such as government insurance programs, including Medicare and Medicaid, private health insurers, health maintenance organizations and other health

care related organizations, who are increasingly challenging the price of medical products and services. Accordingly, coverage and reimbursement may be uncertain. Adoption of any drug by the medical community may be limited if third-party payers will not offer adequate coverage. Additionally, significant uncertainty exists as to the reimbursement status of newly-approved drugs. Cost control initiatives may decrease coverage and payment levels for any drug and, in turn, the price that we will be able to charge and/or the volume of our sales. We are unable to predict all changes to the coverage or reimbursement methodologies that will be applied by private or government payers. Any denial of private or government payer coverage or inadequate reimbursement could harm our business and reduce our revenue. In addition, both the federal and state governments in the United States and foreign governments continue to propose and pass new legislation, regulations, and policies affecting coverage and reimbursement rates, which are designed to contain or reduce the cost of health care. Further federal and state proposals and healthcare reforms are likely, which could limit the prices that can be charged for the product candidates that we develop and may further limit our commercial opportunity. For example, the Inflation Reduction Act of 2022, or IRA, includes several measures intended to lower the cost of prescription drugs and related healthcare reforms, including limits on price increases and subjecting an escalating number of drugs to annual price negotiations with CMS. We cannot be sure whether additional legislation related to the IRA will be issued or enacted, or what impact, if any, such changes will have on the profitability of any of our drug candidates, if approved for commercial use, in the future. There also may be future changes unrelated to the IRA that result in reductions in potential coverage and reimbursement levels for our product candidates, if approved and commercialized, and we cannot predict the scope of any future changes or the impact that those changes would have on our operations. If future reimbursement for approved product candidates, if any, is substantially less than we project, or rebate obligations associated with them are substantially greater than we expect, our future net revenue and profitability could be materially diminished. The size of the potential market for our product candidates is difficult to estimate and, if any of our assumptions are inaccurate, the actual markets for our product candidates may be smaller than our estimates. The potential market opportunities for our product candidates are difficult to estimate and will depend in large part on the drugs with which our product candidates are co-administered and the success of competing therapies and therapeutic approaches. In particular, the market opportunity for oncolytic immunotherapies is hard to estimate given that it is an emerging field with only one existing FDA-approved oncolytic immunotherapy, T-Vec, which has yet to enjoy broad market acceptance. Our estimates of the potential market opportunities are predicated on many assumptions, which may include industry knowledge and publications, third-party research reports, and other surveys. Although we believe that our internal assumptions are reasonable, these assumptions involve the exercise of significant judgment on the part of our management, are inherently uncertain, and their reasonableness has not been assessed by an independent source. If any of the assumptions proves to be inaccurate, the actual markets for our product candidates could be smaller than our estimates of the potential market opportunities. Negative developments in the field of immuno-oncology could damage public perception of our product candidates and negatively affect our business. The commercial success of our product candidates will depend in part on public acceptance of the use of cancer immunotherapies. Adverse events in clinical trials of RP1 or our other product candidates or in clinical trials of others developing similar products and the resulting publicity, as well as any other negative developments in the field of immuno-oncology that may occur in the future, including in connection with competitor therapies, could result in a decrease in demand for our product candidates. These events could also result in the suspension, discontinuation, or clinical hold of or modification to our clinical trials. If public perception is influenced by claims that the use of cancer immunotherapies is unsafe, whether related to our therapies or those of our competitors, our product candidates may not be accepted by the general public or the medical community and potential clinical trial subjects may be discouraged from enrolling in our clinical trials. As a result, we may not be able to continue or may be delayed in conducting our development programs. As our product candidates consist of a modified virus, adverse developments in antiviral vaccines or clinical trials of other oncolytic immunotherapy products based on viruses may result in a disproportionately negative effect for our product candidates as compared to other products in the field of immuno-oncology that are not based on viruses. Future negative developments in the field of immuno-oncology or the biopharmaceutical industry could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of our products. Any increased scrutiny could delay or increase the costs of obtaining marketing approval for our product candidates. Risks related to our financial position and need for additional capital We are a clinical stage biopharmaceutical company with a very limited operating history. We have incurred net losses since our inception and anticipate that we will continue to incur substantial and increasing net losses in the foreseeable future. We may never achieve or sustain profitability. We are a clinical stage biopharmaceutical company with a limited operating history, and we are early in our development efforts. We have no products approved for commercial sale and have not generated any revenue from product sales to date, and we continue to incur significant research and development and other expenses related to our ongoing operations. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain marketing approval and become commercially viable. We have financed our operations to date primarily through the sale of equity securities, including the sale of our common stock and pre-funded warrants in our public offerings. Since our inception, most of our resources have been dedicated to the preclinical and clinical development of our proprietary RPx platform, including our lead product candidate, RP1, and our other product candidates. The size of our future net losses will depend, in part, on our future expenses and our ability to generate revenue, if any. We are not profitable and have incurred losses in each period since our inception. For the three months ended June 30, 2024 and 2023, we reported a net loss of \$53.8 million and \$49.6 million, respectively. At June 30, 2024, we had an accumulated deficit of \$755.1 million. We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek marketing approvals for, RP1, our other product candidates and any additional product candidates we may develop. Even if we succeed in receiving marketing approval for and commercialize RP1 or our other product candidates, we will continue to incur substantial research and development and other expenditures to develop and market additional potential products. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders' equity and working capital. Our ability to generate revenue from product sales and become profitable will depend significantly on our success in achieving a number of goals. We have no products approved for commercial sale, have not generated any revenue from product sales, and do not anticipate generating any revenue from product sales until after we have received marketing approval for the commercial sale of a product candidate, if ever. Our ability to generate revenue and achieve profitability depends significantly on our success in achieving a number of goals, including: completing research regarding, and preclinical and clinical development of, RP1 and our other product candidates; obtaining marketing approvals for RP1 and our other product candidates for which we complete clinical trials; developing a sustainable and scalable manufacturing process for RP1 and our other product candidates, including establishing and maintaining commercially viable supply and manufacturing relationships with third parties; launching and commercializing RP1 and our other product candidates for which we obtain marketing approvals, either directly or with a collaborator or distributor; obtaining market acceptance of RP1 and our other product candidates as viable treatment options; addressing any competing technological and market developments; identifying, assessing, acquiring and developing new product candidates; negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter; obtaining, maintaining, protecting, and expanding our portfolio of intellectual property rights, including patents, trade secrets, and know-how; and attracting, hiring, and retaining qualified personnel. Even if our product candidates or any future product candidates that we develop are approved for commercial sale, we anticipate incurring significant costs associated with commercializing any such product candidate. Our expenses could increase beyond expectations if we are required by the FDA or comparable foreign regulatory authorities to change our manufacturing processes or assays, or to perform clinical, nonclinical, or other types of studies in addition to those that we currently anticipate. If we are successful in obtaining regulatory approvals to market RP1 or our other product candidates, our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain marketing approval, the accepted price for the product, the ability to get reimbursement at any price, and whether we own the commercial rights for that territory. If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect, the labels for our product candidates contain significant safety warnings, regulatory authorities impose burdensome or restrictive distribution requirements, or the reasonably accepted patient population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. If we are not able to generate revenue from the sale of any approved products, we could be prevented from or significantly delayed in achieving profitability. We will require additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development or commercialization efforts. Our operations have consumed substantial amounts of cash since inception. At June 30, 2024, our cash and cash equivalents and short-term investments were \$469.1 million. We expect to continue to spend substantial amounts to continue the clinical and preclinical development of RP1 and our other product candidates. Accordingly, we will need to obtain additional funds to achieve our business objectives. If we are able to gain marketing approval of any product candidate, we will require significant additional amounts of cash in order to launch and commercialize such product. In addition, other unanticipated costs may arise. Our future capital requirements depend on many factors, including: the scope, progress, results and costs of researching and developing RP1 and our other product candidates, and conducting preclinical studies and clinical trials; the timing of, and the costs involved in, obtaining marketing approvals for RP1 and our other product candidates if clinical trials are successful; the success of any collaborations; the cost of commercialization activities for any approved product, including marketing, sales and distribution costs; the cost and timing of operating our manufacturing facility; the cost of manufacturing RP1 and our other product candidates for clinical trials in preparation for marketing approval and commercialization; our ability to establish and maintain strategic licensing or other arrangements and the financial terms of such agreements; the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; the timing, receipt, and amount of sales of, or royalties on, our future products, if any; and the emergence of competing cancer therapies and other adverse market developments. We do not have any committed external source of funds or other support for our development efforts. Until we can generate sufficient product revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. Based on our current operating plan, we expect that our existing cash and cash equivalents and short-term investments, as of June 30, 2024 will enable us to fund operations into the second half of 2026 which includes scale up for the commercialization of RP1 in skin cancers and for working capital and general corporate purposes. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. In addition, because the design and outcome of our planned and anticipated clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of RP1 or our other product candidates. We maintain our cash at financial institutions, often in balances that exceed federally insured limits. Our cash, cash equivalents and short-term investments are held in accounts with banking institutions. The balances of some of these accounts have in the past, and may in the future, exceed the Federal Deposit Insurance Corporation (FDIC) insurance limits. If such banking institutions were to fail, we could lose all or a portion of those amounts held in excess of such insurance limitations. In March 2023, the FDIC took control of Silicon Valley Bank (SVB), where we previously held a portion of our cash. The Federal Reserve subsequently announced that account holders would be made whole and we were able to access all of our cash held at SVB. However, the FDIC may not make all account holders whole in the event of future bank failures. In addition, even if account holders are ultimately made whole with respect to a future bank failure, account holders' access to their accounts and assets held in their accounts may be substantially delayed. Any material loss that we may experience in the future or inability for a material time period to access our cash, short-term investments and cash equivalents could have an adverse effect on our ability to pay our operational expenses, fund our operations or make other payments, which could adversely affect our business. Risks related to intellectual property If we are unable to obtain, maintain and protect our intellectual property rights for our technology and product candidates, or if our intellectual property rights are inadequate, our competitive position could be harmed. Our commercial success will depend in part on our ability to obtain and maintain patent and other intellectual property protection in the United States and other countries with respect to our technology, proprietary RPx platform, including our lead product candidate, RP1, and our other product candidates. We rely on trade secret, patent, copyright and trademark laws, and confidentiality, licensing and other agreements with employees and third parties, all of which offer only limited protection. The patent positions of biotechnology and pharmaceutical companies generally are highly uncertain, involve complex legal and factual questions and have in recent years been the subject of much litigation and subject to change with regulatory agencies and court decisions. As a result, the issuance, scope, validity, enforceability and commercial value of our licensed patents and any patents we own in the future are highly uncertain. The steps we have taken to protect our proprietary rights may not be adequate to preclude misappropriation of our proprietary information, use by third parties of our products or infringement of our intellectual property rights, both inside and outside of the United States. Our pending applications cannot be enforced against third parties practicing the inventions claimed in such applications unless and until a patent issues from such applications. Because the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, our issued patents and issued patents that we license from third parties or may own have been and in the future may be challenged in the courts or patent offices in the United States and abroad. Further, the examination process may require us to narrow the claims for our pending patent applications, which may limit the scope of patent protection that may be obtained if these applications issue. The scope of a patent may also be interpreted or reinterpreted after issuance. The rights that may be granted under our future issued patents may not provide us with the proprietary protection or competitive advantages we are seeking. In addition, defending against challenges in respect of the inventorship, scope, validity or enforceability of our patents may be expensive, time consuming, difficult and in some cases may not be possible. Although we enter into nondisclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, collaborators, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, the patent prosecution process is expensive, time consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. If we are unable to obtain and maintain patent protection for our technology or inventions, or for RP1 or our other product candidates, or if the scope of the patent protection obtained is not sufficient, our competitors could develop and commercialize products similar or superior to ours, and our ability to successfully commercialize RP1 or our other product candidates and future technologies or inventions may be adversely affected. Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time, and our product candidates for which we intend to seek approval as biological products may face competition sooner than anticipated. Given the amount of time required for the development, testing and regulatory review of our product candidates, such as RP1 and our other product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. Filing, prosecuting and defending patents on our technology or inventions in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries or religions outside the United States can be less protective of our products than those in the United States. In addition, the laws and practices of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Changes to the patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect RP1 and our other product candidates. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies or inventions in jurisdictions where we have not obtained patent protection to develop and/or manufacture their own products and may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as that in the United States. These products may compete with our products and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing. Protecting against the unauthorized use of our patented inventions, trademarks and other intellectual property rights is expensive, time consuming, difficult and in some cases may not be possible. In some cases, it may be difficult or impossible to detect third-party infringement or misappropriation of our intellectual property rights, even in relation to issued patent claims, and proving any such infringement or misappropriation may be even more difficult. If we are unable to obtain, maintain, and protect our intellectual property or our competitive

advantage could be harmed, and it could result in a material adverse effect on our business, financial condition, results of operations, stock price and prospects. In addition to seeking patent protection, we also rely on other proprietary rights, including protection of trade secrets, know-how and confidential and proprietary information. Although we enter into confidentiality agreements with our employees, consultants, collaborators, suppliers, manufacturers and other third parties who have access to our trade secrets, and our agreements with employees also provide that any inventions conceived by the individual in the course of rendering services to us shall be our exclusive property, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms or may have conflicting agreements with third parties. In addition, in the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. To the extent that our employees, consultants or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions. If any of our trade secrets, know-how or confidential or proprietary information were to be lawfully obtained, patented or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us and may be blocked from using such trade secrets, know-how or confidential or proprietary information ourselves. The disclosure of our trade secrets or the independent development of our trade secrets by a competitor or other third party would impair our competitive position and may materially harm our business, financial condition, results of operations, stock price and prospects. Third parties may in the future initiate legal proceedings alleging that we are infringing their intellectual property rights, and we may become involved in lawsuits or other administrative procedures to protect or enforce our intellectual property, which could be expensive, time consuming and unsuccessful and have a material adverse effect on the success of our business. Our commercial success depends on our ability and the ability of our current or future collaborators to develop, manufacture, market and sell RP1 and our other product candidates, and to use our related proprietary technologies without 57Table of Contentsinfringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights. We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our current and any other future product candidates. For example, we are aware of U.S. Patent 10,034,938 (the “’938 Patent”) held by Amgen Inc., which includes claims purported to cover methods and kits for treating stage IIIB to IV melanoma by the administration of (i) an effective amount of an anti-PD-1 antibody or anti-CTLA-4 antibody; and (ii) a herpes simplex virus, wherein the herpes simplex virus lacks a functional ICP34.5 encoding gene and a functional ICP47 encoding gene, and comprises a gene encoding human GM-CSF. On November 2, 2022, we filed a petition for inter partes review with the Patent Trial and Appeal Board (PTAB) of the USPTO, seeking to invalidate certain claims of United States Patent 10,034,938 (the “’938 Patent”). In August 2023 we entered into a Settlement Agreement with Amgen and mutually agreed to terminate our challenges to their patents. In connection with the Settlement Agreement, we entered into a License and Covenant Agreement with Amgen in which we agreed to pay Amgen low single-digit royalty payments on net sales of our products that, but for the license, could be found to infringe a valid Amgen patent on a country-by-country and product-by-product basis. Third parties may assert infringement or other intellectual property claims against us based on existing patents or patents that may be filed and/or granted in the future. At times we may attempt to initiate litigation or other administrative procedures to invalidate or otherwise limit the scope of a third party’s intellectual property and these attempts may not be successful. If we are found to infringe a third party’s intellectual property rights, and we are unsuccessful in demonstrating that such intellectual property rights are invalid, unenforceable or otherwise not infringed, we could be required to obtain a license from such third-party to continue developing, manufacturing and commercializing RP1 and our other product candidates. Such a license may not be available on commercially reasonable terms, or at all. Even if we were able to obtain a license, it could be nonexclusive, thereby giving our competitors and other third parties access to the same technologies and inventions licensed to us, and it could require us to make substantial licensing and royalty payments. We also could be forced, including by court order, to cease developing, manufacturing, and commercializing RP1 or our other product candidates or we could be found liable for significant monetary damages if we are found to have willfully infringed a patent or other intellectual property right. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, stock price and prospects. Any claims by third parties that we have misappropriated their know-how, confidential or proprietary information or trade secrets could have a similar material adverse effect on our business, financial condition, results of operations, stock price and prospects. If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering any of our technology or inventions, the defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable. If a third party were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on RP1 and our other product candidates. Such a loss of patent protection could have a material adverse impact on our business, financial condition, results of operations, stock price and prospects. Many of our employees, including our senior management team, were previously employed at, or consulted for, universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we take steps to ensure that our employees do not use, claim as theirs, or misappropriate the intellectual property, confidential or proprietary information, know-how or trade secrets of others in their work for us, we may be subject to claims that we or these employees have used, claimed as theirs, misappropriated or disclosed intellectual property, including trade secrets, know-how or other confidential or proprietary information, of any such individual’s current or former employer. Litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third-party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms, or at all. In addition, we are developing certain of our product candidates in combination with nivolumab and cemiplimab, which are covered by patents or licenses held by BMS and Regeneron, respectively, to which we do not have a license other than for use in connection with the applicable clinical trial. We also may develop our product candidates in combination with products developed by additional companies that are covered by patents or licenses held by those entities to which we do not have a license. In the event that a labeling instruction is required in product packaging recommending that combination, we could be accused of, or held liable for, infringement of the third-party patents covering the product candidate or product recommended for administration with RP1 or our other product candidates. In such a case, we could be required to obtain a license from the other company or institution to use the required or desired package labeling, which license may not be available on commercially reasonable terms, or at all. Competitors may infringe any future licensed patents or any patent we own in the future or misappropriate or otherwise violate our intellectual property rights. We may also be required to defend against claims of infringement and our 58Table of Contentslicensed patents and any patents we own in the future may become involved in priority or other intellectual property related disputes. To counter infringement or unauthorized use, litigation may be necessary in the future to enforce or defend our intellectual property rights, to protect our trade secrets or to determine the validity and scope of our own intellectual property rights or the proprietary rights of others. These proceedings can be expensive and time consuming. Many of our current and potential competitors have the ability to dedicate substantially greater resources to conduct intellectual property related litigation or proceedings than we can. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating our intellectual property. An adverse result in any litigation or other intellectual property related proceeding could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation in the United States, there is a risk that some of our trade secrets, know-how, or proprietary or confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments in any such proceedings. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Any of the foregoing may have a material adverse effect on our business, financial condition, results of operations, stock price and prospects. Risks related to manufacturing and our reliance on third partiesWe have agreements with BMS and Regeneron, and in the future may have agreements with other companies, to obtain the supply of anti-PD-1 therapies for the development of our product candidates. If our relationships with BMS, Regeneron, or any future collaborator or supplier are not successful, we may be delayed in completing the development of our product candidates. We have entered into arrangements with BMS and Regeneron as part of our clinical development for our product candidates where nivolumab or cemiplimab, respectively, are intended to be used for these clinical programs. BMS is providing nivolumab, its anti-PD-1 therapy, for use in our ongoing IGNYTE Phase 1/2 trials with RP1 and our Phase 1/2 clinical trial with RP2 where we intend to use nivolumab and may potentially do so for other clinical trials in the future; Regeneron agreed to provide cemiplimab, its anti-PD-1 therapy, for use in our CERPASS Phase 2 clinical trial and may potentially do so for other clinical trials in the future. We may also enter into agreements with additional companies for the supply of anti-PD-1 therapies for use in the development of RP1 and our other product candidates, similar to our agreement with Roche. The outcome of these clinical trials is dependent, in part, both on the performance of our partners’ products and product candidates and also on our partners’ ability to deliver sufficient quantities of adequately produced product. Should any of our partners’ products or product candidates fail to produce the results that we anticipate, we may have to re-run clinical trials for RP1 or our other product candidates or may otherwise be delayed in the commercialization of RP1 or our other product candidates. Similarly, should any partner fail to provide us with a product or product candidate that suits our requirements, we may have to re-run clinical trials for RP1 or our other product candidates or may be otherwise delayed in the commercialization of RP1 or our other product candidates. Additionally, we are subject to specific risks associated with our collaboration partners, including possible discrepancies as to the timing, nature and the extent of development plans, contract interpretations, and the costs and allocation of costs related to the conduct of our clinical trials. If we and any collaboration partner are unable to agree or fail to perform our respective obligations or effectively manage our relationship, our clinical trials performed under such collaboration could incur additional costs, be delayed or could result in costly or time-consuming legal proceedings that could have an adverse effect on a collaboration or on our business. Our collaboration agreements with any future partners may not be successful, which could adversely affect our ability to develop and commercialize our product candidates. We may in the future seek collaboration arrangements with other parties for the development or commercialization of our product candidates. The success of any collaboration arrangements may depend on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these arrangements. Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration arrangement. Collaborations with biopharmaceutical companies and other third parties often are terminated or allowed to expire by the other party. Any such termination or expiration could adversely affect us financially and could harm our business reputation. 59Table of ContentsAny future collaborations we might enter into may pose a number of risks, including the following:• collaborators may not perform their obligations as expected;• collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators’ strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;• collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;• collaborators could fail to make timely regulatory submissions for a product candidate;• collaborators may not comply with all applicable regulatory requirements or may fail to report safety data in accordance with all applicable regulatory requirements, which could subject them or us to regulatory enforcement actions;• collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;• product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;• a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product candidate or product;• disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time consuming and expensive;• collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; and• collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability. If any collaborations we might enter into in the future do not result in the successful development and commercialization of products or if one of our collaborators subsequently terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under such potential future collaboration. If we do not receive the funding we expect under the agreements, our development of our product candidates could be delayed and we may need additional resources to develop our product candidates and our product platform. Additionally, if any future collaborator of ours is involved in a business combination, the collaborator might de-emphasize or terminate development or commercialization of any product candidate it licenses to us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our reputation in the business and financial communities could be adversely affected. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for any collaboration will depend upon, among other things, our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator’s evaluation of a number of factors. 60Table of ContentsIf we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms, or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our product platform and our business may be materially and adversely affected. We rely, and expect to continue to rely, on third parties to conduct, supervise, and monitor our preclinical studies and clinical trials. If those third parties do not perform satisfactorily, including failing to meet deadlines for the completion of such trials or failing to comply with regulatory requirements, we may be unable to obtain regulatory approval for our product candidates or any other product candidates that we may develop in the future. We rely on third-party CROs, study sites, and others to conduct, supervise, and monitor our preclinical studies and clinical trials for our product candidates and do not currently plan to independently conduct preclinical studies or clinical trials of any other potential product candidates. We expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions, and clinical investigators, to conduct our preclinical studies and clinical trials. Although we have agreements governing their activities, we have limited influence over their actual performance and control only certain aspects of their activities. The failure of these third parties to successfully carry out their contractual duties or meet expected deadlines could substantially harm our business because we may be delayed in completing or unable to complete the studies required to support future approval of our product candidates, or we may not obtain marketing approval for or commercialize our product candidates in a timely manner or at all. Moreover, these agreements might terminate for a variety of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements our product development activities would be delayed and our business, financial condition, results of operations, stock price and prospects may be materially harmed. Our reliance on these third parties for development activities will reduce our control over these activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards and our reliance on third parties does not relieve us of our regulatory responsibilities. For example, we will remain responsible for ensuring that each of our trials is conducted in accordance with the general investigational plan and protocols for the trial. We must also ensure that our preclinical trials are conducted in accordance with the FDA’s Good Laboratory Practice, or GLP, regulations, as appropriate. Moreover, the FDA and comparable foreign regulatory

authorities require us to comply with standards, commonly referred to as GCPs for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. Regulatory authorities enforce these requirements through periodic inspections of trial sponsors, clinical investigators, and trial sites. If we or any of our third parties fail to comply with applicable GCPs or other regulatory requirements, we or they may be subject to enforcement or other legal actions, the data generated in our trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional studies. In addition, our clinical trials must be conducted with product candidates that were produced under cGMP regulations. Failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our preclinical studies or clinical trials in accordance with regulatory requirements or our stated protocols, if they need to be replaced or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our protocols, regulatory requirements or for other reasons, our trials may be repeated, extended, delayed, or terminated; we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates; we may not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates, or we or they may be subject to regulatory enforcement actions. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. To the extent we are unable to successfully identify and manage the performance of third-party service providers in the future, our business, financial condition, results of operations, stock price and prospects may be materially harmed. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative providers or to do so on commercially reasonable terms. Switching or adding additional third parties involves additional cost and may result in delays that could compromise our ability to meet our desired development timelines.

61 Table of Contents We also rely on other third parties to store and distribute our products for the clinical trials that we conduct. Any performance failure on the part of our distributors could delay clinical development, marketing approval, or commercialization of our product candidates, which could result in additional losses and deprive us of potential product revenue. If the manufacturers upon which we rely fail to produce our raw materials or process consumables in the volumes that we require on a timely basis, or fail to comply with stringent regulations applicable to biopharmaceutical manufacturers, we may face delays in the development and commercialization of, or be unable to meet demand for, our product candidates and may lose potential revenues. We continue to rely on third-party contract manufacturers to manufacture our raw materials and certain clinical trial product supplies. As a result, there can be no assurance that our clinical development or commercial supplies will not be limited, interrupted, or of satisfactory quality or continue to be available at acceptable prices. We currently have only one in-house manufacturing site approved for use in our clinical trials. In addition, we do not have any long-term commitments from our suppliers of raw materials or clinical trial material or guaranteed prices for our product candidates or their components. There are a limited number of manufacturers that operate under cGMP regulations and that are both capable of manufacturing and filling our viral product for us and willing to do so. If our existing third-party manufacturers of raw materials or our product candidates, or the third parties that we engage in the future, should cease to work with us, we likely would experience delays in obtaining sufficient quantities of our product candidates for us to meet commercial demand or to advance our clinical trials while we identify and qualify replacement suppliers. Any replacement of our contract manufacturer could require significant effort and expertise because there may be a limited number of qualified replacements. Any delays in obtaining adequate supplies of our raw materials or product candidates that meet the necessary quality standards may delay our development or commercialization. If our manufacturers of raw materials, equipment or process consumables do not perform as agreed or encounter difficulties in production costs and yields, quality control, shortages of qualified personnel or key raw materials, compliance with strictly enforced federal, state, and foreign regulations, or other difficulties, our ability to provide product candidates to patients in our clinical trials could be jeopardized. In addition, if our Framingham manufacturing site cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or other regulatory authorities, we will not be able to secure or maintain regulatory approval for our manufacturing facilities. Any such deviations may also require remedial measures that may be costly and/or time consuming for us or a third party to implement and that may include the temporary or permanent suspension of a clinical trial or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business. Any delays in obtaining raw materials, products or product candidates that comply with the applicable regulatory requirements may result in delays to clinical trials, product approvals, and commercialization. We are ultimately responsible for the manufacturing of our product candidates and therapeutic substances, but, other than through our contractual arrangements, we have limited control over our raw materials or process consumables manufacturers' compliance with these regulations and standards. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. We must also receive FDA approval for the use of any new manufacturers for clinical or commercial supply, including our own manufacturing facility. A failure to comply with the applicable regulatory requirements, including periodic regulatory inspections, may result in regulatory enforcement actions against us (including fines and civil and criminal penalties, including imprisonment) suspension or restrictions of production, injunctions, delay or denial of product approval or supplements to approved products, clinical holds or termination of clinical trials, warning or untitled letters, regulatory authority communications warning the public about safety issues with the product candidate, refusal to permit the import or export of the products, product seizure, detention, or recall, operating restrictions, suits under the civil False Claims Act, corporate integrity agreements, consent decrees, withdrawal of product approval, environmental or safety incidents and other liabilities. If the safety of any quantities supplied is compromised due to our manufacturing failures to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. The transition of our manufacturing operations to, and operating and maintaining, our own manufacturing facility may result in further delays or expenses, and we may not experience the anticipated operating efficiencies.

62 Table of Contents Our approximately 63,000 square foot manufacturing facility in Framingham, Massachusetts is now fully operational. We have completed the process of transferring the manufacturing of RP1, RP2 and RP3 from our third-party contract manufacturer. Comparability analysis of RP1, RP2 and RP3 produced at our in-house Framingham facility with the contract manufacturer material used in our clinical studies is complete. The FDA and some European regulatory agencies have approved the use of material produced at our Framingham facility in ongoing and future clinical trials. The Framingham facility is intended to give us control over key aspects of the supply chain for our products and product candidates. However, we may not experience the anticipated operating efficiencies as we commence manufacturing operations at the new facility. Any such delays may disrupt or delay the supply of our product candidates if we have not maintained a sufficient backup supply of our product candidates through third-party manufacturers. Moreover, changing manufacturing facilities may also require that we conduct additional studies, make notifications to the regulatory authorities, make additional filings to the regulatory authorities, and obtain regulatory authority approval for the new facilities, which may be delayed or which we may never receive. We will further need to comply with the FDA's and applicable foreign regulatory authorities' cGMP requirements for the production of our product candidates for clinical trials and, if approved, commercial supply, and will be subject to FDA and comparable foreign regulatory authority inspections. We may not be able to develop or acquire the internal expertise and resources necessary for compliance with these requirements. If we are not able to comply with the applicable regulatory requirements or produce product that meets our requirements and specifications, we will be subject to the same risks that we would be subject to should third party manufacturers be unable to comply with the applicable regulatory requirements or produce product meeting our requirements or specifications, as described above. If we fail to achieve the operating efficiencies that we anticipate, our manufacturing and operating costs may be greater than expected, which could have a material adverse impact on our operating results. In operating our own manufacturing facility, we may be forced to devote greater resources and management time than anticipated, particularly in areas relating to operations, quality, raw material supply, regulatory, facilities and information technology. Further, should corrective or preventative actions be required, we will be fully responsible for these. If we experience unanticipated employee turnover in any of these areas, we may not be able to effectively manage our ongoing manufacturing operations and we may not achieve the operating efficiencies that we anticipate from the new facility, which may negatively affect our product development timeline, product candidate supplies and, if approved, our commercial products. If we experience any unanticipated shortages of key raw materials, or other difficulties related to our raw material supply, we may not be able to effectively manage our ongoing manufacturing timelines and costs which may negatively affect our product development schedule and our ability to provide clinical trial supplies to patients in our clinical trials, and if approved, our commercial product supplies. Any problems or delays we experience in preparing for commercial scale manufacturing of a product candidate or component may result in a delay in product development timelines and FDA or comparable foreign regulatory authority approval of the product candidate or may impair our ability to manufacture commercial quantities or such quantities at an acceptable cost and quality, which could result in the delay, prevention, or impairment of clinical development and commercialization of our product candidates and may materially harm our business, financial condition, results of operations, stock price and prospects. Any such problems could result in the delay, prevention, or impairment of clinical development and commercialization of our product candidates and may materially harm our business, financial condition, results of operations, stock price and prospects. Risks related to legal and compliance matters: We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability and have to limit the commercialization of any approved products and/or our product candidates. The use of our product candidates in clinical trials, and the sale of any product for which we obtain regulatory approval, exposes us to the risk of product liability claims. We face inherent risk of product liability related to the testing of our product candidates in human clinical trials, including liability relating to the actions and negligence of our investigators, and will face an even greater risk if we commercially sell any product candidates that we may develop. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. Product liability claims might be brought against us by consumers, healthcare providers or others using, administering or selling our products. If we cannot successfully defend ourselves against these claims, we will incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of merit or eventual outcome, liability claims may result in: **63 Table of Contents** **6** loss of revenue from decreased demand for our products and/or product candidates; **6** impairment of our business reputation or financial stability; **6** costs of related litigation; **6** substantial monetary awards to patients or other claimants; **6** diversion of management attention; **6** withdrawal of clinical trial participants and potential termination of clinical trial sites or entire clinical programs; **6** the inability to commercialize our product candidates; **6** significant negative media attention; **6** decreases in our stock price; **6** initiation of investigations and enforcement actions by regulators; and **6** product recalls, withdrawals or labeling, marketing or promotional restrictions, including withdrawal of marketing approval. We believe we have sufficient insurance coverage in place for our business operations. However, our insurance coverage may not reimburse us or may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. We intend to expand our insurance coverage to include the sale of commercial products if we obtain FDA or comparable foreign regulatory approval for our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products approved for marketing, or at all. Failure to obtain and retain sufficient product liability insurance at an acceptable cost could prevent or inhibit the commercialization of products we develop. A successful product liability claim or series of claims brought against us could cause our stock price to fall and, if judgments exceed our insurance coverage, could decrease our cash, and materially harm our business, financial condition, results of operations, stock price and prospects. We are subject to the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act and other anticorruption laws, as well as import and export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect our business, financial condition, results of operations, stock price and prospects. Our operations are subject to anticorruption laws, including the U.S. Foreign Corrupt Practices Act, or FCPA, the U.K. Bribery Act 2010, or the Bribery Act, and other anticorruption laws that apply in countries where we do business. We also may participate in collaborations and relationships with third parties whose actions, if noncompliant, could potentially subject us to liability under the FCPA, Bribery Act or local anticorruption laws. We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United States and the United Kingdom and authorities in the European Union, including applicable import and export control regulations, economic sanctions on countries and persons, anti-money laundering laws, customs requirements and currency exchange regulations, collectively referred to as the trade control laws. We can provide no assurance that we will be completely effective in ensuring our compliance with all applicable anticorruption laws or other legal requirements, including trade control laws. If we are not in compliance with applicable anticorruption laws or trade control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations, stock price and prospects. Likewise, any investigation of any potential violations of these anticorruption laws or trade control laws by U.S., U.K. or other authorities could also have an adverse impact on our reputation, our business, financial condition, results of operations, stock price and prospects.

64 Table of Contents If we fail to comply with federal and state healthcare laws, including fraud and abuse and health and other information privacy and security laws, we could face substantial penalties and our business, financial condition, results of operations, stock price and prospects will be materially harmed. We are subject to many federal and state healthcare laws, such as the federal Anti-Kickback Statute, the federal civil and criminal False Claims Acts, the civil monetary penalties statute, the Medicaid Drug Rebate statute and other price reporting requirements, the Veterans Health Care Act of 1992, or VHCA, the federal Health Insurance Portability and Accountability Act of 1996 (as amended by the Health Information Technology for Economics and Clinical Health Act, or HITECH), or HIPAA, the FCPA, the ACA, and similar state laws. Even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, certain federal and state healthcare laws, and regulations pertaining to fraud and abuse, reimbursement programs, government procurement, and patients' rights are and will be applicable to our business. We would be subject to healthcare fraud and abuse and patient privacy regulation by both the federal government and the states and foreign jurisdictions in which we conduct our business. In the European Union, the data privacy laws are generally stricter than those that apply in the United States and include specific requirements for the collection of personal data of European Union persons or the transfer of personal data outside of the European Union to the United States to ensure that European Union standards of data privacy will be applied to such data. If we, our operations or in some instances our partners actions under clinical trials in which we are the sponsor, are found to be in violation of any federal or state healthcare law, or any other laws or regulations that apply to us, we may be subject to penalties, including civil, criminal, and administrative penalties, damages, fines, disgorgement, suspension and debarment from government contracts, and refusal of orders under existing government contracts, exclusion from participation in U.S. federal or state health care programs, corporate integrity agreements, and the curtailment or restructuring of our operations, any of which could materially adversely affect our ability to operate our business and our financial results. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, it may be subject to criminal, civil or administrative sanctions, including but not limited to, exclusions from participation in government healthcare programs, which could also materially affect our business. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business. We are subject to new legislation, regulatory proposals and healthcare payor initiatives that may increase our costs of compliance, and adversely affect our ability to market our products, obtain collaborators, and raise capital. In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post approval activities and affect our ability to profitably sell any products for which we obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we may receive for any approved products, which could have a material adverse effect on customers for our products, if approved, and, accordingly, on our results of operations. Any reduction in reimbursement from Medicare or other government healthcare programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from commercializing our products and being able to generate revenue, and we could be prevented from or significantly delayed in achieving

profitability.Compliance with the federal track and trace requirements may increase our operational expenses and impose significant administrative burdens. As a result of these and other new proposals, we may determine to change our current manner of operation, provide additional benefits or change our contract arrangements, any of which could have a material adverse effect on our business, financial condition, results of operations, stock price and prospects.Our employees, independent contractors, consultants, commercial partners, principal investigators, CMOs, or CROs may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business. We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees, independent contractors, consultants, commercial partners, principal investigators, CMOs, or CROs could include intentional, reckless, negligent, or unintentional failures to comply with FDA regulations, comply with applicable fraud and abuse laws, provide accurate information to the FDA, properly calculate pricing information required by federal programs, report financial information or data accurately or disclose unauthorized activities to us. This misconduct could also involve the improper use of 65Table of Contentsmisrepresentation of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Moreover, it is possible for a whistleblower to pursue a False Claims Act case against us even if the government considers the claim unmeritorious and declines to intervene, which could require us to incur costs defending against such a claim. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations, stock price and prospects, including the imposition of significant fines or other sanctions.Violations of or liabilities under environmental, health and safety laws and regulations could subject us to fines, penalties or other costs that could have a material adverse effect on the success of our business.We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures, the handling, use, storage, treatment and disposal of hazardous materials and wastes and the cleanup of contaminated sites. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We would incur substantial costs as a result of violations of or liabilities under environmental requirements in connection with our operations or property, including fines, penalties and other sanctions, investigation and cleanup costs and third party claims. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.Although we maintain workersâ€™ compensation insurance to cover costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials.We are subject to stringent and changing obligations related to privacy and security. Our actual or perceived failure to comply with such obligations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business. In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, processing) sensitive information, including personal data, proprietary and confidential business data, trade secrets, intellectual property, data we collect about trial participants in connection with clinical trials, and sensitive third-party data. Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts, and other obligations that govern the processing of personal data by us and on our behalf.In the United States, numerous federal, state, and local governments have enacted numerous data privacy and security laws and regulations, including personal data privacy laws, health information privacy laws, data breach notification laws, personal data privacy laws, and consumer protection laws. For example, HIPAA, as amended by HITECH, imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health information. We may obtain health information from third parties, including research institutions from which we obtain clinical trial data, that are subject to privacy and security requirements under HIPAA, as amended by HITECH, and its implementing rules and regulations. Depending on the facts and circumstances, we could be subject to significant penalties if we obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.Additionally, the California Consumer Privacy Act, or CCPA, imposes obligations on covered businesses. These obligations include, but are not limited to, providing specific disclosures in privacy notices and affording California residents certain rights related to their personal data. The CCPA also allows for statutory fines for noncompliance (up to \$7,500 per violation) and includes a private right of action for certain data breaches. Although there are some exemptions for clinical trial data and health information, the CCPA may impact our business activities and increase our compliance costs and potential liability. In addition, it is anticipated that the California Privacy Rights Act, or CPRA, which became operative on January 1, 2023, will expand the CCPA, including by expanding consumersâ€™ rights with respect to certain sensitive personal data. The CPRA also creates the new California Privacy Protection Agency to implement and enforce the CCPA and the CPRA, which could increase compliance costs. Similar laws have passed in Virginia, Utah, Connecticut and Colorado, and have been proposed in other states and at the federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition. 66Table of ContentsOutside the United States, an increasing number of laws, regulations, and industry standards apply to data privacy and security. For example, the European Unionâ€™s General Data Protection Regulation, or EU GDPR, and the United Kingdomâ€™s GDPR, or UK GDPR, impose strict requirements for processing personal data. For example, under the EU GDPR, government regulators may impose temporary or definitive bans on data processing, as well as fines up to the greater of â‚¬20 million or 4% of annual global revenue. Further, individuals may initiate litigation related to processing of their personal data. Certain jurisdictions have enacted data localization laws and cross-border personal data transfer laws, which could make it more difficult to transfer information across jurisdictions (such as transferring or receiving personal data that originates in the EU or in other jurisdictions outside of the United States). Existing mechanisms that facilitate cross-border personal data transfers may change or be invalidated. For example, absent appropriate safeguards or other circumstances, the EU GDPR generally restricts the transfer of personal data to countries outside of the European Economic Area, or EEA, that the European Commission does not consider to provide an adequate level of data privacy and security, such as the United States. The European Commission released a set of â€œStandard Contractual Clauses,â€ or SCCs, that are designed to be a valid mechanism to facilitate personal data transfers out of the EEA to these jurisdictions. The SCCs, though approved by the European Commission as a suitable alternative, have faced challenges in European courts, and may be further challenged, suspended or invalidated. Additionally, the SCCs impose additional compliance burdens, such as conducting transfer impact assessments to determine whether additional security measures are necessary to protect the at-issue personal data. Other countries in Europe, such as the UK, similarly restrict personal data transfers outside of those jurisdictions to countries such as the United States that do not provide an adequate level of personal data protection. If we cannot implement a valid compliance mechanism for cross-border data transfers, we may face increased exposure to regulatory actions, substantial fines, and injunctions against processing or transferring personal data from Europe or other foreign jurisdictions. The inability to import personal data to the United States could significantly and negatively impact our business operations, limiting our ability to collaborate with parties that are subject to such cross-border data transfer or localization laws; or requiring us to increase our personal data processing capabilities and infrastructure in foreign jurisdictions at significant expense. Risks related to our operationsWe will need to expand the size of our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.As our development and commercialization plans and strategies develop, we expect to need additional managerial, operational, sales, marketing, financial and other personnel. Our future financial performance and our ability to commercialize RP1 and our other product candidates will depend, in part, on our ability to effectively manage any future growth, which would impose significant additional responsibilities on members of management and may divert their attention away from day-to-day activities.We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services. The services include substantially all aspects of clinical trial management and manufacturing, as well as support for our financial reporting and accounting functions. If the services of independent organizations, advisors and consultants become unavailable to us or we are unable to effectively manage our outsourced activities, or if the quality or accuracy of such services is compromised for any reason, our clinical trials may be extended, delayed or terminated, we may not comply with our financial reporting and accounting obligations on a timely basis and we may not be able to obtain marketing approval of RP1 and our other product candidates or otherwise advance our business.If we are not able to effectively expand our organization by hiring qualified new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize RP1 and our other product candidates and, accordingly, may not achieve our research, development and commercialization goals.Our future success depends on our ability to retain our key employees and consultants, and to attract and motivate highly qualified personnel.Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract, motivate and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our executive leadership team, as well as our other scientific, manufacturing, quality and medical personnel. The loss of the services of our key personnel and any of our other executive officers, key employees, and scientific and medical advisors, without our inability to find suitable replacements, could result in delays in product development and harm our business.67Table of ContentsChanges in our management team resulting from the hiring or departure of executives and key employees from time to time could disrupt our business. These changes and any future significant leadership changes or senior management transitions involve inherent risk. Any failure to find a timely and suitable replacement and ensure an effective transition within executive leadership or senior management, including the effective onboarding, assimilation, and retention of our management team and key employees, could hinder our strategic planning, business execution and future performance. In addition, executive leadership transition periods can be disruptive and may result in a loss of personnel with deep institutional or technical knowledge, or result in changes to business strategy or objectives, and may negatively impact our operations and relationships with employees and third-parties due to increased or unanticipated expenses, operational inefficiencies, uncertainty regarding changes in strategy, decreased employee morale and productivity, and increased turnover.To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock option and restricted stock unit grants that vest over time. The value to employees of these equity grants that vest over time may be significantly affected by movements in our stock price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies. Although we have employment agreements with our key employees, these employment agreements generally provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice.If we fail to establish and maintain proper and effective internal control over financial reporting our ability to produce accurate and timely financial statements could be impaired.We are required to maintain internal control over financial reporting. We must perform system and process design evaluation and testing of the effectiveness of our internal controls over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. We continue to be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to incur substantial professional fees and internal costs for our accounting and finance functions, expend significant management efforts, continue to implement plans developed to address areas that we have identified as requiring improvement, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting.If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls over financial reporting, we may not be able to produce timely and accurate financial statements. If that were to happen, our investors could lose confidence in our reported financial information, the market price of our stock could decline and we could be subject to sanctions or investigations by the SEC, Nasdaq or other regulatory authorities.We believe that any internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. We may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our consolidated financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.Our business and operations could suffer in the event of system failures or unauthorized or inappropriate use of or access to our systems.In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, processing) sensitive information, including personal data, proprietary and confidential business data, trade secrets, intellectual property, data we collect about trial participants in connection with clinical trials, and sensitive third-party data. The secure maintenance of this information is critical to our operations and business strategy. Some of this information could be an attractive target of criminal attack or unauthorized access and use by third parties with a wide range of motives and expertise, including organized criminal groups, â€œhacktivists,â€ patient groups, disgruntled current or former employees and others. Cyber-attacks are of ever-increasing levels of sophistication, and despite our security measures, our information technology and infrastructure may be vulnerable to such attacks or may be breached, including due to employee error or malfeasance.68Table of ContentsThe pervasiveness of cybersecurity incidents in general and the risks of cyber-crime are complex and continue to evolve. There can be no assurance that our security efforts and measures will be effective or that attempted security breaches or disruptions would not be successful or damaging. Our internal computer systems and those of our contractors and consultants are vulnerable to damage or interruption from computer viruses, unauthorized or inappropriate access or use, natural disasters, pandemics (including COVID-19), terrorism, war (including the ongoing conflicts in Ukraine and Israel), and telecommunication and electrical failures. Such events could cause interruption of our operations. For example, the loss of pre-clinical trial data or data from clinical trials for our product candidates could result in delays in our regulatory filings and development efforts, as well as delays in the commercialization of our products, and significantly increase our costs. To the extent that any disruption, security breach or unauthorized or inappropriate use or access to our systems were to result in a loss of or damage to our data, or inappropriate disclosure of confidential or proprietary information, including but not limited to patient, employee or vendor information, we could incur notification obligations to affected individuals and government agencies, liability, including potential lawsuits from patients, collaborators, employees, stockholders or other third parties and liability under foreign, federal and state laws that protect the privacy and security of personal information, and the development and potential commercialization of our product candidates could be delayed, or additional information, see the Risk Factor captioned â€œWe are subject to stringent and changing obligations related to privacy and security. Our actual or perceived failure to comply with such obligations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business.â€Risks related to our common stock and general risk factorsAn active trading market for our common stock may not be sustained.Our common stock began trading on the Nasdaq Global Select Market on July 20, 2018. Given the limited trading history of our common stock, there is a risk that an active trading market for shares of our common stock may not be sustained. In the absence of an active trading market for shares of our common stock, our stockholders may not be able to sell their common stock at or above the price at which such stockholder acquired our common stock or at the time that they would like to sell.The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.Our stock price has been and is likely to be volatile. The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common stock at or above the price at which it was acquired. The market price for our common stock may be influenced by many factors, including:â€the success of competitive products or technologies;â€results of clinical trials of RP1 and our other product candidates or those of our competitors;â€regulatory or legal developments in the United States and other countries;â€developments or disputes concerning patent applications, issued patents or other proprietary rights;â€the recruitment or departure of key personnel;â€the level of expenses related to the development of RP1 and our other product candidates or clinical development programs;â€the results of our efforts to discover, develop, acquire or in-license additional product candidates or drugs;â€actual or anticipated changes in

estimates as to financial results, development timelines or recommendations by securities analysts; and variations in our financial results or those of companies that are perceived to be similar to us; changes in the structure of healthcare payment systems; 69Table of Contentsa market conditions in the pharmaceutical and biotechnology sectors; general economic, industry and market conditions; political and economic instability, including the impact of COVID-19, the possibility of an economic recession, international hostilities including, but not limited to, the ongoing Russian-Ukrainian and Israel-Hamas military conflicts, acts of terrorism, governmental restrictions and sanctions, inflation, global supply chain disruptions, trade relationships and military and political alliances; and the other factors described in this Risk Factors section. Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance. Our quarterly and annual operating results may fluctuate significantly in the future, which makes it difficult for us to predict our future operating results. From time to time, we may enter into license or collaboration agreements with other companies that include development funding and significant upfront and milestone payments and/or royalties, which may become an important source of our revenue. Accordingly, our revenue may depend on development funding and the achievement of development and clinical milestones under current and any potential future license and collaboration agreements and sales of our products, if approved. These upfront and milestone payments may vary significantly from period to period and any such variance could cause a significant fluctuation in our operating results from one period to the next. In addition, we measure compensation cost for stock-based awards made to employees at the grant date of the award, based on the fair value of the award as determined by our board of directors, and recognize the cost as an expense over the employee's requisite service period. As the variables that we use as a basis for valuing these awards change over time, including, our underlying stock price and stock price volatility, the magnitude of the expense that we must recognize may vary significantly. Furthermore, our operating results may fluctuate due to a variety of other factors, many of which are outside of our control and may be difficult to predict, including the following: timing and cost of, and level of investment in, research and development activities relating to our current and any future product candidates, which will change from time to time; the total expenses we incur in connection with equipping and operating our manufacturing facility; our ability to engage clinical trial sites in the U.S. and in foreign territories, obtain the approval for conducting our clinical trials in foreign territories from their regulatory authorities, as well as our ability to enroll the number of patients necessary in our clinical trials and the timing of enrollment; the cost of manufacturing our current and any future product candidates, which may vary depending on the FDA's and comparable foreign regulatory authorities' guidelines and requirements, the quantity of production and the terms of any agreements with manufacturers; expenditures that we will or may incur to acquire or develop additional product candidates and technologies; the timing and outcomes of clinical and preclinical studies for RP1 and our other product candidates or competing product candidates; competition from existing and potential future products that compete with RP1 and our other product candidates, and changes in the competitive landscape of our industry, including consolidation among our competitors or partners; any delays in regulatory review or approval of RP1 or our other product candidates; the level of demand for RP1 and our other product candidates, if approved, which may fluctuate significantly and be difficult to predict; 70Table of Contentsa the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing and potential future products that compete with RP1 and our other product candidates; our ability to commercialize RP1 and our other product candidates, if approved, inside and outside of the United States, either independently or working with third parties; the success of and our ability to establish and maintain collaborations, licensing or other arrangements; our ability to adequately support future growth; potential unforeseen business disruptions that increase our costs or expenses; political and economic instability, including the impact of COVID-19, the possibility of an economic recession, international hostilities, including, but not limited to, those resulting from the ongoing Russian-Ukrainian and Israel-Hamas military conflicts, acts of terrorism, governmental restrictions and sanctions, inflation, global supply chain disruptions, trade relationships and military and political alliances; future accounting pronouncements or changes in our accounting policies; and the changing and volatile global economic environment. These factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue and/or earnings guidance we may provide. We have broad discretion in how we use our cash, cash equivalents and investments, and may not use these resources effectively, which could affect our results of operations and cause our stock price to decline. Our management has considerable discretion in the application of our cash, cash equivalents and investments. We intend to use our resources to fund our preclinical and clinical development programs as well as for general corporate purposes, including working capital requirements and other operating expenses. As a result, investors will be relying upon management's judgment with only limited information about our specific intentions for the use of our resources. We may use our resources for purposes that do not yield a significant return or any return at all for our stockholders. In addition, pending their use, we may invest our cash, cash equivalents and investments in a manner that does not produce income or that loses value. We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock, which may never occur, as the only way to realize any return on their investment. Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall. If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after the expiration of contractual or legal restrictions on resale lapse, the market price of our common stock could decline. These sales may make it more difficult for us to sell equity or equity related securities in the future at a time and price that we deem appropriate, or to use equity as consideration for future acquisition. In addition, a significant number of shares of common stock that are either subject to outstanding options and restricted stock units, reserved for future issuance under our equity incentive plans or subject to outstanding warrants are eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and Rule 144 and Rule 471 under the 71Table of Contents Securities Act, including our ESPP if activated. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline. Certain holders of shares of our common stock, or their permitted transferees, are entitled to rights with respect to the registration under the Securities Act of shares of our common stock pursuant to the amended and restated investors' rights agreement by and among us and certain of our stockholders. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares purchased by affiliates. Any sales of securities by these stockholders could have a material adverse effect on the market price of our common stock. We may sell up to \$100.0 million of shares of our common stock in an at-the-market offerings pursuant to a Sales Agreement entered into on August 3, 2023, as amended, with Leerink Partners LLC, or the 2023 Sales Agreement. The sale of a substantial number of shares of our common stock pursuant to the 2023 Sales Agreement, or anticipation of such sales, could cause the trading price of our common stock to decline or make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise desire. In addition, issuances of any shares of our common stock sold pursuant to the 2023 Sales Agreement will have a dilutive effect on our existing stockholders. Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. To the extent that we raise additional capital through the sale of common stock or securities convertible, exercisable or exchangeable into common stock, our existing stockholders' interest will be diluted. Debt financing, if available, would increase our fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to grant rights to develop and market one or more of our product candidates or technologies that we would otherwise prefer to develop and market ourselves. If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. We may evaluate various acquisitions and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies, or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including: increased operating expenses and cash requirements; the assumption of additional indebtedness or contingent liabilities; the issuance of our equity securities; the assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel; the diversion of our management's attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition; retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships; risks and uncertainties associated with the other party to such a transaction, including the prospects of that party, their regulatory compliance status, and their existing products or product candidates and marketing approvals; and our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs. In addition, if we undertake acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense or intangible asset impairment charges. Moreover, we may not be able to locate suitable acquisition opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business. Any of the foregoing may materially harm our business, financial condition, results of operations, stock price and prospects. Unfavorable market and economic conditions may have serious adverse consequences on our business, financial condition, results of operations, stock price and prospects. Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. The most recent global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including a reduced ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the economic climate and financial market conditions could adversely impact our business. Global financial markets have been experiencing extreme disruption in recent months, including, among other things, extreme volatility in securities prices. We are unable to predict the likely duration and severity of the current disruptions in financial markets and adverse economic conditions throughout the world. These economic developments affect businesses such as ours and those of third parties on which we rely in a number of ways that could result in unfavorable consequences to us. Current economic conditions or a deepening economic downturn in the United States and elsewhere have reduced and may continue to reduce our ability or willingness to access capital, which could negatively impact our short-term and long-term liquidity. Although we are not aware of any downgrades, material losses, or other significant deterioration in the fair value of our cash equivalents or short-term investments, we cannot assure you that deterioration of the global credit and financial markets would not negatively impact our current portfolio of cash equivalents or short-term investments, or our ability to meet our financing objectives. Furthermore, our stock price may decline due, in part, to the volatility of the stock market and general economic downturns. Exchange rate fluctuations may materially affect our results of operations and financial conditions. Owing to the international scope of our operations, fluctuations in exchange rates, particularly between the U.S. dollar and the British pound and the euro, may adversely affect us. Although we are based in the United States, we have significant research and development operations in the United Kingdom, and source third-party manufacturing, consulting and other services in the United Kingdom and the European Union. As a result, our business and the price of our common stock may be affected by fluctuations in foreign exchange rates, which may have a significant impact on our results of operations and cash flows from period to period. Currently, we do not have any exchange rate hedging arrangements in place. Unfavorable global economic conditions and geopolitical events could adversely affect our business, financial condition or results of operations. Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict, including the ongoing Russian-Ukrainian and Israel-Hamas military conflicts, terrorism or other geopolitical events. Sanctions imposed by the United States and other countries in response to such conflicts may also adversely impact our clinical trials, the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. A weak or declining economy or political disruption, including any international trade disputes, could disrupt or otherwise adversely impact our operations and those of third parties upon which we rely. Although we do not currently operate in Russia, Ukraine, Israel or territories under Hamas control, if these conflicts broaden it may impact countries or territories in which we do operate or intend to operate, which could have a negative impact on our ability to achieve our objectives or timelines. The increasing focus on environmental sustainability and social initiatives could increase our costs, harm our reputation and adversely impact our financial results. There has been increasing public focus by investors, customers, environmental activists, the media and governmental and nongovernmental organizations on a variety of environmental, social and other sustainability matters. We experience pressure to make commitments relating to sustainability matters that affect us, including the design and implementation of specific risk mitigation strategic initiatives relating to sustainability. If we are not effective in addressing environmental, social and other sustainability matters affecting our business, or setting and meeting relevant sustainability goals, our reputation and financial results may suffer. We may experience increased costs in order to execute upon our sustainability goals and measure 73Table of Contents achievement of those goals, which could have a materially adverse impact on our business and financial condition. In addition, this emphasis on environmental, social and other sustainability matters has resulted and may result in the adoption of new laws and regulations, including new reporting requirements. If we fail to comply with new laws, regulations or reporting requirements, our reputation and business could be adversely impacted. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. There have been no unregistered sales of securities other than previously disclosed by us in our Current Report on Form 8-K, as filed with the SEC on June 13, 2024. Item 3. Defaults Upon Senior Securities. Not applicable. Item 4. Mine Safety Disclosure. Not applicable. Item 5. Other Information. Rule 10b5-1 Plan Trading Arrangements. During the three months ended June 30, 2024, each of the following officers or directors adopted a Rule 10b5-1 trading arrangement (as defined in Item 408 of Regulation S-K) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and our policies on insider trading: Name & Title Date Adopted (1) Aggregate Number of Shares of Common Stock to be Purchased or Sold Pursuant to Trading Arrangement Expiration Date (3) Philip Astley-Sparke Executive Chairman 4/2/2024 (2) 240,000 January 15, 2026 Robert Coffin Director 4/3/2024 (2) 480,000 December 31, 2026 Sushil Patel Chief Executive Officer and Director 4/3/2024 (2) 250,000 March 20, 2025 (1) Date of adoption of Rule 10b5-1 trading arrangements is in accordance with both the Company's insider trading policy and applicable SEC rules and regulations. (2) The first trade pursuant to the Rule 10b5-1 trading arrangement will be, in accordance with both the Company's insider trading policy and applicable SEC rules and regulations, on a date after the date of adoption of the Rule 10b5-1 trading arrangement. (3) The Rule 10b5-1 trading arrangement permits transactions through and including the earlier to occur of (a) the completion of all sales or (b) the date listed in the table. The arrangement also provides for automatic expiration in the event of bankruptcy, insolvency, death or mental incapacity of the adopting person. Other than those disclosed above, none of our directors or officers adopted, modified, or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement in each case as defined in Item 408 of Regulation S-K, during the three months ended June 30, 2024. 74Table of Contents Item 6. Exhibits. Exhibit Incorporated by Reference Number Exhibit Description Form Date Number 1. Securities Purchase Agreement, dated June 12, 2024, by and among Replimune Group, Inc. and each of the investors as party thereto. 8-K June 13, 2024 110.2 Form of Registration Rights Agreement, dated June 14, 2024, by and among Replimune Group Inc. and each of the investors as party thereto. 8-K June 13, 2024 110.231.1 Certification of the Chief Executive Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350). 31.2 Certification of the Chief Financial Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350). 32.1 Certification of the Chief Executive Officer, as required by Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350). 32.2 Certification of the Chief Financial Officer, as required by Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350). 101.INS XBRL Instance Document. 101.SCH XBRL Taxonomy Extension Schema Document. 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB XBRL Taxonomy Extension Label Linkbase Document. 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document. 104* Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). * Filed or furnished herewith. The certifications furnished in Exhibit A 32.1 and Exhibit A 32.2 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed filed for purposes of Section A 18 of the Securities

[illegible]

[Flag] Vesting of RSUs (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Fair value of financial assets and liabilities Fair Value Disclosures [Text Block] Proceeds from exercise of stock options and pre-funded warrants Proceeds from Stock Options Exercised Award Timing Disclosures [Line Items] Other Performance Measure, Amount Other Performance Measure, Amount Master Clinical Trial Collaboration and Supply Agreement - Roche Master Clinical Trial Collaboration and Supply Agreement - Roche [Member] Master Clinical Trial Collaboration and Supply Agreement - Roche Common stock, outstanding (in shares) Common Stock, Shares, Outstanding Total Operating and Finance Lease Liabilities Payments Due Abstract No definition available. Operating lease costs Operating Lease Costs Operating Lease, Cost Lease cost Lease, Cost [Abstract] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Number of shares available for grant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Operating lease liabilities, non-current Operating Lease, Liability, Noncurrent Sushil Patel [Member] Sushil Patel Significant agreements Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Accrued for final payment on debt Subordinated Debt, Current Interest expense on finance lease liability Interest on lease liabilities Finance Lease, Interest Expense Plan Name [Domain] Plan Name [Domain] Price per share (in USD per share) Sale of Stock, Price Per Share United States UNITED STATES Entity Tax Identification Number Entity Tax Identification Number Leases Leases [Abstract] Total lease liabilities Lease, Liability Amount of lease liabilities current and noncurrent. Aggregate Intrinsic Value Aggregate Intrinsic Value No definition available. Schedule of long-term debt Schedule of Long-Term Debt Instruments [Table Text Block] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Issuance of pre-funded warrants (in shares) Pre Funded Warrants Issued It represents number of pre funded warrants to purchase common stock of company. Money market funds Money Market Funds [Member] Philip Astley-Sparke [Member] Philip Astley-Sparke Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Aggregate offering amount Net proceeds Sale of Stock, Consideration Received on Transaction Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] US Treasury bonds US Treasury Securities [Member] Secured Debt Secured Debt [Member] Prepayment fee, after 36 months (as a percent) Long-Term Debt Instrument, Prepayment Fee, After 36 Months Long-Term Debt Instrument, Prepayment Fee, After 36 Months Plan Name [Axis] Plan Name [Axis] Equity Components [Axis] Equity Components [Axis] Total lease payments Finance Lease, Liability, to be Paid Share-Based Compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Award Timing Method Award Timing Method [Text Block] Office equipment Office Equipment [Member] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Options vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Measurement Frequency [Axis] Measurement Frequency [Axis] Minimum market capitalization Debt Instrument, Covenant, Minimum Market Capitalization Debt Instrument, Covenant, Minimum Market Capitalization Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Weighted-average remaining lease term - financing leases Finance Lease, Weighted Average Remaining Lease Term Insider Trading Policies and Procedures [Line Items] Use of estimates Use of Estimates, Policy [Policy Text Block] Number of patients Number Of Patients It represents number of additional Cohort of patients with anti PDI failed melanoma. Adjustment to Compensation, Amount Adjustment to Compensation Amount Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Maximum percentage of holding for exercise warrants (as a percent) Maximum Percentage of Holding For Exercise Warrants The maximum percentage of holding for exercise warrants. Compensation Amount Outstanding Recovery Compensation Amount Minimum payments committed to manufacturing organization Purchase Commitment, Remaining Minimum Amount Committed Supplemental disclosure of non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Geographical [Axis] Geographical [Axis] Payment of issuance costs Payments of Debt Issuance Costs Tabular List, Table Tabular List [Table Text Block] Investment income Investment Income, Interest and Dividend Level 3 Fair Value, Inputs, Level 3 [Member] Stock-Based Compensation Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Number of stock warrants issued (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Short-term investments Debt Securities, Available-for-Sale [Line Items] Antidilutive securities excluded from computation of diluted weighted average shares outstanding (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Less: interest Finance Lease, Liability, Undiscounted Excess Amount Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Unrestricted cash percentage Long-term Debt Instrument, Covenant Requirement, Unrestricted Cash Percentage, of Obligations Long-term Debt Instrument, Covenant Requirement, Unrestricted Cash Percentage of Obligations Credit Facility [Domain] Credit Facility [Domain] Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Total unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Current assets: Assets, Current [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Stock options Options to purchase common stock Share-Based Payment Arrangement, Option [Member] Investment Holdings [Table] Debt Securities, Available-for-Sale [Table] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Depreciation and amortization expense Depreciation Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] 2026 Lessee, Operating Lease, Liability, to be Paid, Year One Term Loan Facility, Tranche One and Two Term Loan Facility, Tranche One and Two [Member] Term Loan Facility, Tranche One and Two Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Less: interest Operating and Finance Lease Liability Undiscounted Excess Amount Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating and finance lease. Weighted-average discount rate - financing leases Finance Lease, Weighted Average Discount Rate, Percent 2026 Long-Term Debt, Maturity, Year Four, Including Interest Long-Term Debt, Maturity, Year Four, Including Interest Minimum restricted cash (as a percent) Debt Instrument, Covenant, Minimum Percentage Of Restricted Cash Debt Instrument, Covenant, Minimum Percentage Of Restricted Cash Warrants to purchase common stock Warrant [Member] Facility charge Payment Of Facility Costs Payment Of Facility Costs Security Exchange Name Security Exchange Name 2026 Finance Lease, Liability, to be Paid, Year One Variable rate (as a percent) Debt Instrument, Basis Spread on Variable Rate Noncash interest expense Paid-in-Kind Interest Award Type [Axis] Award Type [Axis] 2027 Long-Term Debt, Maturity, Year Five, Including Interest Long-Term Debt, Maturity, Year Five, Including Interest Unamortized deferred financing costs Unamortized Deferred Financing Costs Unamortized Deferred Financing Costs Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Number of Restricted Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Property, plant and equipment, net Property, plant and equipment , net Property, Plant and Equipment, Net Total liabilities Liabilities 2024 Long-Term Debt, Maturity, Year Two, Including Interest Long-Term Debt, Maturity, Year Two, Including Interest Long-lived assets Long-Lived Assets Options exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Schedule of short-term investments Debt Securities, Available-for-Sale [Table Text Block] Research and development Research and Development Expense Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Expiration Date Trading Arrangement Expiration Date Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Finance lease costs: Finance Lease Costs [Abstract] No definition available Operating lease liabilities, current Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock, issued (in shares) Common Stock, Shares, Issued Shares issued during period (in shares) Conversion of Stock, Shares Issued Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Research and development incentives receivable Increase (Decrease) in Research and Development Incentives Receivable Amount of increase (decrease) in research and development incentives receivable. Computer equipment Computer Equipment [Member] Accrued Liabilities and Other Liabilities [Abstract] Plant and laboratory equipment Equipment [Member] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less: Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, plant and equipment , gross Property, Plant and Equipment, Gross Exercise of stock options (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Research and development Research and Development Expense [Member] Common stock, authorized (in shares) Common Stock, Shares Authorized Class of Warrant or Right [Table] Class of Warrant or Right [Table] Net unrealized (loss) gain on short-term investments, net of tax of \$0 Unrealized loss on short-term investments OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Weighted average common shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Long-Term Debt, Type [Axis] Long-Term Debt, Type [Axis] Thereafter Long-Term Debt, Maturity, After Year Five, Including Interest Long-Term Debt, Maturity, After Year Five, Including Interest Total stockholders' equity Balance Balance Equity, Attributable to Parent Term Loan Facility, Tranche One Term Loan Facility, Tranche One [Member] Term Loan Facility, Tranche One Percentage of commission Percentage Of Commission Percentage of commission paid under common stock sale agreement Significant agreements Collaborative and other arrangements Collaborative Arrangement Disclosure [Text Block] Robert Coffin [Member] Robert Coffin Term Loan Facility, Tranche Five Term Loan Facility, Tranche Five [Member] Term Loan Facility, Tranche Five Property, plant and equipment, net Property, Plant and Equipment Disclosure [Text Block] Capitalized software Software and Software Development Costs [Member] Recurring Fair Value, Recurring [Member] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Accumulated end of term fee Accumulated Payment in Kind Interest Accumulated Payment in Kind Interest Geographic information Revenues from External Customers and Long-Lived Assets [Line Items] 2018 Plan Omnibus Incentive Compensation Plan 2018 [Member] Represents information pertaining to 2018 omnibus incentive compensation plan. Diluted net loss per share attributable to common stockholders Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Sale of Stock [Domain] Sale of Stock [Domain] Long term debt, net Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus Facility charge and diligence fee Facility Charge And Diligence Fee Facility Charge And Diligence Fee All Executive Categories All Executive Categories [Member] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Outstanding (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Assets Assets [Abstract] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Document Type Document Type Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Research and development incentives Research and Development Incentives Income The amount of research and development incentives income. 2028 Finance Lease, Liability, to be Paid, Year Three Options exercisable (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Maximum Maximum [Member] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Conversion ratio Conversion Of Stock, Ratio Conversion Of Stock, Ratio Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Accounting Policies [Abstract] Accounting Policies [Abstract] Geographic information Geographical Information [Text Block] The entire disclosure for geographical information. Leasehold improvements Leasehold Improvements [Member] Schedule of assumptions used to determine the grant-date fair value of stock options granted Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Less: interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Total lease cost Total lease cost Lease, Cost Short-term investments Short-Term Investments Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Prepayment fee, After First 12 months before 36 months (as a percent) Long-Term Debt Instrument, Prepayment Fee, After First 12 Months Before 36 Months Long-Term Debt Instrument, Prepayment Fee, After First 12 Months Before 36 Months Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Equity Award [Domain] Award Type [Domain] Name Outstanding Recovery, Individual Name 2017 Plan Equity Compensation Plan 2017 [Member] Represents information pertaining to 2017 equity compensation plan. Exercise price for persons holding more than ten percent of voting power (as a percent) Minimum Percentage of Exercise Price, Persons Holding More Than Ten Percent of Voting Power Minimum percentage of exercise price of the fair market value for all incentive options granted to any person possessing more than 10% of the total combined voting power of all classes of shares. Schedule of anti-dilutive securities excluded from the computation of diluted net loss per share attributable to common shareholders Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Thereafter Operating and Finance Lease Liability Payments Due After Year Four Amount of lessee's undiscounted obligation for lease payments for operating and finance lease, due in fifth fiscal year and after fifth fiscal year following latest fiscal year. Term Loan Facility, Tranche Two Term Loan Facility, Tranche Two [Member] Term Loan Facility, Tranche Two Non-PEO NEO Non-PEO NEO [Member] Short-term investments Investments, Fair Value Disclosure Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Accrued Liabilities and Other Liabilities Additional paid-in capital Additional Paid-in Capital [Member] Financing lease liabilities, non-current Finance Lease, Liability, Noncurrent Award Timing Predetermined Award Timing Predetermined [Flag] Term Loan Facility, Tranche Four Term Loan Facility, Tranche Four [Member] Term Loan Facility, Tranche Four Restricted cash Restricted Cash, Noncurrent Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Class of Stock [Axis] Class of Stock [Axis] Net loss per share attributable to common stockholders, diluted (in dollars per share) Earnings Per Share, Diluted 2029 Finance Lease, Liability, to be Paid, Year Four Counterparty Name [Domain] Counterparty Name [Domain] Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Accrued compensation and benefits costs Accrued Employee Benefits, Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Options vested and expected to vest (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Undesignated preferred shares issued (in shares) Preferred Stock, Shares Issued End of term charge Long Term Debt, End Of Term Charge Long Term Debt, End Of Term Charge Unrealized foreign currency transaction (gains) Losses Gain (Loss), Foreign Currency Transaction, before Tax Total lease payments Operating and Finance Lease Liability Payments Due Amount of lessee's undiscounted obligation for lease payments for operating and finance lease Unaudited interim financial information Unaudited Interim Consolidated Financial Information [Policy Text Block] Disclosure of accounting policy pertaining to unaudited consolidated financial information. Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Segments, Geographical Areas [Abstract] Segments, Geographical Areas [Abstract] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Accrued research and development costs Accrued Research and Development Costs The amount relating to accrued research and development costs. Income tax provision Income Tax Expense (Benefit) Stated interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Short-term Investments [Abstract] Short-Term

Investments [Abstract] Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Term Loan Facility, Tranche Three Term Loan Facility, Tranche Three [Member] Term Loan Facility, Tranche Three Expenses expected to be recognized over a weighted average remaining period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Total other income (expense), net Nonoperating Income (Expense) Other non-current liabilities Increase (Decrease) in Other Noncurrent Liabilities Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Proceeds from sales and maturities of short-term investments Proceeds from Sale, Maturity and Collection of Short-Term Investments Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Loss from operations Operating Income (Loss) Additional shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Additional rate (as a percent) Debt Instrument, Additional Rate Debt Instrument, Additional Rate 2022 (remaining three months) Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Total liabilities and stockholders' equity Liabilities and Equity All Adjustments to Compensation All Adjustments to Compensation [Member] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Additional paid-in capital Additional Paid in Capital 2027 Finance Lease, Liability, to be Paid, Year Two Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Schedule of share-based payment arrangement, restricted stock and restricted stock unit, activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Schedule of maturities of long-term debt Schedule of Maturities of Long-Term Debt [Table Text Block] Right-to-use asset obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Underlying Security Market Price Change Underlying Security Market Price Change, Percent 2029 Operating Finance Lease Liability Payments Due Year Four Amount of lessee's undiscounted obligation for lease payments for operating and finance lease, due in fourth fiscal year following latest fiscal year. Significant agreements Significant agreements This concept does not have any references. Individual: Individual [Axis] Vesting of RSUs Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Bristol-Myers Squibb Company Bristol Myers Squibb Company [Member] It represents agreement with Bristol-Myers Squibb Company Cancelled (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Thereafter Lessee, Operating Lease, Liability, to be Paid, After Year Four Amount of lessee's undiscounted obligation for lease payment for operating lease due in fifth fiscal year and after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Minimum unrestricted cash (as a percent) Debt Instrument, Covenant, Minimum Percentage Of Unrestricted Cash Debt Instrument, Covenant, Minimum Percentage Of Unrestricted Cash US Government Agency bonds US Government Agencies Debt Securities [Member] Long-Term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity Address, State or Province Entity Address, State or Province Number of term loan advances Debt Instruments, Number Of Advances Debt Instruments, Number Of Advances Property, plant and equipment, net Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Tax on short-term investments OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Schedule of stockholders equity Schedule of Stockholders Equity [Table Text Block] Operating expenses: Operating Expenses [Abstract] Schedule of property, plant and equipment, net Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Outstanding as of March 31, 2021 (in dollars per share) Outstanding as of June 30, 2021 (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Liabilities and Stockholders' Equity Liabilities and Equity [Abstract] Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Adoption Date Trading Arrangement Adoption Date United Kingdom UNITED KINGDOM Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Outstanding at beginning of the period (in dollars per share) Outstanding at end of the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Right-to-use asset - operating leases Right-to-use operating lease asset Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Outstanding at beginning of the period (in shares) Outstanding at end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Principal loan balance Long-Term Debt, Gross Exercise Price Award Exercise Price Number of operating geographic regions Number Of Operating Geographic Regions The number of operating geographic regions. Net loss per share Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration 2022 (remaining three months) Operating and Finance Lease Liability Payments Remainder Of Fiscal Year Amount of lessee's undiscounted obligation for lease payments for operating and finance lease, due in remainder of fiscal year following latest fiscal year ended Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Exercise of pre-funded warrants Stock Issued During Period, Warrants, New Issues, Value Stock Issued During Period, Warrants, New Issues, Value Stockholders' equity Stockholders' Equity Attributable to Parent [Abstract] Equity, Attributable to Parent [Abstract] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Pre-IPO warrants to purchase common stock Pre Funded Warrants, Pre-IPO [Member] Pre Funded Warrants, Pre-IPO Total lease liabilities Finance Lease, Liability All Individuals All Individuals [Member] Clinical Trial Collaboration and Supply Agreement - Incyte Clinical Trial Collaboration and Supply Agreement - Incyte [Member] Clinical Trial Collaboration and Supply Agreement - Incyte PEO PEO [Member] Income Tax Disclosure [Abstract] Name Trading Arrangement, Individual Name Other income Other Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] ATM Program At Market Offering Program [Member] Represents information pertaining to at the market offering program. Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Exercise of pre-funded warrants (in shares) Stock Issued During Period, Warrants, New Issues Stock Issued During Period, Warrants, New Issues 2024 Pre-funded Warrants 2024 Pre-funded Warrants [Member] 2024 Pre-funded Warrants Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Value of stock options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Intrinsic Value The intrinsic value of options granted during the reporting period. Other income (expense): Other Nonoperating Income (Expense) [Abstract] Common stock reserved for issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Total Long-Term Debt, Including Interest Long-Term Debt, Including Interest Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Pre-funded warrants Pre Funded Warrants [Member] Represents information pertaining to pre-funded warrants. Balance (in shares) Balance (in shares) Shares, Outstanding Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Total operating expenses Operating Expenses Research and development incentives receivable Research and Development Incentives Receivable, Current The amount of research and development incentives receivable, within one year from the balance sheet date, for goods or services that have been delivered or sold in the normal course of business. Maximum amount outstanding for covenant Debt Instrument, Covenant, Maximum Credit Outstanding Debt Instrument, Covenant, Maximum Credit Outstanding Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Decrease in borrowing capacity Line of Credit Facility, Increase (Decrease), Net PEO Total Compensation Amount PEO Total Compensation Amount Out Of Plan Inducement Grants Out Of Plan Inducement Grants [Member] Out Of Plan Inducement Grants Fair value Debt Securities, Available-for-Sale, Excluding Accrued Interest Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Schedule of accrued expenses and other current liabilities Schedule of Accrued Liabilities [Table Text Block] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Schedule of company's long-lived assets held in different geographic regions Long-Lived Assets by Geographic Areas [Table Text Block] Underwriting discounts, commissions and other offering expenses Payments of Stock Issuance Costs Accrued expenses and other current liabilities Increase (Decrease) in accrued expenses and other current liabilities Amount of increase (decrease) accrued expenses and other current liabilities. Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Common stock Common Stock [Member] Measure: Measure [Axis] Share price (in dollars per share) Share Price Undesignated preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Issuance of common stock, net of issuance costs and underwriter fees (in shares) Stock Issued During Period, Shares, New Issues Line of Credit Line of Credit [Member] Entity Emerging Growth Company Entity Emerging Growth Company PSUs Performance Stock Units [Member] Performance Stock Units Entity Central Index Key Entity Central Index Key Prior notice period to change percentage of holding (in days) Minimum Notice Period to Change Percentage Of Holding It represents number of days prior notice for increase or decrease percentage of holding. Nonqualified Stock Options Nonqualified Stock Options [Member] Nonqualified Stock Options Selling, general and administrative General and Administrative Expense [Member] Issuance of prefunded warrants to purchase common stock, net of issuance costs Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Accrued expenses and other current liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Total shares of common stock reserved for future issuance Pre Funded Warrants, Common Stock [Member] Pre Funded Warrants, Common Stock Right-to-use asset - financing leases Right-to-use finance lease asset Finance Lease, Right-of-Use Asset, after Accumulated Amortization Stockholders' equity Pre-funded Warrants Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Weighted Average Contractual Term (Years) Weighted Average Contractual Term (Years) No definition available. Preferred stock, Par Value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Equity Component [Domain] Equity Component [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Title Trading Arrangement, Individual Title Statement [Table] Statement [Table] Interest expense on debt obligations Interest expense on debt obligations Interest Expense, Debt Counterparty Name [Axis] Counterparty Name [Axis] Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Summary of significant accounting policies Significant Accounting Policies [Text Block] City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Expiration period for persons holding ten percent of voting power Share Based Payment Award Expiration Period for Persons Holding Ten Percent of Voting Power Award expiration period for persons possessing ten percent of voting power, in 'PnYmNdTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Cash paid during the period for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Purchase of short-term investments Payments to Acquire Short-Term Investments Purchases of property, plant and equipment and software capitalization Payments to Acquire Productive Assets Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Level 1 Fair Value, Inputs, Level 1 [Member] Total current assets Assets, Current Finance lease, right-of-use-asset Increase (Decrease) Finance Lease, Right Of Use Asset Amount of increase (decrease) in finance lease right-of -use assets. Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Options exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Gross unrealized losses Debt Securities, Available-for-Sale, Unrealized Loss Other information Other Information [Abstract] No definition available. Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Long term debt, net of discount Long-Term Debt, Excluding Current Maturities Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted average grant-date fair value per share of stock options granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Income taxes Income Tax Disclosure [Text Block] Short-term investments Investment [Text Block] 2029 Lessee, Operating Lease, Liability, to be Paid, Year Four Earnings Per Share [Abstract] Earnings Per Share [Abstract] Equity [Abstract] Restricted and performance stock units Pre Funded Warrants, Restricted and Performance Stock Units [Member] Pre Funded Warrants, Restricted and Performance Stock Units Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Total lease assets Lease, Right-of-Use Asset Amount of lessee's right to use underlying asset under lease. Class of Stock [Domain] Class of Stock [Domain] Selling, general and administrative General and Administrative Expense Term Loan Facility Term Loan Facility [Member] Term Loan Facility Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Restricted and performance stock units Unvested restricted and performance stock units Restricted and Performance Stock Units [Member] Restricted and Performance Stock Units 2025 Long-Term Debt, Maturity, Year Three, Including Interest Long-Term Debt, Maturity, Year Three, Including Interest Equity Awards Adjustments Equity Awards Adjustments [Member] Weighted-average discount rate - operating leases Operating Lease, Weighted Average Discount Rate, Percent Total lease liabilities Operating Lease, Liability Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Maximum percentage of increase (decrease) of holding for exercise warrants (as a percent) Maximum Percentage Of Increase (Decrease) Of Holding For Exercise Warrants Represents the maximum percentage of increase (decrease) of holding for exercise warrants. Credit Facility [Axis] Credit Facility [Axis] Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Depreciation and amortization Depreciation, Depletion and Amortization Foreign currency translation (loss) gain Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Fair Value as of Grant Date Award Grant Date Fair Value Amortization of right-to-use asset Finance Lease Costs Finance Lease, Right-of-Use Asset, Amortization Receivables Collaborative Arrangement, Receivable from Other Party Collaborative Arrangement, Receivable from Other Party Number of shares issued (in shares) Sale of Stock, Number of Shares Issued in Transaction Unamortized issuance costs Debt Issuance Costs, Net Level 2 Fair Value, Inputs, Level 2 [Member] Debt Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Geographical [Domain] Geographical [Domain] ESPP Employee Share Purchase Plan [Member] Represents information pertaining to employee share purchase plan. Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Issuance of common stock in connection with private placement, net of placement agent fees and offering costs Stock Issued During Period, Value, New Issues Entity Address, Postal Zip Code Entity Address, Postal Zip Code Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Schedule of stock-based compensation expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Principles of consolidation Consolidation, Policy [Policy Text Block] 2027 Operating and Finance Lease Liability Payments Due Year Two Amount of lessee's undiscounted obligation for lease payments for operating and finance lease, due in second fiscal year following latest fiscal year. Restatement Determination Date: Restatement Determination Date [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Title of 12(b) Security Title of 12(b) Security Common stock, \$0.001 par value; 150,000,000 shares authorized as of June 30, 2024 and March 31, 2024; 68,309,968 and 61,415,105 shares issued and outstanding as of June 30, 2024 and March 31, 2024, respectively Common Stock, Value, Issued Operating cash flows from finance leases Finance Lease, Interest Payment on Liability Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash and

cash equivalents Cash and Cash Equivalents, at Carrying Value Cash paid for amounts included in the measurement of lease liabilities: Cash Paid For Amounts Included in Measurement Of Lease Liabilities [Abstract] Cash paid for amounts included in measurement of lease liabilities. Repayment Fee (as a percent) Long-Term Debt Instrument, Repayment Fee Long-Term Debt Instrument, Repayment Fee Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Gross unrealized gains Debt Securities, Available-for-Sale, Unrealized Gain Options vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Cancelled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Net loss per share attributable to common stockholders, basic (in dollars per share) Earnings Per Share, Basic Accounts payable Increase (Decrease) in Accounts Payable Proceeds from issuance of common stock in connection with private placement, net of placement agent fees and offering costs Proceeds from Issuance of Common Stock Operating cash flows from operating leases Operating Lease, Payments Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Share based payment award expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Expiration period for persons holding more than ten percent of voting power Share Based Payment Award Expiration Period for Persons Holding More Than Ten Percent of Voting Power Award expiration period for persons possessing more than ten percent of voting power, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Principal payment of finance lease obligation Financing cash flows from finance leases Finance Lease, Principal Payments Purchases of property and equipment included in accounts payable and accrued expenses Capital Expenditures Incurred but Not yet Paid Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Net loss Net loss Net Income (Loss) Available to Common Stockholders, Basic Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Total assets Assets Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Stock unit grant (in shares) Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Termination period Collaborative Arrangement, Termination Period Collaborative Arrangement, Termination Period Underwriter rights Over-Allotment Option [Member] Other liabilities, non-current Other Liabilities, Noncurrent Share based payment award percentage of outstanding shares Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingencies (Note 14) Commitments and Contingencies Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Termination Date Trading Arrangement Termination Date Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Nature of the business Nature of Operations [Text Block] Exercise price (in dollars per share) Class of Warrant or Right, Exercise price of Warrants or Rights 2027 Lessee, Operating Lease, Liability, to be Paid, Year Two Stock-based compensation Share-Based Payment Arrangement [Text Block] Entity Address, City or Town Entity Address, City or Town Debt Instrument [Axis] Debt Instrument [Axis] Schedule of stock option activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Stock-based compensation expense Share-Based Payment Arrangement, Expense Net loss Net loss Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Schedule of company's financial assets and liabilities measured at fair value on a recurring basis Fair Value, by Balance Sheet Grouping [Table Text Block] Exercise price for persons holding ten percent of voting power (as a percent) Minimum Percentage of Exercise Price, Persons Holding Ten Percent of Voting Power Minimum percentage of exercise price of the fair market value for all incentive options granted to any person possessing 10% or less of the total combined voting power of all classes of shares. Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Insider Trading Arrangements [Line Items] Amortized cost Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Fair value of financial assets and liabilities Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Three PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Schedule of additional information related to leases Assets And Liabilities, Lessee [Table Text Block] Tabular disclosure of additional information related to leases. Adjustment to Compensation: Adjustment to Compensation [Axis] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Total lease liabilities Operating and Finance Lease Liability Present value of lessee's discounted obligation for lease payments from operating and finance lease. Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Accumulated deficit Retained Earnings [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Weighted average common shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Options vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] RSUs Restricted Stock Units (RSUs) [Member] Increase (decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Accrued professional fees Accrued Professional Fees, Current Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Thereafter Finance Lease, Liability, to be Paid, After Year Four Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year and after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Employee stock purchase plan, available for future grants Pre Funded Warrants, ESPP [Member] Pre Funded Warrants, ESPP Construction in progress Construction in Progress [Member] Cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Operating lease, right-of-use-asset Increase (Decrease) Operating Lease, Right-of-Use Asset Amount of increase (decrease) in operating lease right-of -use assets. Entity Filer Category Entity Filer Category Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Company Selected Measure Name Company Selected Measure Name EX-101.PRE 10 rept-20240630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 RI.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Cover - shares 3 Months Ended Jun. 30, 2024 Aug. 05, 2024 Cover [Abstract] A Document Type 10-Q A Document Quarterly Report true A Document Period End Date Jun. 30, 2024 A Document Transition Report false A Entity File Number 001-38596 A Entity Registrant Name REPLIMUNE GROUP, INC. A Entity Incorporation, State or Country Code DE A Entity Tax Identification Number 82-2082553 A Entity Address, Address Line One 500 Unicorn Park Drive A Entity Address, Address Line Two Suite 303 A Entity Address, City or Town Woburn A Entity Address, State or Province MA A Entity Address, Postal Zip Code 01801 A City Area Code 781 A Local Phone Number 222-9600 A Title of 12(b) Security Common Stock, par value \$0.001 per share A Trading Symbol REPL A Security Exchange Name NASDAQ A Entity Current Reporting Status Yes A Entity Interactive Data Current Yes A Entity Filer Category Non-accelerated Filer A Entity Small Business true A Entity Emerging Growth Company false A Entity Shell Company false A Entity Common Stock, Shares Outstanding A 68,321,396 Entity Central Index Key 0001737953 A Amendment Flag false A Current Fiscal Year End Date --06-30 A Document Fiscal Year Focus 2025 A Document Fiscal Period Focus Q1 A X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:MonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:yearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a-1> + Details Name: dei DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1> + Details Name: dei DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei DocumentType Namespace Prefix: dei_ Data Type: dei:submissionItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Regulation S-T -Number 232 -Section 405> + Details Name: dei EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as

specified in its charter, which is required by forms filled with the SEC. + ReferencesReference 1:

[http://www.xbrli.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18](http://www.xbrli.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18): [http://www.xbrli.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19](http://www.xbrli.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19): [http://www.xbrli.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20](http://www.xbrli.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20):

FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 20: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference> 21: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7> + Details Name: us-gaap_LiabilitiesCurrentNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstractNamespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_LongTermDebtNoncurrentNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479041/842-20-45-1> + Details Name: us-gaap_OperatingLeaseLiabilityCurrentNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479041/842-20-45-1> + Details Name: us-gaap_OperatingLeaseLiabilityCurrentNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479041/842-20-45-1> + Details Name: us-gaap_OperatingLeaseRightOfUseAssetNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_OtherLiabilitiesNoncurrentNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrentNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference> 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference> 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference> 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference> 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478451/942-360-50-1> + Details Name: us-gaap_PropertyPlantAndEquipmentNetNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 2: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference> 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-8> + Details Name: us-gaap_RestrictedCashNoncurrentNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference> 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference> 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference> 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference> 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference> 8: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap_RetainedEarningsAccumulatedDeficitNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference> 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_ShortTermInvestmentsNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference> 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference> 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference> 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference> 12: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference> 13: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference> 14: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480418/310-10-S99-2> + Details Name: us-gaap_StockholdersEquityNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstractNamespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - \$ (shares Jun. 30, 2024 Mar. 31, 2024 Stockholders' Equity Attributable to Parent [Abstract] Å Å Common stock, par value (in dollars per share) \$ 0.001 \$ 0.001 Common stock, authorized (in shares) 150,000,000 150,000,000 Common stock, issued (in shares) 68,309,968 61,415,105 Common stock, outstanding (in shares) 68,309,968 61,415,105 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_CommonStockParOrStatedValuePerShareNamespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1> + Details Name: us-gaap_CommonStockSharesAuthorizedNamespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_CommonStockSharesIssuedNamespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference> 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference> 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference> 6: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3> + Details Name: us-gaap_CommonStockSharesOutstandingNamespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstractNamespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD (\$) in Thousands 3 Months Ended Jun. 30, 2024 Jun. 30, 2023 Operating expenses: Å Å Research and development \$ 42,972 \$ 40,437 Selling, general and administrative 14,395 15,211 Total operating expenses 57,367 55,648 Loss from operations (57,367) (55,648) Other income (expense): Å Å Research and development incentives 438 393 Investment income 4,711 6,186 Interest expense on finance lease liability (534) (544) Interest expense on debt obligations (1,426) (1,115) Other income 406 1,374 Total other income (expense), net 3,595 6,294 Loss before income taxes (53,772) (49,354) Income tax provision 0 201 Net loss \$ (53,772) \$ (49,555) Net loss per share attributable to common stockholders, basic (in dollars per share) \$ (0.78) \$ (0.75) Net loss per share attributable to common stockholders, diluted (in dollars per share) \$ (0.78) \$ (0.75) Weighted average common shares outstanding, basic (in shares) 69,185,885 66,367,702 Weighted average common shares outstanding, diluted (in shares) 69,185,885 66,367,702 X - DefinitionThe amount of research and development incentives income. + ReferencesNo definition available. + Details Name: repl_ResearchAndDevelopmentIncentivesIncomeNamespace Prefix: repl_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference> 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic

5 - SubTopic 60 - Name Accounting Standards Codification - Section 65 - Paragraph 1 - Subparagraph (g) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 4:

Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph \(SAB Topic 6.B\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5](http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 8: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B) + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 6: [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 7: <http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31> + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherNonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1> + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16> + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units or other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10> + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD \$ (\$) in Thousands 3 Months Ended Jun. 30, 2024 Jun. 30, 2023 Statement of Comprehensive Income [Abstract] A A Net loss \$ (53,772) \$ (49,555) Other comprehensive loss: A A Foreign currency translation (loss) gain (432) (1,305) Net unrealized (loss) gain on short-term investments, net of tax of \$0 (99) (458) Comprehensive loss \$ (54,303) \$ (51,318) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(24\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(26\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-50-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5> + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef-Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 26:

Section 50 - Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-1A> + Details Name: us-gaap OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11> + Details Name: us-gaap OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical) - USD (\$) 3 Months Ended Jun. 30, 2024 Jun. 30, 2023 Statement of Comprehensive Income [Abstract] A A Tax on short-term investments \$ 0 \$ 0 X - DefinitionAmount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12> + Details Name: us-gaap OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD (\$) in Thousands Total Common stock Additional paid-in capital Accumulated deficit Accumulated other comprehensive loss Balance (in shares) at Mar. 31, 2023 A 56,676,313 A A Balance at Mar. 31, 2023 A 555,292 \$ 57 1,034,994 \$ (485,488) \$ 5,729 Increase (decrease) in Stockholders' Equity A A A Foreign currency translation adjustment (1,305) A A A (1,305) Unrealized loss on short-term investments (458) A A A (458) Exercise of pre-funded warrants (in shares) A 1,922,655 A A Exercise of stock options (in shares) A 96,146 A A Exercise of stock options 1,209 A 1,209 A Vesting of RSUs (in shares) A 281,211 A A Stock-based compensation expense 8,846 A 8,846 A Net loss (49,555) A A (49,555) A Balance (in shares) at Jun. 30, 2023 A 58,976,325 A A Balance at Jun. 30, 2023 A 514,029 \$ 57 1,045,049 (535,043) 3,966 Balance (in shares) at Mar. 31, 2024 A 61,415,105 A A Balance at Mar. 31, 2024 A 374,508 \$ 61 1,070,874 (701,282) 4,855 Increase (decrease) in Stockholders' Equity A A A Issuance of prefunded warrants to purchase common stock, net of issuance costs 48,500 A 48,500 A Issuance of common stock, net of issuance costs and underwriter fees (in shares) A 5,668,937 A A Issuance of common stock in connection with private placement, net of placement agent fees and offering costs 48,204 \$ 6 48,198 A A Foreign currency translation adjustment (432) A A (432) Unrealized loss on short-term investments (99) A A (99) Exercise of pre-funded warrants (in shares) A 739,225 A A Exercise of pre-funded warrants \$ 1 \$ 1 A A Exercise of stock options (in shares) 22,860 22,860 A A Exercise of stock options \$ 66 A 66 A Vesting of RSUs (in shares) A 463,841 A A Vesting of RSUs 0 A A A Stock-based compensation expense 9,475 A 9,475 A Net loss (53,772) A A (53,772) A Balance (in shares) at Jun. 30, 2024 A 68,309,968 A A Balance at Jun. 30, 2024 A 426,451 \$ 68 \$ 1,177,113 \$ (755,054) \$ 4,324 X - DefinitionStock Issued During Period, Warrants, New Issues + ReferencesNo definition available. + Details Name: repl StockIssuedDuringPeriodWarrantsNewIssues Namespace Prefix: repl Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock Issued During Period, Warrants, New Issues, Value + ReferencesNo definition available. + Details Name: repl StockIssuedDuringPeriodWarrantsNewIssuesValue Namespace Prefix: repl Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12> + Details Name: us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(12\)\(i\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(12)(i)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(ii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(ii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 32: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 33: <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)Reference 36: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)Reference 37: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1) + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20>Reference 3:

Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/214748448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/214748448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionValue of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -

<http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22) + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1> + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for principal payment on finance lease. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(g\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5) + Details Name: us-gaap_FinanceLeasePrincipalPayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17> + Details Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(g\)\(1\) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4) + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in noncurrent operating liabilities classified as other. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17](http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25](http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2> + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25> + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionInterest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_PaidInKindInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph \(c\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13) + Details Name: us-gaap_PaymentsToAcquireProductiveAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13> + Details Name: us-gaap_PaymentsToAcquireShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14) + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14) + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12> + Details Name: us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph \(a\) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A) + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478067/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478067/235-10-S99-1)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 11: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(16\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 17:

graph 1A - Subparagraph (SX 210.13-01(a)(2)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20:

Paragraph 2 - Subparagraph (g) - Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap FairValueDisclosuresTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Short-term investments 3 Months Ended Jun. 30, 2024 Short-Term Investments [Abstract] A Short-term investments Short-term investmentsAs of June30, 2024 and March31, 2024, the Company's available-for-sale investments by type consisted of the following:June 30, 2024AmortizedcostGross unrealizedgainsGross unrealizedlossesCredit LossesFair valueUS Government agency bonds\$171,822Å \$3Å (\$118)\$6Å \$171,707Å US Treasury bonds145,854Å 1Å (96)Å \$145,759Å Å Å Å Total\$317,676Å Å Å (\$214)\$6Å \$317,466Å March 31, 2024Amortized costGross unrealized gainsGross unrealized lossesCredit LossesFair valueUS Government agency bonds199,905Å 33Å (117)\$6Å \$199,821Å US Treasury bonds146,417Å 11Å (38)Å \$146,390Å Å Å Å Total \$346,322Å 44Å (\$155)\$6Å \$346,211Å As of June30, 2024 and March31, 2024, available-for-sale securities consisted of investments that mature within one year X - DefinitionThe entire disclosure for investment. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Topic 321 -Publisher FASB -URI https://asc.fasb.org/321/tableOfContentReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Topic 325 -Publisher FASB -URI https://asc.fasb.org/325/tableOfContent + Details Name: us-gaap InvestmentTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap ShortTermInvestmentsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property, plant and equipment, net 3 Months Ended Jun. 30, 2024 Property, Plant and Equipment [Abstract] A Property, plant and equipment, net Property, plant and equipment, netProperty, plant and equipment, net consisted of the following:June 30, 2024March 31, 2024Office equipment\$1,487Å 1,464Å Computer equipment2,108Å 1,975Å Plant and laboratory equipment10,560Å 10,423Å Leasehold improvements1,886Å 1,886Å Capitalized software4,938Å 3,515Å Construction in progress1,034Å 1,117Å Å Å Å Total property, plant and equipment22,013Å 20,380Å Less: Accumulated depreciation(10,610) (9,897)Å Å Å Å Property, plant and equipment, net\$11,403Å \$10,483Å Depreciation expense was \$0.7 million and \$0.6 million for the three months ended June30, 2024 and 2023, respectively. Depreciation expense is recorded within research and development and selling, general and administrative expenses in the consolidated statement of operations. X - ReferencesNo definition available. + Details Name: us-gaap PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7 + Details Name: us-gaap PropertyPlantAndEquipmentDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accrued expenses and other current liabilities 3 Months Ended Jun. 30, 2024 Accrued Liabilities and Other Liabilities [Abstract] A Accrued expenses and other current liabilities Accrued expenses and other current liabilitiesAccrued expenses and other current liabilities consisted of the following:June 30, 2024March 31, 2024Accrued research and development costs\$16,166Å \$16,376Å Accrued compensation and benefits costs7,447Å 13,906Å Accrued professional fees370Å 369Å Other6,931Å 3,330Å Å Å Å Total accrued expenses and other current liabilities\$30,914Å \$33,981Å X - DefinitionThe entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1 + Details Name: us-gaap AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap AccruedLiabilitiesAndOtherLiabilitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Debt 3 Months Ended Jun. 30, 2024 Debt Disclosure [Abstract] A Debt DebtOn October 6, 2022, the Company entered into a Loan and Security Agreement (the "æœLoan Agreement"), with Hercules Capital, Inc., as administrative agent, collateral agent and as a lender (æœHercules), Pursuant to the Loan Agreement, the Company can borrow term loans in an aggregate maximum principal amount of up to \$200.0Å million under multiple tranches (the æœTerm Loan Facility). Under the Loan Agreement, the Company borrowed an initial amount of \$30.0Å million on the closing date, and at the Company's sole option, could have drawn, but did not draw down, an additional \$30.0Å million on or prior to September 30, 2023. The Company can also draw as additional term loan advances in an aggregate principal amount of up to \$115.0Å million during the term of the Term Loan Facility subject to achievement of specified performance milestones, and two additional term loan advances up to an aggregate principal amount of \$25.0Å million subject to certain terms and conditions, on or prior to the end of the interest-only period. The Company intends to use the proceeds of the Term Loan Facility for working capital and general corporate purposes. The Loan Agreement was subsequently amended (the "Amendment") on June 28, 2023 pursuant to which the Company agreed to draw an initial term loan advance in an aggregate principal amount not less than \$30.0Å million, provided that the aggregate amount of the term loan advances made under tranche 1 do not exceed \$30.0Å million, which reflects a decrease of \$30Å million from the \$60.0Å million in the original Loan Agreement for tranche 1. The total amount of the Loan Agreement, as well as the outstanding balance of the loan, is unchanged, but the option to borrow additional funds were redistributed from tranche 1 to tranche 2. The impact of this amendment is not a modification, as it does not relate to outstanding debt, but is rather an amendment that provides for a future potential benefit. There is no material impact to the financial statements as a result of the Amendment.A second amendment was made to the Loan Agreement (the "Second Amendment") on December 22, 2023 pursuant to which the Company agreed to draw a term loan advance in an aggregate principal amount not less than \$15.0Å million, provided that the aggregate amount of the term loan advances made under tranche 2 do not exceed \$15.0Å million on or prior to December 31, 2023. The Second Amendment re-allocated the total future consideration of the Loan Agreement to the future tranches extending through September 2026, subject to the terms and conditions of the Loan Agreement. The Second Amendment did not change the total aggregate maximum principal amount to be drawn under the Loan Agreement, which remains as up to \$200.0Å million. The Company evaluated the Second Amendment as a modification under relevant accounting guidance, and based on that analysis and the immaterial change in cash flows on current outstanding debt, it was determined that there was no material accounting impact. Upon closing of the Second Amendment, the Company drew down the tranche 2 amount of \$15.0Å million. The Term Loan Facility will mature on October 1, 2027 (the æœMaturity Date). The outstanding principal balance of the Term Loan Facility bears interest payable in cash at a floating rate per annum equal to the greater of (i) 7.25% and (ii) the sum of the Prime Rate (which is capped at 7.25%) and 1.75%. Accrued interest is payable monthly following the funding of each term loan advance. In addition, the principal balance of the Term Loan Facility will bear æœpayment-in-kind interest at the rate of 1.50% (æœPIK Interest), which PIK Interest will be added to the outstanding principal balance of the Term Loan Facility on each interest payment date. Borrowings under the Loan Agreement are repayable in monthly interest-only payments through September 2026. After the interest-only payment period, borrowings under the Loan Agreement are repayable in equal monthly payments of principal and accrued interest until October 2027. At the Company's option, the Company may prepay all or a portion of the outstanding borrowings, subject to a prepayment fee of 3.0% of the principal amount if prepayment had occurred during the 12 months following the closing date, 2.0% after 12 months following the closing date but prior to 36 months following the closing date, and 1.0% thereafter. The Loan Agreement contains customary facility fees, events of default and representations, warranties and affirmative and negative covenants, including a financial covenant requiring the Company to maintain unrestricted cash in an amount not less than 35% of the aggregate outstanding secured obligations under the Loan Agreement in accounts subject to a control agreement in favor of the Agent (the æœUnrestricted Cash) at all times which commenced on January 1, 2024. In addition, the Loan Agreement also contains a financial covenant that beginning on the later of (i) July 1, 2024 and (ii) the date on which the aggregate outstanding principal amount of the Term Loan Facility is equal to or greater than \$100.0Å million, the Company is required to satisfy one of the following requirements: (1) achieve a minimum amount of trailing three-month net product revenue tested on a monthly basis, (2) maintain a market capitalization in excess of \$1.2Å billion and Unrestricted Cash in an amount no less than 50% of the outstanding amount under the Term Loan Facility, or (3) maintain Unrestricted Cash in an amount no less than 85% of the outstanding amount under the Term Loan Facility.The Company paid a \$0.5Å million facility charge and incurred debt issuance costs of \$1.5Å million upon closing of the Loan Agreement. The Loan Agreement also provides for a final payment, payable upon maturity or the repayment of the obligations in full or in part (on a pro rata basis), equal to 4.95% of the aggregate principal amount of Term Loans advanced to the Company and repaid on such date, which is being accrued on the Company's consolidated balance sheet. The amount accrued for the final payment is \$0.6Å million as of June30, 2024 and \$0.5 million as of March31, 2024.Unamortized debt issuance costs are recorded as a reduction of the carrying amount on the term loan and amortized as interest expense using the effective-interest method. In addition, unamortized deferred financing costs of \$1.1Å million and \$1.2Å million were recorded in other assets as of June30, 2024 and March31, 2024, respectively, related to the Company's right to borrow additional amounts from Hercules in the future and amortized to interest expense over the relevant draw period on a straight-line basis. Interest expense for the three months ended June30, 2024 was \$1.4Å million. The summary of obligations under the term loan as of June30, 2024 and March31, 2024 consisted of the following (in thousands):June 30, 2024March 31, 2024Principal loan balance\$45,923Å \$45,749Å Facility charge and diligence fee(251)(266)Unamortized issuance costs(1,123)(1,191)Accumulated end of term fee643Å 517Å Å Å Å Long term debt, net \$45,192Å \$44,809Å The annual principal payments due under the Loan Agreement as of June30, 2024 and March31, 2024 are as follows:June 30, 2024March 31, 202420242024æœ Å æœ Å 2025æœ Å æœ Å 2026æœ Å æœ Å 202720,145Å 20,145Å Thereafter27,769Å 27,769Å Totals\$47,914Å \$47,914Å The table of future payments of long-term debt excludes the end of term charge of \$2.2 million, which is due upon the maturity of the loan X - ReferencesNo definition available. + Details Name: us-gaap DebtDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap DebtDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' equity 3 Months Ended Jun. 30, 2024 Equity [Abstract] A Stockholders' equity Stockholdersæ™ equityCommon stockAs of June30, 2024 and March31, 2024, the Companyæ™s certificate of incorporation, as amended and restated, authorized the Company to issue up to 150,000,000 shares of common stock, par value \$0.001 per share.The Company had reserved for common stock for the exercise of outstanding stock options and the vesting of restricted stock units, the number of shares remaining available for grant under the Companyæ™s 2018 Omnibus Incentive Compensation Plan and the Companyæ™s Employee Stock Purchase Plan (see Note 10) and the exercise of the outstanding warrants to purchase shares of common stock as follows:June 30, 2024March 31, 2024Stock options, issued and outstanding10,157,054Å 8,652,256Å Restricted and performance stock units3,370,183Å 2,397,890Å Stock options and restricted stock units, future issuance1,988,217Å 2,284,141Å Employee stock purchase plan, available for future grants3,405,175Å 2,738,208Å Pre-IPO warrants to purchase common stock497,344Å 497,344Å Pre-funded warrants10,211,969Å 5,281,616Å Å Å Å Total shares of common stock reserved for future issuance29,629,942Å 21,851,455Å Undesignated preferred stockAs of June30, 2024, the Companyæ™s certificate of incorporation, as amended and restated, authorized the Company to issue up to 10,000,000 shares of undesignated preferred stock, par value \$0.001 per share. There were no undesignated preferred shares issued or outstanding as of June30, 2024.ATM programOn August3, 2023, the Company and Leerink Partners LLC (the "Current Agent") entered into a sales agreement, which was subsequently amended on May 16, 2024 (as so amended, the "2023 Sales Agreement"). Under the 2023 Sales Agreement, the Company may sell, from

time to time, at its option, up to an aggregate of \$100.0 million of share of the Company's common stock, \$0.001 par value shares (the "Shares"), through the Current Agent, as the Company's sales agent. Any Shares to be offered and sold under the 2023 Sales Agreement will be issued and sold (i)A by methods deemed to be an àœœat the market offeringàœ (àœœATMàœ) as defined in RuleA 415(a)(4)A promulgated under the Securities Act of 1933, as amended, or if authorized by the Company, in negotiated transactions or block trades, and (ii)A pursuant to a registration statement on FormA S-3 filed by the Company with the Securities and Exchange Commission on August 3, 2023, as amended for an offering of various securities, including shares of the Companyàœ™s common stock, preferred stock, debt securities, warrants and/or units for sale to the public in one or more public offerings. Subject to the terms of the 2023 Sales Agreement, the Current Agent will use reasonable efforts to sell the Shares from time to time, based upon the Companyàœ™s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay the Current Agent a commission of up to 3.0% of the gross proceeds from the sale of the Shares. The Company has also agreed to provide the Current Agent with customary indemnification rights. During the three months ended JuneA 30, 2024, the Company did not issue or sell any shares under the 2023 Sales Agreement. The Company cannot provide any assurances that it will issue any additional Shares pursuant to the 2023 Sales Agreement. Equity offeringsOn June 14, 2024, the Company completed a private placement transaction (the "Private Placement") pursuant to which the Company sold (a) 5,668,937 shares of the Company's common stock, at an offering price of \$8.82, and (b) in lieu of common stock to certain investors, pre-funded warrants to purchase 5,669,578 shares of the Company's common stock at an offering price of \$8.819 per warrant (the "2024 Pre-funded Warrants"). The Company received aggregate net proceeds in the Private Placement of approximately \$96.7 million after deducting placement agent fees and other offering expenses payable by the Company of approximately \$3.3 million. Pre-funded WarrantsThe Company's pre-funded warrants are exercisable at any time after the date of issuance. Unless otherwise modified by a holder of a pre-funded warrant, no holder may exercise a pre-funded warrant if such holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of the Companyàœ™s common stock outstanding immediately after giving effect to such exercise. A holder of the 2024 Pre-funded Warrants may increase or decrease this percentage to any other percentage not in excess of 9.99%, whereas a holder of the Company's pre-funded warrants issued prior to the 2024 Pre-funded Warrants, may increase or decrease this percentage up to 19.99%, by providing at least 61 daysàœ™ prior notice to the Company. The 10,211,969 shares of the Company's common stock underlying the pre-funded warrants issued by the Company are not included in the number of issued and outstanding shares of the Companyàœ™s common stock outstanding as reported on the consolidated balance sheet, though they are included in the Company's annual pool increase calculation as well as the weighted average outstanding common stock in the calculation of basic and diluted net loss per share, as described below in Note 11. During the three months ended JuneA 30, 2024, a holder of the Company's pre-funded warrants exercised 739,225 of its pre-funded warrants for an exercise price of \$0.001 per pre-funded warrant and the Company issued 739,225 shares of Common Stock in exchange thereof. X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(e\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 10: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18) + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Pre-funded Warrants 3 Months Ended Jun. 30, 2024 Equity [Abstract] À Pre-funded Warrants Stockholdersàœ™ equityCommon stockAs of JuneA 30, 2024 and MarchA 31, 2024, the Companyàœ™s certificate of incorporation, as amended and restated, authorized the Company to issue up to 150,000,000 shares of common stock, par value \$0.001 per share. The Company had reserved for common stock for the exercise of outstanding stock options and the vesting of restricted stock units, the number of shares remaining available for grant under the Companyàœ™s 2018 Omnibus Incentive Compensation Plan and the Companyàœ™s Employee Stock Purchase Plan (see Note 10) and the exercise of the outstanding warrants to purchase shares of common stock as follows:June 30, 2024March 31, 2024Stock options, issued and outstanding1,157,054A 8,652,256A Restricted and performance stock units3,370,183A 2,397,890A Stock options and restricted stock units, future issuance1,988,217A 2,284,141A Employee stock purchase plan, available for future grants3,405,175A 2,738,208A Pre-IPO warrants to purchase common stock497,344A 497,344A Pre-funded warrants10,211,969A 5,281,616A À À À À Total shares of common stock reserved for future issuance29,629,942A 21,851,455A Undesignated preferred stockAs of JuneA 30, 2024, the Companyàœ™s certificate of incorporation, as amended and restated, authorized the Company to issue up to 10,000,000 shares of undesignated preferred stock, par value \$0.001 per share. There were no undesignated preferred shares issued or outstanding as of JuneA 30, 2024.ATM programOn AugustA 3, 2023, the Company and Leerink Partners LLC (the "Current Agent") entered into a sales agreement, which was subsequently amended on May 16, 2024 (as so amended, the "2023 Sales Agreement"). Under the 2023 Sales Agreement, the Company may sell, from time to time, at its option, up to an aggregate of \$100.0 million of share of the Company's common stock, \$0.001 par value shares (the "Shares"), through the Current Agent, as the Company's sales agent. Any Shares to be offered and sold under the 2023 Sales Agreement will be issued and sold (i)A by methods deemed to be an àœœat the market offeringàœ (àœœATMàœ) as defined in RuleA 415(a)(4)A promulgated under the Securities Act of 1933, as amended, or if authorized by the Company, in negotiated transactions or block trades, and (ii)A pursuant to a registration statement on FormA S-3 filed by the Company with the Securities and Exchange Commission on August 3, 2023, as amended for an offering of various securities, including shares of the Companyàœ™s common stock, preferred stock, debt securities, warrants and/or units for sale to the public in one or more public offerings. Subject to the terms of the 2023 Sales Agreement, the Current Agent will use reasonable efforts to sell the Shares from time to time, based upon the Companyàœ™s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay the Current Agent a commission of up to 3.0% of the gross proceeds from the sale of the Shares. The Company has also agreed to provide the Current Agent with customary indemnification rights. During the three months ended JuneA 30, 2024, the Company did not issue or sell any shares under the 2023 Sales Agreement. The Company cannot provide any assurances that it will issue any additional Shares pursuant to the 2023 Sales Agreement. Equity offeringsOn June 14, 2024, the Company completed a private placement transaction (the "Private Placement") pursuant to which the Company sold (a) 5,668,937 shares of the Company's common stock, at an offering price of \$8.82, and (b) in lieu of common stock to certain investors, pre-funded warrants to purchase 5,669,578 shares of the Company's common stock at an offering price of \$8.819 per warrant (the "2024 Pre-funded Warrants"). The Company received aggregate net proceeds in the Private Placement of approximately \$96.7 million after deducting placement agent fees and other offering expenses payable by the Company of approximately \$3.3 million. Pre-funded WarrantsThe Company's pre-funded warrants are exercisable at any time after the date of issuance. Unless otherwise modified by a holder of a pre-funded warrant, no holder may exercise a pre-funded warrant if such holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of the Companyàœ™s common stock outstanding immediately after giving effect to such exercise. A holder of the 2024 Pre-funded Warrants may increase or decrease this percentage to any other percentage not in excess of 9.99%, whereas a holder of the Company's pre-funded warrants issued prior to the 2024 Pre-funded Warrants, may increase or decrease this percentage up to 19.99%, by providing at least 61 daysàœ™ prior notice to the Company. The 10,211,969 shares of the Company's common stock underlying the pre-funded warrants issued by the Company are not included in the number of issued and outstanding shares of the Companyàœ™s common stock outstanding as reported on the consolidated balance sheet, though they are included in the Company's annual pool increase calculation as well as the weighted average outstanding common stock in the calculation of basic and diluted net loss per share, as described below in Note 11. During the three months ended JuneA 30, 2024, a holder of the Company's pre-funded warrants exercised 739,225 of its pre-funded warrants for an exercise price of \$0.001 per pre-funded warrant and the Company issued 739,225 shares of Common Stock in exchange thereof. X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(e\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 10: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18) + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based compensation 3 Months Ended Jun. 30, 2024 Share-Based Payment Arrangement [Abstract] À Stock-based compensation Stock-based compensation expenseStock-based compensation expense was classified in the consolidated statements of operations as follows:Three Months EndedJune 30, 20242023Research and development\$4,226A \$3,298A Selling, general and administrative\$5,249A 5,548A \$9,475A \$8,846A À À À The following table summarizes stock-based compensation expense by award type for the three months ended June 30, 2024 and 2023:Three Months EndedJune 30, 20242023Stock options\$5,733A \$5,614A Restricted and performance stock units3,742A 3,323A \$9,475A \$8,846A 2015 Enterprise Management Incentive Share Option PlanThe 2015 Enterprise Management Incentive Share Option Plan of Replimune UK (the àœœ2015 Planàœ) provided for Replimune UK to grant incentive stock options, non-statutory stock options, stock awards, stock units, stock appreciation rights and other stock-based awards. Incentive stock options were granted under the 2015 Plan only to the Companyàœ™s employees, including officers and directors who were also employees. Non-statutory stock options were granted under the 2015 Plan to employees, members of the board of directors, outside advisors and consultants of the Company.2017 Equity Compensation PlanIn July 2017, in conjunction with reorganization by Replimune Limited, pursuant to which each shareholder thereof exchanged their outstanding shares in Replimune Limited for shares in Replimune Group, Inc., on a one-for-one basis (the "Reorganization"), the 2015 Plan was terminated, and all awards were cancelled with replacement awards issued under the 2017 Equity Compensation Plan (the àœœ2017 Planàœ). Subsequent to the Reorganization, no additional grants have been or will be made under the 2015 Plan and any outstanding awards under the 2015 Plan have continued, and will continue with their original terms. The Company concluded that the cancellation of the 2015 Plan and issuance of replacement awards under the 2017 Plan was a modification with no change in the material rights and preferences and therefore no recorded change in the fair value of each respective award. The Companyàœ™s 2017 Plan provides for the Company to grant incentive stock options or non-statutory stock options, stock awards, stock units, stock appreciation rights and

other stock-based awards. Incentive stock options were granted under the 2017 Plan only to the Company’s employees, including officers and directors who were also employees. Restricted stock awards and non-statutory stock options were granted under the 2017 Plan to employees, officers, members of the board of directors, advisors and consultants of the Company. The maximum number of common shares that may be issued under the 2017 Plan was 2,659,885, of which none remained available for future grants as of June 30, 2024. Shares with respect to which awards have expired, terminated, surrendered or cancelled under the 2017 Plan without having been fully exercised will be available for future awards under the 2018 Plan referenced below. In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for the grant of awards. 2018 Omnibus Incentive Compensation Plan On July 9, 2018, the Company’s board of directors adopted, and the Company’s stockholders approved the 2018 Omnibus Incentive Compensation Plan (the “2018 Plan”), which became effective immediately prior to the effectiveness of the registration statement filed in connection with the Company’s initial public offering. The 2018 Plan provides for the issuance of incentive stock options, non-qualified stock options, stock awards, stock units, stock appreciation rights and other stock-based awards. The number of shares of common stock initially reserved for issuance under the 2018 Plan is 3,617,968 shares. If any options or stock appreciation rights, including outstanding options and stock appreciation rights granted under the 2017 Plan (up to 2,520,247 shares), terminate, expire, or are canceled, forfeited, exchanged, or surrendered without having been exercised, or if any stock awards, stock units or other stock-based awards, including outstanding awards granted under the 2017 Plan, are forfeited, terminated, or otherwise not paid in full in shares of common stock, the shares of the Company’s common stock subject to such grants will be available for purposes of the 2018 Plan. The number of shares reserved for issuance under the 2018 Plan will increase automatically on the first day of each April equal to 4.0% of the total number of shares of common stock outstanding on the last trading day in the immediately preceding fiscal year, which includes for these purposes, the 5,281,616 shares issuable upon exercise of those pre-funded warrants as of March 31, 2024, as described in Note 9 to these consolidated financial statements, or such lesser amount as determined by the Board. On April 1, 2024, the number of shares reserved for issuance under the 2018 Plan automatically increased by 2,667,868 shares pursuant to the terms of the 2018 Plan and based on total number of shares of common stock outstanding on March 31, 2024. As of June 30, 2024, 1,988,217 shares remained available for future grants under the 2018 Plan. The 2015 Plan, the 2017 Plan and the 2018 Plan are administered by the board of directors or, at the discretion of the board of directors, by a committee of the board of directors. However, the board of directors shall administer and approve all grants made to non-employee directors. The exercise prices, vesting and other restrictions are determined at the discretion of the board of directors, except that the exercise price per share of incentive stock options may not be less than 100% of the fair market value of the common stock on the date of grant (or 110% of fair value in the case of an award granted to employees who hold more than 10% of the total combined voting power of all classes of stock at the time of grant) and the term of stock options may not be greater than five years for an incentive stock option granted to a 10% stockholder and greater than ten years for all other options granted. Stock options awarded under both plans expire ten years after the grant date, unless the board of directors sets a shorter term. Vesting periods for the plans are determined at the discretion of the board of directors. Incentive stock options granted to employees and non-statutory options granted to employees, officers, members of the board of directors, advisors, and consultants of the Company typically vest over four years. In 2021 the board of directors initiated the award of restricted stock units (“RSUs”), under the 2018 Plan in addition to stock option awards available as part of the Company’s equity incentive for employees, officers, advisors and consultants of the Company. The RSUs typically vest over four approximately equal annual installments with the first such installment occurring on a designated vesting date that is approximately on the one-year anniversary of the date of grant and the subsequent installments occurring on the subsequent three annual anniversaries of the designated vesting date. In 2024 the Board of Directors approved the award of performance stock units (“PSUs”), under the 2018 Plan in addition to the aforementioned stock option awards and RSUs available as part of the Company’s equity incentive for employees, officers, advisors and consultants of the Company. The PSUs will become vested upon the achievement of the approval of the Company’s first Biologics License Application (“BLA”) for RP1 by the Food and Drug Administration (“FDA”) no later than June 30, 2026, and the expense recognized for these awards is based on the grant date fair value of the Company’s common stock multiplied by the number of units granted. The timing of recognition of this stock-based compensation expense is subject to our judgment as to when the performance conditions are considered probable of being achieved. The Company granted 246,110 PSUs under the 2018 Plan during the three months ended June, 2024. If the Company does not achieve the approval of the Company’s first BLA for RP1 before the expiration of June 30, 2026 then no PSU will be earned or vested. Employee Stock Purchase Plan On July 9, 2018, the Company’s board of directors adopted and the Company’s stockholders approved the Employee Stock Purchase Plan (the “ESPP”), which became effective immediately prior to the effectiveness of the registration statement that was filed in connection with the Company’s IPO. The total shares of common stock initially reserved for issuance under the ESPP is 348,612 shares. In addition, as of the first trading day of each fiscal year during the term of the ESPP (excluding any extensions) an additional number of shares of the Company’s common stock equal to 1% of the total number of shares outstanding on the last trading day in the immediately preceding fiscal year, which includes for these purposes, the 5,281,616 shares issuable upon exercise of those pre-funded warrants described in Note 9 to these consolidated financial statements, or 697,224 shares, whichever is less (or such lesser amount as determined by the Company’s board of directors) will be added to the number of shares authorized under the ESPP. In accordance with the terms of the ESPP, on April 1, 2024, the number of shares reserved for issuance under the ESPP automatically increased by 666,967, for a total of 3,405,175 shares reserved for the ESPP. If the total number of shares of common stock to be purchased pursuant to outstanding purchase rights on any particular date exceed the number of shares then available for issuance under the ESPP, then the plan administrator will allocate the available shares pro-rata and refund any excess payroll deductions or other contributions to participants. The Company’s ESPP is not currently active. Out-of-Plan Inducement Grants From time to time, the Company grants equity awards to newly hired executives as a material inducement to enter into employment with the Company. The grants constitute “employment inducement grants” in accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules and was issued outside of the 2018 Plan and each of the other stock incentive plans described above. The inducement grants typically include nonqualified stock options to purchase shares of the Company’s common stock, as well as restricted stock unit grants representing shares of the Company’s common stock. These stock option and restricted stock unit inducement grants have terms and conditions consistent with those set forth under the 2018 Plan and vest under the same respective vesting schedules as stock option and restricted stock unit awards granted under the 2018 Plan. The inducement grants are included in the stock option and RSU award tables below. During the three months ended June 30, 2024, the Company granted 75,000 nonqualified stock options to purchase shares of the Company’s common stock and 50,000 restricted stock units under employment inducement grants, and in the same period in 2023, the Company did not grant any employment inducement grants. Stock option valuation The fair value of stock option grants is estimated using the Black-Scholes option-pricing model. As the Company has limited company-specific historical and implied volatility information, the expected stock volatility is based on a combination of Replimune volatility and the historical volatility of a publicly traded set of peer companies. For options with service-based vesting conditions, the expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of stock options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. The following table presents, on a weighted-average basis, the assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors: Three Months Ended June 30, 2024 2023 Risk-free interest rate 4.43% 3.60% Expected term (in years) 6.06 Expected volatility 76.3% 74.1% Expected dividend yield 0% 0% Stock options The following table summarizes the Company’s stock option activity: Number of Shares Weighted Average Exercise Price Weighted Average Contractual Term (Years) Aggregate Intrinsic Value Outstanding as of March 31, 2024 652,256 \$16.94 6.61 \$5,748 Granted 1,744,401 \$7.73 Exercised (22,860) \$2.91 Cancelled (216,743) \$17.82 Outstanding as of June 30, 2024 10,157,054 \$15.37 6.84 8,837 A Options exercisable as of June 30, 2024 1,524,594 \$16.16 5.40 \$6,541 Options vested and expected to vest as of June 30, 2024 10,157,054 \$15.37 6.84 8,837 A As of June 30, 2024, there was \$35.7 million of unrecognized compensation cost related to unvested common stock options, which is expected to be recognized over a weighted average period of 2.8 years. The weighted average grant-date fair value of stock options granted during the three months ended June 30, 2024 and 2023 was \$5.37 and \$12.09, respectively. The aggregate intrinsic value of stock options exercised during the three months ended June 30, 2024 was \$0.1 million. Restricted and performance stock units In January 2024, the Board approved a one-time PSU award under the 2018 Plan for all employees at the vice president level and below as of January 31, 2024, subject to non-market performance and service conditions. The grants will become vested upon the achievement of the approval of the Company’s first Biologics License Application (“BLA”) for RP1 by the Food and Drug Administration (“FDA”) no later than June 30, 2026. If the Company does not achieve the approval of the Company’s first BLA for RP1 before the expiration of June 30, 2026 then no PSU will be earned or vested. The grant date fair value for the PSUs is determined based on the market price of the Company’s common stock on the grant date and is recognized over the requisite service period if and when the achievement of such performance condition is determined to be probable by the Company. The Company reassesses the probability of achieving the performance condition at each reporting period. As of June 30, 2024, the Company has not recognized any expense related to PSUs. A summary of the changes in the Company’s RSUs and PSUs during the three months ended June 30, 2024 is as follows: Number of Restricted Shares Weighted Average Grant Date Fair Value Outstanding as of March 31, 2024 397,890 17.97 Granted 1,560,527 7.72 Vested (463,841) 22.03 Cancelled (124,393) 15.23 Outstanding as of June 30, 2024 30,183 \$12.77 As of June 30, 2024, there was \$34.5 million of unrecognized compensation cost related to unvested restricted stock units, which is expected to be recognized over a weighted average period of 2.8 years. Of the \$34.5 million of total unrecognized compensation cost, performance based awards tied to the achievement of a company milestone account for approximately \$4.8 million. The performance based awards will vest upon achievement of the performance milestone. The remaining unrecognized compensation cost is related to restricted stock units which vest over time. X - Definition: The entire disclosure for share-based payment arrangement. + References Reference 1:

use of its product candidates in combination with an anti-PD-1 therapy and that restrict Regeneron from entering into a third-party arrangement with respect to the use of cemiplimab in combination with an HSV-1 virus, in each case, for the treatment of a tumor type that is the subject of a clinical trial to which the covenants apply. Unless otherwise mutually agreed in a future study plan, these covenants are only applicable to the Company's ongoing Phase 2 clinical trial in CSCC. The agreement may be terminated by either party if (i) there is no active study plan for which a final study report has not been completed and the parties have not entered into a study plan for an additional clinical trial within a period of time after the delivery of the most recent final study report or (ii) in the event of a material breach. The agreement with Regeneron is accounted for under ASC 808, Collaborative Arrangements (â€œASC 808â€œ), as both parties are active participants and each party pays its own compound costs and share equally in development costs. The Company accounts for costs incurred as part of the study, including costs to supply compounds for use in the study, as research and development expenses within the consolidated statement of operations. The Company recognizes any amounts received from Regeneron in connection with this agreement as an offset to research and development expense within the consolidated statement of operations. In July 2022, Regeneron informed the Company that the costs of the study have reached the initial budget for the initial study plan of June 2018 and that Regeneron's reimbursement of CERPASS study costs to the Company have completed in the period ending June 30, 2022 in relation to the initial study budget. As a result of this notice from, and the ongoing communications with, Regeneron, the Company has not recorded any cost-sharing reimbursements from Regeneron in prepaid expenses and other current assets in the consolidated balance sheet or as an offset to research and development expense within the consolidated statement of operations since Regeneron informed it that Regeneron's reimbursement of CERPASS study costs have completed. The Company does not expect any further reimbursements from Regeneron related to the initial study plan of June 2018. Collaboration and other arrangements. Roche In December 2022, the Company entered into a Master Clinical Trial Collaboration and Supply Agreement with Roche in relation to the Company's RP2 and RP3 programs in colorectal cancer, or CRC, and hepatocellular carcinoma, or HCC. Under the agreement, the companies intended to collaborate in 30 patient cohort signal finding studies in third-line, or 3L, CRC and in first- and second-line, or 1L and 2L, respectively, HCC. Following the Company's re-prioritization of its product development portfolio in December 2023, the Company has agreed with Roche to terminate the CRC collaboration and pursue the 2L cohort in HCC with RP2 only. Roche has expressed its intent to continue to supply its currently approved drugs, atezolizumab and bevacizumab for the 2L cohort in HCC but is unlikely to share costs following the Company's re-prioritization. The Company is in discussions with Roche about revising these agreements following the Company's changes to its RP2 and RP3 development plans. Under the terms of the initial agreement the Company retained the responsibility of operating the clinical trials as well as retaining all the rights to the development and commercialization of its product candidates. The agreement may be terminated by either party upon sixty days prior written notice to the other party. The agreement with Roche is accounted for under ASC 808, Collaborative Arrangements (â€œASC 808â€œ), as both parties are active participants and each party pays its own compound costs. The Company accounts for costs incurred as part of the study, including costs to supply compounds for use in the study, as research and development expenses within the consolidated statement of operations. The Company will recognize any amounts received from Roche in connection with this agreement as an offset to research and development expense within the consolidated statement of operations. During the three months ended June 30, 2024 and 2023, the Company did not make any payments to Roche under the terms of the agreement. The Company recorded \$0.0 million and \$0.7 million as an offset to research and development expenses during the three months ended June 30, 2024, and 2023, respectively. During the three months ended June 30, 2024 and 2023, the Company received payments under the terms of the agreement from Roche of \$1.8 million and \$0.2 million, respectively. As of June 30, 2024 and March 31, 2024, the Company recorded \$0.0 million and \$1.8 million as receivables from Roche in connection with this agreement, respectively. Incyte In July 2023, the Company entered into a Clinical Trial Collaboration and Supply Agreement with Incyte Corporation, or Incyte. Under the agreement, the companies will collaborate in a signal finding study in which Incyte will initiate and sponsor a clinical trial of INCB99280 (oral PD-L1 inhibitor) and RP1 in approximately 40 patients with unresectable, high risk CSCC in the neoadjuvant setting. Under the terms of the agreement, the Company will supply Incyte with RP1 for the study and share costs of the study equally with Incyte. The agreement may be terminated by either party upon (i) a material breach not reasonably cured within thirty (30) days; (ii) the discontinuation of development of its clinical drug candidate; (iii) the unethical or illegal business practices of the other party; or (iv) if the parties have not agreed on the protocol or budget within ninety (90) days of the effective date of the agreement. In addition, the Company may terminate the agreement upon the inappropriate or unsafe use of the RP1 product candidate. On July 30, 2024, Incyte announced it has discontinued further development of its oral small molecule PD-L1 inhibitor, which was the intended study drug in the Company's planned collaboration with Incyte. On August 1, 2024, the Company received notice of termination of the Clinical Trial Collaboration and Supply Agreement from Incyte. During the year ended March 31, 2024, the Company did not make any payments to, or receive any payments from, Incyte under the terms of the agreement. Additionally, no costs were recorded to research and development expenses during the three months ended June 30, 2024 related to this agreement. Amgen In August 2023 the Company entered into a Settlement Agreement with Amgen and mutually agreed to terminate the Company's challenges to Amgen's patents. In connection with the Settlement Agreement, the Company entered into a License and Covenant Agreement with Amgen in which the Company agreed to pay Amgen low single-digit royalty payments on net sales of its products that, but for the license, could be found to infringe a valid Amgen patent on a country-by-country and product-by-product basis. X - Definition This concept does not have any references. + References No definition available. + Details Name: repl SignificantAgreementsAbstract Namespace Prefix: repl Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants. + References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1) Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1) Reference 3:

payments6,196Á 45,754Á 51,950Á Less: interest1,432Á 19,760Á 21,192Á Total lease liabilities\$4,764Á \$25,994Á \$30,758Á The following table provides lease disclosure as of JuneÁ 30, 2024 and MarchÁ 31, 2024:June 30, 2024March 31, 2024LeasesRight-to-use operating lease asset\$4,475Á \$4,635Á Right-to-use finance lease asset\$36,629Á 37,237Á Total lease assets\$41,104Á \$41,872Á Operating lease liabilities, current\$1,164Á \$1,161Á Finance lease liabilities, current2,738Á 2,718Á Operating lease liabilities, non-current3,600Á 3,771Á Finance lease liabilities, non-current23,256Á 23,410Á Total lease liabilities\$30,758Á \$31,060Á The following table provides lease disclosure for the three months ended June 30, 2024 and 2023:Three Months Ended June 30, 20242023Other informationCash paid for amounts included in the measurement of lease liabilities:Operating cash flows from operating leases\$152Á \$263Á Operating cash flows from finance leases\$534Á \$544Á Financing cash flows from finance leases\$134Á \$104Á Right-to-use asset obtained in exchange for new operating lease liabilities\$Á Á \$Á Á Weighted-average remaining lease term - operating leases5.6years6.3yearsWeighted-average remaining lease term - financing leases15.3years16.1yearsWeighted-average discount rate - operating leases10.3Á %10.3Á %Weighted-average discount rate - financing leases8.3Á %8.3Á %The variable lease costs and short-term lease costs were insignificant for the three months ended JuneÁ 30, 2024 and 2024 and 2023.Manufacturing commitmentsThe Company has entered into an agreement with a contract manufacturing organization to provide clinical trial products. As of JuneÁ 30, 2024 and MarchÁ 31, 2024, the Company had committed to minimum payments under these arrangements totaling \$0.9 million and \$0.9 million, respectively.Indemnification agreementsIn the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its executive management team and its board of directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and therefore it has not accrued any liabilities related to such obligations in its consolidated financial statements as of JuneÁ 30, 2024 or MarchÁ 31, 2024.Legal proceedingsThe Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities. X - ReferencesNo definition available. + Details Name: us-gaap CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrl:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Income taxes 3 Months Ended Jun. 30, 2024 Income Tax Disclosure [Abstract] Á Income taxes Income taxesThe Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company's tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. X - ReferencesNo definition available. + Details Name: us-gaap IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrl:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.1.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Geographic information 3 Months Ended Jun. 30, 2024 Segments, Geographical Areas [Abstract] Á Geographic information Geographic informationThe Company operates in two geographic regions: the United States (Massachusetts) and the United Kingdom (Oxfordshire). Information about the Company's™s long-lived assets held in different geographic regions is presented in the tables below:June 30, 2024March 31, 2024United States\$10,006Á \$8,992Á United Kingdom1,397Á 1,491Á \$11,403Á \$10,483Á X - DefinitionThe entire disclosure for geographical information. + ReferencesNo definition available. + Details Name: repl GeographicalInformationTextBlock Namespace Prefix: repl Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap SegmentsGeographicalAreasAbstract Namespace Prefix: us-gaap Data Type: xbrl:stringItemType Balance Type: na Period Type: duration XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Pay vs Performance Disclosure - USD (\$) \$ in Thousands 3 Months Ended Jun. 30, 2024 Jun. 30, 2023 Pay vs Performance Disclosure Á Á Net loss \$ (53,772) \$ (49,555) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd PvpTable Namespace Prefix: ecd Data Type: xbrl:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrl:monetaryItem Type Balance Type: credit Period Type: duration XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Insider Trading Arrangements shares in Thousands 3 Months Ended Jun. 30, 2024 shares Trading Arrangements, by

individual. (4) Material Terms of Trading Arrangements Adopted During the Three Months Ended June 30, 2024, of each of the following officers or directors adopted a Rule 10b5-1 trading arrangement (as defined in Item 408 of Regulation S-K) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and our policies on insider trading: Name & Title Date Adopted (1) Aggregate Number of Shares of Common Stock to be Purchased or Sold Pursuant to Trading Arrangement Expiration Date (3) Philip Astley-Sparke Executive Chairman 4/2/2024 (2) 240,000 January 15, 2026 Robert Coffin Director 4/3/2024 (2) 480,000 December 31, 2026 Sushil Patel Chief Executive Officer and Director 4/3/2024 (2) 250,000 March 20, 2025 (1) Date of adoption of Rule 10b5-1 trading arrangements is in accordance with both the Company's insider trading policy and applicable SEC rules and regulations. (2) The first trade pursuant to the Rule 10b5-1 trading arrangement will be, in accordance with both the Company's insider trading policy and applicable SEC rules and regulations, on a date after the date of adoption of the Rule 10b5-1 trading arrangement. (3) The Rule 10b5-1 trading arrangement permits transactions through and including the earlier of (a) the completion of all sales or (b) the date listed in the table. The arrangement also provides for automatic expiration in the event of bankruptcy, insolvency, death or mental incapacity of the adopting person. Other than those disclosed above, none of our directors or officers adopted, modified, or terminated a Rule 10b5-1 trading arrangement. Non-Rule 10b5-1 trading arrangement, in each case as defined in Item 408 of Regulation S-K, during the three months ended June 30, 2024. Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false Robert Coffin [Member] A Trading Arrangements, by Individual A Name Robert Coffin Title Director Rule 10b5-1 Arrangement Adopted true Adoption Date 4/3/2024(2) Expiration Date December 31, 2026 Arrangement Duration 1002 days Aggregate Available 480 Sushil Patel [Member] A Trading Arrangements, by Individual A Name Sushil Patel Title Chief Executive Officer and Director Rule 10b5-1 Arrangement Adopted true Adoption Date 4/3/2024(2) Expiration Date March 20, 2025 Arrangement Duration 351 days Aggregate Available 250 Philip Astley-Sparke [Member] A Trading Arrangements, by Individual A Name Philip Astley-Sparke Title Executive Chairman Rule 10b5-1 Arrangement Adopted true Adoption Date 4/2/2024(2) Expiration Date January 15, 2026 Arrangement Duration 653 days Aggregate Available 240 X - ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4](http://www.xbrl.org/2003/role/exampleRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1> + Details Name: us-gaap ConsolidationPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap NewAccountingPronouncementsPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/21474](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1)

R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property, plant and equipment, net (Tables) 3 Months Ended Jun. 30, 2024 Property, Plant and Equipment [Abstract] Â Schedule of property, plant and equipment, net Property, plant and equipment, net consisted of the following:June 30, 2024March 31, 2024Office equipment\$1,487Â \$1,464Â Computer equipment2,108Â 1,975Â Plant and laboratory equipment10,560Â 10,423Â Leasehold improvements1,886Â 1,886Â Capitalized software4,938Â 3,515Â Construction in progress1,034Â 1,117Â Â Â Â Â Total property, plant and equipment22,013Â 20,380Â Less: Accumulated depreciation(10,610)(9,897)Â Â Â Â Â Property, plant and equipment, net\$11,403Â \$10,483Â X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accrued expenses and other current liabilities (Tables) 3 Months Ended Jun. 30, 2024 Accrued Liabilities and Other Liabilities [Abstract] Â Schedule of accrued expenses and other current liabilities Accrued expenses and other current liabilities consisted of the following:June 30, 2024March 31, 2024Accrued research and development costs\$16,166Â \$16,376Â Accrued compensation and benefits costs\$7,447Â 13,906Â Accrued professional fees\$70Â 369Â Other\$6,931Â 3,330Â Â Â Â Â Total accrued expenses and other current liabilities\$30,914Â \$33,981Â X - ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Debt (Tables) 3 Months Ended Jun. 30, 2024 Debt Disclosure [Abstract] Â Schedule of long-term debt The summary of obligations under the term loan as of June30 30, 2024 and March31 31, 2024 consisted of the following (in thousands):June 30, 2024March 31, 2024Principal loan balances\$45,923Â \$45,749Â Facility charge and diligence fee(251) (266)Unamortized issuance costs(1,123)(1,191)Accumulated end of term fee\$43Â 517Â Â Â Â Â Long term debt, net \$45,192Â \$44,809Â Schedule of maturities of long-term debt The annual principal payments due under the Loan Agreement as of June30 30, 2024 and March31 31, 2024 were as follows:June 30, 2024March 31, 202420242024â€”Â Â Â Â 2025â€”Â Â Â Â 2026â€”Â Â Â Â 202720,145Â 20,145Â Thereafter27,769Â 27,769Â Total\$47,914Â \$47,914Â X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7 + Details Name: us-gaap_ScheduleOfDebtInstrumentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of maturity and sinking fund requirement for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' equity (Tables) 3 Months Ended Jun. 30, 2024 Equity [Abstract] Â Schedule of stockholders equity The Company had reserved for common stock for the exercise of outstanding stock options and the vesting of restricted stock units, the number of shares remaining available for grant under the Companyâ€™s 2018 Omnibus Incentive Compensation Plan and the Companyâ€™s Employee Stock Purchase Plan (see Note 10) and the exercise of the outstanding warrants to purchase shares of common stock as follows:June 30, 2024March 31, 2024Stock options, issued and outstanding10,157,054Â 8,652,256Â Restricted and performance stock units3,370,183Â 2,397,890Â Stock options and restricted stock units, future issuance1,988,217Â 2,284,141Â Employee stock purchase plan, available for future grants3,405,175Â 2,738,208Â Pre-IPO warrants to purchase common stock497,344Â 497,344Â Pre-funded warrants10,211,969Â 5,281,616Â Â Â Â Â Total shares of common stock reserved for future issuance29,629,942Â 21,851,455Â X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_ScheduleOfStockholdersEquityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based compensation (Tables) 3 Months Ended Jun. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Schedule of stock-based compensation expense Stock-based compensation expense was classified in the consolidated statements of operations as follows:Three Months EndedJune 30, 20242023Research and development\$4,226Â \$3,298Â Selling, general and administrative\$5,249Â 5,548Â \$9,475Â \$8,846Â Â Â Â Â The following table summarizes stock-based compensation expense by award type for the three months ended June 30, 2024 and 2023:Three Months EndedJune 30, 20242023Stock options\$5,733Â \$5,614Â Restricted and performance stock units\$3,742Â 3,232Â \$9,475Â \$8,846Â Schedule of assumptions used to determine the grant-date fair value of stock options granted The following table presents, on a weighted-average basis, the assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors:Three Months EndedJune 30, 20242023Risk-free interest rate4.43Â %3.60Â %Expected term (in years)6.060Expected volatility76.3Â %74.1Â %Expected dividend yield0Â %0Â % Schedule of stock option activity The following table summarizes the Companyâ€™s stock option activity:Number ofSharesWeightedAverageExercisePriceWeightedAverageContractualTerm (Years)AggregateIntrinsicValueOutstanding as of March 31, 20248,652,256Â \$16.94Â 6.61\$5,748Â Granted1,744,401Â \$7.73Â Exercised(22,860)\$2.91Â Cancelled(216,743)\$17.82Â Outstanding as of June 30, 202410,157,054Â \$15.37Â 6.84\$8,837Â Options exercisable as of June 30, 202416,152,459Â \$16.16Â 5.40\$6,541Â Options vested and expected to vest as of June 30, 202410,157,054Â \$15.37Â 6.84\$8,837Â Schedule of share-based payment arrangement, restricted stock and restricted stock unit, activity A summary of the changes in the Company's RSUs and PSUs during the three months ended June 30, 2024 is as follows:Number of Restricted SharesWeightedAverageGrant Date Fair ValueOutstanding as of March 31, 20242,397,890Â 17.97Â Granted1,560,527Â 7.72Â Vested(463,841)\$22.03Â Cancelled(124,393)\$15.23Â Outstanding as of June 30, 20243,370,183Â 12.77Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net loss per share (Tables) 3 Months Ended Jun. 30, 2024 Earnings Per Share [Abstract] Â Schedule of calculation of basic and diluted net loss per share attributable to common stockholders Basic and diluted net loss per share attributable to common stockholders was calculated as follows:Three Months Ended June 30, 20242023Numerator:Net loss \$(53,772)\$(49,555)Denominator:Weighted average common shares outstanding, basic and diluted69,185,885Â 66,367,702Â Net loss per share, basic and diluted\$0.78)(\$0.75) Schedule of anti-dilutive securities excluded from the computation of diluted net loss per share attributable to common shareholders The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:Three Months Ended June 30, 20242023Options to purchase common stock10,157,054Â 9,067,305Â Unvested restricted and performance stock units3,370,183Â 2,069,415Â Warrants to purchase common stock497,344Â 497,344Â 14,024,581Â 11,634,064Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and contingencies (Tables) 3 Months Ended Jun. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Schedule of variable lease components The table below presents the lease-related costs which are included in the consolidated statements of operations for the three months ended June 30, 2024 and 2023:Three Months Ended June 30, 20242023Lease costFinance lease costs:Amortization of right-to-use asset\$607Â \$607Â Interest on lease liabilities\$34Â 544Â Operating lease costs\$281Â 280Â Total lease cost\$1,422Â \$1,431Â The following table summarizes the classification of lease costs in the consolidated statement of operations for the three months ended June 30, 2024 and 2023 as follows:Three Months Ended June 30, 20242023Finance Lease CostsÂ Â Research and development\$607Â \$607Â Other income (expense)\$34Â 544Â Operating Lease CostsResearch and development\$29Â 229Â Â Â Selling, general and administrative\$2Â 51Â Total lease cost\$1,422Â \$1,431Â The following table provides lease disclosure for the three months ended June 30, 2024 and 2023:Three Months Ended June 30, 20242023Other informationCash paid for amounts included in the measurement of lease liabilities:Operating cash flows from operating leases\$152Â \$263Â Operating cash flows from finance leases\$34Â \$544Â Financing cash flows from finance leases\$134Â \$104Â Right-to-use asset obtained in exchange for new operating lease liabilities\$â€”Â \$â€”Â Â Â Weighted-average remaining lease term - operating leases5.6years6.3yearsWeighted-average remaining lease term - financing leases15.3years16.1yearsWeighted-average discount rate - operating leases10.3Â %10.3Â %Weighted-average discount rate - financing leases8.3Â %8.3Â % Schedule of the maturity of company's lease liabilities The following table summarizes the maturity of the Company's lease liabilities on an undiscounted cash flow basis and a reconciliation to the operating and financing lease liabilities recognized on its balance sheet as of June30 30, 2024:June 30, 2024Operating leasesFinancing leaseTotal2025 (remaining nine months)\$872Â \$2,050Â \$2,922Â 20261,171Â 2,799Â 3,970Â 20271,137Â 2,883Â 4,020Â 20281,086Â 2,969Â 4,055Â 20291,005Â 3,058Â 4,063Â Thereafter925Â 31,995Â 32,920Â Total lease payments6,196Â 45,754Â \$1,950Â Less: interest1,432Â 19,760Â 21,192Â Total lease liabilities\$4,764Â \$25,994Â \$30,758Â Schedule of additional information related to leases The following table provides lease disclosure as of June30 30, 2024 and March31 31, 2024:June 30, 2024March 31, 2024LeasesRight-to-use operating lease assets\$4,475Â \$4,635Â Right-to-use finance lease asset\$36,629Â 37,237Â Total lease assets\$41,104Â \$41,872Â Operating lease liabilities, current\$1,164Â \$1,161Â Finance lease liabilities, current\$2,738Â 2,718Â Operating lease liabilities, non-current\$3,600Â 3,771Â Finance lease liabilities, non-current\$23,256Â 23,410Â Total lease liabilities\$30,758Â \$31,060Â X - DefinitionTabular disclosure of additional information related to leases. + ReferencesNo definition available. + Details Name: repl_AssetsAndLiabilitiesLesseeTableTextBlock Namespace Prefix: repl_ Data Type: dtr-types:1:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset

financial lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4> + Details Name: us-gaap LeaseCostTableTextBlockNamespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6> + Details Name: us-gaap LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Geographic information (Tables) 3 Months Ended Jun. 30, 2024 Segments, Geographical Areas [Abstract] A Schedule of company's long-lived assets held in different geographic regions The Company operates in two geographic regions: the United States (Massachusetts) and the United Kingdom (Oxfordshire). Information about the Company's long-lived assets held in different geographic regions is presented in the tables below:June 30, 2024March 31, 2024United States\$10,006\$8,992United Kingdom1,397\$1,491\$11,403\$10,483 X - DefinitionTabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41) + Details Name: us-gaap LongLivedAssetsByGeographicAreasTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap SegmentsGeographicalAreasAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Nature of the business (Details) - USD (\$) \$ in Thousands 3 Months Ended Jun. 30, 2024Jun. 30, 2023Mar. 31, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] A A Net loss \$ 53,772 \$ 49,555 A Accumulated deficit \$ 755,054 A \$ 701,282 X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 15:

[Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income \(available-for-sale\). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income \(available-for-sale\). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income \(available-for-sale\). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income \(available-for-sale\). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(aa\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(aaa\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShortTermInvestmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML \\$2 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property, plant and equipment, net \(Details\) - USD \(\\$\) \\$ in Thousands 3 Months Ended Jun. 30, 2024 Jun. 30, 2023 Mar. 31, 2024 Property, plant and equipment, net Á Á Á Property, plant and equipment , gross \\$ 22,013 Á \\$ 20,380 Less: Accumulated depreciation \(10,610\) Á \(9,897\) Property, plant and equipment , net 11,403 Á 10,483 Depreciation and amortization expense 700 \\$ 600 Á Office equipment Á Á Á Property, plant and equipment, net Á Á Á Property, plant and equipment , gross 1,487 Á 1,464 Computer equipment Á Á Á Property, plant and equipment, net Á Á Á Property, plant and equipment , gross 2,108 Á 1,975 Plant and laboratory equipment Á Á Á Property, plant and equipment, net Á Á Á Property, plant and equipment , gross 10,560 Á 10,423 Leasehold improvements Á Á Á Property, plant and equipment, net Á Á Á Property, plant and equipment , gross 1,886 Á 1,886 Capitalized software Á Á Á Property, plant and equipment, net Á Á Á Property, plant and equipment , gross 4,938 Á 3,515 Construction in progress Á Á Á Property, plant and equipment, net Á Á Á Property, plant and equipment , gross 1,034 Á 1,117 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(8\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(14\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(13\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50](#)

repl_DebtInstrumentCovenantMinimumPercentageOfUnrestrictedCash Namespace Prefix: repl_Data Type: dtr-types:1:percentItemType Balance Type: na Period Type: instant X - DefinitionDebt Instruments, Number Of Advances + ReferencesNo definition available. + Details Name: repl_DebtInstrumentsNumberOfAdvances Namespace Prefix: repl_Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionLong-term Debt Instrument, Covenant Requirement, Unrestricted Cash Percentage of Obligations + ReferencesNo definition available. + Details Name: repl_LongTermDebtInstrumentCovenantRequirementUnrestrictedCashPercentageOfObligations Namespace Prefix: repl_Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLong-Term Debt Instrument, Prepayment Fee, After 36 Months + ReferencesNo definition available. + Details Name: repl_LongTermDebtInstrumentPrepaymentFeeAfter36Months Namespace Prefix: repl_Data Type: dtr-types:1:percentItemType Balance Type: na Period Type: instant X - DefinitionLong-Term Debt Instrument, Prepayment Fee, After First 12 Months Before 36 Months + ReferencesNo definition available. + Details Name: repl_LongTermDebtInstrumentPrepaymentFeeAfterFirst12MonthsBefore36Months Namespace Prefix: repl_Data Type: dtr-types:1:percentItemType Balance Type: na Period Type: instant X - DefinitionLong-Term Debt Instrument, Prepayment Fee, First 12 Months + ReferencesNo definition available. + Details Name: repl_LongTermDebtInstrumentPrepaymentFeeFirst12Months Namespace Prefix: repl_Data Type: dtr-types:1:percentItemType Balance Type: na Period Type: instant X - DefinitionLong-Term Debt Instrument, Repayment Fee + ReferencesNo definition available. + Details Name: repl_LongTermDebtInstrumentRepaymentFee Namespace Prefix: repl_Data Type: dtr-types:1:percentItemType Balance Type: na Period Type: instant X - DefinitionPayment Of Facility Costs + ReferencesNo definition available. + Details Name: repl_PaymentOffFacilityCosts Namespace Prefix: repl_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionUnamortized Deferred Financing Costs + ReferencesNo definition available. + Details Name: repl_UnamortizedDeferredFinancingCosts Namespace Prefix: repl_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1B> + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference> 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference> 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference> 5: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference> 6: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference> 7: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference> 8: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference> 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference> 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference> 11: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference> 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference> 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference> 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference> 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference> 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference> 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference> 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference> 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference> 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference> 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference> 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference> 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference> 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference> 26: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference> 27: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482900/835-30-50-1> + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference> 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference> 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference> 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference> 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-6> + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) of the credit facility. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1> + Details Name: us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-15> + Details Name: us-gaap_PaymentsOfDebtIssuanceCosts Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of the carrying value of subordinated debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle, if longer. Subordinated debt places a lender in a lien position behind debt having a higher priority of repayment in liquidation of the entity's assets. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_SubordinatedDebtCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=repl_TermLoanFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=repl_TermLoanFacilityTrancheFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=repl_TermLoanFacilityTrancheFiveMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=repl_TermLoanFacilityTrancheOneAndTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=repl_TermLoanFacilityTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=repl_TermLoanFacilityTrancheThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=repl_TermLoanFacilityTrancheFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=repl_TermLoanFacilityTrancheFiveMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=repl_TermLoanFacilityTrancheOneAndTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Debt - Schedule of Debt (Details) - Secured Debt - Line of Credit - Term Loan Facility - USD (\$) \$ in Thousands Jun. 30, 2024 Mar. 31, 2024 Debt Instrument [Line Items] Ã Ã Principal loan balance \$ 45,923 \$ 45,749 Facility charge and diligence fee (251) (266) Unamortized issuance costs (1,123) (1,191) Accumulated end of term fee 643 517 Long term debt, net \$ 45,192 \$ 44,809 X - DefinitionAccumulated Payment In Kind Interest + ReferencesNo definition available. + Details Name: repl_AccumulatedPaymentInKindInterest Namespace Prefix: repl_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFacility Charge And Diligence Fee + ReferencesNo definition available. + Details Name: repl_FacilityChargeAndDiligenceFee Namespace Prefix: repl_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt, and other types of debt. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-03(16)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-4> + Details Name: us-gaap_DebtInstrumentsCarryingAmount Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference> 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference> 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference> 5: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference> 6: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference> 7: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference> 8: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference> 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference> 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference> 11: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference> 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference> 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference> 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference> 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference> 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference> 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference> 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference> 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI

20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap DebtInstrumentLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap DeferredFinanceCostsNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap LongTermDebt Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - Details Name: us-gaap CreditFacilityAxis=us-gaap SecuredDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap LongtermDebtTypeAxis=us-gaap LineOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap DebtInstrumentAxis=us-gaap TermLoanFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Debt - Schedule of Maturity of Debt (Details) - USD (\$) in Thousands Jun. 30, 2024 Mar. 31, 2024 Debt Instrument [Line Items] A A End of term charge \$ 2,200 A Line of Credit [Term Loan Facility] Secured Debt A A Debt Instrument [Line Items] A A 2024 0 0 2025 0 0 2026 0 0 2027 20,145 20,145 Thereafter 27,769 27,769 Total \$ 47,914 X - DefinitionLong Term Debt, End Of Term Charge + ReferencesNo definition available. + Details Name: repl LongTermDebtEndOfTermCharge Namespace Prefix: repl Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionLong-Term Debt, Including Interest + ReferencesNo definition available. + Details Name: repl LongTermDebtIncludingInterest Namespace Prefix: repl Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionLong-Term Debt, Maturity, After Year Five, Including Interest + ReferencesNo definition available. + Details Name: repl LongTermDebtMaturityAfterYearFiveIncludingInterest Namespace Prefix: repl Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionLong-Term Debt, Maturity, Year Five, Including Interest + ReferencesNo definition available. + Details Name: repl LongTermDebtMaturityYearFiveIncludingInterest Namespace Prefix: repl Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionLong-Term Debt, Maturity, Year Four, Including Interest + ReferencesNo definition available. + Details Name: repl LongTermDebtMaturityYearFourIncludingInterest Namespace Prefix: repl Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionLong-Term Debt, Maturity, Year Three, Including Interest + ReferencesNo definition available. + Details Name: repl LongTermDebtMaturityYearThreeIncludingInterest Namespace Prefix: repl Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionLong-Term Debt, Maturity, Year Two, Including Interest + ReferencesNo definition available. + Details Name: repl LongTermDebtMaturityYearTwoIncludingInterest Namespace Prefix: repl Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap DebtInstrumentLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap LongtermDebtTypeAxis=us-gaap LineOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap DebtInstrumentAxis=us-gaap TermLoanFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap CreditFacilityAxis=us-gaap SecuredDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' equity - Common Stock and Undesignated Preferred Stock (Details) - \$ / shares Jun. 30, 2024 Mar. 31, 2024 Stockholders' Equity Note [Abstract] A A Common stock, authorized (in shares) 150,000,000 150,000,000 Common stock, par value (in dollars per share) \$ 0.001 \$ 0.001 Undesignated preferred stock, authorized (in shares) 10,000,000 A Preferred stock, Par Value (in dollars per share) \$ 0.001 A Undesignated preferred shares issued (in shares) 0 A X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap CommonStockSharesAuthorized Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap PreferredStockSharesAuthorized Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap PreferredStockSharesAuthorized Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap StockholdersEquityNoteAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' equity - Schedule of Pre-funded Warrants (Details) - shares Jun. 30, 2024 Mar. 31, 2024 Stock options, issued and outstanding A A Class of Warrant or

Right [Line Items] Á Á Issuance of pre-funded warrants (in shares) 10,157,052 8,652,256 Restricted and performance stock units Á Á Class of Warrant or Right [Line Items] Á Á Issuance of pre-funded warrants (in shares) 3,370,183 2,397,890 Stock options and restricted stock units, future issuance Á Á Class of Warrant or Right [Line Items] Á Á Issuance of pre-funded warrants (in shares) 1,988,217 2,284,141 Employee stock purchase plan, available for future grants Á Á Class of Warrant or Right [Line Items] Á Á Issuance of pre-funded warrants (in shares) 3,405,175 2,738,208 Pre-IPO warrants to purchase common stock Á Á Class of Warrant or Right [Line Items] Á Á Issuance of pre-funded warrants (in shares) 497,344 497,344 Pre-funded warrants Á Á Class of Warrant or Right [Line Items] Á Á Issuance of pre-funded warrants (in shares) 10,211,969 5,281,616 Total shares of common stock reserved for future issuance Á Á Class of Warrant or Right [Line Items] Á Á Issuance of pre-funded warrants (in shares) 29,629,942 21,851,455 X - DefinitionIt represents number of pre funded warrants to purchase common stock of company. + ReferencesNo definition available. + Details Name: repl_PreFundedWarrantsIssued Namespace Prefix: repl_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsiarySaleOfStockAxis=repl_PreFundedWarrantsRestrictedAndPerformanceStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsiarySaleOfStockAxis=repl_PreFundedWarrantsStockOptionsAndRestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsiarySaleOfStockAxis=repl_PreFundedWarrantsESPPMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsiarySaleOfStockAxis=repl_PreFundedWarrantsPreIPOMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsiarySaleOfStockAxis=repl_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsiarySaleOfStockAxis=repl_PreFundedWarrantsCommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X Details Name: XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' equity - ATM Program (Details) - USD (\$) \$ / shares in Units, \$ in Millions Jun. 14, 2024 Aug. 03, 2023 Aug. 11, 2020 Jun. 30, 2024 Mar. 31, 2024 Class of Warrant or Right [Line Items] Á Á Á Á Aggregate offering amount \$ 96.7 Á Á Á Á Common stock, par value (in dollars per share) Á Á Á \$ 0.001 \$ 0.001 ATM Program Á Á Á Á Class of Warrant or Right [Line Items] Á Á Á Á Percentage of commission Á Á 3.00% Á Á ATM Program | Common stock Á Á Á Á Class of Warrant or Right [Line Items] Á Á Á Á Common stock, par value (in dollars per share) Á Á \$ 0.001 Á Á Á Á Maximum received on transaction Á \$ 100.0 Á Á X - DefinitionPercentage of commission paid under common stock sale agreement + ReferencesNo definition available. + Details Name: repl_PercentageOfCommission Namespace Prefix: repl_Data Type: dtr-types1:percentItemType Balance Type: na Period Type: duration X - DefinitionSale Of Stock, Maximum Consideration Received On All Transactions + ReferencesNo definition available. + Details Name: repl_SaleOfStockMaximumConsiderationReceivedOnAllTransactions Namespace Prefix: repl_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_SubsiarySaleOfStockAxis=repl_AtMarketOfferingProgramMember Namespace Prefix: Data Type: na Balance Type: Period Type: X Details Name: XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' equity - Equity offerings (Details) - USD (\$) \$ / shares in Units, \$ in Millions Jun. 14, 2024 Jun. 30, 2024 Mar. 31, 2024 Class of Warrant or Right [Line Items] Á Á Á Á Number of shares issued (in shares) 5,668,937 Á Á Price per share (in USD per share) \$ 8.82 Á Á Net proceeds \$ 96.7 Á Á Pre-funded warrants Á Á Á Á Class of Warrant or Right [Line Items] Á Á Á Á Issuance of pre-funded warrants (in shares) Á 10,211,969 5,281,616 Underwriter rights Á Á Á Class of Warrant or Right [Line Items] Á Á Á Underwriting discounts, commissions and other offering expenses \$ 3.3 Á Á 2024 Pre-funded Warrants Á Á Á Class of Warrant or Right [Line Items] Á Á Á Issuance of pre-funded warrants (in shares) 5,669,578 Á Á Share price (in dollars per share) \$ 8.819 Á Á X - DefinitionIt represents number of pre funded warrants to purchase common stock of company. + ReferencesNo definition available. + Details Name: repl_PreFundedWarrantsIssued Namespace Prefix: repl_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15> + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_SubsiarySaleOfStockAxis=repl_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsiarySaleOfStockAxis=repl_A2024PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Pre-funded Warrants - Narrative (Details) - \$ / shares 1 Months Ended 3 Months Ended Oct. 31, 2020 Jun. 30, 2024 Mar. 31, 2024 Jul. 09, 2018 Class of Warrant or Right [Line Items] Á Á Á Á Number of stock warrants issued (in shares) Á Á 10,211,969 Pre-funded warrants Á Á Á Á Class of Warrant or Right [Line Items] Á Á Á Á Number of stock warrants issued (in shares) Á 739,225 Á Á Exercise price (in dollars per share) Á \$ 0.001 Á Á Common stock Á Á Á Á Class of Warrant or Right [Line Items] Á Á Á Á Shares issued during period (in shares) Á 739,225 Á Á Pre-funded warrants Á Á Á Á Class of Warrant or Right [Line Items] Á Á Á Á Maximum percentage of holding for exercise warrants (as a percent) 9.99% Á Á Á Á Maximum percentage of increase (decrease) of holding for exercise warrants (as a percent) 19.99% Á Á Á Prior notice period to change percentage of holding (in days) 61 days Á Á Á Issuance of pre-funded warrants (in shares) Á 10,211,969 5,281,616 Á X - DefinitionThe maximum percentage of holding for exercise warrants. + ReferencesNo definition available. + Details Name: repl_MaximumPercentageOfHoldingForExerciseWarrants Namespace Prefix: repl_Data Type: dtr-types1:percentItemType Balance Type: na Period Type: duration X - DefinitionRepresents the maximum percentage of increase (decrease) of holding for exercise warrants. + ReferencesNo definition available. + Details Name: repl_MaximumPercentageOfIncreaseDecreaseOfHoldingForExerciseWarrants Namespace Prefix: repl_Data Type: dtr-types1:percentItemType Balance Type: na Period Type: duration X - DefinitionIt represents number of days prior notice for increase or decrease percentage of holding. + ReferencesNo definition available. + Details Name: repl_MinimumNoticePeriodToChangePercentageOfHolding Namespace Prefix: repl_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionIt represents number of pre funded warrants to purchase common stock of company. + ReferencesNo definition available. + Details Name: repl_PreFundedWarrantsIssued Namespace Prefix: repl_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3> + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3> + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5> + Details Name: us-gaap_ConversionOfStockSharesIssued1 Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=repl_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsiarySaleOfStockAxis=repl_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based compensation - Classification of expense (Details) - USD (\$) \$ in Thousands 3 Months Ended Jun. 30, 2024 Jun. 30, 2023 Share-Based Compensation Á Á Stock-based compensation expense \$ 9,475 \$ 8,846 Stock options Á Á Share-Based Compensation Á Á Stock-based compensation expense 5,733 5,614 Restricted and performance stock units Á Á Share-Based Compensation Á Á Stock-based compensation expense 3,742 3,232 Research and development Á Á Share-Based Compensation Á Á Stock-based compensation expense 4,226 3,298 Selling, general and administrative Á Á Share-Based Compensation Á Á Stock-based compensation expense \$ 5,249 \$ 5,548 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(h\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=repl_RestrictedAndPerformanceStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based compensation - Additional Information (Details) \$ / shares in Units, \$ in Millions 3 Months Ended Apr. 01, 2023 shares Jul. 09, 2018 shares Jun. 30, 2024 USD (\$) \$ / shares shares Jun. 30, 2023 \$ / shares shares Apr. 01, 2022 shares Jul. 31, 2017 Stock-Based Compensation Á Á Á Á Conversion ratio Á Á Á Á 1 Total unrecognized compensation cost | \$ Á Á \$ 34.5 Á Á Á Expenses expected to be recognized over a weighted average remaining period Á Á 2 years 9 months 18 days Á Á Weighted average grant-date fair value per share of stock options granted | \$ / shares Á Á \$ 5.37 \$ 12.09 Á Á Value of stock options exercised | \$ Á Á \$ 0.1 Á Á Á 2017 Plan Á Á Á Á Á Stock-Based Compensation Á Á Á Á Á Shares authorized (in shares) Á 2,659,885 Á Á Á Number of shares available for grant Á 2,520,247 0 Á Á Á 2018 Plan Á Á Á Á Á Stock-Based Compensation Á Á Á Á Á Shares authorized (in shares) Á 3,617,968 Á Á Á Number of shares available for grant Á 1,988,217 Á Á Á Share based payment award percentage of outstanding shares Á 4.00% Á Á Á Additional shares authorized (in shares) 2,667,868 Á Á Á Á 2018 Plan | Pre-funded warrants Á Á Á Á Á Stock-Based Compensation Á Á Á Á Á Common stock reserved for issuance (in shares) Á 5,281,616 Á Á Á ESPP Á Á Á Á Stock-Based Compensation Á Á Á Á Share based payment award percentage of outstanding shares Á 1.00% Á Á Á Á Common stock reserved for issuance (in shares) 3,405,175 348,612 Á Á 3,405,175 Á Additional shares authorized (in shares) 666,967 697,224 Á Á Á Out Of Plan Inducement Grants Á Á Á Á Á Stock-Based Compensation Á Á Á Á Á Stock unit grant (in shares) Á Á Á Á Stock unit grant (in shares) Á Á Á Á Stock options Á Á Á Á Á Stock-Based Compensation Á Á Á Á Á Exercise price for persons holding ten percent of voting power (as a percent) Á Á 100.00% Á Á Á Exercise price for persons holding more than ten percent of voting power (as a percent) Á Á 110.00% Á Á Á Share based payment award expiration period Á Á 10 years Á Á Á Share based payment award vesting period Á Á 4 years Á Á Á Total unrecognized compensation cost | \$ Á Á \$ 35.7 Á Á Á Expenses expected to be recognized over a weighted average remaining period Á Á 2 years 9 months 18 days Á Á Á Stock options | Maximum Á Á Á Á Á Stock-Based Compensation Á Á Á Á Á Á Á Expiration period for persons holding ten percent of voting power Á Á 5 years Á Á Á Stock options | Minimum Á Á Á Á Á Stock-Based Compensation Á Á Á Á Á Á Á Expiration period for persons holding more than ten percent of voting power Á Á 10 years Á Á Á RSUs Á Á Á Á Á Stock-Based Compensation Á Á Á Á Á Share based payment award vesting period Á Á 4 years Á Á Á RSUs | Out Of Plan Inducement Grants Á Á Á Á Á Stock-Based Compensation Á Á Á Á Á Stock unit grant (in shares) Á Á 50,000 Á Á Á PSUs Á Á Á Á Á Stock-Based Compensation Á Á Á Á Á Total unrecognized compensation cost | \$ Á Á \$ 4.8 Á Á Á PSUs | 2018 Plan Á Á Á Á Á Stock-Based Compensation Á Á Á Á Á Stock unit grant (in shares) Á Á 246,110 Á Á Á Nonqualified Stock Options | Out Of Plan Inducement Grants Á Á Á Á Á Stock-Based Compensation Á Á Á Á Á Stock unit grant (in shares) Á Á 75,000 Á Á Á X - DefinitionConversion Of Stock, Ratio + ReferencesNo definition available. + Details Name: repl_ConversionOfStockRatio Namespace Prefix: repl_Data Type: xbrli:pureItemType Balance Type: na Period Type: instant X - DefinitionMinimum percentage of exercise price of the fair market value for all incentive options granted to any person possessing more than 10% of the total combined voting power of all classes of shares. + ReferencesNo definition available. + Details Name: repl_MinimumPercentageOfExercisePricePersonsHoldingMoreThanTenPercentOfVotingPower Namespace Prefix: repl_Data Type: dtr-types1:percentItemType Balance Type: na Period Type: instant X - DefinitionMinimum percentage of exercise price of the fair market value for all incentive options granted to any person possessing 10% or less of the total combined voting power of all classes of shares. + ReferencesNo definition available. + Details Name: repl_MinimumPercentageOfExercisePricePersonsHoldingTenPercentOfVotingPower Namespace Prefix: repl_Data

Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe intrinsic value of options granted during the reporting period. + ReferencesNo definition available. + Details Name: repl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue Namespace Prefix: repl_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAward expiration period for persons possessing more than ten percent of voting power, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: repl_ShareBasedPaymentAwardExpirationPeriodForPersonsHoldingMoreThanTenPercentOfVotingPower Namespace Prefix: repl_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionAward expiration period for persons possessing ten percent of voting power, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: repl_ShareBasedPaymentAwardExpirationPeriodForPersonsHoldingTenPercentOfVotingPower Namespace Prefix: repl_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: [http://www.xbrli.org/2003/role/exampleRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/exampleRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D>Reference 2: <http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3>Reference 3: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 5: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 6: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 7: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 8: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 9: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 10: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 11: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 12: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 13: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 14: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 15: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 16: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 17: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 18: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 19: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 20: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 21: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 22: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 23: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 24: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 25: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 26: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 27: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 28: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(v\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: [http://www.xbrli.org/2003/role/exampleRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/exampleRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionMaximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrli.org/2003/role/exampleRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/exampleRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=repl_OmnibusIncentiveCompensationPlan2018Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=repl_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=repl_EmployeeSharePurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=repl_OutOfPlanInducementGrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=repl_PerformanceStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=repl_NonqualifiedStockOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based compensation - Assumptions to determine grant-date fair value of stock options (Details) - Stock options 3 Months Ended Jun. 30, 2024 Jun. 30, 2023 Stock-Based Compensation Å Risk-free interest rate 4.43% 3.60% Expected term (in years) 6 years 6 years Expected volatility 76.30% 74.10% Expected dividend yield 0.00% 0.00% X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionThe minimum risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionRate of weighted-average expected volatility for award under share-based payment arrangement. + ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D>Reference 2: <http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3>Reference 3: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 5: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 6: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 7: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 8: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 9: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 10: [http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50](http://www.xbrli.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

[| | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Outstanding at beginning of the period \(in shares\) | 8,652,256 | A | Granted \(in shares\) | 1,744,401 | A | Exercised \(in shares\) | \(22,860\) | A | Cancelled \(in shares\) | \(216,743\) |
| Outstanding at end of the period \(in shares\) | 10,157,054 | | Options exercisable \(in shares\) | 6,152,459 | A | Options vested and expected to vest \(in shares\) | 10,157,054 | | | |
| Weighted Average Exercise Price | A | Outstanding at beginning of the period \(in dollars per share\) | \\$ 16.94 | A | Granted \(in dollars per share\) | 7.73 | A | Exercised \(in dollars per share\) | 2.91 | A |
| Cancelled \(in dollars per share\) | 17.82 | A | Outstanding at end of the period \(in dollars per share\) | 15.37 | A | Options exercisable \(in dollars per share\) | 16.16 | A | Options vested and expected to vest \(in dollars per share\) | \\$ 15.37 |
| Weighted Average Contractual Term \(Years\) | A | Outstanding \(years\) | 6 years 10 months 2 days 6 years 7 months 9 days | | Options exercisable \(years\) | 5 years 4 months 24 days | | Options vested and expected to vest \(years\) | 6 years 10 months 2 days | |
| Aggregate Intrinsic Value | A | Outstanding \\$ | 8,837 | \\$ 5,748 | Options exercisable | 6,541 | A | Options vested and expected to vest \\$ | 8,837 | A |
 X - ReferencesNo definition available. + Details Name: repl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract Namespace Prefix: repl_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: repl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract Namespace Prefix: repl_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options \(or share units\) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYmNdTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYmNdTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph \(e\)\(1\) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYmNdTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of options vested. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options \(or share units\) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYmNdTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days, + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based compensation - Stock option activity (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 12 Months Ended Jun. 30, 2024 Mar. 31, 2024 Number of Shares <table border=)

Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/178-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/178-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based compensation - Summary of RSU Activity (Details) \$ / shares in Units, \$ in Millions 3 Months Ended Jun. 30, 2024 USD (\$) \$ / shares shares Weighted Average Grant Date Fair Value \$ Total unrecognized compensation cost \$ \$ 34.5 Expenses expected to be recognized over a weighted average remaining period 2 years 9 months 18 days Restricted and performance stock units \$ Number of Restricted Shares \$ Outstanding as of March 31, 2021 (in shares) | shares 2,397,890 Granted (in shares) | shares 1,560,527 Vested (in shares) | shares (463,841) Cancelled (in shares) | shares (124,393) Outstanding as of June 30, 2021 (in shares) | shares 3,370,183 Weighted Average Grant Date Fair Value \$ Outstanding as of March 31, 2021 (in dollars per share) | \$ / shares \$ 17.97 Granted (in dollars per share) | \$ / shares 7.72 Vested (in dollars per share) | \$ / shares 22.03 Cancelled (in dollars per share) | \$ / shares 15.23 Outstanding as of June 30, 2021 (in dollars per share) | \$ / shares \$ 12.77 X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/178-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in "PnYmMnDnHnMnS" format, for example, "P1Y5M13D" represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/178-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/178-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/178-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/178-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/178-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/178-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/178-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/178-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/178-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/178-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/178-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=repl.RestrictedAndPerformanceStockUnits(Members) Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net loss per share - Computation of Net Loss per Share (Details) - USD (\$) \$ / shares in Units, \$ in Thousands 3 Months Ended Jun. 30, 2024 Jun. 30, 2023 Numerator: A A Net loss \$ (53,772) \$ (49,555) Denominator: A A Weighted average common shares outstanding, basic (in shares) 69,185,885 66,367,702 Weighted average common shares outstanding, diluted (in shares) 69,185,885 66,367,702 Net loss per share attributable to common stockholders, diluted (in dollars per share) \$ (0.78) \$ (0.75) Net loss per share attributable to common stockholders, basic (in dollars per share) \$ (0.78) \$ (0.75) X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-

0-599-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944-SubTopic 220 -Name Accounting Standards Codification -Section S99-Paragraph 1-Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260-SubTopic 10 -Name Accounting Standards Codification -Section 45-Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap EarningsPerShareDiluted Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65-Paragraph 1-Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50-Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50-Paragraph 11-Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50-Paragraph 11-Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50-Paragraph 11-Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50-Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99-Paragraph 5-Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50-Paragraph 1-Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45-Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45-Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45-Paragraph 60B-Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NetIncomeLossAvailableToCommonStockholdersBasicAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50-Paragraph 1-Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45-Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50-Paragraph 1-Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45-Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net loss per share - Narrative (Details) Jul. 09, 2018 shares Earnings Per Share [Abstract] A Number of stock warrants issued (in shares) 10,211,969 X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50-Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap EarningsPerShareAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 69 R58.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net loss per share - Computation of diluted net loss per share attributable to common stockholders (Details) - shares 3 Months Ended Jun. 30, 2024 Jun. 30, 2023 Diluted net loss per share attributable to common stockholders A Antidilutive securities excluded from computation of diluted weighted average shares outstanding (in shares) 14,024,581 11,634,064 Options to purchase common stock A Diluted net loss per share attributable to common stockholders A Antidilutive securities excluded from computation of diluted weighted average shares outstanding (in shares) 10,157,054 9,067,305 Unvested restricted and performance stock units A Diluted net loss per share attributable to common stockholders A Antidilutive securities excluded from computation of diluted weighted average shares outstanding (in shares) 3,370,183 2,069,415 Warrants to purchase common stock A Diluted net loss per share attributable to common stockholders A Antidilutive securities excluded from computation of diluted weighted average shares outstanding (in shares) 497,344 497,344 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50-Paragraph 1-Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=repl RestrictedAndPerformanceStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R59.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Significant agreements (Details) 1 Months Ended Jan. 31, 2020 patient Bristol-Myers Squibb Company A Significant agreements A Number of patients 125 X - DefinitionIt represents number of additional Cohort of patients with anti PDI failed melanoma. + ReferencesNo definition available. + Details Name: repl NumberOfPatients Namespace Prefix: repl Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50-Paragraph 1-Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srl CounterpartyNameAxis=repl BristolMyersSquibbCompanyMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R60.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Collaboration and other arrangements (Details) - USD (\$) in Millions 3 Months Ended Jun. 30, 2024 Jun. 30, 2023 Mar. 31, 2024 Master Clinical Trial Collaboration and Supply Agreement - Roche A A Significant agreements A A Termination period 60 days A A Offset to research and development expense \$ 0.0 \$ 0.7 A Payments received 1.8 \$ 0.2 A Receivables \$ 0.0 A \$ 1.8 Clinical Trial Collaboration and Supply Agreement - Incyte | Maximum A A A Significant agreements A A A Termination period 90 days A X - DefinitionCollaborative Arrangement, Offset to Research and Development Expense + ReferencesNo definition available. + Details Name: repl CollaborativeArrangementOffsetToResearchAndDevelopmentExpense Namespace Prefix: repl Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCollaborative Arrangement, Receivable from Other Party + ReferencesNo definition available. + Details Name: repl CollaborativeArrangementReceivableFromOtherPartyNamespace Prefix: repl Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCollaborative Arrangement, Termination Period + ReferencesNo definition available. + Details Name: repl CollaborativeArrangementTerminationPeriod Namespace Prefix: repl Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50-Paragraph 1-Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45-Paragraph 28-Subparagraph (a) -SubTopic

https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap LeaseCost Namespaces Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap OperatingLeaseCost Namespaces Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap IncomeStatementLocationAxis=us-gaap ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap IncomeStatementLocationAxis=us-gaap GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 74 R63.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and contingencies - Balance sheet disclosures (Details) \$ in Thousands Jun. 30, 2024 USD (\$) Operating leases 4 2022 (remaining three months) \$ 872 2026 1,171 2027 1,137 2028 1,086 2029 1,005 Thereafter 925 Total lease payments 6,196 Less: interest 1,432 Total lease liabilities 4,764 Financing lease 4 2022 (remaining three months) 2,050 2026 2,799 2027 2,883 2028 2,969 2029 3,058 Thereafter 31,995 Total lease payments 45,754 Less: interest 19,760 Total lease liabilities 25,994 Total 4 2022 (remaining three months) 2,922 2026 3,970 2027 4,020 2028 4,055 2029 4,063 Thereafter 32,920 Total lease payments 51,950 Less: interest 21,192 Total lease liabilities \$ 30,758 X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year and after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: repl_FinanceLeaseLiabilityToBePaidAfterYearFour Namespaces Prefix: repl Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease due in fifth fiscal year and after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: repl_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour Namespaces Prefix: repl Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: repl_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract Namespaces Prefix: repl Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating and finance lease. + ReferencesNo definition available. + Details Name: repl_OperatingAndFinanceLeaseLiability Namespaces Prefix: repl Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments for operating and finance lease + ReferencesNo definition available. + Details Name: repl_OperatingAndFinanceLeaseLiabilityPaymentsDue Namespaces Prefix: repl Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments for operating and finance lease, due in fifth fiscal year and after fifth fiscal year following latest fiscal year. + ReferencesNo definition available. + Details Name: repl_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFour Namespaces Prefix: repl Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments for operating and finance lease, due in next fiscal year following current fiscal year. + ReferencesNo definition available. + Details Name: repl_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths Namespaces Prefix: repl Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments for operating and finance lease, due in third fiscal year following latest fiscal year. + ReferencesNo definition available. + Details Name: repl_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree Namespaces Prefix: repl Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments for operating and finance lease, due in second fiscal year following latest fiscal year. + ReferencesNo definition available. + Details Name: repl_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo Namespaces Prefix: repl Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments for operating and finance lease, due in remainder of fiscal year following latest fiscal year ended + ReferencesNo definition available. + Details Name: repl_OperatingAndFinanceLeaseLiabilityPaymentsRemainderOffiscalYear Namespaces Prefix: repl Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating and finance lease. + ReferencesNo definition available. + Details Name: repl_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount Namespaces Prefix: repl Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments for operating and finance lease, due in fourth fiscal year following latest fiscal year. + ReferencesNo definition available. + Details Name: repl_OperatingFinanceLeaseLiabilityPaymentsDueYearFour Namespaces Prefix: repl Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap FinanceLeaseLiabilitiesPaymentsDueAbstract Namespaces Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap FinanceLeaseLiability Namespaces Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments for finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap FinanceLeaseLiabilityPaymentsDue Namespaces Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap FinanceLeaseLiabilityPaymentsDueNextTwelveMonths Namespaces Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap FinanceLeaseLiabilityPaymentsDueYearFour Namespaces Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap FinanceLeaseLiabilityPaymentsDueYearThree Namespaces Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap FinanceLeaseLiabilityPaymentsDueYearTwo Namespaces Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap FinanceLeaseLiabilityPaymentsRemainderOffiscalYear Namespaces Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap FinanceLeaseLiabilityUndiscountedExcessAmount Namespaces Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Namespaces Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespaces Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Names

gaap_FinanceLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent. + ReferencesReference 1:

[illegible][illegible]

[illegible]

H<46M4>=O>T<Q7SN2>Q-K<M-P0:B>FBA^K2-J,UW1[X9C14,->=]D/S=<GUHUY7&=#\$11 MJHONY4!4L#110,(-Y-46D39PY@2P<H6-9>=&P0=VJR-WH
 N965T66G21 MW;M<P>G6JMB871):DXJ<_9X2<2M<3>XO>74(D4YSA,S//>(>W1K1R:V5-MAN^E+IWUUMHOFD99#RV5J77-1%;LQ2VEQTF<B&K-53)GH;B)ΐ
 W66YV6Y<J>J03>T+7-PW6KBZ4+>=O5-V=UAKUVX5FOUHX<O>W&E1Z3J-MY-1Q;-7DNN2Z4U7;2IAU7U<D9>3>J+3SA4UIM7==B+4+8S(H<C<SNUY-M;A2;D;J
 Z5E52D<C>G;WJBD3876<J>VPY<M<K1)&+JW<O>K>R-MR-52UH5^MH-JV>E1E1G#7VS#W#3K6:QVW12,1^4N<I/1+>+XH2,PBS(C<M#0#0#>=<JZ67H1P6;
 6E6V=<J+VPJ2P-DI-M<M<9>RNEHJ^M<W0X&EJ>@ZQ1RHZ2S2C;B1^AH-UW+V<KT>L1,1&Q>J|HKOML<41^R&SZMU>=5PSGWPB3QWH3Q>U>?<K<
 CH44H145Y)SZNE2IR42BQH<P6;19>=>PH;ZU587FBN0=QK=KG-V%<A-UE1U4MR-(7G<WVSAQ54GXQ'6-DN14F;E;L3*#<VZ4M4J(1%G)&#>%J^FE&#>=M1C?2%
 -#N92M<00Q2<K664-H#H1CR4Q6K1>(<3);2^MJ,QZIS1H-MDU=B\$D<=>Sj67L\$77F1TQ<=>HN=<#>#N2J=<#>#06Z7J<I>F&5:ON6B9J#677BX<=>
 MRZ+>S1-JT3A)PG,T9A30<DXH0A1>|>JQ<K^<F\$T0=>8WEWHNN<K^A-ME0=>=V7L6E1<8#PRQBW<ZEX0B/M2M15CLD)BZHKS2JfU6M(28C?2(6IS;GHPH8&AFELAB,0>P
 MT3<=>S<=>A8)SIZ<=>H1,Q&Q9MB;7J12Z<=>(Y+&VN>=>Y:KN2<=>M>A,C&S1U/8D>9 MHU<=>IORS190T<H7TD001<3TRA1P+K<X<E1
 -JH<7XL1YU<RX+4J)S9&TH7H1J>S<=>55XJ<1,9<1>+JH1F|JZ1H1/MSDSC<=>GTXA1<D604>F\$<N4A7<3>R0P<XQ<E?<=>95ML0VMY651ZIH-M&ZES7E265)+65Q;?<=>
 R<KV,80ZPI3&E;WAF716QJY7R<=>R<M<=>=>5JPI3<=>0D(6<D<O=WVSU^A8P4KYUDJ>E>B1V0X6CQVF<=>7WZJZ
 -#N92M<00Q2<K664-H#H1CR4Q6K1>(<3);2^MJ,QZIS1H-MDU=B\$D<=>Sj67L\$77F1TQ<=>HN=<#>#N2J=<#>#06Z7J<I>F&5:ON6B9J#677BX<=>
 MRZ+>S1-JT3A)PG,T9A30<DXH0A1>|>JQ<K^<F\$T0=>8WEWHNN<K^A-ME0=>=V7L6E1<8#PRQBW<ZEX0B/M2M15CLD)BZHKS2JfU6M(28C?2(6IS;GHPH8&AFELAB,0>P
 MT3<=>S<=>A8)SIZ<=>H1,Q&Q9MB;7J12Z<=>(Y+&VN>=>Y:KN2<=>M>A,C&S1U/8D>9 MHU<=>IORS190T<H7TD001<3TRA1P+K<X<E1
 -JH<7XL1YU<RX+4J)S9&TH7H1J>S<=>55XJ<1,9<1>+JH1F|JZ1H1/MSDSC<=>GTXA1<D604>F\$<N4A7<3>R0P<XQ<E?<=>95ML0VMY651ZIH-M&ZES7E265)+65Q;?<=>
 R<KV,80ZPI3&E;WAF716QJY7R<=>R<M<=>=>5JPI3<=>0D(6<D<O=WVSU^A8P4KYUDJ>E>B1V0X6CQVF<=>7WZJZ
 -#N92M<00Q2<K664-H#H1CR4Q6K1>(<3);2^MJ,QZIS1H-MDU=B\$D<=>Sj67L\$77F1TQ<=>HN=<#>#N2J=<#>#06Z7J<I>F&5:ON6B9J#677BX<=>
 MRZ+>S1-JT3A)PG,T9A30<DXH0A1>|>JQ<K^<F\$T0=>8WEWHNN<K^A-ME0=>=V7L6E1<8#PRQBW<ZEX0B/M2M15CLD)BZHKS2JfU6M(28C?2(6IS;GHPH8&AFELAB,0>P
 MT3<=>S<=>A8)SIZ<=>H1,Q&Q9MB;7J12Z<=>(Y+&VN>=>Y:KN2<=>M>A,C&S1U/8D>9 MHU<=>IORS190T<H7TD001<3TRA1P+K<X<E1
 -JH<7XL1YU<RX+4J)S9&TH7H1J>S<=>55XJ<1,9<1>+JH1F|JZ1H1/MSDSC<=>GTXA1<D604>F\$<N4A7<3>R0P<XQ<E?<=>95ML0VMY651ZIH-M&ZES7E265)+65Q;?<=>
 R<KV,80ZPI3&E;WAF716QJY7R<=>R<M<=>=>5JPI3<=>0D(6<D<O=WVSU^A8P4KYUDJ>E>B1V0X6CQVF<=>7WZJZ
 -#N92M<00Q2<K664-H#H1CR4Q6K1>(<3);2^MJ,QZIS1H-MDU=B\$D<=>Sj67L\$77F1TQ<=>HN=<#>#N2J=<#>#06Z7J<I>F&5:ON6B9J#677BX<=>
 MRZ+>S1-JT3A)PG,T9A30<DXH0A1>|>JQ<K^<F\$T0=>8WEWHNN<K^A-ME0=>=V7L6E1<8#PRQBW<ZEX0B/M2M15CLD)BZHKS2JfU6M(28C?2(6IS;GHPH8&AFELAB,0>P
 MT3<=>S<=>A8)SIZ<=>H1,Q&Q9MB;7J12Z<=>(Y+&VN>=>Y:KN2<=>M>A,C&S1U/8D>9 MHU<=>IORS190T<H7TD001<3TRA1P+K<X<E1
 -JH<7XL1YU<RX+4J)S9&TH7H1J>S<=>55XJ<1,9<1>+JH1F|JZ1H1/MSDSC<=>GTXA1<D604>F\$<N4A7<3>R0P<XQ<E?<=>95ML0VMY651ZIH-M&ZES7E265)+65Q;?<=>
 R<KV,80ZPI3&E;WAF716QJY7R<=>R<M<=>=>5JPI3<=>0D(6<D<O=WVSU^A8P4KYUDJ>E>B1V0X6CQVF<=>7WZJZ
 -#N92M<00Q2<K664-H#H1CR4Q6K1>(<3);2^MJ,QZIS1H-MDU=B\$D<=>Sj67L\$77F1TQ<=>HN=<#>#N2J=<#>#06Z7J<I>F&5:ON6B9J#677BX<=>
 MRZ+>S1-JT3A)PG,T9A30<DXH0A1>|>JQ<K^<F\$T0=>8WEWHNN<K^A-ME0=>=V7L6E1<8#PRQBW<ZEX0B/M2M15CLD)BZHKS2JfU6M(28C?2(6IS;GHPH8&AFELAB,0>P
 MT3<=>S<=>A8)SIZ<=>H1,Q&Q9MB;7J12Z<=>(Y+&VN>=>Y:KN2<=>M>A,C&S1U/8D>9 MHU<=>IORS190T<H7TD001<3TRA1P+K<X<E1
 -JH<7XL1YU<RX+4J)S9&TH7H1J>S<=>55XJ<1,9<1>+JH1F|JZ1H1/MSDSC<=>GTXA1<D604>F\$<N4A7<3>R0P<XQ<E?<=>95ML0VMY651ZIH-M&ZES7E265)+65Q;?<=>
 R<KV,80ZPI3&E;WAF716QJY7R<=>R<M<=>=>5JPI3<=>0D(6<D<O=WVSU^A8P4KYUDJ>E>B1V0X6CQVF<=>7WZJZ
 -#N92M<00Q2<K664-H#H1CR4Q6K1>(<3);2^MJ,QZIS1H-MDU=B\$D<=>Sj67L\$77F1TQ<=>HN=<#>#N2J=<#>#06Z7J<I>F&5:ON6B9J#677BX<=>
 MRZ+>S1-JT3A)PG,T9A30<DXH0A1>|>JQ<K^<F\$T0=>8WEWHNN<K^A-ME0=>=V7L6E1<8#PRQBW<ZEX0B/M2M15CLD)BZHKS2JfU6M(28C?2(6IS;GHPH8&AFELAB,0>P
 MT3<=>S<=>A8)SIZ<=>H1,Q&Q9

[illegible]

[illegible]

```
#FYA664Z:04FFC&Q:69BZ7P6S=-C M8JXD3F>&UWDPMC?FG?J7GPV3~-C8H\&-&ZJE0_-,0_-X,-'1'8_,,'$FC'-M=KKD%M@R7=9_M^8BG-P-SQA-~#20EO+H-
%G%?%)L,;6AN^*M1'B->E7-M8+B(8UO4574VK3G/&ZCV^QM-^#&=&'V-A+8UVLE5Y-YEIF0to5FPUMBU4XL MT&S,SyT-7BM&T+>VT,T=,XT M-W4=C%D8#8(FANVL7$9I;
(OR20--V4G-P[C[G84D]BF1EF[VJVOZ<716,,Y88-0'U,*3#BAAL65V'M43>2c$%'E[N[ TAYFWX]AMOF+<]'<50'=;2VVZ9-='F(S3CLO=>'6'M-M'8EM@TO1'<_&n#N#7,
2GN15';1VP:7HA-'<1&P;(7H=3_P,&s- M&SBf>LGE=M#M83;->,K<11YA(+Y+,Y,X59Y53-J]5Y'<ICGH,MIS $)<S MKNZ>1 #MH)<"2@ZPN@88==>@<X'<3sQ
4741x-YFMFT'4Q,0-%)#KM8TX7-M=PRZJ;6/BODHHBYW<C&GOV/WMBV+BLC+G,W14;IKN>(9BQCXF9J&$V$*'1KGv-Zo$7706
M6&C87&POS&QDDKK<_@)'I55127<-Q>W6j>ORY,M?5U4>_$74$L!#@0(-,%Y%GD>WYE$- (#TG+>&PO7WE);O M-VJR,VMO;VLN>&UL+G)E-/VDNMHT 4A>&M6"P@Y?
N?)TXHYDVHLHD<-^M+9)%U=-M=6'/,/ZBD/(LK%X'8C'+@&$3-IY-E4,[HKM3W>WINO(X'DYYU>S& ML?>14EWORK&M=UU?3NVJ5+C<+UW;8EG'5I(<#=7=
EXWV53;0&F3Y@Y2">+YePr,JkAR/R@<=&8/RA'ACYP>AZA#H<8>;-(AA,M,j]-J'P8 NIVD@X'9F+@=&j],NVX) P-M'X< @G0+@=&V>=
NWHIZX%-BGHK@<ZX>=@ETM,F1;R706L@<=),46(E)6M1 MR;R706L@<=),46(E)6M1 R70VU@<=(#&4CT-M0,R/OVR802PCT-M3,]/OV MU-L(I{#,4VPCT-M3,]/OVU-
L(I{#,4VPCT-M3,]/1VU-L)],4VPGT=M3,]/33V-MRF4MOCIG KTSZF]],Z3GTV<4>ZLAYO?9AK'ZWITGU+>ZWMZ'L67IMG-SCYS3;45_]@M02P,$%<SD (6:5-G'N-O'D'8-l, M
:]0VIN-&5N=N]4>7IE&ULS=K+3LP, ?Z7-ZSKR3GXUXORGQSOWQ'7CXU>+4-O M$X5IP>SJT4+A-39;&]>UF?(NMFU93,A/Q7-B)ZJ>ME4U'MJDV7CY31-M!
PU7I&EKUBV18,G8>PI3Y7GCVF]]>=:MYE'I<6Z/<=Q,P,93DJ]+D0A.M-PA3TFMQSXJ-GB8-DWU#M/]S13ZYLI[G$=GX-R,Q[XO'XO-Q <74B0/A1(-M'QJD#P/QS%('R<@?
9R'1,%G<V@,B12.4HHG(45#FJAR'S58[B]>DE|E(-M#ED)62BR'A19:BJL D56>2(M40')%5H,]/4&05'<)%%GDEBJP215:(JM$D56B MR'H19)4HLDH4626*K
P5H4BZJ'15:(JEID5DBR'A19:8JL D56A2'K1165 M#ABJ4635+'<J%#DUBPJ-15-(JM&D56CR&IO5*9'4HLAH460V'K 9'%5H,BJ_E/M6>=<6 IQ/_L/LJO_T,_EL':X@502P$%",4"-
#0.A9I%?-8H$-"Q M $ @ < % 9&JC4'O<-O87P+GAM;M#+ 0+(4 Q0 M (-,Y,%BDH)/IP "L'1->ID-V.O&UL4$! A0#%< SD (M65Y72.3KI0 MA)+@ ('#@@<-AL+W=O&PO=VJR:W-
H M965T&UL4$! A0#%< SD (69B/F,+1'(1@ M ('LA<-AL+W=O&PO=VJR:W-H965T&UL4$! A0#%< SD (69XI<-W0P CC<+@ (<'Q2(M '-AL+W=O&PO=VJR:W-
H965T&UL4$! A0#%< SD (M6-NO<[H(C)=VJR:W-H965T J.P.-8'9->@05'IX;]/W,W)V(K M&UL4$! A0#%< SD (69I;/<=>P O -M ID (=TH -AL+W=O&PO=VJR:W-
H965T&UL4$! A0#%< SD (67I;2BK0'0 7IH-ID M ('#MT -AL+W=O&PO=VJR:W-H965T M&UL4$! A0# M3J;<SD (6;Y=&Q&5Q6<."2 M+0 &0 @(&S)B
>&PO=VJR:W-H965T&UL4$! A0#%< SD (61-G M#FI+)]Q8-ID ('HJ4 -AL+W=O&PO=VJR:W-H965T&UL4$! A0#%< SD (6&PO M-VJR:W-H965T&UL4$! A0#%< SD (6;LR+Y8 P $ @<-ID ('MK<-AL+W=O&PO=VJR:W-H965T&UL4$! A0#%< SD (60-G6M'T @ 608-ID ('IB=<-AL+W=O&PO=VJR:W-H965T&UL4$! A0#%< SD (63FX*US5
< 508-ID M ('2NP -AL+W=O&PO=VJR:M-W-H965T&UL4$! A0#%< SD (66XX/-<3I 2Q,ID ('is?<-M -AL+W=O&UL4$! A0#%< MSD (&XU BJ)?0 V<-ID (<'l6@OI
'-AL+W=O&PO=VJR:W-H965T&UL4$! A0#%< SD (<6>=%K#X @ MMP@-ID ('10I@ -AL+W=O&PO=VJR:W-H965T&UL4$! A0#%< SD (62U@/44+]44-ID M ('NQI;
'-AL+W=O&PO=VJR:W-H965T&UL4$! A0#%< SD (6424D@/U@->D7X-ID ('Ps>&PO=VJR:W-H965T&UL4$! A0#%< SD (M6&PO=VJR:W-H965T3$@(<(# $ 9 '@5I'
01X;]/W,W)V(K M&UL4$! A0#%< SD (62*SET>(<P QPM-M-ID ('HTFD)-AL+W=O&PO=VJR:W-H965T&UL4$! A0#%< SD (6TRX0+@ L@<-ID M ('IN5;'-AL+W=O&PO=VJR:W-
H965T M&UL4$! A0# M%< SD (6;ICGWIU /1@-ID ('E5Xi'-AL+W=O M&PO=VJR:W-H965T&UL4$! A0#%< SD (6<-T M'#1% P RA0 T (-K&DI'-AL+W-
T>6QE&PO=VJR:VO;VLN>&UL4$! A0#%< SD (61?F5X<M =>/?<+H (-XML 79 Show.js IDEA-XBRL DOCUMENT//Edgar(tm) Renderer was created by staff of the U.S.
Securities and Exchange Commission. Data and content created by investment employees within the scope of their employment are not subject to domestic copyright
protection. 17-U.S.C.-105-var>Show={};Show.LastAR=null;Show.showAR=function(a,r,w){if(!Show.LastAR)Show.hideAR=function(){var
e=a,while(e&&e.nodeName!="TABLE")e=e.nextSibling;if(!e||e.nodeName=="TABLE"){var ref=(window)?w.document.document().getElementById(r):(ref[e]=e.ref.cloneNode(!0);
e.removeAttribute("id");a.parentNode.appendChildChild(e))}if(e.e.style.display="block";Show.LastAR=e;Show.hideAR=function()
{Show.LastAR.style.display="none"};Show.toggleNext=function(a)[var e=a,while(e.nodeName!="DIV")e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else {var
d,p;if(e.style.display=="none">{d='block';p='-'}else{d='none';p='+'}e.style.display=d;if(a.textContent)
{a.textContent+=p+a.textContent.substring(1)}else{a.innerHTMLText=p+a.innerHTMLText.substring(1)}}}} XML 80-report-css:idea: XBRL DOCUMENT /* Updated 2009-11-04 *//*
v2.2.0.24 */-DefRef Styles *-report-table.authRefData { background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; }-report-table.authRefData-a
{ display: block; font-weight: bold; }-report-table.authRefData-p { margin-top: 0px; }-report-table.authRefData-hide { background-color: #2F4497; padding: 1px 3px 0px 0px;
text-align: right; }-report-table.authRefData-hide-a:hover { background-color: #2F4497; }-report-table.authRefData-body { height: 150px; overflow: auto; width: 400px; }
-report-table.authRefData-table { font-size: 1em; } /* Report Styles *-pl.a,.pl.a-visited { color: black; text-decoration: none; } /* table *-report { background-color: white;
border: 2px solid #acf; clear: both; color: black; font: normal Bpt Helvetica, Arial, sans-serif; margin-bottom: 2em; }-report hr { border: 1px solid #acf; } /* Top labels *-report th
{ background-color: #acf; color: black; font-weight: bold; text-align: center; }-report td,void { background-color: transparent; color: #000000; font: bold 10pt Helvetica,
Arial, sans-serif; text-align: left; }-report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; } word-wrap: break-word; }*-report td.pl.a
{ cursor: pointer; display: block; width: 200px; overflow: hidden; }-report td.pl.div-a { width: 200px; }-report td.pl.a:hover { background-color: #ffe; } /* Header
rows... *-report tr.th { background-color: #acf; color: black; font-weight: bold; } /* Calendars... *-report .rc { background-color: #f0f0f0; } /* Even rows... *-report .re;
-report .reu { background-color: #def; }-report .reut td { border-bottom: 1px solid black; } /* Odd rows... *-report .ro; -report .rou { background-color: white; }-report .rou td
{ border-bottom: 1px solid black; }-report .rou table td,-report .rou table td { border-bottom: 0px solid black; } /* styles for footnote marker *-report .fn { white-space:
nowrap; } /* styles for numeric types *-report .num,-report .nump { text-align: right; white-space: nowrap; }-report .nump { padding-left: 2em; }-report .nump { padding:
0px 4em 0px 2em; } /* styles for text types *-report .text { text-align: left; white-space: normal; }-report .text-big { margin-bottom: 1em; width: 17em; }-report .text-more
{ display: none; }-report .text-note { font-style: italic; font-weight: bold; }-report .text-small { width: 10em; }-report sup { font-style: italic; }-report .outerFootnotes { font-
size: 1em; } XML 82-FilingSummary.xml:idea: XBRL DOCUMENT 3.24.2.u1.html 1281-Statement-CONDENSEDCONSOLIDATEDBALANCE SHEETS Sheet
http://www.replimune.com/role/CoverCover Cover 1-false false R2.htm 1952151-Statement-CODENSEDCONSOLIDATED BALANCE SHEETS Sheet
http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSEDCONSOLIDATED BALANCE SHEETS Statements 2-false false R3.htm 9952152-
Statement-CONDENSEDCONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet
http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParentential CONDENSEDCONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3
false false R4.htm 9952153-Statement-CONDENSEDCONSOLIDATED STATEMENTS OF OPERATIONS Sheet
http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS CONDENSEDCONSOLIDATED STATEMENTS OF OPERATIONS Statements 4-false
false R5.htm 9952154-Statement-CONDENSEDCONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet
http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS CONDENSEDCONSOLIDATED STATEMENTS OF COMPREHENSIVE
LOSS Statements 5-false false R6.htm
```

http://www.replimune.com/role/StockholdersequityScheduleofPreferredWarrantsDetails Stockholders' equity - Schedule of Pre-funded Warrants (Details) Details 47 false false R48.htm 9954492 - Disclosure - Stockholders' equity - ATM Program (Details) Sheet http://www.replimune.com/role/StockholdersequityATMProgramDetails Stockholders' equity - ATM Program (Details) Details 48 false false R49.htm 9954493 - Disclosure - Stockholders' equity - Equity offerings (Details) Sheet http://www.replimune.com/role/StockholdersequityEquityofferingsDetails Stockholders' equity - Equity offerings (Details) Details 49 false false R50.htm 9954494 - Disclosure - Pre-funded Warrants - Narrative (Details) Sheet http://www.replimune.com/role/PreferredWarrantsNarrativeDetails Pre-funded Warrants - Narrative (Details) Details 50 false false R51.htm 9954495 - Disclosure - Stock-based compensation - Classification of expense (Details) Sheet http://www.replimune.com/role/StockbasedcompensationClassificationofexpenseDetails Stock-based compensation - Classification of expense (Details) Details 51 false false R52.htm 9954496 - Disclosure - Stock-based compensation - Additional Information (Details) Sheet http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails Stock-based compensation - Additional Information (Details) Details 52 false false R53.htm 9954497 - Disclosure - Stock-based compensation - Assumptions to determine grant-date fair value of stock options (Details) Sheet http://www.replimune.com/role/StockbasedcompensationAssumptionstodeterminegrantdatefairvalueofstockoptionsDetails Stock-based compensation - Assumptions to determine grant-date fair value of stock options (Details) Details 53 false false R54.htm 9954498 - Disclosure - Stock-based compensation - Stock option activity (Details) Sheet http://www.replimune.com/role/StockbasedcompensationStockoptionactivityDetails Stock-based compensation - Stock option activity (Details) Details 54 false false R55.htm 9954499 - Disclosure - Stock-based compensation - Summary of RSU Activity (Details) Sheet http://www.replimune.com/role/StockbasedcompensationSummaryofRSUActivityDetails Stock-based compensation - Summary of RSU Activity (Details) Details 55 false false R56.htm 9954500 - Disclosure - Net loss per share - Computation of Net Loss per Share (Details) Sheet http://www.replimune.com/role/NetlosspershareComputationofNetLossperShareDetails Net loss per share - Computation of Net Loss per Share (Details) Details 56 false false R57.htm 9954501 - Disclosure - Net loss per share - Narrative (Details) Sheet http://www.replimune.com/role/NetlosspershareNarrativeDetails Net loss per share - Narrative (Details) Details 57 false false R58.htm 9954502 - Disclosure - Net loss per share - Computation of diluted net loss per share attributable to common stockholders (Details) Sheet http://www.replimune.com/role/NetlosspershareComputationofdilutednetlosspershareattributabletocommonstockholdersDetails Net loss per share - Computation of diluted net loss per share attributable to common stockholders (Details) Details 58 false false R59.htm 9954503 - Disclosure - Significant agreements (Details) Sheet http://www.replimune.com/role/SignificantagreementsDetails Significant agreements (Details) Details http://www.replimune.com/role/Significantagreements 59 false false R60.htm 9954504 - Disclosure - Collaboration and other arrangements (Details) Sheet http://www.replimune.com/role/CollaborationandotherarrangementsDetails Collaboration and other arrangements (Details) Details http://www.replimune.com/role/Collaborationandotherarrangements 60 false false R61.htm 9954505 - Disclosure - Commitments and contingencies - Components of lease expense (Details) Sheet http://www.replimune.com/role/CommitmentsandcontingenciesComponentsofleaseexpenseDetails Commitments and contingencies - Components of lease expense (Details) Details 61 false false R62.htm 9954506 - Disclosure - Commitments and contingencies - Income Statement Information (Details) Sheet http://www.replimune.com/role/CommitmentsandcontingenciesIncomeStatementInformationDetails Commitments and contingencies - Income Statement Information (Details) Details 62 false false R63.htm 9954507 - Disclosure - Commitments and contingencies - Balance sheet disclosures (Details) Sheet http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails Commitments and contingencies - Balance sheet disclosures (Details) Details 63 false false R64.htm 9954508 - Disclosure - Commitments and contingencies - Other information (Details) Sheet http://www.replimune.com/role/CommitmentsandcontingenciesOtherinformationDetails Commitments and contingencies - Other information (Details) Details 64 false false R65.htm 9954509 - Disclosure - Commitments and contingencies - Additional information (Details) Sheet http://www.replimune.com/role/CommitmentsandcontingenciesAdditionalinformationDetails Commitments and contingencies - Additional information (Details) Details 65 false false R66.htm 9954510 - Disclosure - Geographic information (Details) Sheet http://www.replimune.com/role/GeographicinformationDetails Geographic information (Details) Details http://www.replimune.com/role/GeographicinformationTables 66 false false All Reports Book All Reports repl-20240630.htm repl-20240630.xsd repl-20240630-cal.xml repl-20240630-def.xml repl-20240630-lab.xml repl-20240630-pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/eid/2024 http://xbrl.sec.gov/eid/2024 true true JSON-85 MetaLinks.json IDEA: XBRL DOCUMENT - {"version": "2.2", "instance": {"repl-20240630.htm": {"nsprefix": "repl", "nsuri": "http://www.replimune.com/20240630", "dts": {"inline": {"local": {"repl-20240630.htm": {"schema": {"local": {"repl-20240630.xsd": {"remote": {"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/rr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/rr/role/net-2009-12-16.xsd", "http://www.xbrl.org/rr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "http://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/eid/2024/eid-2024.xsd", "https://xbrl.sec.gov/eid/2024/eid-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"}}, "calculationLink": {"local": {"repl-20240630-cal.xml"}}, "definitionLink": {"local": {"repl-20240630-def.xml"}}, "labelLink": {"local": {"repl-20240630-lab.xml"}}, "presentationLink": {"local": {"repl-20240630-pre.xml"}}, "keyStandard": 260, "keyCustom": 66, "axisStandard": 20, "axisCustom": 0, "memberStandard": 30, "memberCustom": 29, "hidden": {"total": 0, "http://xbrl.sec.gov/eid/2024": 5, "http://xbrl.sec.gov/eid/2024": 3, "http://fasb.org/us-gaap/2024": 1, "contextCount": 182, "entityCount": 1, "segmentCount": 63, "elementCount": 594, "unitCount": 7, "baseTaxonomies": {"http://fasb.org/us-gaap/2024": 548, "http://xbrl.sec.gov/eid/2024": 30, "http://xbrl.sec.gov/eid/2024": 25, "report": {"R1": {"role": {"http://www.replimune.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "menuCat", "order": 1, "firstAnchor": {"contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": {"span": "div", "body", "html"}, "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true, "uniqueAnchor": {"contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": {"span": "div", "body", "html"}, "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true, "uniqueAnchor": {"contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": -3, "ancestors": {"span": "td", "tr", "table", "div", "body", "html"}, "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true, "uniqueAnchor": {"contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": -3, "ancestors": {"span": "td", "tr", "table", "div", "body", "html"}, "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true, "uniqueAnchor": {"contextRef": "c-1", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": -3, "ancestors": {"span": "div", "ix:continuation", "body", "html"}, "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true, "uniqueAnchor": {"contextRef": "c-3", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": -3, "ancestors": {"span": "div", "td", "tr", "table", "div", "body", "html"}, "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true, "uniqueAnchor": {"contextRef": "c-1", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": -3, "ancestors": {"span": "div", "td", "tr", "table", "div", "body", "html"}, "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true, "uniqueAnchor": {"contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": -3, "ancestors": {"span": "div", "td", "tr", "table", "div", "body", "html"}, "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true, "uniqueAnchor": {"contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": -3, "ancestors": {"span": "div", "td", "tr", "table", "div", "body", "html"}, "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true, "uniqueAnchor": {"contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": -3, "ancestors": {"span": "div", "td", "tr", "table", "div", "body", "html"}, "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true, "uniqueAnchor": {"contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": -3, "ancestors": {"span": "div", "td", "tr", "table", "div", "body", "html"}, "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true, "uniqueAnchor": {"contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": -3, "ancestors": {"span": "div", "td", "tr", "table", "div", "body", "html"}, "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true, "uniqueAnchor": {"contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": -3, "ancestors": {"span": "div", "td", "tr", "table", "div", "body", "html"}, "reportCount": 1,

"span", "div", "body", "html", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.replimune.com/role/Shortterminvestments", "longName": "9952161 - Disclosure - Short-term investments", "shortName": "Short-term investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "body", "html", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "body", "html", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.replimune.com/role/Propertyplantandequipmentnet", "longName": "9952162 - Disclosure - Property, plant and equipment, net", "shortName": "Property, plant and equipment, net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "body", "html", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "body", "html", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.replimune.com/role/Accruedexpensesandothercurrentliabilities", "longName": "9952163 - Disclosure - Accrued expenses and other current liabilities", "shortName": "Accrued expenses and other current liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "body", "html", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "body", "html", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.replimune.com/role/Debt", "longName": "9952164 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "body", "html", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "body", "html", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.replimune.com/role/Stockholdersequity", "longName": "9952165 - Disclosure - Stockholders' equity", "shortName": "Stockholders' equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "body", "html", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true }, "uniqueAnchor": null }, "R17": { "role": "http://www.replimune.com/role/PrefundedWarrants", "longName": "9952166 - Disclosure - Pre-funded Warrants", "shortName": "Pre-funded Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "body", "html", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "body", "html", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.replimune.com/role/Stockbasedcompensation", "longName": "9952167 - Disclosure - Stock-based compensation", "shortName": "Stock-based compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "body", "html", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.replimune.com/role/Netlosspershare", "longName": "9952168 - Disclosure - Net loss per share", "shortName": "Net loss per share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "body", "html", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.replimune.com/role/Significantagreements", "longName": "9952169 - Disclosure - Significant agreements", "shortName": "Significant agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "body", "html", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true }, "uniqueAnchor": null }, "R21": { "role": "http://www.replimune.com/role/Collaborationandotherarrangements", "longName": "9952170 - Disclosure - Collaboration and other arrangements", "shortName": "Collaboration and other arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "body", "html", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true }, "uniqueAnchor": null }, "R22": { "role": "http://www.replimune.com/role/Commitmentsandcontingencies", "longName": "9952171 - Disclosure - Commitments and contingencies", "shortName": "Commitments and contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "body", "html", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "body", "html", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.replimune.com/role/Incometaxes", "longName": "9952172 - Disclosure - Income taxes", "shortName": "Income taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "body", "html", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "body", "html", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.replimune.com/role/Geographicinformation", "longName": "9952173 - Disclosure - Geographic information", "shortName": "Geographic information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "repl:GeographicalInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "body", "html", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "repl:GeographicalInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "body", "html", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true } }, "R25": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "body", "html", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "body", "html", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true } }, "R26": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "ecd:MtrTermsOffrArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html", "reportCount": 1

```

"ancestors": null, "ancestors": { "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "R35": { "role": "http://www.replimune.com/role/NetlosspershareTables", "longName": "9954479 - Disclosure - Net loss per share (Tables)", "shortName": "Net loss per share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "R36": { "role": "http://www.replimune.com/role/CommitmentsandcontingenciesTables", "longName": "9954480 - Disclosure - Commitments and contingencies (Tables)", "shortName": "Commitments and contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "R37": { "role": "http://www.replimune.com/role/GeographicinformationTables", "longName": "9954481 - Disclosure - Geographic information (Tables)", "shortName": "Geographic information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html": "1", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html": "1", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "R38": { "role": "http://www.replimune.com/role/NatureofthebusinessDetails", "longName": "9954482 - Disclosure - Nature of the business (Details)", "shortName": "Nature of the business (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "td", "tr", "table", "div", "body", "html": "1", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": null, "R39": { "role": "http://www.replimune.com/role/FairvalueoffinancialassetsandliabilitiesDetails", "longName": "9954483 - Disclosure - Fair value of financial assets and liabilities (Details)", "shortName": "Fair value of financial assets and liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-47", "name": "us-gaap:InvestmentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "body", "html": "1", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-47", "name": "us-gaap:InvestmentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "body", "html": "1", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "R40": { "role": "http://www.replimune.com/role/ShortterminvestmentsDetails", "longName": "9954484 - Disclosure - Short-term investments (Details)", "shortName": "Short-term investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-64", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "R41": { "role": "http://www.replimune.com/role/PropertyplantandequipmentnetDetails", "longName": "9954485 - Disclosure - Property, plant and equipment, net (Details)", "shortName": "Property, plant and equipment, net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "R42": { "role": "http://www.replimune.com/role/AccruedexpensesandothercurrentliabilitiesDetails", "longName": "9954486 - Disclosure - Accrued expenses and other current liabilities (Details)", "shortName": "Accrued expenses and other current liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-3", "name": "repl:AccruedResearchAndDevelopmentCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html": "1", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "repl:AccruedResearchAndDevelopmentCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html": "1", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "R43": { "role": "http://www.replimune.com/role/DebtNarrativeDetails", "longName": "9954487 - Disclosure - Debt - Narrative (Details)", "shortName": "Debt - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-3", "name": "repl:LongTermDebtInstrumentCovenantRequirementUnrestrictedCashPercentageOfObligations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span", "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "repl:LongTermDebtInstrumentCovenantRequirementUnrestrictedCashPercentageOfObligations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span", "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "R44": { "role": "http://www.replimune.com/role/DebtScheduleofDebtDetails", "longName": "9954488 - Disclosure - Debt - Schedule of Debt (Details)", "shortName": "Debt - Schedule of Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-99", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-99", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "R45": { "role": "http://www.replimune.com/role/DebtScheduleofMaturityofDebtDetails", "longName": "9954489 - Disclosure - Debt - Schedule of Maturity of Debt (Details)", "shortName": "Debt - Schedule of Maturity of Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-3", "name": "repl:LongTermDebtEndOfTermCharge", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "repl:LongTermDebtEndOfTermCharge", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "R46": { "role": "http://www.replimune.com/role/StockholdersequityCommonStockandUndesignatedPreferredStockDetails", "longName": "9954490 - Disclosure - Stockholders' equity - Common Stock and Undesignated Preferred Stock (Details)", "shortName": "Stockholders' equity - Common Stock and Undesignated Preferred Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span", "div", "td", "tr", "table", "div", "body", "html": "1", "reportCount": 1, "baseRef": "repl-20240
```

```

20240630.htm", "first": true, "unique": true }, "R53": { "role":
"http://www.replimune.com/role/StockbasedcompensationAssumptionstodeterminegrantdatefairvalueofstockoptionsDetails", "longName": "9954497 - Disclosure - Stock-based
compensation - Assumptions to determine grant date fair value of stock options (Details)", "shortName": "Stock-based compensation - Assumptions to determine grant date
fair value of stock options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": {
"contextRef": "c-130", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "unitRef":
"number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": { "span": "td", "tr", "table", "div", "us-
gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "repl-
20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-130", "name": "us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "unitRef": "number", "xsiNil": "false", "lang":
"en-US", "decimals": "4", "ancestors": { "span": "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
"ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true } }, "R54": { "role":
"http://www.replimune.com/role/StockbasedcompensationStockoptionactivityDetails", "longName": "9954498 - Disclosure - Stock-based compensation - Stock option activity
(Details)", "shortName": "Stock-based compensation - Stock option activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat":
"Details", "order": "54", "firstAnchor": { "contextRef": "c-4", "name": "us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals":
"INF", "ancestors": { "span": "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" },
"reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-1", "name": "us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals":
"INF", "ancestors": { "span": "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" },
"reportCount": 1, "baseRef": "repl-20240630.htm", "unique": true } }, "R55": { "role":
"http://www.replimune.com/role/StockbasedcompensationSummaryofRSUActivityDetails", "longName": "9954499 - Disclosure - Stock-based compensation - Summary of RSU
Activity (Details)", "shortName": "Stock-based compensation - Summary of RSU Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details",
"menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-3", "name": "us-
gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals":
"5", "ancestors": { "span": "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-156",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil":
"false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "td", "tr", "table", "div", "us-
gaap:ScheduleOfShareBasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef":
"repl-20240630.htm", "unique": true } }, "R56": { "role": "http://www.replimune.com/role/NetlosspershareComputationofNetLossperShareDetails", "longName": "9954500 -
Disclosure - Net loss per share - Computation of Net Loss per Share (Details)", "shortName": "Net loss per share - Computation of Net Loss per Share (Details)", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "us-
gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table", "div",
"body", "html" }, "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "uniqueAnchor": null }, "R57": { "role":
"http://www.replimune.com/role/NetlosspershareNarrativeDetails", "longName": "9954501 - Disclosure - Net loss per share - Narrative (Details)", "shortName": "Net loss per
share - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-
159", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF",
"ancestors": { "span": "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "uniqueAnchor": null }, "R58": { "role":
"http://www.replimune.com/role/NetlosspershareComputationofdilutednetlosspershareattributabletocommonstockholdersDetails", "longName": "9954502 - Disclosure - Net
loss per share - Computation of diluted net loss per share attributable to common stockholders (Details)", "shortName": "Net loss per share - Computation of diluted net loss
per share attributable to common stockholders (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58",
"firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false",
"lang": "en-US", "decimals": "0", "ancestors": { "span": "td", "tr", "table", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "repl-
20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-
gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": {
"span": "td", "tr", "table", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true } }, "R59":
{ "role": "http://www.replimune.com/role/SignificantagreementsDetails", "longName": "9954503 - Disclosure - Significant agreements (Details)", "shortName": "Significant
agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-166",
"name": "repl:NumberOfPatients", "unitRef": "patient", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "ix:continuation", "body", "html" },
"reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-166", "name": "repl:NumberOfPatients", "unitRef":
"patient", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "repl-
20240630.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.replimune.com/role/CollaborationandotherarrangementsDetails", "longName": "9954504 -
Disclosure - Collaboration and other arrangements (Details)", "shortName": "Collaboration and other arrangements (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-167", "name": "repl:CollaborativeArrangementTerminationPeriod", "unitRef":
null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "repl-20240630.htm",
"first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-167", "name": "repl:CollaborativeArrangementTerminationPeriod", "unitRef": null, "xsiNil": "false", "lang":
"en-US", "decimals": null, "ancestors": { "span": "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true } },
"R61": { "role": "http://www.replimune.com/role/CommitmentsandcontingenciesComponentsofleaseexpenseDetails", "longName": "9954505 - Disclosure - Commitments and
contingencies - Components of lease expense (Details)", "shortName": "Commitments and contingencies - Components of lease expense (Details)", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-1", "name": "us-
gaap:FinanceLeaseRightOfUseAssetAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table", "div", "us-
gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "uniqueAnchor": null }, "R62": { "role":
"http://www.replimune.com/role/CommitmentsandcontingenciesIncomeStatementInformationDetails", "longName": "9954506 - Disclosure - Commitments and contingencies -
Income Statement Information (Details)", "shortName": "Commitments and contingencies - Income Statement Information (Details)", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-1", "name": "us-
gaap:FinanceLeaseRightOfUseAssetAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table", "div", "us-
gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-126",
"name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table",
"div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "repl-20240630.htm", "unique": true } }, "R63": { "role":
"http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails", "longName": "9954507 - Disclosure - Commitments and contingencies -
Balance sheet disclosures (Details)", "shortName": "Commitments and contingencies - Balance sheet disclosures (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-3", "name": "us-
gaap:LesseesOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr",
"table", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "c-3", "name": "us-gaap:LesseesOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3",
"ancestors": { "span": "td", "tr", "table", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "repl-20240630.htm", "first": true, "unique":
true } }, "R64": { "role": "http://www.replimune.com/role/CommitmentsandcontingenciesOtherinformationDetails", "longName": "9954508 - Disclosure - Commitments and
contingencies - Other information (Details)", "shortName": "Commitments and contingencies - Other information (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details
```

```

"Accrued-Employee-Benefits-Current", "documentation": "Carrying value as of the balance sheet date of obligations, including pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "auth_ref": "r46"}, {"us_gaap_AccruedLiabilitiesAndOtherLiabilities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "calculation": {"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {"parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0}, {"http://www.replimune.com/role/AccruedexpensesandothercurrentliabilitiesDetails": {"parentTag": null, "weight": null, "order": null, "root": true}}, "presentation": {"http://www.replimune.com/role/AccruedexpensesandothercurrentliabilitiesDetails": {"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {"lang": {"en-us": {"role": {"terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Total accrued expenses and other current liabilities", "label": "Accrued Liabilities and Other Liabilities", "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."}}}, "auth_ref": {"us_gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "lang": {"en-us": {"role": {"label": "Accrued Liabilities and Other Liabilities [Abstract]"}}, "auth_ref": {"us_gaap_AccruedProfessionalFeesCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": {"http://www.replimune.com/role/AccruedexpensesandothercurrentliabilitiesDetails": {"parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 2.0}, "presentation": {"http://www.replimune.com/role/AccruedexpensesandothercurrentliabilitiesDetails": {"lang": {"en-us": {"role": {"terseLabel": "Accrued research and development costs", "label": "Accrued Research and Development Costs", "documentation": "The amount relating to accrued research and development costs."}}}, "auth_ref": {"us_gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": {"http://www.replimune.com/role/PropertyplantandequipmentnetDetails": {"parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0}, "presentation": {"http://www.replimune.com/role/PropertyplantandequipmentnetDetails": {"lang": {"en-us": {"role": {"negatedLabel": "Less: Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."}}}, "auth_ref": {"us_gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": {"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {"parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0}, "presentation": {"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {"lang": {"en-us": {"role": {"terseLabel": "Accumulated other comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."}}}, "auth_ref": {"r14", "r15", "r61", "r130", "r533", "r555", "r556"}, "us_gaap_AccumulatedOtherComprehensiveIncomeMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": {"http://www.replimune.com/role/CONSOLIDATEDSTATEMENTSOFSOCKHOLDERSEQUITY": {"lang": {"en-us": {"role": {"terseLabel": "Accumulated other comprehensive loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."}}}, "auth_ref": {"r1", "r8", "r15", "r396", "r399", "r458", "r551", "r552", "r835", "r836", "r837", "r844", "r845", "r846", "r847"}, {"repl_AccumulatedPaymentInKindInterest": {"xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "AccumulatedPaymentInKindInterest", "crdr": "credit", "calculation": {"http://www.replimune.com/role/DebtScheduleofDebtDetails": {"parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 4.0}, "presentation": {"http://www.replimune.com/role/DebtScheduleofDebtDetails": {"lang": {"en-us": {"role": {"terseLabel": "Accumulated end of term fee", "label": "Accumulated Payment In Kind Interest", "documentation": "Accumulated Payment In Kind Interest"}}, "auth_ref": {"ecd_Additional402vDisclosureTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]"}}, "auth_ref": {"r771}}, "us_gaap_AdditionalPaidInCapital": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": {"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {"parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0}, "presentation": {"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {"lang": {"en-us": {"role": {"terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."}}}, "auth_ref": {"r56", "r712", "r972"}, "us_gaap_AdditionalPaidInCapitalMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": {"http://www.replimune.com/role/CONSOLIDATEDSTATEMENTSOFSOCKHOLDERSEQUITY": {"lang": {"en-us": {"role": {"terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."}}}, "auth_ref": {"r566", "r844", "r845", "r846", "r847", "r916", "r973"}, {"ecd_AdjToCompAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount"}}, "auth_ref": {"r784"}, {"ecd_AdjToCompAxis": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Adjustment to Compensation", "label": "Adjustment to Compensation [Axis]"}}, "auth_ref": {"r784"}, {"ecd_AdjToNonPeoNeoCompFnTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"}}, "auth_ref": {"r784"}, {"ecd_AdjToPeoCompFnTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Adjustment to PEO Compensation, Footnote", "label": "Adjustment to PEO Compensation, Footnote [Text Block]"}}, "auth_ref": {"r784"}, "us_gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": {"http://www.replimune.com/role/CONSOLIDATEDSTATEMENTSOFSOCKHOLDERSEQUITY": {"lang": {"en-us": {"role": {"terseLabel": "Stock-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."}}}, "auth_ref": {"r37", "r38", "r327"}, "us_gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": {"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {"lang": {"en-us": {"role": {"terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"}}, "auth_ref": {"ecd_AggtChngPnsnValInSummryCompstnTblForApblYrMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForApblYrMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"}}, "auth_ref": {"r817}}, {"ecd_AggtErrCompAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": {"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount"}}, "auth_ref": {"r743", "r753", "r763", "r795"}, {"ecd_AggtErrCompNotYetDeterminedTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"}}, "auth_ref": {"r746", "r756", "r766", "r798"}, {"ecd_AggtPnsnAdjSvcCstMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjSvcCstMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]"}}, "auth_ref": {"r818"}, {"ecd_AllAdjToCompMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]"}}, "auth_ref": {"r784"}, {"ecd_AllExecutiveCategoriesMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]"}}, "auth_ref": {"r791"}, {"ecd_AllIndividualsMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": {"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "All Individuals", "label": "All Individuals [Member]"}}, "auth_ref": {"r747", "r757", "r767", "r
```

"Diluted net loss per share attributable to common stockholders", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"; "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [] "http://www.replimune.com/role/NetlosspershareComputationofdilutednetlosspershareattributabletocommonstockholdersDetails", "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r24"] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.replimune.com/role/CollaborationandotherarrangementsDetails", "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r387"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r90", "r100", "r125", "r155", "r189", "r193", "r196", "r197", "r231", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r389", "r393", "r426", "r530", "r603", "r679", "r680", "r712", "r734", "r881", "r882", "r931"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "repl_AssetsAndLiabilitiesLesseeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "presentation": ["http://www.replimune.com/role/CommitmentsandcontingenciesTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of additional information related to leases", "label": "Assets And Liabilities, Lessee [Table Text Block]", "documentation": "Tabular disclosure of additional information related to leases." } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r120", "r131", "r155", "r231", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r389", "r393", "r426", "r712", "r881", "r882", "r931"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "repl_AtMarketOfferingProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "AtMarketOfferingProgramMember", "presentation": ["http://www.replimune.com/role/StockholdersequityATMProgramDetails", "lang": { "en-us": { "role": { "terseLabel": "ATM Program", "label": "At Market Offering Program [Member]", "documentation": "Represents information pertaining to at the market offering program." } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain", "crdr": "credit", "presentation": ["http://www.replimune.com/role/ShortterminvestmentsDetails", "lang": { "en-us": { "role": { "terseLabel": "Gross unrealized gains", "label": "Debt Securities, Available-for-Sale, Unrealized Gain", "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r859"] }, "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss", "crdr": "debit", "presentation": ["http://www.replimune.com/role/ShortterminvestmentsDetails", "lang": { "en-us": { "role": { "negatedLabel": "Gross unrealized losses", "label": "Debt Securities, Available-for-Sale, Unrealized Loss", "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r860"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": ["r806"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": ["r807"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": ["r802"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": ["r802"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": ["r802"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": ["r802"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": ["r802"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": ["r802"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails", "http://www.replimune.com/role/StockbasedcompensationAssumptionstodeterminegrantdatefairvalueofstockoptionsDetails", "http://www.replimune.com/role/StockbasedcompensationClassificationofexpenseDetails", "http://www.replimune.com/role/StockbasedcompensationSummaryofRSUActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": ["r805"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": ["r804"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": ["r803"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": ["r803"] }, "repl_BristolMyersSquibbCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "BristolMyersSquibbCompanyMember", "presentation": ["http://www.replimune.com/role/SignificantagreementsDetails", "lang": { "en-us": { "role": { "terseLabel": "Bristol-Myers Squibb Company", "label": "Bristol-Myers Squibb Company [Member]", "documentation": "It represents agreement with Bristol-Myers Squibb Company" } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": ["http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS", "lang": { "en-us": { "role": { "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": ["r21", "r22", "r23"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, At Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r20", "r122", "r670"] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.replimune.com/role/FairvalueoffinancialassetsandliabilitiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r918", "r919"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS", "lang": { "en-us": { "role": { "periodStarLabel": "Cash, cash equivalents and restricted cash at beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r72"] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": ["http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS", "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of non-cash investing and financing activities", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] },

"repl_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract", "presentation": { "http://www.replimune.com/role/CommitmentsandContingenciesOtherInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities.", "label": "Cash Paid For Amounts Included in Measurement of Lease Liabilities [Abstract]", "documentation": "Cash paid for amounts included in measurement of lease liabilities." } } }, "auth_ref": { } }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]", "documentation": "Changed Peer Group, Footnote", "auth_ref": { "r782" } } } }, "ecd_ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdVsDtdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdVsDtdInCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "documentation": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "auth_ref": { "r779" } } }, "ecd_ChngInFrValOfOutstgAndUnvstdEqtyAwrdGrntdInPrYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutstgAndUnvstdEqtyAwrdGrntdInPrYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "documentation": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "auth_ref": { "r777" } } }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": { "http://www.replimune.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city." } } }, "auth_ref": { } }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": { "http://www.replimune.com/role/PrefundedWarrantsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": { "r117", "r127", "r128", "r129", "r155", "r178", "r179", "r182", "r184", "r191", "r192", "r231", "r260", "r262", "r263", "r264", "r267", "r268", "r300", "r301", "r304", "r307", "r314", "r426", "r559", "r560", "r561", "r562", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r591", "r612", "r631", "r640", "r649", "r650", "r651", "r652", "r821", "r840", "r848" } } }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": { "http://www.replimune.com/role/PrefundedWarrantsNarrativeDetails": { "http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Axis]", "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": { "r34" } }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": { "http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Domain]", "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": { } }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": { "http://www.replimune.com/role/PrefundedWarrantsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Exercise price (in dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": { "r315" } }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": { "http://www.replimune.com/role/PrefundedWarrantsNarrativeDetails": { "http://www.replimune.com/role/StockholdersequityATMProgramDetails": { "http://www.replimune.com/role/StockholdersequityOfferingsDetails": { "http://www.replimune.com/role/StockholdersequityScheduleofPrefundedWarrantsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Line Items]", "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { } }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": { "http://www.replimune.com/role/NetlosspershareNarrativeDetails": { "http://www.replimune.com/role/PrefundedWarrantsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Number of stock warrants issued (in shares)", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": { "r315" } }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": { "http://www.replimune.com/role/PrefundedWarrantsNarrativeDetails": { "http://www.replimune.com/role/StockholdersequityATMProgramDetails": { "http://www.replimune.com/role/StockholdersequityOfferingsDetails": { "http://www.replimune.com/role/StockholdersequityScheduleofPrefundedWarrantsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Table]", "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": { "r34" } }, "repl_ClinicalTrialCollaborationAndSupplyAgreementIncyteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "ClinicalTrialCollaborationAndSupplyAgreementIncyteMember", "presentation": { "http://www.replimune.com/role/CollaborationandotherarrangementsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Clinical Trial Collaboration and Supply Agreement - Incyte", "label": "Clinical Trial Collaboration and Supply Agreement - Incyte [Member]", "documentation": "Clinical Trial Collaboration and Supply Agreement - Incyte" } } }, "auth_ref": { } }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount", "documentation": "Company Selected Measure Amount", "auth_ref": { "r783" } } }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name", "documentation": "Company Selected Measure Name", "auth_ref": { "r783" } } }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": { "http://www.replimune.com/role/Collaborationandotherarrangements": { "http://www.replimune.com/role/Significantagreements": { "lang": { "en-us": { "role": { "terseLabel": "Significant agreements", "verboseLabel": "Collaboration and other arrangements", "label": "Collaborative Arrangement Disclosure [Text Block]", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": { "r105", "r107", "r116" } }, "repl_CollaborativeArrangementOffsetToResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "CollaborativeArrangementOffsetToResearchAndDevelopmentExpense", "presentation": { "http://www.replimune.com/role/CollaborationandotherarrangementsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Offset to research and development expense", "label": "Collaborative Arrangement, Offset to Research and Development Expense", "documentation": "Collaborative Arrangement, Offset to Research and Development Expense", "auth_ref": { } }, "repl_CollaborativeArrangementReceivableFromOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "CollaborativeArrangementReceivableFromOtherParty", "presentation": { "http://www.replimune.com/role/CollaborationandotherarrangementsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Receivables", "label": "Collaborative Arrangement, Receivable from Other Party", "documentation": "Collaborative Arrangement, Receivable from Other Party", "auth_ref": { } }, "repl_CollaborativeArrangementTerminationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "CollaborativeArrangementTerminationPeriod", "presentation": { "http://www.replimune.com/role/CollaborationandotherarrangementsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Termination period", "label": "Collaborative Arrangement, Termination Period", "documentation": "Collaborative Arrangement, Termination Period", "auth_ref": { } }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": { "http://www.replimune.com/role/CollaborationandotherarrangementsDetails": { "http://www.replimune.com/role/SignificantagreementsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Significant agreements", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r387" } }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Commitments and Contingencies", "auth_ref": { "r80", "r252", "r253", "r655", "r873", "r878" } } }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": { "http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Common stock reserved for issuance (in shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": { "r55" } }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": { "http://www.replimune.com/role/CONSOLIDATEDSTATEMENTSOFTOCKHOLDERSEQUITY": { "http://www.replimune.com/role/PrefundedWarrantsNarrativeDetails": { "http://www.replimune.com/role/StockholdersequityATMProgramDetails": { "lang": { "en-us": { "role": { "terseLabel": "Common stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": { "r724", "r725", "r726", "r728", "r729", "r730", "r731", "r844", "r845", "r847", "r916", "r971", "r973" } } }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParentetical": { "http://www.replimune.com/role/StockholdersequityATMProgramDetails": { "http://www.replimune.com/role/StockholdersequityCommonStockandUndesignatedPreferredStockDetails": { "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": { "r55" } }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParentetical": { "http://www.replimune.com/role/StockholdersequityCommonStockandUndesignatedPreferredStockDetails": { "lang": { "en-us": { "role": { "terseLabel": "Common stock, authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": { "r55", "r591" } }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParentetical": { "lang": { "en-

us": { "role": { "terseLabel": "Common stock, issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } }, "auth_ref": { "r55" } }, "us-gaap-CommonStockSharesOutstanding": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "lang": { "en-us": { "role": { "terseLabel": "Common stock, outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } }, "auth_ref": { "r9", "r55", "r591", "r609", "r973", "r974" } }, "us-gaap-CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "lang": { "en-us": { "role": { "verboseLabel": "Common stock, \$0.001 par value; 150,000,000 shares authorized as of June 30, 2024 and March 31, 2024; 68,309,968 and 61,415,105 shares issued and outstanding as of June 30, 2024 and March 31, 2024, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } }, "auth_ref": { "r55", "r532", "r712" } }, "ecd-CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } }, "auth_ref": { "r788" } }, "ecd-CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } }, "auth_ref": { "r787" } }, "ecd-CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } }, "auth_ref": { "r789" } }, "ecd-CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } }, "auth_ref": { "r786" } }, "us-gaap-ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "presentation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } }, "auth_ref": { "r16", "r137", "r139", "r143", "r525", "r543", "r544" } }, "us-gaap-ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": { "http://www.replimune.com/role/PropertyplantandequipmentnetDetails": { "parentTag": "us-gaap_ComputerEquipmentMember", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.replimune.com/role/PropertyplantandequipmentnetDetails", "lang": { "en-us": { "role": { "terseLabel": "Computer equipment", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } }, "auth_ref": { "r39", "r674" } }, "us-gaap-ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": { "http://www.replimune.com/role/SummaryofsignificantaccountingpoliciesPolicies": { "parentTag": "us-gaap_ConsolidationPolicyTextBlock", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.replimune.com/role/SummaryofsignificantaccountingpoliciesPolicies", "lang": { "en-us": { "role": { "terseLabel": "Principles of consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } }, "auth_ref": { "r39", "r674" } }, "us-gaap-ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": { "http://www.replimune.com/role/PropertyplantandequipmentnetDetails": { "parentTag": "us-gaap_ConstructionInProgressMember", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.replimune.com/role/PropertyplantandequipmentnetDetails", "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } }, "auth_ref": { "r39", "r674" } }, "us-gaap-ConversionOfStockRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "ConversionOfStockRatio", "presentation": { "http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails": { "parentTag": "us-gaap_ConversionOfStockRatio", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Conversion ratio", "label": "Conversion Of Stock, Ratio", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period." } }, "auth_ref": { "r21", "r22", "r23" } }, "us-gaap-CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/rst/2024", "localname": "CounterpartyNameAxis", "presentation": { "http://www.replimune.com/role/SignificantagreementsDetails": { "parentTag": "us-gaap_CounterpartyNameAxis", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.replimune.com/role/SignificantagreementsDetails", "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period." } }, "auth_ref": { "r21", "r22", "r23" } }, "us-gaap-CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": { "http://www.replimune.com/role/DebtNarrativeDetails": { "parentTag": "us-gaap_CreditFacilityAxis", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.replimune.com/role/DebtNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period." } }, "auth_ref": { "r21", "r22", "r23" } }, "us-gaap-CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": { "http://www.replimune.com/role/DebtNarrativeDetails": { "parentTag": "us-gaap_CreditFacilityDomain", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.replimune.com/role/DebtNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period." } }, "auth_ref": { "r21", "r22", "r23" } }, "us-gaap-DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "presentation": { "http://www.replimune.com/role/DebtDisclosureAbstract": { "parentTag": "us-gaap_DebtDisclosureAbstract", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.replimune.com/role/DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period." } }, "auth_ref": { "r21", "r22", "r23" } }, "us-gaap-DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": { "http://www.replimune.com/role/Debt": { "parentTag": "us-gaap_DebtDisclosureTextBlock", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.replimune.com/role/Debt", "lang": { "en-us": { "role": { "terseLabel": "Debt", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } }, "auth_ref": { "r81", "r153", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000" } }, "us-gaap-DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": { "http://www.replimune.com/role/DebtNarrativeDetails": { "parentTag": "us-gaap_DebtInstrumentAxis", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.replimune.com/role/DebtNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument", "label": "Debt Instrument", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period." } }, "auth_ref": { "r21", "r22", "r23" } }, "us-gaap-DebtInstrumentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTextBlock", "presentation": { "http://www.replimune.com/role/Debt": { "parentTag": "us-gaap_DebtInstrumentTextBlock", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.replimune.com/role/Debt", "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument", "label": "Debt Instrument", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period." } }, "auth_ref": { "r21", "r22", "r23" } }, "us-gaap-DebtInstrumentRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRateAxis", "presentation": { "http://www.replimune.com/role/DebtNarrativeDetails": { "parentTag": "us-gaap_DebtInstrumentRateAxis", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.replimune.com/role/DebtNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Rate", "label": "Debt Instrument Rate", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period." } }, "auth_ref": { "r21", "r22", "r23" } }, "us-gaap-DebtInstrumentRateTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRateTextBlock", "presentation": { "http://www.replimune.com/role/Debt": { "parentTag": "us-gaap_DebtInstrumentRateTextBlock", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.replimune.com/role/Debt", "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Rate", "label": "Debt Instrument Rate", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period." } }, "auth_ref": { "r21", "r22", "r23" } }, "us-gaap-DebtInstrumentRateTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRateTextBlock", "presentation": { "http://www.replimune.com/role/Debt": { "parentTag": "us-gaap_DebtInstrumentRateTextBlock", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.replimune.com/role/Debt", "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Rate", "label": "Debt Instrument Rate", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period." } }, "auth_ref": { "r21", "r22", "r23" } }, "us-gaap-DebtInstrumentRateTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRateTextBlock", "presentation": { "http://www.replimune.com/role/Debt": { "parentTag": "us-gaap_DebtInstrumentRateTextBlock", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.replimune.com/role/Debt", "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Rate", "label": "Debt Instrument Rate", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period." } }, "auth_ref": { "r21", "r22", "r23" } }, "us-gaap-DebtInstrumentRateTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRateTextBlock", "presentation": { "http://www.replimune.com/role/Debt": { "parentTag": "us-gaap_DebtInstrumentRateTextBlock", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.replimune.com/role/Debt", "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Rate", "label": "Debt Instrument Rate", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period." } }, "auth_ref": { "r21", "r22", "r23" } }, "us-gaap-DebtInstrumentRateTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRateTextBlock", "presentation": { "http://www.replimune.com/role/Debt": { "parentTag": "us-gaap_DebtInstrumentRateTextBlock", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.replimune.com/role/Debt", "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Rate", "label": "Debt Instrument Rate", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period." } }, "auth_ref": { "r21", "r22", "r23" } }, "us-gaap-DebtInstrumentRateTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRateTextBlock", "presentation": { "http://www.replimune.com/role/Debt": { "parentTag": "us-gaap_DebtInstrumentRateTextBlock", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.replimune.com/role/Debt", "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Rate", "label": "Debt Instrument Rate", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period." } }, "auth_ref": { "r21", "r22", "r23" } }, "us-gaap-DebtInstrumentRateTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRateTextBlock", "presentation": { "http://www.replimune.com/role/Debt": { "parentTag": "us-gaap_DebtInstrumentRateTextBlock", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.replimune.com/role/Debt", "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Rate", "label": "Debt Instrument Rate", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period." } }, "auth_ref": { "r21", "r22", "r23" } }, "us-gaap-DebtInstrumentRateTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRateTextBlock", "presentation": { "http://www.replimune.com/role/Debt": { "parentTag": "us-gaap_DebtInstrumentRateTextBlock", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.replimune.com/role/Debt", "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Rate", "label": "Debt Instrument Rate", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period." } }, "auth_ref": { "r21", "r22", "r23" } }, "us-gaap-DebtInstrumentRateTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRateTextBlock", "presentation": { "http://www.replimune.com/role/Debt": { "parentTag": "us-gaap_DebtInstrumentRateTextBlock", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.replimune.com/role/Debt", "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Rate", "label": "Debt Instrument Rate", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period." } }, "auth_ref": { "r21", "r22", "r23" } }, "us-gaap-DebtInstrumentRateTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRateTextBlock", "presentation": { "http://www.replimune.com/role/Debt": { "parentTag": "us-gaap_DebtInstrumentRateTextBlock", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.replimune.com/role/Debt", "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Rate", "label": "Debt Instrument Rate", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period." } }, "auth_ref": { "r21", "r22", "r23" } }, "us-gaap-DebtInstrumentRateTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRateTextBlock", "presentation": { "http://www.replimune.com/role/Debt": { "parentTag": "us-gaap_DebtInstrumentRateTextBlock", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.replimune.com/role/Debt", "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Rate", "label": "Debt Instrument Rate", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period." } }, "auth_ref": { "r21", "r22", "r23" } }, "us-gaap-DebtInstrumentRateTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRateTextBlock", "presentation": { "http://www.replimune.com/role/Debt": { "parentTag": "us-gaap_DebtInstrumentRateTextBlock", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.replimune.com/role/Debt", "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Rate", "label": "Debt Instrument Rate", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period." } }, "auth_ref": { "r21", "r22", "r23" } }, "us-gaap-DebtInstrumentRateTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRateTextBlock", "presentation": { "http://www.replimune.com/role/Debt": { "parentTag": "us-gaap_DebtInstrumentRateTextBlock", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.replimune.com/role/Debt", "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Rate", "label": "Debt Instrument Rate", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period." } }, "auth_ref": { "r21", "r2

domain members defined in one or many axes to the table." } } }, "auth_ref": { "r159", "r270", "r271", "r272", "r273", "r274", "r276", "r281", "r282", "r283", "r284", "r286", "r287", "r288", "r289", "r290", "r291", "r294", "r683", "r684", "r685", "r686", "r687", "r710", "r841", "r874", "r875", "r876", "r927", "r928" } }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": { "http://www.replimune.com/role/DebtNarrativeDetails", "http://www.replimune.com/role/DebtScheduleofDebtDetails", "http://www.replimune.com/role/DebtScheduleofMaturityofDebtDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name {Domain}", "label": "Debt Instrument, Name {Domain}", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": { "r13", "r159", "r270", "r271", "r272", "r273", "r274", "r276", "r281", "r282", "r283", "r284", "r286", "r287", "r288", "r289", "r290", "r291", "r683", "r684", "r685", "r686", "r687", "r710", "r841", "r874", "r875", "r876", "r927", "r928" } }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": { "http://www.replimune.com/role/DebtNarrativeDetails", "http://www.replimune.com/role/DebtScheduleofDebtDetails", "http://www.replimune.com/role/DebtScheduleofMaturityofDebtDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": { "r13", "r32", "r33", "r42", "r83", "r84", "r159", "r270", "r271", "r272", "r273", "r274", "r276", "r281", "r282", "r283", "r284", "r286", "r287", "r288", "r289", "r290", "r291", "r294", "r683", "r684", "r685", "r686", "r687", "r710", "r841", "r927", "r928" } }, "repl_DebtInstrumentsNumberOfAdvances": { "xbrltype": "integerItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "DebtInstrumentsNumberOfAdvances", "presentation": { "http://www.replimune.com/role/DebtNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Number of term loan advances", "label": "Debt Instruments, Number Of Advances", "documentation": "Debt Instruments, Number Of Advances" } } }, "auth_ref": { "r239" } }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest", "crdr": "credit", "presentation": { "http://www.replimune.com/role/ShortterminvestmentsDetails" }, "lang": { "en-us": { "role": { "negatedLabel": "Credit Losses", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest", "documentation": "Amount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r239" } }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss", "crdr": "debit", "presentation": { "http://www.replimune.com/role/ShortterminvestmentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Amortized cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss", "documentation": "Amortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r239" } }, "DebtSecuritiesAvailableForSaleExcludingAccruedInterest": { "crdr": "debit", "presentation": { "http://www.replimune.com/role/ShortterminvestmentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Fair value", "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest", "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r872" } }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": { "http://www.replimune.com/role/ShortterminvestmentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Investment Holdings [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212" } }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": { "http://www.replimune.com/role/ShortterminvestmentsTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of short-term investments", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867" } }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "http://www.replimune.com/role/DebtScheduleofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.replimune.com/role/DebtScheduleofDebtDetails" }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Unamortized issuance costs", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": { "r884", "r926", "r927", "r928" } }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": { "http://www.replimune.com/role/PropertyplantandequipmentnetDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": { "r5", "r29" } }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" }, "lang": { "en-us": { "role": { "verboseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": { "r5", "r189", "r194", "r197", "r679", "r680" } }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": { "http://www.replimune.com/role/Stockbasedcompensation" }, "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": { "r325", "r329", "r357", "r358", "r360", "r694" } }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": { "r1" } }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": { "http://www.replimune.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": { "r1" } }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": { "http://www.replimune.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": { "r1" } }, "dei_DocumentPeriodEndDate": { "http://www.replimune.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": { "r1" } }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": { "http://www.replimune.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": { "r738" } }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": { "http://www.replimune.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": { "r770" } }, "dei_DocumentType": { "xbrltype": "submissionItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": { "http://www.replimune.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": { "r1" } }, "ecd_DvdsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRfctdInTtCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvdsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRfctdInTtCompForCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": { "r781" } }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": { "r1" } }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.replimune.com/role/NetlosspershareComputationofNetLossperShareDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Net loss per share attributable to common stockholders, basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": { "r144", "r165", "r166", "r167", "r168", "r169", "r170", "r175", "r178", "r182", "r183", "r184", "r188", "r383", "r386", "r404", "r405", "r526", "r545", "r676" } }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.replimune.com/role/NetlosspershareComputationofNetLossperShareDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Net loss per share attributable to common stockholders, diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": { "r144", "r165", "r166", "r167", "r168", "r169", "r170", "r178", "r182", "r183", "r184", "r188", "r383", "r386", "r404", "r405", "r526", "r545", "r676" } }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": { "http://www.replimune.com/role/Netlosspershare", "lang": { "en-us": { "role": { "terseLabel": "Net loss per share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": { "r174", "r185", "r186", "r187" } }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": -1.0, "order": 4.0 } }, "presentation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" }, "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r431" } }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": { "http://www.replimune.com/role/StockbasedcompensationClassificationofExpenseDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r1" } }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crd": "debit", "presentation": {
"http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails",
"http://www.replimune.com/role/StockbasedcompensationSummaryofRSUActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Total unrecognized compensation cost",
"label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award
under share-based payment arrangement." } } }, "auth_ref": { "r359" } }, "us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": {
"http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Expenses expected to be recognized over
a weighted average remaining period", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation":
"Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDnInHnMnS' format,
for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r359" } }, "repl_EmployeeSharePurchasePlanMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "EmployeeSharePurchasePlanMember", "presentation": {
"http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "ESPP", "label": "Employee Share
Purchase Plan [Member]", "documentation": "Represents information pertaining to employee share purchase plan." } } }, "auth_ref": { } }, "us-
gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": {
"http://www.replimune.com/role/NetlosspershareComputationofDilutedNetlosspershareattributabletoCommonstockholdersDetails",
"http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails",
"http://www.replimune.com/role/StockbasedcompensationAssumptionstodeterminegrantdatefairvalueofstockoptionsDetails",
"http://www.replimune.com/role/StockbasedcompensationClassificationofexpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": {
"terseLabel": "Stock options", "verboselabel": "Options to purchase common stock", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation":
"Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified
period of time." } } }, "auth_ref": { } }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityAddressAddressLine1", "presentation": { "http://www.replimune.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label":
"Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": { } }, "dei_EntityAddressAddressLine2": {
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": {
"http://www.replimune.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two",
"documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": { } }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": { "http://www.replimune.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel":
"Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": { } }, "dei_EntityAddressPostalZipCode":
{ "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": {
"http://www.replimune.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code",
"documentation": "Code for the postal or zip code" } } }, "auth_ref": { } }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": { "http://www.replimune.com/role/Cover", "lang": { "en-us": { "role": {
"terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": { } },
"dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": {
"http://www.replimune.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique
10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": { "r736" } },
"dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding",
"presentation": { "http://www.replimune.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common
Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other
ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as
Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref":
{ } }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": {
"http://www.replimune.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status",
"documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90
days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { } },
"dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": {
"http://www.replimune.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company",
"documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": { "r736" } }, "dei_EntityFileNumber": { "xbrltype":
"fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": { "http://www.replimune.com/role/Cover", "lang": { "en-us": {
"role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may
contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref":
{ } }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": {
"http://www.replimune.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate
whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the
Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { "r736" } },
"dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode",
"presentation": { "http://www.replimune.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or
Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } },
"auth_ref": { } }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent",
"presentation": { "http://www.replimune.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data
Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": { "r820" } },
"dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": {
"http://www.replimune.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact
name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": { "r736" } }, "dei_EntityShellCompany": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": { "http://www.replimune.com/role/Cover", "lang": {
"en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as
defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": { "r736" } }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntitySmallBusiness", "presentation": { "http://www.replimune.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label":
"Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": { "r736" } },
"dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber",
"presentation": { "http://www.replimune.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification
Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } },
"auth_ref": { "r736" } }, "ecd_EqtyAwrdsAdjFnTxnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EqtyAwrdsAdjFnTxnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote",
"label": "Equity Awards Adjustments, Footnote [Text Block]", "auth_ref": { "r775" } }, "ecd_EqtyAwrdsAdjExclgValRprtDnSummryCompstnTblMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValRprtDnSummryCompstnTblMember", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
"label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "auth_ref": { "r816" } }, "ecd_EqtyAwrdsAdjSMember": {
"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjSMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
"lang": { "

"Facility Charge And Diligence Fee","documentation":"Facility Charge And Diligence Fee"} } },"auth_ref":[]},"us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems","presentation":{"http://www.replimune.com/role/FairValueoffinancialassetsandliabilitiesDetails"},"lang":{"en-us":{"role":{"terseLabel":"Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]","documentation":"Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}},"auth_ref":[]},"us-gaap_FairValueByBalanceSheetGroupingTable":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FairValueByBalanceSheetGroupingTable","presentation":{"http://www.replimune.com/role/FairValueoffinancialassetsandliabilitiesDetails"},"lang":{"en-us":{"role":{"terseLabel":"Fair Value, by Balance Sheet Grouping [Table]","label":"Fair Value, by Balance Sheet Grouping [Table]","documentation":"Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."}}},"auth_ref":["r40","r41"]},"us-gaap_FairValueByBalanceSheetGroupingTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FairValueByBalanceSheetGroupingTextBlock","presentation":{"http://www.replimune.com/role/FairValueoffinancialassetsandliabilitiesTables"},"lang":{"en-us":{"role":{"terseLabel":"Schedule of company's financial assets and liabilities measured at fair value on a recurring basis","label":"Fair Value, by Balance Sheet Grouping [Table Text Block]","documentation":"Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."}}},"auth_ref":["r40"]},"us-gaap_FairValueByFairValueHierarchyLevelAxis":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FairValueByFairValueHierarchyLevelAxis","presentation":{"http://www.replimune.com/role/FairValueoffinancialassetsandliabilitiesDetails"},"lang":{"en-us":{"role":{"terseLabel":"Fair Value Hierarchy and NAV [Axis]","label":"Fair Value Hierarchy and NAV [Axis]","documentation":"Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."}}},"auth_ref":["r283","r318","r319","r320","r321","r322","r323","r406","r408","r409","r410","r411","r417","r418","r420","r463","r464","r465","r684","r685","r690","r691","r692","r700","r703"]},"us-gaap_FairValueByMeasurementFrequencyAxis":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FairValueByMeasurementFrequencyAxis","presentation":{"http://www.replimune.com/role/FairValueoffinancialassetsandliabilitiesDetails"},"lang":{"en-us":{"role":{"terseLabel":"Measurement Frequency [Axis]","label":"Measurement Frequency [Axis]","documentation":"Information by measurement frequency."}}},"auth_ref":["r407","r408","r409","r411","r700","r921","r924"]},"us-gaap_FairValueDisclosuresAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FairValueDisclosuresAbstract","lang":{"en-us":{"role":{"terseLabel":"Fair Value Disclosures [Abstract]","label":"Fair Value Disclosures [Abstract]"} } },"auth_ref":[]},"us-gaap_FairValueDisclosuresTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FairValueDisclosuresTextBlock","presentation":{"http://www.replimune.com/role/FairValueoffinancialassetsandliabilities"},"lang":{"en-us":{"role":{"terseLabel":"Fair value of financial assets and liabilities","label":"Fair Value Disclosures [Text Block]","documentation":"The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."}}},"auth_ref":["r413","r415","r416","r417","r420","r421","r422","r423","r424","r524","r700","r704"]},"us-gaap_FairValueInputsLevel1Member":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FairValueInputsLevel1Member","presentation":{"http://www.replimune.com/role/FairValueoffinancialassetsandliabilitiesDetails"},"lang":{"en-us":{"role":{"terseLabel":"Level 1","label":"Fair Value, Inputs, Level 1 [Member]","documentation":"Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."}}},"auth_ref":["r283","r318","r323","r408","r418","r463","r690","r691","r692","r700"]},"us-gaap_FairValueInputsLevel2Member":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FairValueInputsLevel2Member","presentation":{"http://www.replimune.com/role/FairValueoffinancialassetsandliabilitiesDetails"},"lang":{"en-us":{"role":{"terseLabel":"Level 2","label":"Fair Value, Inputs, Level 2 [Member]","documentation":"Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."}}},"auth_ref":["r283","r318","r323","r408","r409","r418","r464","r684","r685","r690","r691","r692","r700"]},"us-gaap_FairValueInputsLevel3Member":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FairValueInputsLevel3Member","presentation":{"http://www.replimune.com/role/FairValueoffinancialassetsandliabilitiesDetails"},"lang":{"en-us":{"role":{"terseLabel":"Level 3","label":"Fair Value, Inputs, Level 3 [Member]","documentation":"Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."}}},"auth_ref":["r283","r318","r319","r320","r321","r322","r323","r408","r409","r410","r411","r418","r465","r684","r685","r690","r691","r692","r700","r703"]},"us-gaap_FairValueMeasurementFrequencyDomain":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FairValueMeasurementFrequencyDomain","presentation":{"http://www.replimune.com/role/FairValueoffinancialassetsandliabilitiesDetails"},"lang":{"en-us":{"role":{"terseLabel":"Fair Value, Measurement Frequency [Domain]","label":"Measurement Frequency [Domain]","documentation":"Measurement frequency."}}},"auth_ref":["r407","r408","r409","r411","r700","r921","r924"]},"us-gaap_FairValueMeasurementsFairValueHierarchyDomain":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FairValueMeasurementsFairValueHierarchyDomain","presentation":{"http://www.replimune.com/role/FairValueoffinancialassetsandliabilitiesDetails"},"lang":{"en-us":{"role":{"terseLabel":"Fair Value Hierarchy and NAV [Domain]","label":"Fair Value Hierarchy and NAV [Domain]","documentation":"Categories used to prioritize the inputs to valuation techniques to measure fair value."}}},"auth_ref":["r283","r318","r319","r320","r321","r322","r323","r406","r408","r409","r410","r411","r417","r418","r420","r463","r464","r465","r684","r685","r690","r691","r692","r700","r703"]},"us-gaap_FairValueMeasurementsRecurringMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FairValueMeasurementsRecurringMember","presentation":{"http://www.replimune.com/role/FairValueoffinancialassetsandliabilitiesDetails"},"lang":{"en-us":{"role":{"terseLabel":"Recurring","label":"Fair Value, Recurring [Member]","documentation":"Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."}}},"auth_ref":["r700","r918","r919","r920","r921","r922","r924"]},"repl_FinanceLeaseCostsAbstract":{"xbrltype":"stringItemType","nsuri":"http://www.replimune.com/20240630","localname":"FinanceLeaseCostsAbstract","presentation":{"http://www.replimune.com/role/CommitmentsandcontingenciesComponentsofleaseexpenseDetails"},"lang":{"en-us":{"role":{"verboseLabel":"Finance lease costs","label":"Finance Lease Costs [Abstract]","documentation":"No definition available."}}},"auth_ref":[]},"us-gaap_FinanceLeaseInterestExpense":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FinanceLeaseInterestExpense","crdr":"debit","calculation":{"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS":{"parentTag":"us-gaap_NonoperatingIncomeExpense","weight":1.0,"order":3.0},"http://www.replimune.com/role/CommitmentsandcontingenciesComponentsofleaseexpenseDetails":{"parentTag":"us-gaap_LeaseCost","weight":1.0,"order":3.0}}},"presentation":{"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"},"http://www.replimune.com/role/CommitmentsandcontingenciesComponentsofleaseexpenseDetails"},"http://www.replimune.com/role/CommitmentsandcontingenciesIncomeStatementInformationDetails"},"lang":{"en-us":{"role":{"negatedLabel":"Interest expense on finance lease liability","terseLabel":"Interest on lease liabilities","label":"Finance Lease, Interest Expense","documentation":"Amount of interest expense on finance lease liability."}}},"auth_ref":["r443","r449","r711"]},"us-gaap_FinanceLeaseInterestPaymentOnLiability":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FinanceLeaseInterestPaymentOnLiability","crdr":"credit","presentation":{"http://www.replimune.com/role/CommitmentsandcontingenciesOtherinformationDetails"},"lang":{"en-us":{"role":{"verboseLabel":"Operating cash flows from finance leases","label":"Finance Lease, Interest Payment on Liability","documentation":"Amount of interest paid on finance lease liability."}}},"auth_ref":["r445","r451"]},"us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FinanceLeaseLiabilitiesPaymentsDueAbstract","presentation":{"http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails"},"lang":{"en-us":{"role":{"terseLabel":"Financing lease","label":"Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"} } },"auth_ref":[]},"us-gaap_FinanceLeaseLiability":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FinanceLeaseLiability","crdr":"credit","calculation":{"http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails":{"parentTag":"repl_OperatingAndFinanceLeaseLiability","weight":1.0,"order":2.0},"http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails_1":{"parentTag":"us-gaap_FinanceLeaseLiabilityPaymentsDue","weight":1.0,"order":2.0}}},"presentation":{"http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails"},"lang":{"en-us":{"role":{"terseLabel":"Total lease liabilities","label":"Finance Lease, Liability","documentation":"Present value of lessee's discounted obligation for lease payments from finance lease."}}},"auth_ref":["r442","r455"]},"us-gaap_FinanceLeaseLiabilityCurrent":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FinanceLeaseLiabilityCurrent","crdr":"credit","calculation":{"http://www.replimune.com/role/CommitmentsandcontingenciesOtherinformationDetails":{"parentTag":"repl_LeaseLiability","weight":1.0,"order":3.0},"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS":{"parentTag":"us-gaap_LiabilitiesCurrent","weight":1.0,"order":4.0}}},"presentation":{"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"},"http://www.replimune.com/role/CommitmentsandcontingenciesOtherinformationDetails"},"lang":{"en-us":{"role":{"verboseLabel":"Financing lease liabilities, current","terseLabel":"Finance lease liabilities, current","label":"Finance Lease, Liability, Current","documentation":"Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."}}},"auth_ref":["r442"]},"us-gaap_FinanceLeaseLiabilityNoncurrent":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FinanceLeaseLiabilityNoncurrent","crdr":"credit","calculation":{"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS":{"parentTag":"us-gaap_Liabilities","weight":1.0,"order":1.0},"http://www.replimune.com/role/CommitmentsandcontingenciesOtherinformationDetails":{"parentTag":"repl_LeaseLiability","weight":1.0,"order":1.0}}},"presentation":{"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"},"http://www.replimune.com/role/CommitmentsandcontingenciesOtherinformationDetails"},"lang":{"en-us":{"role":{"verboseLabel":"Financing lease liabilities, non-current","label":"Finance Lease, Liability, Noncurrent","documentation":"Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."}}},"auth_ref":["r442"]},"us-gaap_FinanceLeaseLiabilityPaymentsDue":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FinanceLeaseLiabilityPaymentsDue","crdr":"credit","calculation":{"http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails":{"parentTag":"repl_OperatingAndFinanceLeaseLiabilityPaymentsDue","weight":1.0,"order":2.0},"http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails_1":{"parentTag":"null","weight":null,"order":null,"root":true}}},"presentation":{"http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails"},"lang":{"en-us":{"role":{"totalLabel":"Total lease payments","label":"Finance Lease, Liability, to be Paid","documentation":"Amount of lessee's undiscounted obligation for lease payments for finance lease."}}},"auth_ref":["r455"]},"us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FinanceLeaseLiabilityPaymentsDueNextTwelveMonths","crdr":"credit","calculation":{"http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails":{"parentTag":"repl_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths","weight":1.0,"order":2.0}}},"presentation":{"http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails"},"lang":{"en-us":{"role":{"terseLabel":"2026","label":"Finance Lease, Liability, to be Paid, Year One","documentation":"Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } },"auth_ref":["r455"]},"us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"FinanceLeaseLiabilityPaymentsDueYearFour","crdr":"credit","calculation":{"http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails":{"parentTag":"us-gaap_FinanceLeaseLiabilityPaymentsDue","weight":1.0;

[illegible]

"r63","r97","r99","r527","r538","r678","r679","r850","r851","r852","r853","r854"}}, {"us-gaap_IncomeStatementAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncomeStatementAbstract","lang":{"en-us":{"role":{"terseLabel":"Income Statement Abstract"},"label":"Income Statement Abstract"}}, {"auth_ref":{"us-gaap_IncomeStatementLocationAxis":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncomeStatementLocationAxis","presentation":{"http://www.replimune.com/role/CommitmentsandcontingenciesIncomeStatementInformationDetails"},"lang":{"en-us":{"role":{"terseLabel":"Income Statement Location {Axis}"},"label":"Statement of Income Location, Balance {Axis}"},"documentation":{"Information by location in statement of income where disaggregated amount has been reported."}}}}, {"auth_ref":{"r244","r250","r251","r412","r414","r419","r548","r550","r615","r667","r702","r943"}}, {"us-gaap_IncomeStatementLocationDomain":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncomeStatementLocationDomain","presentation":{"http://www.replimune.com/role/CommitmentsandcontingenciesIncomeStatementInformationDetails"},"lang":{"en-us":{"role":{"terseLabel":"Income Statement Location {Domain}"},"label":"Statement of Income Location, Balance {Domain}"},"documentation":{"Location in statement of income where disaggregated amount has been reported."}}}}, {"auth_ref":{"r250","r251","r412","r414","r419","r548","r550","r615","r667","r702","r943"}}, {"us-gaap_IncomeTaxDisclosureAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncomeTaxDisclosureAbstract","lang":{"en-us":{"role":{"label":"Income Tax Disclosure Abstract"}}, {"auth_ref":{"us-gaap_IncomeTaxDisclosureTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncomeTaxDisclosureTextBlock"},"presentation":{"http://www.replimune.com/role/Incometaxes"},"lang":{"en-us":{"role":{"terseLabel":"Income taxes"},"label":"Income Tax Disclosure {Text Block}"},"documentation":{"The entire disclosure for income tax."}}}}, {"auth_ref":{"r156","r365","r367","r368","r369","r370","r371","r372","r375","r377","r378","r379","r564","r697"}}, {"us-gaap_IncomeTaxExpenseBenefit":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncomeTaxExpenseBenefit","crdr":"debit","calculation":{"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS":{"parentTag":"us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic","weight":-1.0,"order":2.0},"presentation":{"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"},"lang":{"en-us":{"role":{"verboseLabel":"Income tax provision"},"label":"Income Tax Expense (Benefit)"},"documentation":{"Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."}}}}, {"auth_ref":{"r102","r114","r172","r173","r189","r195","r197","r366","r367","r376","r546","r697"}}, {"repl_IncreaseDecreaseFinanceLeaseRightOfUseAsset":{"xbrltype":"monetaryItemType","nsuri":"http://www.replimune.com/20240630","localname":"IncreaseDecreaseFinanceLeaseRightOfUseAsset","crdr":"credit","calculation":{"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS":{"parentTag":"us-gaap_NetCashProvidedByUsedInOperatingActivities","weight":-1.0,"order":1.0},"presentation":{"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"},"lang":{"en-us":{"role":{"negatedLabel":"Finance lease, right-of-use-asset"},"label":"Increase (Decrease) Finance Lease, Right Of Use Asset"},"documentation":{"Amount of increase (decrease) in finance lease right-of-use assets."}}}}, {"auth_ref":{"us-gaap_IncreaseDecreaseInAccountsPayable":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncreaseDecreaseInAccountsPayable","crdr":"debit","calculation":{"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS":{"parentTag":"us-gaap_NetCashProvidedByUsedInOperatingActivities","weight":1.0,"order":3.0},"presentation":{"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"},"lang":{"en-us":{"role":{"terseLabel":"Accounts payable"},"label":"Increase (Decrease) in Accounts Payable"},"documentation":{"The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."}}}}, {"auth_ref":{"r4"}}, {"us-gaap_IncreaseDecreaseInAccountsReceivable":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncreaseDecreaseInAccountsReceivable","crdr":"credit","presentation":{"http://www.replimune.com/role/CollaborationandotherarrangementsDetails"},"lang":{"en-us":{"role":{"terseLabel":"Payments received"},"label":"Increase (Decrease) in Accounts Receivable"},"documentation":{"The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."}}}}, {"auth_ref":{"r4"}}, {"repl_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities":{"xbrltype":"monetaryItemType","nsuri":"http://www.replimune.com/20240630","localname":"IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities","crdr":"debit","calculation":{"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS":{"parentTag":"us-gaap_NetCashProvidedByUsedInOperatingActivities","weight":1.0,"order":8.0},"presentation":{"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"},"lang":{"en-us":{"role":{"terseLabel":"Accrued expenses and other current liabilities"},"label":"Increase (Decrease) in accrued expenses and other current liabilities"},"documentation":{"Amount of increase (decrease) accrued expenses and other current liabilities."}}}}, {"auth_ref":{"us-gaap_IncreaseDecreaseInOperatingCapitalAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncreaseDecreaseInOperatingCapitalAbstract"},"presentation":{"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"},"lang":{"en-us":{"role":{"terseLabel":"Changes in operating assets and liabilities"},"label":"Increase (Decrease) in Operating Capital Abstract"}}, {"auth_ref":{"us-gaap_IncreaseDecreaseInOperatingLeaseLiability":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncreaseDecreaseInOperatingLeaseLiability","crdr":"debit","calculation":{"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS":{"parentTag":"us-gaap_NetCashProvidedByUsedInOperatingActivities","weight":1.0,"order":2.0},"presentation":{"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"},"lang":{"en-us":{"role":{"terseLabel":"Operating lease liabilities"},"label":"Increase (Decrease) in Operating Lease Liability"},"documentation":{"Amount of increase (decrease) in obligation for operating lease."}}}}, {"auth_ref":{"r822","r838"}}, {"us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncreaseDecreaseInOtherNoncurrentLiabilities","crdr":"debit","calculation":{"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS":{"parentTag":"us-gaap_NetCashProvidedByUsedInOperatingActivities","weight":1.0,"order":14.0},"presentation":{"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"},"lang":{"en-us":{"role":{"terseLabel":"Other non-current liabilities"},"label":"Increase (Decrease) in Other Noncurrent Liabilities"},"documentation":{"Amount of increase (decrease) in noncurrent operating liabilities classified as other."}}}}, {"auth_ref":{"us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets","crdr":"credit","calculation":{"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS":{"parentTag":"us-gaap_NetCashProvidedByUsedInOperatingActivities","weight":-1.0,"order":4.0},"presentation":{"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"},"lang":{"en-us":{"role":{"negatedLabel":"Prepaid expenses and other current assets"},"label":"Increase (Decrease) in Prepaid Expense and Other Assets"},"documentation":{"Amount of increase (decrease) in prepaid expenses, and assets classified as other."}}}}, {"auth_ref":{"r4"}}, {"repl_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable":{"xbrltype":"monetaryItemType","nsuri":"http://www.replimune.com/20240630","localname":"IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable","crdr":"credit","calculation":{"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS":{"parentTag":"us-gaap_NetCashProvidedByUsedInOperatingActivities","weight":1.0,"order":11.0},"presentation":{"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"},"lang":{"en-us":{"role":{"negatedLabel":"Research and development incentives receivable"},"label":"Increase (Decrease) in Research and Development Incentives Receivable"},"documentation":{"Amount of increase (decrease) in research and development incentives receivable."}}}}, {"auth_ref":{"us-gaap_IncreaseDecreaseInStockholdersEquityRollForward":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncreaseDecreaseInStockholdersEquityRollForward"},"presentation":{"http://www.replimune.com/role/CONSOLIDATEDSTATEMENTSOFTOCKHOLDERSEQUITY"},"lang":{"en-us":{"role":{"terseLabel":"Increase (decrease) in Stockholders' Equity"},"label":"Increase (Decrease) in Stockholders' Equity [Roll Forward]"},"documentation":{"A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."}}}}, {"auth_ref":{"repl_IncreaseDecreaseOperatingLeaseRightOfUseAsset":{"xbrltype":"monetaryItemType","nsuri":"http://www.replimune.com/20240630","localname":"IncreaseDecreaseOperatingLeaseRightOfUseAsset","crdr":"credit","calculation":{"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS":{"parentTag":"us-gaap_NetCashProvidedByUsedInOperatingActivities","weight":-1.0,"order":10.0},"presentation":{"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"},"lang":{"en-us":{"role":{"negatedLabel":"Operating lease, right-of-use-asset"},"label":"Increase (Decrease) Operating Lease, Right-of-Use Asset"},"documentation":{"Amount of increase (decrease) in operating lease right-of-use assets."}}}}, {"auth_ref":{"ecd_IndividualAxis":{"xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"IndividualAxis"},"presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"},"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"},"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Individual"},"label":"Individual {Axis}"}}, {"auth_ref":{"r747","r757","r767","r791","r799","r803","r811"}}, {"ecd_InsiderTradingArrLineItems":{"xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"InsiderTradingArrLineItems"},"lang":{"en-us":{"role":{"label":"Insider Trading Arrangements {Line Items}"}}, {"auth_ref":{"r809"}}, {"ecd_InsiderTradingPoliciesProcLineItems":{"xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"InsiderTradingPoliciesProcLineItems"},"lang":{"en-us":{"role":{"label":"Insider Trading Policies and Procedures {Line Items}"}}, {"auth_ref":{"r739","r815"}}, {"ecd_InsiderTrdPoliciesProcAdoptedFlag":{"xbrltype":"booleanItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"InsiderTrdPoliciesProcAdoptedFlag"},"presentation":{"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"},"lang":{"en-us":{"role":{"terseLabel":"Insider Trading Policies and Procedures Adopted"},"label":"Insider Trading Policies and Procedures Adopted {Flag}"}}, {"auth_ref":{"r739","r815"}}, {"ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"InsiderTrdPoliciesProcNotAdoptedTextBlock"},"presentation":{"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"},"lang":{"en-us":{"role":{"terseLabel":"Insider Trading Policies and Procedures Not Adopted"},"label":"Insider Trading Policies and Procedures Not Adopted {Text Block}"}}, {"auth_ref":{"r739","r815"}}, {"us-gaap_InterestExpenseDebt":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InterestExpenseDebt","crdr":"debit","calculation":{"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS":{"parentTag":"us-gaap_NonoperatingIncomeExpense","weight":1.0,"order":5.0},"presentation":{"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"},"http://www.replimune.com/role/DebtNarrativeDetails"},"lang":{"en-us":{"role":{"negatedTerseLabel":"Interest expense on debt obligations"},"terseLabel":"Interest expense on debt obligations"},"label":"Interest Expense, Debt"},"documentation":{"Amount of the cost of borrowed funds accounted for as interest expense for debt."}}}}, {"auth_ref":{"r69","r289","r298","r686","r687"}}, {"us-gaap_InterestPaidNet":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InterestPaidNet","crdr":"credit","presentation":{"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"},"lang":{"en-us":{"role":{"terseLabel":"Cash paid during the period for interest"},"label":"Interest Paid, Excluding Capitalized Interest, Operating Activities"},"documentation":{"Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."}}}}, {"auth_ref":{"r146","r149","r150"}}, {"us-gaap_InvestmentIncomeInterestAndDividend":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InvestmentIncomeInterestAndDividend","crdr":"credit","calculation":{"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS":{"parentTag":"us-gaap_NonoperatingIncomeExpense","weight":1.0,"order":2.0},"presentation":{"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"},"lang":{"en-us":{"role":{"terseLabel":"Investment income"},"label":"Investment Income, Interest and Dividend"},"documentation":{"Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities."}}}}, {"auth_ref":{"r66","r67"}}, {"us-gaap_InvestmentTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InvestmentTextBlock"},"presentation":{"http://www.replimune.com/role/Shortterminvestments"},"lang":{"en-us":{"role":{"terseLabel":"Short-term investments"},"label":"Investment {Text Block}"},"documentation":{"The entire disclosure for investment."}}}}, {"auth_ref":{"r823","r824","r855"}}, {"us-gaap_InvestmentsFairValueDisclosure":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InvestmentsFairValueDisclosure","crdr":"debit","presentation":{"http://www.replimune.com/role/FairvalueoffinancialassetsandliabilitiesDetails"},"lang":{"en-us":{"role":{"terseLabel":"Short-term investments"},"label":"Investments, Fair Value Disclosure"},"documentation":{"Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."}}}}, {"auth_ref":{"r918","r919","r923"}}, {"us-gaap_LeaseCost":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LeaseCost","crdr":"debit","calculation":{"http://www.replimune.com/role/CommitmentsandcontingenciesComponentsofleaseexpenseDetails":{"parentTag":null,"weight":null,"order":null,"root":true},"presentation":{"http://www.replimune.com/role/CommitmentsandcontingenciesComponentsofleaseexpenseDetails"},"http://www.replimune.com/role/CommitmentsandcontingenciesIncomeStatementInformationDetails"},"lang":{"en-us":{"role":{"totalLabel":"Total lease cost",

"terseLabel": "Total lease cost", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": { "r448", "r711" } }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostAbstract", "presentation": { "http://www.replimune.com/role/CommitmentsandcontingenciesComponentsofleaseexpenseDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Lease cost", "label": "Lease, Cost [Abstract]" } } }, "auth_ref": { "r448", "r711" } }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": { "http://www.replimune.com/role/CommitmentsandcontingenciesTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of variable lease components", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": { "r929" } }, "repl_LeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "LeaseLiability", "crdr": "credit", "calculation": { "http://www.replimune.com/role/CommitmentsandcontingenciesOtherinformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.replimune.com/role/CommitmentsandcontingenciesOtherinformationDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total lease liabilities", "label": "Lease, Liability", "documentation": "Amount of lease liabilities current and noncurrent." } } }, "auth_ref": { "r448", "r711" }, "repl_LeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "LeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.replimune.com/role/CommitmentsandcontingenciesOtherinformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.replimune.com/role/CommitmentsandcontingenciesOtherinformationDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total lease assets", "label": "Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under lease." } } }, "auth_ref": { "r448", "r711" }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": { "http://www.replimune.com/role/PropertyplantandequipmentnetDetails": { "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": { "r79", "r456" } }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "presentation": { "http://www.replimune.com/role/CommitmentsandcontingenciesOtherinformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Leases [Abstract]" } } }, "auth_ref": { "r448", "r711" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": { "http://www.replimune.com/role/CommitmentsandcontingenciesIncomeStatementInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r447", "r457" } }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": { "http://www.replimune.com/role/CommitmentsandcontingenciesIncomeStatementInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": { "r447", "r457" } }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": { "http://www.replimune.com/role/CommitmentsandcontingenciesTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of the maturity of company's lease liabilities", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": { "r930" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "parentTag": "repl_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": { "r455" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "parentTag": "repl_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r455" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r455" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r455" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r455" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOffFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOffFiscalYear", "crdr": "credit", "calculation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "parentTag": "repl_OperatingAndFinanceLeaseLiabilityPaymentsRemainderOffFiscalYear", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "lang": { "en-us": { "role": { "terseLabel": "2022 (remaining three months)", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": { "r930" } }, "repl_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "calculation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, After Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due in fifth fiscal year and after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r448", "r711" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "parentTag": "repl_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "lang": { "en-us": { "role": { "terseLabel": "Less: interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": { "r455" } }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": { "r13", "r45", "r46", "r47", "r50", "r51", "r52", "r53", "r155", "r231", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r390", "r393", "r394", "r426", "r589", "r677", "r734", "r881", "r931", "r932" } }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": { "r60", "r94", "r535", "r712", "r842", "r871", "r925" } }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Stockholders' Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": { "r448", "r711" }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": { "r47", "r121", "r155", "r231", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r390", "r393", "r394", "r426", "r712", "r881", "r931", "r932" } }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": { "r448", "r711" }, "us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityIncreaseDecreaseForPeriodNet", "crdr": "credit", "presentation": { "http://www.replimune.com/role/DebtNarrativeDetails": { "lang": { "en-us": { "role": { "negativeLabel": "Decrease in borrowing capacity", "label": "Line of Credit Facility, Increase (Decrease), Net", "documentation": "Amount of increase (decrease) of the credit facility." } } }, "auth_ref": { "r841" } }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": { "http://www.replimune.com/role/DebtNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": { "r44", "r49" } }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditMember", "presentation": { "http://www.replimune.com/role/DebtNarrativeDetails": { "http://www.replimune.com/role/DebtScheduleofDebtDetails": { "lang": { "en-us": { "role": { "terseLabel": "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": { "r448", "r711" }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": { "http://www.replimune.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": { "r448", "r711" }, "us-

gaap-LongLivedAssetsByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "presentation": { "http://www.replimune.com/role/GeographicInformationTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of company's long-lived assets held in different geographic regions", "label": "Long-Lived Assets by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets." } } }, "auth_ref": { "r76" } }, "us-gaap-LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.replimune.com/role/DebtScheduleOfDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.replimune.com/role/DebtScheduleOfDebtDetails": { "lang": { "en-us": { "role": { "totalLabel": "Long-term debt, net", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt-issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": { "r13", "r92", "r282", "r297", "r684", "r685", "r710", "r941" } }, "repl-LongTermDebtEndOfTermCharge": { "xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "LongTermDebtEndOfTermCharge", "crdr": "debit", "presentation": { "http://www.replimune.com/role/DebtScheduleOfMaturityOfDebtDetails": { "lang": { "en-us": { "role": { "terseLabel": "End of term charge", "label": "Long Term Debt, End Of Term Charge", "documentation": "Long Term Debt, End Of Term Charge" } } }, "auth_ref": { "repl-LongTermDebtIncludingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "LongTermDebtIncludingInterest", "crdr": "credit", "calculation": { "http://www.replimune.com/role/DebtScheduleOfMaturityOfDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.replimune.com/role/DebtScheduleOfMaturityOfDebtDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Long-Term Debt, Including Interest", "documentation": "Long-Term Debt, Including Interest" } } }, "auth_ref": { "repl-LongTermDebtInstrumentCovenantRequirementUnrestrictedCashPercentageOfObligations": { "xbrltype": "percentItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "LongTermDebtInstrumentCovenantRequirementUnrestrictedCashPercentageOfObligations", "presentation": { "http://www.replimune.com/role/DebtNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Unrestricted cash percentage", "label": "Long-term Debt Instrument, Covenant Requirement, Unrestricted Cash Percentage of Obligations", "documentation": "Long-term Debt Instrument, Covenant Requirement, Unrestricted Cash Percentage of Obligations" } } }, "auth_ref": { "repl-LongTermDebtInstrumentPrepaymentFeeAfter36Months": { "xbrltype": "percentItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "LongTermDebtInstrumentPrepaymentFeeAfter36Months", "presentation": { "http://www.replimune.com/role/DebtNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Prepayment fee, after 36 months (as a percent)", "label": "Long-Term Debt Instrument, Prepayment Fee, After 36 Months", "documentation": "Long-Term Debt Instrument, Prepayment Fee, After 36 Months" } } }, "auth_ref": { "repl-LongTermDebtInstrumentPrepaymentFeeAfterFirst12MonthsBefore36Months": { "xbrltype": "percentItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "LongTermDebtInstrumentPrepaymentFeeAfterFirst12MonthsBefore36Months", "presentation": { "http://www.replimune.com/role/DebtNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Prepayment fee, After first 12 months before 36 months (as a percent)", "label": "Long-Term Debt Instrument, Prepayment Fee, After First 12 Months Before 36 Months", "documentation": "Long-Term Debt Instrument, Prepayment Fee, After First 12 Months Before 36 Months" } } }, "auth_ref": { "repl-LongTermDebtInstrumentPrepaymentFeeFirst12Months": { "xbrltype": "percentItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "LongTermDebtInstrumentPrepaymentFeeFirst12Months", "presentation": { "http://www.replimune.com/role/DebtNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Prepayment fee, first 12 months (as a percent)", "label": "Long-Term Debt Instrument, Prepayment Fee, First 12 Months", "documentation": "Long-Term Debt Instrument, Prepayment Fee, First 12 Months" } } }, "auth_ref": { "repl-LongTermDebtInstrumentRepaymentFee": { "xbrltype": "percentItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "LongTermDebtInstrumentRepaymentFee", "presentation": { "http://www.replimune.com/role/DebtNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Repayment Fee (as a percent)", "label": "Long-Term Debt Instrument, Repayment Fee", "documentation": "Long-Term Debt Instrument, Repayment Fee" } } }, "auth_ref": { "repl-LongTermDebtMaturityAfterYearFiveIncludingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "LongTermDebtMaturityAfterYearFiveIncludingInterest", "crdr": "credit", "calculation": { "http://www.replimune.com/role/DebtScheduleOfMaturityOfDebtDetails": { "parentTag": "repl-LongTermDebtIncludingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.replimune.com/role/DebtScheduleOfMaturityOfDebtDetails": { "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Long-Term Debt, Maturity, After Year Five, Including Interest", "documentation": "Long-Term Debt, Maturity, After Year Five, Including Interest" } } }, "auth_ref": { "repl-LongTermDebtMaturityYearFiveIncludingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "LongTermDebtMaturityYearFiveIncludingInterest", "crdr": "credit", "calculation": { "http://www.replimune.com/role/DebtScheduleOfMaturityOfDebtDetails": { "parentTag": "repl-LongTermDebtIncludingInterest", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.replimune.com/role/DebtScheduleOfMaturityOfDebtDetails": { "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Five, Including Interest", "documentation": "Long-Term Debt, Maturity, Year Five, Including Interest" } } }, "auth_ref": { "repl-LongTermDebtMaturityYearFourIncludingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "LongTermDebtMaturityYearFourIncludingInterest", "crdr": "credit", "calculation": { "http://www.replimune.com/role/DebtScheduleOfMaturityOfDebtDetails": { "parentTag": "repl-LongTermDebtIncludingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.replimune.com/role/DebtScheduleOfMaturityOfDebtDetails": { "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Four, Including Interest", "documentation": "Long-Term Debt, Maturity, Year Four, Including Interest" } } }, "auth_ref": { "repl-LongTermDebtMaturityYearThreeIncludingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "LongTermDebtMaturityYearThreeIncludingInterest", "crdr": "credit", "calculation": { "http://www.replimune.com/role/DebtScheduleOfMaturityOfDebtDetails": { "parentTag": "repl-LongTermDebtIncludingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.replimune.com/role/DebtScheduleOfMaturityOfDebtDetails": { "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year Three, Including Interest", "documentation": "Long-Term Debt, Maturity, Year Three, Including Interest" } } }, "auth_ref": { "repl-LongTermDebtMaturityYearTwoIncludingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "LongTermDebtMaturityYearTwoIncludingInterest", "crdr": "credit", "calculation": { "http://www.replimune.com/role/DebtScheduleOfMaturityOfDebtDetails": { "parentTag": "repl-LongTermDebtIncludingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.replimune.com/role/DebtScheduleOfMaturityOfDebtDetails": { "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Long-Term Debt, Maturity, Year Two, Including Interest", "documentation": "Long-Term Debt, Maturity, Year Two, Including Interest" } } }, "auth_ref": { "us-gaap-LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap-Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "lang": { "en-us": { "role": { "terseLabel": "Long term debt, net of discount", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt-issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": { "r126" } }, "us-gaap-LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": { "http://www.replimune.com/role/DebtNarrativeDetails": { "http://www.replimune.com/role/DebtScheduleOfDebtDetails": { "http://www.replimune.com/role/DebtScheduleOfMaturityOfDebtDetails": { "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": { "r13", "r874", "r875", "r876" } }, "us-gaap-LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": { "http://www.replimune.com/role/DebtNarrativeDetails": { "http://www.replimune.com/role/DebtScheduleOfDebtDetails": { "http://www.replimune.com/role/DebtScheduleOfMaturityOfDebtDetails": { "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": { "r13", "r31", "r874", "r875", "r876" } }, "repl-MasterClinicalTrialCollaborationAndSupplyAgreementRocheMember": { "xbrltype": "domainItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "MasterClinicalTrialCollaborationAndSupplyAgreementRocheMember", "presentation": { "http://www.replimune.com/role/CollaborationandotherarrangementsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Master Clinical Trial Collaboration and Supply Agreement - Roche", "label": "Master Clinical Trial Collaboration and Supply Agreement - Roche [Member]", "documentation": "Master Clinical Trial Collaboration and Supply Agreement - Roche" } } }, "auth_ref": { "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": { "http://www.replimune.com/role/CollaborationandotherarrangementsDetails": { "http://www.replimune.com/role/DebtNarrativeDetails": { "http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": { "r254", "r255", "r256", "r257", "r324", "r362", "r411", "r492", "r547", "r557", "r581", "r582", "r636", "r638", "r640", "r641", "r643", "r665", "r666", "r681", "r688", "r693", "r703", "r704", "r708", "r709", "r722", "r883", "r933", "r934", "r935", "r936", "r937", "r938" } }, "repl-MaximumPercentageOfHoldingForExerciseWarrants": { "xbrltype": "percentItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "MaximumPercentageOfHoldingForExerciseWarrants", "presentation": { "http://www.replimune.com/role/PrefundedWarrantsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Maximum percentage of holding for exercise warrants (as a percent)", "label": "Maximum Percentage of Holding For Exercise Warrants", "documentation": "The maximum percentage of holding for exercise warrants." } } }, "auth_ref": { "repl-MaximumPercentageOfIncreaseDecreaseOfHoldingForExerciseWarrants": { "xbrltype": "percentItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "MaximumPercentageOfIncreaseDecreaseOfHoldingForExerciseWarrants", "presentation": { "http://www.replimune.com/role/PrefundedWarrantsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Maximum percentage of increase (decrease) of holding for exercise warrants (as a percent)", "label": "Maximum Percentage Of Increase (Decrease) Of Holding For Exercise Warrants", "documentation": "Represents the maximum percentage of increase (decrease) of holding for exercise warrants." } } }, "auth_ref": { "ecd-MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Measure", "label": "Measure [Axis]" } } }, "auth_ref": { "r783" } }, "ecd-MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure-Name" } } }, "auth_ref": { "r783" } }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": { "http://www.replimune.com/role/CollaborationandotherarrangementsDetails": { "http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": { "r254", "r255", "r256", "r257", "r324", "r362", "r411", "r492", "r547", "r557", "r581", "r582", "r636", "r638", "r640", "r641", "r643", "r665", "r666", "r681", "r688", "r693", "r703", "r704", "r708", "r709", "r722", "r883", "r933", "r934", "r935", "r936", "r937", "r938" } }, "repl_MinimumNoticePeriodToChangePercentageOfHolding": { "xbrltype": "durationItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "MinimumNoticePeriodToChangePercentageOfHolding", "presentation": { "http://www.replimune.com/role/PrefundedWarrantsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Prior notice period to change percentage of holding (in days)", "label": "Minimum Notice Period to Change Percentage Of Holding", "documentation": "It represents number of days prior notice for increase or decrease percentage of holding." } } }, "auth_ref": { "repl_MinimumPercentageOfExercisePricePersonsHoldingMoreThanTenPercentOfVotingPower": { "xbrltype": "percentItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "MinimumPercentageOfExercisePricePersonsHoldingMoreThanTenPercentOfVotingPower", "presentation": { "http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Exercise price for persons holding more than ten percent of voting power (as a percent)", "label": "Minimum Percentage of Exercise Price, Persons Holding More Than Ten Percent of Voting Power", "documentation": "Minimum percentage of exercise price of the fair market value for all incentive options granted to any person possessing more than 10% of the total combined voting power of all classes of shares." } } }, "auth_ref": { "ecd-MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": { "r802" } }, "us-gaap-MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": { "http://www.replimune.com/role/FairvalueoffinancialassetsandliabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances,

```
purchase agreements, government securities, certificates of deposit, and other highly liquid securities." } }, "auth_ref": { "r886" }, "ecd_MtrlTermsOfFrdArrTextBlock": {  
  "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfFrdArrTextBlock", "presentation": {  
    "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of  
Trading Arrangement [Text Block]" } } }, "auth_ref": { "r810" } }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":  
    "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": {  
      "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": { "r784" } }, "us-gaap_NatureOfOperations": {  
      "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": {  
        "http://www.replimune.com/role/Natureofthebusiness": { "lang": { "en-us": { "role": { "terseLabel": "Nature of the business", "label": "Nature of Operations [Text Block]"  
        }, "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of  
its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal  
operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are  
being directed toward." } } }, "auth_ref": { "r104", "r115" } }, "repl_NetAmortizationOfPremiumsAndDiscountsOnShortTermInvestments": { "xbrltype": "monetaryItem", "nsuri":  
        "http://www.replimune.com/20240630", "localname": "NetAmortizationOfPremiumsAndDiscountsOnShortTermInvestments", "crdr": "credit", "calculation": {  
          "http://www.replimune.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",  
            "weight": -1.0, "order": 5.0 } }, "presentation": { "http://www.replimune.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS": { "lang": { "en-us": { "role": {  
              "negatedLabel": "Net amortization of premiums and discounts on short-term investments", "label": "Net Amortization Of Premiums And Discounts On Short-term  
Investments", "documentation": "It represents the amount of net amortization of premiums and discounts on short-term investments." } } }, "auth_ref": { } }, "us-  
gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname":  
          "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.replimune.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS": {  
            "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": -1.0, "order": 3.0  
            }, "presentation": { "http://www.replimune.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS": { "lang": { "en-us": { "role": { "totalLabel": "Net cash  
provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities;  
including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their  
investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term  
credit." } } }, "auth_ref": { "r148" } }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024",  
            "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": {  
              "http://www.replimune.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS": { "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing  
activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": { } }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": {  
                "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": {  
                  "http://www.replimune.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS": { "parentTag": "us-  
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": -1.0, "order": 2.0 } }, "presentation": {  
                    "http://www.replimune.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS": { "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by investing  
activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued  
operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment  
and other productive assets." } } }, "auth_ref": { "r148" } }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItem", "nsuri":  
                      "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": {  
                        "http://www.replimune.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS": { "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing  
activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": { } }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": {  
                          "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": {  
                            "http://www.replimune.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS": { "parentTag": "us-  
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": -1.0, "order": 1.0 } }, "presentation": {  
                              "http://www.replimune.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS": { "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating  
activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued  
operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": { "r72",  
                                "r73", "r74" } }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname":  
                                  "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://www.replimune.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS": {  
                                    "parentTag": "us-  
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": -1.0, "order": 1.0 } }, "presentation": {  
                                      "http://www.replimune.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOF CASH FLOWS": { "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating  
activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued  
operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": { } }, "us-gaap_NetIncomeLoss": {  
                                        "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": {  
                                          "http://www.replimune.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOF COMPREHENSIVE LOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight":  
                                            1.0, "order": 3.0 } }, "presentation": { "http://www.replimune.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOF COMPREHENSIVE LOSS": {  
                                            "http://www.replimune.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOF STOCKHOLDERSEQUITY", "http://www.replimune.com/role/NatureofthebusinessDetails",  
                                              "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Net loss", "negatedLabel": "Net loss", "label": "Net Income (Loss) Attributable to  
Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": { "r64", "r74", "r98", "r119",  
                                                  "r136", "r138", "r142", "r155", "r163", "r165", "r166", "r167", "r168", "r169", "r172", "r173", "r180", "r231", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267",  
                                                  "r286", "r383", "r386", "r405", "r426", "r540", "r611", "r629", "r630", "r732", "r881" } }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype":  
                                                "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": {  
                                                  "http://www.replimune.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOF OPERATIONS": { "parentTag": null, "weight": null, "order": null, "root": true } },  
                                                    "presentation": { "http://www.replimune.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOF OPERATIONS";  
                                                      "http://www.replimune.com/role/NetlosspershareComputationsOfNetLossperShareDetails": { "lang": { "en-us": { "role": { "totalLabel": "Net loss", "verboseLabel": "Net loss",  
                                                        "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred  
stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": { "r145", "r165", "r166", "r167", "r168", "r175", "r176", "r181",  
                                                          "r184", "r386" } }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024",  
                                                            "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": {  
                                                              "http://www.replimune.com/role/NetlosspershareComputationsOfNetLossperShareDetails": { "lang": { "en-us": { "role": { "terseLabel": "Numerator", "label": "Net Income (Loss)  
Available to Common Stockholders, Basic [Abstract]" } } }, "auth_ref": { } }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype":  
                                                                "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": {  
                                                                  "http://www.replimune.com/role/SummaryofsignificantaccountingpoliciesPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Recently Issued Accounting Pronouncements",  
                                                                    "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that  
may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": { } },  
                                                                    "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":  
                                                                      "NonGaapMeasureDescriptionTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure  
Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": { "r783" } }, "ecd_NonNeosMember": { "xbrltype": "domainItem", "nsuri":  
                                                                        "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel":  
                                                                          "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": { "r747", "r757", "r767", "r791", "r799" } }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype":  
                                                                            "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": {  
                                                                              "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO  
Average Compensation Actually Paid Amount" } } }, "auth_ref": {
```

```

Financial Lease Liabilities Payments Due Abstract", "documentation": "No definition available." } }, "auth_ref": [ ] }, "repl_OperatingAndFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "OperatingAndFinanceLeaseLiability", "crdr": "credit", "calculation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails_2": { "parentTag": "repl_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 }, "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total lease liabilities", "label": "Operating and Finance Lease Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating and finance lease." } }, "auth_ref": [ ] }, "repl_OperatingAndFinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails_2": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Operating and Finance Lease Liability Payments Due", "documentation": "Amount of lessee's undiscounted obligation for lease payments from operating and finance lease." } }, "auth_ref": [ ] }, "repl_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFour", "crdr": "credit", "calculation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails_1": { "parentTag": "repl_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 }, "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "lang": { "en-us": { "role": { "totalLabel": "Thereafter", "label": "Operating and Finance Lease Liability Payments Due After Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating and finance lease, due in fifth fiscal year and after fifth fiscal year following latest fiscal year." } }, "auth_ref": [ ] }, "repl_OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails_1": { "parentTag": "repl_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 }, "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "lang": { "en-us": { "role": { "totalLabel": "2026", "label": "Operating and Finance Lease Liability Payments Due Next Twelve Months", "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating and finance lease, due in next fiscal year following current fiscal year." } }, "auth_ref": [ ] }, "repl_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails_1": { "parentTag": "repl_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 }, "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "lang": { "en-us": { "role": { "totalLabel": "Operating and Finance Lease Liability Payments Due Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating and finance lease, due in third fiscal year following latest fiscal year." } }, "auth_ref": [ ] }, "repl_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails_1": { "parentTag": "repl_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 }, "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "lang": { "en-us": { "role": { "totalLabel": "2027", "label": "Operating and Finance Lease Liability Payments Due Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating and finance lease, due in second fiscal year following latest fiscal year." } }, "auth_ref": [ ] }, "repl_OperatingAndFinanceLeaseLiabilityPaymentsRemainderOffFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "OperatingAndFinanceLeaseLiabilityPaymentsRemainderOffFiscalYear", "crdr": "credit", "calculation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails_1": { "parentTag": "repl_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 }, "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "lang": { "en-us": { "role": { "totalLabel": "2022 (remaining three months)", "label": "Operating and Finance Lease Liability Payments Remainder Of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating and finance lease, due in remainder of fiscal year following last fiscal year ended" } }, "auth_ref": [ ] }, "repl_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "debit", "calculation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails_2": { "parentTag": "repl_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 }, "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "lang": { "en-us": { "role": { "totalLabel": "Less: interest", "label": "Operating and Finance Lease Liability Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating and finance lease." } }, "auth_ref": [ ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.replimune.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.replimune.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } }, "auth_ref": [ ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": { "http://www.replimune.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } }, "auth_ref": [ ] }, "repl_OperatingFinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "OperatingFinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails_1": { "parentTag": "repl_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 }, "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "lang": { "en-us": { "role": { "totalLabel": "2029", "label": "Operating Finance Lease Liability Payments Due Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating and finance lease, due in fourth fiscal year following latest fiscal year." } }, "auth_ref": [ ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.replimune.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.replimune.com/role/CODENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } }, "auth_ref": { "r99", "r678", "r850", "r851", "r852", "r853", "r854" } }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.replimune.com/role/CommitmentsandcontingenciesComponentsofleaseexpenseDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.replimune.com/role/CommitmentsandcontingenciesComponentsofleaseexpenseDetails": { "http://www.replimune.com/role/CommitmentsandcontingenciesIncomeStatementInformationDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Operating lease costs", "terseLabel": "Operating Lease Costs", "label": "Operating Lease Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } }, "auth_ref": { "r450", "r711" } }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating leases", "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } }, "auth_ref": [ ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "parentTag": "repl_OperatingAndFinanceLeaseLiability", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.replimune.com/role/CommitmentsandcontingenciesBalancesheetdisclosuresDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } }, "auth_ref": { "r442" } }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.replimune.com/role/CODENSEDCONS
```

[illegible]

{ "repl_PerformanceStockUnitsMember": { "xbrlType": "domainItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "PerformanceStockUnitsMember", "presentation": { "http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "PSUs", "label": "Performance Stock Units [Member]", "documentation": "Performance Stock Units", "auth_ref": {} }, "repl_PhilipAstleySparkeMember": { "xbrlType": "domainItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "PhilipAstleySparkeMember", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Philip Astley-Sparke [Member]", "documentation": "Philip Astley-Sparke", "auth_ref": {} }, "us-gaap_PlanNameAxis": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": { "http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement.", "auth_ref": { "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912" }, "us-gaap_PlanNameDomain": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": { "http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement.", "auth_ref": { "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912" }, "ecd_PnsnAdjsPrSvcCstMember": { "xbrlType": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]", "auth_ref": { "r775" }, "ecd_PnsnAdjsSvcCstMember": { "xbrlType": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]", "auth_ref": { "r819" }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]", "auth_ref": { "r774" }, "repl_PreFundedWarrantsCommonStockMember": { "xbrlType": "domainItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "PreFundedWarrantsCommonStockMember", "presentation": { "http://www.replimune.com/role/StockholdersequityScheduleofPrefundedWarrantsDetails": "http://www.replimune.com/role/StockholdersequityScheduleofPrefundedWarrantsDetails", "lang": { "en-us": { "role": { "terseLabel": "Total shares of common stock reserved for future issuance", "label": "Pre Funded Warrants, Common Stock [Member]", "documentation": "Pre Funded Warrants, Common Stock", "auth_ref": {} }, "repl_PreFundedWarrantsESPPMember": { "xbrlType": "domainItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "PreFundedWarrantsESPPMember", "presentation": { "http://www.replimune.com/role/StockholdersequityScheduleofPrefundedWarrantsDetails": "http://www.replimune.com/role/StockholdersequityScheduleofPrefundedWarrantsDetails", "lang": { "en-us": { "role": { "terseLabel": "Employee stock purchase plan, available for future grants", "label": "Pre Funded Warrants, ESPP [Member]", "documentation": "Pre Funded Warrants, ESPP", "auth_ref": {} }, "repl_PreFundedWarrantsIssued": { "xbrlType": "sharesItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "PreFundedWarrantsIssued", "presentation": { "http://www.replimune.com/role/PrefundedWarrantsNarrativeDetails": "http://www.replimune.com/role/PrefundedWarrantsNarrativeDetails", "lang": { "en-us": { "role": { "verboseLabel": "Issuance of pre-funded warrants (in shares)", "label": "Pre Funded Warrants Issued", "documentation": "It represents number of pre-funded warrants to purchase common stock of company.", "auth_ref": {} }, "repl_PreFundedWarrantsMember": { "xbrlType": "domainItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "PreFundedWarrantsMember", "presentation": { "http://www.replimune.com/role/PrefundedWarrantsNarrativeDetails": "http://www.replimune.com/role/PrefundedWarrantsNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Pre-funded warrants", "label": "Pre Funded Warrants [Member]", "documentation": "Represents information pertaining to pre-funded warrants.", "auth_ref": {} }, "repl_PreFundedWarrantsPreIPOMember": { "xbrlType": "domainItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "PreFundedWarrantsPreIPOMember", "presentation": { "http://www.replimune.com/role/StockholdersequityScheduleofPrefundedWarrantsDetails": "http://www.replimune.com/role/StockholdersequityScheduleofPrefundedWarrantsDetails", "lang": { "en-us": { "role": { "terseLabel": "Pre-IPO warrants to purchase common stock", "label": "Pre Funded Warrants, Pre-IPO [Member]", "documentation": "Pre Funded Warrants, Pre-IPO", "auth_ref": {} }, "repl_PreFundedWarrantsRestrictedAndPerformanceStockUnitsMember": { "xbrlType": "domainItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "PreFundedWarrantsRestrictedAndPerformanceStockUnitsMember", "presentation": { "http://www.replimune.com/role/StockholdersequityScheduleofPrefundedWarrantsDetails": "http://www.replimune.com/role/StockholdersequityScheduleofPrefundedWarrantsDetails", "lang": { "en-us": { "role": { "terseLabel": "Restricted and performance stock units", "label": "Pre Funded Warrants, Restricted and Performance Stock Units [Member]", "documentation": "Pre Funded Warrants, Restricted and Performance Stock Units", "auth_ref": {} }, "repl_PreFundedWarrantsStockOptionsAndRestrictedStockMember": { "xbrlType": "domainItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "PreFundedWarrantsStockOptionsAndRestrictedStockMember", "presentation": { "http://www.replimune.com/role/StockholdersequityScheduleofPrefundedWarrantsDetails": "http://www.replimune.com/role/StockholdersequityScheduleofPrefundedWarrantsDetails", "lang": { "en-us": { "role": { "terseLabel": "Stock options and restricted stock units, future issuance", "label": "Pre Funded Warrants, Stock Options And Restricted Stock [Member]", "documentation": "Pre Funded Warrants, Stock Options And Restricted Stock", "auth_ref": {} }, "repl_PreFundedWarrantsStockOptionsMember": { "xbrlType": "domainItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "PreFundedWarrantsStockOptionsMember", "presentation": { "http://www.replimune.com/role/StockholdersequityScheduleofPrefundedWarrantsDetails": "http://www.replimune.com/role/StockholdersequityScheduleofPrefundedWarrantsDetails", "lang": { "en-us": { "role": { "terseLabel": "Stock options, issued and outstanding", "label": "Pre Funded Warrants, Stock Options [Member]", "documentation": "Pre Funded Warrants, Stock Options", "auth_ref": {} }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrlType": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": { "http://www.replimune.com/role/StockholdersequityCommonStockAndUndesignatedPreferredStockDetails": "http://www.replimune.com/role/StockholdersequityCommonStockAndUndesignatedPreferredStockDetails", "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, Par Value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "auth_ref": { "r54", "r300" }, "us-gaap_PreferredStockSharesAuthorized": { "xbrlType": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": { "http://www.replimune.com/role/StockholdersequityCommonStockAndUndesignatedPreferredStockDetails": "http://www.replimune.com/role/StockholdersequityCommonStockAndUndesignatedPreferredStockDetails", "lang": { "en-us": { "role": { "terseLabel": "Undesignated preferred stock, authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "auth_ref": { "r54", "r591" }, "us-gaap_PreferredStockSharesIssued": { "xbrlType": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": { "http://www.replimune.com/role/StockholdersequityCommonStockAndUndesignatedPreferredStockDetails": "http://www.replimune.com/role/StockholdersequityCommonStockAndUndesignatedPreferredStockDetails", "lang": { "en-us": { "role": { "terseLabel": "Undesignated preferred shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.", "auth_ref": { "r54", "r300" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "presentation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "auth_ref": { "r834" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "presentation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock in connection with private placement, net of placement agent fees and offering costs", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity.", "auth_ref": { "r2", "r12" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "presentation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of stock options and pre-funded warrants", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "auth_ref": { "r2", "r12" }, "us-gaap_ProfitLoss": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "presentation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "lang": { "en-us": { "role": { "terseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "auth_ref": { "r119", "r136", "r138", "r147", "r155", "r163", "r169", "r172", "r173", "r231", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r383", "r386", "r388", "r391", "r392", "r405", "r426", "r527", "r539", "r565", "r611", "r629", "r630", "r698", "r699", "r733", "r837", "r881" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "presentation": { "http://www.replimune.com/role/PropertyPlantAndEquipmentDisclosureTextBlock": "http://www.replimune.com/role/PropertyPlantAndEquipmentDisclosureTextBlock", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Abstract]", "label": "Property, Plant and Equipment [Abstract]", "auth_ref": {} }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": { "http://www.replimune.com/role/PropertyPlantAndEquipmentnetDetails": "http://www.replimune.com/role/PropertyPlantAndEquipmentnetDetails", "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "auth_ref": { "r6", "r456" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": { "http://www.replimune.com/role/PropertyPlantAndEquipmentnet": "http://www.replimune.com/role/PropertyPlantAndEquipmentnet", "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "auth_ref": { "r78", "r109", "r112", "r113" }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "presentation": { "http://www.replimune.com/role/PropertyPlantAndEquipmentnetDetails": "http://www.replimune.com/role/PropertyPlantAndEquipmentnetDetails", "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "auth_ref": { "r79", "r123", "r537" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": {

```

http://www.replimune.com/role/PropertyplantandequipmentnetDetails": {"lang": {"en-us": {"role": {"terseLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": {"r456"}}, {"us-gaap_PropertyPlantAndEquipmentNet": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": {"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {"parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0}, {"http://www.replimune.com/role/PropertyplantandequipmentnetDetails": {"parentTag": null, "weight": null, "order": null, "root": true } } }, "presentation": {"terseLabel": "Property, Plant and Equipment, net", "label": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, {"auth_ref": {"r6", "r456", "r528", "r537", "r712"}}, {"us-gaap_PropertyPlantAndEquipmentTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": {"http://www.replimune.com/role/PropertyplantandequipmentnetTables": {"lang": {"en-us": {"role": {"terseLabel": "Schedule of property, plant and equipment, net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": {"r6"}}, {"us-gaap_PropertyPlantAndEquipmentTypeDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": {"http://www.replimune.com/role/PropertyplantandequipmentnetDetails": {"lang": {"en-us": {"role": {"terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": {"r79", "r456"}}, {"us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted", "crdr": "credit", "presentation": {"http://www.replimune.com/role/CommitmentsandcontingenciesAdditionalInformationDetails": {"lang": {"en-us": {"role": {"terseLabel": "Minimum payments committed to manufacturing organization", "label": "Purchase Commitment, Remaining Minimum Amount Committed", "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations." } } }, "auth_ref": {"r52", "r93"}}, {"ecd_PvpTable": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]"} } } }, "auth_ref": {"r772"}}, {"ecd_PvpTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]"} } } }, "auth_ref": {"r772"}}, {"srt_RangeAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": {"http://www.replimune.com/role/CollaborationandotherarrangementsDetails": {"http://www.replimune.com/role/DebtNarrativeDetails": {"http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails": {"lang": {"en-us": {"role": {"terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]"} } } }, "auth_ref": {"r254", "r255", "r256", "r257", "r317", "r324", "r352", "r353", "r354", "r362", "r411", "r466", "r475", "r492", "r547", "r549", "r557", "r581", "r582", "r583", "r586", "r636", "r638", "r640", "r641", "r643", "r665", "r666", "r681", "r688", "r693", "r703", "r704", "r708", "r709", "r722", "r726", "r777", "r883", "r921", "r934", "r935", "r936", "r937", "r938"}}, {"srt_RangeMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": {"http://www.replimune.com/role/CollaborationandotherarrangementsDetails": {"http://www.replimune.com/role/DebtNarrativeDetails": {"http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails": {"lang": {"en-us": {"role": {"terseLabel": "Range [Domain]", "label": "Statistical Measurement [Domain]"} } } }, "auth_ref": {"r254", "r255", "r256", "r257", "r317", "r324", "r352", "r353", "r354", "r362", "r411", "r466", "r475", "r492", "r547", "r549", "r557", "r581", "r582", "r583", "r636", "r638", "r640", "r641", "r643", "r665", "r666", "r681", "r688", "r693", "r703", "r704", "r708", "r709", "r722", "r726", "r777", "r883", "r921", "r934", "r935", "r936", "r937", "r938"}}, {"ecd_RecoveryOfErrCompDisclosureLineItems": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": {"en-us": {"role": {"label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"} } } }, "auth_ref": {"r740", "r750", "r760", "r792"}}, {"srt_RepurchaseAgreementCounterpartyNameDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": {"http://www.replimune.com/role/SignificantagreementsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]"} } } }, "auth_ref": {"r157", "r158", "r273", "r302", "r459", "r476", "r529", "r672", "r673"}}, {"us-gaap_ResearchAndDevelopmentExpense": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": {"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {"parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": {"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {"lang": {"en-us": {"role": {"terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": {"r364", "r667", "r679", "r939"}}, {"us-gaap_ResearchAndDevelopmentExpenseMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": {"http://www.replimune.com/role/CommitmentsandcontingenciesIncomeStatementInformationDetails": {"http://www.replimune.com/role/StockbasedcompensationClassificationofexpenseDetails": {"lang": {"en-us": {"role": {"terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": {}}, {"repl_ResearchAndDevelopmentIncentivesIncome": {"xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "ResearchAndDevelopmentIncentivesIncome", "crdr": "credit", "calculation": {"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {"parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": {"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {"lang": {"en-us": {"role": {"terseLabel": "Research and development incentives", "label": "Research and Development Incentives Income", "documentation": "The amount of research and development incentives income." } } }, "auth_ref": {}}, {"repl_ResearchAndDevelopmentIncentivesReceivableCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "ResearchAndDevelopmentIncentivesReceivableCurrent", "crdr": "debit", "calculation": {"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {"parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": {"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {"lang": {"en-us": {"role": {"verboseLabel": "Research and development incentives receivable", "label": "Research and Development Incentives Receivable, Current", "documentation": "The amount of research and development incentives receivable, within one year from the balance sheet date, for goods or services that have been delivered or sold in the normal course of business." } } }, "auth_ref": {}}, {"repl_ResearchAndDevelopmentIncentivesReceivableNoncurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "ResearchAndDevelopmentIncentivesReceivableNoncurrent", "crdr": "debit", "calculation": {"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {"parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": {"http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {"lang": {"en-us": {"role": {"terseLabel": "Research and development incentives receivable, non-current", "label": "Research And Development Incentives Receivable, Noncurrent", "documentation": "Research And Development Incentives Receivable, Noncurrent"} } } }, "auth_ref": {}}, {"ecd_RestatementDateAxis": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": {"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date [Axis]"} } } }, "auth_ref": {"r741", "r751", "r761", "r793"}}, {"ecd_RestatementDeterminationDate": {"xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": {"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date"} } } }, "auth_ref": {"r742", "r752", "r762", "r794"}}, {"ecd_RestatementDoesNotRequireRecoveryTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]"} } } }, "auth_ref": {"r749", "r759", "r769", "r801"}}, {"repl_RestrictedAndPerformanceStockUnitsMember": {"xbrltype": "domainItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "RestrictedAndPerformanceStockUnitsMember", "presentation": {"http://www.replimune.com/role/NetlosspershareComputationofdilutednetlosspershareattributabletocommonstockholdersDetails": {"http://www.replimune.com/role/StockbasedcompensationClassificationofexpenseDetails": {"http://www.replimune.com/role/StockbasedcompensationSummaryofRSUActivityDetails": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Restricted and performance stock units", "verboseLabel": "Unvested restricted and performance stock units", "label": "Restricted and Performance Stock Units [Member]", "documentation": "Restricted and Performance Stock Units"} } } }, "auth_ref": {}
```

{ "label": "Robert Coffin [Member]", "documentation": "Robert Coffin" } }, { "auth_ref": "ecd_Rule10b51ArrAdoptedFlag", "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": "en-us", { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "auth_ref": "r810"} }, "ecd_Rule10b51ArrTrmmtDFlag", { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmmtDFlag", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": "en-us", { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "auth_ref": "r810"} }, "us_gaap_SaleOfStockConsiderationReceivedOnTransaction", { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": "http://www.replimune.com/role/StockholdersequityATMProgramDetails", "lang": "en-us", { "role": { "terseLabel": "Maximum received on transaction", "label": "Sale Of Stock, Maximum Consideration Received On All Transactions", "documentation": "Sale Of Stock, Maximum Consideration Received On All Transactions" } }, "auth_ref": "us_gaap_SaleOfStockNameOfTransactionDomain", { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": "http://www.replimune.com/role/PrefundedWarrantsNarrativeDetails", "http://www.replimune.com/role/StockholdersequityATMProgramDetails", "http://www.replimune.com/role/StockholdersequityEquityofferingsDetails", "http://www.replimune.com/role/StockholdersequityScheduleofPrefundedWarrantsDetails", "lang": "en-us", { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } }, "auth_ref": "us_gaap_SaleOfStockNumberofSharesIssuedInTransaction", { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberofSharesIssuedInTransaction", "presentation": "http://www.replimune.com/role/StockholdersequityEquityofferingsDetails", "lang": "en-us", { "role": { "terseLabel": "Number of shares issued (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } }, "auth_ref": "us_gaap_SaleOfStockPricePerShare", { "xbrltype": "PerShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": "http://www.replimune.com/role/StockholdersequityEquityofferingsDetails", "lang": "en-us", { "role": { "terseLabel": "Price per share (in USD per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } }, "auth_ref": "us_gaap_ScheduleOfAccruedLiabilitiesTableTextBlock", { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": "http://www.replimune.com/role/AccruedexpensesandothercurrentliabilitiesTables", "lang": "en-us", { "role": { "terseLabel": "Schedule of accrued expenses and other current liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } }, "auth_ref": "us_gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": "http://www.replimune.com/role/NetlosspershareComputationofdilutednetlosspershareattributabletocommonstockholdersDetails", "lang": "en-us", { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } }, "auth_ref": "us_gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTableTextBlock", { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTableTextBlock", "presentation": "http://www.replimune.com/role/NetlosspershareTables", "lang": "en-us", { "role": { "terseLabel": "Schedule of anti-dilutive securities excluded from the computation of diluted net loss per share attributable to common shareholders", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } }, "auth_ref": "us_gaap_ScheduleOfAvailableForSaleSecuritiesLineItems", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": "http://www.replimune.com/role/ShortterminvestmentsDetails", "lang": "en-us", { "role": { "terseLabel": "Short-term investments", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } }, "auth_ref": "r201","r202","r203","r204","r205","r206","r207","r208","r209","r210","r211","r212"} }, "us_gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": "http://www.replimune.com/role/CollaborationandotherarrangementsDetails", "http://www.replimune.com/role/SignificantagreementsDetails", "lang": "en-us", { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } }, "auth_ref": "r387"} }, "us_gaap_ScheduleOfDebtInstrumentsTableTextBlock", { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTableTextBlock", "presentation": "http://www.replimune.com/role/DebtTables", "lang": "en-us", { "role": { "terseLabel": "Schedule of long-term debt", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-term debt instruments or arrangements; including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } }, "auth_ref": "r13","r32","r33","r42","r83","r84","r684","r686","r843","r927"} }, "us_gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": "http://www.replimune.com/role/NetlosspershareTables", "lang": "en-us", { "role": { "terseLabel": "Schedule of calculation of basic and diluted net loss per share attributable to common stockholders", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } }, "auth_ref": "r849"} }, "us_gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": "http://www.replimune.com/role/StockbasedcompensationClassificationofexpenseDetails", "lang": "en-us", { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } }, "auth_ref": "r36"} }, "us_gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock", { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock", "presentation": "http://www.replimune.com/role/StockbasedcompensationTables", "lang": "en-us", { "role": { "terseLabel": "Schedule of stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } }, "auth_ref": "r36"} }, "us_gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": "http://www.replimune.com/role/DebtTables", "lang": "en-us", { "role": { "terseLabel": "Schedule of maturities of long-term debt", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } }, "auth_ref": "r7"} }, "us_gaap_ScheduleOfPropertyPlantAndEquipmentTable", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": "http://www.replimune.com/role/PropertyplantandequipmentnetDetails", "lang": "en-us", { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } }, "auth_ref": "r6","r456"} }, "us_gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": "http://www.replimune.com/role/GeographicinformationDetails", "lang": "en-us", { "role": { "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset." } }, "auth_ref": "r28","r62"} }, "us_gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": "http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails", "http://www.replimune.com/role/StockbasedcompensationAssumptionsfordetermininggrantdatefairvalueofstockoptionsDetails", "http://www.replimune.com/role/StockbasedcompensationSummaryofRSUdetails", "lang": "en-us", { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } }, "auth_ref": "r326","r328","r330","r331","r332","r333","r334","r335","r336","r337","r338","r339","r340","r341","r342","r343","r344","r345","r346","r347","r348","r349","r350","r351","r352","r353","r354","r355"} }, "us_gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": "http://www.replimune.com/role/StockbasedcompensationTables", "lang": "en-us", { "role": { "terseLabel": "Schedule of of stock option activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end-of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } }, "auth_ref": "r10","r11","r86"} }, "us_gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", { "xbrltype": "textBlockItemType", "nsuri": "

are presented." } } }, "auth_ref": { "r9" } }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredDebtMember", "presentation": { "http://www.replimune.com/role/DebtScheduleofMaturityofDebtDetails": { "lang": { "en-us": { "role": { "terseLabel": "Secured Debt", "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": { } }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": { "http://www.replimune.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": { "r735" } }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": { "http://www.replimune.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": { "r737" } }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": { "http://www.replimune.com/role/GeographicalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": { "r198", "r199", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r576", "r579", "r580", "r637", "r639", "r642", "r644", "r654", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r668", "r689", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r723", "r726", "r885", "r942", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970" } } }, "us-gaap_SegmentsGeographicalAreasAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentsGeographicalAreasAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segments, Geographical Areas [Abstract]", "label": "Segments, Geographical Areas [Abstract]" } } }, "auth_ref": { } }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "order": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": { "r4" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": { "http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Share-based payment award vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": { "r694" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": { "http://www.replimune.com/role/StockbasedcompensationSummaryofRSUActivityDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Cancelled (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": { "r346" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": { "http://www.replimune.com/role/StockbasedcompensationSummaryofRSUActivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cancelled (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": { "r346" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": { "http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Stock unit grant (in shares)", "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": { "r344" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": { "http://www.replimune.com/role/StockbasedcompensationSummaryofRSUActivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": { "r344" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": { "http://www.replimune.com/role/StockbasedcompensationSummaryofRSUActivityDetails": { "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding as of March 31, 2021 (in shares)", "periodEndLabel": "Outstanding as of June 30, 2021 (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": { "r341", "r342" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": { "http://www.replimune.com/role/StockbasedcompensationSummaryofRSUActivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Number of Restricted Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": { "http://www.replimune.com/role/StockbasedcompensationSummaryofRSUActivityDetails": { "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding as of March 31, 2021 (in dollars per share)", "periodEndLabel": "Outstanding as of June 30, 2021 (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": { "r341", "r342" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": { "http://www.replimune.com/role/StockbasedcompensationSummaryofRSUActivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value [Abstract]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": { } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": { "http://www.replimune.com/role/StockbasedcompensationSummaryofRSUActivityDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": { "r345" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": { "http://www.replimune.com/role/StockbasedcompensationSummaryofRSUActivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": { "r345" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": { "http://www.replimune.com/role/StockbasedcompensationAssumptionstodeterminegrantdatefairvalueofstockoptionsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": { "r353" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": { "http://www.replimune.com/role/StockbasedcompensationAssumptionstodeterminegrantdatefairvalueofstockoptionsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": { } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "presentation": { "http://www.replimune.com/role/StockbasedcompensationAssumptionstodeterminegrantdatefairvalueofstockoptionsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement." } } }, "auth_ref": { "r352" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": { "http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails": { "http://www.replimune.com/role/StockbasedcompensationAssumptionstodeterminegrantdatefairvalueofstockoptionsDetails": { "http://www.replimune.com/role/StockbasedcompensationSummaryofRSUActivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label":

Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items], "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r326", "r328", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": { "http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Additional shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": { } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": { "http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": { "r696" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": { "http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Number of shares available for grant", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments, and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": { "r35" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": { "http://www.replimune.com/role/StockbasedcompensationStockoptionactivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Options exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": { "r335" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": { "http://www.replimune.com/role/StockbasedcompensationStockoptionactivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Options exercisable (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": { "r335" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": { "http://www.replimune.com/role/StockbasedcompensationStockoptionactivityDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Cancelled (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": { "r339" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": { "http://www.replimune.com/role/StockbasedcompensationStockoptionactivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": { "r337" } }, "repl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue", "crdr": "credit", "presentation": { "http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Value of stock options exercised", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Intrinsic Value", "documentation": "The intrinsic value of options granted during the reporting period." } } }, "auth_ref": { } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": { "http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant-date fair value per share of stock options granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": { "r347" } }, "repl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract", "presentation": { "http://www.replimune.com/role/StockbasedcompensationStockoptionactivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value", "label": "Aggregate Intrinsic Value", "documentation": "No definition available." } } }, "auth_ref": { } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": { "http://www.replimune.com/role/StockbasedcompensationStockoptionactivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": { "r35" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": { "http://www.replimune.com/role/StockbasedcompensationStockoptionactivityDetails": { "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of the period (in shares)", "periodEndLabel": "Outstanding at end of the period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": { "r333", "r334" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": { "http://www.replimune.com/role/StockbasedcompensationStockoptionactivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": { "http://www.replimune.com/role/StockbasedcompensationStockoptionactivityDetails": { "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of the period (in dollars per share)", "periodEndLabel": "Outstanding at end of the period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": { "r333", "r334" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": { "http://www.replimune.com/role/StockbasedcompensationStockoptionactivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": { "r350" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": { "http://www.replimune.com/role/StockbasedcompensationStockoptionactivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Options vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": { "r350" } }, "repl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract", "presentation": { "http://www.replimune.com/role/StockbasedcompensationStockoptionactivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Contractual Term (Years)", "label": "Weighted Average Contractual Term (Years)", "documentation": "No definition available." } } }, "auth_ref": { } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": { "http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Share-based payment award percentage of outstanding shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } } }, "auth_ref": { } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain", "presentation": { "http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Contractual Term (Years)", "label": "Weighted Average Contractual Term (

"http://www.replimune.com/role/StockbasedcompensationClassificationOfExpenseDetails",
"http://www.replimune.com/role/StockbasedcompensationSummaryOfRSUActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Equity Award [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": { "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrlType": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": { "http://www.replimune.com/role/StockbasedcompensationStockoptionactivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": { "r338" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrlType": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": { "http://www.replimune.com/role/StockbasedcompensationStockoptionactivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Cancelled (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": { "r339" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrlType": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": { "http://www.replimune.com/role/StockbasedcompensationStockoptionactivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": { "r337" } }, "repl_ShareBasedPaymentAwardExpirationPeriodForPersonsHoldingMoreThanTenPercentOfVotingPower": { "xbrlType": "durationItem", "nsuri": "http://www.replimune.com/20240630", "localname": "ShareBasedPaymentAwardExpirationPeriodForPersonsHoldingMoreThanTenPercentOfVotingPower", "presentation": { "http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Expiration period for persons holding more than ten percent of voting power", "label": "Share Based Payment Award Expiration Period for Persons Holding More Than Ten Percent of Voting Power", "documentation": "Award expiration period for persons possessing more than ten percent of voting power, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { } }, "repl_ShareBasedPaymentAwardExpirationPeriodForPersonsHoldingTenPercentOfVotingPower": { "xbrlType": "durationItem", "nsuri": "http://www.replimune.com/20240630", "localname": "ShareBasedPaymentAwardExpirationPeriodForPersonsHoldingTenPercentOfVotingPower", "presentation": { "http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Expiration period for persons holding ten percent of voting power", "label": "Share Based Payment Award Expiration Period for Persons Holding Ten Percent of Voting Power", "documentation": "Award expiration period for persons possessing ten percent of voting power, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { } }, "us-gaap_SharePrice": { "xbrlType": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": { "http://www.replimune.com/role/StockholdersecuritiesEquityOfferingsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Share price (in dollars per share)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": { } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrlType": "durationItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": { "http://www.replimune.com/role/StockbasedcompensationAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Share-based payment award expiration period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r695" } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrlType": "durationItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": { "http://www.replimune.com/role/StockbasedcompensationAssumptionstodeterminerantdatefairvalueofstockoptionsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Expected term (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r351" } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrlType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": { "http://www.replimune.com/role/StockbasedcompensationStockoptionactivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Options exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": { "r35" } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrlType": "durationItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": { "http://www.replimune.com/role/StockbasedcompensationStockoptionactivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Options exercisable (years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r35" } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrlType": "durationItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": { "http://www.replimune.com/role/StockbasedcompensationStockoptionactivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Outstanding (years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r87" } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrlType": "durationItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": { "http://www.replimune.com/role/StockbasedcompensationStockoptionactivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Options vested and expected to vest (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares", "documentation": "Number of options vested." } } }, "auth_ref": { } }, "us-gaap_SharesOutstanding": { "xbrlType": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": { "http://www.replimune.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" }, "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": { } }, "us-gaap_ShortTermInvestments": { "xbrlType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" }, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" }, "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": { "r95", "r96", "r833" } }, "us-gaap_ShortTermInvestmentsAbstract": { "xbrlType": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestmentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Short-term Investments [Abstract]", "label": "Short-Term Investments [Abstract]" } } }, "auth_ref": { } }, "us-gaap_ShortTermInvestmentsMember": { "xbrlType": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestmentsMember", "presentation": { "http://www.replimune.com/role/ShortterminvestmentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term Investments [Member]", "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet." } } }, "auth_ref": { "r645", "r646", "r647", "r669" } }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrlType": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": { "http://www.replimune.com/role/Summaryofsignificantaccountingpolicies" }, "lang": { "en-us": { "role": { "terseLabel": "Summary of significant accounting policies", "label": "Significant Accounting Policies [TextBlock]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": { "r75", "r152" } }, "repl_SignificantAgreementsAbstract": { "xbrlType": "stringItem", "nsuri": "http://www.replimune.com/20240630", "localname": "SignificantAgreementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Significant agreements", "label": "Significant agreements", "documentation": "This concept does not have any references." } } }, "auth_ref": { } }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "xbrlType": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "presentation": { "http://www.replimune.com/role/PropertyplantandequipmentnetDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Capitalized software", "label": "Software and Software Development Costs [Member]", "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": { } }, "us-gaap_StatementClassOfStockAxis": { "xbrlType": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": { "http://www.replimune.com/role/PrefundedWarrantsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": { "r117", "r127", "r128", "r129", "r155", "r178", "r179", "r182", "r184", "r191", "r192", "r231", "r260", "r262", "r263", "r264", "r267", "r268", "r300", "r301", "r304", "r307", "r314", "r426", "r559", "r560", "r561", "r562", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r591", "r612", "r631", "r648", "r649", "r650", "r651", "r652", "r821", "r840", "r848" } } }, "us-gaap_StatementEquityComponentsAxis": { "xbrlType": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": { "http://www.replimune.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" }, "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": { "r9", "r55", "r58", "r59", "r118", "r140", "r141", "r142", "r160", "r161", "r162", "r164", "r169", "r171", "r173", "r190", "r232", "r233", "r243", "r316", "r373", "r374", "r380", "r381", "r382", "r384", "r385", "r386", "r395", "r396", "r397", "r398", "r399", "r400", "r403", "r432", "r433", "r434", "r435", "r436", "r437", "r439", "r440", "r458", "r541", "r551", "r552", "r553", "r566", "r631" } } }, "srt_StatementGeographicalAxis": { "xbrlType": "stringItem", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": { "http://www.replimune.com/role/GeographicinformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } } }

```

"auth_ref": {"r198", "r199", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700"}, "us-gaap_StatementLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [{"http://www.replimune.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"}], "lang": {"en-us": {"role": {"terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}}, "auth_ref": {"r160", "r161", "r162", "r190", "r440", "r493", "r558", "r577", "r583", "r584", "r585", "r586", "r587", "r588", "r591", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r604", "r605", "r606", "r607", "r608", "r610", "r613", "r614", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r631", "r627"}, "ecd_StkPrCrfTrsEstimationMethodTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrCrfTrsEstimationMethodTextBlock", "presentation": [{"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"}], "lang": {"en-us": {"role": {"terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]"}}, "auth_ref": {"r744", "r754", "r764", "r796"}}, "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants", "crdr": "credit", "presentation": [{"http://www.replimune.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"}], "lang": {"en-us": {"role": {"terseLabel": "Issuance of prefunded warrants to purchase common stock, net of issuance costs", "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants", "documentation": "Value of preferred stock and warrants for common stock issued."}}}, "auth_ref": [{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}], "lang": {"en-us": {"role": {"terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."}}}, "auth_ref": [{"http://www.replimune.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"}], "lang": {"en-us": {"role": {"terseLabel": "Issuance of common stock, net of issuance costs and underwriter fees (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period."}}}, "auth_ref": {"r9", "r54", "r55", "r85", "r59", "r631", "r649"}}, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [{"http://www.replimune.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"}], "lang": {"en-us": {"role": {"terseLabel": "Vesting of RSUs (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."}}}, "auth_ref": {"r9", "r54", "r55", "r85"}}, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [{"http://www.replimune.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"}], "lang": {"en-us": {"role": {"terseLabel": "Exercise of stock options (in shares)", "label": "Stock Issued During Period, Warrants, New Issues, Value", "documentation": "Value of stock issued as a result of the exercise of stock options."}}}, "auth_ref": {"r9", "r55", "r58", "r59", "r85"}}, "repl_StockIssuedDuringPeriodWarrantsNewIssues": {"xbrltype": "sharesItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "StockIssuedDuringPeriodWarrantsNewIssues", "presentation": [{"http://www.replimune.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"}], "lang": {"en-us": {"role": {"terseLabel": "Exercise of pre-funded warrants (in shares)", "label": "Stock Issued During Period, Warrants, New Issues", "documentation": "Value of stock issued as a result of the exercise of stock options."}}}, "auth_ref": {"r9", "r55", "r58", "r59", "r85"}}, "repl_StockIssuedDuringPeriodWarrantsNewIssuesValue": {"xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "StockIssuedDuringPeriodWarrantsNewIssuesValue", "crdr": "credit", "presentation": [{"http://www.replimune.com/20240630", "localname": "StockIssuedDuringPeriodWarrantsNewIssuesValue", "crdr": "credit", "presentation": [{"http://www.replimune.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"}], "lang": {"en-us": {"role": {"terseLabel": "Exercise of pre-funded warrants", "label": "Stock Issued During Period, Warrants, New Issues, Value", "documentation": "Value of stock issued as a result of the exercise of stock options."}}}, "auth_ref": {"r9", "r55", "r58", "r59", "r85"}}, "repl_StockIssuedDuringPeriodWarrantsNewIssuesValue": {"xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "StockIssuedDuringPeriodWarrantsNewIssuesValue", "crdr": "credit", "presentation": [{"http://www.replimune.com/20240630", "localname": "StockIssuedDuringPeriodWarrantsNewIssuesValue", "crdr": "credit", "presentation": [{"http://www.replimune.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"}], "lang": {"en-us": {"role": {"terseLabel": "Exercise of pre-funded warrants", "label": "Stock Issued During Period, Warrants, New Issues, Value", "documentation": "Value of stock issued as a result of the exercise of stock options."}}}, "auth_ref": {"r9", "r55", "r58", "r59", "r85"}}, "repl_StockIssuedDuringPeriodWarrantsNewIssuesValue": {"xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "StockIssuedDuringPeriodWarrantsNewIssuesValue", "crdr": "credit", "presentation": [{"http://www.replimune.com/20240630", "localname": "StockIssuedDuringPeriodWarrantsNewIssuesValue", "crdr": "credit", "presentation": [{"http://www.replimune.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"}], "lang": {"en-us": {"role": {"terseLabel": "Exercise of pre-funded warrants", "label": "Stock Issued During Period, Warrants, New Issues, Value", "documentation": "Value of stock issued as a result of the exercise of stock options."}}}, "auth_ref": {"r9", "r55", "r58", "r59", "r85"}}, "repl_StockIssuedDuringPeriodWarrantsNewIssuesValue": {"xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "StockIssuedDuringPeriodWarrantsNewIssuesValue", "crdr": "credit", "presentation": [{"http://www.replimune.com/20240630", "localname": "StockIssuedDuringPeriodWarrantsNewIssuesValue", "crdr": "credit", "presentation": [{"http://www.replimune.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"}], "lang": {"en-us": {"role": {"terseLabel": "Exercise of pre-funded warrants", "label": "Stock Issued During Period, Warrants, New Issues, Value", "documentation": "Value of stock issued as a result of the exercise of stock options."}}}, "auth_ref": {"r9", "r55", "r58", "r59", "r85"}}, "repl_StockIssuedDuringPeriodWarrantsNewIssuesValue": {"xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "StockIssuedDuringPeriodWarrantsNewIssuesValue", "crdr": "credit", "presentation": [{"http://www.replimune.com/20240630", "localname": "StockIssuedDuringPeriodWarrantsNewIssuesValue", "crdr": "credit", "presentation": [{"http://www.replimune.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"}], "lang": {"en-us": {"role": {"terseLabel": "Exercise of pre-funded warrants", "label": "Stock Issued During Period, Warrants, New Issues, Value", "documentation": "Value of stock issued as a result of the exercise of stock options."}}}, "auth_ref": {"r9", "r55", "r58", "r59", "r85"}}, "repl_StockIssuedDuringPeriodWarrantsNewIssuesValue": {"xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname": "StockIssuedDuringPeriodWarrantsNewIssuesValue", "crdr": "credit", "presentation": [{"http://www.replimune.com/20240630", "localname": "StockIssuedDuringPeriodWarrantsNewIssuesValue", "crdr": "credit", "presentation":
```

Facility, Tranche One", "label": "Term Loan Facility, Tranche One [Member]", "documentation": "Term Loan Facility, Tranche One" } } }, "auth_ref": {} },
"repl_TermLoanFacilityTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.replimune.com/20240630", "localname":
"TermLoanFacilityTrancheThreeMember", "presentation": { "http://www.replimune.com/role/DebtNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Term Loan
Facility, Tranche Three", "label": "Term Loan Facility, Tranche Three [Member]", "documentation": "Term Loan Facility, Tranche Three" } } }, "auth_ref": {} },
"repl_TermLoanFacilityTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.replimune.com/20240630", "localname":
"TermLoanFacilityTrancheTwoMember", "presentation": { "http://www.replimune.com/role/DebtNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Term Loan
Facility, Tranche Two", "label": "Term Loan Facility, Tranche Two [Member]", "documentation": "Term Loan Facility, Tranche Two" } } }, "auth_ref": {} },
"ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } },
"auth_ref": { "r782" } }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TotalShareholderRtnVsPeerGroupTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder
Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": { "r789" } }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role":
{ "terseLabel": "Trading Arrangement", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": { "r809" } }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": {
"role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": { "r811" } }, "dei_TradingSymbol": {
"xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": { "http://www.replimune.com/role/Cover", "lang":
{ "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } },
"auth_ref": {} }, "us-gaap_TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain", "presentation": {
"http://www.replimune.com/role/FairvalueoffinancialassetsandliabilitiesDetails", "http://www.replimune.com/role/ShortterminvestmentsDetails" }, "lang": { "en-us": { "role": {
"terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to
deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or
another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": { "r201", "r202", "r203", "r204", "r205", "r206",
"r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228",
"r229", "r230", "r294", "r312", "r401", "r425", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r477",
"r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r542", "r700", "r701", "r703", "r704", "r705", "r706", "r707",
"r708", "r709", "r713", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r867", "r868", "r869", "r870", "r917", "r920", "r921", "r922", "r923", "r924" } },
"ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": {
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } },
"auth_ref": { "r812" } }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": {
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }
}, "auth_ref": { "r813" } }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate",
"presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement
Expiration Date" } } }, "auth_ref": { "r813" } }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName",
"presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual
Name" } } }, "auth_ref": { "r811" } }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle",
"presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual
Title" } } }, "auth_ref": { "r811" } }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TrdArrSecuritiesAggAvailAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available",
"label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": { "r814" } }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role":
{ "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": { "r812" } }, "us-gaap_TypeOfArrangementAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": {
"http://www.replimune.com/role/CollaborationandotherarrangementsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other
than Collaborative [Axis]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative
arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": { "r387" } }, "country-US": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": { "http://www.replimune.com/role/GeographicinformationDetails" }, "lang": {
"en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": {} }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": {
"http://www.replimune.com/role/FairvalueoffinancialassetsandliabilitiesDetails", "http://www.replimune.com/role/ShortterminvestmentsDetails" }, "lang": { "en-us": { "role": {
"terseLabel": "US Government Agency bonds", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities
issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA) or Ginnie Mae). Excludes US treasury securities and
debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal
National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": { "r675", "r690", "r940" } }, "us-
gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": {
"http://www.replimune.com/role/FairvalueoffinancialassetsandliabilitiesDetails", "http://www.replimune.com/role/ShortterminvestmentsDetails" }, "lang": { "en-us": { "role": {
"terseLabel": "US Treasury bonds", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the
United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or
less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": { "r675", "r690",
"r692", "r700", "r940" } }, "repl_UnamortizedDeferredFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.replimune.com/20240630", "localname":
"UnamortizedDeferredFinancingCosts", "crdr": "debit", "presentation": { "http://www.replimune.com/role/DebtNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel":
"Unamortized deferred financing costs", "label": "Unamortized Deferred Financing Costs", "documentation": "Unamortized Deferred Financing Costs" } } }, "auth_ref": {} },
"repl_UnauditedInterimConsolidatedFinancialInformationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.replimune.com/20240630", "localname":
"UnauditedInterimConsolidatedFinancialInformationPolicyTextBlock", "presentation": { "http://www.replimune.com/role/SummaryofsignificantaccountingpoliciesPolicies" },
"lang": { "en-us": { "role": { "terseLabel": "Unaudited interim financial information", "label": "Unaudited Interim Consolidated Financial Information [Policy Text Block]",
"documentation": "Disclosure of accounting policy pertaining to unaudited consolidated financial information." } } }, "auth_ref": {} }, "ecd_UndrlygSecurityMktPriceChngPct":
{ "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security
Market Price Change, Percent" } } }, "auth_ref": { "r808" } }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "UseOfEstimates", "presentation": { "http://www.replimune.com/role/SummaryofsignificantaccountingpoliciesPolicies" }, "lang": { "en-us": { "role": {
"terseLabel": "Use of estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the
preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": { "r25", "r26", "r27", "r106", "r108", "r110", "r111" } },
"ecd_VstngDfFrValOfEqtyAwrdGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"VstngDfFrValOfEqtyAwrdGrntdAndVstdInCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Vesting
Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }
}, "auth_ref": { "r778" } }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember",
"presentation": { "http://www.replimune.com/role/NetlosspershareComputationofDilutedNetLosspershareattributabletoCommonstockholdersDetails" }, "lang": { "en-us": {
"role": { "terseLabel": "Warrants to purchase common stock", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of
stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": { "r724", "r725", "r728", "r729", "r730", "r731" } }, "us-
gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
"http://www.replimune.com/role/NetlosspershareComputationofNetLossperShareDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares
outstanding, diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and
outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref":
{ "r177", "r184" } }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": { "http://www.replimune.com/role/NetlosspershareComputationofNetLossperShareDetails" }, "lang":
{ "en-us": { "role": { "terseLabel": "Denominator", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": {} }, "us-
gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesOutstandingBasic", "presentation": { "http://www.replimune.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
"http://www.replimune.com/role/NetlosspershareComputationofNetLossperShareDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares
outstanding, basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for
contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common
shares or units have been outstanding to the total time in that period." } } }, "auth_ref": { "r175", "r184" } },
"ecd_YrEndFrValOfEqtyAwrdGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"YrEndFrValOfEqtyAwrdGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel":
"Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year
that are Outstanding and Unvested [Member]" } } }, "auth_ref": { "r776" } } }, "std_ref": { "r0", "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-
45-1", "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10",
"Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "14", "SubParagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-14", "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20", "r4": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "SubParagraph": "(a)", "SubTopic": "10",
"Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "28", "SubParagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1", "r7": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1", "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1A", "SubParagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481203/810-10-50-1A", "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2", "r10": { "role":

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

50-7",{"r933":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "860","SubTopic": "20","Name": "Accounting Standards Codification","Section": "50","Paragraph": "3","Subparagraph": "(c)(1)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"}, "r934":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "860","SubTopic": "20","Name": "Accounting Standards Codification","Section": "50","Paragraph": "3","Subparagraph": "(c)(2)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"}, "r935":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "860","SubTopic": "20","Name": "Accounting Standards Codification","Section": "50","Paragraph": "3","Subparagraph": "(c)(3)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"}, "r936":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "860","SubTopic": "20","Name": "Accounting Standards Codification","Section": "50","Paragraph": "4","Subparagraph": "(b)(1)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"}, "r937":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "860","SubTopic": "20","Name": "Accounting Standards Codification","Section": "50","Paragraph": "4","Subparagraph": "(b)(2)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"}, "r938":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "860","SubTopic": "20","Name": "Accounting Standards Codification","Section": "50","Paragraph": "4","Subparagraph": "(b)(3)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"}, "r939":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "912","SubTopic": "730","Name": "Accounting Standards Codification","Section": "25","Paragraph": "1","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"}, "r940":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "942","SubTopic": "320","Name": "Accounting Standards Codification","Section": "50","Paragraph": "2","Subparagraph": "(b)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"}, "r941":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "210","Name": "Accounting Standards Codification","Section": "50","Paragraph": "1","Subparagraph": "(a)(16)(a)(2)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147477877/944-210-50-1"}, "r942":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "30","Name": "Accounting Standards Codification","Section": "50","Paragraph": "2B","Subparagraph": "(a)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"}, "r943":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "310","Name": "Accounting Standards Codification","Section": "50","Paragraph": "3","Subparagraph": "(a)(3)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"}, "r944":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "40","Name": "Accounting Standards Codification","Section": "50","Paragraph": "4B","Subparagraph": "(a)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"}, "r945":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "40","Name": "Accounting Standards Codification","Section": "50","Paragraph": "4B","Subparagraph": "(b)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"}, "r946":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "40","Name": "Accounting Standards Codification","Section": "50","Paragraph": "4B","Subparagraph": "(a)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"}, "r947":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "40","Name": "Accounting Standards Codification","Section": "50","Paragraph": "4G","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"}, "r948":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "40","Name": "Accounting Standards Codification","Section": "50","Paragraph": "5","Subparagraph": "(a)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"}, "r949":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "40","Name": "Accounting Standards Codification","Section": "50","Paragraph": "5","Subparagraph": "(b)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"}, "r950":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "40","Name": "Accounting Standards Codification","Section": "50","Paragraph": "5","Subparagraph": "(c)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"}, "r951":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "40","Name": "Accounting Standards Codification","Section": "50","Paragraph": "5","Subparagraph": "(d)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"}, "r952":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "40","Name": "Accounting Standards Codification","Section": "50","Paragraph": "6","Subparagraph": "(a)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"}, "r953":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "40","Name": "Accounting Standards Codification","Section": "50","Paragraph": "6","Subparagraph": "(b)(1)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"}, "r954":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "40","Name": "Accounting Standards Codification","Section": "50","Paragraph": "6","Subparagraph": "(b)(2)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"}, "r955":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "40","Name": "Accounting Standards Codification","Section": "50","Paragraph": "6","Subparagraph": "(b)(3)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"}, "r956":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "40","Name": "Accounting Standards Codification","Section": "50","Paragraph": "6","Subparagraph": "(b)(4)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"}, "r957":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "40","Name": "Accounting Standards Codification","Section": "50","Paragraph": "6","Subparagraph": "(b)(5)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"}, "r958":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "40","Name": "Accounting Standards Codification","Section": "50","Paragraph": "6","Subparagraph": "(b)(6)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"}, "r959":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "40","Name": "Accounting Standards Codification","Section": "50","Paragraph": "6","Subparagraph": "(c)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"}, "r960":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "40","Name": "Accounting Standards Codification","Section": "50","Paragraph": "7A","Subparagraph": "(a)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"}, "r961":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "40","Name": "Accounting Standards Codification","Section": "50","Paragraph": "7A","Subparagraph": "(b)(1)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"}, "r962":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "40","Name": "Accounting Standards Codification","Section": "50","Paragraph": "7A","Subparagraph": "(b)(2)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"}, "r963":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "40","Name": "Accounting Standards Codification","Section": "50","Paragraph": "7A","Subparagraph": "(b)(3)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"}, "r964":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "40","Name": "Accounting Standards Codification","Section": "50","Paragraph": "7A","Subparagraph": "(c)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"}, "r965":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "40","Name": "Accounting Standards Codification","Section": "50","Paragraph": "7A","Subparagraph": "(d)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"}, "r966":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "40","Name": "Accounting Standards Codification","Section": "50","Paragraph": "7B","Subparagraph": "(a)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"}, "r967":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "40","Name": "Accounting Standards Codification","Section": "50","Paragraph": "7B","Subparagraph": "(b)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"}, "r968":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "40","Name": "Accounting Standards Codification","Section": "50","Paragraph": "7B","Subparagraph": "(c)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"}, "r969":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "80","Name": "Accounting Standards Codification","Section": "50","Paragraph": "2","Subparagraph": "(b)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"}, "r970":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "80","Name": "Accounting Standards Codification","Section": "50","Paragraph": "2","Subparagraph": "(c)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"}, "r971":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "946","SubTopic": "205","Name": "Accounting Standards Codification","Section": "45","Paragraph": "4","Subparagraph": "(a)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"}, "r972":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "946","SubTopic": "210","Name": "Accounting Standards Codification","Section": "50","Paragraph": "1","Subparagraph": "(SX 210-6-04(18))","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147479170/946-210-50-1"}, "r973":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "946","SubTopic": "220","Name": "Accounting Standards Codification","Section": "50","Paragraph": "3","Subparagraph": "(SX 210-6-09(4)(b))","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147479134/946-220-50-3"}, "r974":{,"role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "946","SubTopic": "220","Name": "Accounting Standards Codification","Section": "50","Paragraph": "3","Subparagraph": "(SX 210-6-09(7))","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147479134/946-220-50-3"} } ZIP 86 0001737953-24-000013-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001737953-24-000013-xbrl.zip M4L#100 (,Y-%EZ=E1FLFX!) X-1 91ZJG.S2Q=X.FK93MZ0%LE?TJHLS.^V5/(B5& MTF&6&; 151&KB*~P 2F1?69<-NB2&?>(C.LO-=I\$B0U ILS_WU+>J% M4\$!N)J9GV< I-KW I=I. R2IO !+V/7J8K4.W77FCB<#<#)41I.k7Y MBY5RZOT2K7W>U&K6GT-Z2IMG2M85F!M/H=-A!R!L M&7;M!P>-AK91^&HLO7H!-WB!>[YSX?D07V57L5V>X2^L0<S!LD!+M@6TH546KJEHE?<@>9-G3YTR? H2E^XTOFY?32P%YXWYN>7^E~9^?<[KF@ Y) M?U>#D+&F73>ZBIK7X!<(%R=Z>QZX% M=3JRV4X70%E7/01CM21566E=35Y MSCBH0A RFCZG3X<6V(CQ)>+W^&YOZ? M2FVU6E-8MAFE%6K73-P)?+&S3IR-G MX9^X M379+<(+&[!6L4@UZSS^J)NNGO(MLF%MNV7G;J7IRX 2J-W+D(9\$PENK!<Q-?HKY-?D)W>LJ7LRWZ5J&6BTF%K MEAV,#+Y=&V7P@+L!TJNDK!K!9E49?I.M?<@=SQ;3-Z_WOX2/N_5LPJ4+Q+ MAO@D:E>N^?ZR16LSB7.K6O!J^BDXID-!TJUJQE: SOS=-7U?7JXL#7# M2SH@_BP4@=!(C)N!%<[HXB3T-V?>S7V77RJ9C\$2^M.M'32A">J.A9+&WNRM446 !K21+&W!O!<@FF;VA5VH#5>EXO<#+ M/60A<#<~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f<@<(D)Z^M0%WKN<?<3^E M-C2=<?<Z%>2T;8;4ZKC6-7!GC(DKBGD9C<@<N79Q;5E7A-DY;@<SDRO@1CCW-MDE6 EQF2V1?>3B-1 NHX,K^PTA^<J);MVP\$SFFZ4P^>XO!N18SME=Y#8-D MACM)<8;A!L6^<V!>P4!<2D!V!GA0^>V?2F!<WZ78F!V5 M^9)<GR;K;5>D!B-F4+Y!T5ZAW+14 M^<G2-5C5X<K K(!A!H^VP802Y?N!0CMX!F^Y04;1&R!>66>X@Y X@2^6 M%<@<+Z!>VPR^<4K_C.IYKQ6%FPJ !LQ2UA<@>U!9^&=MU12<@<35-5C5OW M-LHA07?> C!>IS_-+X.P.MD\$<?>.K'98<^GB^Z>M\$!>+IW+KD4 M!S!<DZ?>F6;3/(PTH3K;K QF^MNVDP!M\$W!>J7%&+<^>@<8R!>J6!<3J5CZ ML%MA!>?J4RX<+&-. !>=PAJN!J5EIO+NDCW<+&@>#3LIG.C<XYTWXELJG!>M?>4&J7B6;3^M^YCI!MP@YE3!0RW@84ES^OZ!29G5SP#!>!!2ZQ=>I>_GAT M4;9K!5Q!H? M!HT#L\$5Q!<T!>+<0T>?>2^E^ZU<@<M?>T!>+<+>VZ!8VXH?>5B1Y+>3=0Z4=RCQNU^>GEJ.KLEQCFWDB8U!<@<JFV4!K!<N-MXBQ^>B!>^J!P-MQL3!<UL9&1GM99^<P_L^<H!GK6F.3Y4!>=HQTQJ.997 6BA4QV^>3^<UW9<2^<V8!V78W^>=ZBZYW^>BBDGYF^>J!A+O^<I!ERUVD M.WKKPKQ<?<OP2FR&M-A!<IS0 M-UY89^,23!>B!>R!>H7F!>G!>SW8 M!\$6G!> !>AD=>A^!<12DM\$B\$>@<S!>Q/>6%<H!>9);<@<K^S<YQ+OC.@<NE, MU9Y\$56#<I>G>I!>H!>UK\$01=Y\$>D7W6+D!>FW8E^HJCR>#1 5\$78;5Y\$>2>S!B MZ\$<CNXC<0<0 <7<=>=9&1<Z/!VK0BTRV5LXL30S8!VN8LL4-Z04^M!<J6VQ!<5U&Z^YH;3-@<D^>PA<=<3^PG07!RE-27^G!>Q#0<@<PAYU@M^A MD^X!<IS64\$R5-[CS!DZ>D0JVR9WG?B^<CX+<J!>4+>M;R<M<@<G!<BL7?_MJ_P!<=<5NUC)JNU!<TV5FD-1YHJ2!<EM7K-XU>XW^1MY?Fw!>S>@<f!>J+<UW!>UJ!>40 MQWYQ!<+!<F!>H CI+ [ZAY_FPN^<4)9910<=37Y=<CHRR 0<@<VW+70U?GS/M-T!>O>(G?P5A>V9!<+VONKCFY.X8MF742?>(\$<ORMY<4PU?<T^U7U8_<S4O M6DKZ5J?>RCL_P!>H)U<^<I^>887= QM!<U:U?>T2M+>XU7#U=<EC=&6%*>R-MB&79!NE(JGPF.O=71C>P!>V9/L+>P+!>N%>_<1+Y>8>D?<E_>QW^W1S+76?

[illegible]

[illegible]

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

[illegible]

2025-01-10 10:10:10

[illegible]

3KBW>F>PIN>0FOH1211K1V9C.79.10*IXY.4GUA=JX>RAYOK&LQ>HL.M71+7L=>5%>V7.1+0P.1\$Q1.Z1SP1F3.6%7B2G2\$23HV536%>△△.M2?>7@H+IU01./2
SJTQ.52@>7Q2).&XIUU.1C<S<.X>Y.M7L1N.72.3%.H#C%3B.VVY1U.1/."ZY4<+13.M9D.J93<1N<=E8X<+&1166B.T6D<4\$VD.TMU<1U6U+1T4H4F9>0.51MY&5ZGHUXD28X<+
TE.FE.45J0@WPBWJ1<+PMP-10.A3?7D3B*5E.MU2-HZ@J7MD.2\$E.W2.H3.RXWQ<+&11&8X.67X1J6N.>@0S20.45+5.XG(V@+1X0+Q&M.K5R@S.SEE1[s2E96
T.R-11\$8M%W3.100IQ&XW<C/KLUPA.A?F1H0<+1)MVT86G.58L0S9E9HW@F.TU&S.KX<OUF+>=ID"4ZQZF\$7WB>1\$1TUQ0<+&M.Y1YD.WZQ>+1.86F=97.(U@<WR>2M.
67WWH>M7>J\$K5XUBJXN#5N0X<@MIQ&8A0#JZPV.P2%M4.06\$VE(B<@B9>9#Q<+>UJ&KQZ1P%IR@H(G/VV1+1M\$>174Q0Q0.W.VY41H1XIV/H.P.9.1
48R1/IS1&HW71.XBIP1FDV&KAMA.MHFEZ.S2QD>#EDV#1V8#.TH<+P1WE\$XB@1>MFO.81X<RD.9PQ00P+BJ#P.MU+1TYIKN1P8PA<PBDJ/SA<X?P/W.OV51<+
7@A9@&SH8M.VCL1H?M&+J09"8X>N>V17.4YD\$K1JP<."DZ3IGEDIR9&1BA2.&A<+BYDV5L.H+X&B212X%SA%XR&PM5F5FYQ6>=)<5>
LH89X<41>H9DRP.CE2.1\$SYRBYBTR.>4Q18D16R617M.E&H.<+DME>E2.B1&E7W4>9HEZDPBPQB1LSTG3<+1@AY#>BL<P>.<Q0.M8Q.H&3.HH335
>1EG<+F71H1WZ71RH(HN1.2-J\$9.XQA8<05SPHTL#1-5>)>N16<RLH14ZPHYB2.79H.A0.X6X0S<67QJOFGH.NIB<CT84L21.M.8170751?M4T4>2.2.LIYU1?KPYO@&Z2X12F2
9.1&IG<(NHD1UE9#>E.PP.MQT3<@<FBV71Z40<N0V\$X4L1?<61HNNM&=R<O<+012?E?<#O08'6L\$A=8-M8#>S.ZAIK1TKOC".W.\$G\$N<N>.<XDTF2>+<Y
ISQ6<="Y"PAR2<7Z"0A5M4.M7FAD50.F&X4VX%6<M-S>QJY>GR9R'GWNTZVWGI.ZM\$1X1%.CK0K'MU6'7..MO=>7ZQ.92%STECMY(8N+6%FZ17?<+1?<1?<1?
K2<5Y2Q7A<F4H1K1Y<WIN2G.<?<M8H.H.G<GL<1%>%.<?<O.<+IDJ9J474<@<RN3X91AV.UB+3400.M.EH\$Y\$>M2Y1@I#M&K#S6<A.<B.FX@<+
/AM>ZXR71WM71+R.1>N#>0/E<1C8M%QYOW.MGV3=10<+JF<+T+1\$ZCG452VG90D210MMW"R6.<G<?<MYMTV52KDP1V8+>M.TO&R7B9.CR..TA&JVQ6?
X=>09>AF<S<QST50081HEH1#>@MJV1.39#>ALE560&C.H<?<F(18-E)&YWL1264R1ARIS<M.LL1R723P23M8E1200TRZV+61<+1?<FOPC.7F2ISRDLWEJHR<+J0\$>943?M.<?<1
ID=>14.59WH.70Z.HZL1BE8BN57>470&6%7UY<141C6G71YU>H3A1JLH8.M05.7X0.<P>M&B5V<CQ1>R8Y2D00CH1QOUVY40K1P.DQ61=5.5.MT.RFZ=>+?<M7B.YK<?
G4<?<0.8B729.2.91@ORAWPT<@<R8.<#>M&B79>B4V&H7<XVY5M#<S>Z<K&H.M6.CQ@82B1&S<G%>AAQOE03<@<A1+Z1QV5XKOG013-
3N<JOYWA?<F921J&1F1CJW@<1@<MLOYS.41Z.6.MA\$0%<EH22C<S<C2.<1>U&X(Z&F.S<E74V>QUG3.H1+KKNHJ5Q10A<=<#5>-W.MS2#EE3KX'DQ05070/AG6.*9B?<F9D)<+<1Q
<+1?<TK=Q1.P1R<Q1@AU<5"V">?<ZQ?FF7AVJXVYMLX\$7N1<S<R<1<=<XJAZ(8F-Z#2?>=C4L1G/6<G&C&KEY.ND301L.OZU.4.G.M2&S+1VR@82M.A037.HH
G.R7P>Y&V<BLUO2W81GGZRK<SK9.E.F4ZTU1M.<M1(E@<+1/00P%<M1?<61\$95A.<A.T81A1?QE%<R7R.<#<1.TXQZ<32@<1N2A12.RMDKO7.M/\$A%<X%01H"1#>3>.>S'US?<
<6>+Q1<6J3>M.YWY5E<138HUS1<3J7B9?4FJ\$>2.LDORRK&2V6B3Z.XTTRC61Q4.DEX<S2KJ.MU1.J2C1G<CMM3.Q1Y6Q1?>?>V%15=GNJ<XRO?>1JWM060H91R.<S1.81M<D<1
G.YB1V0<S'05%<QN08674..8C.<2UGS43Q.<+D4MV8N1%<=<85E\$?>M&MXM5V+6+8=OU&C.PG<RF/O..G1V<S<KHA>1&F&K<Y<G14QD.1>0K.VUE1R.M1>L2C.<U<XHF6V1.O>=<+3-
256Z1F1D>05%<3EJ01?<6F216M9ZM?<M#1@<N.MI21#<P#<=<?<UL14<B0?<BS'DMHC<QJNUS1QJ0L>LNN?<D.HU.MTYWJG3M9>W>1X1X<@IPJ0<4A<QV0<AXY5?<T=E?<T
9N&ZF1D120C1M147=>@<19R456RU1.#>SW/HWD<YQ@T4413>ZNA<VWH1@5@<15Q?<D14S.M+>ZADQYV?<=<54OF?<2P1@<ZLXPK<XWC<OSSHS1RN.RWSC3R1A7.3KX.G-
M.XP861K-K0A1<1&#<V&3<Z.64L.O1@<D4P43TGV61.G<+417WYZ8.E1D1H12HFY.O1P1U7.GN&8H4U10<G/B+V56N7R403QHL.N1Q.MD1=Q0.8GZ4<M&HQ0?
E1D.Q1J1VY51=<X+1BK6<3.64L.O1@<U3H1C?<?C?P.MP<#>SH1G..18RU<=<1D1P1H1R1P1&PF<@<G#10R919.G%<3.11?<2.QB<=<D62.MJC<4XABO>V1.#2
Y.O1@<82.&FNOR81D1V?<P>=<X+>S'WQ4.N6L1F.<+BOE.M&C.R81D<QU=8.1&5G3<1H27F1M1+1E1E.H.YB=<6%<7F4?>..9YTJZD8<1A?<TQ@<H9?<1P?<T/..%<67MU+1&X
M13LHS21D1E4.T2.<11N8>JLW7SYX13..FN2=>=<Q..5Q..<Y<6S+3WR(SA.MKP.7AZ.8(E)<5Q\$4.91AXX1H<DMRW1<+TD+R1>U16"61%<OWK1<+7Q>+<1
MT+<1N8>#M.UAK\$O.A1.21H7MCLQ1N?<?<71S.KPVWQVW??<7KW1FKVH11.MKQ1@E=<X@0WR+1V"BS>+."1BL<A.6NDMKF722U8H9">#<ZTDMZN=LY<+?<M&K1.9Y<+?<1
R+<YUJQOK1VP101EUC853153.4V4DNE.N51F6Y<@5A.FE.U.M1+>9AUZ2FHAP?<12W&A.HH13+<12K51J1P.87QM.5BVYF+XU0U(41L.MV4S<@<RQ.NH.RS1N1L7F0?<1X'D<+
=<Y3Z>+<R2S<C1?<X%<4FAS8<00Q&A.MP2E6=<165VU719..1+63+WS.VO51B?>MJOH'A..801+50S'WS5#51WR5&Z.MVK1.3BL<+1P?<PF7H6W?<
S2?<2.7<8%<KLT.L5L<C<09Y&6<=KTE<1H/T.M.J&A.<+<U6U<6Q<+P88R9FC=<A+>79.S<51P4A<=<6>2?<OXIMS>?<YVQ<ON>M+H=<B2G>H71>0%9?<#D14T>=<
<S10>+<X.F>?<6548101GRVY&J17=<M.FH<1K<R2&N.W126H.WX1W4.92RKFWPQ\$1275+SHADP>=<S+<

AINY@JIN#O-Y#MV#27FP-TO:ANZ:1233?7:5HJ+IB#02#ZEMJ9FXQ0A7-Y-@T4+IH.MLB:1)1-C-@INB#211P2?7X-5?>L-#BSSO-@%1%D10#BLMT2:~+=M&#+=M+V.UVA+30D.48%&Z=ICQ-9G-@QM-1@8IC4W5#<18-R.AHA#>?T<MHJ@+UPWRGAA-@%S8&R.ITI?Z3&G#2:6K193V@-C:D5BU@-C-IVGEUDY\$B+V+BVJ8D#~XW-~MVL+70/L#SKQ84-WYPP+H#ME/L#<+53R>9G3F-NI<12-L65:ZL5-M72@1#E#S)LX-U#N4WP8;1B-#BRUSG70XTXQ4-P,0;Z&~#FF1M@%VZA.S#<#P1DU-@%BSO-(WGC7P9TE&F#4ORXZ51-M0/MI#JR3>+4:CS0S;=D/DP>6?/C-MVH<P:P.O%L#~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~*U@=A7A>2GRU>=5Y4+M7Q13P1V90CXP14V1914? 2*F6E6N=1W<1RC&S&ZCNZP.(3HA5BW&M=C(G#>DA9MA6(C6C5858B)~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~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

```

8U>_PAS_IYRS71XT?>@C(K0>Q V0&V0-80+H5-BSBFB;_M6@:#?Y6F##+5V1=0*5J7E*^A/H,2J<-6W-M#R-4,9P4UQK0Y@R-19?FISRH?K%)
>>LMJ-N@>X>1&X<1&STK75HF<^CUIV MA -KH,K5;7J;U8FIEY<K>J<7^Q MT0E$J;1WZ?;ELND>_B1^>DRBZEWY^4WID,4+BJED9#_70)B<^Q16123 M0<-%+21B"-FI28
Y>>Y50S>DSBHIF?SHK7?>DQ-0IMYM-M#(H41#F;E#;P#%U79?>ZIO9S>2C1VZ?Q>K-S M^U/A?B$J/>0<16XGQOTWK#6;S<C^PZ02BH-
41<P>^"F1YIRJIMJ9D9RNTKU<_>IV?T?>EYV<^H28I@>Z44EMNN1*EBT8-Q1<_>GBXZV-M>S7PWAPUJ13GHW7IMWW8?KW0A,KS<9%W>X^BFC8N+CYWYU1?&F/2QG3$
M#682U(0K1#VZ,C<X<X<3URXMKY?>34DCKQRTM_Z@H1<_>W0?M-YB,1H<_>#86_4G73YTIU<S<4546G<_
0<6XM38*WJGW>#1X95;&U0JZ5(79+CR4401.&V4#/5K1/?Z^GHWYZG,C">#ZW1H M&S1=$,CWKJ?>Y,FK1%>1%>5X^0>D+1M%Q12)241>XZ?>W-W>?JME8
MKR&U1XN55.Y0B45U(C(1^>K^+6Z-10)>2W/6JLEHS,8%$U/8PY<+1M2XAB85>N1<=>1%>P6*>RP21,1R10$@IMHQ(U@V0U;ZR2$>55V7-MKXF*
63*6AK<VY#X4B1Q0@>@21@<=>C@C@N&P4/H9L;IC31%P1FFH4<_MU1X?P6>0%>M26S1X<=>N&MCFE-21Q/>S<18@62#_?5F<V#>18FK*6G MK=0N
=,4.8%<E8L6K_.XZFK1B0>+>^2_5H>_B0%28C1T1+2NPX2$0%>6U1U<_MM<+1?U0="9">6R%,C>P->->OO_8(29IMRJH=?XGM8^S1#>$BE%JY^M9
M1,01<=>#FD,F1^SXJ<^>UGXG#HF+124+5B(H^R+@1^1^PT&D@L@<_T6->MUOQ%1HRS1#61S#DB
U$0@>9P^FEH^U,EY^0IV<_>2(3Z?1TIGY6H,Q9F8BB-A?568L1?>F>XW1>5.78H,4G0KCGZ?XAG1$SGRL;_M-16^>R4+JU0U@+WN18^>T516CX311<^9MAW-F9YEX5#19;A9JZK32
M#72,/@>3JP1<0A6RZ02&K%>T^T0T5U8CMMWF1(0>Z$EG&E^4T^W>+1F,S@<MNR%#1:1T3^E127TFOXZL0%>U1)HBJOE4PEIFH7XZBMB,,,T100T3^BQ$%M_M+7E1
DME<^E^T>C1(HS8I2UY65V%G0V+2_ML6;3-71=1RYR8FF&0>B1=IR=IP1/A18B)1R1^D+1M(S<36F_M@>OV)>_H(H@8I)=0-JYN(Q)2
2&0$IPY<C>F>FG217RAID=0P<0@KX1-O-M^51V>$G<UEYF,"16 BW,,1DLARIY)2-O1OKK1QVY)2:0LBWIG6HJ,1D
MGH_V9P0L<F>?>2141H,LCDT%>S_4Z<=>5L^L4N^>0JMM#W

```

[illegible][illegible]

P/A3%MRJK:HV;:B?L2DHDX?H.C|&KR'#^-%CB^)"YY9('B;\$M#\$J4,%@@B!YE8Dl,DU%ON=!!T#!-IQ?
f"=_S8O:'TYO<#993Y,+^D2D86-M"*<6lND,NN0P\$F10#,TT9!FQ\$QKF=/M%A_SK*YXEC=")S?
C4A^SQ?;\$FI40EUHL;I4^TG;)XS;X5'M-)Xl+ZT/A2Z M\$G<,^!A&\$K%#,\$RRSC/O^2+OU]=7&P?IV-
Z OR" 6^GX 't+Z>P/G*73 MIS*(D)3@(*G0(S!H"S.L; Z4GB/N'3Y#!0l\$@&T#!>?<19GI^<

M+VJ@HT:/3J7U.ECKP\$!-AG8, FC) 8K45JM<1(ZQM?_A)A&[1!&@8KOICMB*
MYP/H'+>7>FJE*YEAKJHP'9!TF (M*D_,E@LG6<;0WN5ZDXHCA!%V7!|UE2 MJ&R2_@MG,R3;^M5!?
H3+^+K;2N<8E!9L5WV7ZS!|T_YW/%!7\$^"TO3LH_/_/+;+! M8+&8C<+YH@:XWD_?T*Z9+\$ZYCI;^8X
I6MHMR,&S5, XAU%PR7Y|B?:(BG'9<9"D MXX)2A1'O;8&24A+1)"EM:X=6*J?)IPE?|MI-J'(K6F-
VYZ9%8Z|M4|DY1! M+2IK.&.@'&TLL<"!)^Y5R\$::2AJR5JHWGB1X7:"C*4^-8J5Q)A^8N^|Y\$/DF8-
9+9&I2U?EOVAAO MYRLC;A8.00K?Y;J'&JY-'BG'IGU&80K P&?"EDE40OP1E:D-&F10SYZIU
M,'%KH|D"@>2Z1I4MHE_+A'G190DW=RJDI"\$HJ4A, !HR0>NDR6AP^(JK4R&|M*7|S83)^>C!5G&L+^C
MF"J6_C;'Z8<+"5_HM1:M89G.?Z:*K-P-X*MR:Q-C7&0EE)7-4_R&7=-Q0_J@
M\$+\$&+EM'3&@/7KEY3J42'DM*4)0CNRL\$,M"EBR!M#D&H|5-LW=K?Y#P'&# MZ>&|7B/YK4,=MU-
3E!HF+8@.=.DIVH#@=-25*A. %@I:, M.:ND=*)U|+T+7;NJD-
TIKF|>AT%="A5MM<6|BM=XF1+U*>^G)\$*5B.PR|HO MGC6:I!ADGR|E5OVQX*FI'61"0#L.)^)^7\$=
M@9>E!5U(*@VMP-Y^ZG4;2L;3=|I+)<|0<@I'H-UM7E2JG4%&B%8%:"(Y+|N MK#C9VG>Z-
^C<4IEI",CI(XX=(6;^MJ935(?9JB|1%LD"695)J6J(<0T8R1!3 MF)"Y4FN:=@&9FW3MWCIO+M._@-
E*&@.4|5S;-%^_,|IGM%+|GYYG3_G|7+?
M%_%|8F"|"K(P\$)>C:#F3K0HY8N\$THA6|MO'>C|"FH.*T\$,T"AQUJ(WZ9W54K9_M@=@=ZCL;"=V|YM-
_XEU.J*;BVM6EMI'H%|EAW#-@VG,R85D\$|S,")BVD=|QA4|&(!NDW,86E\$C06Z"S)92&%
(MND::6&ELVF9L0!7B#YED|I_|JH M3>:H,VL=QKJ#G*<&D(=(84WK%".RE|*,_2Q|HA+|OCD0,/FHA-
M!5WS)(T-I!ROZ=2|0.4("^(+LTJ>S9|TD7:|JWVI*RA=OZ>'CE?_I'EKNFR
MEH%,J9;KV).EU0(@TP.3|@="77_,UZ5@B>N_.TFG,"H->M:O&VTL-HF\$50K
MU8>/U/OLMD,'A^A#@#07Z>3_.57G/TS+UZ>3|*J_OI9JRDYKR#YR\$|Q1W8L_M"Q:398|Z4.F==,G|"X
M*CG|VH|-ZQBR NXYV9^2&_#9<"@Z9.V2JHE>C2'4E;8G#*!Q#? N?3|N->S MI>WSY19EPDOF16V!
(|0ALT0|""))R+9PY*B|3JU+^393|Z2AU\$1\$ UB.SW'^ MD;A3_ZK9G9|Q_(W|_MH7K.?
R*X^U2BRKD920\$&KYD)6\$Q>!.YY*<9IEV;R5_M&HX;BV7BOM3LKG-R15T0K):&Q_L"!
_1*M+R*#5+Q8.AJB\$LUGMO0A<-O3YUME
M|>8++UQ_67M5K+2\$;&'I5M<(+EH+21N=\$%/FMC4/I"ULRE'@^'EYE'36A8'
MDZ^|P6G":2J;6(3L\$Y)NAV1U.DLV@?;IT_F)PC6/VQV6Y|VYQ#LZWOMP_M#=-MF%W6|MWQWM.?
VOL@0_HS'R+=0T>L8U&|VM\$06,%;D<0>*@2*#?4T1=.=M.M|H>/U*#@?
M8_X|G'7;W32*9|2Z2H)&*F^H\$|0@!DUE*U6=-;GVM'Z4;>#4A,1
M#3&.HEKZ|G2O^93N:0L>):RYP@|S=0|8?_T M\$M\$
3OB|3;5G9|67|O_4GBSSQ8L_X_B|=I=X%B.9M^D56;4S6LW/N4QG^=EX M/VCNA'IGSZ?
Y31:+/MST.%I4C\$|L8_M?:49,F8S|=|6|>Z|B3QF0_XKL0\$NXUX\$+_=\$D4QQ&PTD53L(6EZGJ#F\$S\$V4
M.8><;&O+H3>1WR'V4(GM|I>?PQO.KD)%ZF3^E2=JL;K=-1)>T+>,VBB>;94J049::6-
6"D|P.Q|5.%|+|O83QF|NVJ|0V5(N>X)0_M;3?HXA@1*W6"K42V3,+|5I>N/HA(*>/.9 S\$DIHYB_\$K;J_M5F?
>ZVR)%%N;?_ \$HZP!&|IX&M'3*,HNM,;*6D-U;8LU%=G/RX-|L#C7GOY
MGY.E=Y,|IEG4)M*%:TP=YA,C.\$6T11^3IWTAI&|MI-Q RO\$!H077|S@/;|DC MI\$|:&04V*U>;,"\$=?X;^"-
)S66Q1H75BP|&+?AL>#^"I?EUG0=0&_J_/LVF MG_/UN+? DDW
|+:::U#""|4#)"Q1:IU::=|2_D.ZQ6ACHG@#7K('D=69D3_V0F\$/N 2@N5L#5(A-W M?)_91BX;G,:::|7+|)SE-
/|7\$V++AUF>?P5WTID)H2!6M4?%%,\$Y8\$L? \$PA M",YR;R_?70<'TR:Q|Q|H,3^"Y,?7TDRI@ MB,A,%Z7?
3=\$|H.-!|A (9((KQ_ Q|C(NNE),RM-:&|Z#DZ\$#5C_D8SJFV,ND;;ZMC
MWQ>CSWF+H/3;Y|2(0M|/8*.P2ZTUS9SO^#J H? \$O1JH5F|YH&BM^NHV<_ =MM976GZ+=@|*Y
M\$**JGKT M2T8F?7> WITP)G& SI+YUO=?NA|/R'47LN_#WR\$J_6IZ9;5R MPLK|7PQ==;\$.=Q>U?
30/%FI;)"S)9ZN3K*(77S8<-WR1BH;|K*YZ?G3RUJEYFE6NP3!/= ?KC#0A|M#R)Y|W)-
R<=%=7DE6<64T=Q"UR\$#0 M5Q_*%V"1"8G,2|M;)_|_IF+WEWT+^=P4^7,,'>"^_9N6V+&W|7..C#
MYX;RK|&3T|H;Y044)RN;=I5GDZ0,O+JVE1.U;2;6|X*!LW?
X5\$2F.YX_NXO|S;G|;E7,|/?"U)M0U1_A)AGG5,J@#39P<,PKNLER|A^7+?9|M-!@PXM|>\$O?
^C^DJZ=J*FH(|P|HDO=+HFF;5-4@N MN#5U;H?CVXCZZYN.6-0/XV9#
|R=Q)'45DAD#|TW,D(6O(YX+|)Y%A)*XI*Y MS*7A#SNN;|_KE,7|0(XV5+O(N_E|RV2G84.28N-)#*X6J|A
B^273X,%|HBDK|ZZN.6=H|XV?#5.%|E(IGDW1UWZ2@:7W" 4=6.ST|T\$6 <8X+6QA M!@O;4E&
|_KXCEOLVG+TM?_0X<|GB|_W./EPX3;6@3G.G >Z1CPMDB&@)R,| M,|TL1CF8J?H*3WUFE5-WUU9U-
^||+|ITQ|O8;G|5|WBVW!)_OBYX)S#0VHF^1X IZ3,@\$3NO9K5!%""|RBMJ3|22U|MW'R^Q;@
M|G=6>_GU85ACN?V*?X|SL|6W=-#H2.C#DH|-2;(|/=)U;M,P|23F3A|M>R3WS4MW=U=NQ?9I"YX-
D6|R+03VU75V0>#/TIEL^L=H|N\$Y?D)%E|F2FE MV&|AZ6F5LUNPPL(*S,JKJUUK3W0?
>C;M|KTND^|F 2:>W>_';O|_.*Z|.MRK/TN?;9G-21QU(KTBP*K|_#LLU 1)+JF)DR3*48I>BD--
SHL0?!M5B^0M+C(#1PMUG'\$ MT4DR2SP=;(|3Y9J#8LGZ\$FT>8BAB%|J_SF#2**UZ_5&R#>E);-
Q7"D|+3O M83PMUX4Z;D70W5='5?%0I!#|6):Z>=GO>LOC%G9;)|@|0P>%;VE;-@"MERWG#
MB0ZN2!_@|Z)4)Y>5\$L BT|4JU|ZZ39\$)&\$6AR6XUEG/W.EIW#_96!JMG;8U
M\$ _#|92;@%;EOZ#|A4K|ZF?/+T6R^X,+7Z63Q<7XJDG<8H@+2BND(2XD#6N&A
MN(P8B|3)ZDXG1=|W/VY8#,_LAA|=KL0^*X3J;RB^F%0CS27|QND401" W%O2 MD'P
5+7_??")8U1|OFY)&0V(>1KX;2J2VY"R.X'4%;\$YU"D)%H2Q'!07M?Y(M;|&A%".*)@4_P|0;|B-
FWD>\$&0;SZ><|P->Q.??Q*(5_M^ASG'Z^NT9-R\$|C#|M^)/_3C9H'(AOBK|H&H|_
N*BM2YXJX,+VF^|G(=3_M=K3(VI&P;B//_S2+5HNX=!)>._.SA?S.O1A-/EPJG22IE@_M>AIDA\$HY4,
MLDE<*ZTLX|UPU>^|1X"-_1F|ODW7TAW|E59B>@TVX.R?>?\$1>/^/> M?G/ZG?KD6
DB@:Y)&BISTN:5*+3G^:2-9LH9N3U&-A_P|\$AIQ/HU>-DNRI4S MT3?ORU..BDE?'&!_6^T_)#|Y I&
_LAY9)BZZZ;|N\$|868K|H|S7;^VC<7_M:O|D6<4BELUB3^FM@8<00814VT^C 2|-4TE69U4MD9WBP2N?
_X1R+L|X|8(MT)6_MJ#EC7M1IYE\$<\$ (98(')&)"@UKQO^QWD
M/&X,M,:W&BP,X7)|>|TN/I69B,.*6I<361AO'9=K\$G;IM;>)^:UZ;3|W_7 MXQ;V\$ Q=(^>U*_
_L,Y#_2LT>2BH6I8/#^?S6HU, 30|=HI2+7WKU90Z"# M"\$IQ="*%&C1J/5ML RF/&PS)?
3KT^++_BU5Z"1*UIN\$E"KL""(J+G/N;F.WT-&8|_ *WXNT;F M?
JB&PJMYB=.E&K)E5^U#VO56K@#J0/W%Q:B2!|KS\$@L|_K.(WA/IE?D-J12 M.-WAK>=,

!+*,":6N120'6JH?BH((1G0&:5THNC 6_<:/A#^PGUDW*F_<^N M'G!_86Z8B75P"!D?%I0JG_@B#1V/3\$2-
"NE,; R. ^\OW\$>N]_<7H/?7:66 M[4+34^POW\$M677K,/H31NP*!R:'Y"TX7>?)!6?
JC2\$)X32+4V%HO/.3^ MPLUEWX>.^DOS%EQ.@<)*M>D+EH5^*(YI. \$YV2[9-UZB,*A|A?N)9M|^POW
M8>RN^@M'#)8L3@92UAZ(H9BZU@!?:\$B65UNMK,X_OI"6USL6_-X=_V%NU#U
M5/L+|Y)8M|ZR#V'W|OH+!YZ,8=I#7G9630*),"; EB!1R-ITM;5V7^C|A0?
M0!N|Z:_<"@EU9L'2DIU6@+|@4@6K|!#6E^"<1;ZKK|Q<"T% ^XEG_OI"=A M|F|Z"^<2"O-9@|6A:B L
AI+Fi!; &ZM"-F@:B_O ^PMO<==OR=|=|A?N0M=3 M|2_<2V9=^|H^A.&
H|^<2HE*._@R<*F3=I.QL90Y6U)!H3^_84' MP4\$?/N^HOW J# #4M"9SWD6XE5^C(JZ9H3M*
I(HKJF*!U/V%>S&_0W_A|P;
M_#Y_CK/9E|DP|SZ7F=8\NRS,\$4L+'V5JMU,0\$=0BG2"% ,P+&;!SD|KZ>.W*1&%B|>F
QR5J48+ #F!F*H06)SK><M-!FEQ3C9_NI>2KC1D!+/K?N.WUMO/EEFNBBKR?|>3=(JL>14%\8O<1/CEG%
[9@Y@M5U/#SVMY?!"DV:HA8.">V! MU%('T6<4):D:2AC \$;=Z_ ^,6|H8I M_L!9628\$@8DI""[9,DGCP
=P^LNT2P.W#X|W%|+I0150#N+TDUBUX|Q|V|PX,A'=E!&FN M5GG2U2"4PP_D0>N,A|W'P\$?_
+N|F@.N#EM\$|!D%!;3,2O_N M9A#2H;-9V^2;SP<_W
!N+_G<^| #MP|S=!'#)8N\$|TP*+P|J01O>;XXHL5Q28_MR2CR1-K3"N|N<==OR=_16^9>"V5TH>N|G!
|R:QKX.XA#-|E+?6BR:1 L@Z M'TUE\$<&%6\$!SR:03O-B;/OY'!H3^=Q|<-"SSL*X.8B
MTH5:/1E!5565X0%CSAZ| MK-E&D0XYS&1H|,LE,IUEUJUG'AQR555SV??A|TZ|JK3D;,%2P/A0DX&9!H^U
MGLAE&7T>>N^M;GM(CC#,GEG.*C#K6^3
MJIROPD8%P@9BB"!G"#THN.ZI(0\$W|@='M: ^|Y@1L3VC6|MPFTBM\$|!O4Y|_ MCB4*#21@6=M_D8\$BL-
Z*@@=|A69^_TBL?>T1(V)|-K=,|=I(Z>CS&NBB9XPY M1U=EC#7)5#% 5!\$XVIBLC,GH_@,&|GWM,0-
B:S8W-!,W4KHNMN\$D\$KX!))E MTG=XK&JT"B|!#|BG)'%G'P9MWON;(I+X=&V+|N^V_U1>3=%+J-
Q%MT9HA|C_?+;:QGO^G8WK#
MO\$XC67RY2J=|0U(|K|F2_X6S&4X6|RT20A_TGA89HML0L%'*Z/,QSN&G&|4#A0&.M^ZO83U&HDSIL@
M&486^T&=,(5%@(\$'6*UM.FK5\$MRK#2(M%FP>;^Q?:'EGBC8WL#21P2MW;&D
M_+W|1OE;4GKR:3EG|S*@(Z(J=|4JR)YXH(HD^B0K(+W+A?/DW,U4YDT39.Y_
MV>YMG|8"F@|W=8!DEOT74W!>C:I\$Z?+= '96BW"7=|/HEA1S1/MB>P|1(MD
MQ%D4M1\$C!Q:UXU8R)6|KUTOT96\$(T?*()+8Z>E!=%|M8OG!)<71HXO"90" I M-FH0<%G@8_NBQQ-
!8T.\$|VO?|(<=<JWC+;%S(!SC);+M(M.2A8,?YBV_%V8Z2DE>CK0,2<3K5/2M* M)ZVAN
+:AY"M=\$F4!RK^%R_80TID>Y=T,PYN-/B&CG|>_KF|GTPPS/FH;|
M;C|VF.C6/>3O*)@E,|9FMF"58&39,P5>:P,"G>4QEZA|J?_H)9PB@7R(Y@_M#\$G_)DV")8,Q81;3B_X^F-
5#_GV"63U8??C!+;,*IQL3|)F:D|0 M|0!9D:"E*U';X/G-|J=/'YC51|B=@UE|F+Z?L\$07"K'|LOXBSO|QB8?
(8C^H MJ2V-H|>1+*DC*L4P=.Y" S\$4GIT*-J;615R/+I@U,%CZB*"U_ K9XE><_3,O M3DK)L|DPZ4*>&E-
&>2*(XMTE%H%RD12Y"-+)%T,=#RB?1.ELN=KSE((f67 M4*:#<'2 |NUW"UPLU9072YV?
|.=/TPE|_U_B7(=0%*=8HK-E3A#9E9DD+F0 M.HEL7/_.^G<2=&S*13/F#|!"VY09-
E|N@"U\$#Z11K"=J3&M%.<-.AN#Z |K"> MN*AR4G4\$4,@RU^I\$3F3R!\$5|;@-CR;OX>*%PGXZP8R3T8?
809?^W_*N>*QNU MUY"C6+8?J54D=(G13YU2QF)1S;_-| ^4:B"K;/'H3=528;2V&UG;G-4S_BG^_SL|/-D#
|V7A|#=WS4R,.E:95A1N>/4RLM5"Z|8MZ2YTUJ++&2T)>=*>'+5@WWDWR/@VH?5AQ|PU=\$%CYC
MV|OJ>RX&&"4PS#D)B0H04F>4P!UU|'|AQPI#Z\$"VCZ\$| M1!9|JCE%ZTS* &B2OM;8|"?
JE*H1Z=T4M+VGG+QZ *N X.ECP@&K_ ^Y=A% M8Z64H@_KM:|S;>GL-"TY9T%W="
(SO:1N|LPCROS)8@NF=|JN#B |^OD>|82-G*R,'Q3'0F0| #6ED7;.LUB(S%' X6V;&^>
M6E\$EL@FH22G|LS @O;"U1\$#\$^IH6D!%=>=&6CH4>=|WE: 3=EI#1,^OK_N| M\$D3?5!_K90+
|JVA|D)P9|JUG8)5=#F6FQ4N,()3SPMO"PZ#| ^ZC| ^A7=O8
MJ(C_9M@0W)O9*%XYZEUP#DO1P*TE+FB|I3|_@,V!MDZV3K@!<_2^H>58P??P MA@^N(%
|6P*2@3\$)AYOV|=RT"-|8 K\$X;Q@SPKCR, 7Q0C#N'(B+99AP\$J3%;34<.4P0Q8U2,S1U*7|)^
(+>DJJD#\$SGI%Z6/M,<00L(!D; 82B)|)4DP,?=(U.9-@|E**T+CHXAK8Q;ZBYZA0THSQ&TO*
MV|9';S4A_!W^O2!;Q\$8O?^A+2*B/4G?32A4)""=4)K,T5IDC\$P"FN! ^U08
M*N=TWDD|YNL=A\$)%=7VD\$D%J3G=E'0CK4=2*EB"98CP\$V3K3_ ^!#H7WDWR,4 MVH?
5AQ|*#;4# #O.6C-1TP!83-\$@G;+29V8#QUA:ZRV!*13;2|B=0Z%|F+Z? MH%87"K^0A|BSO|1K8?
(8C^HX5H97K(|XU@F2FLOE2#UBGXFR\$;7#+^UC?OH
M0J\$#@Z6/"85"K76FX19@96>=.W:B|I+L:1KHQ%%JH")W:?'/K|0:"|!= F% M|N'BD)6FE|?
E%:*=0AE5\$5"40|HC::6U|Q.4G;V7/D7K6|NP&XDY-A6B"=, '
M|'U>I^<2!%TH&F|\$|"UJ|EQ7N|VXUMLBV_)ZB'+ "VY2Q.OC4L00ZUF,OYP ^
MV0PN6:%XM\$Z)YC.\$=R3|KJ6D0PN_#XMW4D.J4|:9103O0SWA@H!@F 5&=G:6
M)4?LK7,|U|N|JUD|BT@|J MK9#Y9LG6,,ZF(|SPVS|@&C86L)6.^TID#;LS;^_K|VH (T\$V 466W!_.%U@
M+8E9"V_*E,#H!"33A8XS;|\$ 78K).J>S+2|Q_ ^,>|6#WN.C#1%UY @0JX|RU
MX|0=L|HR0T9Q|+6@O5CO';?YD7D"FDf@BPN@#_M:STFYK"B^7F|ZG|Q'5CZ
M#3/*W|482NV|B'^|(\$-3 MW-X|+EY-XBSC//^2+ Z^DW8AA"18%|!J%BHOW5J">Y FDO9+W).J!|0!P0@Y
M:Np,)!6%|>OO'6B_-?IXB)|J0&-DMW T^N|1X25X?@| ^-"&"AU8'FT3Y8V"TXN"O3|FMR?
X|G,^)WGC_ |3BGG|^LB+ |Q?F|: M^:D*P?G:8*D8L_O6 =HM0#B(NEB5DAF=Y)O=1^AQX^T|J|. #SHR|
|^9QG MU4=PZ2N^7|J|3P|ODHY8,O>S)&7+ZP(8I/E.SJ?O2N1M0;2G10=%V+;_7_C
M<*\$|FB0%4M\$3->A3GLR7B>U+%HW/*"Z_FY;9_UHF|S@|HVG6?_DK1;8*OX
M|; %I^B7G=WGVF8Z.)3)^KG0|OT97K4*^H.FDO,UQ^F\$R^I^<+A3E92+Y%4Z+
M**8J0QH04P&4EAI0.@|!%A=\$A5A2W3GYJO(2M4T3BOYS.:V9,&|(NPBFY;.=5 M*I"DI_
|L0"N5@1\$M(FA%IREYDEF0RQD5UG1^|3UK?R5O2/B4#*P7TWHN.M?
M7Z|S8AR%LX%G6D#P.=,U%"SXHFH;SOQ91 MV0#1M@VDK?(0.A W4\$#V3L+V\$Y)M)L9N|A"!CL'BE-
&N|P'R)"6MC>12XH9 MV&"E*.XS;UL'90<D'M"L_O!1Q_6#X"+MWF>Z8\$?GTW2+_ES'D|_+;<@7*C=
M|X*'FBEODP.9ZMA/+24\$)&=(|R80F9YCZ|YF*"BL/-;|QV7.AH3P2?'+B/3-B5@04?IM)7!MW9C="+LF.#2
M7A(#G"O/_L!9>D^_O#P^8V'&949@#9J|J6X;M*Z&\$K.V1;.G_S>&Q3<\$?-E MMY?+4)U3;G.A^O|^+?-
_7.'5.B;|S1@GM?IF-VEPYJ&*ED< M8#W|T96W@,FZ1BZ'(.A2B&'6|L*GFA/>|K=&8+B04-PU>W-

58!>RYLH.A9"*;!U#%T8UBI(391%9(RD,MK?M6;21F#U6<>Y?
US9EQ3035.L/C)3%;!07.=75YEF9SLYJ(YTEE;^3D%;!MJ3Q%@20XD")&4%'59CTN0PY%RL!*S+%;-E;7-
SYAR PGF2&,@@O!J?U!+LT M8\$YE,(4E'VM;QMKLB9!YA G3==9J3/SS+8^C;H1MHAN/J%T\$
MTY^EM'PTCE!-ECMF:9^W#J7?^9;A NG=%!JK;!6NX!A/<*<8N-/V\$<6C\;TF%-W_V O?R O6"R\$X?*<
V316/!K MI\$TEFEIT5>=H.@@;!N@.!0)?0R2M0ZE/1!<IQ(#!AOL^XAVTWY CRX73V9; M5KJ *I9;D-(!
UF&D%32)3?&W+! 70)NK;2L(^@!D@&N'(X7;F8WK![]?36S MOXI *C*OC08\$2EL/SG@/O"3;=H!GUK;
<7<2!H!U)#0760\$7\$>[*6)ST23C@ MDCE0(2H(GB.96DI+%Y)75GP+L.W#OX_<=_ P0<#3E?
^LRW!^FDW^=XWA41I>8 MO3C_OGJRHV):%00R@I#62V:/+!R !48XHG3LMNM8U&L4XUF/34;U<-?
7=US7SSPJ2!M.'@XSON>#% ^)N;12%S+ZV/A=(!#^8+C?-' ^!^3?%MP7G&E!H\FOS-!EHSEP
MIS6HB!*58^ M0:2_Z/IF&EQF 90A(R 3'DOI5'%VG_"NO_01"N_!;/O>;/2D8G29(^!%"#
M3!LD;VUJ=;PC6KQ#;PV++#4?&W;M_4!3\$H;\$@/TSKFA!W>A9J#8QR%\$+1XN MF0TBWH*M
QX!EU3I&\$K!(!"#!VF=8-@ZA?D;#(*Y_-7DH1;_0YKR'379+H.32J0)%\$1=4 ML;/GT!400&R-
F4.W3JG=G_GXQ7Z0'QMOK!7!9SE<./S6?Q(6DFE;Z5:NJQ(
MA<1J#1!M1"\$X%@6D4*POFB@FPS^",!W!_OX,SF\$W*1Z!O>>U.DC2P6=HIOB1N;5UO;!.VHP>YN";
M@7#1A^F!&IS!E!)%% 4!2S5O=00R>P-POE!F8P1=K!TR(A!#X(Q>\$N@R.*;/M^UK;?
K=ZD+ZMU^*!4S%'QG)-2?2D(@FR1R1HK!Y+5E%8U\$EUDNCZYQ!@_L.P.M)1:M>#Q MMR#;?
*U>;R6^VS![]7Z;R6!HVZP*4.PH+54A ^ ^XH;X&E?%^_5TMC3W3I-"!UOE@!)JVJH;
M0=1%@F6"!V693!U+@X9;RW>4!P;4^ ^A5M&E=U^>GG)POY@N0')#&!G4M@Z)EBH\H!>T"9O/4ESR/5!;
MX/ABA!>A;./.=&\$?7F^.) EVDV !A&?BE=5BP"SQR)DU734BF_",87RV-(MLG7_ AMY\$/CF(#BO&
1QF6U!D5RT0;BE.&)BS4EG06L=&+0%%Y;15#\$ZYW.V MKG6=TX#+>7)8/A1H-!P3YGE![]Y4OXQ7=!/!
MWDS_R+/3XABRDNDJ45M:9! "X.@)7(KD@!H9A^(NX?A;4?.DP'GGB2X<1!-
M3C#XZW26WW_\$R::52/1>%>9 HZT6*F9P/M7P+/!>LF(Z^;=:DK6=TSN1J*W ML6FWPN9Z%KWX!-
H=I'JL6QY19L,MVVFF62N!L%RSE!0F9%MF;RJHTX#>ZGV M8NOF3&!+U!-"YOYE>AN>;A_PO&_'9E#-
%:;#P=I.#0%N.6"NL8TZ;RKH7+YH_!_%1;9IC(#!*PP MU7Q.-9<2#8B;7!^Y"!);CR#=[OJ_-XW#
="._.*J.'^ ^Z_6CT54BD+I84;JJI#VGG73K;+O') MI9A#AM";+;=R+'M8E!-%K/19#Z%*RMCVC#CA_23ZT
3:PSXK!4="SH&8!P7 MK%NYH!4/AE!Y;UR#9!#VQWQ^?G;QHL4TY46>G1%O/13%)=J-%^LCBL8QG
MZ+*F!^-%>HT7Z0637(B,'PM^M0Q1B*3!!PRDJ^M"7^D(27.7!1;48N#VU!C10X.MGU\$N!Q(G680\$3IO;
(Z?E1;4@_RU0.V)A3KH;Y5T^TO\$B MO63=>;Q('T\$=4L'T5Z?;-0/V!6C^SY>SG%^1TCG+[]5;F
O4V)/0!;1F. M655GE4H-C@4&T6B7)?,88^N^&KM;VP'B>V#CYQ![];J3F>\$C2UKIUUJ&!>2K;
M^SP!XZ>VKJQH"8")5.O)ZYSQF""&HT3@17?.OHWW&J>Y@;8/S_J='NI7=
M";C!8SJFIXU'BR!UCY_FXKU-M*6#IBVMHB+>J(A.T8?Z5";AQSRC7#GZ!HF MEC@!X!Q2>X*!-
O!OH!^CE"=IN4"O@E%%.9 H;Y@R%L S+M+QH_NSN* U++XT#_#=[9+APG>=EW8X
MP3G2(KC/2H"WGD!>FW4YZR;4\$77;HB46KL&CBDXEX//2+<.!*E(0>;F;KJ M%;!6>^!;)YR<(3#;
!U0>EPP;D^PC!X)QF16B>"K"(ML![]<:0L90Y)(3K+ MO"GR>W"N'0;N#;!UD<6C"6YT6-
/WX%ROX%POF.PDRO\$ &3!6_#KM0TJA5K'7 MR6+;(!>-
W5(14C9%198ZY\$^CP>WO8)S!P?;J)MW57Z:@IXI>N.P<^Z\$&^,
M\$5!T(QXIER"D0E<;J3!L;A^YZM89H^L;#J 0'URXTZ\$E%F'P!>V4B!4JHDVR Y3N?D;J M &*%
3L7>/N'3HE\$G L&92MTO_"(2640BG&(SZ>2^?1-D8X!HVT!<_*51X M!SK_L93'UW4J9TW;H#EG-
;)TD&P9(9TI\$93R*3D![]10IV;=!WTEXVTA8 M&Z S^G#K)"F4/+J^U"B%-RX(P*(4D-
E76!B(LRN2\$B.5F*>T![]Z5;R_N^ MG?RG;#V2'U?^MS&97T#(AH80Z!9JCA;
2!Z;Y#TI\$&F1V\$L*85!NR)< MWSS""!US=5!TA?LA&3_506;\$!XT;EQ!H\$&\$L>\$3GXZ-Q\$PT&P4=E^W9G
MQVD.S*NB_"!;Z>7G.G(S 4,DP\$#DU!CP;3&-ESW(H!AP#^ ^!S(O9#J!90
MWU9#3&EG;X=>+DA^2A62!\$!HD!V;>1&L>SA8^WCJ63VL=#80@1>[]N9X0! MB0N+ 837-
;6!CK8@4(&PRA!7?(S^L;K7OF_F!J9A!3P8_3@G<_RS;JA=4>;MC@R5YZ CT!&D)&E9#@H3Q94LH!?
3#CG)NN_/LV/LQM/!AZ?Z?/L_/BF*. M200D@9*%48<3%V4@HBDNHRB&';+ZF"
!6YJ5X)+40"/7('B=80>RZ0ENL"3 MJHY'UKK"X!L!H; >O!_ Q0#&PXZ;<2>CZ#O!D+@="KI; 'KR
9C339&)F!- MH!D\$Q!/-_2!WQO8 &D !^X<2!X%+U%#0E.G_\$H&.)B\$DDCELMF!X%K;S@-?
M#VU+!G_+B_%T/O^49_-*9R7A?+&D8%K2;'O.%\$Z^_15<+&;C0+!4QGDQCO_@SCL_I MX2_IO+NV@)/R
F>3T>3#G(Z')6"O3K\$<4M&&[]L^4Z!5;0 ?R7JAS6;#M!5*
MT3HAI17M![]F;NZ=" _!@:KFW6_C/7!8_X*%9IDB^U"[]#W-
4!8SJ0>PTL.&+YC;=G!7^2)%V7Q'X8P5;'P'NM'=S M;3*LE?6-AA03N?;< 0AE!PC*DV70NOV;P?
4N!FMW#KW8>[]#!C;EJ_U*THL; M+BHK(8K+@!_ ML9RDK^4VM8+27#)>[]!2VX0RH2!1/C; HX\$ =LS=X
8Q997Y!SZ?ED<5!4 M"\$Y& SPE@JME#IS2#\$HDIQHQLV.S(ZI(G00D+5CK!NA;IQNFK<^W/T83(J
MHTC;"S_!D5GEVW;?[]UO"8=/3L3W;@C_'PZH!9UAET!W_#5U(OTTG<[]Z34BS&U#PWK/DJ=N4AWAN6-
WN)IP*\$?7N*Y!_% MR>*[]#L_XA+!%EZHG+6UGSJ369")#5;_7!E5U;JU#4;@XFIBZEEW2"ZXAF;Z!
M00&F=^_?%[]L?*\$P;BJ2A85!>9L_G<_B1YSG9ZNK!B;EHU%R+!>%+OP4!G MPG;K!FTCP^FN!+
WM!@!0!;"![]9FJB;ZAD>9&V.&T(TIM V>?PHV> "W2-(M^O"!>6_+GV>C^6(Z_O5+GLW?
=>M!%\$*U6'#R9655.OEM+RWM>M#L#I&>2L98TZE9R,M)VD?/[]N_<+[]%V7W9!#;
!+QKW%[]L%)FM9)=KS&L2WL_M_<[]F'F!VPAA^@!L-%.F.R^%QK0K)\$!*.VJ*##.EL&GG;!&
(ANKTOPJ5OBS%9D!["B M;2\$!WL13VO'1A^;7TWBE!6*Z&Q!2I9;4\$9+4#(9"-EI8"HS3O!YI5PG3#V4
M@B.&TTZ\$TMH7AFO)-3"HI!%6NM;YW)0EMP@5'9.)>-!IX*M^YSBJQ<^ M<;WZXK5NP^4/9#Y-
!6W!>>&V;J7Y"B;F7>#A.L M=U.APH+!#%A!UMH6)Q1_#*(X;55GY!&-98;K!2!L.SU9;A4.I\$ATC4E@-
M2ML\$;K8>)N%E\$%9XSK9\$?=(HIN7!C@F!5"V3UOPK*\$FMB0\$ _!Q&2.1.L3S!5#!H6?
MU)%/24^_5D4;.@4&*@HBVG.DG4;_ M9*(U(6;_H;D3&=!1-K3L!O!+DN\$XRSC/O^2+OU!-
GL584SKF;W/;H!+@P2U M8SP15!"+VFBOSAD_@M0B9S\$;7LU.UN4>ZN&[]\$+7\$P3<8&)K;
7>N2FNR*M5_M!LM6@&[]JZM"194Q@X@9XJ2J 3Q(!"YJV16).2NEMW.X.V_3F)XBBX26TL3M7
MZU2T0Z9G^=T""Y<_LF6I8WWC5NDY6!R03?SG%[]?G\$7S;!M!NES5)3Q5!_QCH4N-3B-
2QU\$3.KT!BSEY7G2Q MNG4=JSTD;7MCKG_!A>=;6V^Y%AEIRDAD4CP4CQ(*+9Y!&WJ6V?-W\$'.KM)?
M6F+@YD77BMN'DHR8Y>^KO^@BJ0ZGHI-63.9P.LZU%;D.E*IG IM5EH;"J

MUC"?IC9ETJF<10JTO-#^,\$KZ.M%6I=P?B!LHQN9.P_624-!C-WAL(8.=M R5Y5\$FDZO
RI*!H@("YM&,"*:=80)"W:I.P!X#T%*>UA6\0FG:WRQ0\$I6D69?;+Y,3HZD+5fZZNA(*?#2J&ADW%%XM_S
M).IP3:0^2V?\$ZOGBPOHEDB5LN=H(!-Q3F>6;8S-U=A.A!T3 M6-I+8H!SY>5H4KL#+96QMWW4XPTGY?
9Z?D8*v>-8VG2U&-I-DQZE&P57FN<ID M(%0'X\ \$EY4&CY#8;H=J//^A(VNXA,Z0U-(0\CAEKI\YJE8'YOE7?
WZ\K0AAFPZ0RD(HC M0EPPX(3A\ID8E.G.(?:60:0CE?+#+>+HCE_S?|_3####H',51\$Y?IG<JXK5+O M3G
CE_E;L@TFYWE>PRLOZ)&S"8Z?G\7I&C.:@CHJ93V+VF":7FO7Z^JCHRI
MJ!6(ZO42Q6CP4G*('@002/5%*W=Z">QBMJ2L:>U)PZ2<4IH1.>\KP0&IS';J"
MJ@20)LJ:NELEP!>WHKB7:GJ=X*IS56I@PMSWV!^FH_VU5J:EG(SJO^)SJ: M=9+: MEQRV8&
D*FJYEKK1RS&(KJ% RD)YIO(P'ISY??'@#3UH)HG)H(@)@ MUTFZI"9T:(IAMOQ&0G:?.H
(4-.AN+PS""2095)202B^SC85\$9 3W'GAEK0Y MF7CJ9!(!=ENCOR+K?
I>3I,+>AQ)=I6;OH^ .PTH%2LL@>6^-M(3A2Y1B^"R M*XP:1X?
970K_?)A^_NGRB1<200SF2L!7HMM*G[?%;JY:WGX!;CVY-H#J6:2G<JF
MM49\J4N<)D/_U>D&\$DN\$BYPY=&0LZU@,+R:%.Z7X\$*/@)@VH/H1>?BO6M
MNWA\LP5S3#IM9UTN&PE,OE_N=TFLW=918Z,7FV^)5
M6VW\NV#D310SADIJFN2L\H/,&4*G\$B/%271KK/(TMW\6:5PR\4DC3Z/\$M\$,ZX\WGSV=MKC_>1NJ:
C2<+9/U?)ARYY4X+7 M4 36R:-2 OI2 DBQF:ARTUOI"!J9L,;#E0\31BR40'=<"=-KC^\$>A>-8I_
M^_!4\$!#!0(-,Y "%G%34^+ @P!+M^"@ 5 &ULU+U!/^0XDB_Z WX*WKD7V\H G-
:#+>@UV\!|=CIG&J2X:5>|> M,VA<)/BT-9/1\$B9U57\Z2^H1Z:2F:DD*5*N7F\|7+; \$B/A1\$0PR@A'_|^
M/BW!%U\5Y7KUGW* Q+!|"? 57;-R1?"?? KE CW, _2_ NO? NT_B\(-\|/MGSZ MVNZ?
>*K#7A3<;SA#/Q>;A\|YI&#_UY7_RR_8""WQ\NOKIX@_*FM3?K MYV\5^?"X 5\$0H?ZO_J_57V.14|:+"#
(A1"1M(IY(##,N1!1+K*0L.CJX:\I MPS@(")@)#D400Q3B#10D""\5X)CPO!"H&719KOIY5_4?
@FL.I'BKNOGG?_H M<;-Y_NN//| ^ ^ ^ | ^4JJY5_6U<./41#\$/_9/_ZE|.01\|_S=-A410_-G_=
M/5J7IQZ4PX8_1^?/WRFC_P)PW)5;_""*@)U^=>Z^>6'-<6;!06+?(&S3ZA_MP?
XQJ'X%PPC&X5^ ^UNQ/_50+1P5.LE_10%4/_JRZ>;LR2+|43/Z\X@YK; M.UZ5:_9Y@ZO-!TSX4G+?
C+;YJLS_|TJU^?2\Y\WO'BLN3@^|K*J#4167A>(R
M3!67_WNR.UF77_+OZ+-8;O)SALJB3&:"\5+_X('JR*B!1HQI0Z6LN#H4')_O-
AJ=%Q9^7BIMG7DE\O7JX7K'WY4I9\PI<&MT/)2;ELMQ\ MNV?U,)8OIWROW- M@J_@+YH!ALNIK+P)P-
T-F>FL^+U>EO1=GV4;"G?H.7TO^2:GO_'CWMVO:"X M_ZP61K\LE,'X!4#'.4.@X0CL6 (J3T
R!117H&+.YZL<^(-.^5<3W@110? MZZ?U5CJA:P&60*XY_<.:%>LK*GZM?1*UV19/C1#
NF+RH<4\|W.I7ZX,9 M\$MT,-0|> 2;GHUQ)M\LU-|JBI?@FYH?L5XNU\^KMZ27R^O-|(-.3MO:WH@
MUU)Y?NOJ)>1KZ@#RUM:J<.:RMX,T#AI+.'F'D'X^ ^P>NJ%PA7\.(D=T_12->2 MVO,&'NB1J-9/KB3?
K%UJMNTL2<;-!85XY7<%YT 8:>(VOH^8/RIN*06E'-6 MOY="W=3U5A&1%?^_JPI+0@N\$;"OE=?
|6|_G_N;A-O XLBA&
MI&>U+S:@O+0V5F/8V9YK\HJMO6D&O5|_XDK(&NYUV(82+/,XB2(M0VJA0"\$@*5L L2Z1U
M\$HQ15IC8*!|>K9E Y:5N;RM:?)S*R^F*\$=OT R#%J.P0^*YS^K/RNV0<|W(-_#| ^T<_ ;G@5W>
ML^_%WOK\$UY%|=H+BK/;:)|@O\Q76F;K05UM%I^D>O"?^1/AU2*7KB3C*(A MS^7&E?
\$0\$OD"3\$7.2:8QDH1\$QX2_-&->SU6TH@=_>KHJPN3JO>.:2CJNZ"?*8 ME:?.ZG" LWI3*E?
M9N@';JMTL7Q1.VZR<\$67,\$LA7:E9_FMO 5Z.-HO2GA&A MU\ S?
|9SE1IG\,VZWMQCLN3W_.OF)\G#/?Q=%Q%&\$J=R"<8P@2G_-9=530FFV7S7'##%UR5BG9WA"IMT?-ZQ-|
;QLO%F_47 M7NWMF0TO\;P@_|CB M39+*3-
6T!|=6KK\GU"GFM._/R_"C2:35)_K!7H..19E&9LP+T2G+^ ;OE M3/F5ZO_?_6M;?
L%+9=X_<3ER23_W_RG\O MMRJ+I-U7^JC6W4\XP\|)Z4IN%DCN_8LXCV\$2(PQ1G')
(AQ#AEC,@EADE&=MH/CKL\YH*ZVG&7'#B!|=S\61T)J\|J_:4@.1%:(EU4ZYNIJB_/,TZ^W
MYG^_DVHWHYD)\X;!@Q>@3WOH'U\$3>.+7QZ^T0H%;G8?1R_7GZ_3C30R:4
M<*""5SIW#\CJSXL@/FIGY6=VKUYF8EU\,*W%ANXE3P933!^S?^FC)B_T*SP.: M%H+"+ Y3B&C\$8\XG&
H1ARA\$2+(*AOP<.,FS^5UOW4AXWDO\7N#Z^ ^_7O=M\O:7^W"\$Z7;0"K=K:)70/V&Z_8A.H
|3EN\$G.U'S3F8>;J#="Q/M9^*#NS MJL:3S6=.U<#J+|@+|+I=J^/?
KZK.TL|=/ZVI3_HTOG)O?:V2V53^@OSCFXJS MN80\$H'DR-GL\TC.1KPNZE2%5+(-,ISU=@QS44
MZPHJON7O>F;.,|!|%V!<>@8QGT/+NSJYA=61|_?SYJXWV#O=+2^Z?HDF\ M;_)2SX\2UFU5R=|OXE!\$
M69(22(HH@RA*\$<0Y"R AB.5!D66<"ATGUTH#WZ&-CJ5F2\WV3*ESE8XKE871
ML74%5NL5|#@S2+VW@G|<0L\|DGEW6\$IV0\$#?L">(2H@.6>)H0&EOB\ VI MW1T&#|":7328
LOH/0.K@>>|9C!%|H-;H&H|@W5=8+1^?OSV1|7)!BH3S M,&PR&D.\$149Q!0+R N\$40IQ4*!\$-
X)U,+)GZ|S1 BTQ_?C5H?27XU?6.ID9 M2\$UOC*)7)UFWBEX=CC1\JJD-/HU>D'+|R@NXJ;ZZ\J GXG17-
DMMG98GK M@|&Y@|=8@_GF*&D2.76-0A\$GD,"T\$C6,1IDA0T0SG1TAU\%GR?XBE*8-WR M#)"U%R^
=M5J:(*8K095GOWA<=@U;.:#7L,#|\@ZHF89+=D#+S^|RS15H>YX M:E;P0>RF_->O+6.:(?
H)D\IX0MZAM7.%+%"VY=- F74\$;(;>3Y:)+D\ZIO MM)'##^G;"&WV-
T:%&W"DY1>01MG>G;HX\|QJRM>KYS:SYNKK)OUT_U MW6SQ#
MESRKKJ0%/|Z|-5@| #T6ZK(+6TICI6B^ (X_7P)=6^G(XTFR*<5* H0:5R\I2'2:HI&' PCDR,"R/P@G M.R'T
V6Z:|)?^J@R.-Z*?),)ON.UWC2C_C)B9B""^/4LJ-10T3%V! MGW:3T#F-
9EH(CR.0MJV7.P:L)X(UH8+DA5)PO(-B 6\$ 69@#C. IAO\$F0#TRPSYHF&-1 M/LF5(
Q(\$DK*UVS|+.W^ ^R5^T-VLG7G==YZ,*&+ '@?YNHSTE=U M#@0WLT079_.*?*.MGT7A+/-)X:<|:MX
6AAIO"2X|:1\|V4TM9OY):&WZ_M7CV7;|N: @Z6=LSA\ B^ (PX-8=|05I<)|NG9O_U||>|&Z"8D'_85KJYS!?
MT(@_.,'|J@"4+W8W(5C+@HJ5THXORP\ P4B+HIV\$(X_+2Y1LHE|5>U\U\$= M\U3^PGX:/X0K?
K/A3Y=*?6J.XC&-| #7YHJ? \$| ^| #&"WQ0'H&'!T0=I(*S5 MEZDS_FR?
J(&PPV_5Y#6+CY;SZF_5>00<%+90_/_VZ.O39G7|M-%=2RX,XWE! M4=1!0QXTL&?");
|:5W%XU9;KUEY1+P&AHLCM.#+5X.AQF6JPG)T&7QA\ M/NW5\$_-);>UX|W:S40(
MA9HUW'0)^M:F82:P59/GRUE;7'^|45W)5%Z0JQ151SF^WT%&K^OD7<>INM|/
M8NX<.:BN.FZ_K_Q:VVO:)TD.QV56KFG3/&=P:6F1(A3G."I@4N 4HC E_JR M.A.N@1.C.|3&1V)\$#I\$5R5E?
(!(273F1NQ;NT9OU4OZ\5J5*OO!|=.)6B)HO5%WJ

M4_<=WWU5<2H+5)&\$\$T8S!..0"2R!8BSB\$EN8CBC.\$HTKJ4-8D5SS:DY:&M
MY7_FICEO&3P'J9AK^%QS8:HF2\$Z8&L8\$KL">YP/OO/KTJ_FQEG_JM-KSM M/#N_N)LY?
TZ@&G4+IU&8SV%T@L2!*^EF1%=.YIE"6(L\$8C&60@#E4"+8H" MC:B"1"0IRS,BHQ:/0:,*?M>*@H6-
E7S-.TM;f="0\$Q?T1;&?:T\GX\H M!>&f>:/GZ+ZR2WH!CLM^Z:4!+)S3CWS3%5EJ%KI;
(3?)3^7VJ6Y27=O_K_7M MZM3!X2*E89I&>0YC% J(F*H% @,"6810P\$ML!!ZE>NFLJ*E3E,*TZG\6'C M7-
>3LV&OR\WO&-0J7I"6?_D6=%P6GTC;7=+1T(Y\$HZ3*#GJRWFLX/X=@4&
MX92;V2\$V1%=G@MK.6FW9R+W6LJIN-3VZ'KGZQKL.T"L'7IRKWL.T.0!SU8Z>_M/Y17ZP"%
Q_6Q7A6UQXGIM6>^&SVZGN\$3K+KAW!8=R"NX/ T#Y?EMYIGNUE M&6WO6KYZMNUET5\+^N!"\5>:-
Z(1W + M)OT^%\$*4RPTF2;"J?HG#&'&>9LK-&V1E3.?)L ?J+ M*G(M_/3YEOK\4*
f:"YCUGPTS.29#K\<#6QG+= CLOH5+\># MK-5Z?
^1995\$81\$6AFA(2:0D)@05G'&*:.1(23C&E)H9PE)IG*Z=H@R^*N%(R M4:[PBI9X"7!=\ZXSD06)VSB*>D:-
&39F\JN!L:IXEJ#CRO@6C(ZLC#CM&:U M'EIBOI0,>B_9:~?U=M::7 MX=4S"4Y!S,+AW@=YKOMR+LS#-
J2.C(E^G-:B"TO7ID/1?M+S>/ TH.S/ M!X,+4B?~\>EMI?M\LG Y6H?+&\$?7-
^&&I7_F;>T8CS7LH)I#1?;RS#YI_M6\>;1UZI.U=CW*#FTP G704=F%44#^!\<=:2OC"\MG9+ILD9-%
E.G^RE=^E M\$9FL-.G4>+/IT8@PORT:>\PBRODSKN77_\$;^N:1X>5_)W*-T>:GLTD>_N+C!5OCR"7*
(H&PW-:%D73X\$D)0P!AN78*WB16 M/*MOROQHF0,-=^" O<;M:QD\$.PX!! V3!N&W:3.B\$>:
<#69M%.)RB-OC.G49@OHND\$B8.8H1+?N\ S47F\U%>RAY MN\!ML !#:. 1!"@ \$88(90G\$+,2P"+
(D%SD3<6R4BC=&S;/J6906_)J>-- M/APR"TW">"8 K0.S,>8?%YO:+/FOQJW\$T+Q)N(!
KEIZCY&:MP&WAM!";U MWK%P(G?9=I*(O&+Q?E!E)Z_X>U-LMOR;UHL)TL\AQ(L(%S!D)(0HE?A
M.OY@\$1891X'J_LH77WA%UEK^HOT7)AHPY\$5;\$9JZ_8^B268&HZ??X_=XFI
MS%OE6W0==0LAY\OYLF^X%K-G\$H.Y.L.&:-9%!=&DNY"1P6\$0QDO98.)A'0MKC
M.! =AFDAOC&,I>WR>B'=S^_(&!)5\$#4.O)Z#AE!1Y1"/("T@X@Q!0N,"IBE% MF#!*,-(ZZ' #S*2+(U!?
>,\$%CT'=)JPMFM*0^RJ\$=2=JWE>%\$<.Y@D"LJ5_MYP5\Z4R./&EGD7;C\%:@-.5!0A.Y(>1Y"E\$>./E30&
0I#C+BB1C:3(S2\$>G,-.C\B.*UX_%G5;6SXXW4M;/ M6A\'+%=WXJNUL=M\!E\>-Q\$5_-&2_-
Q@4*AJNUP2\^C.Y>(+,W?&^+A5)JWHCT!NN\WA. 7U=14AXN49D\$0 M%0+B*.'2!@08XB).(-I(H*S-
(EXP*CGDU(2\U)FKH\W?/0\$AE>E L MS-0MX)*,Z5FA\VS>S(R8@RX: ^UELNO?7!
I\XMI%9G*^KAB;\$K\UAXQ*?XQN M&YI@.^N\H4O/Q3G.IN:1PGBMJHD#PN&BR
B*8(DC:5!#Q"#).!R/U4(SN5V MBH>O4=NCBQ1G.\HXJG%Q!5;K%>S8F'*Z<0!F\..B>A, //O849>&<\$??
UV'(MB*A>SD9.T70%HY(1<= /3L9>M(C%?=16C^7R#F_X4C\EZ.@ECXMZ0PHTM&Q2
M=HJE,XC33)+3+@0SE=1V.6L%*,1E>.WY@N6G.7X(YR_BG;M)/3L:C4-7ZE M;&?^?"J_JC%M<
MYP7W<_FP*D5)U3D"/K.##(. '3N= "JCEE1 V/*DY5Q>O"8H/_JTF56\>10H< MON3VDH)/^)QEX3AD;>:L'?
>@'F?Y>*!A>4BUE818N5)EI=YRLGG3N=))\$;f>(UI96ZHJ\.\$M1=X.6NM>IZ M!9ADP_!Z
Q8FL<[TR\$P=>3V!(&B> 7>N-YA7!#*U7G(&2KS'F>,BWIT&G'A
M<[TK1!C@.&)8.4)H(Q44T\$C!O&L^3(.%&D><%)7HU\32H M:7VV4\K6\?
3ZRLE*9467@79XK""^#J0QA)@0)H180)H7!"/(D4EBD>0\!\$,<% MHCGEV*B^_50\4W?#CX)V\1*HV.
Z9D^1S"8F;^#=#,4KL /\$6:5B ^E<53L8 MH31OK8/+
(A)5.M!XQ;+,@9SVC_B)OUT_X7*UB%ECZPB,56<^!)32(12F\$1! MF!-\$T@QE1D4-
#H;WK+:*&%#4P&\M/<(^ LL\337D(SC300SKRVP\$D97!42
M.!Q\WJH!)P4!*A%P^BG+30%>1EO1W\$*XJTK*!WC5A\$8611\GF,4QI'&4R.41 MQ5*U2
fC.\$8%1C1."Z,DRW.\$?"N9H@6>Y5Z\B1PW=W\^>?QV_QO3BFCC\+< M&#A P7!G("DV(=?
VID^+AR3;QF= f@XN2.9J>W".S+S\@PO""FT0+CUOIKQ-
MS=J\V^*7SXLTR!R)!,D8!%\$>2*J6,12J;8\21&>1YHE3;<#^E9(7\9E6V= M/+E-
T!1.!^*:.YF=\$&;Z\O'F_MW;+G^&O\=Y^GJ\QRR/%\$KJ'6SWI_K%7
MD<%0LRC#,>O\9W_B+V8?)/EXMUJ(_=H_CK#9\Z>:(6QV'M0\11(+D3\$>
MP)Q2HHJZ1S!'10\$%#HLP56!J;SW5^DY%D=6MI \$@>'U+ML&3T-N8S7N.(X M1<%,GZP!T%8Q;>%&-
\$^T6J=_&&O<9='GD41M07L\5/_A0F7!\^I=KCQ)LB(G MZM)
DDE7\$M,\$%D62P8R\$64KSL(B(EJZ>'MZS@K;\$+*X+U#9W!;RD,E.XEHZ_M.P)'(KB\(% "_XNV (1%.7@TX?
LHB;^1%5Y\LB).0NG513F#*(X%+"B3&S)1 ML(D+
NR:+%15YO'%>C\$V\$;LZ.@_;\$U\IZUM#R5/03&N2Q,%M%"D*XT611>%
M,DB:L1?+F/F>M=IXV@209<@U<3&5\MI*5?WF<>.,9W)JGF-/DHCO\HDTICK
MA62=^J5DKR1OGFYJDO:%*/=K5(X1S&/0@OY\$;BS5(1ASJ5;39(HC@G.I*G1 MI^#IAT??
(>2'AZH)7X\$=^;:0LDE&G_)T3\IKP^YF?G\CM\$V26)\==2_RV(4 M?F\$93ZWT0WK&_\$ROV!TF>?
HE91F2H(^<:=6!J)PP2EL\BQ/L-&+C))STM/ST#C.*U7#VV\,HNTIC5936# "/CMOKDZYJ6O@;
fXKN(;EPG.&^'0!N_HUJ'_ MHUIN%YM2E8NMRIE\IC.7NXYF-S*(A=A6J""8Y@DH?1D8Q;!(N4.%B%3J8X)
M#G.C.U:7"/IV2P?DP9\^U93<@8L8ZED)E\@8>H_30#\$V""J2.C('!G-:@QT MA7H"K3?L\@%WU7!?
=/2H\O,7\<JEZ3RLR"4>U5UNBQ=@R1.(F"#.88(R.R M- @B8E#'\ P9DP_;JE*
(M.DM+7\3%^V+S&O83H*FL;VT@\$09AHN"8*68E\W
MH^f;L#D0V&""YT!P%VUO5\O+ \)7X.7GL%F#9SG,8UO>:%_X5CTO__V,5H< M;>TNX#&Z-
SOW\GR;JPO<' ^R.+CUKY\I\O%\O;S_CZ\H\HT.ONXN3M\$ H3FFJ
M\K@Q1!&7)@M%"6S;LA5%B.VNM)TFX\IE5;8B"IX9J\XT:!\L.8*/GC\$R7V,Q
MM<*V!!M+55^&0FOL=XP+Y%!\>&(FA)P\FS07NLU*+).J+=:(4^AX&J5NR#4^#)WIN49 MU\ID+ \N=)
<>MEOI/O+&UP WE7K+Z5<17_Z\DO-V!1\$422AB7-B5Y=Q+D>XS4E\#H"K%L!4<@*VJB"2=-K7
M^SK;_OL.%DD#6/463C\@F1DTA9-B O1-%UAP M1PNO >%9%V-S0%XNT!8C3+I
f&;JJB6QM H7*)TYY^86SV\7@+O4BICD5*"B@_M*(%!\$6\$)S%.,8!!'.(CB/
VX62=X\$^JSA: 700"F43DVZ&9G\VB&HSCD.(\$D M8SE\$@:H*',<%S',<%5\$A@@@
;EBGW\JG5.8RR2\=3TZ?&I&97QA8QB@.;Q3 M('L/TU%>RB^?IZNFS>NW?2RK.RW)PA2+0%VI
MRX,4H@AQF).LAHPE(.B!KX_/:\$8CT;(H;P

/N 2TXS2)(5IQ!A\$ M3.Y<Q66GUEQ1\XRU)J!*,.=R1\$6FKN/*1(:JC &PGG0 MQ+.2N-

HF"(T_JU;@G'A'IO!9!VTN+;U7#RI3!S#MZT!^K4TIS^MO%YM'E6#\$YH%O""09!F%*
L%+%B4P83P",B(EQH'<984?>LG7O"0"!^!;"B M#>(4/#74P0^X!EA5H;#R\$9,4#E.4-
>)7/K\$ST_NSZ9ZJL>T98G MGQ";W_R"*5=D,P#H(87N2PA&;J93KHC)?!+.4JO"YF.\BTNEI-(Z4\CA(6
M1#F.;(8@*L(8\$A0250F(T1#%N1!&V?7#P7V;W7W9*8O>4@;;NDJS7C4U?M5W%-6Y
MX""%,EY!%&22\G#A%D+"09E1HEL%%BUR@US^K5D@1HFE9J-HZ7YE!\$%0IF MBF@,./G61\$X/J
/JF4)B<'NK)GB3W.D5EQX0?JRP!^IZ=TKH>EZNOW'^ME5=?2LK/7(J=-,LK?H5GSA=/ZS*_^LGE?
EFC6=O#_L>F.P*.19\$JLB"BR& M2.0%Q&&.(YBC 3-A&E)FN_8_YGU">:1EH9E9%7I%I U/2D_U6IQ?
MX+J;V"SID\$&_Q<2CNOV)3;,:VBY^.)9X=&0-77,WJ_ 'T!.U+6^N+C)EI MYI0MFI(#JTV//
XYKMK)K6,Z1UWVGXRFJX+Y4FD'+6D)PSFE?
VQ1DHWK<[BT#9WA",C3F+,FL(U2NDSJ.6_4J%D)JM=D-/M:K'H\W\0M&
A4VE5(E39#!'\$S0FA2"GG181B%A@UGC)Q;/VM30![XD:JA]
MB8N>YS!96C/UZP3=T2.0+1V5R%4IT9,TYFTA.B;F4=00T8?-E[C]"C.5M%15
M\WV\6;&FM(GN^G;J7<-JU9\$<=>IKUE'L>L745HK*'^_7 MOS8=;7A%RUHQ^-
^!2'A4SWSA%7I@W5\X4^M_D<=>)DC#.(4.40L1H(??_8Q9><=>F.H53OVYJ7S#5.+&J?MXO.XW
MH1GD^./M/V9Q5"R@PZKTK2>/_M0EV!3L(K.O^0WDW^%#4K!79QT!2*!#+
M"CIA^_RMBF*PQ#.=S%MKF)\$KRO.O\$&HIV+BCJ)@A[\$HPO9D/ M0H.\$8*!0VF4\$.X?
4+!_8&F1A&#S4>?+"+.6^" EV'X4V^9K;YI*@LUM;.# MK&^WFWHCMUKEZF\$1D2!-..
(PQ.WM#9%"4B0!S) H2)KS(DH*LPYL8^1)S:V M7V40#'_L;H6.SLIE1\$+_JSZ0@ZH4?Z/ S-VK3\$?6X
M6YO66I/3'5IL!S!Q5:M7DFC^J"XEA(N4!F\$4J3L!64RD?R9R2 A&L BS7*"\$ M<-&H&<
XNZ@J.I9Z/(CF^+|\$(B&Z=VO)Z1+:B"NNH#.Y:\$.3"">5#TIJU TX6\$|M;+ MDI:\OJO6I(-
F.I F*/X4H2.._O!A3\XYL%8|<+952ZK;.)#Q#L:W"B3KCSQ9=M-
!V&&PT>E._J7\7"T9)&*JN:ISG*B\$8"4AR2F>QABEJ4A\$ MH:7V/SVYW51\$E-5OWA/SK
VR"\$2>NN907QF:MJ)MJ-TU2KJ-./HJ>NLR< MELY5\$9#P>?LCA;+L6WXHJN>J5B1F+*,DP2J
(.DBQ'\$4B-ME/YI(7>H69+E\$0X+Q(GVT>' +T3VKV<=H?^H.%9UA\$2&J=J4^0S4I-.M%L! MJAR(9G-
T5\$MJT;.&-SSVIE'OKQW6U&4XT^+WKYV)-\QV?G^#TX'3O!D\$6Z.?O' 5K%6J^?_MHYYH-W M/-
L'26L;YI0VF9J#D_17^DPR#.?BGK9E;5TLQ*G!PDGQF*>4GA+'+(Q!. M-%_R^
GV#S+&3_WI=1+H!L=4AQTC%VF29TCP&%),4HAHFL\BU.84X9QA'"< M1T:A?
V^<^DY\,SUC|C|U>@|Z=P&XF7EQF7TV8/!NX_Q|EE%T'^^3G+%SO/Y
MATH#NPBWZPRORP0MJE0_XZJL'C7EBC#W*W*OJO^NEXK&^W75IXCUG;\$6L=Q3
MI33(8!&J7(VT*">Y@(*400(%3E!.#5HNV=\$W,146!6!|CIR|6I VSIM#^V M# &QK@#04TGW#?IL"
JR9X:ZQO?&I9G9\4&|.P"QXP1(5O;YN#TSWE SV#EZ M0\N6WG_R,&3^>?
H:NMHA<;HOM)LO/DVG5:2^NQ(I48PWZX.K+^Z@2TMW#?# MS>OY\$3R\O29I.Q.Y+^JDW8AL9@\$-
\$%/U-_V|K*\$5IO=D6%GV_I>%FVX\$=9X MVK)H8M=Q5:5EE,UYQ2\IV65EM?/9_GW#V8)D&4FSB\$..\$
P:1*\$*(XS_\$L# M=>,ZC9C1S6IC#CSK0:GK1-H352JSU
MJK)>T30S%3TK8_+U2!IHL>YJ^"R8\AA74A;+%P5CS2FV^%25MXCLI06@J D
M9I-4RXSWR_7O'Z6<L>;E;I1J>|;KMC|IUIWSSG;5G3Y5I!=CUALF2A,,@ M3:'(TP"B.\$,P+V@ TY
BEJOY;I(Z)EEAUBU)D^2GKV;\$WHS|>TIE&L78&..7!S /%.OV%#GSV' M7GK|N(+D86"_MH-Q+
<*\$#P^;X^KA|M5O?H5+VJ6G|=/3ZUO
M66I6IV0IMWG7STNR_05%9#1C26:~NP|X+AK+/GF49U(JC:V=VUDNSWI5M;P
MFM+MTW;)E:_W\$UJO46Z:HXCKY1+UJ6F|8:K),O=T%-MS0>#&*Q/&@\$.GU.@6\$T|!#70=UA%:!*
<=O%88VKS!6UM@3B(I%H/8GL1Z/3 M7BY_VM;EBM?
UHDB+E(>40QK'D7(!"G1QPMB5M3)SAJC7ZG)D>U=5F7_O_ WSJ4.'GOY+B95,, R/\$LJ+(
M8:2&6+45HS /POQFD0!SEONR:A'83!.'LG;5 M9MW>3-.2RZ|Z|
E1YRM!>TFP@SJT%Q^V6S#;VJEP#I.SWM\OHEHJ!^Y65-Q':VL.A1G76\$-(BYTJ| M.K\$Y\WJ>;NI/_
O?!EW48H*1(4B1B&(6C-HB.BZTN4)2JH3 MX?*R&11CB"*<(IX7@F*C7?)T MEGRGU*CZ59;PGE
7L^*S(NGF;&9?)7-4_W=YB|JLYT#Z_3XLT=@;|NFAV/ M;'I(A.Y?FV_7OU>L=I/>'6CJR|3MHUO5:V-*|O-A
M3\$""^?KA"5|S.^<76L?)A:(69VHF-"9|8S%0OCAJ8O-ZY;)T\$MBNW|U M6WU2=>SZ(B*?.=U63<;&@
&IQ<5O=@O>""#(64)A%10A1B@G_Y;
M(18)*8J"3@RRH.>QHJGV!O250K|VU_556%0Z1^J98\31N>VK/SJ|HT/A M9@37S+ UC"E8.Y+R\$P8-
S2NPAWS/(&@Y5"Y=S^N#8=Q&\$=PN4ITGLC-O'G_M;J|2G-V.*R=K?S ZYJWJ3|?H695-
V8+^1"C%+61!D--";F\$+GD(B @*+ MA(9.Q\$G\$;ZJ+A?H>3^M4M2O^MJU P|T=DM6\$.K9,8? F-
FJ9@8FR!-21V9 MF\$O49C4AFJ*-!&ZKUD>=-%'SK9+?BNNO^!RJ=QFZ9!QDN^MSHKSGF5/I'
M&8((A8"13QY#\$\$@<<4I&(A%:Y,2LK).)=_'5ZIH'VQ*@\$)>|^(!A(H@9FIKG M5+XP,K,438+
(GN(5V'\$#Q;J"BAJ?ATXV +@Z7S*B/)>J1D@TL1Z=&5H/8F9KK MU.9DY7*
|*^1G WE2ZWC+/W4D"U*=RVA5-NQ3M(<*EQO(+H_V9\$ZYAGT->3U?M?.RZ!^CK4G?R>
M3I6L%Z0?_N|KJ'?=SUHJW-@/:A:8-W-H9PHDR/L:3M)@:_?N8)+>
M'\$Y2SZ2JGM2>YE^LI6EL/YWBYLBNNN%I5GOK%;.7=MCMX-;Q7PH,2F7Y>; M+RMU.5Z-
SIED1-JBO1UF+,@2'L D4Y?%\$A;);6\$6P93F09;G29R%J6VGF(O4
M9I@L E5Z@6U6B'WIE\HZZED^J86;@7S5IVG%R!(2^@9<:Y&,"P4/OE\NT M7ZWUBS8L8YU?I
=O>\$" WO2E@F4X\$*N)&\$BMY@HA#C\$.00\$@4@ADER\$T_? MYH3GCT&GG#B= &_"0?
G,^PB)P+BYL3;UV;Q K'7/Z^N^W4?NBZNRJ>I!
MM8TZW>SR\$ _7MFS|\$O^R4FMN5:H+A:H(R+X,BU9E@^-"U002)ZF4#)Q=I MGN8!C@3,<%) %-
!ZF|88!#LX!B""%)M)|*?L\ P97&TW=G<*3R0?_DC/I M;U_2O&J=4|XGW5R'>^F|X@T@_ *%
<-25P5=>TAJ9Y.4W|28I\$%AKY|C1!7/IZ5:9&TZ|!;A M!@W+B5 M
WJXO.!SWG5H/BE\WW!8|G0R4PTJG|KS.7N9T.FRG:IO.'11N47OWI+Q< M?^A.Z^E)2?
OCWR<=TDPG#69-7I^L-7@|_KFI3?%QO_LXWJ@#_PZK|X6 M-
\$@+BG@"418@^1J'=H2&&&DH31(-1890CY(U3S\YNPP/8ROU"3I")T.^N M**@Z.V:&U-^H9\$_.H26?
T8?-L^EU^L5|YL7O=WR^_7;LO|7%B|+ M4=(NU^<?>^TJ?J
<&)65MQO:LG AU+^Q99;M5^Z"7;*E|HFO.J)R9=I^V G9< MU>? U.P*>(/3Z%+L%\$RL;L=;\$9SMFNP4.

(;W92>-,W%J"Z"M@UHN\OD81 E M.8L91(Q'!&.(4X##&D>!D6<)3\$U"SR39 #7TP/K9(
1H&9PTEOO=L"@ @ M(9Q"Q 6'1<@"6")L9QFB--KT&N4WBL^N%V;8>5%7GN&Y6I3F_2B#37@UUA
M9KC=G(*#X^WB;7ZW+;17R;5=Y 8D? *KT-Q5C-@ ,%+@V#RZLPUX-J2 M-?
LTDOIV\BK^T>\ZA;87YLCGYO571--^ _N@M9U>S^KJ82C"N'LJMLM."X2 ME>X(TY1(!RQ(XI;S
4N"D.59CE%,9RDEYUHRV;NY;YW<;6RR6N;A7;&^Z M&5YT^VX@|UW=|C66GV-
Y9LRJ2=|47EQI("QIQP4,*VSEI">5I(AJ299!#^MJFW791WPKYJ*
M#&NO"TZCZZ/;"6SJC.^IN/2VCWEWYE8/AH9?SX6ZMA1/O',Q*KF^WZH|2Y4
M%B8I\$&'((4(IE=H5<)C3(H0%IEF>T)SEU.Q" | @QWY&*?07* 7&=.)LY;J: MYPH,PQ"#-0IV!<I'1=!?
P4J=3XB|F.YV/O3"D'=RNW2%BUVCZ#=#QW M)WJHY1_YUWJ|WSYA?^|7FT>ZT469BG)!(.T"\$*Q,V?
\$LUFO7U)J4QW.E\$JJS '3F86HZAGM^/I1+& S1H0+G=BI=Q'_9WC
M"MRN'.Z4HF+BM/*HFC&=QLUA=V_JPQJO^SL>JW\$/01RX_MJNL5N_IHW<6<@BA/!!
<"1BI8AR(2P#SD*ZLFLEV|ZS2CIF59Z5HQIP=K%8QY.J&6=XM:DR6Q!S8PT-M;|N)>7?
W615AH|ME.R_HJU^@')?YM0%4;+=6V8LS>&DIYQE<704\X5U1JP4-1J\$00)QS@N(DB"&N<_|HX|V-?
%|Q\$E|M:4YE5\$SPO?SRI#.MMH12_VXZ-V^1XCQ,"R0@CIF*\$T32!)Y4!)#VA"D2B(
M5417Z%GG;@98#>SX#|/#-671O M.)N9IHGXC|HYV|'C_<3I3P_%/'LCL|Z%HI=\$DJD2 BPV\$(19*D\$,D?
(0FR M%)**813)/3I7L^TG1>|2^1;9;NI5G (C-YVW%I<PO;|TIQ7W7@I".MLF' M8|^Z" SXIULM-
|NF'+|RK+J_Q5O0L.ZIH6IU(;%2P.(P\$BHINH@XQ(4(88)Y MG 8X"K.XT/;;3M/PK&&|NN52MRJCSB)G(-
%P;Z8+;J9;_850N6#NO&U(3I26 MP.N8+K6=4V\$NO9FW,"|7I#-
PYM7YUOIOW@^6|@N/FMD4QLM%GZ#T|JM4O=4# M_XB?^("(*.\$I0RJ HPABB.
(A@D!;MS!'SGR74D04|3**)Z M;G86DW&+XD)2.W-B**2V-EV29*24FGRU7;|E#_M5^NR
LRC8)7%Z|KXG;- MIV/7;KWN1 MZ7RO4|_7EVP1|_GHI+NYKF0+CE;|4_?7DX:EB08|_9|P7=:?
GRN.V>WJ5UR5_M*G|A=/'11)D3(240\$H*N1T/4PH)R6+(B"G14X99T97J'4)>S8O;TVL&YS
MJ&J.DZY8/Q;|3A@G0<@"6*|/#3C'BM0:8B>0."Y|ID9V|ID)&*=*D1F|M;V=&U))SL_K?Y8KM
I0)CVF1L@SF852HEG,%M(C4<"KX\$R186KDEQR3|&P;M/LH94I&6/I/3KI3)"63T#.
T>4U/&DH&RQ54U|P&7"^+XDAW3Q"854O/"_A2
M'T>>M&R9H"H.WL;PTMH(B|WQ0YPRMEAT#HZ9BU>&;J12^9>2^\$4Q*XZH%P;|A00|.B774
M|^#D0RXSO=IK\$R|R;U#**T8+#"4%JKD> 3S+&"01US5&N%Y7&33;|U.D?;-
MUBD_27+C*|/K)'(N.KVF(N@GTL424>97F-@V&5Z MG1SQ.|CT&I-4+|I-K=0+4_O+J|L.R-
E;+GA5|>Z2@1R_#4V%)_D3'J4P+PA3 M^X84\$NF0)SG*8GR_Z15F*_|CG/)G5
'|'.@4'R/C6.YEU&3V;_L7\$S+0.MX>AI@QUQX^#F93@;.*=36.SLY21XS(RCMK2C!O'R*/.906V)#@R?
EN>"K77 MYZK5=C5IWWWEE%2UK7H|2|O :XJ*5_0;_C F4P((-B;;2>&8T@=)CS;%@ M(L \$..W&
|H|S|XIS53U76W.ZNWH?U^Y|MLH="IGUY?***^*Y&^DVFT2GK-
M%&A\$F|\$NIV(|MFLY^D67Z_KM1+BR1# M<1;C'&*A>I?1F 1!3%; IKF**)Y(8Q;_ ^=EWW=X8JN20|6-
_\$\$V?<.^X6W@ MF2?5T4+V;E/E?B%STPAD)Y?Y59^N|I>YQD_OM: MV|Q;S'R=.D:YL
QA5ZI8R>;G=3?S?6JX>%9\$?-(PLLD#NHQAD1"YB)(
MDB1+8"R"&*413@4WNHPR1LSSNM&3O@+/BGA3F(7WY*_BFN>9&OA1M,%2)
MD+,@@@@)!#C:YRPF C&6"9.*;|YP_R_K-(H;<V<9HZ (S@,LP5V2-SM MD'BW_X(^C@!AGCJ@(:&K)
((Q4O.F\$V@(?918H/.9>^%+@VOY/6"8|J("60 MYTJ<4\$@8)!G.0T*;(4|=BHA.-@;_Z>Z|>@
=OZ(2LS=5J|@|5=|TV| M2%&ACA2_5-2+G=G80A5L M&*NP5YR+GB5A|X159Z^|/7I(P^QS
M.Q_T'P8EU/6"T.BF')(HH)**0JAHJ)T@U0(T2!\$F0.YY%.1\$|FN6\$WXQOS|Y3
MQPS@>VY>MU&XX:QZ/N+W-U>SG^V_C%\$K8;ZGV+3;*7CM@WM#KO|8)_9V4^L MJ-Z20'5SD:?
UZKJH'2'JHOJLIQ*<:T'.UIF"Q8AG%"1 X3Q *YI 0"0%CO5 M;_Q#1
(>T=2LUZ|&3<+P9M|X:@K'"SW/%^:OK.6; >W+.1Z"@ M/5/*I=BQI5(!7C*F9R?LL1RW&K/
+&9#C|\$S\$ORFN_6@Z2*R9%;_J18W?V MA;*|6;&G.(N1F0Q;W*F#V1?7&/?
ANWZ"RZ7RD&2K'S&R|;VEY?&\$T#EA<4 MDE2H;X5I G\$0D)#&N6 T*|*0!Z8%-G2)>|9-
PS:4|>.ZVL-.LXMFQR.)K_# MO-2&-JYZWHLOM.Q.4%-R8|_&%=@Q L6Z@HJ5KOLC<&IZJ#@L/R&-
NG92W"8 M@G*J#(?Q&9&YQ.0N7SH7K%WO(O?+ENL@#>M;4K%IB\$09I%|\$91\$4HK(S*(
MU3XIRWD>9\$F686ZT.QJEYMFL|2;!!2VIVYF3;QTK;>SE P.Q<' P(@W<7 M*I48&P8M
1U9@C%;LZJ^EM@O=5WOI;G-L>WO#;0ME,-8Y-(Q)|DC\$"4HP@6 M64@ACFB|&"S|
M;%JF7|RV2+;\$83.NV-/Y>N5&F;I@O-|3VQ7|.S(H.XK)LE(PU|6#;-U MCYA.O>O9;NZ)@;=C!?
WTY+Q|_#-51#.#&D&8Q#A#_DC#4RJ>T9|W+\$A5)!3+|>|U M4//4G:\$T#79WK/S5;?'
(&8IM|O>&;JKYK3-JCUW"C_X0?%D(3PSV#'\$|@S M!7|KV7+H1ACXBJ=R9R!>1>K
\$Z2HER\DB|7M8M|DI+)3EH G;_%1 44F M0H@83Z5-"C&49RINO.<|4(O.W&-OGNZE=I&EJ+B
T;D|<26T8 M#SIH2-|0U3\$))H(;Y&0|<N ?OC6M6N*E=EXRGA_O#248;U1<%&TZG/OSU?
M|O1%"0X2I2|_>R@5BLWHF>H*_J\$(TWI(X75#W&9N#B|?U4K|R;.;Z?MIHGR^V58KLCY
M3AU&13HX=QA_5M|Y;NMYPM;KE:QE%(H%PNI2L2%G(1+= (8%E\$F|CA) MX@+GEKFE0SJ^SQ
_|DG+AF233-HDD;V&0'6.DMF0X0;-(PTS1EN85;*EZ M20TD)9;|=- #*J^5 GI*U)&TSY/VRJLW-57=9/-
=31VN" %Q|).3UROB.8;4VG3F_9ME*.WW-3^FV%0H"J*O.KF Q
MU>F>;A.^*JV|W6D=&9@H|2FUG/=00_5G>MM|S=WW?_VGR|_KUB|37|Q_N5
M<0KWF==|A|C:4FY=+\$&DO2VRW^|N_7Z|UJ;1V.X? 92_8@?|F"JHAMX=D MZ@MB6CG&Y; M+J
=8=/'0@9XZJW#OE R4WK%A5J/6SYV3;Q5_8|6N1TOX.TEY"Q*&E#X*S& MD0'IF8L@F8-R7"7)8@R+>:
K-BE;JO.PM;_W9G4ZKU(^)_|?N'U)TY^:5) MBV,%151@!M.PCB_20F|10T\$ACV.2YIF@11
L5OQ|W3@;-SR3>='2KZ+5KR%'_MVFIV+@L;E#MN0+5COR!L-6D&Q@W5/*A:6;V>*|_#S|>?
5=GXLZG6>^|_HE1 M-H@?SH6V78BQ/0Y5JT6YPY|_|.^_OO*.(I-N@!M-'PYB;>I#+W8>Z8 MJ"
<.6H&;W5('8*M(XAPFC+JH1)W%\$&5Y '\$N%\$S%| M1!&(D D<&%51FW?)VA<1ESRL*_4-?|_
=ONR6K=F6*Y^KE_-5Z557)EE2J;EWU9I>L_6SW)Z_7^('W3#Q8\$|ZU9"_2W7WHN
M&G53K'"V55&RCB|X.-EA"Z'(9R"8|K+|-(%_*8<126T!;_*D|Q>?390A7; M@@Z#%OHO63N7VZ?
M4IVSO>7|0;=E>UU)|DIYQ|19A!^N0Q2NP8|*Q4D.VK|"+GBQ7ATU9G&XAG.+G;G?AAJVVY-QY.
MP3RQ)W\$|ON/.6G^KUG6|!"A+\$.\$"8HHY1&&0PASG"8P(*@@6(HI"HRZ/X^1 M;V8N=

(EZ4#PXZA/5PJ=G|JR!8F;+O2*^MLH'.ZZ11U(Z;M?5\$OL^@8=2"X
M=L^HP[1@)\$D1(11D:4"FWFOGJ">XJ<-GR??"UHJ@^SWRS0STAX*V0^; MK3NLPE;-
FJMR.^8,S%M7QQJ@HP(Z|B/9%TO==WS|4*|XS88_U0O"! (DS',*M|?G|Q A*#U&\$;
<|)\$&\$3>NBGJ#CV2|L*GONR8+?%&'04#8L'G8.)SVSXT!Z M,|MB);A5X=(1L1S6*#U%9?
9RI".BGJH. O:X^>'X1_S\$F=1ZNE6)&:= "E%3| M@T4._L6!/:MD0Q_L&|H.S;^)=!N7P>|A0|RV|
(6'_QM>:T.PB^//MM! MN+:@PX_P_9=>|77|793;^1V7KH&8QU?|JV72|V.V%:~@+ QYB"@DL6K-@C|
M21:G_L0COB)19+&2ZV_/2W|0 MZTW.=|K9S\$*/U23./L)%Y092N0;95HY1L3.5E|JE^|A*|A|75?
D_G"W" F(4H1@R2- TAPA&". O#R)(XC'(1%S@PJB4| M0LNS%3@L^OW9:T621G@IF<)'%A9@%.%7!|>|
(>Z|<2^>K|LR TNO6@3D6 M^6(MF! O6.KU\$M?UK?AOK|R2S6WU2;D8:T+P*25'@(WV^_(9E;5-
UCT)M-"K^*~?^|@N_6='U\$ _PKH^.:0W;.:WJ MC'SDFUMQC|N8DJB/TC&#+IW*."?
P0.6+H#R#4ZVY;L'"|H VP MS9:1V\$|AEM-I:248?%=AU#YZHLKRV MYBW@ZOC,HU*_KL>W6RQ?
G*|=|W*|H|JUX6RZW|K>MHSTX?ELD*6-QEJ8PX\$C: MUC_1JCQ3#\$48TR(L,&+\$R'\$VI#|72
5WY^BTVPWF|_U.R=M2S;:XM-H=>S MGQX|-3.31S&)EI5=S|Z;
(31>C.&EH"X@4Z7L&06;:9@Y9=+Y%:QQ#.X!:(464)HXA3;#F^?K_ OZ+M^6-TO MGSB3|J=BYE>|
+G&/C*\$9_?MYX|W-T"1EE9M6W'0<#D?NPPVT(RLS7(UAN# M9-R&.43#S":9
."TNKJ&M%:Y>6/CSL:9IR'<."=|YW'K7|H\$C/U\$P5V|R. MV\$AL7|)%|1"17E:A/D9BWXO:
(D\$>5M<>>M:B@K<:|H|:|&6_4E(X"2%69A%|A|8|X:E6(3E+ M^IX5^5|NQ'@3LS&H\$VR!XKA*SX#-
&WO^:D"#4=L0043U=@QQ7HV?+|I\$%| M:|^ (VE6U|H.L60EK>UQ&"U=:##M?
N6|H|F0^*5\$|89D+)C.XS:UOF+)(L RTE1 M)BEF8 (TPP6N& P2U"\$R'I MB+TDQ:>M5H4 M|JSQJN|:NV
M'XJ9/ZLKYZCW>G&0^7Q577D./%/MERR.VQVO5.|5_*#.:?V?GLI:=>|WE>:,^61VSU
MMJ&>|H|:|.PZ8."AD.L@ <5L.:H+|SN|IZE.>^5ZM,23'|VS-A|P'#^MI>NY
M>:|.6HESI^B.W_+W9;>T0\$O.9L=V0D0#?VB:J':^T('CCR:W*,>C4G7IO/
MHSGAX\$W._*8NX,B%3OHOYXHXXK('I@%2:KRMQ"4:ZTJ.H\$%I5\$4AT++>=\$C M|X|18J)Z4A
P&*|8B#8J8 M)\$:EMDR(^SYG&FL!TMRH=|3_PWZ:X0LMPS.JL=X@_O<:_B#X;AWRZKL-&U"T
MVXJXVV_LXGIKL'D=5UQ2Z7|<5_HLZXW=:GI-B9E|X|A MR:~^Q|%_XR%>Q6*UZ8|X3>%(ZCP+WQ
^:Y#TNJ^:NU|<~P/5G_9^4D4: M5.^+WKTN2)J0.(8Y"01\$-..01*2_85S\$048B03)F8D-
TB'HV'SMJ9C9# "RX| M<^\$!#-+H:BWE^:NP(ZH!|M@(|4CDZ!%5VP#7T>AY7H6|W';R<-
VKT.B.QW4DK^%=(~J%KQ(Q'|+@8_1LKBW'W0 MJK8C=K/ZW^6*|:Z51 &AX RF(14=9S%.22<,XBSF
1GH1QH'5I6HN:9_Z M:|?~54Q;@*8XH. FQ^T7(=,X;7<)A)GI&V+0F|2;%5#\$;2XJ703#X)C=)2AV
MI^R3P#\$|:=<5=O2@->(|YVSZ|H<,RN_9)M'XLO?+7E|7O)ZKNOL+BUJ*+JP=EW7?%-
_V/4'1"2/TD3EI\$22A=&K*NG1F-,>UY8XJSG6LZ|G9D1|3D" M2@E
SQ/8,=6((41#FW;\$228JB8"R". "I4#>|X_#LF#K>RB@W0(&61/F& EH&# MYP)U.^?Q6@|?%#F61/85J-
H5=?8.5/V7I>M|_<K7B' M*75U)?WNS?|TY.00L RK-;YKGJE;.@85*P2|XR|.DP%DF,I-C35>,>3;2
M71W3W60V1Y|>O)87>|GR(-UQM:L'JUK,%|ZN,|^GSG@U?E/NJ| MEB9)E(0TA6E:%!|!%>:
(J81/(@B#G>1\$516245N><0|&NBM#|Z+G?O)|1QT M<@'Y|"&GHPX"/KKQ>8/TM6-
_9_G|8T2;+L'K+,YTD9"E_<9++@=5+MY'_"1_M5"G5-:.*J|?K)|GG6N1AGA4H19-C%6K"
<0%Q+D(892Q&-|RS(V:B%XFZ=O" MJJO22EV;B|_M30-"V%JX*9I*YVB86C|S(P-
UK:LKFR0|<)SFM6M \$XLA/Z M:|J7NNTKPRT*S#G)4%.&+(8HY'"\$"<|@ "XM0X)
\$<1R:E&@;#FZDS;.%V12I M-ES,F@%QG<3#H#0TUE;|+^Y4XPIEUNY:M=7@KBK7%?C;
MJRIEY4TZN7|HB7,@C"N0|_G_|\$A/=(<)LQI26K6;.#?F;*TF+@@U;#-QZ5\$S
MM6.|7+SMX@GORYKB99MG|5|~KEZD@N<-55-BH| Q#(\$,5(7D*."|R+*@T (M'>T+|6+:C"UK"7=
(B:~CK;>4X1N-ZZ4QR,|VT\$EI;#;6\$&E\$~7ZKB/* MO2*.CSJ+*FH)UBNCWL,6X>
|~#NX;N2%|4)=;WLI_/G#)^7O.%SGA|2_64Y4C
M.W57+848J_1QEB1Y7(A,+)8|0>58W2O&>@>I:CUE1;M5WI\$5_N+|5D M.&A M22AA/1>&"8OC
(XKK",|+.,~;=|BT=(\$D#':4P7N'&|C\$|)UA81>VML?.\$+!M
M)>9H'E|A/GBS5J2'(28|>XPI^>OE|MW7SEM(BEOP%UX6%>S;/7\$6_HUFL|;ZZ" M4J57#YS=
<5|HK5I0G|~O|N4@-#5P9 C|"MA1HHF:&A?21=V05FM-P;|,~@ MN*R#CJ0W4|\$QP1T7O-
"4T4H3Q|:=31\$UA|OJH<|C\$P+ZY* BIRY"#5HK?VB M\$ _1Z9U48Y'-|W-K A9IB?
>RB_GKVVE|P@|==SO+0UO>T M"*|250|GS?
H*1@1ZFCIY^:6'7HIV|=NZO/CYQO&|H4:NR|2B9?)!11KOJ: M%3RE\$|61TC\$4PQ1S1"/.2|)PJZI#
(T0|Z|NPZHYLKJ&BC3DV(7&-D7*M(0VG6AHC&2KU.H2_.\$LX6*=-Z=.6|OYNT8MNG MUG-
X|_694^DNO^V_E(ROV">|X8N"Y(2'\$85A&JK+X@S+A3Q D.51S.,T#>@DW M6LV|<^S98/4D
>MH@F|E7YY/47ZE:3/8-'XODS'|%G%O5|% C"NPF^)>\$J|\$ M^0Z2T\$U1?^VD=&U^_QA)Z|P.TM:-
R9LGQ:DVLTOIE:NK8H^JUS2C:U_ |HK| MWJ|UWH7ES-61-@R=PS(S# 2|?#?
@UI%D#+@WMX3|KY.8?)LH/6(P?X;:V5_*T%J"Y_5.T MR9FKVDYF.(PW|H0;:L.&@4:R'381-
'O5.G94KM3A|@>.I2\$|L6G2>|OS@_KM MEO|=LG_O(9?F\$T?R_^(8ABA+(4H*JE|W_|C#@A)"\$HX0-
@H@Z5+V;\$3E1Y0; M|H>T=.,\$E PCL_U+(&AZNP(Z+*U6\$BG|PATMV|10CH.'\$8:3(5'A7X2)M
MNO/&C\$SA. H<&0_P.DF*|H|HBL|UBF-|HJ\$"|JR(LY(&F2!Q_%.8*\$! DD M:4)!4,1|3(WJQ;V'"#>+Z3%O&
-|S|CK)BC:3:Q|W^CXG;29(U.T^|+03| ^: MK#AA.KZ39\$4;?"
Y0R8H3ILAULN(45F;.F%"|*S??;E;UIFKV9_7MY|+91BO M.EE^Y:5DO^|=|J|
%HB1)!8RS|LUD)&L.TQ1BQGC_69\$+@0VN|L|_OY;|G'P1 MN*7Y"J7Y3&?38%W|7B;GM1:S5A8P\$
8TTH"-&>_U'53O^LL|1WD5UC.PFNG M69BR_6\$0L'7@!@R@L("))#DF6 MI) 60H11G_8TUC|C.1K9|
|:EHZ5GOX_%C>PDX0QLX=&8<7H_|R/V8XY\$|_# MHR'_M3<8Q^/-
HM%GQ>A5|OP#YK'|@5OM4TE.KK|O\$|H>E\$+QJRA689V>8C>H| MD|1=)W?<#)(0P9X?F_0-0-
NAXK|X6:FFZ:0>8@=VT%A%4(V)#5;)-D.@F% MV7(\$B|BRW#W*_63=%&|ORH|^4A07<2\$B'#.
(Q:G\$|5(P'+) DCC/(XR3GF8 M:"VR(S0|6X|45 I<@91T#8: 2%ITM|JIN#(6^|~KI7X);.<0V"O-/O%M@QJ
M6HAO%K4=%VPT2GOFU?FBLN.'T1A+SSZ*AUT?OIV>H#KKV6|X\$2@F\$KW'Q=;
M:4D\$@5C@&&+\$PH2Q%"?9G\$UUQGCU;.:M7KY3=\$VO!#H<|TSH>^DWDP,|*6 M4S:WWQP=
<+Z/5CJCG/Z1NNOH0.ZXX8X624N#3JG*GZKO|#<5CWBSK:0CNEG\$ M.2L(I@\$2"P@\$CF#.

<(!AG&*\$@ "\$7&ME,-Q,KI-:\$<4/+4#0WG:60T;=YD M>0W-52JJ1_*="0=6J1D5P9F=-
\$YK4/HX(>J2;XTY.T4MJ N_6RI\$K5^T(M,6=%G(0QI#R*5"<#.(P"6\$>1:*/"/><(O-/;\$J'NU4@?
V>LDI!#E.C/1U M(@I6.FL*@\$WBCLGF5GE/\$7H-!X1^(P2CJUA<0RS[!..ES?IAK3I,TB!,,,!
MW.RD*,80X3"">)R2",.>!FD6!D>:!(7*+F69VG-)W70TOCJ,8E!F,*/0, M,IJ3U#F,MT#
XR7&)BGVBODK^KCA@94V7ZWHK?Y2<@(9IP!(5YZ#HR#MERS;0:F4775)ZN;IN5I_-0+;?0GH
F\$2,J@RH"5)BXG M\$),<09X4B0A36L3\$*/E^A)9G I->C#,H!:<-^42-(Z3DJCN0W,VYIT8=4'0+:
M#:1SU6UJA-*!S;,*S/-IRFD?R^MLWE/H_O1#"^HJK1 :?A]_^?NS=KCMQ6TD#_"EJNV(X0
MYG(!MWF3>_T'7=+T2U[XH0?K!*,.=4U""%+:FM^_06X5+\$V\$HD"J9YY.#XM MB41F?F0F\$XE
M=SB@\$2\$416DFE+&_D0CJG:D?A#0/QYD\$>F_8_.\$9DZ/-AVXT\$JZO^/NA*
MZJ%.9N8(#1L^5W+#S)>5R*_.2F,R6753.KOH;)V5QL3J=UD:O=9VWU150MP\ M"9W+LK!?
KWS\8ZUWRCHJ)?B'OYFZ!+JN=%^\$_.%Q(GR4AR).!%*14;H5QF M.&68JVVU5#MM167
Q^5ZKJOf=6RJJB+H3% XK5\$UW7Q-C!=V7:79T)5W+T(DR MZ#Y77L.6U_#EIUYPIQI
<4Y&5#:N\VS+0H-!I>]=/Z1;3M"!:=!QF.66F<%16>(<#%S>Y(8^+!0:NA1?6?=4U?G5Z9A@DE,1YB*0,
M.)1K#I7TJL90,JE9U8H&JH(S\$NJ+3;K35:E=T1^ T*N^_,6C0Y%L47F@T*Z9W^<30-M^V^T^3
:0L:48?JAM)8"IU-:PWH+!-KUTNX76.^WL'I3_-U"CIXDT4&
MT>_%^EY_&=X+NMD59=^JOS6AXXJ"7\$OUUGU7%DSHV4K/C28\V#1VN60"CI?
O\$SJ3SBJ=VT:E)HV(#V2;:5N6W\ZX"5/-1ZC9J_7 M!./ZSV.CIO\,%I' UGWJ-QI'8F!
:E4.S\NW2K^9X'+!G+(7B#^5HN MZ,R7TN40E:VL+Y?KPKVM+!7ZZ_.*!#Z-@^NRO"L?UQO^<47N3?
VOLPM_ %1 M=)\$F!&G**CK 7179VP0XPR,82#&/3@G&:LN9GXWE^."T?=:4:EM'(%SZ\Z MFW,X*EC?
71R_V"XHUW1;KVHJJ;.3*>Y/R_7I^W10;%N=:ZYIH\K003-B51 M--2S+E];
<1CI9ACNB5=L5*4IC^U\W.+E(DDDR1#21C%".LW)A?81RP1*64) M97%&(<<\$_(Z
<=&"YKGS*ILFXJY&LP<+\$D\YK,QBC3_(\$X#9K(89IV?-!B^> MUD%OQJFW8\U\0.WU-?
=7WCZWWJ>Q4V=PQ'&3!T%3J?D=-.XZPR0'X9QYR\I MY8;I
(0HKE_NZ\,76A\;@!>&\$G\Y_!":NC2^I_72/@YNQROS_C<"*#.1H& MKMC%0,
JLKJIF@Q806W!&Z>=Y4&D6OM;J5\;\$*J3U\;3FD \ARM;I0R!S@<'!WW1_1*;SD&5UL<5S8?X\ZZ M;-4
-2#MJH%#G*5YB,2">6PD!"C+;ECA_.9"8J3B'.CYB5&U";62DW(TQ0! MAU6C !FF6
P>HHTN,M)F:D\>|=?QC=9&+K/ MZGD^/C->ND":F-^JNA+N*V7#*A_E
5Z^H_BI6VL)^+4N@6^G=BW=YQ(\L MFFXSWJ5;SJ*0T"C4S>\CKFRAB-4V+HAU0Q@64R:3Q#?
OR^N4M:DW;RUCW\F MK.X\ M2PYSTT_F\;EY;S\#8B'67GZ%K=5J+KTGS:9JH;:VE@O=_L\TIV
M7Y\N:3WM/2VQKUWJ-[K10-U=X)&4_Q2;MLF 5CNR6NW&Y!YV&J#?+;)^;753 MJ5Q5B:K:UH
-W\Z"O7IF?ZXT>5:W;RGJ+H7@B+%5D2O4?Y73^!HIXGJ6\XIO8B68LE9M"0\X%-DS8FMJ_X9ZG^
MK=9H!?-UW"552^9Q:!!^XY'IJ:"#&4=+U"88R62#AU5P&T1HMG"WC?C\+C5
M_1:1HFV#ANLU"YMP7V=CZ_8R\7KMZ_Y2U/U'Y1QCG4_IA3E(F,(1JB781+G
M,1\$FN967L3%QVN3=@R@%T00:80%J3 T"-+,@!3P@VJ9W(60NM4PUK5YVG5ZZ
MAG65IOAKRSKJ;E":MUG !<179@'9+I;2I%-I/W95=UCYJ?*>^RUT"KI:WC?V M7P=.FE8:3QWV^E?
%WN.2\>:-8TJ^+/.#U;_E9L\='^Z:>=K?DSZ6M+6JAW^ M31;K5?
%=K\@B&U%M^G\T%3FY^)\$,1DGL5Y\O(G(Q GO1C\M7L_C:Z_*WPNR M_DA83>.N5'0?Q-
WWHCU0Y,TR0A.\$;&ACW"098A&>8X83X7/\$QD&V*C)GQ&U MB3W8NL!-
T_-P&7PW7(!^SR,X&!S,#L*",#6NP3&LON\ MY8L",Z"F<@!R=%%YC.'TO+L63WCFR\ (9&J?
06@""^RPVJ9>S;9&5;F1M+A0* M9EOZ.>CNVKT/B'!9AOF<2C(@Q,E!0HPY>010?(T
MY;KMN\VM%W6J)G(Z*S,;)<#8S)5B)H(?%WL9W64\;U\%KS,*>AI5&M^LWD0
M9>I7"Y%0I>N2HC3\$#.&\$!H@&L8^83\$4B_"RB&6Q?I8V^AZM6,&/'/.-4HY#3/&45"IL
QAKGN:P1ZQ&JN:@_UNG_K_)78WJ\^YMQC^QA.#'! M#W"SI5WF?
DWGF2X3PP^K=^1HZ72K"ZT\$HDX%I%!"<"X3CGB.D)5TD2)C"%
MF8PXS;I490:Q#FH>T^*.%JN/=0!JJ%0<0;I8\$K'(V8 ?I;0M!2WF"N5=&
M,KK2_\$%:\VJB=A'FFYTDYV&GPS4ZIK\=OAS\$*:QJLHPI@HG\O/&*(1PXCf
M."2^%F6A(L74=+"5,M'*\$+>[SY=XJ]>\H5I?+=0G&3T7X,I;JIT^YDC;86C MF>8IQ
:F^WM';03%';4W2F_H9B.U'^_VJP&P%#T0Q-@>ALR-B4GC\>WY;" M;K' :ACV7K%V8*4@P+U0Y7#%
JH\CM2GG*T+*, -4AI@Y30S/0\$J\$HCD(D>9CF%@ MR66*@TO/(W?DWO!
\$IB%,8I?2.3R6.)3(XF3JQEMW?X*JL-N=3Y@^J(I=IS=K;L9SA*\$Q0R M(A%,28XH#D+*\$2%^F
=9'H.FX)XC+.%UVYUF*(+VO"CLU_2*^7L,ZF4^7EI7%6OV3-?UH;H05
MDKTV_IVEIOLD(5G,I-2B5&W\J>0HDI% L8@#X<<13R-0G1>4@'^U_SDIY9,M&(L,"IC
MK;.&%IQ#.V2ICF6AJG(BZ\7?Z1+I&UG/A;JG&"EW+,".I2B0(D0X"1FB(<,H M"
(*8*/_ "EUB"ZDW/49K8X-3DZFGKJ4AUR&"G<9#K(@3T6'F B8UO AR3")7 MM8QGZ@-
=NIZ6'CXOJEF7B0^B42*?21T+@%.\P21E#,41,J+ M2/Q,^@RDK&?H3*RJ7\OKLC6>;4WVU;:F^>?
EVN/%:D7*WA*&I5G&\$#;3=>X MP23N/CYRFEN)NM/V\$;D_<:V!\$KM!V*:QQ0E
M::2V^H1+E\$'0_=:C%\53^H5>E \$KNJ+ MT?
@<=>E@^43*S6NO1:0@U&=^XB,>DP3A/(0293+0"D3499E 0F.?00U:F=
M^Q\1NFKL" _B@UM)I489U\IP(I8-K5=APUR/Z!-M6I -I=68\ZS_!/?/^\$ M_I2?86\T%\O%A_5&?
3;KX32\$Z0X\IF&O&L/="(BN\I3CK@.4H29X"BC.4=Y
MG/(@\%C0.8Z,6SV.\$)E;AK37H^UIXMXJ2#K<*<%C#2N02 N NUE)Z8T4S%6U M\I02C>:I?
^PT;W3A65315+Q-XVOOZB@Z;/CTZIX%>)7L19RN:FV*NL+(D6@ M\%9HT M;+:)=0<+3)DI1#K"7D?
YRIT^PV1T6\RCMA;%*^,"ZF.F7L+KC3J0 \XCW M^T)47XK-5JUTOA3=M=PZSKS%6?
(0VD9\CBQ%L7&Z\J>-G.#S'W:0%(C;N\ MTX \$4_<^/IH)3W'A?3W_9X*&='#9K=QJ
)G9O&ZXZ'VGW.+N"V;0T8&)3.U M)GHXD.FFZ0?^IV)4.LU_#W4ITH\Z\0OVJ;NL3H?A2R_L'?
4TSKO"K>&PF M7^AIF-JK>28KG887+\$24A\$/*"X"3X688I(&E-\$A1^&(8Z(+W+PY+H?0K2)
MK5_+K=2.UPI-JE64>B\;^JGW5?L IXSO;C(B9G?=#,#R=+:\%0/6 M(A
MG\VIH/35ZU_7BMJ,1+SR6FFOO#IW\AR'WANC?WWEJ;2^CJYMU-'MY)I/='K M:?"Y_I4(3Y=3
'T.P^<-_AARGTL*^? \$XM/NPWZHW5:@M_Z_36FJ>JR:=

M4SD8.,RE'R&:L0I')1C1(H1EB3*\$BX2FH20#^UY4A-^/Y8RJ^0Q4;2:O.I,|+ILC M4SE :%;3-
2JPH2DQN.,B?N[W8GYO|<-|03J<70Q2*G(6=4HIO MCC*%<92C+ HIBG&.<\$SK+8NI88I
MK29:NTZ>)JL+IU;1C: >><2 \$ QG",@I,K@+@ \$5@AG(.5@="=S0_2,5OQE(ML5?
V9G*|959<42KW9MT\$*UE=3U?HDXMB_9OR)Y11K/%6MSKK_L=(#_.G 6C%SEO7N0C1@!>2BG(
M:OD >C1.PUQ;7(NJ>H==H/4XJ_ZI>8L=AGAT<U>I=@#*V;P2\$Y2KBS6&+B*1L+3&@:
MQ&&,B#+O""^5*J'G="R M?Q7K*MBM>3:KVHCL5HJV8|,-R8)D1SM).((ESB7 0^B@+H@1E"6-2\@BG
MB5\$:F0MF)HJLM=OYRX:15D,43_U\@@"I="GX!M9!1DAA:G^'9LN9UV?-V_+F
MJ9@#E6F!AQOP99@1=KN/Q:X)=CT6=E<@_10@K,S/ICU+VA3J.J(I+-9_2"?M?
U>#CAQ!-/CUN)3&?!\41VCL?6-1SET62,C^
M(H%\$'E&\$!2,191(CIH>\$Q6D0I(E1WS\$(T8D_(UL6M.+MS%S'A?=7QX=ML?T0-MGH9'JHY1
AZF7PZ0?5V^@<2N2_2'2+Y-M,X!"&<+ITWNM308XK|V>^13Q7U)
MGAZ6C"@TE%.:2:N%R\$F6X!#ED=1C5:(Y5F4(U_D,LLI3X#5_*4IS85+?TK MK|^15|-@:R=&830T\$B|!
5J("W&IFP=365W9AE%ZIOH&4_&/K(+QC1=D2OYZ MF!FRB),T)#3)\$:-
J*XI#90QHYBN+\$/L\%#C+6IJ#LQ:/R\$SN)R@?"J4Y+?M%
M\$NU@\$(NTP6.D#%7180E!^GTJ36Z7IM,T^2/50YT@-P2%77;:64E=9IH=\$YD_
MZ^NLH"TZIT"SF+:2FRF@G3PPI=.B?%HK2R.VTWOJOY7:(>JV>479Y+,>
MM!72BJASY(K52E|6;R1%Y;!0Z5AR9SE,VX5GSEDZ%:@X1^GH"HO :ENR1%54
M0MWX<+WF|6+6!5/3?%M:D6@N5,"(91D@F).->0 (*D;J&Q M:|I(#S2')R58M4)E>A3G, @!J:9!LO,%I
TEVDO)@FXS78RJ_|\$ MW9&_6|^QK>5350:&<
MC5P|367F6:N#HAX/61V^W\$Y1=2+DIW6U*6NKWGF67|E&U+/%&?BM*W1&:W(N% M1C' 08!RJL%;3
M 0?DT)I8K&:/0%2:6IU EW1L208V!TXBP*!8Q8F%(\$Y|AG*2^2AF(@IHGN81 MA1TE#!",VHCLYK/WB-
N?PS!9AI=-,&*JH<:BSP,\$BC#@NH+-@X@"IF4.*MXT(?!Q8-
JK%4|^>GIU4+=R8K/9GDXZKXWDMFV+ZR/@Y)XD<,923-\$2:S&&4|
MC5\$L(JD476<@@"^8!&J*=6NE|7'A+|FGCIQ+Q54_:^??@4: \$%Q#>^>J!H MZ*.E.? T" NI9U.8"9CI
M1%3D"<+<JU&62H:B &>8Q#YF90L00WH3FY"|@:EW-1>7SP3L@V<02W4+"?_
YB2=D,AF8>.HVR^\$IM;=N|:Z|63)Q^C#X2|N>AW5G3>JNLBI_W<=N_U2:/XA-KI=UOU:UUZJK=RR
MX!^+LOV50BY8Q)R36%", L%CA,P1R0(8Y1*\$6=9EF8T!0UGF)?|B8UR&V*K MIK|4>&56ZX|W8O.(I
|WKCL0:;L#E=ON0\$|UX|Y+O.^!&:XX_|:.*%;T_&\$ ME|:36-LN2C-
==PQ!%1MOQ_>5UW!>EW/U>'YN>=P;F#^9H ML_-;<&\$Y8|18;TL>FT.,UKPN?,8QC9,(^1G/\$9!?
1*6:7)/FS_XRY6W%H8-
TLG@J&2NAGF>I3/OU,XQ<8_&8'VC|54#!3T"A_=SQ\8LRBEX#W8X7|W<#Y&S2!| 0N,LI,"<|=Z(!
M&)03V0?P-2XN66QLV/6Z|FM*!:;V?)%M+_MHM^QC",1906)5&UB<10RE+,L M1W|J^RG-) &4IMZQ>-
*\$_1W)"5Z>WQT;WG750REB\$L^\$IPW3H 7=|+H"IL01 M(KH:D:V)KE:B|MYT
M(^L3ULW^":LR3"3((J8#:X0@|&-EF'(-4QN=F/E)2F). "2S9|0N)D^('CS M|)W*L5=5>?
S/C8|JN^"5L1JER:QW#'\$+NRP?B9F1FPFG&\$&:1|@S=:5US%6 M(HUCK1ZM?C(1PVG-
R*48N2LRL>9D|JJ42R\$|4<9R|9*681VQT6? MSKYF00^MZ^L?E>YQT1#0+97TV*YF^|(2&O(XH"A/
(|PF!&4HUF*!*)"1EBF.\$M <1YC MTA,'?G0U5YWH=2RHL1PT>.(#X"J29\$YXWM 2&)"C6!-!3M#<|:?
T:H+.,@,<8H|% M',6Y+Q\$6/\$.\$QQ3)R|S\$7 F0@:Q*"="H3&PZ-(GF2|Y&|HUT\$J*B60Y>Z;|P!|CDUV!
(%>=5K\$ MC;SFO#Y(JMF%,#UT:Y(CJX:1%F"-1*^4^B"-_4%DE\$B 51&A,6"1P9 M-3:
<@=>)XSP|PMT4#|(E;3_)8HG9Q@/^C&>B'VF@.6DJ89|O1'K/(=EV),E.
MA*E|:CC%>=+&XX_0&Z>SB%W*Q%BQ%N2%EF|^15\$.QJZGDC9^#1D02X0RT,? MX2S\$*"<(!
|F+%;:OR 21@.51RG-9Z&M*P3'T1JVJDXQ@-G\$H_J_AZ:LBL M
*EXKH"P;YJ"P@L|I=\$R,'LV|%YLN|_9%G+^/6Z;+82U#O;Z;N71<6|N/ MRXJ1U3|\$*1|0I7;:
|P+5DJ5P;+5-J M5;/E;:X%? MSXKV(LJ"7Y"8H2B,KU37_|M"|_3;C6#7=+LZ?>&JU6ROO|
|^>NVEH|_?K|4S-/2/S ML%I>+BY,"4WH#APIU;|X5HIU9LG9E&M8I+Z"C5QIN9TFR_|/
MLGH6O|YN_D?2U'JWH*OO^O.@M=_+ZL%8,T%R%&)-:C|F-&4\$YIA"1C/O8Q
M3D@,ZO9C1G9BC=64O9JTMZ5=NV=?KO_T_M(-R#<\$TW"PIAPBX0;X_?@N M&"2LJYVO&=%Y=
|L@((YVN+"|7544W9;BB2SY^W9T?NXD\$JNM#@NJK\$IEKX M813\$1'*4<9U2*X(
920*\$*T2:;#4|@|8|G|!|WT_K=^1HN2%*:7C|3"+49AAW>(0?&DBDU(@UA&'YQQ*9@;:&@>S W?
Y:;\$U16X|W M(V*#C<2(4(ZLP#DJLZKYB*B'>CQV^01G?^?A0|9WWTO%B*E09R\$!\$68A AC
M+)7BJBU+\$ N6RB#EJ0JD&-(=V)%5B|&ZO @KX>7@L|Q2F.++3;'B*CYF. MZ(X%G^
S^69I9N|=|0C#;./#@2>U M3H:7JUO6|PS.F|(Z&VCKB'C=>;X:L:<) M&-1FIG4R *%6TQUV8/
HA8\$CRP>C/:M1LX+ET%|9+7*IKUDGY=/_-/ZO0I%9 MZCZD=8*)XN?@-W^LEXK-
IN#RM3:.=^+OS:|*E^N9\$"#E.HAW3A-\$SYU>YQ4
MUTNFB4BP3LY/\$CNOTSVS\$QNZCO6F\$84NW6D&_SZUI3NDWPRTW'+=))_5ZGWT
MRVD|VW|H(CY^4?H#KF6^_5T_Q|MM0"3.+ +3X>S6|D|7Z7B?:Z&J+ Q/B MIWF>Y%
(BS+'R>?;@1|232/V822%2S").)*|X%.C#CUV"-2=%*L=3T*.*5NC M:H@RU%"|OPYH?NP?>Z#37/3-
|RJ2Z/FL:SL MTU?>2?|&-E&)^D#VAFI(T4#D).XIQ%1=P.O4&*:;|0IT+-7=#,>47+G3Z>% "U_=6OZ
MM?CN|=HRK^I<".N&M9<'C:,-Q/H_77X%U(I-AJ\$D2|FO|>' IX|UJ=U-SM M#I?
<&3X'&#FR@9=P.JLY= #9H65TL20|G_V|-2|7K_??"M;O'W^Y^96.8|B
MW9V'KIH8OC5J|:13H&E|-1 E-I5(=%7XRM#3_YL_ZH7I4% M#UB_6821E
%#.\$@ (RF/NHR@B&8F%E"Q)38HY|VJG>EQS0)@*.WK"Z M3X|)S 3LW(6H)2=V|
%MRI|=DI&B.)H40T'YC4BCM>G)9!_.\$NY7_5ST46JU70O7:SR48/1>_|=|<=0*QQGNP/OA|U?EZAFA+
MO=(Q'X5"Y/_7F_7LHE(^O-J7TIVI/M|1CD6|GW.,T12QE&F(T@@/KS_+&>0/BPK
MKU5BCQ>B|M;%OGL@+|JBXM4K=:Z14^M7)D_(WD'3=WP"O.9-2-)IDR8V1WP
M+>4G|7%|6?)GTA05&FXA|^ ^:V+LB|E.3S|AU_@VT%XDF/G8T7%6_GB>?M|
MW,%2L^W;3HO0WZ>=N<)VRE#!_OFIJX%?Z^V?6JK5X|^K*L=#P_IZ@:*8G,C M/Q:E%,O-LWK
BR1E/\$Q\$AH3.IL"!3!"-U?<|JJE,<1(G<13"Q@Y=QM#:\$OAG MYYU=N=9?O_T|C|U?#+:A(=F,\$
*JACKAH&':WAK9|A>->71)W(6ND:RHM|/ M|AT:W(#6#.QA==R,

!|XS<@<'<|X,C1NI:%C\$QY@|JZ%|M41YZ8K=1VY@F\$ MG^:"8D1=T-0)=#MX|_MR|^!903NPT(DA
(/D|\$U MY@N?&\$JS\$T QO6>B\$2G5N;|T-TU05//??NT;OR|_Q(ZR4#PZQ=1DGOQX6|1 MLF4EZJ|)1E/
M_'6Y4QLF031!@#MK@:.*|MS|M-C KWO|R=9@%>|:'2LV655:~!9: W<*TF,Z?
MUW*0UM+|KVW|=L,P%>|'C>KOC MT6CT|(NZ;7)Z757/C|WG57<(U%%V7>@2+%%+NBS#)
(A1\$6\$^;U=4EE KDIU@0 M|@1OFN>|*|JA7JZ7C|
M;3F%VB#=#R#_6NWX.>|Y0KT:|@|'9=GS)\$0XBR-\$RU|V"*JN)EI"\$#?8X|R"(P8^XU^|+BZACIT=XQY-
|+KL^9I MWF8|UWJ4YD0@.YJSZ0|L2R9Q6F\$&~;~)6?VM9GA:.(# PX--F;N=PA_??E.T MRG7|
>IZ.BE>V@(|P|5-|Q|AE(8N2-\$>4!#|'4801X;E DF\$11A*+B|A|J"\$ M)_X_-/
V_'AU8R|>K188|*QN+!2.0Z<4?+_E7.YB?;_I^F"H)=X7>O.G@N.L8Y)(Y.LL0#BA"2(B MSY"0"<_#
M&0&W#3Y.9V\$+L=W*Y|C1A|Z^&+~#WXOF8S\$S"Y<(#0IA65BN?BPWBWPWK|>?=.AY)ORMBQ>
MEHKYA> IB3FA* B2#.\$X\$8BPC"..2CS12J"W.CC/D9HZI!<3=IK;5|Y-76% MD-21-
U/74;B&%=8E"#5M92?6&U-A1LHMU%+~#JK_K%3U=&%9U%64_\$Z=36^ M_N+03?
7E67^H;^0U?|S9/=4BHYP(&2;Z8)GK (W.>Z(\$I9)G<<(S'\$Y98#F MB-
C\$BMN0T^=;=3|I59"U1UK2UM&|8|3 9:~+<+@HC**TMP5%;>*OW4-A'0ZY M"!(G00|8-)>\$-
<|*"@A>|* _Q5B&*L|(.|"+.WV.W45|V4F4F|2:E:|>77.1 M&/Q)\$ _HN1:~
N*Q6N1^@~.P(8@D.4.8J|E1*2(YVD<_E|&+(HAFX9QDA:~
MMXZ|*^|H1=H1\$|J)CXL|V|730..S784;I&|F:L=*=+;4+;TO:~T!U|_@L.M MAK|CK8=|@1GW8*8
W"X'0'<:5N"W":W|%YBF><|S7&"1|H"D"..=WGXQJNKZA2Q7NHQ8U%^(RNQBOK>D;~7 2=QGLH489_\$
M"*<11=07"2(4*|VD24@SHY*UBSF96(T5!;|8>|5#46Z;3MC+|8NH-H|F-Y># M:~TLT
(LPTW|SY='9X;7'E;9I L2J39N?)^(NU|H-F|9>K-NWRFO_W

X=&=1+@;*D>&QYV-6^W0Q7(=F|/(%X?U|/I0UQ>LU6;U6RVK7==ZPT|^Y M^Z<.:I9EL1;%C 4.:PU-Y?
3EOIFAHU4#H|**S MM1(:\$ZO?5&CTVHM'.NE&_0_%2MU;Z2W\$T:0>SF@:Q|YR|WVI?|(K83U\$6AP2E
M&8K"&9^E_-3^&CT
M^ZXW|5NA&V>R6KUJFLD_ZSN|*2%NHZF|2B^;M;@C3QLU8FMPO|VMN6JK@KW
M7J|_|VK.O|YKWE>Q>2|7YMM^((;CP8#IX(.9"TOD)@=@=V"%B%5 DIHMS&'
M03_X8+F"Q|Q5Y)U)96V*HOU390Q2Z9|G|OYL:NJ|V5 Z.S+Z02?VOS=@/+
M3UBF|4P1YC%#|&JA|6D@4Y_9KG,0\$\$+E|Q;+VVA/OY.9;9T4Z?B9FW|U9(MPPR=)R+KM
MA02EJ\$|=Q6%OH_4TIOW9".V==2+D+(L>0?0#2(D3D4T#SV|KRI-FKS5;>1J9K9QB5|*+@RE.:&4
M<)Z@2&8882E"1"\$2H"A7|4XSJ0?&@WW@Q*>+~.8Z;3_<9^FU<<".8%- \$ MS;Y#4^
\$^U8<0M0=WTJP>@<5UE4UL2G9>>N+@6<51Q#|X=9D*K<+~IV)FTG MC##(&4Y9BN(L#93+33-\$
F4L).V 2TM,S4_%GM8CRI2 M|J:H7<.@=RT|SC(|CJH|2J9IV"G>|WBP;=5;3F7.7P_XM)3K-J4_O="
M9Y|=I/-S^E&H1A_\$S*%0(P#;.(4'G2V9"*9 MU4G2X.*SG1N9B-
<_)3*Z|JZ%MR|/=7J|J<9UUT^L76H3X+U4NJ6;+K>OKZ M^V7%5D7U7 *4:RO=N"+9"
93FD&9VBP/1^>RA|)8ZZJCI?ZH7C|>&VY2>O...8B<%3#O^~/+HL-|M|S|_??
GM_|U|^|N%&|!H>=&O26FN75/V:|>|U/_72ZISSJ7RU M|Y!A\$M P|5&6^3|":8H" T<)0G'DA(:|A|6CV|
(>&H?RR#K%|JT;PJIX=G2 M|\$!?;+~+J@'=.8.2%."-DWZ@4QPR|X4XAO?/G/C|F'TSL'YP'B|)(^
MR2*\$N4_4?Q+U.0X2COR4!ZG|BCB9;.<#ACW|Z=O:#P|H?KM?Y!MU=|\$.VD MH;<|H<^|
(|DF20B5L^;"81|RE'&<(|HESBC.14D|6?+TYCZD5^6BK'OA#+. M_WL?M>\$G|<=|>+
QJH..BFW.1\$^8'VFVHM|_89\$4"N_WO?=5T;N0?E9ZZ(S8+|Z(|3OP8^3)27Q@6Q(B&H4 DS.
(HEFDJ&B| MP2"UJ<|D-#6T*="STGJB"7KH<.@AM"1('B'|@\$1HPPIYXN|W28(>I+W9@V MB?~
I%0\$8K\$6AK|8Y=#E#70=130@#J=\$UD"Z1.WL2^?L18)|GXX&ES;8%!(I
MVM|U(|V5=A#.KJNQ#Y)ZVVJL8?\$/EN1/7B3=7>DKX+I@1&OH-.P4_=-..V
M_8%6KXT_=.A'=)VEZ.R|B3;Y1F2.?15|H?1+)\$HB2(1:~VRG'(^3>-B#1|_FBQ
MCWH3;#6NU>G3RR*~A1OG* Q\$@G#.*H8SU0%&<")DKK|@Y|N&-FR?W31|C|_D MFHX
_A1|D&M\$P_D.&'8Q_?""RU _UL#""OP3A@R."|DT63D87W_?U1 MUT=<5S?RSVJSOG^ T<F)EJ?
Z|+P+T)K&%?MPMGP-UF)&=#G""=PNH+~K;&)+=+X6)Q?"LM?LY-*U M'+=VU89)5DF:9X&*
(B91#AF/B*8Q*NW&I>X.J>^W/AEPP1@6J|@|L-Z-P\$N.&7<303=G5SO MR'M?IX
\$.\$/5+31V8U3O'H2W-GIS_LW1-%5SJ0<'J|HL.1L57.9|L:J FZS M|^(_D%(?=%6WHJPC|H9*^C(+1BG!
<~7MTA84'O_TJ7J|YTYI6U.EM74^BU_8(L/HJ M=
(|K^D^Y<5(RM|_+\$@F|.68H:.\$CS.\$:1B@+~+J"|=RPM.. "QZK+YSN)F|@
MW5_&"T@AMQP9O|GJS0B|G|N:LGZ#-^J5\$MYCL=X|F*9%N #<8#;P'XPPW=|M
M#W3\$N^6L27+UMKQUR0V5M^5;~RT: @!GG"ZP|NPRYL<~;@?2A+GTFE.FJD|C MGRKO>|+~M0
M(IK+|\$5QD@DN(|Q|V\$Q+*=S!7:|T99>TWX#6&('|J9LVS8I7+!O3TW:~WCQ
M&F:|AINK)AWDJFDHVB73;8/+#@S3Q7"XRI #TYW|X6GJ;~^N%+/SG;|3^ MB^@-SJ;Z(K|7?
ZR:CN:~D!&3.\$'8|U/E+F?Z=>)G2"FWV>=^ AFU-\$&3GI& M2_14"B2?|4?=>|HR O#98(:N..3P>3.
G6|7'F*F^~:ZJDR?JER &0ISA"5/E6F5U#| M+X(\$(|&O8YHQ!:87X>J3P67)".H"0*!;(Y
MS77'-8H\$37\$<)2G'801VF-^B6_R|H|O#>|693+NGSHYFNBF|6U>DHIX<'@>.<|WZ8|_2+K;~W66?
X_~^)|G&^=>FA<|G^=Y0L3O4XYYOZ9,N@17M(T:|
^L.U|_G'A|MKT&UP.5|/FW*E:SBJ&|GD7H"U|P*\$ROA9V6) M2CW"N|N |0GDG#;M7\$ B7%E=,"3!>-
Y|_*<=EM=+)@65G4|EQT?H:~7"U MQ<'~+;2D^UH<~7311_>+3|4TWX8SX)
(H|1HS@4.TV:8"R7/TK|D6|1|AMSH MY">I+*Q(C;K3J=8 MMHEDJ|V 2UC
ZC0|9L&CBX6&&~>|?;K74*CN_#)H\$".0AFC;R=6,D72Z|J\$E/;>DG/4ILM@C6V M@-
W#'|C;~2PF>~UAVXY+H1G|F(YVA|D1HUDVJ@B?N+~FUE@2F2R=.C*YZ6U-O4\$B+|O4#@2ZH7N|6
MEKEX_4" X|KUPPLL)TOIO(POQ7|G-HHV8>=;~6!"2\$<~;0&TQ@P1AX5.4 M)U& X|@3M?~DA-
(TSR="PDV-*KOR#"1 M%.=(<2|".0493).4|E1,0BPI|\$L*H% ZH3?S:W|B\$A9/5#|9E"R:8FAD\$ MYTC!
|((3D"~SJ&0!~.RMM,*\$YO-9U+^4ZCU|@KSTK= M|VQW<>G6,BO DSB5|A\$L@|@J:D|@X^>RT|0%1S
M&|R#L+ SD6'Z?KWQ&KI>|H@3WB:V.XP"((#K# V|*.U7|3^*IKD?EF4CTU|
M5G(7Y(J|&DNR%5|WN<#P| MXM?7.|7B|=+~B%|(800|>)\$>T%.)XVDB?H1A|\$D>49"";K=-*

YL7&K.Z?_MOGP1W+M3OU_J4L5ZV*,ZK"OJKB9!# T\WH<(P.S@=:@N)L:<2SFU',C>A1_MC,D1QQ
8SXXX<>N\$?4<6N=H94;4_0EG\$G=*6? 3=-7Q,B+,E[LQ^LF M\$YPJXWC\$ *0?;,C).SL'/A5 &X%
M#80;W@D.+3#C1M! COU|H,D-EG.&JG>KHA)WQ>?UTU(?(!=CT<&EB 9+31VY
M:F9JUBSHC@1WR|>Z"\\WG+|>?>MD*ZCM;LP4<632"TK"-F@ @8)#+!\$!OOKYHC MSWGA(D!Z^!%
((^O/.RW)3-BC\$4J&M|GL|BXJ+|FK)FMXK0!;E M41!\$*) 90YCH0!\$C*<*8"Y_BB\$=4FN|()^1T8B/4C
\$^;)WKB=-.KS_-+Y/M MY@_R%(!;U+JG#37L?4-/!;X9Z&ZSE0+>2/*IPG9\$+_@3!5^Z-5R^PQ>.F7K
MU.R^!60%FOVV/IQ00A=EG=WQ5'/LZE1B#AR^M^-3.C#C%GX&'>W_7.0G"+S M;)>:@G.>)
%%*0TYP@&.4193@?)\$IHPD.!:;0;::&U(^YEHWL^BS<+Z=Y=) M;:6_M;:1)28\$#_!M@-!5S?LJ*.9|C3#K-
%P9(|@!&>U3;-P!HI^X4L|V_9@^#/*W\$C/SP^ MK8I7(.X!DLFSGAFJ_I54?
^ZD5!%*^!7R_!1CEGM?;TKJDU51T@6@F4XPCQ" MB8RIMFD)HEP&*0LCE*6*><(-
!9U\$BXG#CZ=8*9;M?W7E!=!KYZYK4SK&R0)PCSV\$8U)A.(P)IE. M8RDC:3SP5N6_M_R@_K+DRG?
=:0%Y_+WGU6|G>|\$_K^B_50Q7_L|H|!5:UZ|+!4_7DK^CQ+6 MD<(-
M8FIR5ME_LMZ.JIW0<_6W3;OUQ'W;OI-
>GE9+5AR_ZF>F=8/+=-VRB>"WN7'O"K7I5PN:S^9U^!#'S_+G M?
WXP^_RC/#K'+470WFB\$|'3MLL.&B|_4+5V M)TH27!UE7Y)0^?;YE)
T2K<9E'LC8;J.YTVU(60MCRY((!*>!2D*!8(BS1" M1!"):0RR|. @RT*Q:/(1OFU(N3\$.21|2@;R:A|2.WY?
R>JRTY)C>.)0TC!D M.2)!H@PT#1.4<18B*FB0LB@G/@M:>-1W939P.EIO"8UAU/.282TBEM65UR/F
M>'C7*3E<#M'.6W_ ^85;GQ#LY5.KDA99'PJ1ZN%YS_7_VWA* UUV8Z.VB7|
M+B(>9*GD&1+"YPC'+\$4YHZ%RG2@-(Q&0#&>08Q-CRA,|4)J!>I'MRP'P@-<8 M/A.#W2E0
1|H:D":0P7UCOX75_WMX8X3A^>X4.%=G=!:TYWWW!8*Q!%Y+7@! MB|*0^_O-
A|+4AP37CQOC&I'INR;6<\$6L%/=ZK*0B6:Q%\5P=)/S6!V:;H|H
MF<>C0;/BPE3W4DEAA1HGA;*KR=A?;K|RBV,B|!%5;G+X"IB=<+!>_*RQ7MP_J
MH7QY:F9\$A7%&34|KR%H M|CLG<1C6GDNE@YY6&0MFK"!#\$@PHB|JM41;UCYVRG%QL%G49\$J-
3F.%K+OJT M?"DV_Q";|T*|K(-+M>#PHD.#M=|Z,Z08|Q1GWHXUJT_2>:Q 'RHG.#G^?!TC M-'D1
@&EW|MSA-XBV_@J+AGOHS|UE6.73)T&VN4|5(?|+W|J03*(81H+ M1+*J<|G(+*,Q6GJIR;Y'VU2|
O*!>"F|Q@7L|WE1+=+"5'E+JLM3 MQ*H:01SJO|L7 MG>+/+A-
!|T5X|UR6ZI<+|88|PLJ!#1C5&B@Y(CP0R\$^C7.)\$)%%&S6H#|!B MO+Q6A0\$=1W4PA.IXTG5'+5-
>N>4*<0%QW18OZ?#Z;|>|!#UF/%VW'@|=-JZ| MEJ%)\$00<|TV*I'TU*VG2>@M9%ZF8OYA7WO?
EYF&Y|O2NYE7G6FB;4Y>|T098 MHGK021M<>5Y7=:7&?
5'P2MD.KVJ20:LFQ>.!O*A|A%@KHJMED|RA+RI6=5:.(M7G&M#R57'E."- W2Z'.E7(+*V1&D|
<./)R\$KSK?L:6UQ'L'FO:K6'Q.FIR|
M:E/6K|K.|UF3|>8S^7OY^/SX3KTVRTW_*"M,@X#X>8X8X1G"C&)\$THBB*)91
MBG..\$VXT7,2"JL1|O|L5G=WA&L|8RUW_L'A;:@PS\$=8+"OAN;#VS%RY76L M7'D=C
TW1B>,%R,'^&!;AZ#=-U|(MDC#|;:(?%H'\$&+CF?9;:3=<|L6RYA/4JL MU*.*WXOF_S^MMUN(MH!HUSE
!&<<89BR85R|DF(.B)3E"%&.>!=P6_\$TUV P+@;M";*>YY|X! 3DQ!@ZZ@IVM^5UY_3>RL6
?"LGHQ|2 M_UB43>G8%|(%9))>R/"3*XJ2^SH3C*2)2""0P9FDF\$_%IS9|9W5S@MWY=A)^11'V6&
(3:QBBKIW(SU-W|LQT#90!\$02QB S"+HX!)X.#>\$@4T|S1@8@#B*0U#L M B=V+P@L0&(HY&!;\$9&R-
^4(@AM+LQ3Q,H';>.B(RC?!GLMZ#W_!0I8K'=56 MKL0WLA(?)
_FXKP:|9*Y|WW8/(((\$,DE0RE/LT03A(I0' 459&=(R7""DB*/8#WP4I)E\$F 8< MYGB: MF2?'* &#
(.?'|8W|XF|@WK&@4P_F#UWDM/38FF>AB+|_SAH"CA^H MRV|H(.=;|QFO8'UL7#R*|;::
M3B(2FAMU4#&@-;?I;NE;TE|'6VK<;|#F)E9#\$=(\$W\$5GIE(UI\$.LI77M?% MP/6H7P-
1WS1WL6J4T|TGNF,@GCFY';|J|U5>9NUDUJYE|>OK;T(#W|Z6+)K M?
0YSZ?U\$0NT|0HJDKWTP*"88D9;SE"681TD<\$IX:52|:D9_1PU|X/Y'UZT^5 MM|)^^*KVP|JM@;>*>
(+>PIE5F0Z;*TW,@TG
M>K+2CA>09F92#|0."5='NC#B|Q|H6@%S=)QKMXIEM*1B%W=R.UH7OUA|JCL0
M+R07&>\$|0+CN&93*\$%&*&/*3@=(A3O(H3\$!AD@%B\$QNC|I8*D^|Z\$+6^5Y:F
M8OJDM+K2ANEQ655U;7=KJ?0ELB^JEP05_-8B2.H8+;EHZ|JFY=NVTU)0= MAD@,Y',5&QDB-
6|0Q\$#HHVB(R3T6A|7'Z60MWJWJ43EO\$T-L2+5@6
MT90Q@OQ<_H0%S1'U&48!#H*89#GVN5\$#HTL9F=AF7\$|0%KD8^V'S.2>B;--R
M)OUUBM#3Q1@##MIGPMKN\$/YZ6^>VW*+/M^C#H'=5=>8 L,\$#_406G^ ^PWP\$* M>XD
+M;SGX2VW-2?*-T@JUAk#TNLF5IYUO5KM|=*,XIYHAQ)D88IPEF:(L)T MAD!;
R*S2,1A"NH|R(|0>CQTRM3*S/#GS<&0!6.Z=R.K!@WX)#G/8XZ?7# M<|R2Y#(8'\$XX
Q"??;P9')A3L|TL5K'/4=JMNBT+HF\$>AU'LHX E^M@N#Q#) M,\$.I"*6A(213Z\$Y2,=D)C8G=?
L7QO&"X,@&)G9C,LEA|D&"Z&MTH'.R^0P MW>
<\$D=G3>BI=9^#JBR>E=FG04(2|(|4;.090D3*,"%^FG%K|;#7*;W8B(?S3W,T@=3A)9%02|_-
#YTS@'1508/|G1:FZ MNH+ALW+XM;|J U'>#IS>+1,K2TO)L #X4)QAL;A \$IA2M\$28=RJM|;_MSFQU-
2>8|H?4G/KS!6;>;LLE\$PLF\$ZKC M"088=SFCH%EX_N\$>P*=G\$JP?X5M&K20HBP%KS|RS;#"Z^?
-0U'J.;+.(|R M+F2&1" (PGE \$:&)0#*CDL4TX;XPJD4S(S?#X5ZUO%_K.G(|M?AI/'0KCRR M9<-
^;.(FF9ZZ XCF&YNZ7;CY=N|CO;+E.2361TEO4|2&SFA&<3P8|SG8WN
MLIBM|>0HUD)/%GX1Y>O|9W%7M+!'@&_E!3|QJRL4 1=R)2?6|Y83KV/%X|! MS^MJN:D'+N|XN0)7?
D/ &W=1)|(-9@;<0P8;(0D'P&Y.)(#.?.@X<+037RT MN-W2U>|2"P1OIHVV_2(F_1%?*_5"TB'+(H5-
!G>200CKA\$-!<.)20-B#;_M(B%SLUZU..(OU;#J4;O=-&G2%;K0809T7GW M&2
@C08@L+LO|VK5|D.9I5(F*4-Q(|1|'3E#>99AQ#F7(DOR/A|Z8;')";V M2W|2;
|1DWX4*%|R^3\$J88N|+.\$%|^+PP\$W2\$>HL(|7D!A|HZ710CUK-D|JPW
MR|WKAT=1WBM|_JTLOF|>WC4Y^8LP\$3EC28|'5_?6*%U\$4*.1 %JE@QJ2VIT
M5CI'9V+=:RA|'6FOH>VUQ.VG*@TA-.R0#N6':.6EZ*"Y2P:"68U@&EIWMFE;
M|L+U|S.97&Z1D:N^LO4@;L5N_07^8|WIT:=QC-
#\$2GK|H0_03/4/1(9UT;6J2=2*IB*CIJ=M9"O.X!2U1KZ;J*);0A^ 0 M%U-7X)IK9P \$(>X"Q(U4<_X9G%;.?
|BH|NU,XUS2 M.\$V". ;AH)1GSSH=JL8+UUS8T^\$%?LZ*@TJQG2OV@YTIO.AX;GY@R=O)I& MV&Q

-WNI@,2IO(HO M/1%*YZ6OZYFK^KW3|YI.W|BJ|K@S+;B1OV|JZDY_<*ZJIRQPVO0_P\$N.9|+ M9"?
KGI=DN82%1?|2K/_U3%9+N6S/<6^>|Q7N>I,|"+08P"G&.U=PM#1)A(
M48HQ3Q(B_!#0|G>8UL3.5)|XZ|VWY\$&900M|/K#@.8J3TOOLWN;@0@"%U MAX>=X;1X+6"6STS
04LWLL1|ELU,ECU+9GB+W3G;+V(ME&=|O>;7_%&93)WT MK|?8M8?;
|=L898R&),E1GF&JO%#)\$*6AC|)(E|7D69;"DB^-J\$YLS;Z)E;KP_M_LJ|;YBI3W3)'CNP(QPS*,U.=9P#|#-
UO_4@V6=@FS'_O_)+.C|R SFK,> M\$8%@.#PU@MU0:.(HO!?!R:C1!%?<
^I&V/OY|;UKE|D+.XDS0.D*>=(66H| M>SQ2)B661-F6B\$D?U""4H8F-
C3|S!*=G;JS1KCWO26N|VI/ZLX'O8\$P2#RQ-MR"NYY%F9F;LYGP#;DC7^B+9C';TSB2DU@U?
>0;+LWIV.,U4FC4/%RF7MY=7=OA:"4S_)N4!"Y|+AS%=[R"P-
MD(|#H=^*GD*2MIMSSI@FUC%Z=:GO^53^_FMV|?N@|AJ^EN6)>KM; Z^%.O2%\$-M)7/_@|5;|.RJ?
&5IH_:H|^NKV^|KHR|OX-Y390! M;/_&SST6X.C|61@<&R.8J%:U3@;+SU;B9"YJO|O
<)>5^MZ*XHLHKE_NZ|F> M;/_5JO76|+D@)+D65F4%PIZ?6+^M_UBRCUL?+^O->6'4_S ZYR';(2)U=
MP0/797?(0/7.1&9;1IY<>TZ--A'R0)V;K%)C"l%QSIFV@5:COLH.1Y&(<88 MI3G6
W6S!&5!PI|@/N<^"24CQ#P->I3>Q(K?C'9NZ@/@/RQ\$|G;|2ZN|_@M% M/F_TIZR+\$\$2B|=!'38_\$T
%,P**MM<0WP9HKSQ8_RHK6""IUT|AL?^PN9%_5**>%I% (MDIQ&E;:
(^C)"F/L^R@4/)=)M=/_:ISWPA8 7;_|0@KZ|5@FA-#VT*!%R)9F"
MASQ9,Z0/;U;:)V"89Q"|"@")22(4<^41J8OWKYDRK<^K MNH&0|A;+S?) R.#^&!R8.I#?491IB-
L(2.#D0_C/R;W7)"TH#-RE2KIB;.MUR_%1HS|I4U9J).3\$B22)\$X"@2BB<|0113^V%
0^7NPCMW)SV.?G) M\$S40%@D%1C@&_IS_MC^+
|Y_73|MVZXNIG;_Q|>)6ICOHU<>|N^5@GB2H6O;|?C_I80754H\$PT#4/ MBL9XL,T=\$;|3OS\$.)HB-N-
\$.BS3|ZAM*\$|7%"K_Y2Q-4\$19GHA\$.R-VK^_!2,36YR.FUY,>|N& MI_GP?OZ'("6HIG'NOVL0-
/R!'OK_.OY?>%Z;|.8/_QL"Y<|+J3BH3XS(B|D MN=)9|ZX*-M|(K|'PZMP|S1>K?
2.TJP*_|6#BQ;AMZ2|>N9Z&V.LRAK7A"8Y82GV\$J9|CRFB\$|)|SDE!*)|@V|=B(|/2;^/TNX8J/I@3
28|_0VC-MJO?N 0.?M.WW#|=8%:77_-&BIMAH>GM.U4M|3.Y)>HJ?)?J&O<7'@!CN,3YZ MMYTM;>
((VNH5:V74WA?;A=I'KP4I2AF&02(&BA"G'C'F,LP#E(F DHR2;|6@V/P9 M.A.KYI;JMR;|
J0)!;.)9>CH0'J;@-G);'EB>F4QE377WJE'X|P^2@5U"YD/KKZ?%\$S4T'W N?&-UD6|'_?JZ::
<=WQ8Z83GO|M'Y' MGI8;LJH=;'H8%OBJC|^KY49|\$^7+MD>5GO1QWT2D;O|P;* ^8&4*)9,IR11
MCDA\$)8IR/_2EP%.0;|3IV9X8@M3;V)0S9O.BIVE?+<5@<"2OZF?GID"|2;|
M\$Z"MN_WTKAW|@>JHEM>&M;Q>U.M^*2EMASR=M/RNJ#9>CT6'U7|SX>B|'G;|J
M=N>M\$)P) *_:P;GHVO94_O8@5JMNAD F?)X('*(PDBG"F3;G::2KMX7:9I%
M*0,V5.XO/W4LI&DR7%.T':VPA|P>;Q<1F#@ R*>1?_D4U)? M\$N6X;?
+)JVS52'U#BO*I*&O5K2.8|W195_GZKN!B\$=\$HS_)(IRCW=050GJ_L
M8AE*.;3\$(<28P|3JT%ZARC;|@M73<#=#J|^@-2.>Y@2J?|,PFBJD,W"l-/0B
M7"P4UTC;"S1Y>/V95=M(V&-=-|L-'ANY*|ER)3^M^=URLS+Z-|?;+&VUC3;
MPQL'\$HW;NR%@6G774GJ#NL'KCM?OBQYG=(R""|Q6=.;3|EV"">^LFK|_3I
MTUJ|JMZ+;M(U1WPNZ620TQ6&0)(AG>88PP13E6*E83;.*>|%A*AD7:W&O#|_O
MS%7K|'FCURJO7K|C@L;O8D>XBXUYQ=KCBKI7T-7RG@_ZMP^AAI6+'0290"SA
MOIY0PE&>^C|*_#|2>YG,|TAE|@6K@L;M;Z"DYF9NE!ZF*W;"MY2TXT|J8-&
M&0;".+);IRC;|KH&1#RT7T.7PHQ856X6M7&.R#&F=NK>G<>JGG;=778651L3JM.ST>LL5P|HG|DISX
_NRR/=3;C1#%T|SZMP;Q4'7\$|O' MA+?EPC(|S@1-LR^E8XQ@*FP)"3P+QUQ(5QDY|A3GSS-
_#;?|SI\$"A@-ZR.P8|#H. MIBJ9|TGM*H)|@IG3>R ((B*.(^QN^,G6N^7F|;H4I#Y|B6.?XR@D2\$ _VU"\$|
MB6C\$)))1&L68;|DE1B&|PX6G=MKUB8RF|3R.VI-|6|DOD0CHF|L) SI#.L6Y
MU6'1WD*SG0J=8K|_ '/R|Y8C;'9=G=M>SMLZU0|G*;%IJ+Z;J=K9^L1'.?S\$
M'&|NAUD6IR(Q;O/DY|;78|;U|<.3%>93,OHEN9(MO1/K=A|KC?RS;#ZPWT6Y|&4@2;33.#"C6N\$%
(FG@(|RS2."|=O^WRLNCW_9SLFCDTST8, MZLY3456BJD;4Y|;KKV?;M?_6'|>O|;_X?
ZOVL_Z74>R>;J7D_131Z?| R4 MGVZ#?|2?@^C|3_W9X9L'H7|L2ET>+959U12*M?|>|5&K2SU&|
l%8;Q|;@2F; MAZ6Z5#1C|=UWGW#Y_R;2S@A^1;J(UQB=;8UA%;2EQU^ZQSI+V*S2/U(\$(%|M%*
<<(XOCB4@2,Y1%.;1'P19 FH>|/#^U|XUJ|Z)|WHGSSSM#VZU92NU#>)K9|K|TZ;|
|'V5|NHNNO|N%|ZE-W#7; M+%^&IV-9G_>2.WXC+=;_4W.=P|\$.W>V>W@9/_O4|;_
|Z|D7;#IMBS8EV)S MS8NG;@|56|_JO.#D618U'UZ79;@_@>|H&9)*|55/RK.O)8U|YQ*<|2&|7@R
MP*#;#<9J|LI2;|6^9OF5&9+|00+WL_ZA-|LV;Z|2-TT1|U_.R%|>E;_I M^T-
|6K^ (MB)|JD41)1V8H\$@D!_%0-WE@DB;_I@FE>.#^'70Y;68?=R.Z%@EN
M; &MRVXW,UJ=/F@&TT0WWECL6@|V;C-T+MPOX-0>H|DGX MR0 B>*FB,BN6C49T9RW4Q,\$AJ-
&3;_-'1D-99OXLW8)FR|HU<(|0L9UNZ8T MX3""0C)\$ (S|I#-(G2G/ DR)FT&_K3ZHN
M|'VJ0SSZIZJ0F^|Z^L,Z7WIX&(0ETL&Q H|9X9D1|V9H#&E#3DGZ53VXXC> MV|H.<^*|VHVS-
|H8GSYG(>9 M3N?V|V2TG= T?9.S*AOTS(R.TR 0?|+X' TZ&&BX|L18C_2(>Q8SS#NRI; M>OVT?
GK>5+^+|%|S^V@EX@HDD|76D.(P%PE\$B4;.#'(DPCC%G?BYS4#;_*V)
MU;TFY066*.PGH#%39T<"PW2YGI;T+WR6OG')R7;|ZZ>%|%UPNH)2F^3J|I> MY+;)|@.W6;E|K|_|
|?^ (A\$^S6-?|P_2_8UF&2O)\$S>ZB =W=(P?F^;..BL31DAPTZG_19F*FHM(4PI&S+;C|B'K9;|>^J;|I>
MVO,V&3HEUE%'H).76:2T=&VKWHOF_X?&('+"?1O)/I&^EM1T|A|D@PV,B|'S3-
^H9|3H^L|RRB;=H+M<|,TR|=|#;#89U MECEA@;P| M&Q\$JST8&%(G8%SS+?);\$1N.D3(A-'GOH.D>H|
|L;JBI7Q|Y&#_-|@|@UH MU;\$:"/N>&@,2NNZP<8K4V_3;|&#Z;|>-H7LL%?S"L3D?_A8E6U;Z*|B7YWH;
M'B4B3G/EC-%\$=X+>;|'|^8HB#D+|2=I" &N;ZYS#B4U)2|83.|KU7)MZEHWI M/+|I'H^A|7E+T(\$6J|<
M|LOY661U|/_K5+;L.K9HGR|K3;?RJ*J_E@K
M|I'.2_O=-;0("8B"@. \$\$QDV|1UY0D.4D@RS@&98X|QVS@SF8?*_IX2 M|59U
CHP>@6&UC#"-0E<5N93D_9VM*^|+6|(%B72W%UY.V8|S8W#4)DM\$|I" M;6#Z|X;
<.;\$Y"LM9+V01NKO9/(CRT|JIVM"FL=OXI+Z(I4@E\$HSD"/85ZX A MCA"- Y|G,8Z2Q*A5RR"5J=T|3=9;
|N@@"@DEG@3&(MKD0%V89&DE|).&|X6&A M>\$R%|+ _D'-JOP0;#&Z=O7F^2-88_WMAJ|&+|?P?;9+?<
LZR;)-/SQ;8^J(%L0_E5)|G^7OS_W7WK<^2VLM_W M_!7XD)375<(IOA|)5;IDK>2S*>|*V95|Z|0?

IO"4QG=\$ZI <[2I_?0"0,|Y M<0,2,FYMXXM2R3Z 78#Z&|NGAH:VS5:Kuai+8#<3VD,;V-
RYEZ,#S9f.K@ MWDH%QIN2 2\$=,3L.49AT8S\$@XN[68>A12ZB)4EZNJY[DR%|SOUURF-+<)S2,
M81SX8G>>)1&*,0BTGF\$P^%)#,*Q\F,W952ZDNN(KO5**87H""J4@JG=<*<
MPI80;> *PHO1,|7SQS:QUVT*WKL5U|0.?4=-.M.IU"3@Q*Z0INXC"1,;F!@7= M@YD8?GKB6"%;(=?
SV6HG5>'W-I_M>? \$1DBJ",2O!;|>M_9. G& MJSFQ:QVO^TFZOT>T?|RI=98K&)<G-MTD6*|
H3QW@QDG&9QY"@<>R'/H2&#\$ MQ4HB @, WS-(L1|LP*3*,E?ZH%"6.14%R *ETK%PZUA?
E6)^%U+C.IMNR88O>1,HG=HJ^,AF/@NC@'BYG|&4RS.HIB.8H2&\$9\$ M+ %TAI4EJ%0>
(C;RVM*2!@WZ89HR'|20GB|W);>9X^U\$%F3!ANY(&.\$Z\$CI# M45L/F^R0QH0XE#" +FAQ+N-
(78"Q#T).F)AEB P9&-EVO>>1&R:(3#6HF3H:42^&227%21|)#L:04M6:G0B*D M8-
9A.4J.@&3)88;)>4AFN>Y1E4AR-3BT*. %^N: M),YR%B4D%WXER|06WLMAC@F"U,>8!)C&.,25./,PQ0B-
IDA59>>YO(P76-YF. MJDK/E;A0@)G+L)/=V"V<\$LR1^1E,ZF9GQ)VUYQ//FIMBHH:OH%;KTIXG?7
M9L9&^=8.BN#J"JL>?<KOZJ!@>U_3X:J:A,%ZPK?Y_ =BWM0=N(P71G&<800S">@9Q9R+R);
(^4TX%E",NT M:@W.8V/D96/#AL+B>IXPTB4.EI(5@|I?>WT/V_9T6C3S 8(ET/(\$5DQ=@!VM
MIA@#BC.@6#N-^1200:UUY.HV:XX^PQU.ZK2/ELY@P7>|J-/5P%^M@.V2L3/ M^UN9_&5-
6A>,+K:N%P2|3TN%_+V4?&YV3>S(@7|CR*,YA\$&1='@R"&&4TC M&-D3#P>|2@TZH)VFN3(WKY'4-
UQ\$|3-C@8:2@MB(G0DULDT)#Z,?"^&F<, M!B1#491@YC-
D=M/0D=K.N5HXA>+TIK9NOR&SM6Y%&ZP/7! ZBNGH'I_O:KP+ MUA?6TSNH W>M-
A5'P1#"FD8I&&<0A:Q2-IU0Q_*(4^%O|3 M|IT@9|D.-I-U1"D;>T1:ZKD4|, @&^ZX1C2WMM-A9?
7PLB2EF@X|U+A#66R->
M+53@|>Z1:62L60):B6W(-7B5<.;U=RW0VB_!E=7_ZPOK=X80\$H;I6H\$. *JK MA9B.6ZXV?
VT/^9G80.0X(#F. Q3#R\$M|F"<)>A9X?93C-Q23#1D47^R1&WH8I M@O)3:;\$|G?
I9\$#-.T!Q2CMX.X3UPS?V.JJ?\$.X:@PCG8\$|PA.N@.X+N#NBC_P MI)WI_# #!7AHV5"A!+3%B)F!GE*?
GK4Z5(I9Z?|: M4\ V:=#1=F?%FD(Z,NE3U":U:TW1=XU=|S6+O:V1/A:B8H:1%0NMHL?)JG'
M\$T0K&C@ MV4U.IQ|6T"S4?D=CGGR^WW4|?8)K-MN_# @UNX(^|MT6?ICWK4WB4?M
MJA*WU0.JNLY.5V51EXLY:0 MR499\$0|3B%"(?:#C"4QSDAN5*SIA*N105:?
QPNPQ677GW+#H|QIKSD%&U:M M2T'<3)O>3F?RR3|SJU/-@_'FR:G>'&VQW/
TZ4:J1IWMVMN|S=O'BJ5M-D %>JW*AZ2?-@O.13:< /7M2'N MW8BZZ.\$U@/@/Z
&UXTTTC8@VAK5H/#XTI6:-A#>'Z|85U'K 8^2ST M&Q3DL,HE|
G&\$\$8IGG"@ISB-.?:IZ|_7VN.M+69>5%,TBB%Q,|E/S6|6+/X|75N'RS?39IZZMT=|I8-!009EJ-0|";U^L-
5Y=UAAE6.^G MZFK2 BNG|53OL'SJK&JID8NCVBQ>#TFL W|!E;BPWC|5-C7+|B9-M|8BC-
LQ#&EE,\$JS'.89RX2/I3')?9+P3.L"A07MD1,SQ-MM&'F-
W>|_E:|=+>O%#NRS>4*_F_%T7C*,ZDW&\$V)=L|4N3(-BQ"LU#%OF|HO4E_6NU6=|FAIX=63/V-
U4:@T(HJX|VH?\$.F.V/'-_.6|J9IEBV+I* MN@,+|/%#X_V*&B.V342"ZL9ID%)Q|(-
Q%B4P|@B!&68(BM|G.8I1R#W?*)M@ MR,#(-KIB_*|PE:(Q*"2L2,(RO4:-U7E9@&98:QNS2S
B\$HT#/CO7D#?0I): ML0,D/Q>@X|AA9-|2%ZZ"^*;DIXW76RIG+S10.XX++|6^|Y+ A8G299 E%\$"
M(^8G\$#/AFSR?HRQ<1)GH5YHZ@2ET8-1_3+J14=U" #<2\$TV3L1*|#!-|Q9KF M6-
Y@3ZA1C'Y#Y0UM>T_481/>?|S.4K^P1K;>O*O*ESEE)?7WVM&/Q5=@JYX MN"3_-\$5|VK,0YP\$=_0"F-
_F%|=(.8I2';(@Y"?S SY%/=&X^F),VVD.87XD0 MC B6|(^=ZQ('J^8@.@-1|FUFV@6CV#T=A9CY
ZDJUS|WKZ>J#9 3,BU6+ MT&KQ^M#+,NJGY8|. M,/+IXO?-?9D-6?W3_W&Y3|<
G(AL9MN*)#@HL|/4^TG1K.(!QT>=+"IP4K|^ M:.#TPQ99C<_HQ_QI^=3MXL7>_I9_*D@E=PP?6?
006_|/3=EU;5L9:M; MZ;,H8B2*> X1X?*V0Q; G\$4IC%" Y_';,JP+|_|JG!&.>.) M54>V|
<8IAYG8EL(TIW&A;AZBR.S6ZQZ)D5>5EF#04HJD:7KI=5|O>@?.\$Z0U M<|^&@IK?
>3TJBZL|K_L\$IKWS>E3_O3NOQYT,SS*YK+L5|0N5C<+ -##+//2
MV\$|)"CD.&8R2((YCT.81E&21BPA+,MT|&UOY)'-\$T+2&)ZYK40_!5G263 MXH;RD&=G+7C?
T"!C+S3K>AB)H2.8@?'7M^"+^ -|6\$ZN;LFR*LC&X MLC.L&8WXH"NE&*Y49OIPW,% "6W"|" .+@R-
%\$74\$W(HD:KU@V1H1EEQ?C|7 MC,S5U"K@H_K;Y=O^N5|VH.-;QM&7^?@18DK 8?|
^U9N1.7S5ZIS:G6C&S MYE,*<5@".RMJUYW)^E-VYU.5_R|?
G+;+|H9^D>V&5K|O&#<Q=W+|H)JNDN| MLSQ)4H%.:1|R,5QT8L@#K(HX?
AL1C7NA|904|F1+^|J|B(O6HFSD% M+37J^077JC%S#7WJ%V|-OT5*TE&/L61<|
B:;E_%"K|HLP>M>RL\$|V M.Y8|C(H|BLW>_(6UG>QNRHK-'XJK956Q@KS>BZ-
#+>MF% 'WU7XL6"6"l?2S" MFEM^CW|<2=|'\$YJFFN-E(^|YWY=WJ)+%M%Z>1V&" TAI'L HRQ*8|S"/
|3 M*(9)Y%&SVN4IN1Y+|/Q#\$C'-&@V2((B|I(6J_<#FANZKYGG-18A2L(P="+ M|IBQ;
(\$9XUBL*0GV,A(G/*.&Y:#O=8:MUJ7|.49K5M_S%.LM=>|VVL563"4& MV)(#=.U7/_PF+?
("K*9T)1+HR:36UIY40D%PCMGB^T(91155YN!\$2;|3@L.3PN\$3V!8=OU>U>0ZB|8D/G
M7>|;F%V"!|HZIR;(#!+\$/4@ (YG8QQ.:PISC.0RI1_+JWRFBTAC2'GT'5J?
MF+13A:8/FO(N5^T5S#9GNAKEF1_R1"@SRSP.HC/88:1%/I^/,AW\$2:64G
M1|2GC=MKN6BO%XE|5&W:X5M7?7JTA&48N86M_1QJ*%Q4BA&\$/'6W9=*E. MNMDR5,7N-
LGT=8N:|ZMR(7XN6VCL'IS>5T:8_ \$5NHVZ\$5&J_)G93S>L,H|W MD2')\$N9,F109-MXF0;
<"#)#"?/FA/L(J2.=5G4\$8HAKMZJ8=JL.L)MI6'8-%T:.#3E?U;"OO-M5IFS|2"6.7.T8%V+DB|+F9H3_R&
|1=>?ZGHL|?U#L6S,-0\$K 0\$L1C&*6! M#S\$-\$4QXRB*(ASF1A7/)L1'JL4M?;DMKA4'8*Y8!_F1?
<;TXR|B6+U|GAC MJ|JACM-|SJ|1%|BL,;,%@=C=A:*, -4 (HC@B,,EYF"3\$2UA_5YU*|_7=
MS!%R6B:RW:/TWN9:,I>@ES8A-*D.2<3|N'A.9WJNXOP56*,D<,-<@9)7T5-Y M'9"S,PM#S
M(P3C&%_8Q5X&L|@+8.#R!.7\$POXQ:CPV0&OD?8 B|0+ #4.Z:C3#-VX\$-@S9 MK /7\$MU2TKT G?PC%-
-|B.@|C-:=IXS&F1|V(P&J_8+KJXD>A9B|)>5FQ3 MOLUPXL=|&,"
M+;7%@KJAZ+A875.L9XOJ82H3+ZJ#HNXOJL/G|FH?F9(CJO 3->_><56+(M0|>NG2Q/@R!,H@
B1'\$2><3#G/.29JA_ |P;K7,ZE"?+HV)|JR*3+Y<_F'9 MD=-,N88+M6N5V2|=-MJR7|M-I'JFFO1?
IOUW40M1U=|HT',W\$U=-.O|\$\$ M_2LK'RKT_#@G:-%|^4'\$6!_1"EF.%^4K8RJX=BT,C/ M@SS)2*
(%0FCNEF6%3="VOF46N"'+=1<+ B#21MF_9%IW1A MD)5TJ).SP90FA>J|HTJ0GEG5"%N2T\$Q-
"-A*@2K; IY7"GP60|D"=+4Q&#^ M|=08TZ4;-79RB|JOF->N_J5D?

*%5: ^W_+I2M;P)O\X)I:MC3*6@@W6'& ML^(5=9G.\$03+@I7+>M\$UG&!T^JYX_S N>0.*.40M?
I&V\$-I^QZ\$M\I\I-V-P7HC_+@K6W@3Y/F/D/7\ M119#"W=-N@*3HKT%LOX-0
_RGYRQ6AU52\Z9E,PF&Z8W*7I">N>J-O,YI;WV M+FO>,@!:#BY6P7G!1?N
0WQJ(ZE=WF)_27/Z.^ZZ:GAXSUW\95NPITM*Q>=3 MWPDK08O_W^~^BF3K7)0Q!
(&P@C*Y*81Z&#*9!F&*9!K5*<83)CGPI; M3*2.LKPK)FD#01Q(ZJ8(4 <5->P#W(EO>%RPE-
P"%FI(L#/ H0X..S%\$U)!H M^T!1@T_!;I0WNQ6NWO%>EIP_P_0BSC/(IB&ETC9#B\A)(8KJS\SCH/4**V
MD,K(IGFT<+0%5>C]=ULWVCR*<^IV2S9PHH<5JK>_.GZTF.O.>7T/&:J@!ARM
MX8=I3+IF#XJYNT8/VOY)""/C"YEN=SZ,VJESEIC16_B".UI9\4+Q=JZL1/MMUP>6!X*60W6\A54<
XQ10/(LCA!(?9#;#1.6(L M3D=V/RN^54&NW&5!+'F5QY#-9SID#J\K;A/&GSO-
T19F!/#\$XKD#"K6P!UZ M53YMZRK!=3L1;2_R*_0!%PNL9\B:4!_KO7\PO&*5D87:&N#C^C\3GM@6EL
M=>|=LD8G:(D(7Q9UN9A31>M_.\$1>-[X@]_V2I2@VF.IT>57E6DW3! MGIV_1W%J.H*ZPI8?
(C4MRKR&T'MX\SKO6&1HUQT,+PO:OQ>HF78+83UQR53 MW<>_EL\CS_=
1FH.R>|VYC4L3Z+D.DYR0)?050?IKIH" T#1H\ O/6@^~)2
M@PRFC08U.KPCZ\7..VRZC.J=SS8DPJAU9ZI!H(E'D"@JF1-6F0^QY9HW8Y
MXV\IC*%8S@8B:DS3ZQ05!_K&4AS:N<&BY.Z.5WU8..:QN^GITE8<^0^.#N6F;<:2+
M5Y\A\58.^YQQ;+!M?ATU4%'PM&H>)0F'M.15T?>J_4H@H\#/D_.F\6O
M_1L^M.AJ8>=LP.!S7SOL*S.8FLGY+!,O>^/V&J_:@PVYGUX_X_9'9AZ(8-:MF.Z7LD";W_0NE\9=B1-
'>1ZS/(0XR5.8T2@3/U\$"62HV53B@.<^TRE(MZ?)- M NQ65?
&FTZ\W.AM1N=. 'Y9W7SUMJQ\!)SY3ZI(<^2\7LG@-MAS%/RG?;U_1M-
FP6;>5'.4L"F.7"1459CF\$6\0AFOA=OEL49(4@W%:_\^A.2-&0FVP-
M^(_7050UH33..B.86\QKHAFKL\4.J/D^C\$QK%+J>X--ED@_)D8_?7IT&=O MJ2PE4\4S+
<@G\1@*\$A+.#..ZH!_A.8)YY&20)23F-"\$E0_:YN\$O"Y\NSPE\ MZI7'78#_ZOW#WQQ*W BR3_/X ?
>Q>>I_ZW\A!R^:QK\0N1(N;^K^6\0.A M=P'DIZ%6J_ RY@(_?97_P.DV47HY1=YDJ D_)Y%Y.<70A?
O@-:HZKIE(S9P MA>IJS?^!1!#/.NBOA>VT/0\1^=4-YYK/T^FVP(U01UHS>K2NU*7RZCM87&<
M16IWA\X.GM8N/V(I)'GSL=M_52(-4Z<2IH#_FVQ/O+/*5_ C^48HD D4(
MLYQBF*01SU@<1'YX\FSK<<C>Y9-B)&@^A'P1?F\:@';MD):9X"/#FA5SXX=
M:K.MG>@1U(OAGJZ&E%#(&.:KOMB7VQOA5P MR_O)XJ\!GG;O+!*)ZLJDU7\!++OI*DF7F^A*(Q3
'4"BX\5'X9QAS/G0\53:=9.Q=UHH1&1ZGF M6\Y.=.*\N\9J9%!G&BN#T_\$3>C6IZYQ-[A\J#R7\?
_7L\%J40-WERAJGH5_MFXMVT^ZS/(N2*!7'KPC#*MSF\$=I'A/N9P&F!;\$>&56MZ%=_\XJ=TWRL*.V
M3VS#AN\$!1TN\FJ<>UVHQ/JM.*)^Z'%P_5_#5DRXZFAA);2K_Y.6S6E/429J MV#M:&UL
H\N1KY#=#*7S+LV!0%1R@ED4P\WB4\0;- (P-/
M&T\;>@99JK#8,*N9EG4T0<N:GJU6_@NR9ML3M95%!]?@4T_C/0;+!+=^IQ1\$|
M&N\]?>G=I\$9^2OU;XLJ?_)/??6N:FF<*6L8=?YLA"/"T+O2R#8NO;-1+=:E
MW\KBX9Y53Q*\$\U.AQENV\A=P=<-8\/<8RR/_Y#3E(8X9A"\L0>I2EE&/ M^%0?_N3I20-""U-D,1+
(>)(WFCCTNGK36_<:L\X40:4!(+:+T MFKQL8_'3D5NE&#AKM\JQ\9G*G.Y>J+!A3-
8:9SFGJR\3E%0U>_R\JO^HL M^CX5-Q(A);?+IN:JIK^WXN7NJ'7_VY>+H\7M/ZU^AKA@^~JZE_5JF9^LT#1
MFL#(WD\6:4*)ZP)5M?35HXR3R4U%#_92(O2(U#3@?/4:4?&=N\Q5\W%KD2^
M6X\1W&HE8A2M_V\$J#C\^BE9W0RD_QS.Q\^3G6PJS%SOI+/@\$'#+!E.K.16&6P9SQ\$(8^\
IR4T93Y6C5:UAR;I#5\$1;+2U/9H0_L^K^F#XAP+!7<78...D-PXK*U582K.E\ C^M-6
M@MJJ9ZA6U^H@2SB(PQ>1-^F\7UXWCW2);5\1T\DFZ%2
M_NKZASCP\$6LIR.7#0Z4Z\$TJFDH8HRT^086ISP+Q2R*"0P\G (\$0TYI#AE
M>9H\$XLSK&+!%O)4D(IQ^GCW0\37DQH_U\$KL4?EK0Q2)-YMR/9_[MYA(^Q3Z
M%@YX/G^7\!5+L4\0)TPEV/S;?P77O.Y"_EF@6:R%K\$2\$ZSE=)T9>_Y M<@5P\69R3 N
+=;3M0>0\>8;3;QLMB?3;BE5C=YQ\&SZ"02ZSYG\V8IO.E_M-
G(6H@GSK^H@GCJ;S/MFZP;/B)"\$TX>)4\$(3B\XOUE#NPRC 61Q%<1HY M9LBM\T*LT3.?
PE86BZY!*I77H0I_YE5;26Z:;_4=Z&RL9?6-YO?R=?9+B34 M\$[5_V6Z\]O?DO0_KB4\$G0\ID:ICK;7B2-?;
<'I\57D&\O";D5\$;4E.EE"J%RU\A9X_U-OF^W@?X59SDQ<92_M_G\$F-FH\$DPA\ C\)%L#&T(1)BG\$-
\$TID%&0AZ3*9,+AJD#_M M4S\;S\$R3_SA?WV\ZX_ \U#E\Z\CWR7P*CZ?>N(P#"32X\30L^B78?33U"S
M<_7D)*_NLI\5JV(S\DL#((4>PF&^O-"&&5Q^K.L2*"71RGR29S\$46+BH0\2 M&=O\BO/@0A:OK(' #5--
+UZ:1BGT?;I\B.<)S;/_AUX:8)H&4%ZC8"U*8YL MZ2MJ\$J97DC.STM/ZTK-8IUHPL\X5:?!A1?QG>2I
MI#;N+?ZNO>N_&?I=U5)&*/UC6\YU613@0*L@)-F.&4)EX.HR@.)1_%(
M8T@H5+F^WD2&I6KGJ0XLNV0Z+>Q\OGL;2QZ>FKTW(Q3A9NYF6U=JYNXJD^0
MW'D9;5\$=>9G3\";U.MKBIWH9_12MO.P:4S=R%P\BLRB,*%IXNT'D,%6T#^V^#BW9\$9WHV?IXFS
Q\HX0.^6Q% MTIUM#XODR*"/\$)G4BH<%W37=\$T^;9ZTNZ5_WY1TK9P-M/?
UK63=J\;XOP=WUI5;83M;WE\$U1-IH;_2\$UG\$X..=" F?T"@_ ^=-H@2D-6 MJT3-L3\$GR\.<\$*J?
9CGUJ(7YR1#=_=#Y^")Y+G&ZS-WPV\CFZ"D^IG3W(5_M^/SE\A/8P(P9F-
U\134.SX7DAJ8W/(08YG9*0CN#.SKJ="9W2K MHSOY\!G) M2WPZW(YWP^W7\XIG5=OV335WG
4(IR1.90Q<5G/3/(4HP0S&_4D99G&&46B< MKW3\IV<@^0#\$!6L#.%=@#4B;"UHS(X+C@Q")
\Z61J#\!64RM\ASEAEFP-SPI M=AE)EPITF81TPM?T>4>7ZCR8:G1*P\;Z4CY\0Z%FI(2\1E4?^S7.CR
M8K(<^9D)XB"?OJCE&>BN_(H\8\$\$_/8QIR\$D\H);^P3R&B:4.(HOE@K M-SDBCR\Y>M=
I\ZNPTIV;#L%CRR)X\$CRV\IR(5JPPGF2P\D4Q"IXEIP:H1B-- MY\ 'R>39.'+P0\$?
O>^BUGN4=X9_N_'%G_WPXT\J%'PJ6X\2>A\9IE)4LY.2**0EDPU4E4C" I MC3V51?H<7<+*IZ?
BT<%0Q2\1.D-'='&!^&1B(I'238N+K;@A\$;F=3YG5>Z M)O\HL0Z)8^Y3@L(48J(ZW#;?
9D\$6B^4^J_T_0Q2Q;%:H6\4H\PU2\$_+B>2M M\$^E3-PK.@UI3*.
(PMA+_ABQ\ C\HV(-9XY DMNX7G>8.6\$E"AH.T=S4\%6585H\LFRIE\R_62#=# M69Y13&B;
(0MH*\$Y)E(I3\$LEA2B.*O#3*LIP(P\$>7\CE^N+WCI+(59U&)7.R MS6L+N_/OY?Q9N=<^6#3.*0U3CXI?
5K*;G43J*8P=AO84Z/F.11KYD8Z#D"? M!;#B >!E P078G/9*QTEXT;S"1WUKM\ D^S\$[10.E+'?P<P?
8MIF+-51VR3\ C\QU3 MA49:RX\$6#+-V@IP?#PE*AVZ:UC@TZ7W3HAUE9RZ\2SUK@)PKK+)_9:6==K
M5.+I\LE?CU=UGZ.YSL("07)RD4B\Q9F^A#"G-(X9P2S* Z35.P&2N%_1'8#_MAO2-+'S-A?

8'OKKI80R*8*3#S&=IA%D,F9\@&/DT@HCX\')&TJEM)R #Y*7GS?0KO(*4;_R=7V%R/'-&4M=N(.3 M,*
(^9:.\$C6H. \$E8#6;!O5\^/5^29HD6BU>Y' NCA= _I&IT8EP=I#C?R%FLI
M8=VQTW93>JG_T4%T=3P9H.)KJNKTGFL\$+1D>L0P4-\$*AD:'|=A#UFC2F ZOW M\$WH+?MIP5;M-
7*^5T94J\7-C*=1B),HDD'1 8RH4'(>1Q0R&N=1GB8Q#U.3 M?=H^B9&W8O?
R%4!;6OVN7&9[B@.JT=LVG">PE5'W:%Y CJI\1?^X)(f6j0,\$ M)EVZCPNXNSH//&F^/11-
17#Q^8@F,IE(4QI@ZEB%MXP'GCD15E"
f7KU'5;R9R304J>-8B\62K\9\#:\$NC36IMZ\84SIF+F@/SG@72*H/470!/LX7 M2P7Y-
@+2L:U2'&U@C,E/NKV05<[NYL=Z',L.6'7-Y%U>G'D4H1QRX4M@O!(\$ M, ^,%D
8>#OF/,Y1\$)@>1=MA)#A\I(D3+L4-5*K><+S&4QS-<,"V#>'6J+7U8"-4ZV&IM.S/O+BOVZ<I
[*F.A\$XHODDZGF, M\SDU9E)P06EWH&D)\^!#@T;F8 4ZAT@*UL/O%NC+9HS_O= 8+2>\$&>HC/8<
MO+>N1B1847\;W:DD*49^FH8PCX, 1GG*(8DACG-@CC-PR+ K-\$\JU2LCYXA M5YE
L"SF#7A0760D3*2"AJS?36>BG=FD1/Q_R\\$.N)_#*)!@?SIG\$&4I3SR4 MR)*&J\&%RGXNK?
K:M@&Z\I\$^!(V\Q1IR6R3<8FNVA6HE4)_\$Q\IDE/, MOO;LP M9?
OOL;>PG(SI.C0=H6\Q1_M*0ASC4EX&>V\$JUNY9I>*O&Z2%U(MPB'(/\$NYC M&\$41LP<\18+?:H M?
IZ.N\$SS\&3P8WB4?1E=TG8C=[.KM\BS\XHU9_M.DNR1I+N'7OU?QM2RA, M<8RX7"Q*54S?
>N\94W9H"7Q\5D-I&UHG<9HY0DH1KFMV^T6&^7ELT5S"81^E,
MBX1Y2MPL,,R3+U@:K=Q.18J*OI1%5\\$_VRY(<4X(B2#65LM3#Z(PQ-1/XB#"
M"&=A3(VL\BBIDDOF1_8EQW\$ G\>1*0R:7F^L>LJF9CKS M.7(8S?L31XZN\N:R7Z7LS;FW'
M1N7=MLJPJNXV)C99<,>M&QJUW=9C6"-VE\$IAQ9KX:(0+K"0%PA80<1&>_9G
MA,9QXL\$H\9%LQ\$9@'44IA\$-<,(H\Q13HM#E:V0WTZ.L\CR0\FWPX8OL5^! MABG6(=7I;><<*<
<0TCKZMBRVR#N%S3LOF"C%G@.*T(#FG1=[#Q=%XY1V4BGZ= MU_JY4S'VJ1#&Q^I&U@M\GA?
JY\$)R'J\IV&6 JC+\$ (P\ P(^H00FF:>A\I M*C@,&1_9Y4C*D O28-11!M50L>#;3N+
(Q\11V;RH^BQ.E\$1#Y"@95\$JCKT M G1"08.SJ>4TO/4YU93MO>9U7(R1BT0U:0?<
I:IKZC@IY?;E/=3=0^L!U^> ML\B\H\3/B\JZ= /DV5*:N<'I"JG@6= K:0MM=#(<%Sj^'=XQ.G.>(. "10IR
MPP\;GM86J*YO^7\@.6-;2559KP_ED\H7LR", LYSE.9PL\@)*_NY)0&T).7
MY8@?;R&HT6GM.*VQ3VN2L@Q:+=2%BH"B#OYLZ1\568 MG\9."^CJM#9
:=K3VFF1\TYK&J\8(B8BB8EZRL&FV(IGOD^IT.OI&'& @I& M.)1%\5D(XSC"/,+83YA1I&6?
Q.AFW!'4'\L"8&7\;Q@QNAI^WK1L\CSI#4S MU(V@&VJ.8;).B^4*3F^?P+2(>4<%W
/%,_ZDP\7U^@>KR%PAIPF&4Z9>/^0R)'N.7L9<_D_R M\8; UTU:6T9M
>S1.X3RRQCV\VZ5P5.KZM.#Q^73.(W7\O9RA)LCP0YP4/
M)01&/D\@GPJAP983\$.A1@Q=F2'J\DYR4^P=00WL\0?WI>:42MF/FCEI\$+ ML&9EU:%ES"D/4&
(M=/8AYPFL_2ZR1T(A\J,, "D_\$XSS@ M2<*,L\$;Y&?L>D59(03;>D72X\I,29VK.C;#Z\+AKA2R\I%5H?
25^O*WNR^_%C.>4)#YC MD*,LA)"<^6_\$#LIG"2<\$YPY&D="=HC'W<4U1\1_8"2,+R/")ZSFI(?T;
M.OY'4ILY\$RN!M9V'AD@#B1#Q=NL+Q\;S TYB1FK2'4RE1U'K7<=S#<;ZA M7_Z8US-\$2(HYYI
2SX<1BQ%\$- XA2\W8RT@8XMBHL=P^B9&-3Q+L042/R5- MPX3';UH+O=G26MF=(;"FJ_51V5QM?
SN\$YAV13TJX-XB>?Q)R^(R\LCHW0("Y),W1%G^O>I:L\YAD1HORWQ>6286A)FD\$XQ&D 0ASY(
MBY62&)6-GJ-,H\P9VF7\5=G<_0M.54SA2X5RCE;F1+L.*% ^GX8/4S_NFWW M.J.4ACF6::2
(AC%F0>S*,@/15/*64Q8X\G=[-0C^T8QCU636T\9#U-ZCDW
M\IOL,"N3ZC("92&)7B,QZ1*=%;#92Q\ZBL\G;#EHSDB8>7&:>C#U,IEI M"B*(TMR#" (4>2F,
<,9P;U83T1Q^1.3\JHTSE/B,4)Q Q*4^80@%F:4YAF M 8I(EF=YDLP*U4V6CJ6\O-5
G\JD.M#S:M8S;^!\#K2?;)HJCI?J@/E'7*+ M:'%0L#%Z2;YARBC)2\I(IR%;EOV*54;\$\I4KL_ELC>XL#%I-
=2\$!;='1-BNK#X\A-T"N\X&\8M/->#S0G T7_W\X*EM-DD\I@"7-Z)>VDYC\4"(8A) 1W\F M8L,=
USLM.=#;QT<0\MF)K^Y+W8A;Y9U7_#%;EGQ.6I0PE0'CE93;,*3+K2F MRMA=@XW?MX"]
I:Y<11%MDK&Q\JLJC_62ZH(EET3\HR/TI9\G?7?F25+??(MR),TABP/ W%82"*(F1^(PT+.\$HSS-/6U
@GN6!H\;IE=HLK+2L;G2K; 8\L7 M:%BQ0H62#N\%0:>)7\@
Q)N;O57S7)6A\UL>9A+,%W'W@Y8TW;-JX)R M4E/2<2E<7K%Z0S\><@H4JY//@0"1^1S88?
^NYJ3;2@TMFTIW14-M8X_H>H_MQ<+4+N?2A-'J+J0+TO\X#9A4;?)<3R+TYX8L?
0V9DP)+%;J&LY@;fWWV0* M?<'VFD82(+)=EZHT6HNT?CA")G4\7(%JQ&TK3
M(1DIU"P:B/W8\^"&_ TT%G2YQ9GOLHCO&!7HOR&4X@7G.*.1B MJ?68'V:AV560"7D?>67NMS,YI^;
(E#JF1Y\G_-DCX8XAHQ1GX#&-K"Y\$ 3 MM>UMP83@&XG8R\#(>_6+?K1V7^S3=NS)#;SC>\$'2-
;RB5501W?{3) M@KA'!>G'<8\I-Y:\$-Z4%6=S8?#KMF<1#KPD"#%D(4I@%(4!1#@-8(2"/7B
M(.8T7&4B\H\#^H\H\2R2G??FGN)*VLMB\3Y;V>U\JZ-W\2SLX;VJV%^GOU MM#LZ%V^AV;1^?O:HF?
DNE:VQUGP2+00\Z@>5G0&Y5R8T>O:GX1J^3I=[9X M89_+HGFL9WF0\HCE8051"-2.9 RQUH
MV9M*RP9AJFF;1==;S'49:1ZH2Y<_U2#94%24C^6JQW)5L\H5E:M@N)R. MY\4DR%^56_/&NWE;M!?
R)9"16#(+.5%QN?E8E%^ERIUG6KZ?W45 M,7>A^<% ^5D\$IHN/N\#5ECOEA\K6E_2O^KK'V3Q\<
=;'VN M&K&225L^/560+IH6>)K1!_1QTX\$M M2M:#70""UK%N;5E,319+
ME7=L(7R_LN>RZK;F6\I M@POB&A79!!SG&5.S9 F\I4YGWV\>KPVZ%Y^G)*JYB M06ZRP(N*OJ\IF3-
&7=,'UHK6\KL=&NKJOBH;ZCM\6:@2^-/WW^BM?.\$G\ MOEE(TF(7?O52T7\59H*
:F17=?'^&2%W;8I M%F73/OA=9E.^KY@I#.^>Y5PWS(N>>XDIU%Q\;2_\$7?P\F8IM,N;^ (9,O:!
M4T^_8S?I4+=6?M,%_1#',,\$68,Y0E6.NB@!7UL1,!* 2PQ\+FD#
M/P\BKI\#;VOEC4B=6\ISLRD)2=0L@)\V4\$N0\$^C-U*C-RN-&H?DC%5H\$(8; M4Y5VH;
<15&H6\I_5R6\;S'C0Z>.)@MO)NQ;ZL\I&W'4@O#9G=2_=HD%\$X@T M,YK'GA^&\$?33F,"(9 SFB%-
(<@1%/-Y2(V*-5)C^RR6T9D=\$9%E0UO8^DK
M4"JU/HY:S+SQ5G;D*.SM31M25^>PSQ)K7F"K+AS>3W+6"6N+FCI\$YIVBL;Q
M008N:9F/8'Z8^MBM6^V'(K^3&_&;>D8HCK)8N(XX3CT842^'"(NSL/A*/>C ME"615B.>
1IC\Z\$ZJELVH CK\I&.:>?T2)P2R.G\=&W.R M8\@)H?JGL5.VJWM+1+"-1%M5_4=ZW4HC;WCU&9="T\<
M(>KNPGG\J3-ADKM_38OF#_#Q(LYP@CF.4,PPH1 E)\$44ASFB;ACBP DKN M4YDF"+E&#NY^<
(VN"TT=JO#>M*-39XIO560TEQP>JCD0X*=#YR\>K:0"/+!AJV993+?(2HV*="DG"),1.%,&L@N)8G)<
LC1G/M<*7@U3>TBR' M6ID8Z,G>+(VD=VB63GJX: GFU"R#MS?+P,0L TNS/(S6_4IL:Y7*0^SE&4

MPC3(\$ABQ)("OPGD*\$U3SGUZ%K;YAM#8AO=>*VD;-G:;BN|+:W+C1@>:-T M\$ _Y,|/-
JR4;:0.^1>4,D|'UAA_'0#SQO9[C7G#/22) #|BCO&W*&N8>SD\$K4'HDI(%O:8L:(=9G&M/N:1EV%JA 8|
H|CK^6*XQ:UL495()IT/Y8Q-QU=W_G)\$A3MRM6-P.*F7'E'%NPY^3%(6)23?D(*=EQCHG|\$/
MB8DCON9Z3KO/^"LC:/|'"Z&UQN5C<5ZBH93|(V>LZQ9S'G\$20QB2&4>:!CF%?%?
MPLKXG">)&JDHB_=1K,A;U 8:WF89\|F?+,O*"D"-QR MH'BZ "LU;K\$%5GR!VP((SD"?M2DT:U!B,H6&
|4I-QM.T6<7)N1H:K#RQ'GRZ M"HSY=^J1#EL,+LS@BH&OR2D6C+:RTQ?M??X9AX-
LX0S'P9YGL\$(YQ',_%S| M9Y1*;/L@/#26:|^J1&|FS*^)^F.^X3ZM';/+L3VLPMS<".L*^1UGL7EO;|O:K
M>C(ZVGJ>(#;|+E)A-T-H>9;YI>7;H0<9<&\$NY#W-EX_%52&\$W3O(QU^>V2S
ME"3TK_T<\$7#8\$MW(9F9|'3VP(G@!!\$EY86>)%F!09J-+-,B6=V+.3+D9%==
MAD7JWUXY:3=DJC5J_PKDP\$Z,>@MWY21S)#G1QC3'.8HS"*.(58+* PQ8@P MG\$:
(A4;+I3TK(INL^%X"|"2E!6.M?C06%=T;PBG=(Z|9;?:91HYAQ:GBI
M|B9CN/ASS9Z;:O7*PMPMX.=KR='B?@8CDR|YRML=U/@8.0S@.KP.70B? 2, MLL;E#?H/Q5--1?
G%J*NWOLSDK*\$9'\$&&96@ ^ (8 5\$>B)HB'F#,2)(%6D4U MX|Z|N&C RIG&P8L8.?&
&F20|/_H^5&|8E#H?5&X-&|?C7^|E.@E:C G'^^&C M:MDE7-PXC\$Z/#C>JP@^"P8U+T3(8M+7TH(*?
UUMJM0?Y:4I?^C-%!8HZE/ M\$(SR((68QR%,4)SG"G(8|@H/&3(P,@^>|4 1|U(^&:#VT)G-?*"^|R!9JE?
M&W:8.M:Z9M1|1?T:Q|V-|E|X.MK=CJ\$_.F0P|B4I29<1.M.R4|O|D4SEY\$ MRW8<^XM.+=
|E=4\$ _HH;-AKV%\$VG-W(&OH%:7FPX*<1.5INT1)|_8="@" M0|>:#CH>3)6G5_3("ZGUJJ"/-E(+I&:?
J|YV91M%H-|+|F*%0GL^M.!:>WF015X6.8C3A KM^3'\$3.@Q#|TP
M3UG(46)TB=.5|HSQ%|@T>M/S@*ZT89B@.P|JX#P|KB/@B"*KV^2&=
<16@|=|ZRXBH(K4)7|&&\$S=".SF3\$.B00^E+0=@4X."V:5+S|RY&3YF&1^OGR\$T^."F"
MN&0S/V\$AS63RA|A_A*DO&T1PF) @|PD3NY LTVD084K8R%+-^T&TP*C;6/HG
ML"E|O66TS'T8F;-9NGMB9/8/^N2|H4L7EC=M.-J|JO(X|D+.8IB%A,-(N|R(@X1#\$J#
QSGQ0Y_GE7TY%N#JD8S<#\$5_R;F MNBN%?JQ^V=0.*A1Z/E)|KS^+&7T\$H7|Q?<
OO|>V::OS3&F89S"D/KRCF*6 M91 E*(8A"6C*(A;G<=#-|W5!-:SO)+AC#G^7|N"@=#
|^TRQ9F3M/4Z:8:1N MLJYX:Y\$NG*\$|O|D|O/N.>+M|_W_2#^ (= \$S7#>|8 ^8A@T_MZ?^0M)"/MY^
MFQ?L4|>3H7UAU|>SU-T-\$%'=+M/^I^2 : X<'2./BVBU5EZ8-C)SM.G1>N? MJ36>ML==<^<:
(|J=L_KR|_E74|HW&<8A1%.,DI%=MA%,(LP!|T2|PB MSXL|/I&ZS#L1OV/'VU;| 2(8-
\$=|&7.F|8|HTC_9IY+8=|L.+|:|ZA8 =* M|L7OUO.C|>@W^5I=<%(L)<0&P\$@.LY6@;V2A)|!3%+:S-
!#IWB(XS)K>3@^Q, MH/I#6#U3D#7?L?2.=953HYOG.#K R*ZW?QX5A"O5W!T(F7! MRF6|
<^Y1+4|U,R#M7)Z&^=\$ (6: ^T*4NC/9S)V6UVLX='W6RW=Q)P?J;N=:/
M6Y9FH'FE2K1_00MH|>|&6M^K_:\$ M^*IKUB%I M|2H7# L6SIT+O>W8E!HVS%*N8JU"!<
Q|Q1W8,7>|5@SV(^7K'H^#3I6F&N M"BG.96?:8@M'RMLKR' U|KBY97D)|E|>09YE:4@P#4)(6.
|B(49S'.<0>JA M."4)X4GN_@IVGX.1:/X3K-QLLL;|L_UMI9LQ|T7;44/Q-'WN>4|=\$R>A M_-3?
939Z3SVV:>G|@LO"3-\$BT6K_+#,3Q/7Y|9|P=WT+5E3;|)L|G M'9^..#TV>E|X_K+H M
R&U1GXO(ROW|?\$SB^#S/V<|2*#:>1|DB1?|B'M4 D^&,\$|3/_R*\$|Z>.-&
M5\$QL#43J7Z08=,|+7E9/|:=;L062ER7% F9RO=1.M|&9K& MS&R|Y0 (%K;1S%HNP)^*#R 9
8H3S8L|9HR@) <0V-VD)&"WG(A|CQT7L-M62|KHP_N'XX (TWU,0@0J3W8=("OIO)M 4
:OVQ1:D_NB^5QY:WTW2KW_LO MC9V\$HW|MZT8%&|3'UU_ |M|S?
N6E*=W*M8"&CJOH|(YNX|W5|J|LO:MD::K M9C|DP%81^|'\$|.(+JM/OG%|_D)!A/&UP(S*%%=WF\$B.
QS*)KS4%|N.-\$H@ MSDD L4^X%PQ&|SQ>M4>;4*#+|Q;+ M^;FLFADG./|1'D,4Q|&""&
(?'\$Z|1GU4,*|S"-:X#=#1\$9V!&LHA@U=T|(V M1YW8T^P|J;N2VLRV+02V0HX)M%9
|H|@TZ.07%,K\$,P%\$>?M3?! |U\$E?C* M%Z_=%Y9\$2=Q&LEK'&)E#OT,XD08I#!+|B\$4,QQHMP8|0F,J
UR3M;_7>7H MFH|9(EM:G|T5L9W1)ZS;&|WS,E-|XA0ARSOV*,6L;EUF%VLJ@?O9L|(16(S MH|02|Q
MK?&4|A?#|-96AIDJ1_R6.=2IQXY(W,|RJG<7V|L(T(FU.U6|F MHIL,FMSV;D\$D;)|H3O5A\$|SJA>
|0)K8;|2@ZUK4Q8J1/-3K4)K,L<@.P;A MQ?RA/=K+RM/M|J% VGEX!\$ON A"6NG
4C#="E/FE@PE(UNT\$*VV%L M6ZEW@8|V"RBUK1C6\$R\$VX*.-
S,>+6W=;\$7I+/_DBFGGBAY8\$01_MB0=EDD/R^1H M13Y"9-*=UC0W?7UQ-
_6M7|%75S2O^IO+^2J;KK/3K?R|)"|8^?TY\$Y"%KJM
MT|PU^.;JE|DX5EYIWW@|*OBPO;F0V1)P&;4H@|S)|J.TCV""\$BTC"MVZ5>1M7Y&*&W>+L942*W19K0|
|HML-8K|02VO^|ZXB
MMH|5|75W7S;PM@OS,FL>2;JH^-1=^G;%&=BLMIOM=)52"L@+WW|Z"#2N@Y45_M,Z"EG-;
|=Z,2,1.BH|?^K4#1MM&DR\$MMI\$;|&8;%-A(FY_DV'TWMLT-/RC MARFUAD SPE&2(11 XL<^C|C?
043EY>P4)|G'8N|9%K6AH>8'-G7K)H:MLA: M*|4E:PD5STN?WTFEJ#K2=;V|SU5|BZ-X=-#O_8@@#
<|*+>3X/#(=V^D|& M!UG|6S4U"%RZW:&@|0L_7UWJ^J6?V4OK%BR^D:HZ/J|<'\$%6EPMZZ9|\$MY.
M7K8HBX??YB|BEZG*1=55BEARS+D"17%BY-G/ M8F?
L_6+O|M|J*O:9&8<4@6'.H/+SD\$2HFNX+H|N*5:=ND|^9(TY%/IGE#ESV^ MTLT=LQ=-N7+|YS\$SK;-
UHK@|M^IF5-N45-V(XY+PR^KLI'LQ;^JOWW|O@L\$) MCJ(XB1\$.,<\$P|G_X)3Z-\$ A|I'G(5&8\$2#U\$9V?
X*.X3678=WH)|J8<26R: MGUJ|H5|_*<+@@U3"SZ/DJC3\$=):R&J(U<>9*0^S|I);.2W;F_*D@E2QY^|C:
M?W|J%(W"A#"FH1?Y7DYH9M1@?IC<^+4P"JCN4<=<&.*7WA"
M97LQ9TBS'S(2@=|PD|2'N%6K9Z;|FI8AXA-7;*J(2B!"E6=M|P3;-< &%DV MXH|RA1KV4%:O)O
3|U|>V5#7-,*J_!Q&%I3Z?(SA:4S|W970*0S\$HC56R MZ_"(DV6W!@7|H;&|I3L75I?+R<>|/>4T^%?
0+>F)&'4R/C#&R+4D2 MAOU*CPE|VH9H M%_..IB>\$MN|K>FS@;N;GA!OK|?H>O#IV7-'|"
S>)|1>F(1\$G;|1' M;J-A|+\$T""|)LK C%H\$4T(I)|VPN3T.O|W-,&JM.G.|(EWS|R<2"0|_WN?QIH
M;=B|1|2F;4?;QO>1YA5S+0XLY*=<31F<'5V'.W9W:%ML3BW+L|N" |WKL^HW M6|=E.|4KR|A?F<-
X_BGS413095ZE^F3|1G>^!OO)1=..35F17P4>^O ^B: MS+!:#"S>GS^U8Q6%=.!M|4;?'|DQ?
KOJU^BBH%*71(1|B|SFK|>@VGO@5L M_UQV:"14|GOX(+2|4)>#G|5A\$9"GUU="C;_#@90|QL-
|TU87.9M^X+6|QN ML9S<5>Q&?/6_@>2F?FOOYV=|?E\$%"<>%Z6Y=#+Q=(1Y7D@JYY3Z#.>D"PF
MC&5:5<^G"(U|C|IZ7I2OC(E07N8:GL5CC|J4Q5.7 *U:Y|0F06PD*.6#XM# M6PZI46-!
<:0P\$DX=,9&#,%&*P/CA1A#:IP6"&.G)Z<(-> M;NC|Z=R:AA1;?DSG>;N@|56L.G

2.ZMCA\$;&0'UB.V@MO2BM:YT8.:G=L5? MT1TA4:PGH*- [2"I2<.T.D+O:FFUWCFC2-JF*V]7QW=35IS-
Y3)>"[41GB6 MQ0&)&Y1#BH0+B&+DPRS(*X\GZ*]7?0%/VT7M^Z_?D AW^/IN>G
M5>RLI;D&*8O3Y6X2?/M=SE=YL>Z6_UXS53\$X(PG&*. 93,(DAA%A(<1:RB/
M0NR%F<_3'.EY:7/BHSO?#;+=HHW859(6'*XK;E4.-<&QRTSQ6J<0-TKRUEM
MSUXWK;+KS0E^VC+DT31G<0=38/G1C?GA^O,RNT/PF3H1V31V;".M4=W3H\$16
M;4^'1YRLTFF0H'Z)T_"#QVRIK_7?Q\$ _|/L?B/^ (2IG_|_|O| 4\$L#!0 M (,Y "%G0|:3&\$94 %,C|P 5
&UL MY+W9EINYHWGW;L0OSX&7|+)6&;2VKE#J2RC|N&RX, 8F|4Z1,,E4E
M\WTR)Q'#OCY0^6UL:O4*D7\$|"0\$0A\$ _/_N/+Z4_?<+&KK_X|_|_H M7_^(B|_SA>??A;:R9|O?
OLOYL ^QYW? UVN?YM|IW|> ^WEKRZG| TB?2S _M^?_|^N9#^HQ? DQGRU68I;K RT_UO|^J?
WUCR05^/9U^_9OA7|AR|_U M-WY^/B=\$\$*WK?
JOZ_A7_^2_+Z9>OIWCQL|++|/_E_HOH2J5&O|E^>AHBG MZYI,.DXGZTH|I>K14BK26\$Q&6<%
(A,E\$@\$*NX#;.^*9H9I5.(FSY7F)I&I M5L,2TU|_S;_|3!_|U Y M"B|@90-L28?
&2HOL(+*OKW:3ZNL*2,9(AT7&1=D."Z6"XMT1|DW(70^&S|_M#00Z(\$B?IZ?YXE^7Q?
Q+ "UVMY@TDMU\$+D?N7GXCK@HL%YC<;K3S(W)JS%9E3 M7/|F"XW_H.PH\$|_|?
X>OIX7|TD64:N8&\$30\$K&@\$E'/\$)AB"152Q1331/FW
M%MX*|Z)_'PBSTX@|OX7TWE^.%).SB20&+B4=H%)H<"XKT%*(\$@6R M%\$(30-
Q8=BLXR/|AL+|L.P'#QT68+;=5|>_9DY:RXT#%50AB;|(|@+86R\$^* MP3+'T"A.H?
\$@=)=&14O)RM|HOOKZ:G^/_L2|3%1'J1B+SJ5"=# MYBUEH|/0 +G3/A:4J>3#7)S;*VZ% MTO"@Z28|??:
X^?IE4(L|7;+4GG&/4 M6G%(BH(FE0|"MX+D4I2,/FOCA6^@)NK;H4"TSL*#|!D%TAX3:|@DS86O_?
M2/|X?'XV6RV^/Y|GG&0GO?,4>0LM LFF& C5R@G4+@\$>F:_'11;\$+53FSO
M.&DGYRY@|S|13J3^*9ENLE1G%M"B|:|H:Z2XQ\$4MQI"BAZLL#88B4GST@P
M#RR_%51<|U|I(=LN0/(L9U+|AOP;Z8SY).D;|_|!S'1*.F|C|'CCF|*P"B3 M,=+Q|@ "Y9^FMP.%
|H>A.NT4&&)B*9)*.AMPFE%W \$5 ZF\$<^1T MQ^"Q'3|NK;X=.CK.=383;4|0>3=?
KL+I_SO|NG:J.0ORFZ, 9;.#Q8J#H).J M9A CET:K?%@;_.&UMX-'Q|G/1F(=&1S5ZCU;8%C3K;\$8QET
YY4'%:6%8#R' MPH2)Q@E5|&\$..QO75M@- QYG.O44WLLKKG?GIN|_SV65NCAATT1%'TM;..+V|
M.O'IBTW6>P*K/2RW=70%|53?<7KS(!&.K/X/F,X6!%TNXL?ZA0G0B0T-I.O M,=0CLB.3
J(1)NEWK,'7;U=70%|f=3?<5|S(!&.K/Z/BU#KDCY|_Q+G|Q.E M#*DD>YB'>6&X|Q7>)UL^I=|L|A|@G7
MF7CA2F',2-#')E-:&026,F0IN2E>21YLDXU_?=7M,|Q|O)@4781#CP_6U|Q M;.>YF*Z1)!V?
+"3DOS+EH(&E%GBO) 9P4%G2QEE\$,K'EV!T'BL=6W@T;W^<<& MHNT"
(J|G|&DDCNDW?|!%6X9RM"7(9HLH<,KDY9/6"(JO'-'2;08FT\$4)J 9'| M5| ^N?
JK|1&0#T78|D7K|OW@>50A|OO@^83%|EPH'7B0AW+A\$|K I@\$\$9\$TA. M*;3(0Y8=#M
=)^#W%^07>#@PY=P>OK+V7(ZP^5R\$D.TB6F"<1\$4"Y=".(Y& MT|F(O#C+8S:'!13W++H=#KK/-
NXOR"YPI/(++C|1D?>WQ?SWU>?G|R|?P^S|_M)"G&@N8*8JSUPLK1R6>U@T"1D95,2NUU SS'IZ
M0;T35L18(@15+^M-O9/E0=*1)X/EO!'?'PLS<6W-|=#0<<|Q0#%V 0(B_\$LM
M)|FGOW_X3');GIRMZLN>&EE/9);:Z%3?;'F*j5V,X-%\$R%A-(6;I=8M*R|=H MV
XD'624S.%CM.8343;R>N=*R9>T4^6\$^D4DX6\$P VC
MTPVEA2ABAIAR9#IR5I@Z"!4/++P=*#1.8+80:%>8V#Q,VS"A; H&N88B7;R7 M=|H<3P%D=,XQ\$Y-
@AUUS/|CT=L_|.LY:MA%J,V3|T|W|!F&?K#_4_V3MR|>
MOOWP|@5| ^DS>L7SSZ^?/' +LS?/WCY_>?%?7|H^_.\$F"UN^XW_Z4QL|H M^1 M_|_|)PMX5,(7R?
KDKB*BI/R:CH+LS0E;PW;_XN\$;<|6A-(R5"EU&<;AH'W
MS@)CUF7|LE;LL=Q/"KY<5/KK;@+G3M:V\$NUGBV7.)J>"N,+JDOES_P&!(N+|<#<0|XG%TD_IS
MA^N2"1|1K*0Y&|+ #S3OX?3,YRX;|_M)P%)60_* M*QF|N ++Z #76GA98F/L;\$58#U@Z" #SH;71
<0^?)XO5A|Q|>7U|H|N5|J5N M+R=>|,25E9"* (1ZTYQ|MIB^>&S2U@91K;8WNHV.<_BC#
>A@68^ (E^H3MZY3 M|FCUN@M>X#<|G7^M+R>?)?HZ)9;>8T+;_% \$4+XL8I*=8 @T(9"0DP1V%B8:#
MP<)>Y#B\$RM\$^YSOLM/4XWE?;@.8+@|X8519-QWL@002+PS2_.,KSI9(C)ZL M/E.P>EV.\$|FJ
*4%25NC,A5IFR0)@|N>G61*RL=>J.QCE|8@:YPF+<_9J=:: MZ."4NTF%LX&0|%&K,D)E8N
R|CYE05=3"Q)^VBIZA'.|CC|7(8#S/2W1|; MU4X;61WYE|QL?
K^|C20.&:YNG9KZ_H65Q;F\$W66D@QU^O1B.3,J0@,ZKY|H|TN|Z@LSBC56|LN'4Z_=J)H*P"D^
M@%*K*E7*2.>|X|_|H|V36*X_/U2+NB:2G"1OW\$|P.6(U5T@';_H:2%XQ<-|^8 M1|X\$.E-
Q: ^K6X8Q.>\$XD/N>,2LX7|B|'#?MO4S1N\$G(@9#540@>0NAZ1WN%%
M4SQJA78@8A53S:0ZD1Q(I)8I^K#_6Q=R/D;N%G(@>#43 %=Y 3N"FDBD|>\$ M(4!OM<&%
(>|R1|LAVAA18F"/=;|O(U'/FX&??J5GR|PK|JSD6M% M@Y50:'.05=8*G*JE>L|GYG-(4NW;Z?DFXJ
\$34H>KH-S=3M2O<.)S2ID-MF04D:VOAEN?@=6:@;&N8Z%0*S3.
<#U/3C5|UX%'81A4=@.I&YL.ZD(4E6J64 MH)*H+|XQ@Y21U|_(ITRM2|YV33D-=|J%
H.3X3L+NP"NO762FFW<+|2',2%8= M09RERDK*.CH6#111F|B@)|@ MD9|TO#A5VUZ6XD|Y+L
+X2\$H5)1C"O9_"G28;?'S=M|'55C531A=-|K>G5 MYFU>|5J|X"2X(@-M'R;EZB;642I>
<@%F|^40\$7#V&^SVVCW'E.TMZ'|@.JS MG-?5%>'T79CFU|GX>N43LT)P?GU'E=A.LA,BQF=
@OGZ5T|N7L-*PPO|_R3=|5)'_9C8L" M+&>%XH|\$!'E/E|P|>F&^>|Z.JG\$S20-AJK\$R.H#7-
0|6.6=MIKG_SSA; M3K|A'93|!=-,E|NWN#H|'|.DX@V^A3JDZM.T.?BN1|'|:(L2DD=D:O6=74|
MDCANNFDH8S:@FCLX5VI3;O.BO.D(=180Q53P)F\$U=L.R?/D0_|F+M4C)MI M&@A+!PH@US!4|*1
B+SND"9ET/|4Y#.%9"SIDXD25?&_U^L.K?<48>CY5|_M.EPMS6|V_|YN|H8J^8RK:2+?
^@8_K1JZW5SB6-W='F'LF*W>F&\$F|IY(DO|';G**P@;4_&H9O|?;(KLPB|&*+
&DU;9RB';@0&\$2=@^2<8IC0 MOKG=09FJ<50 |8*0';)4NZBA_Z_J6NJ\$=N|8BVZO.ZBO;/%NE?
|1&J=|<_* M.KKZ(-Z1(Z\$|@R*2Y9+389"&2*T_0=;8\$&N#@ (V8:A1J+?)6EZZY2U;O|Q|E!|Q@=1(Z7=;:
S720 =P^AO.2\$;GQ.NS_&4Z
MFU;YU(YF%^P8'KWRR@*Y>-7I4X4\$Y0+HD&WQB5MO6C=5>8*D<_.V82#54@L=
M@J.D".V8\$*,&KCOM>H|8=T5_FB/2"^9+D(|GKJ@HAQ@|5A@'.8I#NXMKMD MX.K">L(%VIR|_J|5
B7J;QM5GQ*BC9S0|J5O74|P#QGCVE|?;_J9=T#7&JA MP|OY;'Z3E8O>T1=2X@F5|D)#<*'6N6.JNZF
|,2;D"JHT+KP)X*DDOR1D;2VH4(=A.Q=|6.MD3MICO&6H|FRLNUEO9&=Z M \$7OTF)W#YEWX I=C=

f8T/4Z1H-/ZE<3KJ-,(R)!)+DA>B MLQ)*D:(HY@6_::R:/BR_1<{(SOCPZ&JEBMU1Y3>HFN&G>I?
#^K=8>,<6J.GF*E#A/H?CYV/8I M^8/"FH@ZQ:S. 7%:N2HD\A%:ZVT\XP\H9IWF7^)1U<.L M.*
M% "I"\$.LBTRQ(2G2,9VZ*)QYTI R+^&&P&NS)^1%@U48-'20;KM(DKTB.
MFQ?/9I34>1YE/EO^@F6^.'HKI3^@JVE@?XED7:Z MEL?&FDI*0T923<"3J&/XLH.0G-898N;9)6FP=3?7
=D9IQ0>(JW1B^ZIV0;\$ MXODY_@5G6*.K248G5?0<4J@V8MT34(E K@CC-D4KN1@&PG=(&?
>D'@Y^A\F MCS.95U=;Z=FW.#VMJ94_SJ5IYU7^OT2EM.TR0I=2%%#9B+63C8:O).%HBW<
M:Y>XM:UIM2.)XYI?0X!M2!UU8+|N'N9>%%1OF#!6QR1TJ1=N8MTH"3S%WX#6 M<(:*T=?6?8?
N)637>02;O-Q(OIZIE%PO.BU@06 X22:PEU0(I MV6.K& 5\$W.;(6F?1'B!EW.8POP#.C+O
#K_@76@\$N9G=(Z&3_CV!\$O\$Q4FY M4P-[84R%""\$SXH9";954,>U!)N59XD5,J>MD_
!\$3CN&I4A8#:6;DP_#U.S?7>5(I?-/L-?^L?0&N>M>?7<:@UPUC6#>
M&./L.V:H*5%JDG>5.=P!ZF"4YRWKI39D<2F\$>B\$ _A)ICL\IT&3+OHR.'(? M0=-GH3;.C9OR7:#@+%?
L0Z'CD>CRIWDWL\$QNDU#G7?SQ5IOJH5B&L16FYAY MTP\A4H!%)8\L9TC>:W*!
KMV2)HE'1V""JR.9W.:3ZV(I CCP24.73=16|N M(<9?S1?
DH.PVHSS2IX^+,%L2@Y7_65I_Z70#A/S_G6T*:+80T\1AL(D\A.
MY5KT4!N\)/IA&5<^A)3:/UJZ@.=E"==VP0;F1QI=3YR?9+3<^D.R*91*<8)_8H&-"E.>E)LO-
IQ)0K'HVO=I45IIV4%':Z109% M0I>'S3U.7S+CO'QJDPB-L\2.LN0<6E;
4>#+ "A9A<^LDQ"/D=%".#)*6^GJ MQ^K7IFBP/DS MAV6"M+<=3^;MOY^B:XDF4\$69.?N>CO!?
M.V6QWRFOWIVEB*A.@6PI Y63-BY?O/ISW\^/_OB?>OK6;3^IF0W=BYWVYO*1
MQCW"9)V*%73>T\F08D3PA% PP."*60IR X8SDMLVBCR
^XJ\USTRLYBP#.SP5.#\$A*%\$B1!.R1&&06Y&#SZWO31XE:-PD M;GOXM)-^!U"Z/8SHG
N96*0I8:\$&C*!TS."DR*!9,.G0.<^:=&ZGY)Q.&96#+B0K77QES%(4P9F#PE.PTOA @45K8I0M<,>.^0AO
M.VBE0I@=NDUOJ&MLWXH5SLB"*95@.@K!T\$X\!5'E.(J)AMJKKU IVI5'12 M\MM(P_MI/P!U
A."IJ)TS7N#FOZJG=.,I^>GIZ_FBI_#(D^R2LF6Z""&6B&; M4AU S"5@8B.*
((OSI5OH\1B)X':GHBX^SQQ./5T@+Z!%=C2>AVM=6"EIMV8 MH@
2480BM=4*B\!46MNG_0KA!ZR#TJEM^W70?+?&T!/?<3&=9IHJBU6C<^I. MM#.K74%6'S"A)7^O
_.@42"D:+D@JXXAMC_GIAH\ V1GR^!Z3-J(6D9)A
M'V&Q"/+5^42.%V<+VAOOUFMM1@9=\$G\HRN0#Z5YI%:9QT7IL;3:P_%;Z;+Y.;JO\7?
UW^UG*CH4^2IH5FM==! M"N!407N/(8>0@^E\1BR\2@;O=O)<9'95E=-%".^P-=ZFUVQ)=%X;
I0'&V1M MS.TU'1HE BNV:&U=XJKIVZ@M"!N\W*Q:I#JP%I\$ 5"-CJIRHF(VI W=7B@.2VV*X|>C&9PX
VG@A%56NO:Z*EB3FE M DE;#PJY <D+7\NKH@._H%@?J!"+;+C&="M4N@O*UK3\$;
QRUPAJ"^MC\IL48?SH1=61E-;.#I0LKXH.L2_T8Z9G)!S MU?JZ_&"BMT/PG^?:ZF@*[A?1ZRVI%;^U2A-
S=86R4.0*10XA21*Y0XKK? Q! M'M,\$M/SG^>"ZUCJH0#.5VF&Y9,2Y0'65;/X\$>FJ?M MML.?
XE:M*WATL%UN=HJ32OA0-ARO6>1WI_B/NHP!1Q8 M6_5RUF:RW3T58JB# \$9D
MM0%DF23H":1PI@7WL9A!ZDYVKI'C?XJKG-5 MT!1(QV\T\ S#O\YZ< (? S4\OOST8I4NI^=JTOGH?
EYU>G\^7EUT.@I&Z MAHX1'4SWRWF=11M_N7I;^0+OIY= MSG!_EE;3;YM+S0L)>0B.YTI-
@H6E&8!HN<;N+(I-P5L!1@;X6(.ULULSJ1X\$PWFV@6_#E(S5D&(4D,161I4 MF*,<)&"I0FX-G5\A-
P7V1ZFK@Y JP)Y31=TTI?G^Y)2>BS+I7L\I W/(4@ ME\$-BPM;)6JJ(>JID T+
(H@M&PTKKAI'T#6NA>P.D,U5.6JEQ;K4B:1YG?J3 MFZ!7Z9G7Y;\$UHOI,LW/2/HGLP^?
Z7<^XN++ZIDW/-?) "CEO%0)7,RE.NH: M0@D1/_R5QT,K?LY@,U: <0,>I SM&X0>E1=
IHY.OT'M##_5-AIMXJ#U-E%!"Z#L,HH>9?9024648K+/>H3&^ WGC/ECK M#H#*?
90\ AQP/8MEI(AO)^FJ.(WGC&7DM1H.BV!*<06D##;S\$H-BK2MW
MMJ=NW;=EW0%W(+6_0#B+EO02=%\$S^?JO^W)U_K5J@WZ.OTV^U!B_AI-NZ M3U.)7""%?
X"FI9,S% CWN66 M/JOY^A.*?HYI\U+5%G%JP?PCU;+I%!(7)AL@NUAY/;#A3Z^A Z.?2T>BL
MI;6MW_KN1VEO'6B.XO6(2AP5K?NRTM)OJE_>E_G')4.I76S\$U"4@%1,!"< MT4;Z""JJ?
RJ(I.VH7BWG\I%!=G>.LD;QW;::;\$ _A+V:S@ (9^7LY8R\6:F" MFG?BS&*H!?,C/5;
<6NBO'T_M'6^EFTMVXPPZ,KE08Z/6J?I4W"ZEWXOO8> MHO/BQB\Y=HH,7\$#/@HIK\H@IA9G%VZ
M S='=_4LRY\$JL:.-U%64M0*%6,B%(KT MK0JM*WIVH: ^W_B?0FC(A74 QNV+HB.Z<*%Y>BTRMJH
MUK=IVU/76Z.408 XD+*C2MN#L/A?GI"?WB8TIQ_6Q+DR -JITUR 5+3S/5V9MA6%9
M0@Y&\$4.*T^8R\$8K6D@5C9;.MP^GB>JR1KP9*NY4.K1441=)F3LLW5LZQ*O0
MC"@T#)B2UOPT4AP)0E;I\$JW>6N/?+V+@T=GGWT=IWL*KZ0.IBGA#S\A7) MM_.0_#6L:@_)
I^LIX:>GF#%;FMF5I>832A9\LOBVC1.>...L-ZR";(VM#":Y*HRMFF&BD?.Z\5U"WF+B?
Y:*TL2I%#I,+4"TV\$@.P M-I\$4);#PYG.P'Z>HRUCFN&C;2SD=0.UZF<:I090\$IK4V&=N\$;Y,VI%
IDJ@NPXICF+;#5=2!==M>?I.D4I2*DZ&6I5X\KMOB
M>@Z.A.>IS\HTG^_U/77C5G(=&84*.*V#X/8E\9=\$.=C+I+G./N\$IFXGLPI ML_7:UNS;^&T6O>K?K?
U+YI\LT?7/O-B7<^OHN%O.UBE<;>XW46)O.1I/OOZI70MRG!Z(# D#J&8#ESDB\XS MM1L-I;I3"F-
SYD(I0ZM(1)G(YT&#I5I9(+).H?7@I5LDC-Q=P@UWRE3WU_F
M'4#F0BRUK)Z^O.KXG^5\B2UO=;I?FVP\$09U5:L%"JBC:QFW420XK5N68B M(D2BCR.
<I60V@>MV\T./U.*KL KKK&O_U<[F]&=WT>O.V)/IRMGH\7_TG MKG?E)#@9+<8(D;F\IG-
I2Z\I\HHO4TYY.-*K.E;5S|>%\$S\$W(K.KI!LO6 MHOG>UM(G)259XQGR^D.EIN;-&W@^&^CVDS;.%)
AM-53A9? JS\I.-S^>S MY?QTFI-Y@I%WU\@_*><0#*>7%O/*3IKHC(M&05&<@FAA(WBE'2@C#/-*9L-:
M9R*.\$I P/=1.2R?E-/1D3%QIEA;7Z5S9>G(<"5 U);#RDI%PC"XT/R^Z0X5
MX\JOXV\JSE7387KIUFQI-/OR)2R^S\MR^FDV+=.4Z%.W;1'H;/A*@DIU5G\$/ M2I;E)I/M
\$IORSVN';AOIS(PU5!"QYC9.S\RY=J7U
MZ*>J3DXUW\$EV;N+?"1A_G)."-^BDIR;6H*@(VJH9);'4@Y+^7"RH?UBI0PRZ?7'L_O8:RV_NPV
MYFH_5AH9K+KX>K#GE;I_!486I'26.0BR7ADH52<I*P8B.&Y#*=ZZUB7*C\I%\$ M<-
'B/9HM2T2YU8E"L9ER74.L*QIH>C)\$N'-RI>8FOI_ "A\XYJH9KBX4Y\8 M3_G=VJ;+%UI3:R_AIG&:
ION<1B\2DR2V&JMWXSXO-JTRL\$2455NK+S5H62,>1 M%XR#YXB>91-*I\VC\I%\$>+^XB.O
&V9%XEK#X;7RD?))'C.*R"DRE%\$P\1L MWS;U#ADC)^9;8>I N-OXP@7=K0=XMYA1.\$GFG-72A;?A?9I-
U"^ (9KO:Q)(I^ M7AN+LCW)C2S+Q8+OZH(4^K^I6/"JFC1G-.XZ.IR"K"%^(&A%18&Y%-HJ'V(;

MX*WXT0U*(>_?X&KX_1J+PB9E)*(H/1Z+Y1"VTIQL-YG&X+QB;6^K=F%OG&M
M4EO\W%,3/XR>NK59Y_T;R?(9F>>W@==Z^Z\0;/L:/V/-JF2F71:IKGZM MY=F%=\CK/HJZSRZ<<5U
K%./W<(J7;"2,X)H01J;#V<>="<"#YIV>;QZU9K M7^VR\WZ;5YL-?7 Z>0XIT193T62@J"4"EN"B%-Q8U?
I4.;O;Z+FK@;Y9[CG M>'KOULB^P+B7
IC^=VU,XUT2&EF\^L'WW#HS. @%9=A;0QU2+);S\$P#7A2)>0 MG#78_*7*_90-;
ME@;ZOSO;G"1=VL+UD\MA\5"B;I9;4D[K\$&1;WCIE?9."@V_6KHEM\|EOYRN\#|2N.*.D
M,W2@88!;%0W18(%D8DJT8T0RK=;L;4WE8-M)D5JJWF,Y!0'+D;E5V<.5#0;%C4=D-
+ZUM;SQS0INV\B?Y.RBSKZ=E-B'7B? MK@V\W\WM5N?M)#=V5)\AL%>A/B\\${=-4=7=6LRWN"(9++_2
M,I75O2K';WU\$HZKQQPAKY7R%Q6PZ^U0?YZI5?
0FKF+AEECN@XB6@ONZW/K<*_QF\$5CB7\$+O/FR8="IOY%)+;G@V0NGF;5D>
M(F9DAZL%#NXT5FDB^&X-O\4"T/I@;A_Y=&I'13(T7J;R--R7K@VO5BV,ME M+D%DHW6%D3_-
G2<0!1L@<S,SDSB>K G(CI7U*2\$|O<_"M_DI_71>WQA\|PVSRI\NO...5XWO9FJ<_M(W=V9'XKA\;|
<'4<2LE4)E(R\3K?@0 YV M\$#9I%,WGX'3Q &Z7'6:0<2%B\H?U3J>."(ZL.&#:EU0\!A%:RZA\ S@>"@^Q
ME;MHLN-,>NTD/MU4NY*Y2?/UZ\ M\|8LJ6A9(*&ADAF#K4SRN,55 N-6_1MPN\A\NZ+1;15N?
LBK36>HA8WZ_F M&K\85L Z+-QE5*(T\|ZV\$X4C-SL8#%MW+=M@>NO6\$7PHV\|Q%?I8SY1=-^=M
M3->#!#4R590/_QC^N<\46CE"O? F)=U#&@1%S*#D)AF3KMH?OZRT?(3 Y M^>29'7X\$W6N.UB
Z"VTP%0H@F"TA<<:ZQ1%#:WP\^1L^X)J85)NX9A=Q&|V: MCI_A_-B?/T3=.K ES(|&)+|/ZB-
2=F"R%9OY/#3^OBX6C&K1=PIESQC*X"6C M6,,D0V&&03#>A83::KPIY_"!!-U3*XW_-
*ZIZB\|L27L1=VM*MNOU<=\$\$8;-|<M^&XK'+.%R?UL#=-*1!%RZHT("EO>-
/16%4K40!\$@(&HYKW8QJNE\|=*.K,Q M" C6K_O,-F=0*Y;WDN)C/Z-NTR?=O.+O#
MG\XD.^,@F_I^+V(\$YX(;1/7J\!US;>L\4KCN-.|C)V@RJH6\|^VY8'^O+ MT\$&?)VO<-
Q67->Q=8R&7I%#@*IKEFJ>2YZWA5(D0M3")\|084N--2I2&7\| M_X4\$3?OFPV?\$U=|6|
|.OM)NN\|HQ7.M.V%%"3|+1GR(\|FOC\|T=N9N*)J<\$: MG3U\|6\|=MP'9\RX-MP%JJIEMS=E^|K?U-UR.-?
EQWL_%TJ/H= #PJE\|=&+ MJ0U2#
3A\5B9++GWRAG5_)7C@#W"ZHOD#YC.%IL.!M_"|+0*JM5\|2&BX\|I>*IPU6>Z&+Z\$4(|U@.HKFO.|"7|
FZ; '> M7?N;J2T^= ?C68P..K;<;2\GKO^UX#L M:D^HPGEP 4\$&YVH33PN_8W6KDL! M5.QQQ=
'G63K5G\| #M:|0F_|-^Z\NUH4XA-+L.%GPJF MC\$68TCP.?I*J+AN&|8**A\U(\$T5T<-
%SQ=&O=6K1VB">E#?SFF.-?+G632 Z->U3G"H\$@66,"OKDTVL>0^8'6D<|U9\4-@-H*1NS\|'|>(.R(D^
MJ\|E#-;.;|+2\U6M(^3L;T07PI9#|25@@@9)-! KIC Q*QM80>QOWG\|H\$HW6
M\|=PK9,JNLY\|Q4C\|15%9+R\KPK/+R7"FC&MJR\|P|=5UUh-H%#0^;FZ8*Z=00
MW.GM="*Q>>CSAQ'-;2+?5C3'QM">Z3M2ST_5'KM_8OLA.OJZGJ-:"@ (TXELNS+YN?
W3J\7\1%U_ \0C\|D@6(B7MG;1@3(U#JBA\X \$ M\NH>BU8N+4'"1031)O@Q?3TC;
+;Q;53LB"0:ZT\|>5D8X*GSADE5GQ7*\$Q MK;N%|DEJ\|U\$=|'0(Q>8\$KKZE1_-EM-JSP+Z;45P)6H39JY
*?0TW?DU'.GE1<#%DPTXF+<.&Y@1(^BZFY/ MY\$?ZHNU_.C_|H8,W=1OPU-ZM_59,C=-8;P7F?
PV0U#Q)4M S\|706\|441NEE MUN\|X/DYE:O^M91P&VW@H*ZUR.4.LP(28Z#\|Q#7QO8LU\!MS1_@)0?
J5G; M+FBY;>):..**#0_D-+I>() ^1^ARJJ-5<7'6_?STL(;@='Q2=67\$F0>6VGX\$;D
M%NF\|J)FDH*G^H'55\|AYDCGN\|A.(PVI\|P\$8'S\|O6DF(U^HP-SS?8LHG7:1) M""@"IYA=>6-+
J_Z&ZC\|W:6/G9%@I M@LF;W?#+|ZN5UNO<+G4Q.>JL\$T3+)9E7Q2%&'H%|ITU-A=L\|HWM1&'OK>IV
MP="=|W X775KMM\|68Q\|G9?49X\|ER.B\|_)787JZ7\|KWX4\|KE\|=DMRN)B=8
MH8H2G\$-2.6^:B+F8\|3-&://A&A,XTW=Q>2\$M\|C:|)%\|,UN)RPD\$S%Q*+4B M65F=:6?
2\|C1>6:>CL1H;9\|QN\$#\GF'ZP"Y+N-O'95QN\|&R^_V:TS_%3O\|H\$ MF^_K-
HAOLCS\|4OH;O9^JHP\|19R8E83F5&39Y\|!N)T>>:K)UK#HZFTUM MBM6Z..%JL8-)L>'76.-
<3B6\VB#CA?>UWBN\|VCAR)\VT"Y\|F%0H5H3/M'7 M+IU%0TST1PI;";%>D8G\|6JF\|H)#A,*GD/-E:
%#(#_4B@);.;ND=,TO ML+;AJ^-64;N@9=643NK\|C\|C6>?J7HAF15K?ZK\|?I7&<|2IV=_3)<3CCJ8
MK\|B@1@=*I=JL,R70G*\|1R3H>6\|NN6Y#5"%AL#513\$|8NX^A%_OY"), MG.(16B?J4-5<7=)
D;6*4\$3VY""PXF3K-V9;D-4-UMI X2&H=)+IU\|;OJ# M\| O;G;_BEXB+2;9%LL@E9*7(Y?
1<0TB1\|=R8*X4D9\|*MV&KDI_U@H;6X#M MC\|WTA+9?OEJ^>Z_3.M0S?2\|^K_AZ7J\|L\|XRJ\$ *B-
\|3H8HK*T95,HW.8@ MA6_=)6(|RL8-3X\|YE+923T^@N\|Z1\|O)WOF5S8CQSS^KL2DY^+TO@/08(60MI
MG3/2M'ZNM\!G1B\|A@C9QN\|XU45=/'6\|P\^WJV6JXEQL\|M>=\$E9RL<,%6OCH4R M\$(P5Q)3\|+
()QY?J>CODW26G\$YRU\|!%#<#M0(YV"2UPX" MJBM#:"*2/LEG5 MJ>ET0,2@#?*>D;6>M?
P(.9V<&*4045\|5\$JF7J\|C-9;4A MG*369E4++>^AW^\$G"+A<8%USX;Z0%<5^-+OIWK?
T(H9V4/A9@F0=0DGAQ M+"@41-SN01G6T\|1?("43D UF.??0 \$=X.CC(LR6M'*MH\|MT;R#I7+NMN\|X>
MCCYR>?J?G>J-G4H*WCOPK\|X"A1@1Z\|S>EZ5L-IFD5K\|8RW\|JF\|P&H>2?;
M\|0#90\|YG^/W7L\|@|KEZ=S?+RW,Y3.)6S\|PJR3PP4=Q1HL6C\|91*HIS)M"X1 MOY^2<=\$V'C+FS=74
=A^>^ "W^3=-@UCWDQG M^)\H^M)RD@JCR^OV&CL005Q E;33.,AT#+ 2O6M?
='4KSN+U/CGCM<025=@#A MYV\YN3YEHO_4#J+?PNF-'55=-!\$!X&Z2C4&01N="UG3"
&XX\|D4IQG*UB'0 MUL1UDJ_ ^"F9NS\|>1(\$=//:8+#[N\|!%<&68S0G\$D.*4" Y*3A1*-<(F(KIU
M1_W'*>HDCST&|ANJJMOG/O=-53R@'OFQCQMN#.20=<./3O03B4N;E:ECC0E=
M2E=T4>0;2I&*TO\|W\$DA'9Q_#V5-N0C*9I8_?0X4* 4+SED*SIW/2\|8U"-?|JO;
M>Y\|Y\|YDLLCOH25TFGF*W6QD>@325_6_1%X% \5ZQFF%2HG6;
MO\!;XX\|J#+"&4Y7'0#Q<>\$|^T;K@|H=TD-YUQ;>N?#Q\|^/2,R:|O^@F6^MP#K;4J5_ ^ISXF*|6;4#
(VS"Y&-Y)U-ZX"4T=?%QH.LP?&"6 MIDX-#0?
&G7)%QT5&!QOEM@|NBN=O"V+IMQFY1=5*|^K)YW42 S)^EA6U;Z# M18%GC+
|3+#!|FD8ZLUD_:=R9R7.M\|/#_J\|T?#9\|K_5.ZLO2\|.;^UPG-Q_8#QTR)#K;|/7RH&5O Y) MDZK.I;@E-
84\$|CDE<#(B&'V\|C\|BGE4SK&"(=2%Z2_9"> M^>2>OHM,TS,0*
JD(MUW\|5UG\|WRRXMU+Z_|L_*9D\|!%):I?>G"13=I&*T;_!E\$?DM<2593@8.&&256\|+@)!<0
MLW;J.*ZE;?T\; NR>DDZM<3#?%CE\| (RWRM#Y?4@(@C;4D\$|@ZQ%/%^NS<,POT M#;D &C'9UN_-
MR"K4^NV+Q2VA=J>>ND :B>E3\|>.,G+1TX\|YK\|2\$|9V..) M@F?9@;&@A2?
M\$H72Q\$OR*7O:@T(VGYGR "GCYJJ\|E\$+^7< H\|OD&TENJ#(*+"I7VYH%,M.& MOD3IN2RVJ-*Z?

F1U6O L7WSI MHO9YFJ_E53/*%XPY)J(WP0/R.A:.(R>!2:0-XV-06J@<6@-L: ^+&S9H.#;=A M=-0! ^.H(E-
7B+!%5%09Z1&#^1YBXW4M:(A%"0JENH4D[@C?) ,7/(.0K.L'4Y
MZS%ZMH*8^5\$AUDP3' :#J05E=W5Q8F9VW4D-MU@Y*94:1L)0@.4KF"K>E^3.Z MIZGJI;HDC*S5?
JKI&6SK.H2)+!^86MQ=4J&M8W@&SXVI+H%4,<04>.M6.8I3-MU&EN84_I;PNOW971
:1NC.8B(M)TK2?Z_A3/9X:=7_VO?_X@|Q-1C'9.UW<% MG/C.7\$,L2.8)V=B#K+Q%XD9D'E &8(XB
M<^6S! ^? (W3"EOM.J)0=L'6@|1D^G&9&+!>:NBMC?7LY7X;11:=#5'IH\$D^M ML41|H/C--&!7G
AM+?9!>P=6.AZ^MW:K>:W'?O+>=N"W+.JXSPCZIX6V(= MHSA??<9%G81#GHE5N3.:
f0IU3F.M49U.^=\$O+E:C4|Y4NFX_J/+P8!9A.QJ MRPZLB7P;Z#2+R\$ \$SI%P93<%LZ|!)P+WM5-
5.O%TD:H3;9NIW(FWJ.1 M6A2PB=>R.D2*XRT'*0+CR\$)T*C^%MBW7&C<:&
X6%R9K")'W\$1E4CEZ2W9E_M1_P%9UBFJ^7SS::>I*A%C"E"?;D.|3\$G^&B1_?BB5W,*;!-M #/%
(UI&@X/
MLP"TT@_*R)DHN%R2LL+I*|1+;C++U0.D#96D1WA7?|C8|:LR6C;&M)B*'!'-5@"T15,"4FK16M@|"
M*1KW9O-X*&NHEPY0MI7<)EYHZ80BBVPHZE6|7G34Z5R!&^>L.13.#) H>YJP
M<+WCV|9&FJH65JB=*!>K_O6=DAHN|@-J|VGP54K5WTFY'B M0ED4A%0I%|D4|FE(V-74W8AYVA+:-
JK|BX5XV/E(7>+G@X3.K=X>2|B0F M5%'Z6HR.)3.??K-W2L'ET^'T'#9%#J\$6=TUBLY?B-7G-
BYYSR0RC:QU8? \$I=(S?-WE M|7.PI#M\$R_D.\$IZEDF4|HZRK8LG@LPY06*+(\$+/*S9_HW4_)N:;E<T_
9D| MQ-T#:*8S/"D;TWMN)*VJ>0'N(&F!0/QJB*5FE@ (3.E"D:U/K8LR|5/0%EGUT M>QLNAPFZ
ZC.Y4QJ)>%M<|5QJ:NVIRY".C0R#C|D.&S6//ZFY|4ET MH)2|P|G:|.5B^TBM'?
IH@*M00\$E5(*1D0(IH=" @%1?-!>_1TE/PO+N.X7.MG@(? \$3CKJH#.&/G-/;PN_/^+%S19RLB1@5).U-
:W|J)+L@XM5<24<\$+?;B#S M0/'%_9_? \$P|V5=R|K11| T+MWYT^X|D,+
|JTFV"CC1P<|XJL*R+XM)ZGX9.) M; >1P^V7EEI"XO5)/(NSX(3"Y7*DG_V-
F.PGV5YA0AJ_0#UCP7\$C\$Z#@'|06"1Z%A)*Y9_ZY M-'R_(^;N6N.6*QP/*GM*MU.PO)J?+2Z>7@|F0L-
Y)*YVF(Q@2^<-JAUSHX)
ME/P@HW*UU+@U|D>#RIZR|14ITV|7N(")N\$*0E&VGJ69C"0C:2%|D@I>)7YI
M=.V.2+E<:MR7T.=#RGZR|10IY'0JF^6K.S5'3?(0#GA@M2.V\$3C+Q6KR/LP^;9+4.C+'F?-1Z4GH;
P5/P M%|H.CP-(*\$)/@D+0EWTEJZ?-6J?AM5#|F0N0_9=U6|QZ2&UGA0X8_IE_.OEP./XR%
M(%V'.RD>Z|D6P6|=J&O
MIQS|GH!XY*ZWJ7;&#F9N"FOY|JR:W)/R+|^K(TZ6DU"XU(IV9N%URC5:|&*M_'=DRC"54Y*WD/9
%//\$0CUEY@^#3'.Q=FJ<7L|2G;J++W#SWU?SQ3M<3.>Y M-K;
(VB=F&0(BB4LEAW4X.H(ABRYK3_.L.0S48S3VE.0?SD@UTU(776UN2NV7 ML)PN/Q
U(9_ CTLM67>\$^+|4GDP0:A#20GR:P9((=)|3HV+9^I(LMJYX MVI:VGH+Q-
K@;|'M|'8S/;NVH4|@RLFDR"R\$|20>%^M8<4\$G?&8)>"Q2B&@L MR|JM=#VV2D|N>O.C|0"! =G
>WN3E8G96Y>3#JAH|K&I*NL3<::S0Z4\$L.1T M|1SF2%YTYH=
0"@NE.A:W=O3UU/%PU#V*)FFAG;&M7RU8_GY:M7I+VCOPO? MZW>O\$%|-%L5%|_.9ZO/RXG(OG:
f4\$ Q|YG:G#D\$SP4AR&D(FVV>BL+M>O* M/=U#-+!:@PK^!T#5LT)KW>!P,T1;FG-
^C=;Y>2\$@<(&_)A_01@JH#+J|/"05_M9=JN=JL|.5MAS_V9L=4/3)*^*8PUC'J%HOQG)07-2G9\$*#-
"+&XH41)33% MWDY|WZH.TE^#Y1|7S^#6=AMGI?V|LNUO,EZD1K^NMI(C?A>5A^OG(53LI)
M)U^6BMX.=%|TB.0DKU5B.J.G^"I&ZMBH|JZ*+V|Z|N?JV2|NR'QR61|+<MV+"|G^GSG;/FQW-
RMEK6X;#3V:>)TEF:8C5H3_E4(":#E0S09*Z55L;Q|4"Y MV|K:0>Z'2/4/+?5.36=K:|P^+ON'H>ODY7X?
2|&_8D:HY).5^?9A>R|K)V MGE4>=.\$J9.T3M|L5O.V|:P^E&O UK+OFMD7;?%|V|8Z8G/C|4H.NA:P*60
M4ZBD1\$ W&=M-%/R./Q|3_IVZ'LA|@")H>?ABLW?8)CPH)GUQ\$&*P-3/M)%9?(&7.VJ9N=@N6-
B:A.WP|D.D_H^HB| \$|1VX3_YV4BRNU34-C(C+R&!(.MF.M@PV#_2T->95:O M|S>L9&-MK.5+7K!
(F#8)G%&6&0RQ4'H;CY9|H%RML//#Y7;R7|L0W*_6'M
M^VO)EHE%XB74JGGC:LDCXW7@2'TX8VH7D|R-EL9EZ?7V@XH|WK"?F_I=F|T M|IQ%4L-TMIEB%/%
<7#8(CSRPX1H(16(=MH89(JA)*<60X8|TU|8T-S@.D;(>A M'R+QWE+H8QN:WV9A.JR|JK|9_A5Q-
\$NU6%M-F.4WJ<4@*5Z_!9KP4>=0)K M35;|^O|.QZP.T|NM1U\$?
IR4>5O9=F|E+J|*7V|EV%2:38HLP6N00>N2#I9_M0'WY"U\$4D3SW"9M;F'O(V*XT|)=(
|<2=K=SGBHG%W-.YVL_|<#V_=_6+OV MVUL0.VP|MIZ(<9ZEG!&H7"0I5|0:A""B>"|H<=@.>
MT9%2'UC:SA^C|O9-NM^G|O8N@.P#++W?;0G!6G.4H06*OO2_K@B^:0 MHQ.GVR!_"Z<7_6@1A@
ER).@A9>PJW M=E9^F|H<.VEXNQH8SU.6(|A+^T.7?|/Z<&|DXZW
M|<&|B|#'O@)ZH'MT+BOH\$@\$X|Q/92%=H*U6W';/TKHBBMBQ>^:%Z<.^DN"UZ M<.|BQ>XLR-
5%AA!%FA1J%_""0'\$Z*[T/%A*WD43&K0BMAYD?TICHN'WJFITY M^|F|_|@|#XO%|^GLTL|O|
|/9:B(82HRE@SVU_6)| Q2#"U"(16%*0"Z&=55N MTM.3X=E3X8^"Z #ICWT27=;|?0Z+3|6'YPOZXR>
<):PE:~D8OXX6:T\$@%&UN9Z,<6FNJ^VJ@G%9&N# M!!-
J@5|H|3U\$IE_R_W7E)Z"HQ:V9C#93X^@M9;XEE*9U_.3M>= M'C8%?Z|G_S:=Y8N"BXDNC(?
(^0RB9%7O1@9(YEZLWV>C MGT.LRM|2W1|9|U4X/5IATZIA=::@D|=QB=|/SM\$|=6#
Q:IE1DYL72L1*8 MDXC1'^M.H@*.^Y*DR.&+UC-.CUCV9%DB!RM"\$3:_.G4(5("M'!%1L=-%..V
M^NVW|&D7O6|5|K2#J#LY=N|F.\$CLT3.'O? M/1^W|&D7Y6YS|H+I#M\$RWD>DT2BC"
'RRK:~4HG7MOY:'!>BUPB.YP/X:| M\$'?VEXN|OG7<3=VCN7HGZJ&7RCH%D20\$Y7|*|2PA"NN
L:IM|P'SA:=-MTZZ??KN>1=|P"5>V|_R"/G&4D@185:&49VUW%0%45T0'DVHU:~0R718X@ZQ1
A2*|BZF YD))C3NYVV_9|S|H|3CK>|M>|Y%X&-G_!^X-<4B(EG"4M_%U=Z>=Y%B
M|Q:DGF)U(>F(-5\$|JEC'B#*\$D)T\$(EYD:I-VS6?|_G<-=*N3N< MG:|=PV-(B|Z|K%4|B7910'*RHN4R;
(T2=>MF_C_-\$CK?UD&GRHCQLVW6|'G|U<57RGO@6 M'W^?OYZET|/://RYI-
H+Z6..UT*O|ND41(P+NL*2>DL\$F|L)\$ \$Z(L")\C |L=UR3F0A4V'8>G>=7M* MN
R)IL.%WBN>7LW/%GLW8HH2A2A.HR"1VF%9OXP.-V|;\$|!
MU8!H.ESDW8)I^NV>:1(|8|PY|B)3JM6FBD\$(*@\$/-F4K4S9Z|VD+3R|:DW.T
M))@.%GF/8%|C7B8/5ND0|L+9%X:H6AIZ"!G\$@HC<^Q%S(*|O1'U^HUEPU MA55#X?
>\$K7O:R&D\$CZ#9\$C^(\$|ULE419\$2?L|3\$MIQ1^<^@R?SO))J7_8U.1/M#9:2|DA*1JH|H'
8,&:8T*B43F_.YGUJU%^IQX MU@08AXBSVQYU'U;S|/?A|SE=718->&RSUH24YT.N&:1P<>@N6 M.4(-

!6R^8/XQRDZ^)KC2N8?;&?A\MG9ZO+4;N)3B(F;1D2B)G'VE('B>TD-M(8L<2N8Z&
<"D\$*.LAP7V/E75B<+.#.33O\JG)[A.URL MN9L\$S:~?CH*N)2CI VR1ZU9A2@%E%"?6Z8:I<%
X'9*CFPO/6I4"/4S1N%FI;#541>P>G"S M2).5X-P\B\5)\$#FBFP'AT2GDT75J\O* M^UD-
E_XC+!9AMEHV#2BW6&>H&')7%AN%C1MH7FNI7?L:6 Y6UXD+49+;;HL!
M877T(NB8;H\B/W@#WZ3@8\$?^-"R7)^5<=">+H-/G\K.ECOAF-\$\$(8X4L\3
M@:X4='6X7TF)^5;U^4_3.VX0>\$!6K_CIK<1>?GVH>SN)SE:5A\Q\1:2L
M\^BZ2M\!;7+F%@P*3<&L\$N"(ICJ'D\DA\$NA>4W<0\2,7\O72-MW1P4U\$'T/
M&+HBOU:NGY2)*4LE"7#^HC'(*VL15Y:F)O<\$82\T M40QS\MI DZHNGOENH'-
X\Z)7O\A0Z(W58)!&9\$+NRD>= M1292BZR-'KIC'0%\-
BNSU<.,>1;2;\$6DT1S>WG\^>/VP9_2#.00BP@-!'B M\!+C(H+.YI9JSD*,ZC!4W7^D,X:=)
(=AY.%G*HT\)\ULR MA8)\OE\$B<3\!L)W?~!ND=Q)L7\$ 1YM#Q8,T18:F>WZ\;-
W=2K\!S'YP9"0UM#9\=-%1MZ082* B.LK\$2<P5: MD1)D\&6DUS+4+QE:>^ZGI>
(P4:"PJA.4VT20\$*\$(C'@#L:A7WQS S8,1\3W.77?BE.JK+H\G'=7 T9:626VZ+D@Q4\$CY-(Y25\I M&I
M5'+MP/G'V(+Q:B(<*Z 3)>EB,A\$!\+HL/%VXT?UH0%4/RJ0.\$T(#\LSNK@XGD-MB5"+P+
/4X2\$1A8GA@33R0OE#"E>27N&^=0ATNZ=3QW"^A8P\+R+D8=&>:H. MHB%740'@D>\$)
(^12B9H\Y4\UD:GFT\=)/\A^=0ALJAM/H\FIG_X\+BP3? MGLRN-L.\$QKF4EG\BL8?3ISC BTH,AZ7\$
+%CM';+2.UE1>-13\YU\$"\$4:A M;@M:*!2MYK>!\V^?>WWK90"OB\69\$LXE3G*?
VJ1B)B9?H\ZC2"@3@4:IBT^/ MW+NA=AWW8VZT8B)H \$!\+AM\OCX'G.KHLLYIX\!,@A 25AB'(8!Z-
181QM MW4AMT\J8H+O27&\.C^'00WAR@LC4\1TU<8T-R\$ A0H_U9Q+9L,?!\%C"=8 M<'N?GMV
)=;\@,DS83(6;1*B12G&.&%SI')STZHU8KXF#PWI6L0"P2,1RNY M&.G.*BB\$!B#UP#IHW>:8^ (M\
(BJ1T6>'!^?K=-3.YOKG<GM'+MV+7OTVVB;&5?P^Y8>ZR\$;A\23\5#?G18\ZOF.P%SP3DD"*
M&Z^ULKI\9-15@V\3\$!\GG0H'#S#E*+!\,@M;) 5U>Q19\$Q8"L\A!-&""\X M M":^=L38@I6+
(OPTPLIX1)+&-W@5.&35_ ^ZSN(&GWSNH.87T+&'H^62LTC)\$
M@1C)17XD4&2X2\IEZY\Y+P+TJWJ_N;+.Z@10_/L\1!;5+>D=->9.*L8830BG M\PKS_G2
E@4(PU,\U#K*?0SI8^HVJ^9R1TDQ#Y5^T.XVH#.N?@>Y^B=LN<M6UJ->L0HA)G.6J#B\$T4\+(E2).
(=4)AT@H\%7I I*=FVG^N>LA,"HK@MH: MYE66YJY#\$3AG)E*)F*\$J/V41R)I;?IQZL:XKQM@&% M\TQ\
W2D#T\$#VO,T DX=1UJ#(2A"=#2DF+L;2V?Z7N/8TSF@D)H %(/C\Y- M/A/P+P^ZO\U_E-
HA6&*F\$\$.**Y>;6.;>J-8CRK6A1B7B1NTS\JS^&O30#L3% M'H.ZJ)#: N#'^<3?
9WBTT\JF)!!1^K@F;\QIR52T8'FCTI3/6(1H\J-^C'
MB@/K<.;7MIYVO;.*CLM@&=SKPF2305EDI\$K)\VTDQ\)*G7H93L>\6JN5'#L\$ M%<6X6?#5VA&*)0-
YA>I+%Y+P&'- \$B,+ #)E+\$@0H\1P\T%)R\XN'\$>^W G1* M\!CE<1B#V\IS>A2T>.^P3?F13>").\$T
MMJ6\YNI;3\T.(B-BK)@0FDWP_13\^4/^Q.(T!&9><7+9/2\IC Y<3I8\$X<1 M9\XCQSG \$N"-
_N%VEA1'TSDG)9^D7VR#M8T1T)#\H@) C>W\JC%W/,FO\QS# M\!G6.F71JWFZH^0^H#<!"&MV
J\49)E;2Q+BS;_H MW/P@(?;)S0_A: LZ_Y_-YT8YWY>S2WS/%&4N,Z3N(SN74<2B:(PTSPRI3V
MK'9N\I' 1>U2UJ+B>\Q7PHKUM RTV/?\$6(*FIOD3\$N'R)'D9-8(1P2CBQ%;V-IO\&Q M9\3'2O79-11#6-
P"1K9IW-79H988RCA&DL=HWC MA_>^E6J\G#F5BK#^E8QM#E<45 IDV<(PS\$"
(PW.A%\$V(=#*06\$MHDKB%("AJ MX9X)\/^.#J^ZTZ3M1RJ8U22//<9U\A"7Z#-
D)=U+&.*+B&3M.Q:37QV;.: MPLI6\N\9:S)"53B-AX*JU7.#3M*J\!=!Q86GS:N/=\$L=
M)H3;&F;SM/KAV\G_Z:9A,KMZUAW?_@4_GBSB\9&YM-3%0&U\$5HN.(Y\I %E
M)E&3DK#2\H2,>BS#6JC X7=G83S5?/FNVA\/_S:1?Q35S_?2^UE%(&>CDA MP?;\548BQ*#F/3@2
"&7>'XFS(1AJ_(R#O&D4UV_36:9U@_="G" ME^U5SN\BEM.'MP*+C\$O-4J&Y\BI
D_@2IU;6=CU%G)63_@#?IN@fY<@9R-MQ_OZ*FY7\29G1"2M)\$K4BOP\$QB%'.! E:~*1JLCH@>+
J2SUBI4\!@J;C9 M1+G85@;=0>(F8^64\BXX6=3F\XY<26FRYL/ 20-439JF=Y>_>O"HCO?
GE'(IGDSFF3@WHE:4%5 M.Z6158(BX#I8K(HRK\$Y2F?3<1HNC2R.T)B:P&W0R4=&
JGM\$E3/Q812X3 M20PN XQT9&"0&1&0=4PC;*+5)AJ=/"X-PKT\JCN>;ARTE1-\$LZ6X*H<.\$\$! M?
00MSA:K)5=,G:2)7_U;E^)?^5?5.<>J)V"/B.(K%0#>^;R<)/N\7-?VS MI6XKG^(T=Y-<%7BO(+;;
I&T9^UG)HPYY=;FJ\U'7.0!\@1089)PW/D7"(B\= MW7C\$@H_.W0<_Z5RH\ZT^V I*<"A>US<&(74#A2?5
MAD_%/-5AT8"1\X&RBS>;;\MB%Q?Y&*T9&18U8 MR_-/6/(62!.\$R_=D&6(+TSK)>VF@37(2#HQ15(
R#f-(<[BW\$Z\HE?A>C*; M9).D\H\3)0R3^@I\3)\XTVIA H\82<\TF(Q9TJ\V;TV5C=+Q\0RDNE:B\I
M^J^=AR_PAU=JWB0TSEX1GCTSA"57'?> 0ZZE\&1\J6SN3FC)N_=WRB)\1ZUTW3,2.M2 M\!\$*
(0SQL/J2<20\2S0*"=-!Z18Z.S=3V\1HSOW^1 119<8EEA3?45;2?
28LT20\EP99S%WVT@2"TV90LE0*YW.>K/3=7IB\$ MRAV\F\?;R*D@0.RH2R&\810'==+YF3"P?
C<*~*W8H)K\JQ0 KS6BHF(#5:E MS81^_ZO<6J8F>)XZ8N4E>68)\U\IR9K*J\WEM MI-J\I M%Z"A8 \$U8
TK2@R/@7D\+=TH8Q\I*!I3-++T"-BFS_KE/H0S.Y.J9\2_"W8\$(IB-98;81.5R.O<
MB#^D\!'<828@.:3*R03EI2&K0#_10G2)62% 1\@I#)-(G\$;QC"53(7F9WQWE
M.2\!SC3RJ&D+0W6>=PZ4S42P_*#H+5*8*R0V3<_YWQ_>.U3\$9_!C%PGQ
MI#!RC"E\$9&3.1Y\$BH7\^G<*R@f"2>^@f!A-8""^XC??8SOT^<;@J< MI21G6 (XHLH@+8U\)
4XX)\H\$T)A\!-=T N,U1Z#PG+"JYT>V\=K\DDSS\$ZA& MA.4IN@L(13)QP;0+ABOZ&(2\9YH?
E008+QS:"K"*RJ(VICYTL_?LK\6YF_D@@H\7(XIA\&J2-%<J61)%I+CGN\8X15'URA&_W M5^C#
192>%3#KSV<\RW Y;L#DO0HH(@HH5 W%N&_.LMJ1S)3>=58*G70^T^ M@*EINO\AK*?
B/H\SE06^Z91R.XEID2SH.V04)WG"/R3EP)XT8A.F*N 1S/+V4^KU M>N@YP3\+T+HIC@#^9?+
fTK9VTTGB\&4<<-DBNRJN%S.^F>S=;&N4Q\Z' MXB.>'GR_E0*FO'O@^71\$)8V-K?P+B7K*
(HF=QUDA(*S&Y\5.0S'+@L/S"L MH9#SX9+< 8D#V%K;GUT/_IXBC(Q%%3DK9"1HA)907+S&*.
(M\$ _13\233OL.C?>Y+;6#A\$!\%V8_&S-C@NKF<3=[XAO=T2;?XQ;R\I(8LS1AA MFB>4.!"-
YYYIVN\J\$*\$DV2\6B=?UZC'+!\C2B;@\$)"Q3@+*&./ "fLV@@P)\@_%6V%8\MC%
M>.'W)MR@.D\j%7*W@V=4X,8;@:PQ)+Y87\Z)#!(TDB4RO/23M)/L 5OJ9# M\!S&&+IVK?;KH\$.F'...+
(V92=2>\$1).D.\$8PMBU)24.\HLSG-AMCD/3Z
MS.88PLH&\JSRGF7;O\I\LD&\$=;9_!>."X0\IFM0LHABD2BP%0\4M7RAR_MZ\H=>-NX'\$L^JK*
fZ<^G)\RO9>.:^@QCKETTX I2W6>A@T&J\$V1>ZJL"+R7 M\I MN^?

N/5@X5%W)7E[SDKR+NNUZMKNZ]NEE^>7[V=JD=8<)1A91@'!.*?@X<M6PG.3DI".DRC;T9?
fB*B\6K\$<5#=#B1>T)GX;B?3?(N\Z^:K<.!EX%:##"R M M0"JP(C)Q)#"E/BN.
(F%'\Y,Q8MC9=5GL<).0H@YWQ0'LYZN;A9+I9VEN>I MK ?\$K@M\$+JD3# 04\$".2E(;/5
"L(8:2YPU%:1*Z<&f8l+3>+5HHP>F-%: M.#0/9B& MM\F2SM=:X/<0W+^/090!N\NEC?
SF#OHYU+M2\8CAQ\1"*QP/EL M3?+@\$'72)\$6\ZQT;X;FZSL<.:%H@B;6*
(T=%7WGUS@Y_0^NP5HPK)(1P MB#NAD/9!(LN\U\K\$J'3HUW CDE-WK.RY*OK",*D=C-D4.SZ\OAX-
X(%?++K9 M8C/G\DN<.;?ID1?JS6)/G;_C?/+I+.%*>2AQBHA+DA ADJ+&+-\$T2!<->-HE
M8Q_HP>.V4W>"35[X;V;QR\?I6P7YJ:128; V.M; Z\S) M2VNE\$(18//=@>I2
ZX@.N55CO\1BV7WU0K9YBK M8\BG5Q*#);X<-^TKUE7<[V^U@PW1)&L#BIAE[1\F(-@'0:%
M#7>.:>R:24D-I*W?Z?DGH7M"!#41\^_5 /M#+H5.Y-D"F2>+I\W23A_^/C=E M_ = M_Q67\^VQ+
fT(0#".*)!.\$6>"(DO@+Y(\$\U22..72@P\Z;Z?Z7FIV=TV M;+130:
(^Y0)='D_87+DMCOM/V3N3X\GMH)+9?@S?098N^YV-%YGL;D;XYS:L M9K&XN5ZS8-F%")NX\F%
<96X\$T 0)-,WS(N+?)_WZW ;/EI-D=M8\1Q_ ^48 MU,8\,.*\$P&QUI(100*-++(1\J
T^&V\/*6S#G*0T"&6<=6%8B MP3\CX(@.FJ;K*G+ZH^WDX@V\UBGDX0V3<
,YWCU;4RN\908QG(<."T61 MA9\A0:W0P/(81!HKDODWF(IY^\$.5H#Z"O@0\4 W/(B(21HQXB9P(
M#AGJ=9(1')#B R^/W_5+&2MPC'EP8MF2\JKO(I0/W/_D\6 W\UC?#^##<.% M\A-
X%IL;\DN7%%9>2H05S^.&F4 :.XR\%#HR.*SW\MSG8\VOF^"PI@M=63& M\! K\^N06L-
M2.DSN_.0KR\Q?DTN5>9\$@\$PYS\$)NDQ&1LSXBH\0FCJ<3.E\ M\GC4G'T+E;./3WV0M')
<2JF1)UFU/\LIK#:=+J\D?7(9DS\$J@/P M0'QOD MQ1-46/XE7"Y%U/+
J%>ZLZ^WTHS=U\$Y\$+VTXW6K;Y.OD\G(450POWDB>N M\$;LYZG\XK;14T2C5;
(*YR5NIF=17Z+.0A=+.X?I;.B<65+W\WTF\TOHE\$+W\I
M43QCN^<.;8Z9C^Y+61J\52,P520P117EN=|R1380AQ6S7KN(26E;N7*N\|<@R MC ?
=DSYUT^F\IY>2E(2E.)@Y9G&E\$;\$^KB""@YE MLX;R+.%YE*(O)U0\3G&2FUG>OVH-X-;
(0GRR1K\$24CK\O=6<\$V\$8\;X9AHX M\B;C3*-"I;K^8Z'R(L\+SQ9CBE121G(K*>
#|SPB39)\$SD0LG2*DH8CJ48Y% M>P\SVSTKQ\D2;?B\;R-L*Y5G.YSX8)TJ0@\$S.@ " K7J\.\$&8H=
(E)0XIF5 M#I<>CEVHC"Z:FLZ\+4/E3M NKO<^0NE5;..PE2M+EE M3Q "F1@3CA\$1;H.PF
CM3QYM*\$?>BTG7-\$F*\N^I'YUAS2WT \K 8 ML B:O*!"S\|V6I B\8AZ W:.UL\HDX_F# MC; !:X4L3J"Z
G5(&PP6AG .S\FBTR?O\%:8QA>3ZCJ+XSDF_ A@:8R\;51 M*8&F0DRG\HKIPX3&W\$:(Y5"-RY49I'-
>)9GD.VK8GC6 %N+R MI;8\U#&@P+NMG6RYM4LW#WB M\?
/^G(K2.J;8\YY;R+B'#N0\$^@WCNC1G@_ZV5BAQ'<=WAN6=| DX(M/O
M1OR\$9\B\I\$SUL#K;K;2XXV=YJ?V\V(ETAL5)9(AEP7)S)N@+3(ZA\HP_
MR6B,U*!XX;KSNM<):.1T\K>==G**7EN+D>8@HV?Q:61".#*\$2
M*2*T(TYSX%IC%2L'D%DG/=^@Y@N7OXP-P!=P1G=?^KM81"Z\TPE'EZNQP0_G
M407DO&1(.Z&"#\$Q(-1(4\$CHQ(E,\$F-J3^+U;=J?Y;GGY^K=%1!V*U=5F13(DWD/VF'*+#+(
M8Z6\FA7\$A.(>TQ@!\#6\1%8B2I(+42=G*F8\.' 2K4XP.'" +CVA'^ M3V"JSR=^;
<%_C\4S;_MS*J'TOTQFRP7FEXT(@\$OI03768\CP;D.R(4\$NH 2 M@STVGO#PG\DI\Z(N-/PD?'1C=V%
(Z\Q7\^+@&K8&TR"G<1P8#3W%\$6N5^H0+ M'YFC(313+;_2YL;>(QM<&+9GS;W_I\G\ESL\IS-0
C1VW3-D\PD1P#3YTRJN^Y0094'Q(Q9B",2Q1VD\;P"" M3W\8#X#;^?
3D.9@J\CF7%JCK>8TY(Y%\$7&596BH12%81CG'I*\$&60-L\I-N M"/_I+!X\MA=J);XS@'=X5K)&
(U#BA#@BV4;.44TDN#\8A)H\!*&>S2%\3-N9 MMY28?P"+
=V/_^RQFF7;+>4DG\CC(1T.Y5.C/NID%:8;)><5XL0RY'0@" MB'&=,>ORR M?<;V^NV\I-Y#-S.O=M.?<
^8\>,"S.N\?@\$;Y&\7\4-#4D\$2\$BCFI*,'65QX9 MEKL6<45SRTW)XRC5Q^VPX\$S\|S\.)MHX&QQ?
M>09GWV5TV/#\$;I0H*+!;>8@0M M&!.2F#GK;L5M" P"+_X&YX\Z=!)3 (Q7^[\^_S_-<;
(6%1H2"U#E/(\3 M/(FJ" LD12?CQ(82/R9WN_*TTP)IY?M"P."SX/-D"H0JZQ U(A<-@C)U MU')\$%9?
1>.I.=<@=1E%<,Y1\!>@";;\$XM6\ !;@O=0G\CRPU;PEM0G\AB M\ GS1%
#OF)0@AC1S*Q'HI2_ ^+Y"U !HR\Y19_ _X43AQKS"RR #PI01(M+G&O)5)1TN3Q"QJ/?
B(\0OX.R\A.)&HOMOK\I-NQ\Q?H\I\$Q;?M\|QC@4K MCBV^=\$L\??C\ (3R0\?5UQ^BKZ\FDW^3\SE
_GIX"DBGG#\$"0G(X C^D'8D M**.)+JYC9S1BSM1,+Q-Q;P,B#=#R4HS%B\5F&MS*\AYE&\#;92DKQ
P4H'WCG#R\$K; M4 I@8*BHN=.EHTTC7TNEVZAB,MIMUB G;(\;V;N%DOVR7XW6_KWZVH.**/
MR@%?*=-(Y5CR"G52>60GN2?IXN\F6W?)@+!3\ X\HG>JGP/B8F?KJ_
R/U7\T@/K\O9ZL7LUVX*;GX\QV'B M\UMN6&_U2+'SFVN)*5(ZP##54IKA/**Z-
)%60=NM6Y*MPB&GEY.IQ!; S2; M0#(O+<&6\X0U98AL%PM<@)3)\$6E\I'D_"
I=NFC@%NMB\22P.0ZJ@V\X;\$2_ MQ\GK"H'T220^L%7\3V134RCB(66X\$X)3TJ_
MNAJZQ\HY\U%4YJAB;D\7H5O?;6;R?0&?OH3C9=<T:%34B\$/*A#*8*L6+W759A*
M'54TYC2XW+7%N\JQ\606\$5X#V'OZS6SHN@R*\$YRTS1V'@(P\<98P9\$1+#+@X
M=E3@TC/'=FRE;DCH%@K(8P&.;56VHPK22,1B\&AWZ\TG8"S\B",78V6OA) MZ2YV6S=2-
YA;%4 #!=%L"^4GP;\$=CZ\1;7#/3\IM.0H4;W\&Q\A.=PPD)X
MI\$0\$0XHZ#+Z\$;@C\Z&P*0AL21SZ3I4)XKZ=VL;A(\YOY.5M>S#_E_8I2+^<3\W+3N.S)*JBT>!!4
M&BG\<=QFQD^2%&36V(J84XJ3T@9Y\C&.3<;5=OK\$4\7VG MR%>SY60E\|C>I@_OVI\|98^0Y4R@-
Q7:2G&UJWB\026"(QR6^0X4@;('M MCF"R2"D9(IPQ69HS92EH5\$T/0=SN;O\$G%W\$#\LV1-
/_R8_L"J\H4G;3E\$^(M;+QPI*2-L8\$09AV2\UY+ITAXTO\$XB6)T2 M1S\HCSBG>3BX\$0@I+5421
7L3G(\$FNEH'Z0\$DV@,R\ZJ=L#*YKJC<= MTBD-0F2WPBHG\$=B*U\|S>ZWTSCHO.11LO;C
*>13C>1F"%L1Q M.Z\@Z\$>F.G\G\4.V0#L8@P80*EL40BO>J?2\NKF8497/X8QNX.HZTD3X
M\;Y0/+J0A"0\A0\ X5XY9+SR2\$6M'%%).5JZ\6.IQ:2#8VHB=;P#7V^1L.MP;R5\?X\&@V MA\YS>-
Z+L\OPV3WK5=H;FSO+1\9C%\5;L_VJN\K\W\1J8. M2\XYB G/X0S?S M.W\H\?YI 1O)KX?7\TI004FQ^*
I^+9'A P^"O\|V#)=WVXELET""UU\!P50&UJ?X\6:NOH%O#NO3TG;.)>2
M.B.H\4<0RVR9X/R;UK\$M\XY+V4B3^&^\$@J#6>T-U(%A&YMW8 J@J(O67^62Q M*_X#E/O_G9N)<-
CWMI_=M?(\$(*#H ("ER:5\B"8Q.*Q&+U\OK9XDU_0R. M9SY4#R0CR;4;B M+
M_K.)O\GT^CMNBFDI ^(+P\0%-%^G=!\#;G)W;Z&7\|RQ-F23A.B\$")>[B2 MI7=(2W"(A1

A6AN89J7C"T4VWF"HALG(@\T)3#B)<#JYS_1.3(4K&UN+)>R M=)W,2PG5U,/T":(Z0W#1@-7[!?!<17I
T=j.)%QJYR,R3B?=\$=8Q(YV>^+'G*MD_@V90:AHRLMJ@;PIC/SI'9^;9Q(#V<8IPC>:62KYRP4N13!
MG.*6*VQQ.*ETDX"!6ZR+T0*@>)K&&U%"M3V:W^T"5GH-OYMX_TRG^3>:0^L M,J#W\|VW;I;?
=T&33QTH@0VEAIDD1<0H\$>-RIP(@FAR#J@TXCD3.A7+W;4 M-
BIGFL=\$1U=%5+5!.83&JS/_8WE+9%0F!\$44&#V"(Z M%QX/W4'E>L930?\$D JJ=B,F,6]T=(3B.!?
>YNR[<'50HI\W)ER91:QZD.;UJ MT)Y+M-Q^,7%&@^Q\0X700NXV<"=JXBE-
H!TFY4N^&/(21N1328*H9*FG)1" M3O7RF"">BKN SA76>_"@RZ\OKF^06>U93P S!E5 G&A
K*2">14I(PYKJ3N M99X_())"ZTL]\$.SUI7@7VW\|V\|>;P3S:\$CN9(_D3S%+"#GUN_IM;.*^Q1+
M%||^FB=FZ*8X_F7P-N>]4B2+;\$>VC:8J@.CNM>VBI(XOYL5G:8=JB_3-AR'KU!C*758X(\$C.88.Z?
%I%W45*BIC\TGT"4#Q OX7O\Q3U!+ #B<>|<"D898N+K@|?@7W:57 @\$GMMHZ|US8Z MR\NQ
>/A_S5HIG8K3%I^CCY/OJ\$K)"8Q*BL0/-/BL=
M!5]*^*LER1&4TATO^RKIF5?;RCB;:517I/3GZPM)KO|C\$73%XJC*D-1"*2 MLNUO
D.&.P%!.#>#&#/*Z<|=WVY;L;Z@<7UH-UTY=7T^6*VL6?#=#D!
MNF<^M^#KKKJUL_R;+DWS@8SKJ^&H:J#OU:JOJH.N84JKAYL!|H#^N%VWDP6 M?
MHM;A|U|S+\$N8"1P+E8CU&*M M*"GGCG+!|2|=7G?0!H^|PW_+7.^SI>XH
MJB8*T.D>!9SK;C#VZZ>B/LC(E)>|B%|1W@\$4_|2)VH\6 AY>OT>Q_WZ+5G6 M!5OQCHS|ZBU_O/
"+@ (N6>|TX-RPCF4A!\$AZ6B4\$;VNU9V?J(N1(R77%6=B M\$VU5'TRZAU|D?Y8Q%<+|U>77?
SY:8H\|+VK:B">|L)XG/G=3@S1N3!GY8H MKG&@N'0 C)Y;J_C(M1
_NO%%TAS6WN<'4%QYT@+KVA*BH+'DFYC"AD\PAV MHTA0F"FNBC?
@WK.=.H&1\$V'J&-8W\$.X^!;S|S&|NF/1)>_!6 M(*>M0H|(S#3P/YYZA,<7T_ ^TB|K!M#*W6R\$>-
Z%M|K=NF7.IZ(0(\$>#LDB21 ME0G\4_GOSIK"2LIG'(8*D:+6I5%O6\$K/GKY MB^X|<|_W3'?
B#)55Q|K9B_ ^5ETC-H|> 5!.CF.)_YA3\$P0M'A+JA.|H#D MK2_I-W'AYY-5Z|U:E@HN(1%C2B&?/L3GY
AGJ%DA2;>>AQ-Z5=;>|9S3N|^M\$-3|K/+*2*0!N^G)?
|M_P=97KER+JD0!68ACRH!4C@PRSDP!E,B01@G'5B> MY5,^N|93.TY02.0_)VZ*|+|=*&W:6_1C>:
AEU%)AKC '(\$|H)"4,BFI'+7% M)IKNW5!:=!43>S|X'2"#!@ "U_!E^V\0DVF@37(2#HQI5(R#|<|
JYT"1_-"|60VR>9!SF(^)HJ':(@%CPC' M_%PD>8ETVQ&|WZ7?N#38V8>3 M< #%;P6RT4BD;
R&))&4*#U'X9DMU8Y>C6-SE91# |#JFQD0EA(>243"6U#, M3AJD S=
(6\$94E#2W%OL)6M&<.:!69LALFD,08 M(8B.*)7D4H91"!>+C&M|=^K'1\$SI#B*V2S2\$.8Z^M
MR_"GSVYA"P-%&FB+-8*|*-4VGPX:3;GL>;|6+=9+H:Q/'1_EAW*;RY9X9S
MGC00'/BV%ICAM,V21R2@E')>|.EN|S-61_YY3O&8*K_:=E09DU<8_F.V0| MA3|NZ?L475G#!!%.
(:AH0-IDC*R1&EB0;N)#,QM(A M_<-W6|F5XF@(VAK;&%V?
\$K@H7NMZ|VV!=IC17E&D,W\|C63CF\$G8O)\$>92_-1NMEC70VX.H(<(|MQP"4"+EX(929WFR-B(\$5=)
(|_+M1X|SQ S)/V|1_*VP.%EWM)^|H?O2_1(_VDEXE>|K=^1)+K3"8%T' MAG/;4VV1A|!#1&YT28%F9X-
+AWX|5Z(DV>+N%-(Y(OTX241A.=Z?|1,IHM) M@;17#/&@K"4B>:|+UT7UW5LO)"JS1>*HHBKV;&
(D"/XQRT'EU2"SV|8O#W|T M,S88,V:9B1+)|F'(C12^0T<\$A&Z,*P02J9.E(YD\$;|05_+;+!642(#2C+>1=
M*J4=R*6HH\$5(7QN*.K?1"FSE|M)401!.O!Q_67#S# M+Y.|A0L"8(C!TLV!&2MP'G.
(HV>*Y=8:9#UWUWM'F^G2MR,)*!&=-LVRIZ) M|X/SY"2+&JP+C|?=
|JUF'ERM/|M3)6G|F/5_YY"F&OLO/6!94'C_JLJL7RK MN.82O'X&|(#QFULV4Y0B)X&+9*
JG349N@>ZZK-%L|YK.!;UYP/8OC6.I7' M-"%L|WAD%CBR3&A\$DM-
@Z|JDBO?/ZKFUNDF71F|XB)C.;17VK*+TG/\$5.0<|+ M|BSC>20R|KO'2R\$-H3PE7+H"MO?
FZJ966D+@8%&="0;7P5'-K#+)(*IE'E/ M)"*2B1|IMUIDL;Z=(N4OGNKFT!|(&#;|54|;.*5J.W|>1Z2\$UR
6@|&L&R28'E@<6^G9&3676E&"J48L"/&_+U3J. MDDXF@-NN>UW MN)C."8R75B<_IH5
WFEPMARX7;G\$MZ4'-8).5X93MC MZ#1@8IW/L4)_E.">"F-P NLV&>*T<%X\$4@9R;24VVL1?
\$3\$U#|9+| PEFF@\$ MNV%*X7 M>56ZP8FHL';H&3U:|JA1 Y|AU0@DGE./%>EWRR)>_>
MX(ICP)%@FB_P)34R2A\$|H/R4M-DN.EE=Q|_@7&G91X'@3)|;Z#P<=<=#|MZ?HYC>(|V M'(VG|R:
|OXFH4ONOFZU3;XOW,3V|!"#.|GOP/T@5.9D1?|>|F0<(&^.=, M1"!)!AE!E0?L08Y8E0
Y|!2ZWJ|Z>BMU*QJ+X*%KH@&K|N'IMKMZG|2TN4 M(USYY+T2N?5I0|J#PC44W,D4-
:&|H'CW|3NIB*X38V&O'7V08|J U|9!A|M: M+FB8|W?F25(&28+|>ECO:L2E@Q_CE!FQ:2%|M9Q:
<1=>\$W@N"::SWV<3X! M|^2;G=Z+=D,_,UP*E)B*B%NFD-! P_YL\$R29^:;\$5Q^_&*KZ*=^QXFI
M"=0|">U?N*6=S#(GW_|EOUHPDX'+NQJA&DMYB#@B'IP"-G*.G.LMU\$+PT7L9 MXM-
&)T=C|HCM5GQ(41>OIQ)Q Y?Z8S+^V_*8W@%|9>Q?6#SMM??HGS:W|I
MHN:);8M8PL!7|H"EVEE\$J30"6_C_.ZHPN?W6/\$=1DMV9F%A-@#6AS=)#^J4
MTBDF0A\$6.0>GC4.:48TB"W 2*8|.COG-+034<=YJM&2%|9D S#=>PS2;JS M|HEE!CG2A7|CZ0!
(=|QYB;<#\$/B")2!&->4J|8#-N\$NOY/59|X|&P3CU6 MF V=<|1W\$=P-*IW/_2^=P|CNK|EX8))SE.L?
QG1JS560AH(|S&*19G7JL M_|QVONK\$"9Y?3L=O9Y_|Z=&+^K03VB5RGZL)/%2)T1%'D(8:\$(F.(=
(QAK M\$F/4I6O%3EK9_%F#CIA(MY_|Z""1W^>GUSO=8%Z|_#F:P\$HSHD)PB2/_=, M>.Z0Y5PA|
1C23#E?_E^;8.W>4|O X8@|*G2!%=ZS>K-7V-W-??ODY|&>6X M=|TR&K#_E@NIN<Q:H7
^P_|Z:LYW*YWP/*N!0%11+G1BY"TCO;-2 'U|73 MAE"2Q_D9S=U5"K|P|VUR|V|IFS>^|HBE?|6E_L
K|!Q*RN=GI&"F6&LP M2H08BL_BZ+?9.OGO57|Y45_Z/\$=&\$V-^!\$?/9?8|B9QH0T*7Z/LYNX>-<, M?
0L'<0YVR>N.Q:.*|AH^L.O^M T|H|AU.TQ0977RQ:AH0!97)12N0)\$XA:F76
M|A=9X(PCFETSN.\$@|L@1X0Q)1(CH62.CUYOOR1L9J@('R2).G@|BJR0^#Y=|U;_>73R+XK*
(:"0#HX+/GH%HL^K#_P MZK|V'KY.KB>SJ_LPL_/AR*U78UYT#28?|C&T_0L#_Y0';|Y48/(K(/.7NXCA
M=7?|+K&H_BS%A M|BB<_92W!RN@:1E+|':W|_O|H/F/>(&8\$GM^U;5GA6G0,<@EM=!Q0K Q^J#
M8U7_%TE3J8"FCWUZWQ+-_O/C9U.TF2#P(MOF0|#1/S.\$E4;/IQ.ROWX6\$?0
M8(==KLFY7ME?|U|H|;B|A4+;/'WV;=)7O0+V(2_P_"762;|Z|Q3=Z5A.W MJ.K%D8K1FT?
|B|N072@LKR=K5@F@'|M|_QH1%8?X;|+^?4LO)O:JR*2>KQB
M%;O^(#EMY40C4LHG_O5L\$>;EQ/1DR2H6|L':|V=>-"H_ ^G^>|(^_LAIPQ))5 MK.:#!+>?_
Y4%>'>G3JYCKDK/|N&?>GKT<=NW;A53>)#H>G"EA8.W>#WM%O%+ M=|?>G*/J>6;_*>Y_A1|?>
EYJ5YTABK/,(H#T&A:'^UF8?)^\$FTU%UC&" M>K)47:=L^|YQA0^RA-I_?|VAK!&7J(MBU834(|>-|U8T

#A0IWG:7IA^:0 MLZR|U.T5ZF%!?6J5/?VZEZ6DT|9G"R/MS?7G^;=C|B?!. '263M/L/
M=2N%3YA>1;5#J:PO#=PNW"5(7;^P/^.*"Z/Z8A?GTQ|7GZ&_FZA?|UOCY;9U
MU5ZJ'=>7VCZ6M""RMW_.,TOW\$EW= M'%L_YM3O;"|7O7|;#;\$!+GZ9VY GOCZPR1|O_ B*VSV?
*5)VVY>,(VMO*X6> M!A8Z?>I@A>7K+J7)5C=T5SWKS_1901#EOO!6UXO6BI5FGV160-I.T.33 ?S_
M^;^J%|OJR_Z=E-.LXX0=3;Z|6BRG|<=GH/7?<4@1YZ|_N%ZQ1U|9/\$=WO8J| MG|3S3Q?J@?
F4GL=G|Y7|Y 8P_/C^W=<=&*J87G9/0N-G'C,I&Z?W6CD|.
M/5FJFFSVU)TSS+D.YW<'L5TZ7N&3I36_B=K MW!. *OR_GT|SF>7&1OLP#B*|,C=.,>9:M!=-
@5_#QCJE_\$>5/5ZIF<0|U MD;.:0WXI(ODR61UNOCY;J5DM|H% >.: "R5#|="3"/|3H|L-(3NVS(>7_*^:|UJ
MI=/#Y/0.2RH+|\$.W&T-F>Y:M5C8|3&S/;Z8);C:5^X/YK|@O7J50R2UG1M-"K-S7IC
M!41TMU2|0I5#A/.4 TV(Y4'UV=75J^|V.CVV,& ?NO7*4PX1V%|>M%J@|G: ^
M>IDY4B>XGU>_G>|6+/"|F6D+Y MYXGJ|AG&H>&.#|S\$K(93'*S5=+|F3|G;NE;@L&*O8NW
UI7:H9=""3;55WM75 MXOYE|6|>+Y60| ^K|DA)>'ZB66#Y4JD/85EG"%S=+T/&S542GG"K=
MO6JU;/.ALGR60>U<@!^ZY; BW4T=2S7_Z_!;JGI|?ELVRK+.%WL&@WB|>4
MEJAZV|DM;3UH5+) #8K|STDW7;Y(OU=OU?KZ>) 6; _X;L|WZL7M|) +Z+!& # %FS;V M?
K|/!+:O7^ (L|LGRZ&X>|WVP7FZ^)!SZK4M2(-F|K99L|OK|_E^+5\$NX#I#"PO/YE/K;
M":&_HK|93K|'UZ FKKKYCZ+1|:O6\$|_3_G=|22^=B|Y.GVZO4DL5\$2R>^%Z MU5=|1=\$-
XTMET7V.70\$YW:|2LZ;D>5YW>PBO7^0#6_101|O/UZK9F6N048P MX9|:Q5/>- / 4) Y3GSA-
N'_^|*M_/ %CC|?CE;J54>T|'5N)K2V Z?1N6V6. MQM/EZEWK6|G=|&|ME"NK|KMKJSQ>O/"X?
W|WU|3|NM5C.OKCIN| ^ZMO4 M3?U+R&SP5^K::GMDEA7@'T-B#WO&4AYC1FWG MH|2<#I;1.?
M.>YW_5C1B)0^SN?%|?5TS7KGZ0|9|6|:(|2C=?Y8_7OUW'A9Y MBP5\$M6V|FNV->ZB|/2QH13@CFR-
#OE,OCK='3-ND>38VR"/"WO|EIU=@07WZ M-E^>DH?4+|2;|> (V|_A_ P9E>O9N&V?%A;A0
P,\$2;>/H#Y-O5X|9E; &2W:OWL|W^G^|T*3U@; /OK M7N(^/_RK;2B-@|%R+LKP^5/(/#JS7(KWH\$. ^/4=
|O_9/C7JAF%9>|Q;'O; MT2*O%A=I0|9%6B'XCHS"Z#CXH|6>>1;7(0S<- M*|I>=|P>#.'?RB%G\$);J/PM
R.R@JB,JK>? |A<3&_6'Z=OX4=+CZ&B|D= M-1^6^>?_77Q*4Y_) ^K*<9@:|YU8,4B6^7^UQ:QD|11!
|:ZN*-3F0_7 MJ7;|I\$MD;B&T=J|WL|LRM=(KU:OVN*X|LO6GIV|C|':?3+X.OK%R?85
MZ^7_#Y/77K|4+B^#K82|6JR+E"8>UGTW*W/6GE^|G@H3);| ^55;9|8X_W7>
MW7Q|OUC<%)3HOG6KV;Z'ZM'G>51;HW|-\$|?"W49+27?'NM4LSD.UZ_ |JGX6 MNR_=TDY+/-|
|NE:U+BD'G|FMO* @OH5=^>6.GTQ|?|204\$M2V);OU0SE<7GLX M4|NF*J?
<88U#8|;POZ7WV_*J8;=RY:KT|H5;F M_ ^QI2'JKG3W0\$ "6%N&WM>NU%"LAR#|_
:4*5W6RVN4>N7*|QR#%Z|3E&5:_S MN9DL?_QHS=K5H)|<|V>G#9)L)D(U);2|L|/U>L3+46?
M|C*ON4_ ^L?P.YR;| ^W?Z"7JE@)|7 YE7^U1;=S.U|HFBV7|5/?N57N)LZ5P MUK;|JBW
GS7+T2;MR_9JUJA|6#6?M94C_S? *O_R GQN|5Z2;"F4U9-9%45Z MLT!7UGZ|O#|72MZNT4L>+
<5@GA#?1HGWT>(86J|*6PJ3-%BFVLU^ M|<-EL|\$W<>'GDU4;IE"=ZO/|JQ)B2P&0_BRK?
B^%2=Z7G7);OH35RK|_SJ MO23;4BRD-|J7VNSQ>R765KF)T3%ZH|WK-
GK34|+49%GF%.|@N#^|5>Y4H'M M;_8274MAD&>8T^KT@?>SQ028^65N|
|R;C|UTXB=Q|7>^<<=|/W(4P9|%)E+ MT>; D,*=G_ J)WPML^/W3+S5;+J.O^7ZGV?K*HG/?P;WR-
OOE%_HNSB_C_E_ M/U|+ P04 " #.0 A9SH?IO2T(|!*" @&@')E<&PM-C,P,C R'^@Q
M;_%X97@S;3\$N:'1M|5IM4QNW%OY^?X4NS\$UAQC9>VP0P)#,.. "TS'4C|3-M/M=|2|6J|&|6HK;6U|?
_U)|*W?L&E;DP;3;3XX|;KHZ+P|>LZ1|+49;+|6KZ3.93%1?);@:TFJVN17 MJ>
|YB|IQPXU@|Z=ZS@|H|F|6^0LE/'D_5G,1X3'fW;X\$6LWPX0E08<>==HT M/&'A?%1'U| ^+@3-O|;f&
JQ/T<;2;'O=O)>%Y/F5V_VVDUC@X+@KS_9|>S;HRJH;09V31#5K09-B#J5|AWG7N;CC54W%
M(RFDZNxVW;|3.U);/;.%I/O#&@=&=,DRLV)CQ>.H\$?PG\$U="EK6B?Y#RD-N2#MH|;L>;&9|A;
S|4+&G=O|HK>D=W'|=" M6/(??KF8M)LM*PM7MJZ_V|H-A|Y5_19_ =O/_ =^G7K;S;=S35'S'Y|&|_N
M;F>MNY;8|%D7+ #'=|ML7 MJ MD0=\$)N0^UR;|8N'K.83HWPZ8@D3 "M0GA;.3TB9&U4R>(#-
XAH'Y(F2 M#\$ ^*4T\$2&N&5(C)#+3/2RZT(Y"QB6E,UL2(9O6=8=T&GQKL8QF|)X;H.K&\$% M(|H094
LQW18\$C_%QBF/4|)+^S&?V;.*54JL QG7 AV&|6S&W*1P4|)=|:KP=OC"0|T8M..89K
%L\$,>P6ACG>0)^H(9# M#|C4<;0"90LI*L&A"+*062;/%I<20\$'(5|O6C18'QF%O%-2M1"@@=1+0
M<;MI9T|S=4H2(<=Z"DG% AEP;1;\$0M2^|W;"RMH L/35FQ=I7";|:UH%KL)2) M-|O'K>#H5%?
PJ>JYW?PR23@>78XN"57;H0'9Y.%@-FN\$ 8*AX.@'(&|%,A"? M)3_|'|=":E+S+.4J*3PL"B4C%B,UYKL
04Q-ZO|JOL/44KS(2;|L_U_*2#A M>N'#|;OIKI>Y#
|Y1VZ;HS#T>HGEI(64.I18VW9> *%D::\$\$"UD_V,7\$K9" M?V&_LX30SN&+(11GBVV!;'#8;
EL("Z81G^;+E;I7DHU6P9C6BI-Y|BZUG(-M(MJ)5|A9:F@
\$PTXMKQ&Z18|O38%G2.C(OLJIB@#F=5B9QC|58QKOWD8\$G8 MHJ7@L;L|T&6H>
ME8);\$H=;SHAYD<8,7_(7.Q7|%3(K")I%?;8_CU>W%|2A-N&XW5G%|<.\$M0+G MS:EN8U1C)XQX;.%*M
ZSR'+\$='(0|MC+#"|ADK@J|: MPQ=|BQ=@| ^|%P-\$V=@3<7|S1>G8RF;7)0FZ03Y"7O2;KF|62VS
OOYQ?;/G M|(D)8\$|MV|E0EN9|'S:I#W0FS6ROG'S^+\$/|".1?NMB#SD8 |#FYV@>|
BZCJ|0V|PO%T^0ES.|HKU5*=6S3L.RGP;IBUU9'Z/E WY)#UV'CS6|PMGFZ^OG7#C_N/BZ>XK(V9P9+
M5(O8F).\$S>XSZOU*YS@SC);|-%+I68EU+Z RR|@QC/T)#8<21=R.QOSV.25| M0!|83UM6Q?
^VAYW"GOU1;K|H;E1<76;_!Z+DG*DX2.WUU/=44+?P\$-) #W4P4*.*&M#/' M="N^JM\$%;S98?G(RE&S-
:>G_ZK&VM5D2/+"B\$G#%/C5'I&I\$OX|=Z^2F%N M/(F"1U|KX|S@+B&|_OP|8BM?
=\$|GAM(8F76;|RDTQ#F|_*M3/O/=N|_U51S M@3C50^RA^SI-X&"7BC&=Z)UO|I7|X1/?AMWFIQYKG
\$K_|@A::=;-G**> M%8).NCOW.*33BOM5<#L B-%-'5(NX|?SPW(E&TSMB8+V)IRM7PPTW=&#B
MU;_.VT9P\$CPYW&P|/?G:AOMX.CK;|7&MC92>^ "X8.|>.N"YN|VVCMT+AM MVFT5#R18Sj'=N8|#
|J|H0G-Y?0"%.&:- (KAR4ZG>.. ^UW+ #*55+%ZYFQ|F MRYW.| ^5F|T.J-
=|+GUOO^3FAF|M\$M>U;|*:#40K5G(%O4|<|*4HF0;D-85X MN|*Z99%S&KO<8+5H@UB>IYPE|/_
HM*6W^ MNN ^ZK<"WTZ_1."71)UU|ZY/^6H_J|J;EO+__CSP/WH|/102P.\$% @ MSD (6&5X.S\$R+FAT
M;>U;4|C.1+ ^?K_"Q^AF04I"7H<0&*0.9'8BK6_6@G;OT|E|5R<6|G;O|4| (M_?JKLCMOA.R\$N|N=@':D
J|7*Z7QT^5W7T^=HFZ.|#%Q=.|HN_|.NM3\$?L%P'V@97+A=2ESF9&CL;U:OU)OM%FP&YDT|:Q5S/
M^7&X/C_VDYP/M9A=G LY85)|\) @XN8'T3JM|>:P&;7AM-VN@X#HI%O?#B- MHG_5#G HBH

HW?:=8K)ZW,G4VE<-.K5K|QX\$703B/=>IP M/H/CPY|!S:8R;D:HS^FL4ZNC)@>/KLR5'4=
[^)I4#47C|32IO.NZO^=T9-R MS!I9IT7!C(RZYARFYUPM,?
2I:GMFS!R#@ (60EOO!MQ\$G\Y#2Z|VT' < ^R.^C?7+.O|H=W|HWK M 10|E@-
U|9K731K/\$NG>L>W7S== "[6O,?_?(Q:53K)(NN M|KU_ =|W;3|WKWEWYYM>?>O^<>UFO5G?
&Y|1N>/-9P_LEUB.U| (M4JL0B,\$|& M, ^; &W+U_UYJ?06Q9R51@%CJ_#|_GUIE;O&?/_M9QH7
2E!6\$+M.O5UI41CZ M;,PGP Q,) \$RQ6+BQM.SGG!M\$*;|1% C)M'-I^ZQ-PFK5|L,QW1;R21/@?UH
M=)Z56#^_*|B1TU>7D?K>9>03MY@'C'@R8P^IGBH0(RB%Q)B0#J'1A%1CB<<9
MN\$P93V2|3&/F!XEZ9|J|7*!1.E*NDJ|C.\$FL0COQ0W|+25;B4U+ZE 8ZDGGQ\$EK: T
MH(9LV7FB>&VB&"J:T.I1&4TXKG=?0C5LR\$@+(J90H74N4\$%R\$03:3V_H12D7@|U MN\$MF7&57
X|HG!4E|U/2 ME%LJKG96E^)/1MJ"V@0;O_IH R;0AGEBA.)HUO>B&61QA&AY*|V*OC7\$@\$@0
M>1:'@W@9K^XOCH?|A.-&'6S)"|WPJ HWT"<"#BWH2KW+,5 M91?B&+M!:
<&|V&>ZND40L0|A|LOG&SV/5OR(S&E#.SG4N=MNP2|U@2^D@7KE M^M|&3;<=^%"^4*(|
KCX4830'(B7V"7,&9(9N;J* ===&X^22/0N\%3\$GU
M7\$=1;BCW*|7S&V)M@|OTXDAZK(1*OHM',BPPRU#8@0Q'ZL_MK*1W%79CV!U*1!IM9VEC'\$E
+1E>,"F0)_H#H;NC-2;7U?Z<|LYX<|+P)< ML1T)APG/D!@7.-#"@L.V@K/H1G\$((@R;OE(HIA8KQ
M4B'2P|U/%^MU;) V2IAV\$R'P/%'S 7"2J'&A,_C#*D| M4WS6D:D/H1|T5F@?;N=TXB>84#W
KJ&8Q;17'A=OY\$|/*^U6@U|*X/ Q7SB MXGU|Q;^O/W9B\UGS0Z79;FY|7*W4MCH|;6-
RDEC^|C_5JLWMK63VF;2B!_, M# +?->/KOH'\$P'U M%/'EEM/86\$V:
<1#|'|^|Y>R_1#B"A>' +W^LFX|RK/'M MDO|@9_/(A:OW,U/L_4; S;|>O^NB:3C?ZZ)E|SH5IFOUKL\$9@?
1@D| M|C(A>\$T!W|>@OJ:X78XEQ.SSHNS=A(W&7T%|21/OX8S1XS?1B2/ MG@OEW,"YEM @?
H PKHEZZXY|^|2|FS|NF^E%7KR@6"FK7|W F00":P|U-=#N%#9*;<0|YOE>&Q<_PS>.Q_1;R/U|+ P04
" #.0 A9J|/4 MPI\$ \$ "Y\$P &@ ')E<&PM-C.P.C R-'@Q,%X97@S,C\$N:1M|5AM;|LV
M\$/Z^7W%SL#0!+\$62Y3B6G0"NXVP9ACB-'73|-- 291&A1)6DDGB_?D=*SFNS
MN1C:IL6"P+!TK|SQR/-8:9S?C3,*\$F.?AC^Z#AP+.(JIX6&6%*B:0*58L42 MWB=478'C-%IC4:XD6V8:
B|X;V05^R:U'+-*=':S_#O?IYN&>##!<'K9R M5C@9-?&C,!'
|W5(/:EBBL|CWO)|:505HF(I'8SR)|O77VLUS9T0NT9|69>0' MZ\$G36^T0SI9%9"&V:E=K|5AP(,MS_X-
C,1)2<|X*GHS9SE5<\$9OX\$+D|C3 M5J10CJ*2L;6B8G|1S!&#V,>.&D(/_7!6T#4D/S @)K<96S-
G<#U'R/8+/-<8 MR:2R*R4_GES,3T|QZ/YZ?0;SB|O9I>CLSG,I^?P*4|<|&XD@>
<%G|9FK\$@06=39+S_ \$@D_"NZT@%@4!8TU\$P7<.)V!SBB|JXA\$QOD* M+F@H
84G@B9@^|Y|T"DYC5G>550^%F*JFS#;1&|L&-LM|<.@L;C\$5>DF)E MG_S|+J1"6MMV&
<,9IB'(RKV36%:9JR&)-&K|:RP=:VD18K0)%F*;;7AK*2JB)8 M2" T>+M2&8+M0#4"2B-)L#0_5UTJFT9I
_R(7I*#F=YRNH)1K(W\$-)|J:0*R9
MT5M092494W!5B!MD;XF|=@|&&S=D29(\$MRF" TU1'^YTG+>H\$O:_6HSO^|AK%
MEP__F!>_ZW9"0X0A05D::<5QG<38\$MPTZ%W32OJA8I*:'5R9VMSWP |9!5P- M?GB)FB:X%MX
M6&S"S%0L)56FKFTC)IP#FF\$VA&/558F%5O6(25E!BMB\1X<)|LZ|!\$M BM=M
M(4HJ;4SU9+JXFY2Z^|*)19,%IVOJA9 XZ1PDF)-2T6C|99 P57*RBEAA::)& M@|:
|0F@M3;+A1F|W+!\$U&MCJMM4'3A5%0WH+_N:(F M,9|27K|Y=>KK>DQ|K;=2V!4+2O<: |JG?
JN|QLNOG&8;U>+|SO_17V5M@; M*/OYZ(SS'::&S>H9M*V-J-E
M9E*=LJD1?|60)K0KXEBE|7K; ^.;>LQ8AJC MQ1MP^<+!^W|:_QNM.^>2X3FDQ/(.VYWGY
|9T|G_";_71^LGMPS E4+9 MDU D*2GG)OJR6=5|UE=G>_;*|F|02P,\$% M @ SD (6=Q"1&5X,S(R
M+ FAT;>U8;4_C1A#^WE|Q#>H=2+%C.PXA3D#*A7!51&.!%W|J=IXU|F*M=>W M7@/TK^LVH\$
1YM3VSON5(2B) //Z|/#.L_ %@J5-Q-%@R0H|^&SH.' LXS)E MF898;.(9A;+@V0(^4%9<@>/46B.9KQ1?
+ #4\$7A#""|ZFN^#6IY)IKP8|6?@:M MZO.@98,,YI*NC@:47P.GAPT>LI"RWISZB9^<\$<9?
UVO-+PRI= #/P1GO_L- M\$7URJ;0*|\$.&RG/G'4S|;,P<+N=7/=O.-7+R/>|GQ|6B0R\$QC/(7VU=O*
MS5-G1"W0GY9YY?H2;-|1#!%UED(38J5VOU6 J|HAW/_O6-Q\$E(RL4J>CWC M*2O@C-W
A4Q)|K|9D*QP"J9X4BD6_ ^&.6(0^&F@M!%U/XG; W)#PR(>V2 M\$|F&=N &#Q%LEWN,Y#|UE9(?
C2J|FIR>GH^L= ('&YY<7T|OAV0QF\$ _/X-*= MNB,7IN.1E?KMCM=|N%N+032?%IKTCN>?
LP.8'9NS%,AQ=O MAF?CJ3Y|9?Q;S 4406M??S_Z(A)|\$=YI!++.,Q9K+ #&ZX M7H)>,GA?
\$H6,BQ5@TS,UX*G9<;@K9)EWH33+9AU|B^MVCD(|_DFE.LI7|Y/?WQ)*NOY8N0:&V'G|C"Y>|?
C|7K_M->TD: (|G.\$" MA7|I3%E<*JYXB89A?%MO"39@N\$,35->% "9U_#>:% D2SF1_D27B,*-
/8U:4VO:8&J\$R-Q?#IOLR:19'6A*U)ODK' FMX*M M8!AK(S%M9@ 0;V;TYJRP\$LP'KC)Y@|PMD-
7.07_K=LP|H7A).8(E.MIO/VIO M)^A^M0|=|??
6*+Y|(^>| ^|VW'1HB#.GUP4A*@7T38TL(TYYW+;08QY(K9N|O MPM3FO@=VR1|@6?
|NW3OKM+W#7|7W'6Y_5X|Q%KV^J;UOX=Z|B^SGCS#"942 M6R0"D0\$&.A2ZJ_9/<31!T2+EU
M; >87;I6B:@N9,V5C% H^FB|M-J3O|/N:S 5;Z|^EPCGG(&"Y 6+UF_ZE!>Y M(*N(9Y8F;|200<^EUC*U
+!->(N)J(8>)6XWAA|/?>@TS9+H|9-4=-UXJ? M=.T^V=+TJ2S<=|OM|K-BS_6?E?VE6Q?OD7_?
JTFVMYZ;EB6B(@/I+K"@AXUV M8VU0-V\$4Y+?@/RRAZ40B>90FEGMO#_?:?
UGM.Z>*XZ\$YLCH\$V|WGI+;LFO!9_P|M_13SH@VK1X^</(2Z'QEV(?N3<@3 MWA(,+C 1" &UL4\$L!
M A0#% @ SD (6<5-3XL"# \$ NWX*!4 (!_7L"')E M<&PM,C R-# V,S!?:&%B+GAM;%|+ 0(4 Q0(,Y
""G0|:3&\$94 %,C M|P 5" 3*(P|R97|L+3(P,C0P-C,P7W|R92YX;6Q02P\$ " M%,4 " #.0 A9SH?I02T(!
|* @ & @ %V'00 # \$P<7AE>#;Q,2YH=&U02P\$"% ,4 " #.0 A9S*R8^00(M |R*0 & @ @ ';)00
\$P<7AE>#;Q M,BYH=&U02P\$"% ,4 " #.0 A9J|/4PI\$ \$ "Y\$P &@ M@ \$7+@0
\$P<7AE>#;R,2YH=&U02P\$"% ,4 " #. M0 A9W\$)%S94\$ # \$ \$P & @ @ '@,@0
\$P<7AE>#;R,BYH=&U02P4& H "@|J @ K3<\$ end XML 87 repl-20240630_hm.xml IDEA: XBRL
DOCUMENT 0001737953 2024-04-012024-06-30 0001737953 2024-08-05 0001737953 2024-06-30
0001737953 2024-03-31 0001737953 2023-04-012023-06-30 0001737953 us-
gaap:CommonStockMember 2024-03-31 0001737953 us-gaap:AdditionalPaidInCapitalMember 2024-
03-31 0001737953 us-gaap:RetainedEarningsMember 2024-03-31 0001737953 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001737953 us-

[illegible]

~~0001737953 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001737953 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001737953 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001737953 us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001737953 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-06-30 0001737953 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-04-012024-06-30 0001737953 us-gaap:USTreasurySecuritiesMember 2024-06-30 0001737953 us-gaap:USTreasurySecuritiesMember 2024-04-012024-06-30 0001737953 us-gaap:ShortTermInvestmentsMember 2024-06-30 0001737953 us-gaap:ShortTermInvestmentsMember 2024-04-012024-06-30 0001737953 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-03-31 0001737953 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-04-012024-03-31 0001737953 us-gaap:USTreasurySecuritiesMember 2024-03-31 0001737953 us-gaap:USTreasurySecuritiesMember 2023-04-012024-03-31 0001737953 us-gaap:ShortTermInvestmentsMember 2024-03-31 0001737953 us-gaap:ShortTermInvestmentsMember 2023-04-012024-03-31 0001737953 us-gaap:OfficeEquipmentMember 2024-06-30 0001737953 us-gaap:OfficeEquipmentMember 2024-03-31 0001737953 us-gaap:ComputerEquipmentMember 2024-06-30 0001737953 us-gaap:ComputerEquipmentMember 2024-03-31 0001737953 us-gaap:EquipmentMember 2024-06-30 0001737953 us-gaap:EquipmentMember 2024-03-31 0001737953 us-gaap:LeaseholdImprovementsMember 2024-06-30 0001737953 us-gaap:LeaseholdImprovementsMember 2024-03-31 0001737953 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-06-30 0001737953 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-03-31 0001737953 us-gaap:ConstructionInProgressMember 2024-06-30 0001737953 us-gaap:ConstructionInProgressMember 2024-03-31 0001737953 us-gaap:SecuredDebtMemberrepl:TermLoanFacilityMemberus-gaap:LineOfCreditMember 2022-10-06 0001737953 us-gaap:SecuredDebtMemberrepl:TermLoanFacilityTrancheOneMemberus-gaap:LineOfCreditMember 2022-10-06 0001737953 us-gaap:SecuredDebtMemberrepl:TermLoanFacilityTrancheTwoMemberus-gaap:LineOfCreditMember 2022-10-06 0001737953 us-gaap:SecuredDebtMemberrepl:TermLoanFacilityTrancheThreeMemberus-gaap:LineOfCreditMember 2022-10-06 0001737953 us-gaap:SecuredDebtMemberrepl:TermLoanFacilityTrancheFourMemberus-gaap:LineOfCreditMember 2022-10-06 0001737953 us-gaap:SecuredDebtMemberrepl:TermLoanFacilityTrancheFiveMemberus-gaap:LineOfCreditMember 2022-10-06 0001737953 us-gaap:SecuredDebtMemberrepl:TermLoanFacilityTrancheOneAndTwoMemberus-gaap:LineOfCreditMember 2023-06-282023-06-28 0001737953 us-gaap:SecuredDebtMemberrepl:TermLoanFacilityTrancheOneAndTwoMemberus-gaap:LineOfCreditMember 2022-10-06 0001737953 us-gaap:SecuredDebtMemberrepl:TermLoanFacilityTrancheTwoMemberus-gaap:LineOfCreditMember 2023-12-22 0001737953 us-gaap:SecuredDebtMemberrepl:TermLoanFacilityMemberus-gaap:LineOfCreditMember 2022-10-062022-10-06 0001737953 srt:MaximumMemberus-gaap:SecuredDebtMemberrepl:TermLoanFacilityMemberus-gaap:LineOfCreditMember 2022-10-062022-10-06 0001737953 us-gaap:SecuredDebtMemberrepl:TermLoanFacilityMemberus-gaap:LineOfCreditMember 2024-06-30 0001737953 us-gaap:SecuredDebtMemberrepl:TermLoanFacilityMemberus-gaap:LineOfCreditMember 2024-03-31 0001737953 us-gaap:SecuredDebtMemberrepl:TermLoanFacilityMemberus-gaap:LineOfCreditMember 2024-04-012024-06-30 0001737953 repl:PreFundedWarrantsStockOptionsMember 2024-06-30 0001737953 repl:PreFundedWarrantsStockOptionsMember 2024-03-31 0001737953 repl:PreFundedWarrantsRestrictedAndPerformanceStockUnitsMember 2024-06-30 0001737953 repl:PreFundedWarrantsRestrictedAndPerformanceStockUnitsMember 2024-03-31 0001737953 repl:PreFundedWarrantsStockOptionsAndRestrictedStockMember 2024-06-30 0001737953 repl:PreFundedWarrantsStockOptionsAndRestrictedStockMember 2024-03-31 0001737953 repl:PreFundedWarrantsESPPMember 2024-06-30 0001737953 repl:PreFundedWarrantsESPPMember 2024-03-31 0001737953 repl:PreFundedWarrantsPreIPOMember 2024-06-30 0001737953 repl:PreFundedWarrantsPreIPOMember 2024-03-31 0001737953 repl:PreFundedWarrantsMember 2024-06-30 0001737953 repl:PreFundedWarrantsMember 2024-03-31 0001737953 repl:PreFundedWarrantsCommonStockMember 2024-06-30 0001737953 repl:PreFundedWarrantsCommonStockMember 2024-03-31 0001737953 us-gaap:CommonStockMemberrepl:AtMarketOfferingProgramMember 2023-08-032023-08-03 0001737953 us-gaap:CommonStockMemberrepl:AtMarketOfferingProgramMember 2023-08-03 0001737953 repl:AtMarketOfferingProgramMember 2020-08-112020-08-11 0001737953 2024-06-142024-06-14 0001737953 2024-06-14 0001737953 repl:A2024PreFundedWarrantsMember 2024-06-14 0001737953 us-gaap:OverAllotmentOptionMember 2024-06-142024-06-14 0001737953 repl:PreFundedWarrantsMember 2020-10-012020-10-31 0001737953 repl:PreFundedWarrantsMember 2024-06-30 0001737953 us-gaap:CommonStockMember 2024-04-~~

~~012024-06-30 0001737953 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-012024-06-30 0001737953 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-012023-06-30 0001737953 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-012024-06-30 0001737953 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-012023-06-30 0001737953 us-gaap:EmployeeStockOptionMember 2024-04-012024-06-30 0001737953 us-gaap:EmployeeStockOptionMember 2023-04-012023-06-30 0001737953 repl:RestrictedAndPerformanceStockUnitsMember 2024-04-012024-06-30 0001737953 repl:RestrictedAndPerformanceStockUnitsMember 2023-04-012023-06-30 0001737953 2017-07-31 0001737953 repl:EquityCompensationPlan2017Member 2024-06-30 0001737953 repl:OmnibusIncentiveCompensationPlan2018Member 2018-07-09 0001737953 repl:EquityCompensationPlan2017Member 2018-07-09 0001737953 repl:OmnibusIncentiveCompensationPlan2018Member 2018-07-092018-07-09 0001737953 repl:PreFundedWarrantsMemberrepl:OmnibusIncentiveCompensationPlan2018Member 2018-07-09 0001737953 repl:OmnibusIncentiveCompensationPlan2018Member 2023-04-012023-04-01 0001737953 repl:OmnibusIncentiveCompensationPlan2018Member 2024-06-30 0001737953 us-gaap:EmployeeStockOptionMember 2024-06-30 0001737953 srt:MaximumMemberus-gaap:EmployeeStockOptionMember 2024-04-012024-06-30 0001737953 srt:MinimumMemberus-gaap:EmployeeStockOptionMember 2024-04-012024-06-30 0001737953 us-gaap:RestrictedStockUnitsRSUMember 2024-04-012024-06-30 0001737953 repl:PerformanceStockUnitsMemberrepl:OmnibusIncentiveCompensationPlan2018Member 2024-04-012024-06-30 0001737953 repl:EmployeeSharePurchasePlanMember 2018-07-09 0001737953 repl:EmployeeSharePurchasePlanMember 2018-07-092018-07-09 0001737953 repl:EmployeeSharePurchasePlanMember 2023-04-012023-04-01 0001737953 repl:EmployeeSharePurchasePlanMember 2022-04-01 0001737953 repl:EmployeeSharePurchasePlanMember 2023-04-01 0001737953 repl:NonqualifiedStockOptionsMemberrepl:OutOfPlanInducementGrantsMember 2024-04-012024-06-30 0001737953 us-gaap:RestrictedStockUnitsRSUMemberrepl:OutOfPlanInducementGrantsMember 2024-04-012024-06-30 0001737953 repl:OutOfPlanInducementGrantsMember 2023-04-012023-06-30 0001737953 2023-04-012024-03-31 0001737953 repl:RestrictedAndPerformanceStockUnitsMember 2024-03-31 0001737953 repl:RestrictedAndPerformanceStockUnitsMember 2024-06-30 0001737953 repl:PerformanceStockUnitsMember 2024-06-30 0001737953 2018-07-09 0001737953 us-gaap:EmployeeStockOptionMember 2024-04-012024-06-30 0001737953 us-gaap:EmployeeStockOptionMember 2023-04-012023-06-30 0001737953 repl:RestrictedAndPerformanceStockUnitsMember 2024-04-012024-06-30 0001737953 repl:RestrictedAndPerformanceStockUnitsMember 2023-04-012023-06-30 0001737953 us-gaap:WarrantMember 2024-04-012024-06-30 0001737953 us-gaap:WarrantMember 2023-04-012023-06-30 0001737953 repl:BristolMyersSquibbCompanyMember 2020-01-012020-01-31 0001737953 repl:MasterClinicalTrialCollaborationAndSupplyAgreementRocheMember 2024-04-012024-06-30 0001737953 repl:MasterClinicalTrialCollaborationAndSupplyAgreementRocheMember 2023-04-012023-06-30 0001737953 repl:MasterClinicalTrialCollaborationAndSupplyAgreementRocheMember 2024-06-30 0001737953 repl:MasterClinicalTrialCollaborationAndSupplyAgreementRocheMember 2024-03-31 0001737953 srt:MinimumMemberrepl:ClinicalTrialCollaborationAndSupplyAgreementIncyteMember 2024-04-012024-06-30 0001737953 srt:MaximumMemberrepl:ClinicalTrialCollaborationAndSupplyAgreementIncyteMember 2024-04-012024-06-30 0001737953 country:US 2024-06-30 0001737953 country:US 2024-03-31 0001737953 country:GB 2024-06-30 0001737953 country:GB 2024-03-31 0001737953 repl:RobertCoffinMember 2024-04-012024-06-30 0001737953 repl:SushilPatelMember 2024-04-012024-06-30 0001737953 repl:PhilipAstleySparkeMember 2024-04-012024-06-30 0001737953 repl:PhilipAstleySparkeMember 2024-06-30 0001737953 repl:RobertCoffinMember 2024-06-30 0001737953 repl:SushilPatelMember 2024-06-30 shares iso4217:USD iso4217:USD shares repl:advance pure repl:patient repl:region0001737953false--06-30202501P4YP653DP1002DP351D10-Qtrue2024-06-30false001-38596REPLIMUNE GROUP, INC.DE82-2082553500 Unicorn Park DriveSuite 303WoburnMA01801781222-9600Common Stock, par value \$0.001 per shareREPLNASDAQYesYesNon-accelerated Filertruefalsefalse68321396151658000744570003174660003462110004933000492200062630008070.0010.0011500000001500000006830996868309968614151056141510568000610001177113000107755054000-701282000432400048550004264510003745080005349650004877220004297200040437000143950057367000-556480004380003930004711000618600053400054400014260001115000406000137400035950006253772000-493540000201000-53772000-49555000-0.78-0.78-0.75-0.7569185885691858856636770266367702-53772000-49555000-432000-130500000-99000-458000-54303000-5131800061415105610001070874000-70128200048550003745080004850000048500000566893760004819800048204000-432000-432000-99000-9900073922510001000228606600066000463841094750009475000-53772000-5377200068309968680001177113000-755054000432400042645100056676313570001034994000-4854880005729000555292000-1305000-1305000-458000-~~

~~4580001922655961461209000120900028121188460008846000-49555000-4955500058976325570001045049000-5350430003966000514029000-53772000-495550009475000884600073600062100027880004091000383000257000406000137400043700039318170001577000-164000-148000-607000-607000-1615000-816000-3160000-1215000-171000-1530000107000-49167000-4858800016690004490001054750001693300001369100001771400002976600073610004820400004350001300077201000-4010900076157000148226000153358000108117000105200065300087000412000~~

~~Nature of the business~~

~~Replimune Group, Inc. (the "Company") is a clinical-stage biotechnology company with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. The Company's proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Replimune Group, Inc., whose predecessor was founded in 2015, is the parent company of its wholly owned, direct and indirect subsidiaries: Replimune Limited ("Replimune UK"); Replimune, Inc. ("Replimune US"); Replimune Securities Corporation; and Replimune (Ireland) Limited.~~

~~The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, third-party intellectual property, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting capabilities. Even if the Company's product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.~~

~~The Company's proprietary oncolytic immunotherapy product candidates, the RPx product candidates, are based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with added payloads intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The Company currently has three RPx product candidates, RP1, RP2 and RP3. RP1 is currently under development in multiple clinical trials, the most advanced being the anti-PD1 failed melanoma cohort of the IGNYTE clinical trial, that, as reported in June 2024, had positive topline primary data analysis by independent central review. RP2 is currently in clinical development with planning underway for a potentially registration enabling clinical trial in uveal melanoma.~~

~~Basis of presentation~~

~~The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred recurring losses since its inception, including net losses of \$53.8 million and \$49.6 million for the three months ended June 30, 2024 and 2023, respectively. In addition, as of June 30, 2024, the Company had an accumulated deficit of \$755.1 million. The Company expects to continue to generate operating losses for the foreseeable future. As of the issuance date of these consolidated financial statements, the Company expects that its cash and cash equivalents and short-term investments will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance of these consolidated financial statements.~~

~~53800000-49600000-755100000Summary of significant accounting policies~~

~~Principles of consolidation~~

~~The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and its direct and indirect wholly owned subsidiaries, Replimune UK, Replimune US, Replimune Securities Corporation and Replimune (Ireland) Limited after elimination of all intercompany accounts and transactions.~~

~~Use of estimates~~

~~The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and its direct and indirect wholly owned subsidiaries, Replimune UK, Replimune US, Replimune Securities Corporation and Replimune (Ireland) Limited after elimination of all intercompany accounts and transactions.~~

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances.

Unaudited interim financial information

The accompanying consolidated balance sheet as of June 30, 2024, the consolidated statements of operations, of comprehensive loss and of stockholders' equity for the three months ended June 30, 2024 and 2023 and the consolidated statements of cash flows for the three months ended June 30, 2024 and 2023 are unaudited. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company's financial position as of June 30, 2024 and the results of its operations for the three months ended June 30, 2024 and 2023 and its cash flows for the three months ended June 30, 2024 and 2023. The financial data and other information disclosed in these consolidated notes related to the three months ended June 30, 2024 and 2023 are unaudited. The results for the three months ended June 30, 2024 are not necessarily indicative of results to be expected for the year ending March 31, 2025, any other interim periods or any future year or period. The financial information included herein should be read in conjunction with the financial statements and notes in the Company's Annual Report on Form 10-K for the year ended March 31, 2024, which was filed with the Securities and Exchange Commission on May 16, 2024 (the "Annual Report").

During the three months ended June 30, 2024, there have been no changes to the Company's significant accounting policies as described in the Annual Report.

Recently Issued Accounting Pronouncements

In December 2023, the Financial Accounting Standards Board issued Accounting Standards Update ("ASU") No. 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures." This ASU updates income tax disclosure requirements primarily by requiring specific categories and greater disaggregation within the rate reconciliation and disaggregation of income taxes paid by jurisdiction. This ASU is effective for annual periods beginning after December 15, 2024 and is applicable to the Company's fiscal year beginning April 1, 2025, with early application permitted. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and disclosures.

In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures". The amendments in this update expand segment disclosure requirements, including new segment disclosure requirements for entities with a single reportable segment among other disclosure requirements. This update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company is currently evaluating the potential impact of this adoption on the consolidated financial statements and related disclosures.

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and its direct and indirect wholly owned subsidiaries, Replimune UK, Replimune US, Replimune Securities Corporation and Replimune (Ireland) Limited after elimination of all intercompany accounts and transactions.

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and

[illegible]

[illegible]

[illegible]

[illegible]

—		
199,821	US Treasury bonds	—
146,390	146,390	146,390
\$	—	\$
387,288	387,288	387,288

The underlying securities in the money market funds held by the Company are all government backed securities.

During the three months ended June 30, 2024 and 2023, there were no transfers between levels.

Valuation of cash equivalents and short-term investments

Money market funds, U.S. Government Agency bonds and U.S. Treasury bonds were valued by the Company using quoted prices in active markets for similar securities, which represent a Level 2 measurement within the fair value hierarchy. Cash equivalents consisted of money market funds at June 30, 2024 and money market funds at March 31, 2024.

The following tables present information about the Company's financial assets and liabilities measured at fair value on a recurring basis:

			Fair Value Measurements as of June 30, 2024 Using:																				
			Level 1			Level 2			Level 3			Total											
Cash equivalents																							
Money market funds			\$			20,097			\$			20,097			\$			20,097					

[illegible]

[illegible]

[illegible]

family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">387,288</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">387,288</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt">As of June 30, 2024 and March 31, 2024, the Company's available-for-sale investments by type consisted of the following:</div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:top;bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized cost</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross unrealized gains</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross unrealized losses</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Credit Losses</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Fair value</td></tr></table></div></div>

0200970000200970000171707000017170700001457590000145759000003375630000033756300

term investments

As of June 30, 2024 and March 31, 2024, the Company's available-for-sale investments by type consisted of the following:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

[illegible]

[illegible]

Fair value					
US Government agency bonds					
199,905					
33					
(117)					
\$					
—					
199,821					
US Treasury bonds					
146,417					
11					
(38)					
—					
146,390					
—					
Total					
\$					
346,322					
\$					

[illegible]

[illegible]

Fair value

US Government agency bonds	199,905	33	(117)	\$	—	199,821	US Treasury bonds	146,417	11	(38)	\$	346,322	\$	44
-----------------------------------	----------------	-----------	--------------	-----------	----------	----------------	--------------------------	----------------	-----------	-------------	-----------	----------------	-----------	-----------

bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(155)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">—</td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">346,211</td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>17182200030001180000171707000145854000100096000014575900031767600040002140000

plant and equipment, net<div style="margin-top:12pt;text-indent:36pt">Property, plant and equipment, net consisted of the following:</div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:73.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2024</td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">Office equipment</td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,464</td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Computer equipment</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,108</td><td colspan="3" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,975</td><td colspan="3" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom"><span

Plant and laboratory equipment		
10,560		
10,423		
Leasehold improvements		
1,886		
1,886		
Capitalized software		
4,938		
3,515		
Construction in progress		
1,034		
1,117		
Total property, plant and equipment		
22,013		
20,380		
Less: Accumulated depreciation		
(10,610)		
(9,897)		
Property, plant and equipment, net		

weight:400;line-height:100%">\$</td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">11,403</td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10,483</td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">Depreciation expense was \$0.7 million and \$0.6 million for the three months ended June 30, 2024 and 2023, respectively. Depreciation expense is recorded within research and development and selling, general and administrative expenses in the consolidated statement of operations.</div><div style="margin-top:12pt;text-indent:36pt">Property, plant and equipment, net consisted of the following:</div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:73.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2024</td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">Office equipment</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,487</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,464</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Computer equipment</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,108</td><td colspan="3" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,975</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">Plant and laboratory equipment</td><td colspan="2" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,560</td><td colspan="3" style="background-

[illegible]

color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10,483</td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>14870001464000210800019750001056000010423000188600018860004938000351500010340

expenses and other current liabilities<div style="margin-top:12pt;text-indent:36pt">Accrued expenses and other current liabilities consisted of the following:</div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2024</td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued research and development costs</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">16,166</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">16,376</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued compensation and benefits costs</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,447</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,906</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued professional fees</td><td colspan="2" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">370</td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">369</td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Other</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">

6,931			3,330		
Total accrued expenses and other current liabilities			30,914		
\$			\$		
33,981			33,981		
Accrued expenses and other current liabilities consisted of the following:			June 30, 2024		
			March 31, 2024		
Accrued research and development costs			\$		
16,166			16,376		
Accrued compensation and benefits costs			7,447		
13,906					

Accrued professional fees	
370	
369	
Other	
6,931	
3,330	
Total accrued expenses and other current liabilities	
\$	
30,914	
\$	
33,981	
16166000163760007447000139060003700003690000693100033300003091400033981000Debt	
On October 6, 2022, the Company entered into a Loan and Security Agreement (the "Loan Agreement"), with Hercules Capital, Inc., as administrative agent, collateral agent and as a lender ("Hercules"). Pursuant to the Loan Agreement, the Company can borrow term loans in an aggregate maximum principal amount of up to \$200.0 million under multiple tranches (the "Term Loan Facility"). Under the Loan Agreement, the Company borrowed an initial amount of \$30.0 million on the closing date, and at the Company's sole option, could have drawn, but did not draw down, an additional \$30.0 million on or prior to September 30, 2023. The Company can also draw as additional term loan advances in an aggregate principal amount of up to \$115.0 million during the term of the Term Loan Facility subject to achievement of specified performance milestones, and two additional term loan advances up to an aggregate principal amount of \$25.0 million subject to certain terms and conditions, on or prior to the end of the interest-only period. The Company intends to use the proceeds of the Term Loan Facility for working capital and general corporate purposes.	
The Loan Agreement was subsequently amended (the "Amendment") on June 28, 2023 pursuant to which the Company agreed to draw an initial term loan advance in an aggregate principal amount not less than \$30.0 million, provided that the aggregate amount of the term loan advances made under tranche 1 do not exceed \$30.0 million, which reflects a decrease of \$30 million from the \$60.0 million in the original Loan Agreement for tranche 1. The total amount of the Loan Agreement, as well as the outstanding balance of the loan, is unchanged, but the option to borrow additional funds were redistributed from tranche 1 to tranche 2. The impact of this amendment is not a modification, as it does not relate to outstanding debt, but is rather an amendment that provides for a future potential benefit. There is no material impact to the financial statements as a result of the Amendment.	

A second amendment was made to the Loan Agreement (the "Second Amendment") on December 22, 2023 pursuant to which the Company agreed to draw a term loan advance in an aggregate principal amount not less than \$15.0 million, provided that the aggregate amount of the term loan advances made under tranche 2 do not exceed \$15.0 million on or prior to December 31, 2023. The Second Amendment re-allocated the total future consideration of the Loan Agreement to the future

tranches extending through September 2026, subject to the terms and conditions of the Loan Agreement. The Second Amendment did not change the total aggregate maximum principal amount to be drawn under the Loan Agreement, which remains as up to \$200.0 million. The Company evaluated the Second Amendment as a modification under relevant accounting guidance, and based on that analysis and the immaterial change in cash flows on current outstanding debt, it was determined that there was no material accounting impact. Upon closing of the Second Amendment, the Company drew down the tranche 2 amount of \$15.0 million.

The Term Loan Facility will mature on October 1, 2027 (the "Maturity Date"). The outstanding principal balance of the Term Loan Facility bears interest payable in cash at a floating rate per annum equal to the greater of (i) 7.25% and (ii) the sum of the Prime Rate (which is capped at 7.25%) and 1.75%. Accrued interest is payable monthly following the funding of each term loan advance. In addition, the principal balance of the Term Loan Facility will bear "payment-in-kind" interest at the rate of 1.50% ("PIK Interest"), which PIK Interest will be added to the outstanding principal balance of the Term Loan Facility on each interest payment date.

Borrowings under the Loan Agreement are repayable in monthly interest-only payments through September 2026. After the interest-only payment period, borrowings under the Loan Agreement are repayable in equal monthly payments of principal and accrued interest until October 2027. At the Company's option, the Company may prepay all or a portion of the outstanding borrowings, subject to a prepayment fee of 3.0% of the principal amount if prepayment had occurred during the 12 months following the closing date, 2.0% after 12 months following the closing date but prior to 36 months following the closing date, and 1.0% thereafter.

The Loan Agreement contains customary facility fees, events of default and representations, warranties and affirmative and negative covenants, including a financial covenant requiring the Company to maintain unrestricted cash in an amount not less than 35% of the aggregate outstanding secured obligations under the Loan Agreement in accounts subject to a control agreement in favor of the Agent (the "Unrestricted Cash") at all times which commenced on January 1, 2024. In addition, the Loan Agreement also contains a financial covenant that beginning on the later of (i) July 1, 2024 and (ii) the date on which the aggregate outstanding principal amount of the Term Loan Facility is equal to or greater than \$100.0 million, the Company is required to satisfy one of the following requirements: (1) achieve a minimum amount of trailing three-month net product revenue tested on a monthly basis, (2) maintain a market capitalization in excess of \$1.2 billion and Unrestricted Cash in an amount no less than 50% of the outstanding amount under the Term Loan Facility, or (3) maintain Unrestricted Cash in an amount no less than 85% of the outstanding amount under the Term Loan Facility.

The Company paid a \$0.5 million facility charge and incurred debt issuance costs of \$1.5 million upon closing of the Loan Agreement. The Loan Agreement also provides for a final payment, payable upon maturity or the repayment of the obligations in full or in part (on a pro rata basis), equal to 4.95% of the aggregate principal amount of Term Loans advanced to the Company and repaid on such date, which is being accrued on the Company's consolidated balance sheet. The amount accrued for the final payment is \$0.6 million as of June 30, 2024 and \$0.5 million as of March 31, 2024.

Unamortized debt issuance costs are recorded as a reduction of the carrying amount on the term loan and amortized as interest expense using the effective-interest method. In addition, unamortized deferred financing costs of \$1.1 million and \$1.2 million were recorded in other assets as of June 30, 2024 and March 31, 2024, respectively, related to the Company's right to borrow additional amounts from Hercules in the future and amortized to interest expense over the relevant draw period on a straight-line basis. Interest expense for the three months ended June 30, 2024 was \$1.4 million.

The summary of obligations under the term loan as of June 30, 2024 and March 31, 2024 consisted of the following (in thousands):

--	--

width:0.1%	width:1.0%	width:18.198%
width:0.1%	width:0.1%	width:0.384%
width:0.1%	width:1.0%	width:18.200%
width:0.1%		
June 30, 2024		
March 31, 2024		
Principal loan balance		
\$		
45,923		
\$		
45,749		
(251)		
(266)		
Unamortized issuance costs		
(1,123)		
(1,191)		
Accumulated end of term fee		
643		
517		
Long term debt, net		
\$		
45,192		

color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">44,809</td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt">
</div><div style="text-indent:36pt">
</div><div style="text-indent:36pt">
</div><div style="text-indent:36pt">The annual principal payments due under the Loan Agreement as of June 30, 2024 and March 31, 2024 were as follows:</div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2024</td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">2024</td><td colspan="2" style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">2025</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">—</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">—</td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">2026</td><td colspan="2" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td><td colspan="3" style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—</td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">2027</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,145</td><td colspan="3" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,145</td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px

Thereafter

27,769		
27,769		

Total

\$		
47,914		
47,914		

The table of future payments of long-term debt excludes the end of term charge of \$2.2 million, which is due upon the maturity of the loan

200000000300000000300000000115000000222500000025000000300000000300000000-3000000006000000001500000015000000200000000150000000.07250.07250.01750.01500.0300.0200.0

The summary of obligations under the term loan as of June 30, 2024 and March 31, 2024 consisted of the following (in thousands):

	59.718%	0.1%	1.0%	18.198%	0.1%
	0.384%	0.1%	1.0%	18.200%	0.1%
June 30, 2024					
March 31, 2024					
Principal loan balance					
\$					
45,923					
\$					
45,749					

Facility charge and diligence fee		(251)
Unamortized issuance costs		(1,123)
Accumulated end of term fee		643
Long term debt, net		\$ 45,192
The annual principal payments due under the Loan Agreement as of June 30, 2024 and March 31, 2024 were as follows:		
June 30, 2024		
March 31, 2024		
2024		

[illegible]

equity

Common stock

As of June 30, 2024 and March 31, 2024, the Company's certificate of incorporation, as amended and restated, authorized the Company to issue up to 150,000,000 shares of common stock, par value \$0.001 per share.

The Company had reserved for common stock for the exercise of outstanding stock options and the vesting of restricted stock units, the number of shares remaining available for grant under the Company's 2018 Omnibus Incentive Compensation Plan and the Company's Employee Stock Purchase Plan (see Note 10) and the exercise of the outstanding warrants to purchase shares of common stock as follows:

			June 30, 2024						March 31, 2024								
			Stock options, issued and outstanding			10,157,054							8,652,256				
			Restricted and performance stock units			3,370,183								2,397,890			
			Stock options and restricted stock units, future issuance			1,988,217								2,284,141			
			Employee stock purchase plan, available for future grants			3,405,175											

2,738,208

Pre-IPO warrants to purchase common stock		
497,344		
497,344		
10,211,969		
5,281,616		
Total shares of common stock reserved for future issuance		
29,629,942		
21,851,455		

Undesignated preferred stock

As of June 30, 2024, the Company's certificate of incorporation, as amended and restated, authorized the Company to issue up to 10,000,000 shares of undesignated preferred stock, par value \$0.001 per share. There were no undesignated preferred shares issued or outstanding as of June 30, 2024.

ATM program

On August 3, 2023, the Company and Leerink Partners LLC (the "Current Agent") entered into a sales agreement, which was subsequently amended on May 16, 2024 (as so amended, the "2023 Sales Agreement"). Under the 2023 Sales Agreement, the Company may sell, from time to time, at its option, up to an aggregate of \$100.0 million of share of the Company's common stock, \$0.001 par value shares (the "Shares"), through the Current Agent, as the Company's sales agent.

Any Shares to be offered and sold under the 2023 Sales Agreement will be issued and sold (i) by methods deemed to be an "at the market offering" ("ATM") as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or if authorized by the Company, in negotiated transactions or block trades, and (ii) pursuant to a registration statement on Form S-3 filed by the Company with the Securities and Exchange Commission on August 3, 2023, as amended for an offering of various securities, including shares of the Company's common stock, preferred stock, debt securities, warrants and/or units for sale to the public in one or more public offerings.

align:justify;text-indent:36pt">Subject to the terms of the 2023 Sales Agreement, the Current Agent will use reasonable efforts to sell the Shares from time to time, based upon the Company's instructions (including any price, time or size limits or other customary parameters or </div><div style="margin-top:12pt;text-align:justify">conditions the Company may impose). The Company will pay the Current Agent a commission of up to 3.0% of the gross proceeds from the sale of the Shares. The Company has also agreed to provide the Current Agent with customary indemnification rights.</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">During the three months ended June 30, 2024, the Company did not issue or sell any shares under the 2023 Sales Agreement. The Company cannot provide any assurances that it will issue any additional Shares pursuant to the 2023 Sales Agreement. </div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">Equity offerings</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">On June 14, 2024, the Company completed a private placement transaction (the "Private Placement") pursuant to which the Company sold (a) 5,668,937 shares of the Company's common stock, at an offering price of \$8.82, and (b) in lieu of common stock to certain investors, pre-funded warrants to purchase 5,669,578 shares of the Company's common stock at an offering price of \$8.819 per warrant (the "2024 Pre-funded Warrants"). The Company received aggregate net proceeds in the Private Placement of approximately \$96.7 million after deducting placement agent fees and other offering expenses payable by the Company of approximately \$3.3 million.</div> Pre-funded Warrants<div style="margin-top:12pt;text-align:justify;text-indent:36pt">The Company's pre-funded warrants are exercisable at any time after the date of issuance. Unless otherwise modified by a holder of a pre-funded warrant, no holder may exercise a pre-funded warrant if such holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of the Company's common stock outstanding immediately after giving effect to such exercise. A holder of the 2024 Pre-funded Warrants may increase or decrease this percentage to any other percentage not in excess of 9.99%, whereas a holder of the Company's pre-funded warrants issued prior to the 2024 Pre-funded Warrants, may increase or decrease this percentage up to 19.99%, by providing at least 61 days' prior notice to the Company. </div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">The 10,211,969 shares of the Company's common stock underlying the pre-funded warrants issued by the Company are not included in the number of issued and outstanding shares of the Company's common stock outstanding as reported on the consolidated balance sheet, though they are included in the Company's annual pool increase calculation as well as the weighted average outstanding common stock in the calculation of basic and diluted net loss per share, as described below in Note 11. </div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">During the three months ended June 30, 2024, a holder of the Company's pre-funded warrants exercised 739,225 of its pre-funded warrants for an exercise price of \$0.001 per pre-funded warrant and the Company issued 739,225 shares of Common Stock in exchange thereof.</div>1500000001500000000.0010.001<div style="margin-top:12pt;text-align:justify;text-indent:36pt">The Company had reserved for common stock for the exercise of outstanding stock options and the vesting of restricted stock units, the number of shares remaining available for grant under the Company's 2018 Omnibus Incentive Compensation Plan and the Company's Employee Stock Purchase Plan (see Note 10) and the exercise of the outstanding warrants to purchase shares of common stock as follows:</div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.269%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.856%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3"></td><td colspan="3"></td><td colspan="3"></td><td colspan="3"></td></tr></table></td><td colspan="3"></td><td colspan="3"></td></tr><tr><td colspan="3"></td><td colspan="3"></td><td colspan="3"></td></tr></div>June 30, 2024</td><td colspan="3"></td><td colspan="3"></td></tr><tr><td colspan="3"></td><td colspan="3"></td><td colspan="3"></td></tr></table>March 31, 2024</td></tr><tr><td colspan="3"></td><td colspan="3"></td><td colspan="3"></td></tr></table>

Stock options, issued and outstanding		
10,157,054		
Restricted and performance stock units		
3,370,183		
Stock options and restricted stock units, future issuance		
1,988,217		
Employee stock purchase plan, available for future grants		
3,405,175		
Pre-IPO warrants to purchase common stock		
497,344		
Pre-funded warrants		
10,211,969		
5,281,616		

1pt;text-align:left;vertical-align:bottom">Total shares of common stock reserved for future issuance</td><td colspan="2" style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29,629,942</td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,851,455</td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>10157054865225633701832397890198821722841413405175273820849734449734410211969

based compensation<div style="margin-top:12pt;text-align:justify;text-indent:36pt">Stock-based compensation expense</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">Stock-based compensation expense was classified in the consolidated statements of operations as follows:</div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:72.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.791%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">Research and development</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,226</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,298</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Selling, general and administrative</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-

5,249

5,548

9,475

8,846

The following table summarizes stock-based compensation expense by award type for the three months ended June 30, 2024 and 2023:

	2024	2023
Stock options	5,733	5,614

			Top: 1pt solid #000000; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom;

			3,742

			3,232

			\$

			9,475

			\$

			8,846

2015 Enterprise Mana gement Incentive Share Option Plan

The 2015 Enterprise Management Incentive Share Option Plan of Replimune UK (the "2015 Plan") provided for Replimune UK to grant incentive stock options, non-statutory stock options, stock awards, stock units, stock appreciation rights and other stock-based awards. Incentive stock options were granted under the 2015 Plan only to the Company's employees, including officers and directors who were also employees. Non-statutory stock options were granted under the 2015 Plan to employees, members of the board of directors, outside advisors and consultants of the Company.

2017 Equity Compensation Plan

In July 2017, in conjunction with reorganization by Replimune Limited, pursuant to which each shareholder thereof exchanged their outstanding shares in Replimune Limited for shares in Replimune Group, Inc., on a one-for-one basis (the "Reorganization"), the 2015 Plan was terminated, and all awards were cancelled with replacement awards issued under the 2017 Equity Compensation Plan (the "2017 Plan"). Subsequent to the Reorganization, no additional grants have been or will be made under the 2015 Plan and any outstanding awards under the 2015 Plan have continued, and will continue with their original terms. The Company concluded that the cancellation of the 2015 Plan and issuance of replacement awards under the 2017 Plan was a modification with no change in the material rights and preferences and therefore no recorded change in the fair value of each respective award.

The Company's 2017 Plan provides for the Company to grant incentive stock options or non-statutory stock options, stock awards, stock units, stock appreciation rights and other stock-based awards. Incentive stock options were granted under the 2017 Plan only to the Company's employees, including officers and directors who were also employees. Restricted stock awards and non-statutory stock options were granted under the 2017 Plan to employees, officers, members of the board of

directors, advisors and consultants of the Company. The maximum number of common shares that may be issued under the 2017 Plan was 2,659,885, of which none remained available for future grants as of June 30, 2024. Shares with respect to which awards have expired, terminated, surrendered or cancelled under the 2017 Plan without having been fully exercised will be available for future awards under the 2018 Plan referenced below. In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for the grant of awards.

2018 Omnibus Incentive Compensation Plan

On July 9, 2018, the Company's board of directors adopted, and the Company's stockholders approved the 2018 Omnibus Incentive Compensation Plan (the "2018 Plan"), which became effective immediately prior to the effectiveness of the registration statement filed in connection with the Company's initial public offering. The 2018 Plan provides for the issuance of incentive stock options, non-qualified stock options, stock awards, stock units, stock appreciation rights and other stock-based awards. The number of shares of common stock initially reserved for issuance under the 2018 Plan is 3,617,968 shares. If any options or stock appreciation rights, including outstanding options and stock appreciation rights granted under the 2017 Plan (up to 2,520,247 shares), terminate, expire, or are canceled, forfeited, exchanged, or surrendered without having been exercised, or if any stock awards, stock units or other stock-based awards, including outstanding awards granted under the 2017 Plan, are forfeited, terminated, or otherwise not paid in full in shares of common stock, the shares of the Company's common stock subject to such grants will be available for purposes of the 2018 Plan. The number of shares reserved for issuance under the 2018 Plan will increase automatically on the first day of each April equal to 4.0% of the total number of shares of common stock outstanding on the last trading day in the immediately preceding fiscal year, which includes for these purposes, the 5,281,616 shares issuable upon exercise of those pre-funded warrants as of March 31, 2024, as described in Note 9 to these consolidated financial statements, or such lesser amount as determined by the Board. On April 1, 2024, the number of shares reserved for issuance under the 2018 Plan automatically increased by 2,667,868 shares pursuant to the terms of the 2018 Plan and based on total number of shares of common stock outstanding on March 31, 2024. As of June 30, 2024, 1,988,217 shares remained available for future grants under the 2018 Plan.

The 2015 Plan, the 2017 Plan and the 2018 Plan are administered by the board of directors or, at the discretion of the board of directors, by a committee of the board of directors. However, the board of directors shall administer and approve all grants made to non-employee directors. The exercise prices, vesting and other restrictions are determined at the discretion of the board of directors, except that the exercise price per share of incentive stock options may not be less than 100% of the fair market value of the common stock on the date of grant (or 110% of fair value in the case of an award granted to employees who hold more than 10% of the total combined voting power of all classes of stock at the time of grant) and the term of stock options may not be greater than five years for an incentive stock option granted to a 10% stockholder and greater than ten years for all other options granted. Stock options awarded under both plans expire ten years after the grant date, unless the board of directors sets a shorter term. Vesting periods for the plans are determined at the discretion of the board of directors. Incentive stock options granted to employees and non-statutory options granted to employees, officers, members of the board of directors, advisors, and consultants of the Company typically vest over four years. In 2021 the board of directors initiated the award of restricted stock units ("RSUs"), under the 2018 Plan in addition to stock option awards available as part of the Company's equity incentive for employees, officers, advisors and consultants of the Company. The RSUs typically vest over four approximately equal annual installments with the first such installment occurring on a designated vesting date that is approximately on the one-year anniversary of the date of grant and the subsequent installments occurring on the subsequent three annual anniversaries of the designated vesting date. In 2024 the Board of Directors approved the award of performance stock units ("PSUs"), under the 2018 Plan in addition to the aforementioned stock option awards and RSUs available as part of the Company's equity incentive for employees, officers, advisors and consultants of the Company. The PSUs will become vested upon the achievement of the approval of the Company's first Biologics License Application ("BLA") for RP1 by the Food and Drug Administration ("FDA") no later than June 30, 2026, and the expense recognized for these awards is based on the grant date fair value of the Company's common stock multiplied by the number of units granted. The timing of recognition of this stock-based compensation expense is subject to our judgment as to when the performance conditions are considered probable of being achieved. The Company granted 246,110 PSUs under the 2018 Plan during the three months ended June, 2024. If the Company does not achieve the approval of the Company's first BLA for RP1 before the expiration of June 30, 2026 then no PSU will be earned or vested.

Employee Stock Purchase Plan

**top:12pt;text-align:justify;text-indent:36pt">On July 9, 2018, the Company's Board of directors adopted and the Company's stockholders approved the Employee Stock Purchase Plan (the "ESPP"), which became effective immediately prior to the effectiveness of the registration statement that was filed in connection with the Company's IPO. The total shares of common stock initially reserved for issuance under the ESPP is 348,612 shares. In addition, as of the first trading day of each fiscal year during the term of the ESPP (excluding any extensions), an additional number of shares of the Company's common stock equal to 1% of the total number of shares outstanding on the last trading day in the immediately preceding fiscal year, which includes for these purposes, the 5,281,616 shares issuable upon exercise of those pre-funded warrants described in Note 9 to these consolidated financial statements, or 697,224 shares, whichever is less (or such lesser amount as determined by the Company's board of directors) will be added to the number of shares authorized under the ESPP. In accordance with the terms of the ESPP, on April 1, 2024, the number of shares reserved for issuance under the ESPP automatically increased by 666,967, for a total of 3,405,175 shares reserved for the ESPP. If the total number of shares of common stock to be purchased pursuant to outstanding purchase rights on any particular date exceed the number of shares then available for issuance under the ESPP, then the plan administrator will allocate the available shares pro-rata and refund any excess payroll deductions or other contributions to participants. The Company's ESPP is not currently active.</div><div style="text-align:justify;text-indent:36pt">
</div><div style="text-align:justify;text-indent:36pt">Out-of-Plan Inducement Grants</div><div style="margin-top:12pt;text-indent:36pt">From time to time, the Company grants equity awards to newly hired executives as a material inducement to enter into employment with the Company. The grants constitute "employment inducement grants" in accordance with Rule 5635(c) (4) of the Nasdaq Listing Rules and was issued outside of the 2018 Plan and each of the other stock incentive plans described above. The inducement grants typically include nonqualified stock options to purchase shares of the Company's common stock, as well as restricted stock unit grants representing shares of the Company's common stock. These stock option and restricted stock unit inducement grants have terms and conditions consistent with those set forth under the 2018 Plan and vest under the same respective vesting schedules as stock option and restricted stock unit awards granted under the 2018 Plan. The inducement grants are included in the stock option and RSU award tables below. During the three months ended June 30, 2024, the Company granted 75,000 nonqualified stock options to purchase shares of the Company's common stock and 50,000 restricted stock units under employment inducement grants, and in the same period in 2023, the Company did not grant any employment inducement grants.</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">Stock option valuation</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">The fair value of stock option grants is estimated using the Black-Scholes option-pricing model. As the Company has limited company-specific historical and implied volatility information, the expected stock volatility is based on a combination of Replimune volatility and the historical volatility of a publicly traded set of peer companies. For options with service-based vesting conditions, the expected term of the Company's stock options has been determined utilizing the "simplified" method for awards that qualify as "plain-vanilla" options. The expected term of stock options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">The following table presents, on a weighted-average basis, the assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors:</div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:11.329%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="display:none"></td></tr></table></div>**

2024		
2023		
Risk-free interest rate		
4.43		
%		
3.60		
%		
Expected term (in years)		
6.0		
6.0		
Expected volatility		
76.3		
%		
74.1		
%		
Expected dividend yield		
0		
%		
0		
%		

Stock options

The following table summarizes the Company's stock option activity:

--	--

[illegible]

[illegible]

height:100%">\$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">6,541</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Options vested and expected to vest as of June 30, 2024</td><td colspan="2" style="background-color:#ceeeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,157,054</td><td style="background-color:#ceeeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ceeeff;padding:2px 0;text-align:right;vertical-align:bottom">15.37</td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:right;vertical-align:bottom">6.84</td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ceeeff;padding:2px 0;text-align:right;vertical-align:bottom">8,837</td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">As of June 30, 2024, there was \$35.7 million of unrecognized compensation cost related to unvested common stock options, which is expected to be recognized over a weighted average period of 2.8 years.</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">The weighted average grant-date fair value of stock options granted during the three months ended June 30, 2024 and 2023 was \$5.37 and \$12.09, respectively. The aggregate intrinsic value of stock options exercised during the three months ended June 30, 2024 was \$0.1 million.</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">Restricted and performance stock units</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">In January 2024, the Board approved a one-time PSU award under the 2018 Plan for all employees at the vice president level and below as of January 31, 2024, subject to non-market performance and service conditions. The grants will become vested upon the achievement of the approval of the Company's first Biologics License Application ("BLA") for RP1 by the Food and Drug Administration ("FDA") no later than June 30, 2026. If the Company does not achieve the approval of the Company's first BLA for RP1 before the expiration of June 30, 2026 then no PSU will be earned or vested. The grant date fair value for the PSUs is determined based on the market price of the Company's common stock on the grant date and is recognized over the requisite service period if and when the achievement of such performance condition is determined to be probable by the Company. The Company reassesses the probability of achieving the performance condition at each reporting period. As of June 30, 2024, the Company has not recognized any expense related to PSUs.</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">A summary of the changes in the Company's RSUs and PSUs during the three months ended June 30, 2024 is as follows:</div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Number of Restricted Shares</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-

Weighted Average Grant Date Fair Value		
Outstanding as of March 31, 2024		
2,397,890		
17.97		
Granted		
1,560,527		
7.72		
Vested		
(463,841)		
22.03		
Cancelled		
(124,393)		
15.23		
Outstanding as of June 30, 2024		
3,370,183		
\$		
12.77		

As of June 30, 2024, there was \$34.5 million of unrecognized compensation cost related to unvested restricted stock units, which is expected to be recognized over a weighted average period of 2.8 years. Of the \$34.5 million of total unrecognized compensation cost, performance based awards tied to the achievement of a company milestone account for approximately \$4.8 million. The performance based awards will vest upon achievement of the performance milestone. The remaining unrecognized compensation cost is related to restricted stock units which vest over time.

Stock-based compensation expense was classified in the consolidated statements of operations as follows:

	2024	2023
Research and development	\$4,226	\$5,548
Selling, general and administrative	\$5,249	\$9,475
	\$9,475	\$15,023

8,846

	2024	2023
Stock options	\$5,733	\$5,614
Restricted and performance stock units	3,742	3,232
	9,475	

000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">8,846</td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>42260003298000524900055480009475000884600057330005614000374200032320009475000

align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">74.1 </td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Expected dividend yield</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>0.04430.0360P6YP6Y0.7630.74100<div style="margin-top:12pt;text-align:justify;text-indent:36pt">The following table summarizes the Company's stock option activity:</div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Number of
Shares</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted
Average
Exercise
Price</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted
Average
Contractual
Term
(Years)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Aggregate
Intrinsic
Value</td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">Outstanding as of March 31, 2024</td><td colspan="2" style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,652,256 </td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">\$ </td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">16.94 </td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">6.61</td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">6.61</td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">6.61</td></tr></table></div>

[illegible]

[illegible]

Number of Restricted Shares		
Weighted Average Grant Date Fair Value		
Outstanding as of March 31, 2024		
2,397,890		
17.97		
Granted		
1,560,527		
7.72		
Vested		
(463,841)		
22.03		
Cancelled		
(124,393)		
15.23		
Outstanding as of June 30, 2024		
3,370,183		
\$		
12.77		

239789017.9715605277.7246384122.0312439315.23337018312.7734500000P2Y9M18D345000

loss per share

height:120%">Basic and diluted net loss per share attributable to common stockholders was calculated as follows:

			Three Months Ended June 30,																	
			2024									2023								
Net loss			\$(53,772)									\$(49,555)								
Denominator:			69,185,885									66,367,702								
Weighted average common shares outstanding, basic and diluted			69,185,885									66,367,702								
Net loss per share, basic and diluted			\$ (0.0008)									\$ (0.0007)								

color:#ccccff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ccccff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">(0.78)</td><td style="background-color:#ccccff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccccff;padding:0 1pt"></td><td style="background-color:#ccccff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ccccff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">(0.75)</td><td style="background-color:#ccccff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">The 10,211,969 shares of the Company's common stock issuable upon exercise of pre-funded warrants described in Note 9 to these consolidated financial statements are included as outstanding common stock in the calculation of basic and diluted net loss per share. </div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">The Company's potentially dilutive securities, which include stock options, unvested restricted and performance stock units and warrants to purchase shares of common stock that resulted from the conversion of warrants to purchase shares of series seed preferred stock existing before the Company's IPO, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Three Months Ended June 30, </div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ccccff;padding:2px 1pt;text-align:left;vertical-align:bottom">Options to purchase common stock</td><td colspan="2" style="background-color:#ccccff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,157,054 </td><td colspan="3" style="background-color:#ccccff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccccff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,067,305 </td><td colspan="3" style="background-color:#ccccff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Unvested restricted and performance stock units</div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,370,183 </td><td colspan="3" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"></td></tr></table></div>

<td >497,344<="" colspan="2" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%" td=""><td >497,344<="" colspan="3" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%" td=""></td></td>			<td >497,344<="" colspan="3" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%" td=""></td>				
<td >11,634,064<="" colspan="2" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%" td=""><td >11,634,064<="" colspan="3" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%" td=""></td></td>			<td >11,634,064<="" colspan="3" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%" td=""></td>				

<td ><="" style="width:72.498%" td=""><td ><="" style="width:0.1%" td=""><td ><="" style="width:1.0%" td=""><td ><="" style="width:11.731%" td=""><td ><="" style="width:0.1%" td=""><td ><="" style="width:0.1%" td=""><td ><="" style="width:0.537%" td=""><td ><="" style="width:0.1%" td=""><td ><="" style="width:1.0%" td=""><td ><="" style="width:11.734%" td=""><td ><="" style="width:0.1%" td=""><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></td></td></td></td></td></td></td></td></td></td></td>	<td ><="" style="width:0.1%" td=""><td ><="" style="width:1.0%" td=""><td ><="" style="width:11.731%" td=""><td ><="" style="width:0.1%" td=""><td ><="" style="width:0.1%" td=""><td ><="" style="width:0.537%" td=""><td ><="" style="width:0.1%" td=""><td ><="" style="width:1.0%" td=""><td ><="" style="width:11.734%" td=""><td ><="" style="width:0.1%" td=""><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></td></td></td></td></td></td></td></td></td></td>	<td ><="" style="width:1.0%" td=""><td ><="" style="width:11.731%" td=""><td ><="" style="width:0.1%" td=""><td ><="" style="width:0.1%" td=""><td ><="" style="width:0.537%" td=""><td ><="" style="width:0.1%" td=""><td ><="" style="width:1.0%" td=""><td ><="" style="width:11.734%" td=""><td ><="" style="width:0.1%" td=""><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></td></td></td></td></td></td></td></td></td>	<td ><="" style="width:11.731%" td=""><td ><="" style="width:0.1%" td=""><td ><="" style="width:0.1%" td=""><td ><="" style="width:0.537%" td=""><td ><="" style="width:0.1%" td=""><td ><="" style="width:1.0%" td=""><td ><="" style="width:11.734%" td=""><td ><="" style="width:0.1%" td=""><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></td></td></td></td></td></td></td></td>	<td ><="" style="width:0.1%" td=""><td ><="" style="width:0.1%" td=""><td ><="" style="width:0.537%" td=""><td ><="" style="width:0.1%" td=""><td ><="" style="width:1.0%" td=""><td ><="" style="width:11.734%" td=""><td ><="" style="width:0.1%" td=""><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></td></td></td></td></td></td></td>	<td ><="" style="width:0.1%" td=""><td ><="" style="width:0.537%" td=""><td ><="" style="width:0.1%" td=""><td ><="" style="width:1.0%" td=""><td ><="" style="width:11.734%" td=""><td ><="" style="width:0.1%" td=""><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></td></td></td></td></td></td>	<td ><="" style="width:0.537%" td=""><td ><="" style="width:0.1%" td=""><td ><="" style="width:1.0%" td=""><td ><="" style="width:11.734%" td=""><td ><="" style="width:0.1%" td=""><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></td></td></td></td></td>	<td ><="" style="width:0.1%" td=""><td ><="" style="width:1.0%" td=""><td ><="" style="width:11.734%" td=""><td ><="" style="width:0.1%" td=""><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></td></td></td></td>	<td ><="" style="width:1.0%" td=""><td ><="" style="width:11.734%" td=""><td ><="" style="width:0.1%" td=""><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></td></td></td>	<td ><="" style="width:11.734%" td=""><td ><="" style="width:0.1%" td=""><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></td></td>	<td ><="" style="width:0.1%" td=""><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></td>	<td colspan="3" style="display:none"></td> <td colspan="3" style="display:none"></td> <td colspan="3" style="display:none"></td> <td colspan="3" style="display:none"></td>															
<td >2024<="" colspan="3" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%" td=""><td >2023<="" colspan="3" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%" td=""><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></td></td>			<td >2023<="" colspan="3" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%" td=""><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></td>			<td colspan="3" style="display:none"></td> <td colspan="3" style="display:none"></td> <td colspan="3" style="display:none"></td> <td colspan="3" style="display:none"></td>																				
<td colspan="3" style="display:none"></td> <td colspan="3" style="display:none"></td> <td colspan="3" style="display:none"></td> <td colspan="3" style="display:none"></td> <td >numerator:<="" colspan="3" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%" td=""><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></td>															<td colspan="3" style="display:none"></td> <td colspan="3" style="display:none"></td> <td colspan="3" style="display:none"></td>											
<td >(\$<="" colspan="3" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%" td=""><td >(53,772)<="" colspan="3" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%" td=""><td ><="" colspan="3" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%" td=""><td ><="" colspan="3" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%" td=""><td ><="" colspan="3" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%" td=""></td></td></td></td></td>			<td >(53,772)<="" colspan="3" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%" td=""><td ><="" colspan="3" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%" td=""><td ><="" colspan="3" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%" td=""><td ><="" colspan="3" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%" td=""></td></td></td></td>			<td ><="" colspan="3" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%" td=""><td ><="" colspan="3" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%" td=""><td ><="" colspan="3" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%" td=""></td></td></td>			<td ><="" colspan="3" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%" td=""><td ><="" colspan="3" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%" td=""></td></td>			<td ><="" colspan="3" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%" td=""></td>														

\$			(49,555)					
Denominator:								
Weighted average common shares outstanding, basic and diluted			69,185,885					
66,367,702								
Net loss per share, basic and diluted			\$(0.78)					

Options to purchase common stock

10,157,054	9,067,305
Unvested restricted and performance stock units	3,370,183
	2,069,415
Warrants to purchase common stock	497,344
	497,344
	14,024,581
	11,634,064

101570549067305337018320694154973444973441402458111634064

Significant agreements

Agreement with Bristol-Myers Squibb Company

In February 2018, the Company entered into an agreement with Bristol-Myers Squibb Company (“BMS”). Pursuant to the agreement, BMS will provide to the Company, at no cost, a compound for use in the Company’s ongoing clinical trial of RPI. Under the agreement, the Company will sponsor, fund and conduct the clinical trial in accordance with an agreed-upon protocol. BMS granted the Company a non-exclusive, non-transferrable, royalty-free license (with a right to sublicense) under its intellectual property to its compound in the clinical trial and agreed to supply its compound, at no cost to the Company, for use in the clinical trial. In January 2020, this agreement was expanded to cover an additional cohort of 125 patients with anti-PD-1 failed melanoma.

Unless earlier terminated, the agreement will remain in effect until (i) the completion of the clinical trial, (ii) all related clinical trial data have been delivered to both parties and (iii) the completion of any statistical analyses and bioanalyses contemplated by the clinical trial protocol or any analysis otherwise agreed upon by the parties. The agreement may be terminated by either party (x) in the event of an uncured material breach by the other party, (y) in the event the other party is insolvent or in bankruptcy proceedings or (z) for safety reasons. Upon termination, the licenses granted to the Company to use BMS’s compound in the clinical trial will terminate.

In April

2019, the Company entered into a separate agreement with BMS on terms similar to the terms set forth in the agreement described above, pursuant to which BMS will provide to the Company, at no cost, nivolumab for use in the Company's Phase 1 clinical trial of RP2 in combination with nivolumab.

Agreement with Regeneron Pharmaceuticals, Inc.

In May 2018, the Company entered into an agreement with Regeneron Pharmaceuticals, Inc. ("Regeneron"). Pursuant to the agreement the Company agreed to undertake one or more clinical trials with Regeneron for the administration of the Company's product candidates in combination with cemiplimab, an anti-PD-1 therapy developed by Regeneron, across multiple solid tumor types. The first of which, agreed in June 2018, is the Company's ongoing clinical trial testing RP1 in combination with cemiplimab versus cemiplimab alone in patients with CSCC. Each clinical trial will be conducted pursuant to an agreed study plan which, among other things, will identify the name of the sponsor and which party will manage the particular study, and include the protocol, the budget and a schedule of clinical obligations.

Pursuant to the terms of the agreement, each party granted the other party a non-exclusive license of their respective intellectual property and agreed to contribute the necessary resources needed to fulfill their respective obligations, in each case, under the terms of agreed study plans. The Company does not expect any further reimbursements from Regeneron related to the initial study plan of June 2018 and the CERPASS trial. The agreement contains representations, warranties, undertakings and indemnities customary for a transaction of this nature. The agreement also contains certain time-based covenants that restrict the Company from entering into a third-party arrangement with respect to the use of its product candidates in combination with an anti-PD-1 therapy and that restrict Regeneron from entering into a third-party arrangement with respect to the use of cemiplimab in combination with an HSV-1 virus, in each case, for the treatment of a tumor type that is the subject of a clinical trial to which the covenants apply. Unless otherwise mutually agreed in a future study plan, these covenants are only applicable to the Company's ongoing Phase 2 clinical trial in CSCC.

The agreement may be terminated by either party if (i) there is no active study plan for which a final study report has not been completed and the parties have not entered into a study plan for an additional clinical trial within a period of time after the delivery of the most recent final study report or (ii) in the event of a material breach.

The agreement with Regeneron is accounted for under ASC 808, Collaborative Arrangements ("ASC 808"), as both parties are active participants and each party pays its own compound costs and share equally in development costs. The Company accounts for costs incurred as part of the study, including costs to supply compounds for use in the study, as research and development expenses within the consolidated statement of operations. The Company recognizes any amounts received from Regeneron in connection with this agreement as an offset to research and development expense within the consolidated statement of operations.

In July 2022, Regeneron informed the Company that the costs of the study have reached the initial budget for the initial study plan of June 2018 and that Regeneron's reimbursement of CERPASS study costs to the Company have completed in the period ending June 30, 2022 in relation to the initial study budget. As a result of this notice from, and the ongoing communications with, Regeneron, the Company has not recorded any cost-sharing reimbursements from Regeneron in prepaid expenses and other current assets in the consolidated balance sheet or as an offset to research and development expense within the consolidated statement of operations since Regeneron informed it that Regeneron's reimbursement of CERPASS study costs have completed. The Company does not expect any further reimbursements from Regeneron related to the initial study plan of June 2018.

Collaboration and other arrangements

Roche

In December 2022, the Company entered into a Master Clinical Trial Collaboration and Supply Agreement with Roche in relation to the Company's RP2 and RP3 programs in colorectal cancer, or CRC, and hepatocellular carcinoma, or HCC. Under the agreement, the companies intended to collaborate in 30-patient cohort signal finding studies in third-line, or 3L, CRC and in first- and second-line, or 1L and 2L, respectively, HCC. Following the Company's re-prioritization of its product development

portfolio in December 2023, the Company has agreed with Roche to terminate the CRC collaboration and pursue the 2L cohort in HCC with RP2 only. Roche has expressed its intent to continue to supply its currently approved drugs, atezolizumab and bevacizumab for the 2L cohort in HCC but is unlikely to share costs following the Company's re-prioritization. The Company is in discussions with Roche about revising these agreements following the Company's changes to its RP2 and RP3 development plans. Under the terms of the initial agreement the Company retained the responsibility of operating the clinical trials as well as retaining all the rights to the development and commercialization of its product candidates. The agreement may be terminated by either party upon sixty days prior written notice to the other party.

The agreement with Roche is accounted for under ASC 808, Collaborative Arrangements ("ASC 808"), as both parties are active participants and each party pays its own compound costs. The Company accounts for costs incurred as part of the study, including costs to supply compounds for use in the study, as research and development expenses within the consolidated statement of operations. The Company will recognize any amounts received from Roche in connection with this agreement as an offset to research and development expense within the consolidated statement of operations.

During the three months ended June 30, 2024 and 2023, the Company did not make any payments to Roche under the terms of the agreement. The Company recorded \$0.0 million and \$0.7 million as an offset to research and development expenses during the three months ended June 30, 2024, and 2023, respectively. During the three months ended June 30, 2024 and 2023, the Company received payments under the terms of the agreement from Roche of \$1.8 million and \$0.2 million, respectively. As of June 30, 2024 and March 31, 2024, the Company recorded \$0.0 million and \$1.8 million as receivables from Roche in connection with this agreement, respectively.

Incyte

In July 2023, the Company entered into a Clinical Trial Collaboration and Supply Agreement with Incyte Corporation, or Incyte. Under the agreement, the companies will collaborate in a signal finding study in which Incyte will initiate and sponsor a clinical trial of INCB99280 (oral PD-L1 inhibitor) and RP1 in approximately 40 patients with unresectable, high risk CSCC in the neoadjuvant setting. Under the terms of the agreement, the Company will supply Incyte with RP1 for the study and share costs of the study equally with Incyte. The agreement may be terminated by either party upon (i) a material breach not reasonably cured within thirty (30) days; (ii) the discontinuation of development of its clinical drug candidate; (iii) the unethical or illegal business practices of the other party; or (iv) if the parties have not agreed on the protocol or budget within ninety (90) days of the effective date of the agreement. In addition, the Company may terminate the agreement upon the inappropriate or unsafe use of the RP1 product candidate. On July 30, 2024, Incyte announced it has discontinued further development of its oral small molecule PD-L1 inhibitor, which was the intended study drug in the Company's planned collaboration with Incyte. On August 1, 2024, the Company received notice of termination of the Clinical Trial Collaboration and Supply Agreement from Incyte. During the year ended March 31, 2024, the Company did not make any payments to, or receive any payments from,

Incyte under the terms of the agreement. Additionally, no costs were recorded to research and development expenses during the three months ended June 30, 2024 related to this agreement.

Amgen

In August 2023 the Company entered into a Settlement Agreement with Amgen and mutually agreed to terminate the Company's challenges to Amgen's patents. In connection with the Settlement Agreement, the Company entered into a License and Covenant Agreement with Amgen in which the Company agreed to pay Amgen low single-digit royalty payments on net sales of its products that, but for the license, could be found to infringe a valid Amgen patent on a country-by-country and product-by-product basis.

125P60D0.070000018000002000000.01800000P30DP90DCommitments and contingencies

Leases

The table below presents the lease-related costs which are included in the consolidated statements of operations for the three months ended June 30, 2024 and 2023:

collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%">											

height:100%">281 </td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">280 </td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total lease cost</td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$ </td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,422 </td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$ </td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,431 </td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">The following table summarizes the classification of lease costs in the consolidated statement of operations for the three months ended June 30, 2024 and 2023 as follows:</div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.543%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30, </td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance Lease Costs</td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">— Research and development</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$ </td><td style="padding:2px 0;text-align:right;vertical-align:bottom">607 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td

607			
Other income (expense)			
534			
544			
Operating Lease Costs			
Research and development			
229			
229			
52			
51			
Total lease cost			
\$			
1,422			

height:100%">\$</td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,431</td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">The following table summarizes the maturity of the Company's lease liabilities on an undiscounted cash flow basis and a reconciliation to the operating and financing lease liabilities recognized on its balance sheet as of June 30, 2024:</div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Operating leases</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Financing lease</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">2025 (remaining nine months)</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">872</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,050</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,922</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">2026</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,171</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">2,799</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:0 1pt"></td><td colspan="2" style="padding:0 1pt"></td></tr></table></div>

3,970

2027

1,137

2,883

4,020

2028

1,086

2,969

4,055

2029

1,005

3,058

4,063

Thereafter

925

31,995

32,920

Total lease payments

6,196

[illegible]

[illegible]

[illegible]

Three Months Ended June 30,			2024								
Other information											
Cash paid for amounts included in the measurement of lease liabilities:											
Operating cash flows from operating leases			\$			152			263		
Operating cash flows from finance leases			\$			534			544		
Financing cash flows from finance leases			\$								

[illegible]

10.3

Weighted-average discount rate - financing leases

8.3

The variable lease costs and short-term lease costs were insignificant for the three months ended June 30, 2024 and 2023.

Manufacturing commitments

The Company has entered into an agreement with a contract manufacturing organization to provide clinical trial products. As of June 30, 2024 and March 31, 2024, the Company had committed to minimum payments under these arrangements totaling \$0.9 million and \$0.9 million, respectively.

Indemnification agreements

In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its executive management team and its board of directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and therefore it has not accrued any liabilities related to such obligations in its consolidated financial statements as of June 30, 2024 or March 31, 2024.

Legal proceedings

The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities.

The table below presents the lease-related costs which are included in the consolidated statements of operations for the three months ended June 30, 2024 and 2023:

	2024	2023
Lease expense	\$11.731 million	\$11.734 million
Short-term lease expense	\$0.537 million	\$0.537 million
Variable lease expense	\$0.122 million	\$0.122 million
Lease expense, net of short-term and variable lease expense	\$11.072 million	\$11.075 million

[illegible]

1,422

1,431

The following table summarizes the classification of lease costs in the consolidated statement of operations for the three months ended June 30, 2024 and 2023 as follows:

	2024	2023	Finance Lease Costs	Operating Lease Costs	Research and development
	607	607			

534	544			
Operating Lease Costs				
Research and development				
229				
229				
Selling, general and administrative				
52				
51				
Total lease cost				
\$				
1,422				
\$				
1,431				

The

544		
Financing cash flows from finance leases		
\$	134	
\$	104	
Right-to-use asset obtained in exchange for new operating lease liabilities		
\$		
—		
\$		
—		
Weighted-average remaining lease term - operating leases		
5.6		
years		
6.3		
years		
Weighted-average remaining lease term - financing leases		
15.3		
years		
16.1		

years		
Weighted-average discount rate - operating leases		
10.3		%
Weighted-average discount rate - financing leases		
8.3		%
Operating leases		
Financing lease		
Total		
2025 (remaining nine months)		\$

[illegible]

[illegible]

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,994 </td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$ </td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">30,758 </td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>87200020500002922000117100027990003970000113700028830004020000108600029690004 style="margin-top:12pt;text-indent:36pt">The following table provides lease disclosure as of June 30, 2024 and March 31, 2024:</div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2024</td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">Leases</td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Right-to-use operating lease asset</td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$ </td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">4,475 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$ </td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">4,635 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">Right-to-use finance lease asset</td><td colspan="2" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">36,629 </td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">37,237 </td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total lease assets</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$ </td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">\$ </td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">\$ </td></tr></table></div>

[illegible]

30,758

31,060

The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company's tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.

The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.

Geographic information

The Company operates in two geographic regions: the United States (Massachusetts) and the United Kingdom (Oxfordshire). Information about the Company's long-lived assets held in different geographic regions is presented in the tables below:

	June 30, 2024	March 31, 2024
United States	10,006	

colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td><td style="background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8,992</td><td style="background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">United Kingdom</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,397</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,491</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td><td style="background-color:#e6e6ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#e6e6ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">11,403</td><td style="background-color:#e6e6ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td><td style="background-color:#e6e6ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#e6e6ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10,483</td><td style="background-color:#e6e6ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt">The Company operates in two geographic regions: the United States (Massachusetts) and the United Kingdom (Oxfordshire). Information about the Company's long-lived assets held in different geographic regions is presented in the tables below:</div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:73.126%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.123%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2024</td></tr><tr><td colspan="3" style="background-color:#e6e6ff;padding:2px 1pt;text-align:left;vertical-align:bottom">United States</td><td style="background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10,006</td><td style="background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td><td style="background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8,992</td><td style="background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tr></div>

[illegible]

January 15, 2026

Robert Coffin		
Director		
4/3/2024	(2)	480,000
December 31, 2026		

Sushil Patel
Chief Executive Officer and Director

4/3/2024	(2)	25000
March 20, 2025		

Date of adoption of Rule 10b5-1 trading arrangements is in accordance with both the Company's insider trading policy and applicable SEC rules and regulations.

(1)

(2)

The first trade pursuant to the Rule 10b5-1 trading arrangement will be, in accordance with both the Company's insider trading policy and applicable SEC rules and regulations, on a date after the date of adoption of the Rule 10b5-1 trading arrangement.

(3)

The Rule 10b5-1 trading arrangement permits transactions through and including the earlier to occur of (a) the completion of all sales or (b) the date listed in the table. The arrangement also provides for automatic expiration in the event of bankruptcy, insolvency, death or mental incapacity of the adopting person.

Other than those disclosed above, none of our directors or officers adopted, modified, or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," in each case as defined in Item 408 of Regulation S-K, during the three months ended June 30, 2024.

Philip Astley-Sparke
Executive Chairman
4/2/2024
(2)
240000
January 15, 2026
Robert Coffin
Director
4/3/2024
(2)
480000
December 31, 2026
Sushil Patel
Chief Executive Officer and Director
4/3/2024
(2)
25000
March 20, 2025
false
false
false